tenofovir profile

tenofovir (anhydrous) : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	464205
CHEMBL ID	483
CHEBI ID	63625
SCHEMBL ID	39724
MeSH ID	M0254881

Synonym
AC-760
AB01274787-01
gs-1278
pmpa-(r)
phosphonic acid, [[(1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy]methyl]- & hippeastrum hybrid agglutinin( hha)
gna & tenofovir
phosphonic acid, [[(1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy]methyl]- & galanthus nivalis agglutinin (gna)
hha & tenofovir
truvada
tenofovir gel (gs-1278)
pmpa gel
(r)-pmpa
[(1r)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methylphosphonic acid
phosphonic acid, [[(1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy]methyl]-
9-pmpa
tenofovir ,
147127-20-6
(((r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy)methyl)phosphonic acid, monohydrate
phosphonic acid, ((2-(6-amino-9h-purin-9-yl)-1-methylethoxy)methyl)-, (r)-
(r)-9-(phosphonomethoxypropyl)adenine
viread (prodrug for tenofovir)
phosphonic acid, (((1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy)methyl)-
(((1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy)methyl)phosphonic acid
(r)-9-(2-phosphonomethoxypropyl)adenine
gs 1275
9-(2-phosphonylmethoxypropyl)adenine
{[(1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy]methyl}phosphonic acid
[(2r)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid
pmp-a
chebi:63625 ,
gs-1275 ,
CHEMBL483
9-pmpa (tenofovir)
A808613
[(2r)-3-(6-aminopurin-9-yl)-2-methyl-propyl] dihydrogen phosphate
HMS3264H05
d,l-tenofovir
tenofovir gel
ec 604-571-2
tfv gel
unii-w4hfe001u5
(r)-(1-(6-amino-9h-purin-9-yl)propan-2-yloxy)methylphosphonic acid
tenofovir [usan:inn:ban]
w4hfe001u5 ,
[[(1r)-2(6-amino-9h-purin-9-yl)-1-methylethoxy]methyl]phosphonic acid
BCPP000049
anhydrous tenofovir
({[(2r)-1-(6-amino-9h-purin-9-yl)propan-2-yl]oxy}methyl)phosphonic acid
anh. tenofovir
tenofovir (anhydrous)
tenofovir (anh.)
tenofovir [mi]
tenofovir anhydrous
tenofovir [who-dd]
tenofovir [inn]
phosphonic acid, p-(((1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy)methyl)-
AKOS015856701
AKOS015894941
BRD-K15891719-001-02-8
(r)-(((1-(6-amino-9h-purin-9-yl)propan-2-yl)oxy)methyl)phosphonic acid
CS-1609
HY-13910
phosphonic acid, p-[[(1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy]methyl]-
AM20090678
SCHEMBL39724
KS-5021 ,
9-[(r)-2-(phosphonomethoxy)propyl]adenine
SGOIRFVFHAKUTI-ZCFIWIBFSA-N
(r)-9-[2-(phosphonomethoxy) propyl] adenine
T3006
Q-201787
(r)-[[2-(6-amino-9h-purin-9-yl)-1-methylethoxy]methyl]phosphonic acid
(r)-9-(2-phosphonoylmethoxypropyl)adenine
AB01274787_03
AB01274787_02
DTXSID9040132 ,
mfcd00943794
C17407
gs 1278
SR-01000883934-1
sr-01000883934
tenofovir, >=98% (hplc)
[2-(6-amino-9h-purin-9-yl)-1-methylethoxy]methylphosphonic acid
TFO ,
bdbm50450813
147127-20-6 (tenofovir)
tenofovir (viread)
DB14126
rac tenofovir
Q155954
CCG-267345
gtpl10948
[[(1r)-2(6-amino-9h-purin-9-yl)-1-methylethoxy]methyl]phosphonic acid;
NCGC00167535-16
tenofovir- bio-x
BT164455
EN300-123033
tenofovirum
(r)-9-(phosphonomethoxypropyl)adenine hydrate
(((1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy)methyl)phosphonic acid, monohydrate
(r)-9-(2-phosphonomethoxypropyl)adenine hydrate
((((2r)-1-(6-amino-9h-purin-9-yl)propan-2-yl)oxy)methyl)phosphonic acid
tenofovir (usp-rs)
dtxcid7020132
tenofovir (mart.)
j05af07
Z1546616194

Excerpt	Reference	Relevance
" All subjects tolerated dosing without significant adverse events."	( Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Barditch-Crovo, P; Cundy, KC; Deeks, SG; Hellmann, NS; Hwang, F; Kahn, JO; Lietman, PS; Rooney, JF; Safrin, S, 1998)	0.3
" Grade III or IV adverse events were limited to laboratory abnormalities, including elevated creatine phosphokinase and liver function tests, which resolved with or without drug discontinuation and without sequelae."	( Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Barditch-Crovo, P; Coakley, DF; Coleman, RL; Collier, A; Deeks, SG; Kahn, JO; Kearney, BP; Lamy, PD; Lietman, PS; McGowan, I; Miller, M; Safrin, S, 2001)	0.31
"Drug-associated dysfunction of mitochondria is believed to play a role in the etiology of the various adverse symptoms that occur in human immunodeficiency virus (HIV)-infected patients treated with the nucleoside reverse transcriptase inhibitors (NRTIs)."	( Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Birkus, G; Cihlar, T; Hitchcock, MJ, 2002)	0.31
"The rise in didanosine concentrations in plasma when given with tenofovir raises concern for a high risk of toxic effects."	( Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults. Blanco, JL; de Lazzari, E; García, F; Gatell, JM; Larrousse, M; Mallolas, J; Martínez, E; Milinkovic, A; Miró, JM; Ravasi, G, )	0.13
" Twelve subjects in the QD Group (14%) discontinued treatment due to adverse events, mainly nevirapine-related hepatitis (6%)."	( Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach. Burger, D; Clotet, B; Galindos, MJ; Gel, S; Miralles, C; Moltó, J; Muñoz-Moreno, JA; Negredo, E; Pedrol, E; Puig, J; Ribera, E; Rodriguez Fumaz, C; Rodríguez, E; Ruiz, L; Viciana, P; Videla, S, 2004)	0.32
" These data have now provided a clear and clinically relevant understanding of the individual profiles of drugs within the nucleoside analogue reverse transcriptase inhibitor , HIV protease inhibitor and non-nucleoside analogue reverse transcriptase inhibitor drug classes, and have provided a rational basis for assessing and monitoring these adverse effects in clinical practice."	( Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. Mallal, S; Nolan, D; Reiss, P, 2005)	0.33
"Despite the recent publication of case reports describing various manifestations of tenofovir-related nephrotoxicity, data regarding the incidence of and risk factors for this adverse effect are currently lacking."	( Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. Antoniou, T; Chirhin, S; Gough, K; Govan, V; Loutfy, M; Raboud, J; Rachlis, A; Yoong, D, 2005)	0.33
" Although 92% of the women reported at least one adverse event, the majority were mild (87%) and involved the genitourinary tract (70%)."	( Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. El-Sadr, WM; Eshleman, SH; Gai, F; Hendrix, C; Justman, J; Kwiecien, A; Maslankowski, LA; Mâsse, B; Mayer, KH; Morrow, K; Rooney, JF; Soto-Torres, L, 2006)	0.33
" Together, these in vitro results indicate that combination with other antiretrovirals does not significantly increase the toxic potential of TFV in RPTECs."	( In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells. Alvarez, ML; Cihlar, T; Cordobilla, B; Domingo, JC; Domingo, P; Giralt, M; Guallar, J; López-Dupla, M; Sánchez de la Rosa, R; Saumoy, M; Torres, F; Vidal, F; Villarroya, F, 2006)	0.33
" The US Food and Drug Administration's Adverse Event Reporting System was searched for reports of nephrolithiasis in HIV-infected patients taking an atazanavir-based regimen."	( Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System. Birnkrant, DB; Chan-Tack, KM; Struble, KA; Truffa, MM, 2007)	0.34
"To assess adverse events associated with antiretroviral regimens for human immunodeficiency virus (HIV) postexposure prophylaxis (PEP), with a particular focus on the treatment combination of zidovudine, lamivudine, and tenofovir (ZDV-3TC-TDF)."	( Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus. Antenozzi, S; Hulse, S; Luque, A; Shahzad, U; Smith, B; Tanzman, E; Wang, D, 2007)	0.34
"Retrospective chart review for individuals who received HIV PEP for occupational and nonoccupational exposure, and multivariate analyses to identify risk factors for noncompletion of PEP and adverse events associated with PEP."	( Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus. Antenozzi, S; Hulse, S; Luque, A; Shahzad, U; Smith, B; Tanzman, E; Wang, D, 2007)	0.34
"Preventive treatment of adverse events may be necessary to ensure completion of HIV PEP."	( Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus. Antenozzi, S; Hulse, S; Luque, A; Shahzad, U; Smith, B; Tanzman, E; Wang, D, 2007)	0.34
"A tenofovir DF expanded access program (EAP) was initiated in 2001; safety data were examined from this program and from the manufacturer's database, which contained reports of all postmarketing adverse drug reactions received up to 30 April 2005."	( The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. Bischofberger, N; Chen, SS; Clotet, B; Cooper, DA; Curtis, S; Gazzard, B; Katlama, C; Lange, J; Lazzarin, A; Montaner, JS; Nelson, MR; Rooney, JF; Schewe, K; Smith, S; Wyatt, C, 2007)	0.34
"The EAP enrolled 10 343 patients; serious adverse events (SAEs) were reported in 631 (6%)."	( The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. Bischofberger, N; Chen, SS; Clotet, B; Cooper, DA; Curtis, S; Gazzard, B; Katlama, C; Lange, J; Lazzarin, A; Montaner, JS; Nelson, MR; Rooney, JF; Schewe, K; Smith, S; Wyatt, C, 2007)	0.34
"The SCOLTA Project is a prospective, observational, multicenter study involving 25 infectious disease departments in Italy created to assess the incidence of severe adverse events in patients receiving new antiretroviral drugs."	( Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project. Bonfanti, P; Carradori, S; De Socio, GV; Grosso, C; Landonio, S; Madeddu, G; Marconi, P; Melzi, S; Miccolis, S; Mura, MS; Penco, G; Quirino, T; Ricci, E; Rosella, E, 2008)	0.35
" No patient discontinued due to renal adverse events."	( The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients. Cassetti, I; Cheng, AK; Enejosa, J; Etzel, A; Madruga, JV; Suleiman, JM; Zhong, L, )	0.13
" TDF treatment was not associated with renal adverse events or limb fat loss in antiretroviral-naïve patients."	( The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients. Cassetti, I; Cheng, AK; Enejosa, J; Etzel, A; Madruga, JV; Suleiman, JM; Zhong, L, )	0.13
"Simplification to a once-daily regimen containing TDF, 3TC, and EFV is virologically and immunologically effective, well-tolerated, and safe with benefits in the lipid profile in the majority of patients."	( Effectiveness and safety of simplification therapy with once-daily tenofovir, lamivudine, and efavirenz in HIV-1-infected patients with undetectable plasma viral load on HAART. Aguirrebengoa, K; Alvarez, ML; Arazo, P; Arrizabalaga, J; Chocarro, A; Echevarría, S; Fariñas, MC; Ferrer, P; García-Palomo, D; Iribarren, JA; Labarga, P; Letona, S; Muñoz-Sánchez, MJ; Oteo, JA; Peralta, G; Pinilla, J; Uriz, J, )	0.13
" All other combinations exhibited more pronounced adverse effects on mitochondrial endpoints."	( Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. Melkaoui, K; Setzer, B; Venhoff, N; Walker, UA, 2007)	0.34
"Changing from drugs that have significant mitochondrial toxicity to less toxic compounds may be of benefit in human immunodeficiency virus (HIV)-positive patients who receive highly active antiretroviral therapy."	( Effects of the change from Stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function. Cossarizza, A; Dentone, C; Di Biagio, A; Esposito, R; Ferraresi, R; Mussini, C; Nasi, M; Nemes, E; Pinti, M; Repetto, E; Rosso, R; Viscoli, C, 2008)	0.35
" A relatively uncommon adverse effect of this drug is Fanconi syndrome."	( Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. Gupta, SK, 2008)	0.35
" Symptoms disappeared after discontinuation of antiretroviral therapy and we suggest that syncope may be a side effect to one of the three antiretroviral drugs that has not been described previously."	( Syncope as a probable side effect to combination antiretroviral therapy initiated during primary HIV-1 infection. Larsen, CS; Lybaek, D, 2008)	0.35
"100 patients were evaluated; 17 patients discontinued early including 6 for adverse events."	( Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily. Cohen, C; Ebrahimi, R; Elion, R; Fisher, A; Flaherty, J; Kearney, B; McColl, D; Ortiz, R; Reddy, YS; Ruane, P; Ward, D, )	0.13
"In two randomized, controlled trials, small differences in glomerular filtration rate over time were noted but no clinically relevant renal disease or adverse events were demonstrated in antiretroviral-naive patients treated with TDF through 144 weeks."	( The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. Chen, SS; Cheng, AK; DeJesus, E; Enejosa, JV; Gallant, JE; Pozniak, AL; Winston, JA, 2008)	0.35
" Although frequency of severe renal toxicity was higher than has been reported in the literature, it was safe in patients with no comorbid renal conditions."	( Effectiveness and safety of generic fixed-dose combination of tenofovir/emtricitabine/efavirenz in HIV-1-infected patients in Western India. Bele, V; Dravid, A; Gupte, N; Joshi, K; Pujari, S, 2008)	0.35
"To identify adverse effects of tenofovir use during pregnancy in HIV-infected women and their infants."	( Adverse effects of tenofovir use in HIV-infected pregnant women and their infants. Hayes, E; Mondy, K; Nurutdinova, D; Onen, NF; Overton, ET, 2008)	0.35
" Each woman's chart was reviewed for clinical data and adverse events during the pregnancy; each infant's chart was reviewed for growth parameters from birth to 12 months."	( Adverse effects of tenofovir use in HIV-infected pregnant women and their infants. Hayes, E; Mondy, K; Nurutdinova, D; Onen, NF; Overton, ET, 2008)	0.35
"The use of nucleoside analogues, especially that of thymidine analogues, depletes mitochondrial DNA, which is the cause of many of the adverse effects of this family of antiretroviral drugs, among them lipodystrophy."	( [Tenofovir as a strategy to avoid or limit adverse effects]. Portilla, J, 2008)	0.35
"Lipoatrophy is the most stigmatizing side effect of stavudine therapy."	( Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study). Castella, E; Crespo, M; Curran, A; Del Saz, SV; Diaz, M; Falcó, V; Feijoo, M; García-Arumí, E; Ocaña, I; Pahissa, A; Paradiñeiro, JC; Planas, M; Puiggròs, C; Ribera, E; Sauleda, S; Sureda, D, )	0.13
" Significantly fewer drug-related clinical adverse events occurred in patients on raltegravir (n=124 [44."	( Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Barnard, RJ; Berger, DS; DeJesus, E; DiNubile, MJ; Lazzarin, A; Leavitt, R; Lennox, JL; Madruga, JV; Miller, MD; Nguyen, BY; Pollard, RB; Rodgers, AJ; Sklar, P; Williams-Diaz, A; Xu, X; Zhao, J, 2009)	0.35
" Data on CD4 cell count, HIV viral load, metabolic parameters and adverse events of grade 3-4 are collected through an on-line system every six months."	( Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study. Abeli, C; Bonfanti, P; Gianelli, E; Giuntini, R; Grosso, C; Madeddu, G; Marconi, P; Martinelli, C; Palvarini, L; Pellicano, G; Penco, G; Quirino, T; Ricci, E; Vichi, F, 2010)	0.36
"Our results suggest that, in unselected clinical settings, ATV-containing antiretroviral therapy is durable and safe in both its formulations."	( Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study. Abeli, C; Bonfanti, P; Gianelli, E; Giuntini, R; Grosso, C; Madeddu, G; Marconi, P; Martinelli, C; Palvarini, L; Pellicano, G; Penco, G; Quirino, T; Ricci, E; Vichi, F, 2010)	0.36
" Treatment-related gastrointestinal adverse events were greater in patients taking lopinavir/ritonavir."	( Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. Absalon, J; Andrade-Villanueva, J; Chetchotisakd, P; Corral, J; David, N; Echevarria, J; Lataillade, M; Mancini, M; McGrath, D; Molina, JM; Moyle, G; Percival, L; Wirtz, V; Yang, R, 2010)	0.36
" Atazanavir/ritonavir had a better lipid profile and fewer gastrointestinal adverse events than lopinavir/ritonavir."	( Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. Absalon, J; Andrade-Villanueva, J; Chetchotisakd, P; Corral, J; David, N; Echevarria, J; Lataillade, M; Mancini, M; McGrath, D; Molina, JM; Moyle, G; Percival, L; Wirtz, V; Yang, R, 2010)	0.36
" The adverse event rate was similar between arms (except drug hypersensitivity, reported more in the abacavir/lamivudine arm)."	( Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. Branco, T; Cavassini, M; Domingo, P; Fisher, M; Givens, N; Khuong-Josses, MA; Lim, ML; Moyle, GJ; Norden, AG; Pearce, HC; Podzamczer, D; Post, FA; Rieger, A; Stellbrink, HJ; Vavro, C, 2010)	0.36
" No increase in the overall adverse event rates was observed."	( Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Abdool Karim, Q; Abdool Karim, SS; Arulappan, N; Baxter, C; Frohlich, JA; Gengiah, TN; Grobler, AC; Kharsany, AB; Maarschalk, S; Mansoor, LE; Mlisana, KP; Mlotshwa, M; Morris, L; Omar, Z; Sibeko, S; Taylor, D, 2010)	0.36
" Through 96 weeks, 77 subjects from each group discontinued prematurely; adverse or HIV-related events contributed to discontinuation of 36 subjects overall, with no significant differences between treatment groups."	( Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized t Bernstein, B; Cohen, D; da Silva, B; Fredrick, L; González-García, J; Johnson, M; Naylor, C; Sloan, L, 2010)	0.36
" Renal biopsy revealed toxic acute tubular necrosis, with distinctive proximal tubular eosinophilic inclusions representing giant mitochondria visible by light microscopy."	( Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. D'Agati, VD; Herlitz, LC; Markowitz, GS; Mohan, S; Radhakrishnan, J; Stokes, MB, 2010)	0.36
" There were no significant adverse effects from these drugs and no alteration of renal function during the follow-up period."	( Efficacy and safety of entecavir and/or tenofovir for prophylaxis and treatment of hepatitis B recurrence post-liver transplant. de la Cruz-Lombardo, J; Jiménez-Pérez, M; Lozano-Rey, JM; Mongil Poce, L; Rodrigo-López, JM; Sáez-Gómez, AB, 2010)	0.36
"Therapy with ETV and/or TDF seems to be efficient and safe when used in the prophylaxis and treatment of HBV recurrence after liver transplantation."	( Efficacy and safety of entecavir and/or tenofovir for prophylaxis and treatment of hepatitis B recurrence post-liver transplant. de la Cruz-Lombardo, J; Jiménez-Pérez, M; Lozano-Rey, JM; Mongil Poce, L; Rodrigo-López, JM; Sáez-Gómez, AB, 2010)	0.36
" Ten percent (13/123) of the subjects discontinued the treatment due to adverse events."	( Evaluation of the safety and effectiveness of nevirapine plus coformulated tenofovir/emtricitabine as first-line therapy in routine clinical practice. Blanch, J; Cervantes, M; Domingo, P; Ferrer, E; Knobel, H; Llibre, JM; Mallolas, J; Pedrol, E; Vallecillo, G, 2012)	0.38
" All regimens were safe and well tolerated."	( Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants. Bardeguez, A; Cotter, A; Fiscus, SA; Flynn, PM; Heckman, B; Huang, S; Jean-Philippe, P; Kearney, B; Mirochnick, M; Mofenson, LM; Purswani, M; Robbins, B; Rodman, J; Rooney, JF; Shapiro, DE; Thorpe, E; Van Rompay, KK; Watts, DH, 2011)	0.37
" The occurrence of treatment-related, moderate/severe adverse events was similar between treatment groups through 48 weeks of treatment."	( Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results. Fredrick, LM; Gathe, J; Lawal, A; Nilius, AM; Podsadecki, TJ; Pulido, F; Reynes, J; Soto-Malave, R; Tian, M, )	0.13
"US-based prospective cohort study of HEU children to examine potential adverse effects of prenatal TDF exposure."	( Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. DiMeglio, LA; Griner, R; Hazra, R; Jacobson, DL; Kacanek, D; Mendez, H; Miller, T; Mofenson, LM; Rich, KC; Seage, GR; Siberry, GK; Tassiopoulos, K; Watts, DH; Williams, PL, 2012)	0.38
" Several studies suggest that NAs long-term administration have been associated with low rates of serious adverse events (AEs), including lactic acidosis, renal function impairment, osteopenia and osteoporosis."	( Safety of long-term nucleos(t)ide treatment in chronic hepatitis B. Ridruejo, E; Silva, MO, 2012)	0.38
" There was no significant increase of any genital adverse event in the tenofovir group."	( Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial. Baxter, C; Frolich, J; Grobler, A; Karim, QA; Karim, SS; Kharsany, AB; Maarshalk, S; Mansoor, LE; Miya, N; Mlisana, K; Sibeko, S; Sokal, DC; Yende-Zuma, N, 2013)	0.39
" With the increased realization of receptive anal intercourse among heterosexual couples often in conjunction with vaginal intercourse, having a safe and effective microbicide for both mucosal sites is critical."	( Safety and efficacy of tenofovir/IQP-0528 combination gels - a dual compartment microbicide for HIV-1 prevention. Buckheit, KW; Buckheit, RW; Dezzutti, CS; Gwozdz, G; Mahalingam, A; Shetler, C; Ugaonkar, SR, 2012)	0.38
" Safety endpoints included clinical adverse events (AEs) and mucosal safety parameters."	( RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate. Anton, PA; Bumpus, NN; Carballo-Diéguez, A; Cranston, RD; Cumberland, WG; Dennis, R; Elliott, J; Hendrix, CW; Janocko, L; Ju, C; Kashuba, A; Khanukhova, E; Mauck, C; McGowan, I; Richardson-Harman, N, 2012)	0.38
" The rings were safe and exhibited sustained release at controlled rates over 28 days."	( Safety and pharmacokinetics of intravaginal rings delivering tenofovir in pig-tailed macaques. Baum, MM; Butkyavichene, I; Cortez, C; Gilman, J; Guenthner, P; Hendry, RM; Holder, A; Kennedy, S; Kopin, E; Malone, AM; Martin, A; McNicholl, J; Mitchell, J; Moss, JA; Nguyen, C; Pau, CP; Sinha, P; Smith, JM; Smith, TJ; Srinivasan, P, 2012)	0.38
" Laboratory test results, clinical outcomes, and drug-related adverse events were compared among groups."	( Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. Akbal, E; Akin, E; Alkan, E; Ataseven, H; Aygün, C; Başar, O; Baykal, O; Coban, S; Demir, M; Gülşen, MT; Ibiş, M; Koçkar, MC; Köklü, S; Köksal, AŞ; Küçükazman, M; Nadir, I; Ozdil, K; Pürnak, T; Tuna, Y; Yildirim, B; Yüksel, I; Yüksel, O, 2013)	0.39
"Tenofovir and entecavir are effective and safe for long-term use in patients with compensated or decompensated cirrhosis from HBV infection."	( Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. Akbal, E; Akin, E; Alkan, E; Ataseven, H; Aygün, C; Başar, O; Baykal, O; Coban, S; Demir, M; Gülşen, MT; Ibiş, M; Koçkar, MC; Köklü, S; Köksal, AŞ; Küçükazman, M; Nadir, I; Ozdil, K; Pürnak, T; Tuna, Y; Yildirim, B; Yüksel, I; Yüksel, O, 2013)	0.39
" Overall incidences of all-causality treatment-related or grade 3/4 adverse events (AEs) or AE-related discontinuations were lower with lersivirine than with efavirenz, and serious AEs occurred at similar rates across treatment groups."	( Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial. Cooper, DA; Craig, C; Goodrich, J; Kaplan, R; Lazzarin, A; Mori, J; Pozniak, A; Pulik, P; Tawadrous, M; Valdez, H; Vernazza, P; Wang, C; Weil, E, 2013)	0.39
" No severe adverse events associated with entecavir or tenofovir were reported."	( Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice. Arenas, J; Canós, AP; Díaz-Sánchez, A; Jiménez, M; Miquel, M; Núñez, Ó; Trapero-Marugán, M, )	0.13
"Overall, 71 of 281 raltegravir recipients (25%) and 98 of 282 efavirenz recipients (35%) discontinued the study; discontinuations due to adverse events occurred in 14 (5%) and 28 (10%) patients in the respective groups."	( Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. DeJesus, E; DiNubile, MJ; Leavitt, R; Lennox, JL; Miller, M; Nguyen, BY; Rockstroh, JK; Rodgers, AJ; Saag, MS; Sklar, P; Teppler, H; Walker, ML; Wan, H; Yazdanpanah, Y, 2013)	0.39
" Over the entire study, fewer patients experienced neuropsychiatric and drug-related adverse events in the raltegravir group than in the efavirenz group."	( Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. DeJesus, E; DiNubile, MJ; Leavitt, R; Lennox, JL; Miller, M; Nguyen, BY; Rockstroh, JK; Rodgers, AJ; Saag, MS; Sklar, P; Teppler, H; Walker, ML; Wan, H; Yazdanpanah, Y, 2013)	0.39
" HIV serostatus, clinical and laboratory adverse events (AEs), adherence (pill count, Medication Event Monitoring System, and self-report), and sexual and other sociobehavioral data were assessed at 3-month intervals for 24 months."	( Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. Ackers, ML; Buchbinder, SP; Chillag, KL; Collins, BM; Grant, RM; Grohskopf, LA; Gvetadze, R; Liu, AY; Mayer, KH; Oʼhara, B; Pathak, SR; Paxton, LA; Rose, CE; Thompson, M, 2013)	0.39
" There were no significant differences between the numbers of ≥ Grade 2 adverse events across the arms of the study."	( A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007). Andrew, P; Ayudhya, RK; Carballo-Dieguez, A; Cranston, RD; Dai, JY; Hladik, F; Hoesley, C; Janocko, L; Mayer, K; McGowan, I; Piper, J, 2013)	0.39
"The reduced glycerin formulation of tenofovir 1% gel was safe and well tolerated rectally and should be advanced to Phase 2 development."	( A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007). Andrew, P; Ayudhya, RK; Carballo-Dieguez, A; Cranston, RD; Dai, JY; Hladik, F; Hoesley, C; Janocko, L; Mayer, K; McGowan, I; Piper, J, 2013)	0.39
" We compared rates of upper digestive serious adverse events (sAEs) between TDF/FTC+EFV and TDF/FTC+ZDV patients during the first six months of treatment."	( Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts. Anglaret, X; Bohoussou, F; Carrou, JL; Danel, C; Eholie, SP; Gabillard, D; Konan, R; Moh, R; Ouattara, E; Peytavin, G, 2013)	0.39
" We suggest that further early prescriptions of TDF+XTC+ZDV should be carefully monitored and that whenever possible, the rate of early upper digestive adverse events should be compared to that occurring in-patients taking other drug regimens."	( Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts. Anglaret, X; Bohoussou, F; Carrou, JL; Danel, C; Eholie, SP; Gabillard, D; Konan, R; Moh, R; Ouattara, E; Peytavin, G, 2013)	0.39
"There were no colposcopic findings or adverse events attributable to either applicator."	( A randomized, comparative safety study of a prefilled plastic and user-filled paper applicator with candidate microbicide tenofovir 1% gel. Brache, V; Callahan, M; Cochon, L; Cohen, JA; Foster, J; Schwartz, J, 2013)	0.39
" Tenofovir gel, when used intermittently, was safe to use in women with HBV infection."	( Safety of coitally administered tenofovir 1% gel, a vaginal microbicide, in chronic hepatitis B virus carriers: results from the CAPRISA 004 trial. Abdool Karim, Q; Abdool Karim, SS; Baxter, C; Tshabalala, P; Yende-Zuma, N, 2013)	0.39
"Combined prophylaxis with TDF/ETV nucleoside plus nucleotide analogs and cessation of immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective."	( Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective. Braat, AE; Claas, EC; Coenraad, MJ; Knoester, M; van Hoek, B; Vossen, AC; Wesdorp, DJ, 2013)	0.39
" We assessed adherence (compared between groups and with nonstudy controls) and clinical and adverse events at weeks 1, 2 and 4, and efficacy at week 12."	( Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence. Carr, A; Ingersoll, A; McAllister, J; McNulty, A; Read, P; Tong, WW, 2014)	0.4
" Although information is limited, TDF appears to be safe during pregnancy."	( Safety of tenofovir during pregnancy for the mother and fetus: a systematic review. Bulterys, M; Ellington, S; Kourtis, AP; Legardy-Williams, J; Wang, L, 2013)	0.39
"6% interrupted cART due to adverse events,19."	( Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study. Aguirrebengoa, K; Arazo, P; Blanco, JR; Caro-Murillo, AM; Castaño, MA; Domingo, P; Ferrer, P; Gómez-Sirvent, JL; Olalla, J; Pedrol, E; Portilla, J; Pulido, F; Riera, M; Romero-Palacios, A; Vera, F, )	0.13
"In a population of HIV-infected subjects who were ≥50 years old, our study suggests that the use of FTC/TDF is generally safe and effective, with a longer persistence as compared to other regimens."	( Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study. Aguirrebengoa, K; Arazo, P; Blanco, JR; Caro-Murillo, AM; Castaño, MA; Domingo, P; Ferrer, P; Gómez-Sirvent, JL; Olalla, J; Pedrol, E; Portilla, J; Pulido, F; Riera, M; Romero-Palacios, A; Vera, F, )	0.13
"Due to ongoing neuropsychiatric adverse events in some efavirenz (EFV)-treated patients, a switch to an alternative non-nucleoside reverse transcriptase inhibitor may be considered."	( Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens. Brinson, C; Cheng, AK; Chuck, SK; Cohen, C; Dejesus, E; Mills, AM; Ramanathan, S; Wang, MH; White, K; Williams, S; Yale, KL, )	0.13
" No subjects discontinued the study due to an adverse event."	( Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens. Brinson, C; Cheng, AK; Chuck, SK; Cohen, C; Dejesus, E; Mills, AM; Ramanathan, S; Wang, MH; White, K; Williams, S; Yale, KL, )	0.13
" No significant adverse event was observed due to TDF administration; renal function pre- and post-LT were also acceptably preserved."	( One year of hepatitis B immunoglobulin plus tenofovir therapy is safe and effective in preventing recurrent hepatitis B post-liver transplantation. Lilly, LB; Renner, EL; Selzner, N; Tanaka, T; Therapondos, G, 2014)	0.4
" Factors associated with these drug-related adverse events are poorly characterized."	( Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events. Baldelli, S; Castagnoli, L; Cattaneo, D; Clementi, E; Fucile, S; Galli, M; Gervasoni, C; Landonio, S; Meraviglia, P; Riva, A; Rizzardini, G, 2013)	0.39
" There were no differences between the groups in terms of adverse events in mothers or congenital deformities, gestational age, height, or weight in infants."	( Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. Ay, M; Ayaz, C; Barcin, T; Celen, MK; Dal, MS; Dal, T; Gulsun, S; Kalkanli, S; Kaya, S; Mert, D; Yildirim, N, 2013)	0.39
"TDF therapy during the second or third trimester reduced perinatal transmission rates of HBV and no adverse events were observed in mothers or infants."	( Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. Ay, M; Ayaz, C; Barcin, T; Celen, MK; Dal, MS; Dal, T; Gulsun, S; Kalkanli, S; Kaya, S; Mert, D; Yildirim, N, 2013)	0.39
" The most commonly observed adverse events were headache, nausea and flatulence, which occurred similarly across the three groups."	( Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. Coakley, D; Kearney, B; Lee, WA; Markowitz, M; Miller, MD; Ruane, P; Squires, K; Wulfsohn, M; Zhong, L; Zolopa, A, 2014)	0.4
"TDF-based rescue treatment is effective in reducing HBV DNA levels and is safe for patients with CHB who failed prior antiviral treatments."	( Efficacy and safety of tenofovir-based rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure. Byun, KS; Choe, WH; Kim, JH; Kim, YS; Kwon, SY; Lee, CH; Lee, CI; Yeon, JE; Yoon, EL, 2014)	0.4
" Most adverse events were mild in severity and considered unrelated to study drug."	( Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings. Bae, H; Chan, S; Lou, L; Pan, CQ; Trinh, H; Yao, A, 2014)	0.4
" Tenofovir released from TDF undergoes active renal secretion via organic anion transporters (OAT1 and OAT3), leading to higher exposure of renal proximal tubules to tenofovir and a potential for renal adverse effects in a small subset of TDF-treated patients."	( Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity. Bam, RA; Cihlar, T; Yant, SR, 2014)	0.4
"TDF and ETV are similarly effective and safe in chronic HBV patients after 24 weeks and 48 weeks of anti-viral therapy."	( Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis. Gao, Y; Ke, W; Liu, L; Yang, Y; Ye, X; Zhang, C; Zhou, S, 2014)	0.4
" No adverse events were observed, and there were no toxicological findings."	( Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model. Baum, MM; Brooks, AA; Butkyavichene, I; Dinh, CT; Lopez, G; Martin, A; Moss, JA; Smith, JM; Smith, TJ; Srinivasan, P, 2014)	0.4
" Combination therapy with tenofovir plus entecavir in this setting with multidrug resistance is safe and effective."	( Efficacy and safety of tenofovir in a kidney transplant patient with chronic hepatitis B and nucleos(t)ide multidrug resistance: a case report. Shan, C; Wu, P; Yin, GQ, 2014)	0.4
" Bayesian fixed-effect network meta-analysis models adjusting for the type of nucleoside reverse transcriptase inhibitor backbone (tenofovir disoproxil fumarate/emtricitabine [TDF/FTC] or abacavir/lamivudine [ABC/3TC]) were used to evaluate week 48 efficacy (HIV-RNA suppression to <50 copies/mL and change in CD4+ cells/µL) and safety (lipid changes, adverse events, and discontinuations due to adverse events) of DTG relative to all other treatments."	( 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis. Camejo, RR; Cuffe, R; Gilchrist, KA; Lim, JW; Nichols, G; Patel, DA; Pulgar, S; Snedecor, SJ; Stephens, J; Sudharshan, L; Tang, WY, 2014)	0.4
" Dolutegravir had better or equivalent changes in total cholesterol, LDL, triglycerides, and lower odds of adverse events and discontinuation due to adverse events compared to all treatments."	( 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis. Camejo, RR; Cuffe, R; Gilchrist, KA; Lim, JW; Nichols, G; Patel, DA; Pulgar, S; Snedecor, SJ; Stephens, J; Sudharshan, L; Tang, WY, 2014)	0.4
" This meta-analysis explored the frequency of discontinuation attributed to renal adverse events (AEs) in randomized, controlled clinical studies that used TDF-containing regimens for ART-naïve, HIV-infected patients."	( Discontinuation of tenofovir disoproxil fumarate for presumed renal adverse events in treatment-naïve HIV-1 patients: meta-analysis of randomized clinical studies. Canada, RB; Chonchol, M; Durr, J; Gallant, J; Hindman, J; Liu, H; Martin, P; Patel, K; Piontkowsky, D; Winston, J, )	0.13
"One of the most common in vitro assays to evaluate the probability of a compound to cause adverse effects is a cytotoxicity assay."	( Intracellular concentrations determine the cytotoxicity of adefovir, cidofovir and tenofovir. Leach, KL; Piotrowski, M; Wang, R; Zhang, H; Zhang, X, 2015)	0.42
" No subject experienced an adverse event that was serious or severe (grade 3/4)."	( Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. Agarwal, K; Cheng, W; Flaherty, JF; Foster, GR; Fung, SK; Gane, EJ; Lawson, E; McHutchison, JG; Nguyen, TT; Ryder, SD; Sicard, E; Subramanian, GM; Zhao, S, 2015)	0.42
"Tenofovir alafenamide was safe and well tolerated; declines in HBV DNA were similar to tenofovir disoproxil fumarate at all doses evaluated."	( Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. Agarwal, K; Cheng, W; Flaherty, JF; Foster, GR; Fung, SK; Gane, EJ; Lawson, E; McHutchison, JG; Nguyen, TT; Ryder, SD; Sicard, E; Subramanian, GM; Zhao, S, 2015)	0.42
" No cases of acute renal failure associated with TDF or LAM, mild or serious adverse events, or HBV recurrence were observed among the patients."	( The efficacy and safety of tenofovir in the prevention of hepatitis B virus recurrence following liver transplantation. Akarsu, M; Astarcıoğlu, İ; Hakim, GD; Karademir, S; Unek, T, 2014)	0.4
"The results of this study, after a 36-month follow-up period, were encouraging and demonstrated that TDF therapy is safe and efficacious in treating HBV-positive organ transplant patients."	( The efficacy and safety of tenofovir in the prevention of hepatitis B virus recurrence following liver transplantation. Akarsu, M; Astarcıoğlu, İ; Hakim, GD; Karademir, S; Unek, T, 2014)	0.4
" No subjects discontinued study drug because of an adverse event in the 48 weeks of randomized phase."	( A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppression. Arterburn, S; Castaño, E; Cheng, AK; Chuck, SL; Church, J; Deville, J; Enejosa, JV; Estripeaut, D; Gaur, A; Rathore, M; Rhee, MS; Saez-Llorens, X; White, K, 2015)	0.42
" No serious adverse event related to tenofovir."	( Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing. Aurpibul, L; Chokephaibulkit, K; Cressey, TR; Phongsamart, W; Sirisanthana, V; Sricharoenchai, S; Sudjaritruk, T; Wittawatmongkol, O, 2015)	0.42
"TDF substitution in children and adolescents who were otherwise stable while receiving a first-line nonnucleoside reverse transcriptase inhibitor-based regimen achieved adequate exposure without clinically significant renal or bone adverse events over 96 weeks."	( Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing. Aurpibul, L; Chokephaibulkit, K; Cressey, TR; Phongsamart, W; Sirisanthana, V; Sricharoenchai, S; Sudjaritruk, T; Wittawatmongkol, O, 2015)	0.42
" The FDA-recommended rabbit vaginal irritation (RVI) model serves as a first line selection tool for vaginal products; however, for decades it has been limited to histopathology scoring, insufficient to select safe anti-HIV microbicides."	( A quantitative multiplex nuclease protection assay reveals immunotoxicity gene expression profiles in the rabbit model for vaginal drug safety evaluation. Chandra, N; Doncel, GF; Fichorova, RN; Mendonca, K; Murray, R; Yamamoto, HS, 2015)	0.42
" Adverse events and serious adverse events were summarised by treatment group."	( Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Amin, J; Belloso, W; Carey, D; Cooper, DA; Crabtree-Ramirez, B; Emery, S; Foulkes, S; Jessen, H; Kumar, S; Lee, MP; Losso, M; Mohapi, L; Phanupak, P; Puls, R; Winston, A, 2015)	0.42
" Adverse events were reported by 291 (91%) of 321 patients in the efavirenz 400 mg group and by 285 (92%) of 309 in the 600 mg group (p=0·48)."	( Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Amin, J; Belloso, W; Carey, D; Cooper, DA; Crabtree-Ramirez, B; Emery, S; Foulkes, S; Jessen, H; Kumar, S; Lee, MP; Losso, M; Mohapi, L; Phanupak, P; Puls, R; Winston, A, 2015)	0.42
" Fewer efavirenz-related adverse events were reported with the 400 mg efavirenz dose than with the 600 mg dose."	( Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Amin, J; Belloso, W; Carey, D; Cooper, DA; Crabtree-Ramirez, B; Emery, S; Foulkes, S; Jessen, H; Kumar, S; Lee, MP; Losso, M; Mohapi, L; Phanupak, P; Puls, R; Winston, A, 2015)	0.42
"Intramuscular hepatitis B immunoglobulin in combination with lamivudine or tenofovir and discontinuation of hepatitis B immunoglobulin after 1 year posttransplant may provide safe and cost-effective protection against posttransplant hepatitis B reinfection."	( Efficacy and safety of lamivudine or tenofovir plus intramuscular hepatitis B immunoglobulin in prevention of hepatitis B virus reinfection after liver transplant. Ahmadinejad, Z; Dashti, H; Jafarian, A; Kasraianfard, A; Moini, M; Najafi, A; Nassiri-Toosi, M; Salimi, J, 2015)	0.42
"All three gels were found to be safe and acceptable."	( A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study). Abebe, K; Anton, PA; Cranston, RD; Dezzutti, CS; Duffill, K; Elliott, J; Engstrom, JC; Hendrix, CW; Hiruy, H; Jacobson, C; Khanukhova, E; Marzinke, MA; Mauck, C; Mcgowan, I; Nikiforov, A; Rehman, KK; Richardson-Harman, N; Rohan, LC; Siegel, A; Spiegel, HM, 2015)	0.42
"All three formulations were found to be safe and acceptable."	( A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study). Abebe, K; Anton, PA; Cranston, RD; Dezzutti, CS; Duffill, K; Elliott, J; Engstrom, JC; Hendrix, CW; Hiruy, H; Jacobson, C; Khanukhova, E; Marzinke, MA; Mauck, C; Mcgowan, I; Nikiforov, A; Rehman, KK; Richardson-Harman, N; Rohan, LC; Siegel, A; Spiegel, HM, 2015)	0.42
" Safety and tolerability were evaluated by the occurrence of adverse events (AEs), serious AEs, laboratory abnormalities, discontinuation of the study drug due to AEs, or death."	( Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B. Bae, H; Chan, S; Lou, L; Pan, CQ; Trinh, H; Yao, A, 2015)	0.42
" There was no case with serious adverse event."	( Virologic response and safety of tenofovir versus entecavir in treatment-naïve chronic Hepatitis B patients. An, SH; Choe, WH; Chung, HA; Jeong, GW; Jeong, TG; Kim, J; Kim, JH; Kwon, SW; Kwon, SY; Min, JK; Yu, HM; Yun, SU, )	0.13
" The study limitations include its retrospective design, the relatively short follow-up, and the absence of data concerning the severity of clinical adverse events; however, it does provide new information concerning the laboratory changes that occur in patients switching from PI-based or PI-sparing regimens to RTE STR."	( Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy. Bossolasco, S; Castagna, A; Cernuschi, M; Cinque, P; Galli, L; Gianotti, N; Lazzarin, A; Maillard, M; Nozza, S; Poli, A; Spagnuolo, V; Tambussi, G, 2015)	0.42
" No adverse effects were observed or dose reductions required associated with ETV or TDF."	( Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients. Abradelo, M; Calvo, J; Cambra, F; Castellano, G; Fernández, I; García, A; Hernández, O; Jiménez, C; Loinaz, C; Manrique, A; Manzano, M, 2015)	0.42
"Maintenance therapy with newer NAs, after discontinuation of HBIG prophylaxis, was safe and effective, with a low rate of serological recurrence and no evident clinical, biochemical, or virological consequences."	( Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients. Abradelo, M; Calvo, J; Cambra, F; Castellano, G; Fernández, I; García, A; Hernández, O; Jiménez, C; Loinaz, C; Manrique, A; Manzano, M, 2015)	0.42
" Most of the adverse events were mild in severity."	( Efficacy and safety of tenofovir in nucleos(t)ide-naïve patients with genotype C chronic hepatitis B in real-life practice. Byun, SS; Jung, SW; Kim, CJ; Kim, JH; Kim, MH; Park, BR; Park, NH; Shin, JW, 2015)	0.42
" Safety data were consistent with the known TDF safety profile; the most commonly reported adverse events possibly related to TDF were fatigue (2."	( Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany. Boeker, K; Eisenbach, C; Felten, G; Hartmann, H; Heyne, R; Hueppe, D; John, C; Krause, W; Leuschner, M; Loehr, HF; Mauss, S; Petersen, J; Ruppert, S; Schiffelholz, W; Schlaak, J; Trautwein, C; Trein, A; Warger, T; Wiese, M, 2016)	0.43
"There were 43 total, 23 reproductive tract, and eight product-related grade 1 adverse events."	( A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring. Anderson, PL; Atrio, JM; Espinoza, L; Frank, B; Fredricks, DN; Hendrix, CW; Herold, BC; Keller, MJ; Kiser, PF; Lo, Y; Marzinke, MA; Mesquita, PM; Rabe, L; Srinivasan, S; Teller, R, 2016)	0.43
" For any biomedical prevention intervention, the bar for tolerating adverse effects in healthy persons is high compared to therapeutic interventions."	( Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention. Baeten, JM; Mugwanya, KK, 2016)	0.43
"TDF-based pre-exposure prophylaxis is a potent intervention against HIV acquisition when taken which is generally safe and well tolerated."	( Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention. Baeten, JM; Mugwanya, KK, 2016)	0.43
"The aim of this study was to systematically review and critically appraise the literature relating to the reported renal and bone adverse effects of TDF-based regimens in the treatment of HIV-infected children from 2 to 19 years old."	( Renal and Bone Adverse Effects of a Tenofovir-Based Regimen in the Treatment of HIV-Infected Children: A Systematic Review. Effa, EE; Okonkwo, RI; Weidmann, AE, 2016)	0.43
" Data on study characteristics, participant's characteristics, therapeutic intervention and adverse effects were extracted using a piloted tool."	( Renal and Bone Adverse Effects of a Tenofovir-Based Regimen in the Treatment of HIV-Infected Children: A Systematic Review. Effa, EE; Okonkwo, RI; Weidmann, AE, 2016)	0.43
"We identified 19 studies that reported the presence of renal and bone adverse effects of TDF and these included a total of 1100 study participants."	( Renal and Bone Adverse Effects of a Tenofovir-Based Regimen in the Treatment of HIV-Infected Children: A Systematic Review. Effa, EE; Okonkwo, RI; Weidmann, AE, 2016)	0.43
"This systematic review summarises the reports of renal and bone adverse effects of a TDF-containing regimen in the treatment of HIV-infected children."	( Renal and Bone Adverse Effects of a Tenofovir-Based Regimen in the Treatment of HIV-Infected Children: A Systematic Review. Effa, EE; Okonkwo, RI; Weidmann, AE, 2016)	0.43
"Tenofovir disoproxil fumarate is effective and safe for NA-naïve and NA-experienced CHB patients and should be used cautiously in patients with comorbidities because of a renal dysfunction risk."	( Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naïve and nucleos(t)ide analog-experienced chronic hepatitis B patients. Chang, KC; Chen, CH; Hu, TH; Hung, CH; Kee, KM; Lee, CM; Lu, SN; Tseng, PL; Wang, HM; Wang, JH; Yen, YH, 2016)	0.43
"This combination ART regimen is safe and effective for patients with HIV/HBV co-infection."	( Efficacy and Safety of Tenofovir and Lamivudine in Combination with Efavirenz in Patients Co-infected with Human Immunodeficiency Virus and Hepatitis B Virus in China. Cai, WP; He, HL; Huang, SB; Ling, XM; Liu, YF; Wang, H; Wang, M; Wang, XC; Wei, FL; Wu, H; Wu, YS; Wu, ZY; Yang, L; Zhang, FJ; Zhang, WW, 2016)	0.43
"This study indicates that newer antivirals are effective and safe in HTR with CHB."	( Efficacy and safety of tenofovir, entecavir, and telbivudine for chronic hepatitis B in heart transplant recipients. Andini, R; Durante-Mangoni, E; Falco, E; Iossa, D; Maiello, C; Parrella, A; Ragone, E; Utili, R; Vitrone, M; Zampino, R, 2016)	0.43
" However, tenofovir disoproxil fumarate is associated with renal and bone toxic effects; the novel prodrug tenofovir alafenamide achieves 90% lower plasma tenofovir concentrations."	( Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, activ Abram, ME; Brinson, C; Cheng, AK; Clumeck, N; Daar, ES; DeJesus, E; Gallant, JE; Johnson, M; Morales-Ramirez, J; Osiyemi, O; Plummer, A; Raffi, F; Rhee, MS; Ruane, P; Ward, D; Yan, M, 2016)	0.43
" Seven patients in the tenofovir alafenamide (2%) and three (1%) in the tenofovir disoproxil fumarate group discontinued due to adverse events."	( Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, activ Abram, ME; Brinson, C; Cheng, AK; Clumeck, N; Daar, ES; DeJesus, E; Gallant, JE; Johnson, M; Morales-Ramirez, J; Osiyemi, O; Plummer, A; Raffi, F; Rhee, MS; Ruane, P; Ward, D; Yan, M, 2016)	0.43
" This systematic review and meta-analysis evaluated the evidence for use of oral PrEP containing tenofovir disoproxil fumarate as an additional HIV prevention strategy in populations at substantial risk for HIV based on HIV acquisition, adverse events, drug resistance, sexual behavior, and reproductive health outcomes."	( Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. Baggaley, R; Dalglish, SL; Fonner, VA; Grant, RM; Hodges-Mameletzis, I; Kennedy, CE; Koechlin, FM; O'Reilly, KR; Rodolph, M, 2016)	0.43
" Adverse events were similar between PrEP and placebo groups."	( Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. Baggaley, R; Dalglish, SL; Fonner, VA; Grant, RM; Hodges-Mameletzis, I; Kennedy, CE; Koechlin, FM; O'Reilly, KR; Rodolph, M, 2016)	0.43
" There was no statistically significant differences in the risk difference for serious adverse events (5."	( An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy. Behrens, G; Borg, P; Bouee, S; M Llibre, J; Moyle, G; Piontkowsky, D; Raffi, F; Reilly, G; Rogatto, F, 2016)	0.43
" There were no discontinuations due to adverse events."	( Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment. Custodio, JM; Fordyce, M; Garner, W; Kearney, BP; Ling, KH; Ramanathan, S; Vimal, M, 2016)	0.43
" The majority of adverse events (AEs) were infections (N = 56) or gastrointestinal (N = 46) and were mild (69."	( Project Gel a Randomized Rectal Microbicide Safety and Acceptability Study in Young Men and Transgender Women. Brand, RM; Carballo-Diéguez, A; Cranston, RD; Dolezal, C; Duffill, K; Engstrom, JC; Febo, I; Frasca, T; Giguere, R; Jacobson, C; Leu, CS; Mayer, KH; McGowan, I; Nikiforov, A; Park, SY; Schwartz, JL; Siegel, A, 2016)	0.43
" TFV gel was safe and acceptable and should be further developed as an alternative HIV prevention intervention for this population."	( Project Gel a Randomized Rectal Microbicide Safety and Acceptability Study in Young Men and Transgender Women. Brand, RM; Carballo-Diéguez, A; Cranston, RD; Dolezal, C; Duffill, K; Engstrom, JC; Febo, I; Frasca, T; Giguere, R; Jacobson, C; Leu, CS; Mayer, KH; McGowan, I; Nikiforov, A; Park, SY; Schwartz, JL; Siegel, A, 2016)	0.43
" We postulate that this adverse drug reaction may have been secondary to the known interaction between ledipasvir and TDF, which results in increased TDF exposure."	( Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection. Bunnell, KL; Gallagher, MA; Glowacki, RC; Huhn, G; Osei, AM; Vibhakar, S, 2016)	0.43
"WHO recommends tenofovir, efavirenz, and lamivudine or emtricitabine for first-line antiretroviral therapy (ART) in adults, which replaced more toxic regimens using stavudine, zidovudine or nevirapine."	( Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen. Cohen, K; Maartens, G; Mouton, JP, 2016)	0.43
" Secondary endpoints are maternal and infant adverse events, acute exacerbations of maternal hepatitis B disease (ALT >300 IU/L, defined as a "flare") following discontinuation of study treatment, infant HBV infection status and growth up to 12 months of age."	( Prevention of mother-to-child transmission of hepatitis B virus: a phase III, placebo-controlled, double-blind, randomized clinical trial to assess the efficacy and safety of a short course of tenofovir disoproxil fumarate in women with hepatitis B virus Achalapong, J; Bowonwatanuwong, C; Chotivanich, N; Chung, RT; Cressey, TR; Decker, L; Harrison, L; Hongsiriwon, S; Hua, L; Jourdain, G; Khamduang, W; Klinbuayaem, V; Murphy, TV; Ngo-Giang-Huong, N; Pol, S; Puthanakit, T; Salvadori, N; Siberry, GK; Sirirungsi, W; Thongsawat, S; Tierney, C; Traisathit, P; Watts, DH, 2016)	0.43
" Moreover, histological analysis of genital tissues and cytokine/chemokine levels in vaginal lavages upon 14days of daily vaginal administration to mice confirmed that tenofovir-loaded NPs-in-film was safe and did not induce any apparent histological changes or pro-inflammatory response."	( Development and in vivo safety assessment of tenofovir-loaded nanoparticles-in-film as a novel vaginal microbicide delivery system. Araújo, F; Cunha-Reis, C; das Neves, J; Ferreira, D; Machado, A; Nunes, R; Sarmento, B; Seabra, V, 2016)	0.43
" Results, including those from in vivo testing, sustain that the proposed system is safe and holds potential for further development as a vaginal microbicide product."	( Development and in vivo safety assessment of tenofovir-loaded nanoparticles-in-film as a novel vaginal microbicide delivery system. Araújo, F; Cunha-Reis, C; das Neves, J; Ferreira, D; Machado, A; Nunes, R; Sarmento, B; Seabra, V, 2016)	0.43
"TAF has a similar tolerability, safety, and effectiveness to TDF and probably less adverse events related to renal and bone density outcomes in the treatment of naive and experienced patients with HIV-1."	( The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis. Lu, X; Wang, H; Xu, N; Yang, X, 2016)	0.43
" The regimen was well tolerated and no discontinuations related to adverse events occurred."	( Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial. Batra, J; Chakraborty, R; Gaur, AH; Kizito, H; Kosalaraksa, P; Luesomboon, W; Myers, M; Porter, D; Prasitsueubsai, W; Quirk, E; Rakhmanina, N; Rassool, M; Rhee, MS; SenGupta, D; Shao, Y; Ting, L, 2016)	0.43
"To develop a seminal enzyme bioresponsive, mucoadhesive nanofibers (NFs) as safe and effective nanocarriers for the prevention of HIV vaginal transmission."	( Stimuli-sensitive thiolated hyaluronic acid based nanofibers: synthesis, preclinical safety and in vitro anti-HIV activity. Agrahari, V; Christenson, LK; Dim, DC; Ezoulin, MJ; Hung, WT; Meng, J; Molteni, A; Youan, BC; Youm, I, 2016)	0.43
"HA-SH-NFs developed in this study could potentially serve as a safe nanotemplate for topical intravaginal delivery of HIV/AIDS microbicides."	( Stimuli-sensitive thiolated hyaluronic acid based nanofibers: synthesis, preclinical safety and in vitro anti-HIV activity. Agrahari, V; Christenson, LK; Dim, DC; Ezoulin, MJ; Hung, WT; Meng, J; Molteni, A; Youan, BC; Youm, I, 2016)	0.43
" Relevant articles were hand-searched for renal (Grade 3-4 serum creatinine/estimated glomerular filtration rate elevations, renal adverse events [AEs], discontinuation due to renal AEs, and urinary biomarkers) and bone outcomes (bone mineral density [BMD] reductions, bone turnover markers, and fracture), and results compiled qualitatively."	( Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection. Bedimo, R; Myers, J; Rosenblatt, L, 2016)	0.43
"We reviewed research reports/conference abstracts with maternal/child adverse outcome data in HIV-infected and HIV-uninfected pregnant/lactating women receiving TDF alone or in combination with other drugs compared with non-TDF regimens."	( Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding. Baggaley, RC; Mameletzis, I; Mofenson, LM, 2017)	0.46
"Long-term TDF treatment appears to be safe and effective in patients with prior failure of LAM and a suboptimal response to ADV therapy."	( Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy. Angus, P; Bowden, S; Desmond, P; George, J; Lee, A; Lim, L; Locarnini, S; Marion, K; Nicoll, A; Patterson, S; Roberts, S; Sievert, W; Strasser, S; Thompson, A, 2017)	0.46
"To improve biosafety of clinical analysis, we used antiviral drugs of adefovir and tenofovir as model drugs and developed a safe pretreatment method combining sealing technique with direct injection technique."	( A novel pretreatment method combining sealing technique with direct injection technique applied for improving biosafety. An, J; Du, C; Gao, JL; Jiang, Y; Li, M; Ma, H; Wang, X; Zhang, L, 2017)	0.46
" Safe and acceptable topical HIV prevention methods that target the rectum are needed."	( MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel. Bekker, LG; Carballo-Diéguez, A; Chariyalertsak, S; Chitwarakorn, A; Cranston, RD; Galaska, B; Gonzales, P; Grossman, C; Hendrix, CW; Ho, KS; Holtz, TH; Jacobson, CE; Johnson, S; Kunjara Na Ayudhya, RP; Lama, JR; Leu, CS; Liu, AY; Liu, K; Lucas, J; Marzinke, MA; Mayer, KH; McGowan, I; Parikh, UM; Patterson, KB; Pickett, J; Piper, JM; Richardson, BA; Rooney, J; Schwartz, JL; Zorrilla, C, 2017)	0.46
"Rectal application of RG TFV gel was safe in MSM and TGW."	( MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel. Bekker, LG; Carballo-Diéguez, A; Chariyalertsak, S; Chitwarakorn, A; Cranston, RD; Galaska, B; Gonzales, P; Grossman, C; Hendrix, CW; Ho, KS; Holtz, TH; Jacobson, CE; Johnson, S; Kunjara Na Ayudhya, RP; Lama, JR; Leu, CS; Liu, AY; Liu, K; Lucas, J; Marzinke, MA; Mayer, KH; McGowan, I; Parikh, UM; Patterson, KB; Pickett, J; Piper, JM; Richardson, BA; Rooney, J; Schwartz, JL; Zorrilla, C, 2017)	0.46
"Switching from ATV/r to unboosted ATV appears to be safe and effective in selected virologically suppressed patients receiving TDF-containing regimens, and may have favorable effects on bilirubin and renal function."	( Efficacy and safety of "unboosting" atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF. Ganase, B; Guillemi, SA; Harrigan, PR; Harris, M; Hull, MW; Saeedi, R; Watson, B; Zhang, W, 2017)	0.46
"Tenofovir (TDF) has been associated with renal function deterioration, but local data regarding the incidence and risk factors for this adverse event were lacking."	( Tenofovir-induced nephrotoxicity: A retrospective cohort study. Koh, HM; Suresh, K, 2016)	0.43
" Given that the use of tenofovir is escalating in Malaysia, increased awareness about this adverse event is essential."	( Tenofovir-induced nephrotoxicity: A retrospective cohort study. Koh, HM; Suresh, K, 2016)	0.43
" We reviewed participants weekly for the first month for adverse events followed by 4 weekly visits for renal function assessment, adverse event monitoring and adherence."	( Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial. Decloedt, EH; Joska, JA; Lesosky, M; Maartens, G, 2017)	0.46
"Our results demonstrate the efficacy of switching to TDF monotherapy in virologically suppressed CHB patients receiving long-term LAM+ADV therapy, with a low rate of adverse events."	( Long-term efficacy and safety of switching from lamivudine+adefovir to tenofovir disoproxil fumarate in virologically suppressed patients. Angarano, G; Fasano, M; Fiore, JR; Leone, A; Maggi, P; Santantonio, TA; Volpe, A, 2017)	0.46
"There are limited data on adverse effects of tenofovir disoproxil fumarate (TDF)-based antiretroviral therapy (ART) on pregnant women and their infants."	( Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis. Anderson, JR; Doherty, MC; Essajee, S; Ford, N; Kanters, S; Mills, EJ; Mofenson, LM; Nachega, JB; Renaud, F; Uthman, OA, 2017)	0.46
"We conducted a systematic review of studies published between January 1980 and January 2017 that compared adverse outcomes in HIV-infected women receiving TDF- vs."	( Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis. Anderson, JR; Doherty, MC; Essajee, S; Ford, N; Kanters, S; Mills, EJ; Mofenson, LM; Nachega, JB; Renaud, F; Uthman, OA, 2017)	0.46
"TDF-based ART in pregnancy seems generally safe for women and their infants."	( Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis. Anderson, JR; Doherty, MC; Essajee, S; Ford, N; Kanters, S; Mills, EJ; Mofenson, LM; Nachega, JB; Renaud, F; Uthman, OA, 2017)	0.46
" Concerning safety, the study found that no adverse events were observed during the 48 weeks."	( Efficacy and Safety of Tenofovir Disoproxil Treatment for Chronic Hepatitis B Patients with Genotypic Resistance to Other Nucleoside Analogues: A Prospective Study. Huang, JR; Lian, JS; Liu, YY; Pan, LF; Yang, JL; Zhou, J, 2017)	0.46
"TDF monotherapy is an effective and safe salvage treatment for CHB patients who are resistant to other NAs."	( Efficacy and Safety of Tenofovir Disoproxil Treatment for Chronic Hepatitis B Patients with Genotypic Resistance to Other Nucleoside Analogues: A Prospective Study. Huang, JR; Lian, JS; Liu, YY; Pan, LF; Yang, JL; Zhou, J, 2017)	0.46
" In this report, we use metabolomics and proteomics with HK-2 cells and animal models to dissect the molecular pathways underlying nephropathy caused by TFV and its more toxic analog, adefovir (ADV)."	( Tenofovir and adefovir down-regulate mitochondrial chaperone TRAP1 and succinate dehydrogenase subunit B to metabolically reprogram glucose metabolism and induce nephrotoxicity. Chen, J; Chen, L; Cheng, L; Chi, W; Deng, H; Huo, Y; Lan, Z; Liu, X; Siegenthaler, JA; Song, W; Sun, K; Xu, L; Zhao, X, 2017)	0.46
" Tenofovir is safe and tolerable for both the mother and foetus."	( Systematic review with meta-analysis: the efficacy and safety of tenofovir to prevent mother-to-child transmission of hepatitis B virus. Byun, KS; Hyun, MH; Je, JH; Kim, JH; Lee, YS; Yeon, JE; Yoo, YJ, 2017)	0.46
" Phase II and III randomized clinical trials evaluate the efficacy and safety of EVG/c/TAF/FTC and tenofovir disoproxil fumerate (TDF)-containing arms; renal impairment, bone mineral density, metabolic effects, and other adverse events are topics explored within this review."	( A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection. Angione, SA; Cherian, SM; Özdener, AE, 2018)	0.48
" The most common adverse events were diarrhea, nausea, and headache."	( A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection. Angione, SA; Cherian, SM; Özdener, AE, 2018)	0.48
" Data seem to suggest it may also be effective and safe in patients with mild to moderate renal impairment."	( A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection. Angione, SA; Cherian, SM; Özdener, AE, 2018)	0.48
"Patients initiating EVG/COBI/FTC/TDF were enrolled in the SCOLTA project, a multicenter observational study reporting grade 3-4 Adverse Events in subjects beginning new antiretroviral drug regimens."	( Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project. Bandera, A; Bonfanti, P; Calza, L; Carenzi, L; Celesia, BM; Cordier, L; De Socio, GV; Di Biagio, A; Falasca, K; Gori, A; Madeddu, G; Maggi, P; Martinelli, C; Orofino, G; Pellicanò, GF; Quirino, T; Ricci, E; Rusconi, S; Squillace, N; Vichi, F, 2017)	0.46
" However, TDF induced more drug-related adverse events (OR = 2."	( Efficacy and safety of tenofovir disoproxil fumarate in preventing vertical transmission of hepatitis B in pregnancies with high viral load. Chen, JQ; Chen, JZ; Cheng, XY; Huang, FL; Huang, Z; Liao, ZW; Liu, JQ; Su, RK; Wang, WB, 2017)	0.46
" The toxic and genotoxic potential of EFV and TDF alone and in combinations {EFV+combivir [zidovudine (AZT)+lamivudine (3TC)] and TDF+3TC} were assessed using the comet assay and the somatic mutation and recombination test (SMART) in Drosophila melanogaster."	( In vivo genotoxicity evaluation of efavirenz (EFV) and tenofovir disoproxil fumarate (TDF) alone and in their clinical combinations in Drosophila melanogaster. Chen-Chen, L; Cunha, KS; de Jesus Silva Carvalho, C; de Melo E Silva, D; de Moraes Filho, AV; Gonçalves, MW; Rohde, C; Verçosa, CJ, 2017)	0.46
" The safety of RPV/FTC/TDF (incidence of adverse events leading to discontinuation and laboratory abnormalities) and adherence to this regimen were evaluated, and the cost of switching was analysed."	( Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks. Arrabal-Durán, P; Chamorro-de-Vega, E; Gijón-Vidaurreta, P; Herranz-Alonso, A; Rodríguez-González, CG; Sanjurjo-Sáez, M, 2017)	0.46
" However, the relatively high rates of virological failure and treatment discontinuation because of adverse events make this combination a less favourable choice over other regimens currently available."	( Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks. Arrabal-Durán, P; Chamorro-de-Vega, E; Gijón-Vidaurreta, P; Herranz-Alonso, A; Rodríguez-González, CG; Sanjurjo-Sáez, M, 2017)	0.46
" However, the overall impact of this adverse effect has not comprehensively evaluated."	( Reversal of tenofovir induced nephrotoxicity: case reports of two patients. Chesire, E; Kigen, G; Koech, M; Some, F, 2017)	0.46
" Numbers of discontinuations related to adverse events (11 [1%] of 763 patients in the study group vs four [1%] of 378 patients in the control group) and grade 3-4 adverse events (52 [7%] patients vs 31 [8%] patients) were similar between the two groups."	( Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppr Arribas, JR; Eron, JJ; Gathe, J; Hufkens, V; Lathouwers, E; Molina, JM; Negredo, E; Opsomer, M; Orkin, C; Petrovic, R; Van Landuyt, E; Vanveggel, S, 2018)	0.48
" Investigators monitored adverse events to assess safety."	( Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Aboud, M; Angelis, K; Blair, EA; Brinson, C; Castelli, F; Gartland, M; Girard, PM; Hung, CC; Kahl, LP; Llibre, JM; Smith, K; Underwood, M; Vandermeulen, K; Wynne, B, 2018)	0.48
" 395 (77%) of 513 participants in the dolutegravir-rilpivirine group and 364 (71%) of 511 participants in the CAR group reported adverse events."	( Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Aboud, M; Angelis, K; Blair, EA; Brinson, C; Castelli, F; Gartland, M; Girard, PM; Hung, CC; Kahl, LP; Llibre, JM; Smith, K; Underwood, M; Vandermeulen, K; Wynne, B, 2018)	0.48
" The form is designed to obtain information on the demographics of the patients, WHO clinical stage of their HIV infection, HAART regimen for the patients, and suspected adverse events associated with the antiretroviral drugs used by the patients."	( A prospective study of adverse events to antiretroviral therapy in HIV- infected adults in Ekiti State, Nigeria. Awodele, O; Oshikoya, KA; Popoola, TD, 2016)	0.43
" About half (57%) of the participants reported clinical adverse events; 92% of which were reported within two weeks of HAART initiation."	( A prospective study of adverse events to antiretroviral therapy in HIV- infected adults in Ekiti State, Nigeria. Awodele, O; Oshikoya, KA; Popoola, TD, 2016)	0.43
"Antiretroviral drugs exposure often presents with adverse events, an observation similar to other studies."	( A prospective study of adverse events to antiretroviral therapy in HIV- infected adults in Ekiti State, Nigeria. Awodele, O; Oshikoya, KA; Popoola, TD, 2016)	0.43
" However, this side effect is not due to a direct dysfunction of the kidneys."	( [Nephrotoxicity of antiretrovirals other than tenofovir]. Amet, S; Deray, G; Isnard-Bagnis, C; Loens, C; Tourret, J, 2018)	0.48
"Tenofovir is less toxic than other nucleoside reverse-transcriptase inhibitors used in antiretroviral therapy (ART) and may improve retention of human immunodeficiency virus (HIV)-infected patients on ART."	( Medication Side Effects and Retention in HIV Treatment: A Regression Discontinuity Study of Tenofovir Implementation in South Africa and Zambia. Bärnighausen, T; Bor, J; Boulle, A; Brennan, AT; Davies, MA; Fatti, G; Fox, MP; Prozesky, H; Sikazwe, I; Stinson, K; Tanser, F; Wandeler, G; Wood, R; Zanolini, A, 2018)	0.48
"1%) experienced ≥1 treatment-emergent adverse event; the majority were mild or moderate in severity."	( Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment. Agarwal, K; Ahn, SH; Andreone, P; Bulusu, A; Cathcart, AL; Chuang, WL; Elkhashab, M; Gaggar, A; Kim, HJ; Lau, AH; Nguyen, MH; Subramanian, GM; Tian, X; Woo, J, 2018)	0.48
" The overall incidence and severity of adverse events was similar between groups, although headache occurred more frequently in the bictegravir group than in the boosted protease inhibitor group."	( Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, ph Andreatta, K; Cheng, A; Creticos, C; Crofoot, G; Custodio, J; Daar, ES; DeJesus, E; Graham, H; Koenig, E; Liu, YP; Martin, H; Molina, JM; Oguchi, G; Quirk, E; Rockstroh, JK; Ruane, P, 2018)	0.48
"Fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide might be a safe and efficacious alternative to continued boosted protease inhibitor therapy in adults with HIV-1 infection."	( Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, ph Andreatta, K; Cheng, A; Creticos, C; Crofoot, G; Custodio, J; Daar, ES; DeJesus, E; Graham, H; Koenig, E; Liu, YP; Martin, H; Molina, JM; Oguchi, G; Quirk, E; Rockstroh, JK; Ruane, P, 2018)	0.48
" We assessed safety by adverse events, colposcopy, vaginal microbiota, epithelial integrity, mucosal histology and immune cell numbers and phenotype, cervicovaginal [CV] cytokines and antimicrobial proteins and changes in systemic laboratory measurements, and LNG and TFV pharmacokinetics in multiple compartments."	( Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women. Asin, SN; Brache, V; Chandra, N; Clark, MR; Dezzutti, CS; Doncel, GF; Fichorova, R; Herold, BC; Hillier, SL; Kiser, P; Marzinke, MA; McCormick, T; Rollenhagen, C; Schwartz, JL; Stanczyk, FZ; Thurman, AR; Weiner, D, 2018)	0.48
" Moreover, tenofovir was safe and tolerable for both mothers and their infants."	( Efficacy and safety of tenofovir in preventing mother-to-infant transmission of hepatitis B virus: a meta-analysis based on 6 studies from China and 3 studies from other countries. Jia, L; Li, W; Tang, H; Wu, X; Zhao, X, 2018)	0.48
" Grade 2 and higher adverse events (AEs) related to study product were compared across study arms using Fisher's exact test."	( FAME-04: A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir. Bunge, KE; Dezzutti, CS; Hendrix, CW; Hillier, SL; Marzinke, MA; Meyn, LA; Moncla, BJ; Richardson-Harman, N; Rohan, LC; Schwartz, JL; Spiegel, HML, 2018)	0.48
"Films were safe and well tolerated."	( FAME-04: A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir. Bunge, KE; Dezzutti, CS; Hendrix, CW; Hillier, SL; Marzinke, MA; Meyn, LA; Moncla, BJ; Richardson-Harman, N; Rohan, LC; Schwartz, JL; Spiegel, HML, 2018)	0.48
" Safety was assessed by adverse events (AEs), colposcopy, and culture-independent analysis of the vaginal microbiome (VMB)."	( Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial. Anton, PA; Baum, MM; Butkyavichene, I; Churchman, SA; Cortez, JM; Dawson, L; Fanter, R; Gunawardana, M; Guthrie, KM; Hendrix, CW; Marzinke, MA; Miller, CS; Moss, JA; Olive, TJ; Pyles, RB; Rosen, RK; Vargas, SE; Vincent, KL; Yang, F, 2018)	0.48
"An innovative pod-IVR delivery device with 3 different formulations delivering different regimens of ARV drugs vaginally appeared to be safe and acceptable and provided drug concentrations in CVFs and tissues exceeding concentrations achieved by highly protective oral dosing, suggesting that efficacy for vaginal HIV PrEP is achievable."	( Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial. Anton, PA; Baum, MM; Butkyavichene, I; Churchman, SA; Cortez, JM; Dawson, L; Fanter, R; Gunawardana, M; Guthrie, KM; Hendrix, CW; Marzinke, MA; Miller, CS; Moss, JA; Olive, TJ; Pyles, RB; Rosen, RK; Vargas, SE; Vincent, KL; Yang, F, 2018)	0.48
" EFV, relative to GSK3532795, had more serious adverse events (9% versus 5%) and adverse events leading to discontinuation (17% versus 5%)."	( Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial. Bogner, JR; DeGrosky, M; Dicker, IB; Gartland, M; Joshi, SR; Lataillade, M; Llamoso, C; Lombaard, J; Min, S; Molina, JM; Morales-Ramirez, J; Pene Dumitrescu, T; Stock, DA, 2018)	0.48
" The elvitegravir group showed more discontinuations because of renal adverse events (2."	( Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observ Bagella, P; Baldin, G; Capetti, A; Ciccullo, A; Cossu, MV; De Luca, A; Di Giambenedetto, S; Giacomelli, A; Lagi, F; Latini, A; Madeddu, G; Rusconi, S; Sterrantino, G, 2019)	0.51
" Adverse events assessments included measures of bone density and body fat."	( Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial. Akpomiemie, G; Arulappan, N; Becker, S; Chersich, MF; Duncombe, C; Feldman, C; Hill, A; Kambugu, A; Kumarasamy, N; Majam, M; Moorhouse, M; Poongulali, S; Ripin, DHB; Sokhela, S; Venter, WDF; Vos, A, 2019)	0.51
" Drug-related adverse event discontinuations were higher with d4T (6."	( Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial. Akpomiemie, G; Arulappan, N; Becker, S; Chersich, MF; Duncombe, C; Feldman, C; Hill, A; Kambugu, A; Kumarasamy, N; Majam, M; Moorhouse, M; Poongulali, S; Ripin, DHB; Sokhela, S; Venter, WDF; Vos, A, 2019)	0.51
" What is known of the differences in adverse effects between zidovudine, tenofovir and abacavir? How should their respective adverse effect profiles influence the choice between available combinations? We sought answers to these questions by reviewing the literature using the standard Prescrire methodology."	( Zidovudine, tenofovir or abacavir? Different adverse effect profiles. , 2016)	0.43
" Overall, 32 (26%) patients reported an adverse event."	( Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials. Buti, M; Crans, G; Flaherty, J; Flisiak, R; Gaggar, A; Gane, E; Janssen, HLA; Jump, B; Kaita, K; Kitrinos, K; Manns, M; Marcellin, P; Op den Brouw, M; Wong, DK, 2019)	0.51
"We pooled clinical renal safety data across 26 treatment-naive and antiretroviral switch studies to compare the incidence of proximal renal tubulopathy and discontinuation due to renal adverse events between participants taking TAF-containing regimens vs."	( Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. Arribas, JR; Brainard, D; Carter, C; Clarke, AE; Das, M; Elion, RA; Eron, JJ; Esser, S; Guo, S; Gupta, SK; Martin, H; Mudrikova, T; Negredo, E; Orkin, C; Podzamczer, D; Post, FA; Pozniak, AL; Rockstroh, JK; Sax, PE; SenGupta, D; Stellbrink, HJ; Waters, L; Wohl, DA; Zhong, L, 2019)	0.51
"001) discontinued due to a renal adverse event."	( Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. Arribas, JR; Brainard, D; Carter, C; Clarke, AE; Das, M; Elion, RA; Eron, JJ; Esser, S; Guo, S; Gupta, SK; Martin, H; Mudrikova, T; Negredo, E; Orkin, C; Podzamczer, D; Post, FA; Pozniak, AL; Rockstroh, JK; Sax, PE; SenGupta, D; Stellbrink, HJ; Waters, L; Wohl, DA; Zhong, L, 2019)	0.51
" The incidence of adverse events was similar in both groups (TDF-TDF, 56."	( Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results. Chen, C; Chen, S; Cheng, J; Gao, Z; Hou, J; Jia, J; Li, J; Liang, X; Mao, Q; Mao, Y; Ning, Q; Niu, J; Pan, C; Ren, H; Sheng, J; Tan, D; Tang, H; Wang, H; Wu, S; Xie, Q; Xiong, C; Xu, M; Zhang, J; Zhang, W; Zhang, X; Zhao, W, 2019)	0.51
" Entecavir and tenofovir were safe and well tolerated, while treatment with telbivudine was associated with development of myopathy in 13% of cases."	( Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B. Abdurakhmanov, DT; Ibragimov, EK; Moiseev, SV; Nikulkina, EN; Odintsov, AV; Panevkina, SV; Rozina, TP; Tanaschuk, EL, 2019)	0.51
"In this small group of patients, the generic scheme 3TC/TDF/EFV is effective and safe in the treatment of patients with HIV/AIDS naïve, and its effectiveness and safety profile is similar to show by innovator scheme 3TC/TDF/EFV in patients with similar clinical conditions."	( [Effectiveness and safety of generic version of lamivudine/tenofovir and efavirenz in treatment naïve HIV-infected patients: a nonrandomized, open-label, phase IV study in Cali-Colombia, 2012-2014]. Amariles, P; Castañeda, C; Galindo, J; Mueses-Marín, HF, 2019)	0.51
" The primary endpoint was the proportion of participants discontinuing due to adverse events (AEs) through Week 48."	( Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus-1: An Integrated Safety Analysis. Cahn, P; Hanna, G; Hwang, C; Kumar, S; Martin, E; Molina, JM; Orkin, C; Rodgers, A; Sax, P; Squires, K; Teppler, H; Thompson, M; Xu, X, 2020)	0.56
" In the period between Year 8 and Year 10, the safety profile of TDF was similar to previous reports, with few patients experiencing renal- or bone-related adverse events."	( Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. Buggisch, P; Buti, M; Cathcart, AL; Crans, G; Flaherty, J; Flisiak, R; Gaggar, A; Jump, B; Kaita, K; Krastev, Z; Lee, SS; Manns, M; Marcellin, P; Op den Brouw, M; Petersen, J; Sievert, W; Wong, DK, 2019)	0.51
" However, less attention has been put on their adverse events."	( Bayesian Network Meta-Analysis for Assessing Adverse Effects of Anti-hepatitis B Drugs. Ji, J; Jia, Y; Shen, Y; Xun, P; Zhou, J, 2019)	0.51
" Poisson-prior-based Bayesian NMA was performed to synthesize both direct and indirect evidence with reporting hazard ratios (HRs) and 95% credible intervals (CrIs) for serious adverse events (SAEs) and hepatic/renal impairments."	( Bayesian Network Meta-Analysis for Assessing Adverse Effects of Anti-hepatitis B Drugs. Ji, J; Jia, Y; Shen, Y; Xun, P; Zhou, J, 2019)	0.51
" Few discontinued due to adverse events (2% D/C/F/TAF arm)."	( Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/ Brown, K; Cunningham, D; De Wit, S; Eron, JJ; Hufkens, V; Jezorwski, J; Lathouwers, E; Opsomer, M; Orkin, C; Petrovic, R; Post, FA; Pulido, F; Van Landuyt, E, 2019)	0.51
"Short-term administration of the entry inhibitor myrcludex-B (MyrB) has been shown to be safe and effective in phase II studies in patients coinfected with hepatitis B virus (HBV) and hepatitis delta virus (HDV)."	( Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients. Bertoletti, A; Borghi, M; Ceriotti, F; Ferenci, P; Giovanelli, S; Greco, L; Holzmann, H; Lampertico, P; Loglio, A; Lunghi, G; Perbellini, R; Porretti, L; Prati, D; Tham, CYL; Trombetta, E; Uceda Renteria, SC; van Bömmel, F, 2019)	0.51
" Proportions of women engaged in care, incidence of DAIDS grade ≥ 2 laboratory toxicity, grade ≥ 3 adverse events (AEs), viral suppression (<1000 copies/mL), birth outcomes and infant HIV infections are reported."	( Safety and efficacy of Option B+ ART in Malawi: few severe maternal toxicity events or infant HIV infections among pregnant women initiating tenofovir/lamivudine/efavirenz. Chagomerana, MB; DiPrete, BL; Harrington, BJ; Hosseinipour, MC; Jumbe, AN; Limarzi, L; Ngongondo, M; Wallie, SD, 2019)	0.51
" While some women experienced adverse laboratory events, clinical symptom monitoring is likely reasonable."	( Safety and efficacy of Option B+ ART in Malawi: few severe maternal toxicity events or infant HIV infections among pregnant women initiating tenofovir/lamivudine/efavirenz. Chagomerana, MB; DiPrete, BL; Harrington, BJ; Hosseinipour, MC; Jumbe, AN; Limarzi, L; Ngongondo, M; Wallie, SD, 2019)	0.51
" However, there are several reasons as to why patients may discontinue their antiretroviral therapy, with adverse events being one of the main reasons reported in the literature."	( Factors associated to modification of first-line antiretroviral therapy due to adverse events in people living with HIV/AIDS. Azevedo, LN; Miranda-Filho, DB; Montarroyos, UR; Monteiro, P; Ximenes, RAA, )	0.13
" No subject experienced a serious adverse event or nephrotoxicity."	( Safety, efficacy, and pharmacokinetics of pradefovir for the treatment of chronic hepatitis B infection. Chen, H; Ding, Y; Jin, W; Li, C; Li, X; Liu, C; Liu, J; Niu, J; Wu, M; Zhang, D; Zhang, H; Zhu, X, 2020)	0.56
" Drug-related grade ≥2 adverse events and withdrawals due to adverse events occurred in 17 (4."	( Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phas Aboud, M; Ait-Khaled, M; Ajana, F; Bisshop, F; De Wit, S; Gartland, MJ; Nascimento, MC; Osiyemi, O; Pappa, KA; Portilla Sogorb, J; Routy, JP; Smith, KY; Tenorio, AR; van Wyk, J; Wang, R; Wright, J; Wyen, C; Wynne, B, 2020)	0.56
" Both treatments were safe and well-tolerated, and most adverse events were similar as mild to moderate in severity."	( Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials. Chen, Y; Lu, Y; Tao, X; Zhang, L; Zhou, Y, 2020)	0.56
" However, gastrointestinal adverse effects (vomiting) occurred more frequently in TDF-treated than LdT-treated patients (6."	( Clinical efficacy and safety in telbivudine- or tenofovir-treated hepatitis B e antigen-positive pregnant women. Chen, K; Deng, H; Gao, H; Jiao, Q; Lei, Y; Li, H; Liang, S; Lin, L; Liu, H; Shi, Y; Xu, M; Zhuo, L, 2020)	0.56
"This study revealed that the clinical efficacy in LdT- or TDF-treated HBeAg-positive Chinese pregnant women is similar, and gastrointestinal adverse effects occurred more frequently in TDF-treated patients."	( Clinical efficacy and safety in telbivudine- or tenofovir-treated hepatitis B e antigen-positive pregnant women. Chen, K; Deng, H; Gao, H; Jiao, Q; Lei, Y; Li, H; Liang, S; Lin, L; Liu, H; Shi, Y; Xu, M; Zhuo, L, 2020)	0.56
"The combination of hepatitis B virus RNA and hepatitis B core-related antigen performed satisfactorily in predicting clinical relapse and hepatitis B surface antigen loss after stopping nucleos(t)ide analogue treatment among noncirrhotic hepatitis B e antigen-positive patients with chronic hepatitis B and could be used to guide safe discontinuation."	( Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B. Bai, X; Chen, X; Fan, R; Hou, J; Niu, J; Peng, J; Ren, H; Sheng, J; Sun, J; Tan, D; Tang, H; Wang, H; Wang, M; Wu, Y; Xie, Q; Xu, M; Zhou, B, 2020)	0.56
" Drug-related adverse events occurred more frequently in the participants receiving the standard dose regimen compared with the lower dose one (63."	( Efficacy and safety of lower dose tenofovir disoproxil fumarate and efavirenz versus standard dose in HIV-infected, antiretroviral-naive adults: a multicentre, randomized, noninferiority trial. Chen, J; Chen, R; Hu, Z; Huang, Q; Liu, L; Lu, H; Qi, T; Shen, Y; Song, W; Sun, J; Tang, Y; Wang, J; Wang, X; Wang, Z; Wei, H; Xie, R; Zhang, R, 2020)	0.56
" These findings provide reassurance that the combination of TAF, boosted PIs and ledipasvir/sofosbuvir is safe in HIV/HCV-coinfected populations."	( Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir. Anderson, PL; Blum, J; Brooks, KM; Bushman, LR; Castillo-Mancilla, JR; Cendali, F; Choi, YJ; Gomez, J; Haas, H; Ibrahim, ME; Johnson, B; Kiser, JJ; MaWhinney, S; Morrow, M; Roon, L; Rowan, SE; Wyles, DL; Zheng, JH, 2020)	0.56
" We included studies that enrolled pregnant women with chronic infection with HBV who received antiviral prophylaxis anytime during pregnancy; that included any of the following antivirals: adefovir, emtricitabine, entecavir, lamivudine, telbivudine, tenofovir alafenamide fumarate, and tenofovir disoproxil fumarate; and that reported the following outcomes: MTCT, indicated by infant HBsAg positivity or HBV DNA positivity, or both, at age 6-12 months, and any infant or maternal adverse events."	( Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis. Boucheron, P; Bulterys, M; Chou, R; Funk, AL; Lu, Y; Shimakawa, Y; van Holten, J; Yoshida, K; Zhao, T, 2021)	0.62
" Secondary assessments included maternal HBV DNA reduction at delivery, and maternal or infant adverse events during follow up."	( Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: a national cohort study. Cao, L; Chen, B; Chen, R; Ding, Y; Fan, J; Gan, W; Huang, Y; Lin, C; Liu, Y; Pan, CQ; Sheng, Q; Wang, S; Wang, Y; Zhu, L, 2020)	0.56
" No severe adverse effects were reported in either mothers or infants."	( Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: a national cohort study. Cao, L; Chen, B; Chen, R; Ding, Y; Fan, J; Gan, W; Huang, Y; Lin, C; Liu, Y; Pan, CQ; Sheng, Q; Wang, S; Wang, Y; Zhu, L, 2020)	0.56
" Women treated with TDF and their infants did not result in serious adverse events that are statistically different as compared to the women who did not receive any treatment."	( Efficacy and Safety of Tenofovir in the Prevention of Perinatal Transmission of Hepatitis B, a Meta-Analysis. Flomo, KT; Ma, Y; Yang, Q; Yang, Y; Zhong, Z, 2020)	0.56
" Throughout the study, tolerability was assessed based on adverse events, vital signs, and clinical laboratory tests."	( A randomized, open-label, crossover study to compare the safety and pharmacokinetics of two tablet formulations of tenofovir (tenofovir disoproxil and tenofovir disoproxil fumarate) in healthy subjects. Choi, YS; Hoe, KL; Hong, JH; Kan, HS; Kim, N; Kwon, IS; Lee, M; Nam, SK; Oh, TY; Yeun, JS; Yun, JN, 2020)	0.56
" Grade 3/4 adverse events (especially efavirenz-related neuropsychiatric adverse events) leading to regimen discontinuation were also noted."	( Efficacy and safety of a single-tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV-1-infected subjects on nonnucleoside reverse transcriptase inhibito Betha, TP; Dravid, A; Dravid, M; Gawali, R; Kore, S; Kulkarni, M; Mahajan, U; Rathod, N; Saraf, C; Sharma, AK, 2020)	0.56
" Grade 3/4 adverse events leading to TLE400 STR discontinuation were seen in 11 (2."	( Efficacy and safety of a single-tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV-1-infected subjects on nonnucleoside reverse transcriptase inhibito Betha, TP; Dravid, A; Dravid, M; Gawali, R; Kore, S; Kulkarni, M; Mahajan, U; Rathod, N; Saraf, C; Sharma, AK, 2020)	0.56
" Despite a safe renal profile in the clinical trials, long-term use of tenofovir disoproxil fumarate (TDF) has been associated with proximal renal tubulopathy although the underlying mechanisms remain undetermined."	( Design and methods of the prevalence and pharmacogenomics of tenofovir nephrotoxicity in HIV-positive adults in south-western Nigeria study. Dickens, C; Duarte, R; Hassan, MO; Lasisi, AO; Mabayoje, VO; Naicker, S, 2020)	0.56
"Nephrotoxicity is a dose-limiting side effect of long-term use of tenofovir, a reverse transcriptase inhibitor that is used for the treatment of HIV infection and chronic hepatitis B infection."	( Melatonin protects against tenofovir-induced nephrotoxicity in rats by targeting multiple cellular pathways. Abraham, P; Isaac, B; Ramamoorthy, H, 2021)	0.62
" Because TDF can lead to renal impairment and a decrease in bone mineral density (BMD), the prodrug tenofovir alafenamide (TAF) may be considered a viable alternative with fewer adverse effects."	( Safety and efficacy of tenofovir alafenamide in liver transplant recipients: A single center experience. Achterfeld, A; Herzer, K; Rashidi-Alavijeh, J; Straub, K; Wedemeyer, H; Willuweit, K, 2021)	0.62
" After 1 year, 22 patients were still taking TAF; two patients had been lost to follow-up; one patient had died; and four patients had discontinued therapy because of TAF-related adverse effects."	( Safety and efficacy of tenofovir alafenamide in liver transplant recipients: A single center experience. Achterfeld, A; Herzer, K; Rashidi-Alavijeh, J; Straub, K; Wedemeyer, H; Willuweit, K, 2021)	0.62
" PrEP was well tolerated with only minor adverse events (grade 2) thought to be related to study drug, which included headache (n=4, 3%), gastrointestinal upset (n=8, 5%), and skin rash (n=2, 1%)."	( Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial. Bekker, LG; Dietrich, J; Fynn, L; Gill, K; Gray, G; Hosek, S; Johnson, L; Jones, K; Marcus, R; Mendel, E; Myer, L; Pidwell, T; Rooney, J; Slack, C; Spiegel, H; Strode, A; Wallace, M; Wiesner, L, 2020)	0.56
"In this cohort of self-selected South African adolescents at risk of HIV acquisition, PrEP appears safe and tolerable in those who continued use."	( Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial. Bekker, LG; Dietrich, J; Fynn, L; Gill, K; Gray, G; Hosek, S; Johnson, L; Jones, K; Marcus, R; Mendel, E; Myer, L; Pidwell, T; Rooney, J; Slack, C; Spiegel, H; Strode, A; Wallace, M; Wiesner, L, 2020)	0.56
"6%) patients because of adverse effects."	( Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients. Cheng, CY; Cheng, SH; Ho, MW; Huang, SH; Huang, YS; Hung, CC; Lee, CH; Lee, YT; Lin, SP; Liou, BH; Liu, CE; Lu, PL; Sun, HY; Tang, HJ; Tsai, HC; Yang, CJ, 2021)	0.62
" No drug-related adverse events were observed within a 48-week observation period."	( The 48-week safety and therapeutic effects of tenofovir alafenamide in hbv-related acute-on-chronic liver failure: A prospective cohort study. Lai, J; Li, J; Li, X; Peng, L; Shu, X; Xie, C; Xie, J; Xu, W; Zhang, Y; Zhu, X, 2021)	0.62
" Former participants from The Ring Study, who remained HIV-negative and who did not discontinue the study due to an adverse event or safety concern that was considered to be related to the investigational product, were eligible."	( Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study. Bekker, LG; Carter, A; Craig, C; Devlin, B; Gill, K; Gwetu, T; Kotze, P; Kusemererwa, S; Louw, C; Mabude, Z; Malherbe, M; Mans, W; Moraba, R; Nel, A; Rosenberg, Z; Steytler, J; Tempelman, H; Van Baelen, B; van der Ryst, E; van Niekerk, N, 2021)	0.62
" 616 (65·5%) of 941 participants reported treatment-emergent adverse events."	( Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study. Bekker, LG; Carter, A; Craig, C; Devlin, B; Gill, K; Gwetu, T; Kotze, P; Kusemererwa, S; Louw, C; Mabude, Z; Malherbe, M; Mans, W; Moraba, R; Nel, A; Rosenberg, Z; Steytler, J; Tempelman, H; Van Baelen, B; van der Ryst, E; van Niekerk, N, 2021)	0.62
" No serious adverse events or grade 3 or higher adverse events observed were assessed as related to the DVR."	( Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study. Baeten, JM; Balán, IC; Brown, ER; Bunge, K; Chinula, L; Chirenje, ZM; Garcia, M; Gati Mirembe, B; Govender, V; Hendrix, CW; Hillier, SL; Hunidzarira, P; Jacobson, C; Jiao, Y; Jones, J; Livant, E; Makanani, B; Mansoor, LE; Mayo, AJ; Mellors, JW; Mgodi, NM; Mhlanga, F; Naidoo, L; Nair, G; Nakabiito, C; Nel, A; Ngure, K; Palanee-Phillips, T; Parikh, UM; Patterson, K; Peda, M; Ramjee, G; Rosenberg, Z; Scheckter, R; Singh, D; Singh, N; Siva, S; Soto-Torres, LE; Szydlo, DW; Taha, TE; Torjesen, K; van der Straten, A, 2021)	0.62
" No cases of renal injury or other obstetric adverse events occurred in either group of women."	( Analysis of long-term safety and efficacy of nucleos(t)ide analogue therapy for chronic hepatitis B throughout pregnancy. Bai, L; Liu, H; M Ise, R; Shang, J; Tang, H; Tu, Y; Wen, Q, 2021)	0.62
" Primary safety outcomes, compared pairwise among treatment groups, were the occurrence of a composite adverse pregnancy outcome (ie, either preterm delivery, the infant being born small for gestational age, stillbirth, or spontaneous abortion) in all participants with a pregnancy outcome, and the occurrence of grade 3 or higher maternal and infant adverse events in all randomised participants."	( Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2 Amico, KR; Brummel, SS; Cassim, H; Chakhtoura, N; Chinula, L; Coletti, A; Currier, J; Fairlie, L; Frenkel, LM; Hanley, S; Hoffman, RM; Holmes, LB; Jean-Philippe, P; João, E; Johnston, B; Korutaro, V; Krotje, C; Lockman, S; Masheto, G; McCarthy, K; Mmbaga, BT; Momper, JD; Moyo, S; Purdue, L; Rooney, JF; Sax, PE; Shapiro, RL; Stranix-Chibanda, L; Stringer, JS; Thoofer, NK; Ziemba, L, 2021)	0.62
" Significantly fewer participants in the dolutegravir, emtricitabine, and tenofovir alafenamide fumarate group (52 [24%] of 216) had a composite adverse pregnancy outcome than those in the dolutegravir, emtricitabine, and tenofovir disoproxil fumarate group (70 [33%] of 213; estimated difference -8·8% [95% CI -17·3 to -0·3], p=0·043) or the efavirenz, emtricitabine, and tenofovir disoproxil fumarate group (69 [33%] of 211; -8·6% [-17·1 to -0·1], p=0·047)."	( Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2 Amico, KR; Brummel, SS; Cassim, H; Chakhtoura, N; Chinula, L; Coletti, A; Currier, J; Fairlie, L; Frenkel, LM; Hanley, S; Hoffman, RM; Holmes, LB; Jean-Philippe, P; João, E; Johnston, B; Korutaro, V; Krotje, C; Lockman, S; Masheto, G; McCarthy, K; Mmbaga, BT; Momper, JD; Moyo, S; Purdue, L; Rooney, JF; Sax, PE; Shapiro, RL; Stranix-Chibanda, L; Stringer, JS; Thoofer, NK; Ziemba, L, 2021)	0.62
" The dolutegravir, emtricitabine, and tenofovir alafenamide fumarate regimen had the lowest frequency of composite adverse pregnancy outcomes and of neonatal deaths."	( Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2 Amico, KR; Brummel, SS; Cassim, H; Chakhtoura, N; Chinula, L; Coletti, A; Currier, J; Fairlie, L; Frenkel, LM; Hanley, S; Hoffman, RM; Holmes, LB; Jean-Philippe, P; João, E; Johnston, B; Korutaro, V; Krotje, C; Lockman, S; Masheto, G; McCarthy, K; Mmbaga, BT; Momper, JD; Moyo, S; Purdue, L; Rooney, JF; Sax, PE; Shapiro, RL; Stranix-Chibanda, L; Stringer, JS; Thoofer, NK; Ziemba, L, 2021)	0.62
" Adverse events were reported in 8 (7%) patients."	( [Effectiveness, safety, and economic impact of the bictegravir/emtricitabine/tenofovir alafenamide regimen in real clinical practice cohort of HIV-1 infected adult patients]. Gutiérrez-Lorenzo, M; Rubio-Calvo, D; Urda-Romacho, J, 2021)	0.62
" However, we found a large difference between the high percentages of patients reporting an adverse event in three phase 3 clinical trials and our results."	( [Effectiveness, safety, and economic impact of the bictegravir/emtricitabine/tenofovir alafenamide regimen in real clinical practice cohort of HIV-1 infected adult patients]. Gutiérrez-Lorenzo, M; Rubio-Calvo, D; Urda-Romacho, J, 2021)	0.62
" TAF was well tolerated and only 4 patients discontinued therapy due to adverse event during a median duration of TAF dosing of 74 weeks."	( Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV. Bernstein, DE; Fried, MW; Lok, AS; Mospan, AR; Schiff, ER; Smith, CI; Trinh, HN; Zink, RC, 2022)	0.72
" The treatment using NAs was well-tolerated and there was no serious drug-related adverse event reported."	( Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B. Chen, T; Chen, Y; Fu, M; Fu, S; Gao, Z; He, Y; Hu, C; Li, J; Liu, J; Yan, T; Yang, Y; Zhang, R; Zhao, Y; Zhou, M, 2021)	0.62
" In rats, systemic and local findings were considered not adverse due to their low severity and reversibility; therefore, the "no observed adverse effect level" (NOAEL) was set at 1,000 μg/kg/day."	( A 28-Day Toxicity Study of Tenofovir Alafenamide Hemifumarate by Subcutaneous Infusion in Rats and Dogs. Alessi, T; Feldman, PL; Felx, M; Jain, R; Roller, S; Shelton, J; Singh, R; Wang, Y; Yang, B; Zane, D, 2021)	0.62
"Emtricitabine and tenofovir alafenamide is safe and effective for longer-term pre-exposure prophylaxis in cisgender men and transgender women who have sex with men."	( Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. Asmuth, DM; Baeten, JM; Brainard, DM; Brunetta, JM; Carter, C; Cox, S; Das, M; Ebrahimi, R; Gilson, R; Henry, K; Kintu, A; Kronborg, G; Ogbuagu, O; Podzamczer, D; Ruane, PJ; Salazar, LC; Shao, Y; Spinner, CD; Whitlock, G; Wohl, D, 2021)	0.62
" Week 48 virologic suppression (HIV-1 RNA <50 copies/mL), resistance, adverse events (AEs), and laboratory parameters were assessed."	( Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials. Ajana, F; Brainard, D; Chuck, SK; Collins, SE; Gandhi-Patel, B; Kityo, C; Koenig, E; Liu, Y; Makadzange, T; McNicholl, I; Natukunda, E; Orkin, C; Pikora, C; Wang, H; Wei, X; White, K, 2021)	0.62
"In individuals with a history of PRT on TDF, 96 weeks of TAF was not associated with recurrent PRT or adverse effects on renal tubular function, bone turnover, or BMD."	( Safety of Tenofovir Alafenamide in People With HIV Who Experienced Proximal Renal Tubulopathy on Tenofovir Disoproxil Fumarate. Barbini, B; Burling, K; Campbell, L; Cromarty, B; Hamzah, L; Johnson, M; Jones, R; Post, FA; Samarawickrama, A; Williams, D; Winston, A, 2021)	0.62
" Treatment-related adverse events occurred in 51 (15%) patients (all Grade 1-2) and led to 8 discontinuations."	( Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV. Cruz, D; DeJesus, E; Hinestrosa, F; Nguyen, V; Patel, K; Rolle, CP, 2021)	0.62
"ETV, TDF, and TAF were safe antiviral agents and showed similar antiviral effect for CHB at 48 weeks."	( Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B. Jeong, S; Kim, HI; Shin, HP, 2022)	0.72
" However, no serious adverse events were observed in infants and mothers of all groups."	( Comparison of the efficacy and safety of tenofovir and telbivudine in interrupting mother-to-child transmission of hepatitis B virus. Chen, L; Chen, X; Dai, E; Li, C; Li, S; Lv, X; Zhao, Z; Zhu, B, 2021)	0.62
" Drug-related adverse events were more frequent with DTG/3TC (15%; leading to discontinuation in 4%) than TAF-based regimens (5%; leading to discontinuation in 1%) through week 144, but rates were comparable after week 48 (4%; leading to discontinuation in 1% in both groups)."	( Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 F Aboud, M; Ait-Khaled, M; Ajana, F; Bisshop, F; De Wit, S; George, N; Leone, P; Osiyemi, O; Pappa, KA; Portilla, J; Routy, JP; Smith, KY; van Wyk, J; Wang, R; Wright, J; Wyen, C; Wynne, B, 2022)	0.72
" Despite its effectiveness and few adverse effects, it is related to renal and bone toxicity."	( Tenofovir-induced renal and bone toxicity: report of two cases and literature review. Distenhreft, JIQ; Fioroti, CEA; Lacchine, K; Luchi, WM; Paulino, BB; Ramos, DR; Seguro, AC, 2022)	0.72
" Adverse events were observed in 15% of the patients, and the regimen was discontinued in only six patients."	( Effectiveness and safety of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet combination among HIV-infected patients in Turkey: results from a real world setting. Aydin, OA; Bilge, B; Bolukcu, S; Dokmetas, I; Gumuser, F; Gunduz, A; Karaosmanoglu, HK; Mete, B; Tabak, F; Yildiz, DS, 2021)	0.62
"Real world data on the effectiveness and safety of E/C/F/TDF is comparable with the phase 3 trial results Adverse events are uncommon and manageable."	( Effectiveness and safety of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet combination among HIV-infected patients in Turkey: results from a real world setting. Aydin, OA; Bilge, B; Bolukcu, S; Dokmetas, I; Gumuser, F; Gunduz, A; Karaosmanoglu, HK; Mete, B; Tabak, F; Yildiz, DS, 2021)	0.62
" The proportions of participants with any grade 3-4 adverse event were similar between the dolutegravir (26 [11%]) and darunavir (28 [12%]) groups and between the tenofovir (22 [9%]) and zidovudine (32 [14%]) groups."	( Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non Asienzo, J; Ategeka, G; Balyegisawa, A; Borok, M; Castelnuovo, B; Hoppe, A; Kaimal, A; Kambugu, A; Kiragga, A; Kityo, C; Lugemwa, A; Mirembe, G; Mugerwa, H; Musaazi, J; Odongpiny, ELA; Paton, NI; Siika, A; Walimbwa, S, 2022)	0.72
" This post hoc analysis evaluated gastrointestinal adverse events of interest (AEOIs; diarrhea, nausea, abdominal discomfort, flatulence [MedDRAv21]) through Wk96 among patients enrolled in the phase 3 AMBER (treatment-naïve) and EMERALD (virologically suppressed) studies of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg."	( Low Incidence and Brief Duration of Gastrointestinal Adverse Events with Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Over 96 Weeks: Post hoc Analyses of AMBER and EMERALD. Anderson, D; Baugh, B; Bejou, N; Campbell, J; Dunn, K; Luo, D; Seyedkazemi, S, )	0.13
"PrEP is safe and effective in MSM, serodiscordant couples and PWIDs."	( Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations. Harrington, P; Hayes, C; Marshall, L; Moran, P; O Murchu, E; Ryan, M; Teljeur, C, 2022)	0.72
" As, this product is proposed for adults and adolescents safe from HIV but at high risk of infection, the question is to know if there is a safety concern about this use."	( [HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine: What about safety?] Davani, S; Grandvuillemin, A; Jacomet, C; Lebeller, C; Schiestel, T; Valnet-Rabier, MB, )	0.13
"In both database, 808 cases correspond to an indication of HIV prexposure prophylaxis who represent 2058 adverse effects (AEs) mainly distributed in gastro-intestinal disorders (38."	( [HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine: What about safety?] Davani, S; Grandvuillemin, A; Jacomet, C; Lebeller, C; Schiestel, T; Valnet-Rabier, MB, )	0.13
" We identify 24% of unexpected and potentially serious adverse effects in France mainly among chemsex users."	( [HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine: What about safety?] Davani, S; Grandvuillemin, A; Jacomet, C; Lebeller, C; Schiestel, T; Valnet-Rabier, MB, )	0.13
"Gastrointestinal adverse events are common after treatment initiation but usually resolve within weeks."	( Safety of oral tenofovir disoproxil - emtricitabine for HIV preexposure prophylaxis in adults. Liegeon, G, 2022)	0.72
"Oral tenofovir disoproxil-FTC for HIV PrEP appears safe and well tolerated for most individuals."	( Safety of oral tenofovir disoproxil - emtricitabine for HIV preexposure prophylaxis in adults. Liegeon, G, 2022)	0.72
" Consistent with previous findings, we observed adverse local toxicity and necrosis near the tenofovir alafenamide implant site."	( Safety and efficacy of a biodegradable implant releasing tenofovir alafenamide for vaginal protection in a macaque model. Dobard, C; García-Lerma, JG; Gary, J; Gatto, G; Heneine, W; Holder, A; Johnson, L; Khalil, G; Krovi, A; Li, L; Luecke, E; Massud, I; Mills, P; Mitchell, J; Nishiura, K; Pan, Y; Ruone, S; van der Straten, A, 2022)	0.72
" Safety was assessed by adverse event (AE) reporting."	( Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine. Afani Saud, A; Bettacchi, C; Chahin Anania, C; Correll, T; Eves, K; Grandhi, A; Hanna, GJ; Hepler, D; Hwang, C; Klopfer, SO; Molina, JM; Robertson, MN; Yazdanpanah, Y, 2022)	0.72
"Previous clinical data have shown that raltegravir-based antiretroviral therapy (ART) with fewer drug-drug interactions (DDIs) and adverse events (AEs) is a good regimen in patients with HIV infection who need cancer chemotherapy."	( Safety and efficacy of pharmacotherapy containing INSTIs and chemotherapy drugs in people living with HIV and concomitant colorectal cancer. Chen, T; Gui, F; Tan, J; Wei, G; Yang, J; Zhao, Y, 2022)	0.72
" Safety was assessed by adverse events and changes from baseline in mucosal histology and immune mediators."	( Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study. Brache, V; Chandra, N; Clark, MR; Cochon, L; Doncel, GF; Erikson, DW; Fichorova, RN; Hanif, H; Herold, BC; Jacot, T; Ju, S; Marzinke, MA; Ouattara, LA; Parikh, U; Peet, M; Schwartz, JL; Thurman, AR; Tolley, E; Yousefieh, N, 2022)	0.72
" No drug-related serious or grade 3 or 4 adverse events occurred."	( Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014. Aurpibul, L; Best, BM; Campbell, H; Cassim, H; Cooper, E; Flynn, P; Gray, KP; Krotje, C; McCarthy, K; McFarland, E; Melvin, AJ; Moye, J; Ounchanum, P; Rungmaitree, S; Scheckter, R; Teppler, H; Tobin, NH; Townley, E; Wan, H; Yedla, M; Yee, KL, 2023)	0.91
" DTG + 3TC achieved virological suppression more rapidly and stably versus TDF + 3TC + EFV in ART-naïve HIV-1-infected adults, with better immunological response and less adverse drug effect, and reduced total HIV-1 DNA effectively."	( Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-naïve HIV-1-infected adults. Chen, D; Du, Y; Huang, Z; Li, J; Wang, Y; Wen, Z; Yin, S; Zhong, H, 2022)	0.72
" Bulevirtide was well tolerated, there was no deterioration in tolerability compared with patients without cirrhosis, there were no serious adverse events and cases of treatment cancellation due to adverse events."	( [Efficacy and safety of bulevirtide in patients with chronic hepatitis D and compensated cirrhosis]. Bogomolov, PO; Bueverov, AO; Chulanov, VP; Gusev, DA; Ivashkin, VT; Maev, IV; Sagalova, OI; Sleptsova, SS; Yushuk, ND; Zhdanov, KV, 2021)	0.62
" Significantly lower study drug-related adverse events were observed in TLE 400 group compared to TLE 600 group (52."	( Efficacy and safety of 400 mg efavirenz versus standard 600 mg dose when taken with tenofovir and lamivudine combination in Indian adult patients with HIV-1 infection: An open-label, interventional, randomized, non-inferiority trial. Bhrusundi, M; Dravid, A; K R, R; Kulkarni, V; Madhukarrao, KM; Morkar, DN; Nageswaramma, S; Naik, KS; Pilawan, AS; Ramapuram, JT; S, A, 2022)	0.72
"ETV, TDF, and TAF are comparably safe and effective antiviral agents against CHB."	( Comparison of the side effects of antivirals in chronic hepatitis B patients: a single-center experience. Celik, U; Dusunceli, I; Gok Sargin, Z; Ustundag, Y, )	0.13
" Across the studies, one grade 3/4 adverse event was considered drug-related (intermediate uveitis)."	( Effectiveness and safety of tenofovir alafenamide in children and adolescents living with HIV: a systematic review. Castro, H; Collins, IJ; Jesson, J; Judd, A; Leroy, V; Milanzi, E; O'Rourke, J; Penazzato, M; Renaud, F; Townsend, CL; Vicari, M, 2023)	0.91
" Safety was assessed by treatment-emergent adverse events (TEAEs)."	( A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir. Anderson, PL; Bushman, LR; Clark, M; Doncel, GF; Fang, X; Hanif, H; Ouattara, LA; Singh, O; Thurman, AR; Yousefieh, N, 2023)	0.91
" The inserts were safe and highly acceptable."	( A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir. Anderson, PL; Bushman, LR; Clark, M; Doncel, GF; Fang, X; Hanif, H; Ouattara, LA; Singh, O; Thurman, AR; Yousefieh, N, 2023)	0.91
" Primary safety analyses were pairwise comparisons between ART regimens of the proportion of maternal and infant adverse events of grade 3 or higher up to 50 weeks post partum."	( Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial. Amico, KR; Boyce, C; Brummel, S; Cassim, H; Chakhtoura, N; Chinula, L; Coletti, A; Currier, JS; Fairlie, L; Frenkel, LM; Hoffman, R; Jean-Philippe, P; Johnston, B; Knowles, K; Korutaro, V; Krotje, C; Lockman, S; Masheto, G; McCarthy, K; Mmbaga, BT; Moyo, S; Patel, F; Purdue, L; Rooney, JF; Sax, PE; Shapiro, R; Stranix-Chibanda, L; Stringer, J; van Wyk, J; Ziemba, L, 2023)	0.91
" Up to the week 50 post-partum visit, the estimated probability of experiencing an adverse event of grade 3 or higher was 25% in the dolutegravir, emtricitabine, and tenofovir alafenamide group; 31% in the dolutegravir, emtricitabine, and tenofovir disoproxil fumarate group; and 28% in the efavirenz, emtricitabine, and tenofovir disoproxil fumarate group (no significant difference between groups)."	( Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial. Amico, KR; Boyce, C; Brummel, S; Cassim, H; Chakhtoura, N; Chinula, L; Coletti, A; Currier, JS; Fairlie, L; Frenkel, LM; Hoffman, R; Jean-Philippe, P; Johnston, B; Knowles, K; Korutaro, V; Krotje, C; Lockman, S; Masheto, G; McCarthy, K; Mmbaga, BT; Moyo, S; Patel, F; Purdue, L; Rooney, JF; Sax, PE; Shapiro, R; Stranix-Chibanda, L; Stringer, J; van Wyk, J; Ziemba, L, 2023)	0.91
"01), but more tolerated injection sites adverse events (p < 0."	( Efficacy and safety of long-acting cabotegravir versus oral tenofovir disoproxil fumarate-emtricitabine as HIV pre-exposure prophylaxis: A systematic review and meta-analysis. Chen, X; Kou, L; Li, J; Li, Y; Wei, D; Xie, X, 2023)	0.91
" Tenofovir disoproxil fumarate (TDF) increases the risk of renal tubular toxicity and adverse effects on bone, but Tenofovir alafenamide (TAF) and Tenofovir amibufenamide (TMF) have favorable safety profile on the kidneys and bones."	( Medication safety in chronic kidney disease. Singh, S, 2023)	0.91
" Frequency of adverse events was similar between the treatment groups."	( Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial. Adeyeye, A; Cardozo, N; Cohen, MS; Coutinho, C; Donnell, D; Eshleman, SH; Feliciano, KG; Ford, S; Franks, J; Grinsztejn, B; Hanscom, B; Jalil, E; Jennings, A; Khan, T; Landovitz, RJ; Lucas, J; Maia, B; Marzinke, MA; McCauley, M; Middelkoop, K; Psaros, C; Richardson, PA; Rinehart, AR; Rooney, JF; Safren, SA; Sanchez, N; Singh, Y; Sullivan, P; Valencia, J; Wang, Z, 2023)	0.91
" Our results suggest that injectable cabotegravir is a safe and effective pre-exposure prophylaxis option for transgender women."	( Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial. Adeyeye, A; Cardozo, N; Cohen, MS; Coutinho, C; Donnell, D; Eshleman, SH; Feliciano, KG; Ford, S; Franks, J; Grinsztejn, B; Hanscom, B; Jalil, E; Jennings, A; Khan, T; Landovitz, RJ; Lucas, J; Maia, B; Marzinke, MA; McCauley, M; Middelkoop, K; Psaros, C; Richardson, PA; Rinehart, AR; Rooney, JF; Safren, SA; Sanchez, N; Singh, Y; Sullivan, P; Valencia, J; Wang, Z, 2023)	0.91
" The primary safety endpoint was grade 2 or higher adverse events during each randomised period of 24 weeks of ring and oral PrEP."	( Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial. Akello, CA; Anderson, P; Baeten, JM; Bekker, LG; Brown, ER; Bunge, K; Celum, C; Garcia, M; Hendrix, C; Hillier, SL; Hosek, S; Jacobson, C; Johnson, S; Levy, L; Livant, E; Macdonald, P; McClure, T; Milan, G; Muhlanga, F; Nair, G; Nakabiito, C; Nakalega, R; Ngure, K; Palanee-Phillips, T; Parikh, U; Reddy, K; Rooney, JF; Siziba, B; Soto-Torres, L; Steytler, J; Szydlo, D; Tahuringana, E; van der Straten, A, 2023)	0.91
" 54 grade 2 or higher product-related adverse events were reported during oral PrEP and five during dapivirine ring use, with no product-related serious adverse events."	( Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial. Akello, CA; Anderson, P; Baeten, JM; Bekker, LG; Brown, ER; Bunge, K; Celum, C; Garcia, M; Hendrix, C; Hillier, SL; Hosek, S; Jacobson, C; Johnson, S; Levy, L; Livant, E; Macdonald, P; McClure, T; Milan, G; Muhlanga, F; Nair, G; Nakabiito, C; Nakalega, R; Ngure, K; Palanee-Phillips, T; Parikh, U; Reddy, K; Rooney, JF; Siziba, B; Soto-Torres, L; Steytler, J; Szydlo, D; Tahuringana, E; van der Straten, A, 2023)	0.91
" Safety endpoints assessed included all the adverse events (AEs) related to the study treatment (TLE400 and TLE600)."	( Safety of low dose efavirenz regimen in Indian adults with HIV-1 infection: Insights from a phase 4 interventional randomised trial. Anuradha, S; Bhrusundi, M; Dravid, AN; Kulkarni, V; Madhukarrao, KM; Morkar, DN; Nageswaramma, S; Naik, KS; Pilawan, AS; Ramapuram, JT; Raveendra, KR, 2023)	0.91
" However, greater adverse effects on renal function were observed for TDF than ETV at 60 months compared to 12 months."	( Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis. Liu, S; Liu, Z; Ma, X; Xin, Y; Zhao, Z, 2023)	0.91
"Long-term administration of TDF has resulted in stronger adverse effects than TAF and ETV in regard to both renal function and bone tissue in CHB patients."	( Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis. Liu, S; Liu, Z; Ma, X; Xin, Y; Zhao, Z, 2023)	0.91
" Adverse events were compared across treatment groups and time periods (blinded vs unblinded)."	( Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary anal Adeyeye, A; Anderson, PL; Berman, R; Clement, ME; Cohen, MS; Del Rio, C; Donnell, D; Eron, JJ; Eshleman, SH; Fields, SD; Grinsztejn, B; Hanscom, BS; Hendrix, CW; Kallas, EG; Kofron, RM; Landovitz, RJ; Lucas, JP; Magnus, M; Marzinke, MA; McCauley, M; Piwowar-Manning, EM; Richardson, PA; Rinehart, AR; Rooney, JF; Sanchez, J; Scott, H; Spinelli, MA; Sued, O; Sullivan, PA; Tran, HV, 2023)	0.91
" Adverse events were generally consistent with previous reports; incident hypertension in the long-acting PrEP group requires further investigation."	( Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary anal Adeyeye, A; Anderson, PL; Berman, R; Clement, ME; Cohen, MS; Del Rio, C; Donnell, D; Eron, JJ; Eshleman, SH; Fields, SD; Grinsztejn, B; Hanscom, BS; Hendrix, CW; Kallas, EG; Kofron, RM; Landovitz, RJ; Lucas, JP; Magnus, M; Marzinke, MA; McCauley, M; Piwowar-Manning, EM; Richardson, PA; Rinehart, AR; Rooney, JF; Sanchez, J; Scott, H; Spinelli, MA; Sued, O; Sullivan, PA; Tran, HV, 2023)	0.91
"In this first study of a long-acting HIV prevention agent in pregnancy, adverse pregnancy outcomes and complications were uncommon when DVR and TDF/FTC were used in the third trimester of pregnancy, suggesting a favorable safety profile for both prevention products."	( DELIVER: A Safety Study of a Dapivirine Vaginal Ring and Oral PrEP for the Prevention of HIV During Pregnancy. Balkus, JE; Bunge, K; Chakhtoura, N; Chappell, CA; Fairlie, L; Gadama, L; Hillier, SL; Matrimbira, M; Mayo, AJ; Mgodi, N; Nakabiito, C; Piper, J; Richardson, B; Szydlo, DW, 2024)	1.44

Excerpt	Reference	Relevance
" Pharmacokinetic parameters were dose proportional and demonstrated no change with repeated dosing."	( Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Barditch-Crovo, P; Coakley, DF; Coleman, RL; Collier, A; Deeks, SG; Kahn, JO; Kearney, BP; Lamy, PD; Lietman, PS; McGowan, I; Miller, M; Safrin, S, 2001)	0.31
" A two compartment pharmacokinetic model is employed to determine the time evolution of the intracellular concentrations of the active forms of drugs, and thereby drug efficacy."	( Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay. Dixit, NM; Perelson, AS, 2004)	0.32
"Phase I, open-label, fixed-sequence, pharmacokinetic drug-drug interaction study."	( Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadone. Berenson, CS; Booker, BM; Bullock, JM; Cloen, D; Coakley, DF; Flaherty, JF; Haas, CE; Kearney, BP; Liaw, S; Smith, PF; Yale, K, 2004)	0.32
" Both AUCss and Cmax met the strict criteria for bioequivalence between the two study periods for total, R-, and S-methadone, indicating a lack of drug interaction when tenofovir DF was coadministered with methadone."	( Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadone. Berenson, CS; Booker, BM; Bullock, JM; Cloen, D; Coakley, DF; Flaherty, JF; Haas, CE; Kearney, BP; Liaw, S; Smith, PF; Yale, K, 2004)	0.32
"On day 1, 12 h pharmacokinetic profiles for saquinavir/ritonavir (1000/100 mg given twice daily) were obtained for 18 subjects."	( Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects. Back, D; Boffito, M; Di Perri, G; Gazzard, B; Hill, A; Moyle, G; Nelson, M; Pozniak, A; Stainsby-Tron, M; Tomkins, J, 2005)	0.33
" Pharmacokinetic data for 23 subjects were thus evaluable."	( Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers. Buffels, R; Burger, DM; Droste, JA; Hekster, YA; Kearney, BP; Vanhorssen, PJ; Verweij-van Wissen, CP, 2005)	0.33
"The nucleotide analogue, tenofovir, has been shown to lower plasma atazanavir levels in pharmacokinetic trials, an interaction that may be partly reversed by the addition of ritonavir, whereas plasma tenofovir levels are themselves raised when the drug is combined with lopinavir/ritonavir."	( The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients. Becker, M; Breske, A; Esser, S; Hill, A; Koerber, A; Kopperman, M; Kruse, G; Kurowski, M; Möcklinghoff, C; Ross, B; Stocker, H; Wiehler, H, 2005)	0.33
"Eighteen patients received nelfinavir 1250 mg twice daily plus prescribed nucleoside reverse transcriptase inhibitors for at least 14 days, with pharmacokinetic measurements performed on day 15."	( The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients. Becker, M; Breske, A; Esser, S; Hill, A; Koerber, A; Kopperman, M; Kruse, G; Kurowski, M; Möcklinghoff, C; Ross, B; Stocker, H; Wiehler, H, 2005)	0.33
" TFV-DP also had persistent intracellular levels on TDF discontinuation (median half-life of 150 hours, range: 60 to >175 hours)."	( Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. Clark, N; Guyer, B; Hawkins, T; Kearney, BP; St Claire, RL; Veikley, W, 2005)	0.33
" Steady-state RTV AUCtau and Cmax levels were not significantly altered, whereas Ctau was 23% higher upon coadministration of SQV/RTV and TDF."	( Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state. Adda, N; Begley, JA; Blum, MR; Chittick, GE; Kearney, BP; Sorbel, JJ; Zong, J, 2006)	0.33
" Pharmacokinetic sampling was performed on days 1 through 4 and 22 through 25."	( Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects. Cheng, A; Ebrahimi, R; Kearney, BP; Mittan, A; Ramanathan, S, 2006)	0.33
"A population pharmacokinetic analysis was performed in the context of therapeutic drug monitoring (87 patients, 121 samples)."	( Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients. Arvieux, C; Dailly, E; Jolliet, P; Perré, P; Raffi, F; Tattevin, P; Tribut, O, 2006)	0.33
"We evaluated the impact of modelling intra-subject variability on the likelihood ratio test (LRT) and the Wald test based on non-linear mixed effects models in pharmacokinetic interaction and bioequivalence cross-over trials."	( Impact of modelling intra-subject variability on tests based on non-linear mixed-effects models in cross-over pharmacokinetic trials with application to the interaction of tenofovir on atazanavir in HIV patients. Mentré, F; Panhard, X; Piketti, C; Taburet, AM, 2007)	0.34
" A pharmacokinetic study in healthy volunteers was conducted to assess the potential for a drug interaction between these agents."	( Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. Cheng, AK; Ebrahimi, R; Kearney, BP; Mathias, A; Mittan, A; Sayre, J, 2006)	0.33
" Pharmacokinetic assessments were performed over 24 hours on days 7, 21, and 35."	( Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. Cheng, AK; Ebrahimi, R; Kearney, BP; Mathias, A; Mittan, A; Sayre, J, 2006)	0.33
" Pharmacokinetic (PK) blood draws were performed on days 7, 17, and 27."	( Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. Cheng, A; Kearney, BP; Ramanathan, S; Shen, G, 2007)	0.34
" We evaluated the possibility of a pharmacokinetic interaction between TFV and EFV by assessing cross-sectional and longitudinal data in 169 individuals receiving EFV."	( Does tenofovir influence efavirenz pharmacokinetics? Buclin, T; Colombo, S; Décosterd, L; Furrer, H; Rotger, M; Telenti, A, 2007)	0.34
"Although there is no clear evidence for a pharmacokinetic interaction between TFV and EFV, we cannot rule out an interaction between these drugs restricted to individuals who are slow EFV metabolizers."	( Does tenofovir influence efavirenz pharmacokinetics? Buclin, T; Colombo, S; Décosterd, L; Furrer, H; Rotger, M; Telenti, A, 2007)	0.34
" As both drugs are extensively renally eliminated, a randomized, 3-way crossover study was conducted in 19 healthy volunteers to formally evaluate the potential pharmacokinetic interaction when the drugs are administered alone and together (ie, 200 mg emtricitabine qd for 7 days, 300 mg tenofovir disoproxil fumarate qd for 7 days, and 200 mg emtricitabine plus 300 mg tenofovir disoproxil fumarate qd for 7 days) with no washout between treatments."	( Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers. Begley, JA; Blum, MR; Chittick, GE; Zong, J, 2007)	0.34
"The effect of tenofovir disoproxil fumarate (TDF) in combination with two boosted fosamprenavir regimens on amprenavir pharmacokinetic parameters was assessed in this prospective phase I crossover study with 30 healthy volunteers."	( Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir. Banik, N; Breske, A; Kruse, G; Kurowski, M; Mazur, D; Richter, H; Stocker, H; Walli, RK, 2007)	0.34
"TMC114 is a new HIV protease inhibitor, used in combination with low-dose ritonavir (TMC114/r) as a pharmacokinetic enhancer."	( Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers. De Doncker, P; De Pauw, M; Hill, A; Hoetelmans, RM; Lefebvre, E; Mariën, K; Peeters, M; Sekar, V; Woodfall, B, 2007)	0.34
" Pharmacokinetic parameters estimated by noncompartmental method were reported as 90% confidence intervals (CIs) about the geometric mean ratio (GMR)."	( Lopinavir/Ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy. Acosta, EP; Binongo, JN; Chuck, SK; Lennox, JL; Ofotokun, I; Palau, M, 2007)	0.34
"Atazanavir/ritonavir plasma concentrations were measured by liquid chromatography tandem mass spectrometry, and the geometric means of minimum and maximum concentrations (C(min), C(max)), the area under the time-concentration curve (AUC), half-life (t(1/2)) and total clearance (CL(tot)) were subject to a matched pairs-analysis."	( Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults. Dauer, B; Haberl, A; Harder, S; Klauke, S; Lutz, T; Staszewski, S; von Hentig, N, 2007)	0.34
"The coadministration of tenofovir-DF did not impair the plasma concentrations of ritonavir-boosted atazanavir in a pharmacokinetic analysis of patient pairs matched for gender, ethnicity, weight and CDC status."	( Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults. Dauer, B; Haberl, A; Harder, S; Klauke, S; Lutz, T; Staszewski, S; von Hentig, N, 2007)	0.34
" The clinical consequences of these substantial pharmacokinetic changes should be investigated."	( Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma. Corona, G; Innocenti, F; Sandron, S; Sartor, I; Tirelli, U; Toffoli, G; Vaccher, E, 2008)	0.35
" HIV-infected subjects > or =18 to <25 years old receiving (> or =28 days) 300/100 mg atazanavir-ritonavir plus 300 mg tenofovir disoproxil fumarate (TDF) plus one or more other nucleoside analogs underwent intensive 24-h pharmacokinetic studies following a light meal."	( Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. Cunningham, CK; Fletcher, CV; Flynn, PM; Harris, DR; Havens, PL; Kapogiannis, BG; Kiser, JJ; Liu, NX; Major-Wilson, H; Muenz, LR; Viani, RM; Wilson, CM, 2008)	0.35
"A pharmacokinetic study of blood plasma (BP) and GT TFV concentrations in 9 men was conducted after 1 and > or =14 doses of TDF."	( The pharmacokinetics and viral activity of tenofovir in the male genital tract. Chen, YC; Cohen, MS; Fiscus, SA; Hui, J; Kashuba, AD; Kearney, BP; Patterson, KB; Rezk, NL; Rooney, JF; Tappouni, HL; Vourvahis, M, 2008)	0.35
"To assess the potential of cotrimoxazole and tenofovir, drugs which are inhibitors and/or substrates of renal transporters, to alter the pharmacokinetic profile of maraviroc."	( The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers. Abel, S; Muirhead, GJ; Ridgway, CE; Russell, D; Whitlock, LA, 2008)	0.35
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
"An open-label, randomized, 3-way crossover, drug-drug interaction study of the investigational anti-HBV combination agent, emtricitabine/tenofovir DF and the antirejection agent, tacrolimus was conducted in healthy volunteers to evaluate the potential for a pharmacokinetic interaction between these drugs."	( Pharmacokinetics of emtricitabine/tenofovir disoproxil fumarate and tacrolimus at steady state when administered alone or in combination. Alianti, JR; Begley, JA; Blum, MR; Chittick, GE; Sorbel, JJ; Zong, J, 2008)	0.35
" Drug concentrations were measured by LC/MS/MS and steady state pharmacokinetic parameters were calculated for each drug using noncompartmental methods."	( Pharmacokinetics of emtricitabine/tenofovir disoproxil fumarate and tacrolimus at steady state when administered alone or in combination. Alianti, JR; Begley, JA; Blum, MR; Chittick, GE; Sorbel, JJ; Zong, J, 2008)	0.35
"The 90% confidence intervals (CIs) of the geometric least-squares mean ratio for AUCtau, Cmax and Ctau for each drug together vs."	( Pharmacokinetics of emtricitabine/tenofovir disoproxil fumarate and tacrolimus at steady state when administered alone or in combination. Alianti, JR; Begley, JA; Blum, MR; Chittick, GE; Sorbel, JJ; Zong, J, 2008)	0.35
"It was concluded that there was no clinically relevant pharmacokinetic interaction between emtricitabine/tenofovir DF and tacrolimus when administered together."	( Pharmacokinetics of emtricitabine/tenofovir disoproxil fumarate and tacrolimus at steady state when administered alone or in combination. Alianti, JR; Begley, JA; Blum, MR; Chittick, GE; Sorbel, JJ; Zong, J, 2008)	0.35
"6-h half-life (30%)."	( Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Arrivé, E; Avit, D; Blanche, S; Coffié, P; Dabis, F; Ekouévi, DK; Hirt, D; Lalsab, S; Leang, SK; McIntyre, J; Nerrienet, E; Rey, E; Tréluyer, JM; Urien, S, 2009)	0.35
"Two open-label, randomized, cross-over trials in healthy volunteers were conducted to investigate the pharmacokinetic interaction between etravirine and tenofovir disoproxil fumarate."	( Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers. Aharchi, F; Beets, G; De Smedt, G; Hoetelmans, RM; Kakuda, TN; Peeters, MP; Schöller-Gyüre, M; Vandermeulen, K; Woodfall, BJ, 2009)	0.35
"Etravirine was administered as either 800 mg twice a day (bid) (phase II formulation in Study 1) or 200 mg bid (phase III formulation in Study 2) for 8 days followed by a 12 h pharmacokinetic evaluation."	( Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers. Aharchi, F; Beets, G; De Smedt, G; Hoetelmans, RM; Kakuda, TN; Peeters, MP; Schöller-Gyüre, M; Vandermeulen, K; Woodfall, BJ, 2009)	0.35
" Statistical analyses were performed on pharmacokinetic parameters: the area under the concentration-time curve from 0 to 4 h (AUC(0-4)), the maximum concentration of the drug (C(max)), and the residual concentration of the drug at the end of the dosing interval (C(trough)) for plasma and the AUC(0-4) and C(trough) for intracellular data."	( Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. Ayen, R; Clotet, B; Grassi, J; Levi, M; Negredo, E; Pruvost, A; Puig, J; Théodoro, F, 2009)	0.35
"Prospective, open-label, pharmacokinetic study in 12 HIV-infected patients stabilized on FPV/RTV 1400 mg/200 mg + tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) 300 mg/200 mg QD (TELEX II)."	( Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II). Acosta, EP; Jennings, HC; Pakes, GE; Parks, DA; Taylor, C, )	0.13
" Four weeks after reducing RTV, changes in Cmin and AUC24h were: APV: +26%, +0."	( Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II). Acosta, EP; Jennings, HC; Pakes, GE; Parks, DA; Taylor, C, )	0.13
"Thirty-day, open-label, fixed-sequence, pharmacokinetic drug-drug interaction study."	( Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives. Kearney, BP; Mathias, A, 2009)	0.35
" Geometric mean ratios (90% confidence intervals) for the pharmacokinetic parameters for deacetyl norgestimate and ethinyl estradiol were estimated by using analysis of variance and compared with the no-effect criterion for bioequivalence."	( Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives. Kearney, BP; Mathias, A, 2009)	0.35
"Objective An open-label, three-period pharmacokinetic study was conducted to investigate the drug interaction potential between fosamprenavir (FPV) and tenofovir disoproxil fumarate (TDF)."	( Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers. Andrews, M; Condoluci, DV; Luber, AD; Olson, K; Pakes, GE; Pappa, KA; Peloquin, CA; Slowinski, PD, 2010)	0.36
"Nucleoside-sparing combination antiretroviral therapy (cART) regimens might be an attractive therapeutic option for HIV type-1 (HIV-1)-infected patients; however, the pharmacokinetic profiles of such regimens are frequently unknown."	( The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients. Back, D; Dickinson, L; Erlwein, OW; Garvey, L; Latch, N; Mackie, NE; McClure, MO; Scullard, G; Walsh, J; Winston, A, 2010)	0.36
"Fourteen HIV-1-infected patients (age 21-55 years, 64% male) on stable cART with plasma HIV RNA <50 copies/ml entered this Phase I pharmacokinetic study."	( The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients. Back, D; Dickinson, L; Erlwein, OW; Garvey, L; Latch, N; Mackie, NE; McClure, MO; Scullard, G; Walsh, J; Winston, A, 2010)	0.36
"A pharmacokinetic trial was conducted to evaluate the potential for once-daily etravirine in antiretroviral regimens without and with darunavir/ritonavir."	( Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults. DeJesus, E; Kakuda, TN; Lalezari, JP; Osiyemi, OO; Ruane, PJ; Ryan, R; Witek, J, 2010)	0.36
"Of 23 enrolled patients (male 87%, Caucasian 39%), pharmacokinetic profiles for etravirine were available for 21 and 20 patients on day 14 and 28, respectively."	( Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults. DeJesus, E; Kakuda, TN; Lalezari, JP; Osiyemi, OO; Ruane, PJ; Ryan, R; Witek, J, 2010)	0.36
" Pharmacokinetic data were available in 577 patients randomized to receive etravirine."	( Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients. Corbett, C; De Smedt, G; Hoetelmans, RM; Kakuda, TN; Leopold, L; Nijs, S; Peeters, MP; Schöller-Gyüre, M; Snoeck, E; Vingerhoets, J; Vis, P; Wade, JR; Woodfall, BJ, 2010)	0.36
"Intensive steady-state 24-hour pharmacokinetic profiles were performed during the third trimester and at 6-12 weeks postpartum."	( Atazanavir pharmacokinetics with and without tenofovir during pregnancy. Basar, M; Best, BM; Burchett, SK; Capparelli, EV; Hawkins, E; Hu, C; Mirochnick, M; Read, JS; Rossi, SS; Smith, E; Stek, AM, 2011)	0.37
" A total of 151 ATV plasma concentrations were obtained, and a population pharmacokinetic model was developed with NONMEM."	( Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents. Blanche, S; Dollfus, C; Firtion, G; Foissac, F; Hirt, D; Laurent, C; Treluyer, JM; Urien, S, 2011)	0.37
" We report the pharmacokinetic parameters of tenofovir in combination with efavirenz, darunavir-ritonavir, or atazanavir-ritonavir in HIV-infected children."	( Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients. Acosta, EP; Britto, P; Carey, V; Graham, B; Hazra, R; Jean-Philippe, P; King, JR; Wiznia, A; Yogev, R, 2011)	0.37
"Significant pharmacokinetic interactions can result between acid-suppressing agents and some protease inhibitors (PIs) in the management of HIV infection."	( Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients. Bertz, R; Boffito, M; Child, M; Chung, E; Kashuba, A; Mahnke, L; Patterson, K; Tebas, P; Wang, X; Wu, Y; Zhang, J; Zhu, L, 2011)	0.37
"Tenofovir concentrations were monitored on a routine basis and measured in 93 children aged 5 to 18 years; 283 tenofovir plasma concentrations were used to perform a population pharmacokinetic analysis."	( Population pharmacokinetics of tenofovir in HIV-1-infected pediatric patients. Benaboud, S; Blanche, S; Bouazza, N; Foissac, F; Frange, P; Hirt, D; Rey, E; Tréluyer, JM; Urien, S, 2011)	0.37
" The gel also prevents infection in macaques when applied intravaginally or intrarectally prior to challenge with simian-human immunodeficiency virus (SHIV), but very little pharmacokinetic information for macaques is available to help extrapolate the data to humans and thus inform future development activities."	( Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques. Allen, P; Kashuba, A; Nuttall, J; Roberts, J; Romano, J; Wang, R; White, N, 2012)	0.38
" More comprehensive in vivo pharmacokinetic data are required to justify the potential use of these agents as safe and effective options during pregnancy."	( Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid). Back, DJ; Else, LJ; Khoo, SH; Taylor, S, 2011)	0.37
"Comparative pharmacokinetic study in sheep."	( Tenofovir and tenofovir disoproxil fumarate pharmacokinetics from intravaginal rings. Baum, MM; Butkyavichene, I; Gilman, J; Kennedy, S; Kopin, E; Malone, AM; Moss, JA; Motamedi, M; Nguyen, C; Smith, TJ; Vincent, KL; Willis, RA, 2012)	0.38
" The proposed assay method was found to be applicable to a pharmacokinetic study in human male volunteers."	( A novel LC-MS/MS method for simultaneous quantification of tenofovir and lamivudine in human plasma and its application to a pharmacokinetic study. Burugula, L; Inamadugu, JK; J V L N, SR; Matta, MK; Pilli, NR, 2012)	0.38
" The impact of changing the current gel formulation to reduce its osmolality was evaluated using pharmacokinetic assessments and local tissue effects in the rabbit."	( Pharmacokinetics and topical vaginal effects of two tenofovir gels in rabbits. Clark, MR; Friend, DR, 2012)	0.38
" We developed a pharmacokinetic model for TDF and its active anabolite tenofovir-diphosphate (TFV-DP) and validated it with data from 4 different trials, including 4 distinct dosing regimes."	( Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection. Duwal, S; Schütte, C; von Kleist, M, 2012)	0.38
"This study was designed to assess the safety, acceptability, pharmacokinetic (PK), and pharmacodynamic (PD) responses to rectal administration of tenofovir (TFV) 1% vaginally formulated gel and oral tenofovir disoproxil fumarate (TDF)."	( RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate. Anton, PA; Bumpus, NN; Carballo-Diéguez, A; Cranston, RD; Cumberland, WG; Dennis, R; Elliott, J; Hendrix, CW; Janocko, L; Ju, C; Kashuba, A; Khanukhova, E; Mauck, C; McGowan, I; Richardson-Harman, N, 2012)	0.38
"This is the first pharmacokinetic modelling of antiretroviral disposition in BP and CVF."	( Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women. Cohen, MS; Dumond, JB; Forrest, A; Garonzik, SM; Kashuba, AD; Kendrick, RN; Nicol, MR; Patterson, KB, 2012)	0.38
" Twenty-four-hour pharmacokinetic curves were recorded in the third trimester (preferably week 33) and postpartum (preferably week 4-6)."	( The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women. Burger, DM; Colbers, AP; Giaquinto, C; Gingelmaier, A; Hawkins, DA; Ivanovic, J; Kabeya, K; Moltó, J; Rockstroh, JK; Sadiq, ST; Taylor, GP; Weizsäcker, K; Wyen, C, 2013)	0.39
"Although pharmacokinetic exposure of the NRTIs TDF and FTC during pregnancy is approximately 25% lower, this was not associated with virological failure in this study and did not result in mother-to-child transmission."	( The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women. Burger, DM; Colbers, AP; Giaquinto, C; Gingelmaier, A; Hawkins, DA; Ivanovic, J; Kabeya, K; Moltó, J; Rockstroh, JK; Sadiq, ST; Taylor, GP; Weizsäcker, K; Wyen, C, 2013)	0.39
" Drug concentrations at two trough values of 12 and 24 h after dosing (C(12) and C(24)), area under the concentration-curve values (AUC), maximum drug concentration (C(max)), and the time at which this concentration occurred (T(max)) in plasma were estimated with noncompartmental pharmacokinetic methods and compared to data from a subset of white subjects randomized to the RAL twice a day (plus TDF/FTC) arm of the QDMRK study, a phase III study of the safety and efficacy of once daily versus twice daily RAL in treatment naive patients."	( Raltegravir pharmacokinetics in treatment-naive patients is not influenced by race: results from the raltegravir early therapy in African-Americans living with HIV (REAL) study. Blevins, S; Dumond, JB; Eron, JJ; Floris-Moore, M; Hudgens, MG; Kashuba, AD; Massengale, K; Pittard, D; Ragan, D; Richardson, A; Walsh, K; Wang, R; Wohl, DA, 2013)	0.39
" The pharmacokinetic properties and the effects of food intake on tenofovir dipivoxil have not yet been reported in healthy adults."	( Pharmacokinetics and food interaction of a novel prodrug of tenofovir, tenofovir dipivoxil fumarate, in healthy volunteers. Chen, L; Chen, M; Ding, Y; Jia, Y; Lu, C; Song, Y; Sun, X; Wen, A; Yang, J, 2013)	0.39
" Pharmacokinetic parameters of tenofovir given in each treatment period were calculated using non-compartmental analysis."	( Pharmacokinetics and food interaction of a novel prodrug of tenofovir, tenofovir dipivoxil fumarate, in healthy volunteers. Chen, L; Chen, M; Ding, Y; Jia, Y; Lu, C; Song, Y; Sun, X; Wen, A; Yang, J, 2013)	0.39
"After a single dose of 150, 300 and 600 mg, the main pharmacokinetic parameters for tenofovir were as follows: Cmax 209·6, 456·7, 989·8 ng/mL; AUClast 1744·9, 2663·5, 6010·2 ng h/mL, respectively."	( Pharmacokinetics and food interaction of a novel prodrug of tenofovir, tenofovir dipivoxil fumarate, in healthy volunteers. Chen, L; Chen, M; Ding, Y; Jia, Y; Lu, C; Song, Y; Sun, X; Wen, A; Yang, J, 2013)	0.39
"International Maternal Pediatric Adolescent AIDS Clinical Trials Group 1026s is a prospective, nonblinded, pharmacokinetic study of HIV-infected pregnant women taking antiretrovirals for clinical indications, including 2 cohorts (with or without tenofovir) receiving atazanavir/ritonavir 300/100 mg once daily during the second trimester, 400/100 mg during the third trimester, and 300/100 mg postpartum (PP)."	( Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy. Best, BM; Burchett, SK; Byroads, M; Caparelli, E; Cressey, TR; Hawkins, E; Kreitchmann, R; Mirochnick, M; Rossi, S; Shapiro, DE; Smith, E; Stek, A; Wang, J; Watts, DH, 2013)	0.39
"Atazanavir pharmacokinetic data were available for 37 women without tenofovir, 35 with tenofovir; median (range) pharmacokinetic parameters are presented for second trimester, third trimester, and PP and number who met target/total."	( Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy. Best, BM; Burchett, SK; Byroads, M; Caparelli, E; Cressey, TR; Hawkins, E; Kreitchmann, R; Mirochnick, M; Rossi, S; Shapiro, DE; Smith, E; Stek, A; Wang, J; Watts, DH, 2013)	0.39
" Noncompartmental pharmacokinetic analysis was used to estimate PK parameters [area under the concentration-time curve over 24 h (AUC0-24h ) and maximal concentration (Cmax )]."	( Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study. Adams, JL; Corbett, AH; Dumond, JB; Forrest, A; Jennings, SH; Kashuba, AD; Kendrick, RL; Malone, S; Patterson, KB; Prince, HM; Sykes, C; Wang, R; White, N, 2013)	0.39
" Compared with the general population, these elderly subjects had 8-13% decreased TFV AUC0-24h and Cmax , and 19-78% increased FTC and RTV AUC0-24h and Cmax ."	( Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study. Adams, JL; Corbett, AH; Dumond, JB; Forrest, A; Jennings, SH; Kashuba, AD; Kendrick, RL; Malone, S; Patterson, KB; Prince, HM; Sykes, C; Wang, R; White, N, 2013)	0.39
"To investigate pharmacokinetic interactions associated with coadministration of lersivirine with zidovudine, tenofovir disoproxil fumarate (DF)/emtricitabine (Truvada(®)) or abacavir/lamivudine (Epzicom(®)/Kivexa(®))."	( Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine. Choo, HW; Davis, J; Fang, J; Hansson, AG; Langdon, G; Layton, G; Tawadrous, M; Vourvahis, M, 2013)	0.39
" Pharmacokinetic parameters were calculated by standard non-compartmental methods."	( Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine. Choo, HW; Davis, J; Fang, J; Hansson, AG; Langdon, G; Layton, G; Tawadrous, M; Vourvahis, M, 2013)	0.39
" Plasma TFV demonstrated triphasic decay with terminal elimination half-life median [interquartile range (IQR)] 69 h (58-77)."	( Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue. Anderson, JR; Bakshi, R; Cao, YJ; Everts, S; Fuchs, EJ; Hendrix, CW; Liberman, RG; Louissaint, NA; Nimmagadda, S; Skipper, PL; Tannenbaum, SR, 2013)	0.39
" A pharmacokinetic interaction between tenofovir and ritonavir may have resulted in the toxicity."	( Tenofovir induced Fanconi syndrome: a possible pharmacokinetic interaction. Desai, C; Desai, M; Dikshit, RK; Kapadia, J; Patel, S; Shah, AN; Shah, S, )	0.13
" The method was successfully applied to the pharmacokinetic study of two tenofovir agents."	( [Pharmacokinetics of tenofovir in Beagle dogs after oral dosing of tenofovir dipivoxil fumarate using HPLC-MS/MS analysis]. Chen, H; Hu, JP; Li, Y; Sheng, L; Wang, BL, 2013)	0.39
"The pharmacokinetic data support coadministration of daclatasvir with atazanavir/ritonavir, efavirenz and/or tenofovir."	( Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Bertz, R; Bifano, M; Grasela, D; Hartstra, J; Hwang, C; Kandoussi, H; Oosterhuis, B; Sevinsky, H; Tiessen, R; Velinova-Donga, M, 2013)	0.39
" Pharmacokinetic sampling was performed on cohort 1 and 3 mothers and all infants."	( Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life. Emel, L; Eshleman, SH; Fowler, MG; George, K; Herron, C; Hudelson, SE; Joao, E; Kearney, B; Kreitchmann, R; Kumwenda, N; Mirochnick, M; Mofenson, L; Nielsen-Saines, K; Parsons, T; Pinto, J; Richardson, P; Santos, B; Sato, P; Taha, T, 2014)	0.4
" Separate pharmacokinetic properties may be associated with distinct TDF toxicities: tenofovir with parathyroid hormone and altered calcium balance and tenofovir diphosphate with hypophosphatemia and FGF23 regulation."	( Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency? Baker, A; Bethel, J; Flynn, PM; Gordon, CM; Havens, PL; Hazra, R; Kapogiannis, BG; Kiser, JJ; Liu, N; Lujan-Zilbermann, J; Mulligan, K; Pan, CG; Rutledge, B; Stephensen, CB; Van Loan, MD; Wilson, CM; Woodhouse, LR, 2013)	0.39
" Increasing epithelial thickness delayed initial TFV delivery to stroma and its decline: tmax increased but AUC at 24 hours was not significantly altered."	( Multicompartmental pharmacokinetic model of tenofovir delivery by a vaginal gel. Gao, Y; Katz, DF, 2013)	0.39
" Although its use for the treatment of HIV has been approved by the Chinese State Food and Drug Administration, there are no data on the pharmacokinetic profile of TDF in Chinese individuals."	( Pharmacokinetics and tolerability of Tenofovir disoproxil fumarate 300 mg once daily: an open-label, single- and multiple-dose study in healthy Chinese subjects. Chen, Q; Dong, J; Hu, CY; Jia, JY; Li, J; Li, X; Liu, Y; Liu, YM; Lu, C; Sun, SX; Wang, W; Wu, K; Yu, C, 2013)	0.39
"This study aimed to investigate the pharmacokinetic properties and tolerability of TDF in healthy Chinese subjects."	( Pharmacokinetics and tolerability of Tenofovir disoproxil fumarate 300 mg once daily: an open-label, single- and multiple-dose study in healthy Chinese subjects. Chen, Q; Dong, J; Hu, CY; Jia, JY; Li, J; Li, X; Liu, Y; Liu, YM; Lu, C; Sun, SX; Wang, W; Wu, K; Yu, C, 2013)	0.39
" Pharmacokinetic parameters were estimated using a noncompartmental model."	( Pharmacokinetics and tolerability of Tenofovir disoproxil fumarate 300 mg once daily: an open-label, single- and multiple-dose study in healthy Chinese subjects. Chen, Q; Dong, J; Hu, CY; Jia, JY; Li, J; Li, X; Liu, Y; Liu, YM; Lu, C; Sun, SX; Wang, W; Wu, K; Yu, C, 2013)	0.39
" TDF exhibited a pharmacokinetic profile similar to that of healthy Western subjects in a historical comparison."	( Pharmacokinetics and tolerability of Tenofovir disoproxil fumarate 300 mg once daily: an open-label, single- and multiple-dose study in healthy Chinese subjects. Chen, Q; Dong, J; Hu, CY; Jia, JY; Li, J; Li, X; Liu, Y; Liu, YM; Lu, C; Sun, SX; Wang, W; Wu, K; Yu, C, 2013)	0.39
"The objectives of this analysis were to develop a population pharmacokinetic model (PPK) for tenofovir without using potentially unreliable patient reported dosing records and to retrace patient dosing history using pharmacokinetic simulations conditioned on protocol design constraints to assess patient adherence."	( Estimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies. Chaturvedula, A; Fossler, MJ; Hendrix, CW, 2014)	0.4
"Intensive pharmacokinetic studies of tenofovir in a large, diverse cohort of HIV-infected women over 24 h at steady state were performed and factors that influenced exposure [assessed by areas under the concentration-time curves (AUCs)] identified."	( Common clinical conditions - age, low BMI, ritonavir use, mild renal impairment - affect tenofovir pharmacokinetics in a large cohort of HIV-infected women. Anastos, K; Bacchetti, P; Baxi, SM; Cohen, M; Gandhi, M; Gange, SJ; Greenblatt, RM; Huang, Y; Minkoff, H; Scherzer, R; Shlipak, MG; Young, M, 2014)	0.4
"HIV-infected women (n = 101) on tenofovir-based therapy underwent intensive 24-h pharmacokinetic sampling."	( Common clinical conditions - age, low BMI, ritonavir use, mild renal impairment - affect tenofovir pharmacokinetics in a large cohort of HIV-infected women. Anastos, K; Bacchetti, P; Baxi, SM; Cohen, M; Gandhi, M; Gange, SJ; Greenblatt, RM; Huang, Y; Minkoff, H; Scherzer, R; Shlipak, MG; Young, M, 2014)	0.4
"Administration of 40 mg of tenofovir alafenamide for 14 days resulted in lower tenofovir Cmax (13 versus 207 ng/mL) and lower systemic exposures (AUC0-t, 383 versus 1810 ng · h/mL) compared with subjects who received tenofovir disoproxil fumarate."	( Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. Coakley, D; Kearney, B; Lee, WA; Markowitz, M; Miller, MD; Ruane, P; Squires, K; Wulfsohn, M; Zhong, L; Zolopa, A, 2014)	0.4
" In this open-label, randomized, three-way crossover study, the pharmacokinetic profiles of elvitegravir, cobicistat, emtricitabine, and tenofovir were evaluated when administered with a standard breakfast, under fasting conditions, or with a nutritional protein-rich drink."	( Effects of a protein-rich drink or a standard meal on the pharmacokinetics of elvitegravir, cobicistat, emtricitabine and tenofovir in healthy Japanese male subjects: a randomized, three-way crossover study. Ikeda, A; Irie, S; Ishikawa, T; Kimura, M; Matsuki, S; Nishino, N; Shiomi, M, 2014)	0.4
" The authors studied ATV pharmacokinetic (PK) parameters among children who received atazanavir/ritonavir co-administered with TDF."	( Pharmacokinetics of atazanavir/ritonavir among HIV-infected Thai children concomitantly taking tenofovir disoproxil fumarate. Ananworanich, J; Bunupuradah, T; Keadpudsa, S; Prasitsuebsai, W; Puthanakit, T; Sahakijpicharn, T; Srimuan, A; Techasaensiri, C; Thammajaruk, N, 2014)	0.4
"The objective of this analysis was to develop and qualify a population pharmacokinetic model describing plasma tenofovir (TFV) concentrations and tenofovir-diphosphate (TFV-DP) concentrations in peripheral blood mononuclear cell (PBMC) in healthy women volunteers from the MTN-001 clinical trial, an open label 3-way crossover study of oral tenofovir disoproxil fumarate 300 mg tablet, TFV 1% vaginal gel, or both."	( Population pharmacokinetics of tenofovir and tenofovir-diphosphate in healthy women. Burns, RN; Chaturvedula, A; Hendrix, CW, 2015)	0.42
"This was an open-label, three-period, longitudinal pharmacokinetic study with patients serving as their own controls."	( Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults. Back, DJ; Byakika-Kibwika, P; Else, L; Katwere, M; Khoo, SH; Lamorde, M; Merry, C; Mukisa, L; Sempa, JB; Walimbwa, S, 2015)	0.42
" Pharmacokinetic parameters were unchanged during administration with a low-fat meal, except for C24, which was significantly increased by 15% (1."	( Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults. Back, DJ; Byakika-Kibwika, P; Else, L; Katwere, M; Khoo, SH; Lamorde, M; Merry, C; Mukisa, L; Sempa, JB; Walimbwa, S, 2015)	0.42
"A food effect was observed for steady-state pharmacokinetic parameters of rilpivirine (AUC0-24 and C24) when TDF/FTC/RPV was administered in the fasted state compared with the moderate-fat meal."	( Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults. Back, DJ; Byakika-Kibwika, P; Else, L; Katwere, M; Khoo, SH; Lamorde, M; Merry, C; Mukisa, L; Sempa, JB; Walimbwa, S, 2015)	0.42
" The objective of this study was to assess the pharmacokinetic (PK) profile in older HIV-infected subjects (>60 years) switching combination antiretroviral therapy (cART) to a raltegravir (RAL) containing regimen."	( The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age. Back, D; Barber, T; Boffito, M; Dickinson, L; Else, L; Jackson, A; Mora-Peris, B; Vera, JH; Winston, A, )	0.13
"2 years, n = 38) based on population pharmacokinetic analysis."	( The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age. Back, D; Barber, T; Boffito, M; Dickinson, L; Else, L; Jackson, A; Mora-Peris, B; Vera, JH; Winston, A, )	0.13
" We performed a 3-month general toxicology study, a preliminary pharmacokinetic study using drug-loaded vaginal gel, and a detailed assessment of the kinetics of dapivirine delivery to plasma, vaginal, and rectal fluid and rectal, vaginal, and cervical tissue over 28 days of exposure and 3 and 7 days after removal of the ring."	( The sheep as a model of preclinical safety and pharmacokinetic evaluations of candidate microbicides. Cameron, D; Dias, N; Dreier, P; Holding, J; Holt, JD; Muntendam, A; Nuttall, J; Oostebring, F; Rohan, L, 2015)	0.42
" From the interaction between atazanavir and DTG via CYP3A4 and UGT1A1 and placental efflux transporter inhibition and considering the infant's probable enzymatic immaturity, the DTG elimination half-life was estimated to be 4-fold longer in neonates than in adults."	( Pharmacokinetics of dolutegravir in a premature neonate after HIV treatment intensification during pregnancy. Amiel, C; Caseris, M; Charpentier, C; Descamps, D; Desnoyer, A; Farnoux, C; Lassel, L; Lê, MP; Pain, JB; Peytavin, G; Pialoux, G, 2015)	0.42
"This was an open-label pharmacokinetic study."	( Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment. Avihingsanon, A; Bowonwatanuwong, C; Cressey, TR; Fletcher, CV; Halue, G; Jaisieng, N; Jourdain, G; Klinbuayaem, V; Leenasirimakul, P; Podany, AT; Sukrakanchana, PO; Tawon, Y, 2015)	0.42
"International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT) P1026s is a prospective, nonblinded pharmacokinetic study of HIV-infected pregnant women that included a cohort receiving 300 mg TDF once daily."	( Pharmacokinetics of tenofovir during pregnancy and postpartum. Best, BM; Burchett, S; Byroads, M; Capparelli, EV; Fletcher, CV; Hawkins, E; Hu, C; Li, H; Mirochnick, M; Smith, E; Stek, A; Wang, J; Watts, DH, 2015)	0.42
" Finally the method was successfully applied for human pharmacokinetic study in eight healthy male volunteers after the oral administration of 600 mg darunavir along with 100 mg ritonavir and 100 mg tenofovir as boosters."	( Development and validation of a rapid ultra high performance liquid chromatography with tandem mass spectrometry method for the simultaneous determination of darunavir, ritonavir, and tenofovir in human plasma: Application to human pharmacokinetics. Aris, AB; Jaafar, J; Madhavi, G; Majid, ZA; Reddy, AV; Talib, J; Umar, K, 2015)	0.42
" Pharmacokinetic sampling was performed over 12-hour periods, 4 weeks after initiation of RAL together with RIF (period 1), 4 weeks after RIF discontinuation (period 2), and after the RAL dose reduction in arm 2 (period 3)."	( Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy. Assuied, A; De Castro, N; Fagard, C; Grinsztejn, B; Grondin, C; Molina, JM; Pilotto, JH; Sauvageon, H; Taburet, AM; Veloso, V, 2015)	0.42
"Tenofovir is an efficacious drug with a long half-life and high activity against both HIV and HBV."	( Population pharmacokinetics of tenofovir in HIV/HBV co-infected patients. Avihingsanon, A; Burger, D; Lewin, SR; Matthews, G; Punyawudho, B; Ruxrungtham, K; Thammajaruk, N; Thongpeang, P, 2015)	0.42
" The population pharmacokinetic model of tenofovir was developed by a nonlinear mixed-effects modeling approach (NONMEM®)."	( Population pharmacokinetics of tenofovir in HIV/HBV co-infected patients. Avihingsanon, A; Burger, D; Lewin, SR; Matthews, G; Punyawudho, B; Ruxrungtham, K; Thammajaruk, N; Thongpeang, P, 2015)	0.42
" Thus, we conducted a single-dose pharmacokinetic study of TFV gel applied 1 or 24 hours before or 1 hour before and 1 hour after (BAT) sex and compared results with dosing without sex."	( Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel. Chen, BA; Dezzutti, CS; Galaska, B; Hendrix, CW; Herold, BC; Hillier, S; Kelly, CW; Levy, L; Marzinke, MA; McGowan, I; Piper, JM; Salata, RA, 2016)	0.43
"Transplacental parameters estimated from ex vivo human placenta perfusion experiments were implemented in pregnancy-physiologically based pharmacokinetic (p-PBPK) models in order to predict fetal PK."	( Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models. Benaboud, S; Blanche, S; Bouazza, N; De Sousa Mendes, M; Foissac, F; Hirt, D; Lê, MP; Lui, G; Peytavin, G; Pressiat, C; Treluyer, JM; Urien, S; Valade, E; Vinot, C, 2016)	0.43
" MTN-003D, an ancillary study using in-depth interviews (IDIs) and focus group discussions (FGDs), together with retrospective disclosure of plasma tenofovir pharmacokinetic results, explored adherence challenges during VOICE."	( Disclosure of pharmacokinetic drug results to understand nonadherence. Bennie, T; Cheng, H; Etima, J; Grossman, CI; Hartmann, M; Laborde, N; Levy, L; Marrazzo, J; Mensch, B; Montgomery, ET; Musara, P; Naidoo, S; Piper, J; van der Straten, A, 2015)	0.42
"We systematically recruited participants with pharmacokinetic data (median six plasma samples), categorized as low (0%, N = 79), inconsistent (1-74%, N = 28) or high (≥75%; N = 20) on the basis of frequency of tenofovir detection."	( Disclosure of pharmacokinetic drug results to understand nonadherence. Bennie, T; Cheng, H; Etima, J; Grossman, CI; Hartmann, M; Laborde, N; Levy, L; Marrazzo, J; Mensch, B; Montgomery, ET; Musara, P; Naidoo, S; Piper, J; van der Straten, A, 2015)	0.42
" The most common reactions to pharmacokinetic results included surprise (41%; low pharmacokinetic), acceptance (39%; inconsistent pharmacokinetic) and happiness (65%; high pharmacokinetic)."	( Disclosure of pharmacokinetic drug results to understand nonadherence. Bennie, T; Cheng, H; Etima, J; Grossman, CI; Hartmann, M; Laborde, N; Levy, L; Marrazzo, J; Mensch, B; Montgomery, ET; Musara, P; Naidoo, S; Piper, J; van der Straten, A, 2015)	0.42
"Retrospective provision of pharmacokinetic results seemingly promoted candid discussions around nonadherence and study participation."	( Disclosure of pharmacokinetic drug results to understand nonadherence. Bennie, T; Cheng, H; Etima, J; Grossman, CI; Hartmann, M; Laborde, N; Levy, L; Marrazzo, J; Mensch, B; Montgomery, ET; Musara, P; Naidoo, S; Piper, J; van der Straten, A, 2015)	0.42
" Much attention has focussed on pharmacokinetic interactions attributable to effects on hepatic microsomal enzymes, but not on competition for the renal organic anion transport system."	( The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapy. Bendle, M; Boffito, M; Bower, M; Dalla Pria, A; Ramaswami, R, 2016)	0.43
" MTX elimination half-life was correlated with age, renal function and antiretroviral regimen."	( The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapy. Bendle, M; Boffito, M; Bower, M; Dalla Pria, A; Ramaswami, R, 2016)	0.43
" The median MTX elimination half-life was 21."	( The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapy. Bendle, M; Boffito, M; Bower, M; Dalla Pria, A; Ramaswami, R, 2016)	0.43
"Although there is potential competition for active renal tubular transporters between MTX and tenofovir, no prolongation of MTX half-life was observed."	( The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapy. Bendle, M; Boffito, M; Bower, M; Dalla Pria, A; Ramaswami, R, 2016)	0.43
"In the Microbicide Trial Network MTN-003 (VOICE) study, a Phase IIB pre-exposure prophylaxis trial of daily oral or vaginal tenofovir (TFV), product adherence was poor based on pharmacokinetic (PK) drug detection in a random subsample."	( Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study. Brown, ER; Chirenje, MZ; Gomez, K; Hendrix, CW; Liu, K; Marrazzo, JM; Marzinke, MA; Piper, JM; van der Straten, A, 2016)	0.43
" Here, we provide the first case series of tenofovir disoproxil fumarate (TDF) pharmacokinetic in four HIV-infected patients before and after sleeve-gastrectomy."	( Tenofovir pharmacokinetic after sleeve-gastrectomy in four severely obese patients living with HIV. Alvarez, JC; Carette, C; Czernichow, S; Gbedo, C; Muzard, L, )	0.13
" We developed a population pharmacokinetic model for tenofovir and investigated the impacts of different dose reporting methods."	( Population Pharmacokinetics of Tenofovir in HIV-1-Uninfected Members of Serodiscordant Couples and Effect of Dose Reporting Methods. Baeten, JM; Bangsberg, D; Celum, CL; Chaturvedula, A; Fossler, MJ; Goti, V; Haberer, JE; Hendrix, CW; Lu, Y; Sale, ME, 2016)	0.43
" A precise method is required to quantify the drug concentration in biological matrices to study pharmacokinetic behavior and tissue distribution profile in animals and/or humans."	( Simultaneous quantification of tenofovir, emtricitabine, rilpivirine, elvitegravir and dolutegravir in mouse biological matrices by LC-MS/MS and its application to a pharmacokinetic study. Destache, CJ; Mandal, S; Prathipati, PK, 2016)	0.43
"Between May 22, 2013, and July 22, 2014, we enrolled 50 participants, and all 50 received the assigned treatment; 24 participated in the intensive pharmacokinetic assessment."	( Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial. Batra, J; Chakraborty, R; Gaur, AH; Kizito, H; Kosalaraksa, P; Luesomboon, W; Myers, M; Porter, D; Prasitsueubsai, W; Quirk, E; Rakhmanina, N; Rassool, M; Rhee, MS; SenGupta, D; Shao, Y; Ting, L, 2016)	0.43
"The elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide regimen was well tolerated and achieved component plasma pharmacokinetic exposures similar to those in adults."	( Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial. Batra, J; Chakraborty, R; Gaur, AH; Kizito, H; Kosalaraksa, P; Luesomboon, W; Myers, M; Porter, D; Prasitsueubsai, W; Quirk, E; Rakhmanina, N; Rassool, M; Rhee, MS; SenGupta, D; Shao, Y; Ting, L, 2016)	0.43
" Single-dose oral pharmacokinetic studies were performed by concomitant administration of TDF with each of the selected FJs and excipients."	( Oral pharmacokinetic interaction of ester rich fruit juices and pharmaceutical excipients with tenofovir disoproxil fumarate in male Wistar rats. Myneni, S; Ravi, PR; Saha, P; Shailender, J, 2017)	0.46
" They can also inform interpretations of experimental pharmacokinetic measures such as drug concentrations in biopsies."	( Multicompartmental Pharmacokinetic Model of Tenofovir Delivery to the Rectal Mucosa by an Enema. Gao, Y; Katz, DF, 2017)	0.46
"Organic anion transporters (OATs) are important in the renal secretion, and thus, the clearance, of many drugs; and their functional change can result in pharmacokinetic variability."	( Quantitative Prediction of Human Renal Clearance and Drug-Drug Interactions of Organic Anion Transporter Substrates Using In Vitro Transport Data: A Relative Activity Factor Approach. Feng, B; Litchfield, J; Mathialagan, S; Piotrowski, MA; Tess, DA; Varma, MV, 2017)	0.46
" Pharmacokinetic data were analyzed as geometric mean ratios (GMRs) with 90% confidence intervals."	( The Effect of Food on Doravirine Bioavailability: Results from Two Pharmacokinetic Studies in Healthy Subjects. Behm, MO; Fackler, P; Levine, V; Liu, R; Panebianco, D; Yee, KL, 2017)	0.46
"To our knowledge, there is no published data on the pharmacokinetic (PK) profile of antiretroviral (ART) drugs on patients undergoing extracorporeal membrane oxygenation (ECMO) therapy."	( The effect of veno-venous ECMO on the pharmacokinetics of Ritonavir, Darunavir, Tenofovir and Lamivudine. Ashworth, A; Barker, J; Davies, A; Feddy, L; Fedor, I; Ghazi Suliman, MA; Hayes, T; Kosmidis, C; Malagon, I; Ogungbenro, K; Stirling, S; Szabo-Barnes, A, 2017)	0.46
"A randomized, open-label, clinical pharmacokinetic study of tenofovir in healthy adult volunteers without HIV or Hepatitis B infection in Thailand."	( A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study. Baeten, J; Cressey, R; Cressey, TR; Drain, PK; Klinbuayaem, V; Kubiak, RW; Quame-Amaglo, J; Siriprakaisil, O; Sirirungsi, W; Sukrakanchana, PO; Than-In-At, K, 2017)	0.46
"To develop a population pharmacokinetic model and identify sources of variability, genetic and nongenetic factors, of tenofovir."	( Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients. Avihingsanon, A; Burger, DM; Mitruk, S; Punyawudho, B; Rungtivasuwan, K; Ruxrungtham, K; Sukasem, C; Thammajaruk, N, 2017)	0.46
" A nonlinear mixed effects model was used to develop the population pharmacokinetic model and investigate the influence of these polymorphisms and other patient specific covariates on the pharmacokinetics of tenofovir."	( Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients. Avihingsanon, A; Burger, DM; Mitruk, S; Punyawudho, B; Rungtivasuwan, K; Ruxrungtham, K; Sukasem, C; Thammajaruk, N, 2017)	0.46
" The Data Convergence Interview (DCI) and the Pharmacokinetic Data Convergence Interview (PK-DCI) were brief, collaborative interactions conducted with participants during adherence counseling sessions to improve accurate measurement of adherence to study product use."	( Brief Participant-Centered Convergence Interviews Integrate Self-Reports, Product Returns, and Pharmacokinetic Results to Improve Adherence Measurement in MTN-017. Ayudhya, RPKN; Balán, IC; Brown, W; Carballo-Diéguez, A; Cranston, RD; Giguere, R; Hendrix, CW; Horn, S; Lama, JR; Marzinke, MA; McGowan, I; Patterson, K; Piper, JM, 2018)	0.48
" Although colonic biopsies should be collected in the absence of medium for accurate TFV concentrations, the presence of medium does not significantly impact TFV-DP-dependent pharmacokinetic or pharmacodynamic assays."	( Short Communication: Specimen Processing Impacts Tissue Tenofovir Pharmacokinetic Measurements. Bakshi, RP; Breakey, J; Fuchs, EJ; Jois, B; Manohar, M; Marzinke, MA, 2018)	0.48
"Intensive pharmacokinetic sampling of maternal dried blood spots (DBS), dried breast milk spots (DBMS) and infant DBS from 30 Ugandan and 29 Nigerian mothers receiving first-line ART and their infants was conducted."	( Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother-infant pairs. Khoo, S; Kyohaire, I; Lamorde, M; Nakalema, S; Olagunju, A; Owen, A; Waitt, C, 2018)	0.48
"A single-arm, prospective, nonrandomized, cross-over, pharmacokinetic study in patients receiving a TDF-containing regimen (TDF 300 mg/FTC 200 mg/EVG 150 mg/COBI 150 mg) switched to a TAF-containing FDC regimen (TAF 10 mg/FTC 200 mg/EVG 150 mg/COBI 150 mg)."	( Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. Bares, SH; Dyavar, SR; Fletcher, CV; Havens, J; Lee, S; O'Neill, J; Podany, AT; Scarsi, KK; Swindells, S, 2018)	0.48
" To provide insights into the complex mechanisms of absorption and disposition of TLC-ART101, we constructed novel mechanism-based pharmacokinetic (MBPK) models."	( Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulation. Collier, AC; Collins, C; Ho, RJY; Kinman, L; Koehn, J; Kraft, JC; McConnachie, LA; Shen, DD; Sun, J, 2018)	0.48
"In this study of 14 days each of vaginal and rectal application of TFV reduced-glycerin 1% gel, we found only a small degree of cross-compartment distribution of TFV in RF and vaginal fluids and no pharmacodynamic activity in ex vivo testing."	( Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing. Balar, B; Dai, JY; Dezzutti, CS; Galaska, B; Hendrix, CW; Justman, JE; Kunjara Na Ayudhya, RP; Levy, L; Marzinke, MA; McGowan, I; Mushamiri, I; Nair, GL; Pan, Z; Piper, JM; Schwartz, JL, 2018)	0.48
" TFV pharmacodynamic activity was measured by evaluating CV fluid [CVF] and tissue for antiviral activity using in vitro models."	( Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women. Asin, SN; Brache, V; Chandra, N; Clark, MR; Dezzutti, CS; Doncel, GF; Fichorova, R; Herold, BC; Hillier, SL; Kiser, P; Marzinke, MA; McCormick, T; Rollenhagen, C; Schwartz, JL; Stanczyk, FZ; Thurman, AR; Weiner, D, 2018)	0.48
" Population pharmacokinetic models were developed using measured intracellular metabolite, endogenous nucleotide competitors, and extracellular parent drug concentrations."	( A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs. Chen, J; Cottrell, ML; Dumond, JB; Garrett, KL; Maas, BM; Prince, HA; Schauer, AP; Sykes, C; White, N, 2018)	0.48
"We conducted a 3-arm randomized, pharmacokinetic study of tenofovir disoproxil fumarate (TDF) 300 mg/emtricitabine (FTC) 200 mg among adults living with human immunodeficiency virus."	( Urine Tenofovir Concentrations Correlate With Plasma and Relate to Tenofovir Disoproxil Fumarate Adherence: A Randomized, Directly Observed Pharmacokinetic Trial (TARGET Study). Bacchetti, P; Baeten, JM; Cressey, R; Cressey, TR; Drain, PK; Gandhi, M; Klinbuayaem, V; Kubiak, RW; Okochi, H; Punyati, P; Quame-Amaglo, J; Siriprakaisil, O; Sirirungsi, W; Sukrakanchana, PO; Tanasri, S, 2020)	0.56
" Using in vitro kinetic parameters for TFV and the OAT1 and OAT3 inhibitor probenecid, a bottom-up physiologically-based pharmacokinetic model was successfully developed for the first time that accurately describes the probenecid-TFV interaction."	( Probenecid-Boosted Tenofovir: A Physiologically-Based Pharmacokinetic Model-Informed Strategy for On-Demand HIV Preexposure Prophylaxis. Desta, Z; Gufford, BT; Liu, SN, 2020)	0.56
"3) were applied to determine pharmacokinetic parameters and assess demographic covariates and relationships with SNPs (SLCO3A1, SLCO1B1, NR1I2, NR1I3, CYP3A53, CYP3A422, ABCC2, ABCC10, ABCG2 and SCL47A1)."	( Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001 Boffito, M; Bonora, S; Cursley, A; D'Avolio, A; Di Perri, G; Dickinson, L; Fäetkenheuer, G; Gurjar, R; Molina, JM; Owen, A; Pozniak, A; Raffi, F; Richert, L; Stöhr, W; Vandekerckhove, L, 2020)	0.56
" The half-life of PMEA in the pradefovir group was 11."	( Safety, efficacy, and pharmacokinetics of pradefovir for the treatment of chronic hepatitis B infection. Chen, H; Ding, Y; Jin, W; Li, C; Li, X; Liu, C; Liu, J; Niu, J; Wu, M; Zhang, D; Zhang, H; Zhu, X, 2020)	0.56
" No differences in TFV pharmacokinetic parameters during the washout were observed across the study arms."	( Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate. Baeten, JM; Cressey, R; Cressey, TR; Drain, PK; Gandhi, M; Klinbuayaem, V; Kubiak, RW; Okochi, H; Quame-Amaglo, J; Siriprakaisil, O; Sukrakanchana, PO; Tawon, Y, 2020)	0.56
" We used mixed effects linear regression models to compare pharmacodynamic measures for each participant at predrug baseline, after PrEP alone, and after PrEP and DMPA."	( Pharmacokinetic and Pharmacodynamic Impacts of Depot Medroxyprogesterone Acetate Use on HIV Pre-exposure Prophylaxis in Women. Achilles, SL; Chen, BA; Hendrix, CW; Marzinke, MA; Meyn, LA; Tarleton, J, 2020)	0.56
" Pharmacokinetic sampling, urine biomarker collection [urine protein (UPCR), retinol binding protein (RBP) and β2 microglobulin (β2M) normalized to creatinine] and safety assessments occurred at the end of each phase."	( Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir. Anderson, PL; Blum, J; Brooks, KM; Bushman, LR; Castillo-Mancilla, JR; Cendali, F; Choi, YJ; Gomez, J; Haas, H; Ibrahim, ME; Johnson, B; Kiser, JJ; MaWhinney, S; Morrow, M; Roon, L; Rowan, SE; Wyles, DL; Zheng, JH, 2020)	0.56
" Data were combined from a pharmacokinetic study of pregnant women with HIV on ART (PANNA), and a study assessing TFV pharmacokinetics in pregnant women with HBV (iTAP)."	( Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy. Bukkems, VE; Burger, DM; Colbers, AP; Cressey, TR; Jourdain, G; Smolders, EJ, 2021)	0.62
"This study was performed to compare the pharmacokinetic properties and assess bioequivalence for the test formulation (HUG116 tablet; tenofovir disoproxil) and reference formulation (Viread tablet; tenofovir disoproxil fumarate)."	( A randomized, open-label, crossover study to compare the safety and pharmacokinetics of two tablet formulations of tenofovir (tenofovir disoproxil and tenofovir disoproxil fumarate) in healthy subjects. Choi, YS; Hoe, KL; Hong, JH; Kan, HS; Kim, N; Kwon, IS; Lee, M; Nam, SK; Oh, TY; Yeun, JS; Yun, JN, 2020)	0.56
" Serial blood samples for pharmacokinetic evaluation were collected up to 72 hours post dose, and the pharmacokinetic parameters were estimated by noncompartmental methods."	( A randomized, open-label, crossover study to compare the safety and pharmacokinetics of two tablet formulations of tenofovir (tenofovir disoproxil and tenofovir disoproxil fumarate) in healthy subjects. Choi, YS; Hoe, KL; Hong, JH; Kan, HS; Kim, N; Kwon, IS; Lee, M; Nam, SK; Oh, TY; Yeun, JS; Yun, JN, 2020)	0.56
"The test formulation showed similar pharmacokinetic profiles to those of the reference formulation."	( A randomized, open-label, crossover study to compare the safety and pharmacokinetics of two tablet formulations of tenofovir (tenofovir disoproxil and tenofovir disoproxil fumarate) in healthy subjects. Choi, YS; Hoe, KL; Hong, JH; Kan, HS; Kim, N; Kwon, IS; Lee, M; Nam, SK; Oh, TY; Yeun, JS; Yun, JN, 2020)	0.56
"Pregnant women receiving TAF 10 mg with cobicistat or TAF 25 mg without boosting as part of clinical care had intensive pharmacokinetic assessments performed during the second and third trimesters, and 6-12 weeks postpartum."	( Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV. Barr, E; Best, BM; Brooks, KM; Capparelli, EV; Chakhtoura, N; Cielo, M; Denson, K; Deville, JG; Espina, R; Febo, IL; George, K; Haubrich, R; Mirochnick, M; Momper, JD; Pinilla, M; Rooney, JF; Rungruengthanakit, K; Shapiro, DE; Smith, E; Stek, AM; Weinberg, A, 2021)	0.62
" Pharmacokinetic (PK) data from study RMP-02/MTN-006 comparing single dose oral tenofovir disoproxil fumarate with single and multiple dose rectal tenofovir (TFV) gel administration in HIV-1 seronegative adults was used to construct a multicompartment plasma-rectal tissue population PK model for TFV and tenofovir-diphosphate (TFVdp) in plasma and rectal tissue."	( A Mechanistic In Vivo/Ex Vivo Pharmacokinetic-Pharmacodynamic Model of Tenofovir for HIV Prevention. Anton, P; Bumpus, NN; Garcia-Cremades, M; Hendrix, C; Jayachandran, P; Savić, R; Vučićević, K, 2021)	0.62
" This phase I, open-label, 2-period, 1-way study assessed potential pharmacokinetic (PK) interactions between GSK3640254 and tenofovir alafenamide/emtricitabine (TAF/FTC; including the metabolite tenofovir [TFV]) in healthy volunteers."	( A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants. Butcher, L; Davidson, AM; Johnson, M; Joshi, SR; Lataillade, M; Min, S; Pene Dumitrescu, T; Webster, L; Xu, J; Zhan, J; Zimmerman, E, 2021)	0.62
"3) ADVAN 13, based on a previously established pharmacokinetic model."	( Pharmacokinetic-pharmacodynamic modelling of atazanavir in hair among adolescents on antiretroviral treatment in Zimbabwe. Chawana, TD; Ngara, B; Nhachi, CFB; Rusakaniko, S; Zvada, S, 2021)	0.62
" However, no real-world pharmacokinetic (PK) data are available in treatment-experienced patients with antiretroviral resistance receiving BIC/FTC/TAF plus a boosted protease inhibitor."	( Brief Report: Pharmacokinetics of Bictegravir and Tenofovir in Combination With Darunavir/Cobicistat in Treatment-Experienced Persons With HIV. Best, BM; Hill, L; Momper, JD; Patel, N; Salama, E, 2021)	0.62
"This prospective, single-center, nonrandomized pharmacokinetic study enrolled adult treatment-experienced persons with HIV and creatinine clearance >30 mL/min receiving BIC/FTC/TAF + DRV/c as part of routine clinical care."	( Brief Report: Pharmacokinetics of Bictegravir and Tenofovir in Combination With Darunavir/Cobicistat in Treatment-Experienced Persons With HIV. Best, BM; Hill, L; Momper, JD; Patel, N; Salama, E, 2021)	0.62
" The median (interquartile range [IQR]) BIC AUC0-tau,exp and Cmax values were 128."	( Brief Report: Pharmacokinetics of Bictegravir and Tenofovir in Combination With Darunavir/Cobicistat in Treatment-Experienced Persons With HIV. Best, BM; Hill, L; Momper, JD; Patel, N; Salama, E, 2021)	0.62
" Physiologically based pharmacokinetic (PBPK) modelling is a non-invasive solution for understanding lymph node penetration of ARVs across multiple species."	( A cross-species comparison of antiretroviral penetration into lymph nodes using novel physiologically based pharmacokinetic models. Cao, Y; Kashuba, ADM; Scholz, EMB, 2021)	0.62
" Although TFV exalidex (TXL), a phospholipid-derived prodrug of TFV, was designed to address this issue, clinical pharmacokinetic studies indicated substantial hepatic extraction, redirecting clinical development of TXL toward HBV."	( ω-Functionalized Lipid Prodrugs of HIV NtRTI Tenofovir with Enhanced Pharmacokinetic Properties. Bartsch, PW; Basson, AE; Burton, SL; Bushnev, A; D'Erasmo, M; Dasari, M; Derdeyn, CA; Giesler, KE; Hwang, SS; Iskandar, S; Liotta, DC; Miller, EJ; Pribut, N; Raghuram, A; Sharma, SK, 2021)	0.62
"The Microbicide Trials Network-017 study was undertaken to characterize the safety, acceptability, pharmacokinetic (PK), and pharmacodynamic profile of the reduced-glycerin (RG) 1% tenofovir (RG-TFV) gel compared to oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)."	( An Open-Label Pharmacokinetic and Pharmacodynamic Assessment of Tenofovir Gel and Oral Emtricitabine/Tenofovir Disoproxil Fumarate. Brand, RM; Chitwarakorn, A; Cranston, RD; Curlin, ME; Doncel, G; Hendrix, CW; Holtz, TH; Johnson, S; Kunjara Na Ayudhya, RP; Marzinke, MA; McGowan, IM; Piper, J; Raengsakulrach, B; Rooney, JF; Schwartz, JL, 2022)	0.72
"We previously developed a mechanism-based pharmacokinetic (MBPK) model to characterize the PK of a lymphocyte-targeted, long-acting 3 HIV drug-combination nanoparticle (DcNP) formulation of lopinavir, ritonavir, and tenofovir."	( Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 2: Model for the Drug-combination Nanoparticles. Ho, RJY; Perazzolo, S; Shen, DD, 2022)	0.72
"This is an open-label, randomized, fixed sequence single intravenous dosing study to assess pharmacokinetic interactions between remdesivir and TDF/3TC (Study A, crossover design) or TDF/3TC plus ATV/r (Study B)."	( An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR). Byakika-Kibwika, P; D'Avolio, A; Kaboggoza, JP; Lamorde, M; Waitt, C; Walimbwa, SI, 2021)	0.62
" Furthermore, this study will deliver pharmacokinetic datasets for remdesivir drug concentrations and demographic characteristics which could support pharmacometric approaches for simulation of remdesivir treatment regimens in patients concurrently using tenofovir/lamivudine and/or atazanavir/ritonavir."	( An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR). Byakika-Kibwika, P; D'Avolio, A; Kaboggoza, JP; Lamorde, M; Waitt, C; Walimbwa, SI, 2021)	0.62
" A non-compartmental analysis was performed to estimate the main pharmacokinetic parameters."	( Pharmacokinetics and tissue distribution of tenofovir, emtricitabine and dolutegravir in mice. Barrail-Tran, A; Benzemrane, MS; Bourgeois, C; Gelé, T; Gouget, H; Labarthe, L; Lambotte, O; Le Calvez, P; Le Grand, R; Legrand, N, 2022)	0.72
"ARV plasma pharmacokinetic parameters in both strains were similar to those estimated in the clinical context."	( Pharmacokinetics and tissue distribution of tenofovir, emtricitabine and dolutegravir in mice. Barrail-Tran, A; Benzemrane, MS; Bourgeois, C; Gelé, T; Gouget, H; Labarthe, L; Lambotte, O; Le Calvez, P; Le Grand, R; Legrand, N, 2022)	0.72
"Tenofovir alafenamide (TAF) is a key component of HIV treatment, but pharmacokinetic data supporting the use of TAF during pregnancy are limited."	( Pharmacokinetics of Tenofovir Alafenamide With Boosted Protease Inhibitors in Pregnant and Postpartum Women Living With HIV: Results From IMPAACT P1026s. Barr, E; Best, BM; Brooks, KM; Browning, R; Capparelli, EV; Chakhtoura, N; Deville, JG; Febo, IL; George, K; Knowles, K; Mirochnick, M; Paul, ME; Pinilla, M; Rungruengthanakit, K; Shapiro, DE; Stek, AM, 2022)	0.72
" Intensive pharmacokinetic assessments were performed during the second and third trimesters and 6-12 weeks postpartum."	( Pharmacokinetics of Tenofovir Alafenamide With Boosted Protease Inhibitors in Pregnant and Postpartum Women Living With HIV: Results From IMPAACT P1026s. Barr, E; Best, BM; Brooks, KM; Browning, R; Capparelli, EV; Chakhtoura, N; Deville, JG; Febo, IL; George, K; Knowles, K; Mirochnick, M; Paul, ME; Pinilla, M; Rungruengthanakit, K; Shapiro, DE; Stek, AM, 2022)	0.72
" TAF was only quantifiable in 2/25 maternal delivery samples and below the limit of quantification in all cord blood and infant washout samples, likely because of the short half-life of TAF."	( Pharmacokinetics of Tenofovir Alafenamide With Boosted Protease Inhibitors in Pregnant and Postpartum Women Living With HIV: Results From IMPAACT P1026s. Barr, E; Best, BM; Brooks, KM; Browning, R; Capparelli, EV; Chakhtoura, N; Deville, JG; Febo, IL; George, K; Knowles, K; Mirochnick, M; Paul, ME; Pinilla, M; Rungruengthanakit, K; Shapiro, DE; Stek, AM, 2022)	0.72
" Population pharmacokinetic (popPK) models and simulations would aid in understanding potential differences in emtricitabine/tenofovir disproxil fumarate (F/TDF) parent-metabolite concentrations in TGW on GAHT when compared to cisgender men (CGM) not exposed to GAHT."	( Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women. Bakshi, RP; Chaturvedula, A; Fuchs, EJ; Hendrix, CW; Marzinke, MA; Shieh, E; Tanaudommongkon, A, 2022)	0.72
" Non-compartmental analyses were performed to quantify the pharmacokinetic parameters."	( Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection. Cottrell, M; Crane, H; Di Girolamo, J; Dumond, J; Gane, E; Kashuba, A; Kayes, T; Levy, MT; Lim, TH; Manandhar, S; Symonds, A, 2022)	0.72
"In this first pharmacokinetic study of TAF monotherapy in breastfeeding women with CHB, concentrations of TAF and TFV were low in breast milk with negligible infant exposure, supporting the use of TAF to prevent MTCT."	( Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection. Cottrell, M; Crane, H; Di Girolamo, J; Dumond, J; Gane, E; Kashuba, A; Kayes, T; Levy, MT; Lim, TH; Manandhar, S; Symonds, A, 2022)	0.72
" Modeled TFV pharmacodynamic antiviral activity was evaluated in vaginal and rectal fluids and cervicovaginal tissue ex vivo."	( Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study. Brache, V; Chandra, N; Clark, MR; Cochon, L; Doncel, GF; Erikson, DW; Fichorova, RN; Hanif, H; Herold, BC; Jacot, T; Ju, S; Marzinke, MA; Ouattara, LA; Parikh, U; Peet, M; Schwartz, JL; Thurman, AR; Tolley, E; Yousefieh, N, 2022)	0.72
" Physiologically-based pharmacokinetic (PBPK) modeling offers a unique modality to predict PK in pregnant women."	( Physiologically-Based Pharmacokinetic Modeling of Tenofovir Disoproxil Fumarate in Pregnant Women. He, Q; Luo, T; Ma, WY; Xu, M; Yang, H; Yang, Y; Zhang, X, 2023)	0.91
" Model-based simulations revealed 294% and 515% increases of median tenofovir Cmin in patients with CLCR of 15-29 mL/min (CKD stage 3), and less than 15 mL/min (stage 4), respectively, compared with normal renal function (CLCR = 90-149 mL/min)."	( Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration. Alves Saldanha, S; Andre, P; Buclin, T; Cavassini, M; Courlet, P; Decosterd, LA; Desfontaine, V; Guidi, M; Kusejko, K; Thoueille, P, 2023)	0.91
" At steady state, 8-9 blood samples were taken to construct pharmacokinetic curves."	( First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial. Bamford, A; Burger, DM; Bwakura-Dangarembizi, M; Chabala, C; Colbers, A; Denti, P; Doerholt, K; Gibb, DM; Griffiths, AL; Makumbi, S; McIlleron, HM; Monkiewicz, LN; Mulenga, V; Mumbiro, V; Musiime, V; Nangiya, J; Szubert, AJ; Waalewijn, H; Wasmann, RE; Wiesner, L, 2023)	0.91
" For each combination, tenofovir GM (CV%) AUCtau and Cmax remained below reference values in adults taking 25 mg TAF with a boosted protease inhibitors."	( First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial. Bamford, A; Burger, DM; Bwakura-Dangarembizi, M; Chabala, C; Colbers, A; Denti, P; Doerholt, K; Gibb, DM; Griffiths, AL; Makumbi, S; McIlleron, HM; Monkiewicz, LN; Mulenga, V; Mumbiro, V; Musiime, V; Nangiya, J; Szubert, AJ; Waalewijn, H; Wasmann, RE; Wiesner, L, 2023)	0.91
" Peer-reviewed publications were included if they met all criteria: adults (≥ 18 years of age) living with or without HIV; report any pharmacokinetic parameter or plasma concentration of at least one of the following ARVs: tenofovir alafenamide fumarate (TAF); doravirine (DOR), rilpivirine (RIL) and etravirine (ETR); darunavir (DRV), tipranavir (TPV) and fostemsavir (FTR); dolutegravir (DTG), raltegravir (RAL), bictegravir (BIC) and elvitegravir (EVG); maraviroc (MVC); ibalizumab (IBA); cobicistat (COBI)."	( Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV: A Systematic Review. Cardoso, SW; Castro, T; Estrela, R; Grinsztejn, B; Oliveira, VG; Toledo, T; Torres, TS; Veloso, VG, 2023)	0.91
"Among 97 studies included, 20 reported pharmacokinetic evaluation in older individuals (age ≥ 50 years)."	( Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV: A Systematic Review. Cardoso, SW; Castro, T; Estrela, R; Grinsztejn, B; Oliveira, VG; Toledo, T; Torres, TS; Veloso, VG, 2023)	0.91
" The aim of this study was to investigate the effect of food on the single-dose pharmacokinetic properties of TMF."	( Effect of Food on the Pharmacokinetics of Tenofovir Amibufenamide: A Phase I, Randomized, Open-Label, Two-Period Crossover Trial in Healthy Adult Subjects. Huang, Q; Jiang, Y; Kai, J; Lin, M; Liu, J; Qiu, Y; Wu, M; Zhai, Y; Zheng, Y, 2023)	0.91

Excerpt	Reference	Relevance
" Adefovir and PMPA both demonstrated strong synergistic anti-HIV activity in combination with AZT."	( Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses. Cherrington, JM; Mulato, AS, 1997)	0.3
" We tested MPA alone and in combination with abacavir (ABC), didanosine (DDI), lamivudine (3TC) and tenofovir (TFV) against wild-type human immunodeficiency virus type-1 (HIV-1) and nucleoside reverse transcriptase inhibitor (NRTI)-resistant HIV-1."	( Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. Coull, JJ; Drusano, GL; Hossain, MM; Margolis, DM, 2002)	0.31
"Mutations selected or deselected during passage of human immunodeficiency virus strain HXB2 or resistant variants with tenofovir (TFV), abacavir (ABC), and lamivudine (3TC) differed depending on the drug combination and virus genotype."	( Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine. Ait-Khaled, M; Craig, C; Griffin, P; Stone, C; Tisdale, M, 2004)	0.32
"Tenofovir disoproxil fumarate (tenofovir DF) was studied in combination with rifampin in 24 healthy subjects in a multiple-dose, open-label, single-group, two-period study."	( Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers. Buffels, R; Burger, DM; Droste, JA; Hekster, YA; Kearney, BP; Vanhorssen, PJ; Verweij-van Wissen, CP, 2005)	0.33
"The nucleotide analogue, tenofovir, has been shown to lower plasma atazanavir levels in pharmacokinetic trials, an interaction that may be partly reversed by the addition of ritonavir, whereas plasma tenofovir levels are themselves raised when the drug is combined with lopinavir/ritonavir."	( The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients. Becker, M; Breske, A; Esser, S; Hill, A; Koerber, A; Kopperman, M; Kruse, G; Kurowski, M; Möcklinghoff, C; Ross, B; Stocker, H; Wiehler, H, 2005)	0.33
"The drug-drug and drug-food interactions between tenofovir DF and didanosine EC were evaluated in 2 pharmacokinetic studies in healthy adult subjects."	( Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine. Chen, SS; Cheng, AK; Flaherty, JF; Kaul, S; Kearney, BP; Sayre, JR, 2005)	0.33
"Tenofovir disoproxil fumarate (DF) has been studied in combination with efavirenz in healthy volunteers and no interaction was found."	( Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients. Burger, DM; Droste, JA; Hekster, YA; Kearney, BP, 2006)	0.33
" Six different groups were studied: 200 mg nevirapine twice daily, 400 mg nevirapine once daily, 600 mg efavirenz once daily, all without tenofovir DF (groups 1, 2, and 3, respectively), and the same groups with the drugs combined with tenofovir 300 mg once daily (groups 4, 5, and 6, respectively)."	( Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients. Burger, DM; Droste, JA; Hekster, YA; Kearney, BP, 2006)	0.33
" The most common drugs given with tenofovir were ritonavir or lopinavir-ritonavir (21 of 27 patients), atazanavir (5 of 27 patients), and didanosine (9 of 27 patients)."	( Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Bedford, J; Braden, G; Hoffman, R; Morris, A; Pizzoferrato, T; Zimmermann, AE, 2006)	0.33
" Together, these in vitro results indicate that combination with other antiretrovirals does not significantly increase the toxic potential of TFV in RPTECs."	( In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells. Alvarez, ML; Cihlar, T; Cordobilla, B; Domingo, JC; Domingo, P; Giralt, M; Guallar, J; López-Dupla, M; Sánchez de la Rosa, R; Saumoy, M; Torres, F; Vidal, F; Villarroya, F, 2006)	0.33
"Study 903 is a phase 3 trial with a completed 144-week, double-blind phase comparing tenofovir DF (TDF) to stavudine (d4T) in combination with lamivudine (3TC) and efavirenz (EFV) and an ongoing additional 336-week open-label extension phase."	( The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients. Cassetti, I; Cheng, AK; Enejosa, J; Etzel, A; Madruga, JV; Suleiman, JM; Zhong, L, )	0.13
"We evaluated the mitochondrial toxicity of tenofovir (TFV), emtricitabine (FTC) and abacavir as carbovir (CBV) alone, with each other, and in combination with additional NRTIs."	( Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. Melkaoui, K; Setzer, B; Venhoff, N; Walker, UA, 2007)	0.34
"Study 903 is a phase 3 trial with a completed 144-week, double-blind phase comparing tenofovir DF (TDF) with stavudine (d4T), in combination with lamivudine (3TC) and efavirenz (EFV), and an ongoing 336-week open-label extension phase."	( The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy. Cassetti, I; Cheng, AK; Enejosa, J; Etzel, A; Holmes, CB; Madruga, JR; Suleiman, JM; Zhong, L, )	0.13
" Pharmacokinetic profiles were also determined in HIV-1-infected patients dosed with raltegravir monotherapy versus raltegravir in combination with TDF and lamivudine."	( Lack of a significant drug interaction between raltegravir and tenofovir. Breidinger, SA; Chen, J; Friedman, EJ; Gottesdiener, KM; Iwamoto, M; Kost, JT; Lasseter, KC; Stek, JE; Stone, JA; Teppler, H; Wagner, JA; Wenning, LA, 2008)	0.35
" These mt-QSARs offer also a good opportunity to construct drug-drug Complex Networks (CNs) that can be used to explore large and complex drug-viral species databases."	( Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E, 2009)	0.35
" regimen and it's recommended by most of the clinical guidelines as a start regimen in combination with two other drugs."	( [Clinical data I. Clinical experience with tenofovir in combination with nonnucleoside analogue transcriptase inhibitors]. Arribas López, JR; Bernardino de la Serna, JI; Mora Rillo, M, 2008)	0.35
" Most data on safety and efficacy in this scenario initially came from clinical trials in which tenofovir was combined with non-nucleoside reverse transcriptase inhibitors."	( [Clinical data II. Clinical experience of tenofovir DF in combination with protease inhibitors]. Fiorante, S; Pulido, F, 2008)	0.35
"Emtricitabine, a nucleoside reverse transcriptase inhibitor (RTI), and tenofovir disoproxil fumarate (tenofovir DF), a nucleotide RTI, as a fixed-dose combination tablet (emtricitabine/tenofovir DF) for once-daily oral administration, are used as the nucleoside/nucleotide RTI backbone in combination with other antiretroviral agents, including ritonavir-boosted protease inhibitors (PIs), in the treatment of adults with HIV-1 infection."	( Emtricitabine/tenofovir disoproxil fumarate: in combination with a protease inhibitor in HIV-1 infection. Perry, CM, 2009)	0.35
"A new drug combination regimen, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate (TDF), is described for the treatment of HIV-1 infection."	( A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate. De Clercq, E, 2009)	0.35
" However, N348I significantly decreases tenofovir susceptibility when combined with thymidine analogue mutations and etravirine susceptibility when combined with Y181C."	( N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations. Moore, K; Radzio, J; Sluis-Cremer, N; Sonza, S; Tachedjian, G, 2010)	0.36
"International, multicenter, open-label, 96-week noninferiority randomized trial of atazanavir/ritonavir 300/100 mg once daily vs lopinavir/ritonavir 400/100 mg twice daily, each in combination with fixed-dose tenofovir/emtricitabine 300/200 mg once daily, in antiretroviral-naive, HIV-1-infected patients."	( Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. Absalon, J; Andrade-Villanueva, J; Chetchotisakd, P; Corral, J; David, N; Echevarria, J; Lataillade, M; Mancini, M; McGrath, D; Molina, JM; Moyle, G; Percival, L; Wirtz, V; Yang, R, 2010)	0.36
"Forty-eight-week data are presented from this multicenter, randomized, open-label study comparing the safety profiles of abacavir/lamivudine and tenofovir/emtricitabine, both administered with efavirenz, in HLA-B*5701-negative HIV-1-infected adults."	( Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. Branco, T; Cavassini, M; Domingo, P; Fisher, M; Givens, N; Khuong-Josses, MA; Lim, ML; Moyle, GJ; Norden, AG; Pearce, HC; Podzamczer, D; Post, FA; Rieger, A; Stellbrink, HJ; Vavro, C, 2010)	0.36
" We investigated the activity of clevudine (CLV) in combination with other nucleoside/nucleotide analogues to determine if these combinations were compatible in vitro."	( Evaluation of the in vitro anti-HBV activity of clevudine in combination with other nucleoside/nucleotide inhibitors. Bao, H; Furman, PA; Korba, B; Micolochick Steuer, HM; Murakami, E; Niu, C; Tolstykh, T, 2010)	0.36
"Using the HepAD38 cell line, which expresses wild-type HBV, and a real-time PCR assay, we tested the anti-HBV activity of CLV in combination with entecavir, lamivudine, adefovir, tenofovir and telbivudine (TBV)."	( Evaluation of the in vitro anti-HBV activity of clevudine in combination with other nucleoside/nucleotide inhibitors. Bao, H; Furman, PA; Korba, B; Micolochick Steuer, HM; Murakami, E; Niu, C; Tolstykh, T, 2010)	0.36
"When CLV was combined with entecavir, lamivudine, adefovir or tenofovir, a synergistic antiviral effect was observed; however, the combination of CLV and TBV gave an antagonistic antiviral response."	( Evaluation of the in vitro anti-HBV activity of clevudine in combination with other nucleoside/nucleotide inhibitors. Bao, H; Furman, PA; Korba, B; Micolochick Steuer, HM; Murakami, E; Niu, C; Tolstykh, T, 2010)	0.36
"We retrospectively evaluated the durability and reasons for discontinuation of nevirapine (NVP) in combination with a tenofovir (TDF) and emtricitabine (FTC) or lamivudine (3TC)-containing antiretroviral therapy (ART) regimen in an Australian outpatient setting."	( Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects. Chan, DJ; Jeganathan, S; Maruszak, H; Smith, DE, 2011)	0.37
" nevirapine on the same background, in naïve HIV-1-infected patients) study compared prospectively ritonavir-boosted atazanavir (ATZ/r) 300 mg/100 mg once daily (qd) with immediate release nevirapine (NVP) 200 mg twice daily or 400 mg qd, each combined with fixed-dose tenofovir 300 mg/emtricitabine 200 mg qd in 569 ARV-naïve HIV-1-infected patients."	( Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study). Andrade-Villanueva, J; Cairns, V; Clotet, B; de Rossi, L; Domingo, P; Gellermann, HJ; Podzamczer, D; Reiss, P; Rockstroh, JK; Soriano, V; Taylor, S, 2011)	0.37
"ARTEN is a randomized, open-label, non-inferiority trial that compares nevirapine (NVP) 200 mg twice daily or 400 mg once daily to atazanavir/ritonavir (ATZ/r) 300 mg/100 mg once daily, each combined with fixed-dose tenofovir disoproxil fumarate (TDF) 300 mg/emtricitabine (FTC) 200 mg once daily, in antiretroviral-naive HIV-1 patients with CD4(+) T-cell counts <400 (men) and <250 cells/mm(3) (women)."	( Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Andrade-Villanueva, J; Antunes, F; Arastéh, K; de Rossi, L; Di Perri, G; Domingo, P; Gellermann, H; Lutz, T; Migrone, H; Opravil, M; Podzamczer, D; Soriano, V; Taylor, S, 2011)	0.37
"NVP demonstrated at week 48 non-inferior antiviral efficacy compared with ATZ/r when given along with TDF/FTC, despite more drug-related discontinuations with NVP than ATZ/r."	( Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Andrade-Villanueva, J; Antunes, F; Arastéh, K; de Rossi, L; Di Perri, G; Domingo, P; Gellermann, H; Lutz, T; Migrone, H; Opravil, M; Podzamczer, D; Soriano, V; Taylor, S, 2011)	0.37
" In order to improve ATV exposure, plasma and intracellular (IC) PK of ATV in patients administered with ATV 400 mg once daily and TDF/emtricitabine (FTC) and switched to ATV 200 mg twice daily were studied."	( Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. Baietto, L; Bonora, S; Calcagno, A; D'Avolio, A; Di Perri, G; Gonzalez de Requena, D; Siccardi, M; Simiele, M; Tettoni, M; Trentini, L, 2011)	0.37
"Limited data are available on the use of unboosted atazanavir in combination with nucleoside reverse transcriptase inhibitors (NRTIs) in treatment-experienced HIV-infected patients."	( Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy. Ammassari, A; Castagna, A; Delaugerre, C; Ghosn, J; Medrano, J; Molina, JM; Pavie, J; Porcher, R; Rusconi, S; Torti, C; Valin, N, 2011)	0.37
" NRTIs used in combination with atazanavir were tenofovir, abacavir and emtricitabine/lamivudine in 36."	( Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy. Ammassari, A; Castagna, A; Delaugerre, C; Ghosn, J; Medrano, J; Molina, JM; Pavie, J; Porcher, R; Rusconi, S; Torti, C; Valin, N, 2011)	0.37
"In patients with virological suppression and no prior history of virological failure, a switch to unboosted atazanavir in combination with NRTIs is associated with a low probability of virological failure and a good safety profile."	( Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy. Ammassari, A; Castagna, A; Delaugerre, C; Ghosn, J; Medrano, J; Molina, JM; Pavie, J; Porcher, R; Rusconi, S; Torti, C; Valin, N, 2011)	0.37
"Eligible patients with HIV-1 RNA (vRNA) levels >5000 copies/mL and without baseline resistance to efavirenz, tenofovir, or emtricitabine were randomized in a double-blind, noninferiority study to receive raltegravir or efavirenz, each combined with tenofovir/emtricitabine."	( Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Dejesus, E; Dinubile, MJ; Lazzarin, A; Leavitt, R; Lennox, JL; Nguyen, BY; Rockstroh, JK; Rodgers, AJ; Saag, MS; Sklar, P; Teppler, H; Walker, ML; Wan, H; Xu, X; Zhao, J, 2011)	0.37
"When combined with tenofovir/emtricitabine in treatment-naive patients, raltegravir produced durable viral suppression and immune restoration that was at least equivalent to efavirenz through 156 weeks of therapy."	( Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Dejesus, E; Dinubile, MJ; Lazzarin, A; Leavitt, R; Lennox, JL; Nguyen, BY; Rockstroh, JK; Rodgers, AJ; Saag, MS; Sklar, P; Teppler, H; Walker, ML; Wan, H; Xu, X; Zhao, J, 2011)	0.37
" Mean plasma concentration-time profiles for atazanavir, tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), darunavir (DRV, administered with ritonavir [RTV]), and drospirenone/ethinylestradiol were similar following co-administration of GSK2248761."	( Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor. de Serres, M; Gould, E; Johnson, M; Kim, J; Lou, Y; Mayers, D; Pietropaolo, K; Piscitelli, S; White, S; Zhou, XJ, 2012)	0.38
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."	( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012)	0.38
"To explore the durability of three first-line tenofovir/emtricitabine-based regimens in combination with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in HIV-1-infected patients."	( Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort. Borghi, V; Capetti, A; Cicconi, P; Di Biagio, A; Di Giambenedetto, S; Francisci, D; Giacometti, A; Giannarelli, D; Maggiolo, F; Monno, L; Penco, G; Prinapori, R; Sterrantino, G; Zoncada, A, 2013)	0.39
"Drug transporters such as P-glycoprotein and OATPs regulate intestinal permeability of atazanavir and may contribute to its poor oral bioavailability and drug-drug interactions with other protease inhibitors and TDF."	( Role of drug efflux and uptake transporters in atazanavir intestinal permeability and drug-drug interactions. Bendayan, R; Hoque, MT; Kis, O; Walmsley, SL; Zastre, JA, 2013)	0.39
"Comprehensive information on the effects of cytochrome P450 2B6 (CYP2B6) polymorphisms, clinical factors, and drug-drug interactions on efavirenz concentrations in HIV/tuberculosis-coinfected (HIV/TB) patients is unavailable."	( Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients. Lueangniyomkul, A; Mankatitham, W; Manosuthi, S; Manosuthi, W; Nilkamhang, S; Sukasem, C; Sungkanuparph, S; Thongyen, S, 2013)	0.39
" The objective of this study was to compare changes in body composition between ritonavir-boosted atazanavir (ATV/r) and ritonavir-boosted lopinavir (LPV/r) over 96 weeks using data from a substudy of CASTLE, which compared once-daily ATV/r with twice-daily LPV/r, both in combination with tenofovir disoproxil fumarate/emtricitabine in treatment-naïve patients with HIV-1 infection."	( Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection. DeGrosky, M; Farajallah, A; Hardy, H; McGrath, D; Moyle, GJ, 2014)	0.4
" When ATV-LNPs were prepared with ritonavir (RTV), a metabolic and cellular membrane exporter inhibitor, and tenofovir (TFV), an HIV reverse-transcriptase inhibitor, stable, scalable, and reproducible anti-HIV drug combination LNPs were produced."	( Evaluation of atazanavir and darunavir interactions with lipids for developing pH-responsive anti-HIV drug combination nanoparticles. Duan, J; Freeling, JP; Ho, RJ; Koehn, J; Shu, C, 2014)	0.4
"Electrospun drug-eluting fabrics have enormous potential for the delivery of physicochemically diverse drugs in combination by controlling the underlying material chemistry and fabric microarchitecture."	( Delivery of multipurpose prevention drug combinations from electrospun nanofibers using composite microarchitectures. Blakney, AK; Jiang, YH; Krogstad, EA; Woodrow, KA, 2014)	0.4
" Finally, we showed that the drug-loaded nanofibers are noncytotoxic and that the antiviral activity of TFV is preserved through the electrospinning process and when combined with LNG."	( Delivery of multipurpose prevention drug combinations from electrospun nanofibers using composite microarchitectures. Blakney, AK; Jiang, YH; Krogstad, EA; Woodrow, KA, 2014)	0.4
"We report an unusual case of pulmonary aspergillosis in a patient with AIDS and we demonstrated the drug-drug interactions between voriconazole, darunavir/ritonavir and tenofovir/emtricitabine."	( Drug interactions between voriconazole, darunavir/ritonavir and tenofovir/emtricitabine in an HIV-infected patient treated for Aspergillus candidus lung abscess. Becker, A; Desprez, S; Froidure, M; Gagneux, M; Huguet, D; Leduc, D; Legout, L; Sifaoui, F; Vignoli, P, 2015)	0.42
" Clinical evaluation and laboratory findings excluded the presence of systemic diseases that might have been able to explain the drug inefficacy, while pharmacological evaluation suggested a possible drug-drug interaction."	( Reactivation of chronic hepatitis B during treatment with tenofovir disoproxil fumarate: drug interactions or low adherence? Caroleo, B; Gallelli, L; Perticone, F; Staltari, O, 2015)	0.42
"International, randomized double-blind active-controlled trial to evaluate the efficacy and safety of COBI vs ritonavir (RTV) as a pharmacoenhancer of atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate in HIV treatment-naive patients followed through week 144."	( Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results. Abram, ME; Andrade-Villanueva, JF; Antunes, F; Arastéh, K; Cao, H; Chetchotisakd, P; DeJesus, E; Fehr, J; Gallant, JE; Koenig, E; Liu, HC; Rizzardini, G; Szwarcberg, J, 2015)	0.42
"Compared with zidovudine-lamivudine, the use of tenofovir-lamivudine or emtricitabine in combination with nevirapine was a strong predictor of virologic failure in our cohort, which was not explained by other risk factors or criteria for regimen selection."	( Superior Effectiveness of Zidovudine Compared With Tenofovir When Combined With Nevirapine-based Antiretroviral Therapy in a Large Nigerian Cohort. Agbaji, OO; Darin, KM; Eisen, G; Gashau, W; Kanki, PJ; Meloni, ST; Murphy, RL; Nkado, R; Okonkwo, P; Onwujekwe, DI; Rawizza, HE; Scarsi, KK; Tchetgen Tchetgen, EJ, 2016)	0.43
" The 3D regimen of 150/100 mg daily paritaprevir/ritonavir, 25 mg daily ombitasvir, and 400 mg twice-daily dasabuvir was administered alone or in combination with 200 mg daily of emtricitabine and 300 mg daily of tenofovir disoproxil fumarate (tenofovir DF), 25 mg daily of rilpivirine, or 400 mg of raltegravir twice daily."	( Evaluation of Drug-Drug Interactions between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and Rilpivirine. Awni, W; Dunbar, M; Dutta, S; Khatri, A; Menon, R; Podsadecki, T; Trinh, R, 2016)	0.43
"To assess the safety and efficacy of rilpivirine in combination with emtricitabine and tenofovir (RPV/FTC/TDF) as a once-daily single-tablet regimen (STR) in HIV-1-infected children and adolescents we performed a multicenter case series study of HIV-1-infected patients."	( Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients: A multicenter study. Briz, V; De Ory, SJ; Falcon-Neyra, L; Fortuny, C; Frick, MA; González-Tomé, MI; López-Cortés, LF; Moreno, EB; Navarro Gómez, ML; Neth, O; Noguera-Julian, A; Olbrich, P; Palladino, C; Santos, JL; Soler-Palacín, P, 2016)	0.43
"In general, DTG 50 mg given once daily combined with an active background drug is a better choice in terms of both efficacy and safety."	( Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials. Chen, H; Guo, W; Huang, J; Jiang, J; Liang, B; Liang, H; Liao, Y; Su, J; Xu, X; Ye, L; Zang, N, 2016)	0.43
" This mechanistic static approach was further applied to quantitatively predict renal drug-drug interactions (AFE ∼1."	( Quantitative Prediction of Human Renal Clearance and Drug-Drug Interactions of Organic Anion Transporter Substrates Using In Vitro Transport Data: A Relative Activity Factor Approach. Feng, B; Litchfield, J; Mathialagan, S; Piotrowski, MA; Tess, DA; Varma, MV, 2017)	0.46
" To the best of our knowledge, this is the first report of severe hypokalemia and proximal tubular renal dysfunction as a result of a possible drug-drug interaction between vinblastine, tenofovir and ritonavir-boosted atazanavir."	( Severe hypokalemia due to a possible drug-drug interaction between vinblastine and antiretrovirals in a HIV-infected patient with Hodgkin's lymphoma. Arcondo, F; Cordova, E; Morganti, L; Odzak, A; Rodriguez, C; Silva, M; Zylberman, M, 2017)	0.46
"A PBPK modelling approach was used to predict organic anion transporter (OAT) mediated drug-drug interactions involving S44121, a substrate and an inhibitor of OAT1 and OAT3."	( Prediction of renal transporter-mediated drug-drug interactions for a drug which is an OAT substrate and inhibitor using PBPK modelling. Ball, K; Chenel, M; Denizot, C; Jamier, T; Mallier, A; Parmentier, Y, 2017)	0.46
" A single subcutaneous (SC) injection of this first-generation formulation of drug combination nanoparticles (DcNPs), named TLC-ART101, provided persistent ARV levels in macaque lymph node mononuclear cells (LNMCs) for at least 1 week, and in peripheral blood mononuclear cells (PBMCs) and plasma for at least 2 weeks, demonstrating long-acting pharmacokinetics for all three drugs."	( Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulation. Collier, AC; Collins, C; Ho, RJY; Kinman, L; Koehn, J; Kraft, JC; McConnachie, LA; Shen, DD; Sun, J, 2018)	0.48
" No clinically relevant differences in the pharmacokinetics (PK) of SOF, SOF metabolite GS-331007, or VEL were observed other than an approximate 50% decrease in VEL exposure when administered with EFV/FTC/TDF."	( Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers. Brainard, DM; Ling, KHJ; Mathias, A; Mogalian, E; Osinusi, A; Shen, G; Stamm, LM, 2018)	0.48
" This case presents the combination of tenofovir disoproxil in combination with a protease inhibitor as a new potential dual treatment regimen."	( Dual antiretroviral therapy with tenofovir (TDF) and darunavir/ritonavir (DRV/RTV) in an HIV-1 positive patient: a case report, review, and meta-analysis of the literature on dual treatment strategies using protease inhibitors in combination with an NRTI. Höring, S; Löffler, B; Pletz, MW; Rößler, S; Schleenvoigt, BT; Weis, S, 2018)	0.48
" We report a potential drug-drug interaction in 2 female patients both receiving treatment for HIV and cerebral toxoplasmosis: one case between E/C/F/TAF with calcium carbonate and a second case involving leucovorin as calcium salt."	( HIV Viral Rebound Due to a Possible Drug-Drug Interaction between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Calcium-Containing Products: Report of 2 Cases. El-Sayed, D; Kang-Birken, SL; Prichard, J, )	0.13
"Treatment of individuals coinfected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) requires careful consideration of potential drug-drug interactions."	( Assessment of Drug Interaction Potential Between the Hepatitis C Virus Direct-Acting Antiviral Agents Elbasvir/Grazoprevir and the Nucleotide Analog Reverse-Transcriptase Inhibitor Tenofovir Disoproxil Fumarate. Butterton, JR; Caro, L; Fandozzi, C; Feng, HP; Guo, Z; Hanley, WD; Huang, X; Iwamoto, M; Jumes, P; Mangin, E; Marshall, W; Martinho, M; Panebianco, D; Talaty, JE; Valesky, R; Yeh, WW; Zhu, Y, 2019)	0.51
" The combination with ACC007 significantly increases the dose reduction index value of lamivudine and tenofovir disoproxil fumarate, compared with two-drug combination."	( The New NNRTI ACC007 Combined with Lamivudine and Tenofovir Disoproxil Fumarate Show Synergy Anti-HIV Activity In Vitro. Chen, H; Hu, XL; Huang, XS; Luo, RH; Shen, XN; Tang, CR; Xiang, SY; Zhang, CT; Zheng, YT, 2020)	0.56
" Here, we evaluate TDF and FTC in combination with the broadly neutralizing antibody VRC01-N using a highly reproducible humanized mouse model."	( Highly synergistic drug combination prevents vaginal HIV infection in humanized mice. Baum, MM; Bobardt, M; Gallay, PA; Gunawardana, M; Moss, JA; Ramirez, CM, 2020)	0.56
" Confirmatory clinical trials may further define the in vivo triapine metabolic fate and quantify any drug-drug interactions."	( In vitro evaluation of the metabolic enzymes and drug interaction potential of triapine. Beumer, JH; Chaphekar, N; Chu, E; Guo, J; Jones, R; Joshi, A; Kiesel, BF; Kunos, CA; Taylor, S; Venkataramanan, R, 2020)	0.56
"Dolutegravir in combination with NRTIs was effective in treating patients with HIV-1 infection, including those with extensive NRTI resistance in whom no NRTIs were predicted to have activity."	( Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV. Asienzo, J; Ategeka, G; Balyegisawa, A; Castelnuovo, B; Hakim, J; Hoppe, A; Kaimal, A; Kambugu, A; Kiragga, A; Kityo, C; Mirembe, G; Mugerwa, H; Musaazi, J; Paton, NI; Siika, A; Tukamushabe, P; Walimbwa, S, 2021)	0.62
" We did not find an elevated risk of AMI when abacavir-lamivudine was combined with efavirenz or raltegravir."	( Acute myocardial infarction associated with abacavir and tenofovir based antiretroviral drug combinations in the United States. Baxi, SM; Choden, T; Desai, M; Dorjee, K; Hubbard, AE; Reingold, AL, 2021)	0.62
" Because islatravir may be coadministered with other antiretroviral agents, assessment of potential drug-drug interactions are warranted."	( Lack of a Clinically Meaningful Drug Interaction Between the HIV-1 Antiretroviral Agents Islatravir, Dolutegravir, and Tenofovir Disoproxil Fumarate. Armas, D; Fillgrove, KL; Fox-Bosetti, S; Friedman, E; Iwamoto, M; Matthews, RP; Rudd, DJ; Stoch, SA; Zhang, S, 2021)	0.62
"The aim of this international multicentre study was to review potential drug-drug interactions (DDIs) for real-life coadministration of combination antiretroviral therapy (cART) and coronavirus disease 2019 (COVID-19)-specific medications."	( Retrospective evaluation of an observational cohort by the Central and Eastern Europe Network Group shows a high frequency of potential drug-drug interactions among HIV-positive patients receiving treatment for coronavirus disease 2019 (COVID-19). Antoniak, S; Begovac, J; Dragovic, G; Fleischhans, L; Gokengin, D; Harxhi, A; Hofman, S; Jilich, D; Kase, K; Kowalska, J; Lakatos, B; Matulionyte, R; Oprea, C; Papadopoulus, A; Rukhadze, N; Vassilenko, A; Vasyliev, M; Verhaz, A; Wasilewski, P; Yancheva, N, 2022)	0.72
" Following a 2 × 2 factorial design and stratified by site and screening HIV-1 RNA concentration, participants were randomly assigned (1:1:1:1) to receive a 96-week regimen containing either dolutegravir (50 mg once daily) or ritonavir-boosted darunavir (800 mg of darunavir plus 100 mg of ritonavir once daily) in combination with either tenofovir (300 mg once daily) plus lamivudine (300 mg once daily) or zidovudine (300 mg twice daily) plus lamivudine (150 mg twice daily)."	( Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non Asienzo, J; Ategeka, G; Balyegisawa, A; Borok, M; Castelnuovo, B; Hoppe, A; Kaimal, A; Kambugu, A; Kiragga, A; Kityo, C; Lugemwa, A; Mirembe, G; Mugerwa, H; Musaazi, J; Odongpiny, ELA; Paton, NI; Siika, A; Walimbwa, S, 2022)	0.72
" Patients (n = 303) enrolled were randomly administered peg-IFN-α-2b combined with TDF, GM-CSF, and hepatitis B vaccine (experimental group); peg-IFN-α-2b plus TDF (control group 2); or interferon-α-2b alone (control group 1)."	( Pegylated interferon-α-2b combined with tenofovir disoproxil fumarate, granulocyte-macrophage colony-stimulating factor, and hepatitis B vaccine treatment for naïve HBeAg-positive chronic hepatitis B patients: A prospective, multicenter, randomized contro Bai, L; Gu, J; Jia, H; Kuang, W; Lian, J; Lu, X; Lu, Y; Lv, Y; Wang, K; Yang, D; Yang, Y; Ye, C; Yu, J; Yu, Y; Zhang, J; Zhang, X; Zhang, Y; Zhao, P; Zhao, Y, 2022)	0.72
"We retrospectively enrolled 70 unresectable HCC patients who were seropositive for HBsAg and accepted tenofovir alafenamide fumarate (TAF) therapy before anti-PD-1 in combination with an antiangiogenic treatment."	( Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis. Chen, J; Hu, X; Li, Q; Li, R; Yuan, G; Zang, M, 2022)	0.72
"Baseline HBV loads do not affect the prognosis of HCC patients receiving anti-PD-1 in combination with an antiangiogenic therapy, while PD-1 inhibitors do not aggravate HBV reactivation and hepatic impairment in patients simultaneously subjected to TAF prophylaxis."	( Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis. Chen, J; Hu, X; Li, Q; Li, R; Yuan, G; Zang, M, 2022)	0.72
"Lenacapavir warrants further investigation as a potential antiretroviral used orally and as injection in combination with other antiretroviral drugs."	( Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial. Baeten, JM; Benson, P; Berhe, M; Crofoot, G; Dvory-Sobol, H; Gupta, SK; Koenig, E; Liu, SY; McDonald, C; Ramgopal, M; Rhee, MS; Ruane, P; Sanchez, WE; Scribner, A; Sims, J; VanderVeen, LA, 2023)	0.91
" NNRTIs are typically administered in combination with two nucleoside reverse transcriptase inhibitors as first-line recommended regimens in several guidelines."	( No Meaningful Drug-Drug Interactions Are Associated with the Coadministration of ACC007, Lamivudine, and Tenofovir Disoproxil Fumarate. Hao, X; Li, B; Li, L; Ni, J; Tian, Z; Wu, L; Xiao, Y; Zhang, W; Zhao, D; Zhao, X, 2023)	0.91
" The aim was to investigate the expression of IL-1β in CHB patients treated with Peg-IFN-α combination with TDF and TDF/Peg-IFN-α monotherapy."	( The expression of interleukin-1β in patients with chronic hepatitis B treated with pegylated-interferon-alpha combined with tenofovir disoproxil fumarate and monotherapy. Hu, X; Li, Y; Luo, H; Qin, B; Tan, G, 2023)	0.91
" A single-center cohort study of prospective recruitment of CHB patients: untreated CHB (Group A), TDF combined with Peg-IFN-α therapy (Group B), Peg-IFN-α monotherapy (Group C), TDF monotherapy (Group D)."	( The expression of interleukin-1β in patients with chronic hepatitis B treated with pegylated-interferon-alpha combined with tenofovir disoproxil fumarate and monotherapy. Hu, X; Li, Y; Luo, H; Qin, B; Tan, G, 2023)	0.91
"The increased expression of IL-1β may enhance the efficacy of TDF combined with Peg-IFN-α therapy in achieving an early response for CHB patients."	( The expression of interleukin-1β in patients with chronic hepatitis B treated with pegylated-interferon-alpha combined with tenofovir disoproxil fumarate and monotherapy. Hu, X; Li, Y; Luo, H; Qin, B; Tan, G, 2023)	0.91
" This study aimed to scrutinize the role of TF alone or combined with doxorubicin (DOX) in 7,12-dimethylbenz(a)anthracene (DMBA)-induced breast carcinoma rat model."	( Tenofovir alone or combined with doxorubicin abrogates DMBA-induced mammary cell carcinoma: An insight into its modulatory impact on oxidative/Notch/apoptotic signaling. Abdеlaziz, RR; Abouelezz, HM; El-Kashef, DH; Nader, MA, 2023)	0.91
" In parallel, histopathological assessment displayed that mammary glands from animals treated with TF alone or combined with DOX showed better histopathological scores."	( Tenofovir alone or combined with doxorubicin abrogates DMBA-induced mammary cell carcinoma: An insight into its modulatory impact on oxidative/Notch/apoptotic signaling. Abdеlaziz, RR; Abouelezz, HM; El-Kashef, DH; Nader, MA, 2023)	0.91
" Heart transplant (HT) is a very effective therapeutic strategy for end-stage heart failure (HF); however, clinicians may be hesitant due to concerns of complex drug-drug interactions (DDIs) between ART and HT immunosuppressive regimens and the potential impact of ART on long-term HT outcomes."	( Heart transplantation and human immunodeficiency virus-navigating drug-drug interactions: a case report. Almangour, TA; Chang, PP; Corbett, A; Farel, CE; Rodgers, JE; Skersick, PT, 2023)	0.91

Excerpt	Reference	Relevance
" Adefovir dipivoxil, an orally bioavailable prodrug of adefovir is currently in phase III clinical trials for the treatment of HIV and phase II clinical trials for the treatment of HBV infections."	( Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses. Cherrington, JM; Mulato, AS, 1997)	0.3
"A series of prodrugs designed to enhance the oral bioavailability of the antiretroviral agent 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA; 1) have been synthesized, including a bis-(acyloxymethyl) ester 2 and a series of bis-(alkoxycarbonyloxymethyl) esters 3-9."	( Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Arimilli, MN; Cundy, KC; Kim, CU; Lee, WA; Oliyai, R; Shaw, JP; Sueoko, CM, 1997)	0.3
" Oral bioavailability of PMPA from each prodrug was determined in fasted beagle dogs."	( Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Arimilli, MN; Cundy, KC; Kim, CU; Lee, WA; Oliyai, R; Shaw, JP; Sueoko, CM, 1997)	0.3
" In fasted beagle dogs, bis-[(pivaloyloxy)methyl] PMPA (bis-POM PMPA) 2 had the highest oral bioavailability as PMPA (37."	( Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Arimilli, MN; Cundy, KC; Kim, CU; Lee, WA; Oliyai, R; Shaw, JP; Sueoko, CM, 1997)	0.3
" We recently described the synthesis, metabolism, and biological activities of bis(isopropyloxymethylcarbonyl)PMPA [bis(poc)PMPA] as an orally bioavailable prodrug for PMPA."	( Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strains. Fridland, A; Srinivas, RV, 1998)	0.3
" GS-7340 (9-[(R)-2-[[[[(S)-1-(isopropoxycarbonyl)ethyl] amino] phenoxy-phosphinyl]-methoxy] propyl] adenine) is a prodrug which is orally bioavailable in dogs as the intact prodrug and has demonstrated anti-HIV activity in cell culture of over 1000-fold greater than that of PMPA."	( Metabolism of GS-7340, a novel phenyl monophosphoramidate intracellular prodrug of PMPA, in blood. Eisenberg, EJ; He, GX; Lee, WA, )	0.13
"The practical synthesis of a mixed phenoxy-amidate derivative of PMPA with high oral bioavailability and favorable pharmacokinetics is described."	( Practical synthesis, separation, and stereochemical assignment of the PMPA pro-drug GS-7340. Chapman, H; Kernan, M; Prisbe, E; Rohloff, J; Sparacino, M; Terhorst, T; Yu, R, )	0.13
" The oral bioavailability of tenofovir is enhanced by administration with a high-fat meal, but is similar at steady state when administered with or without a typical meal."	( Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Flaherty, JF; Kearney, BP; Shah, J, 2004)	0.32
" After a single oral dose of GS 7340 (10 mg-eq/kg tenofovir) to male beagle dogs, the plasma bioavailability of tenofovir compared to an intravenous dose of tenofovir was 17%."	( Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Cihlar, T; Cundy, KC; Eisenberg, E; He, GX; Lee, WA; Mulato, A; Swaminathan, S, 2005)	0.33
" Physicochemical properties, cellular permeation, renal toxicity, and bioavailability all had to be addressed during the development of these compounds."	( Perspectives on the development of acyclic nucleotide analogs as antiviral drugs. Lee, WA; Martin, JC, 2006)	0.33
" From these results, additional studies will be needed to determine whether a similar mutation in HIV RT develops in patients receiving PMPA or its orally bioavailable prodrug, tenofovir dipivoxil fumarate."	( In vitro selection and characterization of human immunodeficiency virus type 1 resistant to Zidovudine and tenofovir. Hong, SK; Lee, SG; Paik, SY; Park, SS; Yoo, WC; Yoon, JS, 2007)	0.34
" Tenofovir is not orally bioavailable but becomes orally active against HIV-1 infection as the disoproxil ester (tenofovir disoproxil fumarate [Viread])."	( Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections. Aldern, KA; Almond, MR; Beadle, JR; De Clercq, E; Hostetler, KY; Korba, BE; Lampert, BM; Neyts, J; Painter, GR; Trost, LC, 2007)	0.34
" This drug is administered orally in the form of disoproxil ester, which is deesterified to achieve a bioavailability of more than 20%."	( [Tenofovir: pharmacology and interactions]. Azanza, JR; García Quetglas, E; Gómez-Giu, A; Sádaba, B, 2008)	0.35
"This study evaluated the relative bioavailability and pharmacokinetics of elvitegravir (EVG), emtricitabine (FTC), tenofovir disoproxil fumarate (TDF), and a investigational pharmacoenhancer, cobicistat (GS-9350, COBI) coformulated as a fixed-dose combination tablet (FDC) compared with ritonavir-boosted EVG and FTC + TDF in healthy subjects."	( Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. German, P; Hui, J; Kearney, BP; Warren, D; West, S, 2010)	0.36
" The lead candidates, both 1a (PBHBV-001) and 3c (PBHBV-2-15), were well-tolerated in both normal and HBV-transgenic mice and exhibited acceptable pharmacokinetics and bioavailability in Sprague-Dawley rats."	( Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion. Block, TM; Clearfield, E; Cuconati, A; Goddard, C; Guo, H; Mills, C; Morrey, JD; Motter, NE; Xiao, T; Xu, X; Yu, W; Zhao, K, 2011)	0.37
" A BW allometric scaling was used; and the typical population estimates (interindividual variability), standardized for 70 kg, for apparent clearance, central and peripheral volume of distribution, intercompartmental clearance, and absorption rate constant, were 59."	( Population pharmacokinetics of tenofovir in HIV-1-infected pediatric patients. Benaboud, S; Blanche, S; Bouazza, N; Foissac, F; Frange, P; Hirt, D; Rey, E; Tréluyer, JM; Urien, S, 2011)	0.37
" In addition, the bioavailability of tenofovir dipivoxil fumarate was evaluated in healthy male fasted subjects after a single comparatively equivalent dose."	( Relative bioavailability study of a novel prodrug of tenofovir, tenofovir dipivoxil fumarate, in healthy male fasted volunteers. Ding, Y; Jia, Y; Liu, W; Lu, C; Song, Y; Sun, X; Wen, A; Yang, J, 2012)	0.38
" Bioavailability of the drug was assessed in accordance with the State Food and Drug Administration bioequivalence criteria."	( Relative bioavailability study of a novel prodrug of tenofovir, tenofovir dipivoxil fumarate, in healthy male fasted volunteers. Ding, Y; Jia, Y; Liu, W; Lu, C; Song, Y; Sun, X; Wen, A; Yang, J, 2012)	0.38
"The relative bioavailability of tenofovir dipivoxil was 20% higher compared with tenofovir disoproxil fumarate; this result was consistent with the preclinical data."	( Relative bioavailability study of a novel prodrug of tenofovir, tenofovir dipivoxil fumarate, in healthy male fasted volunteers. Ding, Y; Jia, Y; Liu, W; Lu, C; Song, Y; Sun, X; Wen, A; Yang, J, 2012)	0.38
"Drug transporters such as P-glycoprotein and OATPs regulate intestinal permeability of atazanavir and may contribute to its poor oral bioavailability and drug-drug interactions with other protease inhibitors and TDF."	( Role of drug efflux and uptake transporters in atazanavir intestinal permeability and drug-drug interactions. Bendayan, R; Hoque, MT; Kis, O; Walmsley, SL; Zastre, JA, 2013)	0.39
" The bioavailability of tenofovir dipivoxil fumarate was increased by approximately 25% as measured by AUClast after a single dose when taken with food, compared with fasting."	( Pharmacokinetics and food interaction of a novel prodrug of tenofovir, tenofovir dipivoxil fumarate, in healthy volunteers. Chen, L; Chen, M; Ding, Y; Jia, Y; Lu, C; Song, Y; Sun, X; Wen, A; Yang, J, 2013)	0.39
" These findings suggest that elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate should be administered with food, and that the bioavailability of elvitegravir and tenofovir is not affected by the type of meal ingested."	( Effects of a protein-rich drink or a standard meal on the pharmacokinetics of elvitegravir, cobicistat, emtricitabine and tenofovir in healthy Japanese male subjects: a randomized, three-way crossover study. Ikeda, A; Irie, S; Ishikawa, T; Kimura, M; Matsuki, S; Nishino, N; Shiomi, M, 2014)	0.4
"Nonionic surfactant vesicles (niosomes) were formulated with an aim of enhancing the oral bioavailability of tenofovir disoproxil fumarate (TDF), an anti-HIV drug."	( Formulation and characterization of drug loaded nonionic surfactant vesicles (niosomes) for oral bioavailability enhancement. Bala, S; Kamboj, S; Saini, V, 2014)	0.4
"Due to the differences between bioavailability of efavirenz (EFV) and tenofovir (TDF), the single-tablet regimen of EFV/emtricitabine (FTC)/TDF is not approved as initial antiretroviral therapy (ART) in Europe by the European Medical Agency."	( Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1. De Castro, N; Delaugerre, C; Flandre, P; Gallien, S; Molina, JM; Nguyen, N, 2015)	0.42
" An adherence adjustment was included to account for nonadherence by explicitly modeling a bioavailability parameter on the previous day's dose."	( Population pharmacokinetics of tenofovir and tenofovir-diphosphate in healthy women. Burns, RN; Chaturvedula, A; Hendrix, CW, 2015)	0.42
" Our case-series showed a transient and reversible decrease of TDF bioavailability one month after sleeve-gastrectomy without any consequences on CD4 cells and HIV viral load."	( Tenofovir pharmacokinetic after sleeve-gastrectomy in four severely obese patients living with HIV. Alvarez, JC; Carette, C; Czernichow, S; Gbedo, C; Muzard, L, )	0.13
" This study investigated the differences in bioavailability between WHO-prequalified first-line antiretroviral generics by means of adjusted indirect comparisons to ensure interchangeability between these generics."	( Interchangeability between first-line generic antiretroviral products prequalified by WHO using adjusted indirect comparisons. García-Arieta, A; Gordon, J; Gwaza, L; Leufkens, H; Potthast, H; Stahl, M; Welink, J, 2017)	0.46
" HA-SH-NFs significantly enhanced both TFV retention and bioavailability in vaginal tissue compared with the 1% TFV-gel."	( Stimuli-sensitive thiolated hyaluronic acid based nanofibers: synthesis, preclinical safety and in vitro anti-HIV activity. Agrahari, V; Christenson, LK; Dim, DC; Ezoulin, MJ; Hung, WT; Meng, J; Molteni, A; Youan, BC; Youm, I, 2016)	0.43
" The in vivo studies also showed that both CBJ and GFJ enhanced the oral bioavailability of TDF as the AUC was increased by 24% and 97%, respectively."	( Oral pharmacokinetic interaction of ester rich fruit juices and pharmaceutical excipients with tenofovir disoproxil fumarate in male Wistar rats. Myneni, S; Ravi, PR; Saha, P; Shailender, J, 2017)	0.46
"Tenofovir disoproxil fumarate (TDF), the bisphosphonate ester prodrug of tenofovir (TFV), has poor bioavailability due to intestinal degradation and efflux transport."	( Development of a Novel Formulation That Improves Preclinical Bioavailability of Tenofovir Disoproxil Fumarate. Domanico, PL; Lutz, L; Nowakowski, M; Park, S; Powell, K; Ramabhadran, R; Randolph, R; Watkins, ME; Wring, S, 2017)	0.46
" In two open-label, single-dose, randomized, two-period, crossover trials, the bioavailability of doravirine administered alone or in a fixed-dose combination (FDC) was determined under fed and fasted conditions."	( The Effect of Food on Doravirine Bioavailability: Results from Two Pharmacokinetic Studies in Healthy Subjects. Behm, MO; Fackler, P; Levine, V; Liu, R; Panebianco, D; Yee, KL, 2017)	0.46
" The versatile HA-PQ10 entrapped all drugs and achieved an enhanced relative bioavailability of EFV, TDF, and FTC compared to the market formulation for potentially enhanced HIV treatment."	( 3D printed, controlled release, tritherapeutic tablet matrix for advanced anti-HIV-1 drug delivery. Choonara, YE; du Toit, LC; Kondiah, PPPD; Kumar, P; Pillay, V; Siyawamwaya, M, 2019)	0.51
" Lactobacillus crispatus actively transported tenofovir leading to a loss in drug bioavailability and culture supernatants from Gardnerella vaginalis, but not Atopobium vaginae, blocked tenofovir endocytosis."	( Vaginal microbiome modulates topical antiretroviral drug pharmacokinetics. Cameron, SA; Cheshenko, N; Frank, B; Fredricks, D; Herold, BC; Keller, MJ; Mesquita, PM; Reagle, K; Sinclair, S; Srinivasan, S; Taneva, E; Weinrick, B, 2018)	0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" BIC has demonstrated a high genetic barrier to resistance development in vitro, can be administered with or without food, and has a bioavailability of > 70%."	( Bictegravir, a novel integrase inhibitor for the treatment of HIV infection. Bhatia, R; Rizza, S; Temesgen, Z; Zeuli, J, 2019)	0.51
" Proficient bioavailability coupled with no predicted in silico toxicity rendered them as prospective alternatives for designing and development of novel combinatorial therapy formulations for improving existing treatment regimes to combat COVID-19."	( Computational drug re-purposing targeting the spike glycoprotein of SARS-CoV-2 as an effective strategy to neutralize COVID-19. Banerjee, DI; Darji, SA; Lipsa Rath, S; Toor, HG, 2021)	0.62
" Tenofovir has a very low oral bioavailability following oral administration."	( Treatment of chronic hepatitis B: virological and pharmacological aspects Foucault, T; Gaudy-Graffin, C; Handala, L; Marlet, J; Paintaud, G, 2022)	0.72
" The latter was further converted to two orally bioavailable prodrug forms, TDF and TAF, and both TDF and TAF were further combined with other antiviral drugs, thus giving rise to a broad array of antiviral drug combinations for the treatment of HIV infections."	( The Elegance of the Acyclic Nucleoside Phosphonates (ANPs), Honorary Tribute to Antonín Holý, Who Passed Away on 16 July 2012, at the 10th Anniversary of His Death. De Clercq, E, 2022)	0.72
"0 suggests that an increase in vaginal pH could improve TDF bioavailability at earlier time points."	( Chitosan-poly(ethylene oxide) nanofibrous mat as a vaginal platform for tenofovir disoproxyl fumarate - The effect of vaginal pH on drug carrier performance. Ciach, T; Dąbrowska, J; Krzyżowska, M; Nowicka, M; Szymańska, E; Winnicka, K; Wojasiński, M, 2022)	0.72
"A crossover, randomized trial in healthy adults (NCT04244448) investigated the bioavailability of two off-label uses of BIC/TAF/FTC (50/200/25 mg), dissolved in water or crushed in apple compote, compared with the solid tablet."	( Bioavailability of dissolved and crushed single tablets of bictegravir, emtricitabine, tenofovir alafenamide in healthy adults: the SOLUBIC randomized crossover study. Alix, A; Bois, J; Brucato, S; Dargere, S; Fournel, F; Fournier, A; Got, L; Gregoire, N; Hocqueloux, L; Lefeuvre, S; McNicholl, I; Parienti, JJ; Peyro-Saint-Paul, L; Prazuck, T; Valentin, C, 2022)	0.72

Excerpt	Relevance	Reference
" Within < or = 2 weeks of treatment, PMPA in both dosing regimens reduced SIV levels by >99% in the plasma or peripheral blood mononuclear cells; in some macaques SIV levels were reduced to below the lower quantitation limit."	( Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques. Beck, TW; Bischofberger, N; Dailey, PJ; Follis, KE; Sabo, A; Tsai, CC, 1997)	0.3
" All subjects tolerated dosing without significant adverse events."	( Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Barditch-Crovo, P; Cundy, KC; Deeks, SG; Hellmann, NS; Hwang, F; Kahn, JO; Lietman, PS; Rooney, JF; Safrin, S, 1998)	0.3
" Variables that can be experimentally manipulated to address specific questions relevant to postexposure prophylaxis (PEP) include timing of initiation of treatment, duration of treatment, dosing regimen, virus strain, and virus inoculum."	( Animal studies of prophylaxis. Black, RJ, 1997)	0.3
" Both prophylactic and therapeutic dosing regimens were effective."	( Chemokines, nitric oxide and antiarthritic effects of 9-(2-phosphonomethoxyethyl)adenine (Adefovir). Franková, D; Holý, A; Zídek, Z, 1999)	0.3
" Advertising that promoted the improved drug has been withdrawn at the request of Project Inform because of the lack of warning labels necessary due to dosing problems."	( Update on antivirals. , 1997)	0.3
" Information on tenofovir, such as the dosage normally prescribed and cost of treatment is listed."	( What they say about: nucleotide drugs. , )	0.13
" The recommended dosage of tenofovir DF in adults is 300 mg/d PO; pharmacokinetic and efficacy studies in children are ongoing."	( Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection. Fung, HB; Piacenti, FJ; Stone, EA, 2002)	0.31
" The approved dosage of tenofovir is 300 mg (one tablet) once/day with meals."	( Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection. Antoniou, T; Park-Wyllie, LY; Tseng, AL, 2003)	0.32
" The steady-state, geometric mean AUC for the 24-h dosing interval was 2,920 ng."	( Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children. Balis, FM; Blanche, S; Bresson, JL; Coakley, DF; DeCarlo, E; Flaherty, JF; Hazra, R; Kearney, BP; Poblenz, M; Steinberg, SM; Tullio, AN; Worrell, CJ; Yale, K; Zeichner, SL; Zhong, L; Zuckerman, JA, 2004)	0.32
" Plasma concentration of ddI was prospectively determined in eight of these patients receiving ddI 400 mg + TDF + NVP and 3 weeks after a ddI dosage reduction."	( Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. Burger, D; Clotet, B; Grassi, J; Juan, M; Masmitjà, E; Moltó, J; Negredo, E; Paredes, R; Pruvost, A; Puig, J; Ribera, E; Ruiz, L; Viciana, P, 2004)	0.32
"Gilead Sciences is developing a fixed-dose co-formulation of two of its reverse transcriptase inhibitors, emtricitabine [Emtriva] and tenofovir disoproxil fumarate [Viread], for once-daily dosing in combination with other antiretrovirals for the treatment of HIV infection."	( Emtricitabine/tenofovir disoproxil fumarate. , 2004)	0.32
" With the exception of didanosine and atazanavir, which require dosage modifications, no clinically significant drug interactions have been observed with tenofovir DF."	( Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Flaherty, JF; Kearney, BP; Shah, J, 2004)	0.32
" Bioequivalence testing was conducted of total, R-, and S-methadone area under the serum or plasma concentration-time curve during the 24-hour dosing interval at steady state (AUCss) and maximum concentration in serum or plasma (Cmax)."	( Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadone. Berenson, CS; Booker, BM; Bullock, JM; Cloen, D; Coakley, DF; Flaherty, JF; Haas, CE; Kearney, BP; Liaw, S; Smith, PF; Yale, K, 2004)	0.32
" Didanosine was prescribed at a reduced dosage due to the known interaction with tenofovir."	( Acute onset of pancreatitis with concomitant use of tenofovir and didanosine. Fulco, PP; Higginson, RT; Kirian, MA, 2004)	0.32
" Reduced didanosine dosage (250 mg) should be used to reduce serum didanosine concentrations and subsequent toxicities."	( Acute onset of pancreatitis with concomitant use of tenofovir and didanosine. Fulco, PP; Higginson, RT; Kirian, MA, 2004)	0.32
" Tenofovir DF provides a simple and convenient once-daily dosage regimen, and is generally well tolerated and able to produce sustained suppression of viral replication."	( Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection. Lyseng-Williamson, KA; Plosker, GL; Reynolds, NA, 2005)	0.33
" To limit this interaction, the dosage of ddI may be reduced to 250 mg once daily when co-prescribed with TDF."	( The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily. Bower, M; Gazzard, B; Mandalia, S; Nelson, M; Tung, MY, 2005)	0.33
" The relevance of a dosage adjustment based on BW/S(CR) should be further evaluated."	( Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy. Dupin, N; Jaffray, P; Jullien, V; Krivine, A; Lescoat, A; Lillo-Le Louet, A; Moachon, L; Pons, G; Rey, E; Salmon, D; Tréluyer, JM; Urien, S, 2005)	0.33
" When atazanavir 300 mg was coadministered with ritonavir 100 mg on a once-daily dosage regimen, atazanavir AUC from 0 to 24 hours and minimum plasma concentration were increased by 3- to 4-fold and approximately 10-fold, respectively, compared with atazanavir 300 mg alone."	( Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Barrail, A; Goujard, C; Le Tiec, C; Taburet, AM, 2005)	0.33
" Tenofovir, nelfinavir, and M8 pharmacokinetics was unaltered when tenofovir and nelfinavir were coadministered, and tenofovir administration did not affect the M8/nelfinavir area under the concentration-versus-time curve over the dosing interval (AUC(tau)) ratio."	( Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate. Boffito, M; Higgs, C; Kearney, BP; Mathias, A; Pozniak, A; Shah, J; Zhong, L, 2005)	0.33
"Antiretroviral combinations that reduce the number of pills and dosing frequency have the potential to simplify therapy."	( Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. Berger, DS; Gallant, JE; Johnson, J; Liao, Q; Lim, ML; Rodriguez, AE; Ross, L; Shaefer, MS; Weinberg, WG; Young, B, 2005)	0.33
" When 400 mg was dosed with tenofovir DF, mean didanosine AUC was increased by 44% to 60% following fasted or fed administration."	( Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine. Chen, SS; Cheng, AK; Flaherty, JF; Kaul, S; Kearney, BP; Sayre, JR, 2005)	0.33
" We designed this study to provide preliminary pediatric safety and dosing information on tenofovir DF, while also providing potentially efficacious salvage therapy for heavily treatment-experienced, HIV-infected children."	( Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Balis, FM; DeCarlo, E; Flaherty, J; Gafni, RI; Hazra, R; Kearney, BP; Maldarelli, F; Steinberg, SM; Tullio, AN; Worrell, CJ; Yale, K; Zeichner, SL, 2005)	0.33
" Blood samples for tenofovir (TFV) and SQV/RTV PK were drawn over respective 24- and 12-h dosing intervals, and drug concentrations were measured by liquid chromatography-tandem mass spectrometry."	( Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state. Adda, N; Begley, JA; Blum, MR; Chittick, GE; Kearney, BP; Sorbel, JJ; Zong, J, 2006)	0.33
"Tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) are nucleoside reverse transcriptase inhibitors (NRTIs) with once-daily dosing approved for use in HIV-1 infection."	( In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine. Borroto-Esoda, K; Miller, MD; Myrick, F; Ray, AS; Vela, JE, 2006)	0.33
" However, early HAART often consisted of drugs with complex dosing schedules, strict food requirements, treatment-limiting adverse effects, and the need to take 16-20 pills/day."	( An update and review of antiretroviral therapy. Piacenti, FJ, 2006)	0.33
" The single daily dosing was expected to improve adherence to treatment."	( Change to a once-daily combination including boosted atazanavir in HIV-1-infected children. Blanche, S; Delaugerre, C; Jullien, V; Macassa, E; Rouzioux, C; Teglas, JP; Tréluyer, JM; Veber, F, 2006)	0.33
" Tenofovir requires surveillance of glomerular filtration rate and dosing interval adjustment when creatinine clearance is less than 50 ml/min and avoidance less than 30 ml/min."	( Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone. Arribas López, JR; Muñoz de Benito, RM, 2006)	0.33
"As expected for a renally eliminated drug, subjects with and without hepatic impairment displayed similar tenofovir systemic exposures without evidence of substantial alterations in drug disposition, and therefore no dosage adjustments were warranted in these patients."	( Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment. Flaherty, JF; Kearney, BP; Shah, J; Yale, K; Zhong, L, 2006)	0.33
"Tenofovir measurements with an area under the concentration-time curve over the dosing interval, maximum concentration, and concentration at the end of the dosing interval (Ctau) were 32%, 15%, and 51% higher, respectively, when TDF was coadministered with LPV/r (n = 24)."	( Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. Cheng, AK; Ebrahimi, R; Kearney, BP; Mathias, A; Mittan, A; Sayre, J, 2006)	0.33
" Individually, these agents have long half-lifes that allow for once-daily dosing and may provide a pharmacologic bridge for the occasional missed dose."	( Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all? Best, B; Goicoechea, M, 2007)	0.34
" Tenofovir is largely prescribed at the standard dosage of 300 mg once daily: therefore, the per kilogram dose is higher in Thailand than in the USA."	( No change in calculated creatinine clearance after tenofovir initiation among Thai patients. Ananworanich, J; Chetchotisakd, P; Gayet-Ageron, A; Hirschel, B; Jupimai, T; Le Braz, M; Prasithsirikul, W; Rooney, JF; Ruxrungtham, K; Ubolyam, S, 2007)	0.34
" Tenofovir could be safely prescribed at a standard dosage of 300 mg once daily in the Thai population."	( No change in calculated creatinine clearance after tenofovir initiation among Thai patients. Ananworanich, J; Chetchotisakd, P; Gayet-Ageron, A; Hirschel, B; Jupimai, T; Le Braz, M; Prasithsirikul, W; Rooney, JF; Ruxrungtham, K; Ubolyam, S, 2007)	0.34
" Lack of PK alteration for FTC, tenofovir (TFV), and GS-9137 was defined as a 90% confidence interval (CI) for the estimated ratio of geometric least squares means (coadministration/alone) between 70% and 143% for the primary PK parameters: maximum observed plasma concentration (Cmax), area under the plasma concentration-time curve over dosing interval (AUCtau), and trough concentration (Ctau)."	( Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. Cheng, A; Kearney, BP; Ramanathan, S; Shen, G, 2007)	0.34
" We investigated whether tenofovir plus didanosine at a weight-adjusted dosage could be responsible for such an effect, and factors associated with CD4 + T cell count evolution under this combination."	( CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load. Antinori, A; Antonucci, F; Barreiro, P; Carosi, G; De Silvestri, A; El Hamad, I; Ladisa, N; Lapadula, G; Maggiolo, F; Mandalia, S; Maserati, R; Migliorino, G; Pierotti, P; Sighinolfi, L; Soriano, V; Suter, F; Torti, C, 2007)	0.34
" This study evaluated the pharmacokinetics (PK) and bioequivalence of an investigational coformulation of EFV/FTC/TDF (test) single-tablet regimen compared with the commercially available individual dosage forms (EFV+FTC+TDF; reference treatment) in healthy subjects."	( Bioequivalence of efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen. Hinkle, J; Hui, J; Kaul, S; Kearney, BP; Mathias, AA; Menning, M, 2007)	0.34
" Group 1 was treated subcutaneously with a human-equivalent dose of emtricitabine (FTC), group 2 received orally the human-equivalent dosing of both FTC and tenofovir-disoproxil fumarate (TDF), and group 3 received subcutaneously a similar dosing of FTC and a higher dose of tenofovir."	( Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. Adams, DR; Cong, ME; Delinsky, D; Folks, TM; García-Lerma, JG; Heneine, W; Jackson, E; Janssen, R; Johnson, JA; Kim, C; Lipscomb, J; Luo, W; Masciotra, S; Monsour, M; Otten, RA; Qari, SH; Schinazi, RF, 2008)	0.35
" The likelihood of renal toxicity (proximal renal tubular dysfunction [PRTD]) correlated with plasma drug concentrations, which depended on the dosage regimen and age-related changes in drug clearance."	( Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Abel, K; Bischofberger, N; Brignolo, LL; Cihlar, T; Durand-Gasselin, L; Jerome, C; Kearney, BP; Marthas, ML; Moore, J; Ray, AS; Reiser, H; Spinner, A; Van Rompay, KK, 2008)	0.35
" Pharmacokinetic profiles were also determined in HIV-1-infected patients dosed with raltegravir monotherapy versus raltegravir in combination with TDF and lamivudine."	( Lack of a significant drug interaction between raltegravir and tenofovir. Breidinger, SA; Chen, J; Friedman, EJ; Gottesdiener, KM; Iwamoto, M; Kost, JT; Lasseter, KC; Stek, JE; Stone, JA; Teppler, H; Wagner, JA; Wenning, LA, 2008)	0.35
" Tenofovir concentrations (median 2; range, 1-5) were measured in 175 patients during several dosing intervals."	( Population pharmacokinetics of tenofovir in AIDS patients. Barkil, ME; Boibieux, A; Cotte, L; Gagnieu, MC; Guitton, J; Livrozet, JM; Miailhes, P; Tod, M, 2008)	0.35
" When implementing HAART, physicians should be aware of and monitor potential patient misunderstanding of instructions on dosage and administration and for possible complications in medicinal combinations and potential side effects."	( [A case of acute renal failure involving high amounts of tenofovir after HAART start]. Kasahara, K; Konishi, M; Maeda, K; Mikasa, K; Nakagawa, C; Uno, K; Yonekawa, S; Yoshimoto, E, 2008)	0.35
" The results demonstrated that the procedure is accurate, precise and reproducible (relative standard deviation <2%), while being simple, cheap and less time consuming and can be suitably applied for the estimation of tenofovir disoproxil fumarate in different dosage forms."	( Application of UV-spectrophotometric methods for estimation of tenofovir disoproxil fumarate in tablets. A, SA; H, BC; J, SS, 2009)	0.35
" Because of this latter characteristic, dosage adjustments are required in patients with renal insufficiency."	( [Tenofovir: pharmacology and interactions]. Azanza, JR; García Quetglas, E; Gómez-Giu, A; Sádaba, B, 2008)	0.35
" The only available formulation is an adult tablet, introducing the possibility of dosing errors in children."	( Tenofovir use in human immunodeficiency virus-1-infected children in the United kingdom and Ireland. Boyd, K; Butler, K; Cliff, D; Doerholt, K; Gibb, D; Judd, A; Lyall, H; Menson, E; Riordan, A, 2009)	0.35
" Statistical analyses were performed on pharmacokinetic parameters: the area under the concentration-time curve from 0 to 4 h (AUC(0-4)), the maximum concentration of the drug (C(max)), and the residual concentration of the drug at the end of the dosing interval (C(trough)) for plasma and the AUC(0-4) and C(trough) for intracellular data."	( Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. Ayen, R; Clotet, B; Grassi, J; Levi, M; Negredo, E; Pruvost, A; Puig, J; Théodoro, F, 2009)	0.35
" A new combination therapy consisting of the TFV pro-drug (300 mg) and another reverse transcriptase inhibitor, emtricitabine (FTC, 200 mg) has become available in a convenient once-daily dosage form (Truvada)."	( The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards. Bushman, L; Delahunty, T; Fletcher, CV; Robbins, B, 2009)	0.35
" We report 12-month changes in renal profiles among 19 such patients (6 patients with history of and 13 patients with current renal disease) in the HIV Outpatient Study (HOPS) who initiated TDF-containing highly active antiretroviral therapy (HAART) during 2001-2005 with TDF dosed mostly at 300 mg once daily."	( Renal function in patients with preexisting renal disease receiving tenofovir-containing highly active antiretroviral therapy in the HIV outpatient study. Brooks, JT; Buchacz, K; Moorman, A; Wood, KC; Young, B, 2009)	0.35
"Tenofovir DF and norgestimate-ethinyl estradiol are not involved in a clinically significant drug-drug interaction; tenofovir DF did not affect the steady-state pharmacokinetics of norgestimate or ethinyl estradiol, including the concentration at the end of the dosing interval."	( Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives. Kearney, BP; Mathias, A, 2009)	0.35
"Once-daily treatment with ritonavir-boosted saquinavir was well tolerated and resulted in similar saquinavir drug exposure despite much lower ritonavir concentrations when compared with a twice-daily dosing schedule."	( Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients. Bickel, M; Bodtländer, A; Gute, P; Klauke, S; Knecht, GK; Kurowski, M; Lutz, T; Stephan, C; von Hentig, N, 2009)	0.35
" Its favorable profile in terms of high efficacy, low toxicity and once-daily dosing makes TDF one of the most attractive antiretroviral agents, and therefore, it is widely used."	( Pharmacogenetics of tenofovir treatment. Labarga, P; Rodriguez-Novoa, S; Soriano, V, 2009)	0.35
" No differences were noted in adverse events among dosing periods."	( Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers. Andrews, M; Condoluci, DV; Luber, AD; Olson, K; Pakes, GE; Pappa, KA; Peloquin, CA; Slowinski, PD, 2010)	0.36
" We investigated the relationship of NVP dosing with safety and efficacy."	( Safety and efficacy of once-daily nevirapine dosing: a multicohort study. Battegay, M; Calmy, A; de Wolf, F; Hirschel, B; Hogg, RS; Lange, JM; Lima, VD; Montaner, JS; Nguyen, A; Reiss, P; Vallier, N; Wit, FW; Yip, B, 2009)	0.35
" Daily drug dosage was 300 mg Tenofovir, 200mg Emtricitabine and 400 mg Nevirapine once daily."	( Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR-trial). Flux, K; Gholam, P; Hartmann, M; Hueter, E; Weberschock, T, 2009)	0.35
" We hypothesized that intermittent prophylactic treatment with long-acting antiviral drugs would be as effective as daily dosing in blocking the earliest stages of viral replication and preventing mucosal transmission."	( Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Barr, JR; Cong, ME; Folks, TM; García-Lerma, JG; Hanson, DL; Heneine, W; Holder, A; Kuklenyik, Z; Lipscomb, J; Martin, A; Masciotra, S; Mitchell, J; Otten, R; Pau, CP; Paxton, L; Youngpairoj, AS; Zheng, Q, 2010)	0.36
" Following oral dosing (3mg/kg) in Beagle dogs, high levels (>9."	( Discovery of GS-9131: Design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148. Birkus, G; Boojamra, CG; Cihlar, T; Desai, MC; Douglas, JL; Gao, Y; Grant, D; Hui, HC; Laflamme, G; Lin, KY; Mackman, RL; Markevitch, DY; McDermott, M; Mishra, R; Pakdaman, R; Petrakovsky, OV; Ray, AS; Vela, JE; Zhang, L, 2010)	0.36
" Irrespective of the dosing strategy used, the rsIL-7gly administration transiently increased proliferation of both central memory and naive cells, in both CD4(+) and CD8(+) subsets, without increasing SIV levels in the blood."	( Increased CD4+ T cell levels during IL-7 administration of antiretroviral therapy-treated simian immunodeficiency virus-positive macaques are not dependent on strong proliferative responses. Assouline, B; Axthelm, MK; Legasse, A; Leone, A; Lifson, JD; Morre, M; Okoye, A; Piatak, M; Picker, LJ; Rohankhedkar, M; Sodora, DL; Villinger, F, 2010)	0.36
" Emergence of postbaseline resistance mutations occurred at similar low rates in each dosing group."	( Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized t Bernstein, B; Cohen, D; da Silva, B; Fredrick, L; González-García, J; Johnson, M; Naylor, C; Sloan, L, 2010)	0.36
" Relative to ritonavir-boosted EVG, the geometric least-squares means ratios (GMR) [90% confidence interval (CI)] for EVG area under plasma concentration-time curve from time zero until the end of the dosing interval (AUC)tau, maximum concentration (Cmax), and trough concentration (Ctau) were 118 (110 to 126), 108 (100 to 116), and 110 (95."	( Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. German, P; Hui, J; Kearney, BP; Warren, D; West, S, 2010)	0.36
"Addition of darunavir/ritonavir to etravirine, all dosed once daily, did not have a clinically significant effect on the pharmacokinetics of etravirine."	( Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults. DeJesus, E; Kakuda, TN; Lalezari, JP; Osiyemi, OO; Ruane, PJ; Ryan, R; Witek, J, 2010)	0.36
" This review identifies important cellular pharmacology considerations for tenofovir and emtricitabine, which include drug penetration into relevant tissues and cell types, race/ethnicity/pharmacogenetics, gender, cellular activation state and appropriate episodic or alternative dosing strategies based on pharmacokinetic principles."	( Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. Anderson, PL; Gardner, EM; Grant, RM; Kiser, JJ; Meditz, A; Rower, JE, 2011)	0.37
" Healthy volunteer studies have demonstrated a decrease in glucose disposal associated with dosing with specific antiretrovirals."	( Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men. Back, DJ; Boffito, M; Jackson, AG; Mandalia, S; Moyle, GJ; Randell, PA; Taylor, J; Tjia, JF, 2010)	0.36
" Dosing was separated by a wash-out period of 14 days."	( Bioequivalence study of two oral tablet formulations containing tenofovir disoproxil fumarate in healthy volunteers. Feleder, EC; Halabe, EK; Yerino, GA; Zini, E, 2011)	0.37
" Decreases in estimated glomerular filtration rate occurred within the first few weeks of dosing in participants receiving EVG/COBI/FTC/TDF, remained within the normal range and did not progress at week 24 or 48; no participant experienced a clinical adverse event or discontinued study drug due to changes in serum creatinine or renal function."	( Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. Chuck, SL; Cohen, C; DeJesus, E; Elion, R; Kearney, BP; Liu, HC; Ramanathan, S; Rashbaum, B; Ruane, P; Shamblaw, D; Warren, DR; Yale, K, 2011)	0.37
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."	( FDA-approved drug labeling for the study of drug-induced liver injury. Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011)	0.37
" Dosage of 200 mg might provide an option to patients showing suboptimal ATV exposure with standard unboosted dosing."	( Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. Baietto, L; Bonora, S; Calcagno, A; D'Avolio, A; Di Perri, G; Gonzalez de Requena, D; Siccardi, M; Simiele, M; Tettoni, M; Trentini, L, 2011)	0.37
" Dosing scheme, according BW and LPV/r coadministration were simulated to produce the same 24-hr exposure as adults after 300-mg TDF dose."	( Population pharmacokinetics of tenofovir in HIV-1-infected pediatric patients. Benaboud, S; Blanche, S; Bouazza, N; Foissac, F; Frange, P; Hirt, D; Rey, E; Tréluyer, JM; Urien, S, 2011)	0.37
"Children without LPV/r should receive: 150 mg TDF from 20 to 30 kg, 225 mg TDF from 30 to 40 kg, and the adult dosage of 300 mg TDF over 40 kg."	( Population pharmacokinetics of tenofovir in HIV-1-infected pediatric patients. Benaboud, S; Blanche, S; Bouazza, N; Foissac, F; Frange, P; Hirt, D; Rey, E; Tréluyer, JM; Urien, S, 2011)	0.37
" Low concentrations at birth support infant dosing as soon after birth as possible."	( Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants. Bardeguez, A; Cotter, A; Fiscus, SA; Flynn, PM; Heckman, B; Huang, S; Jean-Philippe, P; Kearney, B; Mirochnick, M; Mofenson, LM; Purswani, M; Robbins, B; Rodman, J; Rooney, JF; Shapiro, DE; Thorpe, E; Van Rompay, KK; Watts, DH, 2011)	0.37
" At all doses, concentrations at the dosing site were typically 1 to 2 log units higher than those in the opposite compartment and 4 to 5 log units higher than those in plasma."	( Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques. Allen, P; Kashuba, A; Nuttall, J; Roberts, J; Romano, J; Wang, R; White, N, 2012)	0.38
" Forty-seven were randomized to once (QD) or twice daily (BID) dosing for 2 weeks and to collection of genital tract samples at 4, 8 or 24 hrs after the final dose, but two discontinued prior to gel application."	( A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. Brache, V; Creinin, MD; Kashuba, AD; Kearney, BP; Poindexter, A; Rountree, W; Schwartz, JL, 2011)	0.37
" Despite continued gel dosing postinfection, neither breakthrough infection had evidence of drug resistance by ultrasensitive testing of SHIV in plasma and vaginal lavage."	( Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue. Dobard, C; García-Lerma, JG; Hanson, DL; Heneine, W; Holder, A; Kuklenyik, Z; Lipscomb, J; Martin, A; Novembre, FJ; Pau, CP; Sharma, S; Smith, J, 2012)	0.38
"Atazanavir geometric mean (CV%) C(max), C(min) and AUC over the dosing interval were 2897 (46) ng/mL, 526 (57) ng/mL and 28 605 (46) ng · h/mL, respectively, and for lopinavir they were 10 655 (51) ng/mL, 5944 (68) ng/mL and 90 946 (59) ng · h/mL, respectively."	( Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study. Bertz, R; Child, M; Eley, T; Farajallah, A; Krystal, M; Liao, S; McGrath, D; Molina, JM; Persson, A; Sevinsky, H; Xu, X; Zhang, J; Zhu, L, 2012)	0.38
" Dosing antiretroviral agents with kidney metabolism should be adjusted when eGFR is bellow 50 mL/min/1."	( [Kidney and HIV infection]. Lescure, FX; Plaisier, E; Ronco, P, 2012)	0.38
" Dosing strategies (e."	( Formulation, pharmacokinetics and pharmacodynamics of topical microbicides. Adams, JL; Kashuba, AD, 2012)	0.38
" Although some trial results appear conflicting, behavioral factors, adherence to dosing and pharmacokinetic properties of the different tenofovir formulations and dosing approaches offer plausible explanations for most of the variations in effectiveness observed in different trials."	( A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection. Abdool Karim, SS; Baxter, C; Gengiah, TN; Kharsany, AB; Mansoor, LE, 2012)	0.38
" Median TFV concentrations in iliac lymph nodes ranged from 44 ng/g to 196 ng/g; differences between iliac lymph node TFV concentrations following dosing of the two gels were insignificant."	( Pharmacokinetics and topical vaginal effects of two tenofovir gels in rabbits. Clark, MR; Friend, DR, 2012)	0.38
" Raltegravir must be dosed twice daily, as once daily raltegravir displays decreased virologic efficacy compared to twice daily dosing."	( Role of raltegravir in HIV-1 management. Bookstaver, PB; Bryant, JE; Millisor, VE; Rokas, KE; Shamroe, CL; Sutton, SS; Weissman, SB, 2012)	0.38
"Little is known about safety of and adherence to intermittent HIV PrEP regimens, which may be more feasible than daily dosing in some settings."	( Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. Anzala, O; Bangsberg, D; Barin, B; Chetty, P; Fast, P; Haberer, JE; Mark, D; Mugo, P; Mutua, G; Priddy, FH; Rooney, JF; Sanders, E, 2012)	0.38
"Adherence to intermittent dosing regimens, fixed doses, and in particular coitally-dependent doses, may be more difficult than adherence to daily dosing."	( Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. Anzala, O; Bangsberg, D; Barin, B; Chetty, P; Fast, P; Haberer, JE; Mark, D; Mugo, P; Mutua, G; Priddy, FH; Rooney, JF; Sanders, E, 2012)	0.38
" Adherence by type of ART and dosing frequency were compared by Brown-Mood median tests."	( Impact of antiretroviral dosing frequency and pill burden on adherence among newly diagnosed, antiretroviral-naive HIV patients. Buscher, A; Giordano, TP; Hartman, C; Kallen, MA, 2012)	0.38
" The use of SF and PK-PD disease models can be a valuable tool to predict dose-response of NMEs and support rational dose selection for monotherapy trials."	( From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a framework. Fang, J; Jadhav, PR, 2012)	0.38
" We developed a pharmacokinetic model for TDF and its active anabolite tenofovir-diphosphate (TFV-DP) and validated it with data from 4 different trials, including 4 distinct dosing regimes."	( Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection. Duwal, S; Schütte, C; von Kleist, M, 2012)	0.38
" Optimal PrEP agents and dosing regimens now need to be identified."	( Considerations regarding antiretroviral chemoprophylaxis in MSM. Grulich, AE; Poynten, IM; Zablotska, I, 2012)	0.38
"The Microbicide Trials Network 003 study, a large phase IIb trial, was unable to show that daily dosing with 1% tenofovir vaginal gel was effective for HIV prevention."	( Current status of topical antiretroviral chemoprophylaxis. Szpir, M; Van Damme, L, 2012)	0.38
" Phase II and III trials continue to explore different dosing strategies for topical products that contain one or more ARV agents."	( Current status of topical antiretroviral chemoprophylaxis. Szpir, M; Van Damme, L, 2012)	0.38
" Dosing was discontinued on day 30 and blood was collected on days 35, 45, and 60 during the washout period."	( Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. Anderson, PL; Bushman, LR; Castillo-Mancilla, JR; Fernandez, C; Gardner, EM; Kiser, JJ; Langness, J; Meditz, A; Predhomme, J; Rower, JE; Zheng, JH, 2013)	0.39
" We conclude that rectal dosing with TFV 1% gel resulted in greater TFV-DP tissue detection than oral dosing with reduced ex vivo biopsy infectibility, enabling PK-PD correlations."	( RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate. Anton, PA; Bumpus, NN; Carballo-Diéguez, A; Cranston, RD; Cumberland, WG; Dennis, R; Elliott, J; Hendrix, CW; Janocko, L; Ju, C; Kashuba, A; Khanukhova, E; Mauck, C; McGowan, I; Richardson-Harman, N, 2012)	0.38
" Vaginal dosing achieves measurable tenofovir concentrations in the rectum and vice versa."	( The clinical pharmacology of antiretrovirals for HIV prevention. Hendrix, CW, 2012)	0.38
" Directly observed dosing in a separate study, the STRAND trial, yielded TFV-DP concentrations that, when analyzed according to the iPrEx model, corresponded to an HIV-1 risk reduction of 76% for two doses per week, 96% for four doses per week, and 99% for seven doses per week."	( Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Anderson, PL; Bekker, LG; Buchbinder, S; Bushman, LR; Casapía, M; Chariyalertsak, S; Glidden, DV; Grant, RM; Guanira, JV; Kallás, EG; Lama, JR; Liu, A; Mayer, KH; McMahan, V; Montoya-Herrera, O; Schechter, M; Veloso, VG, 2012)	0.38
" This is the first vaginal dosage form to provide sustained delivery of milligram quantities of TFV for 90 days."	( Quantitative evaluation of a hydrophilic matrix intravaginal ring for the sustained delivery of tenofovir. Clark, JT; Clark, MR; Fabian, J; Friend, DR; Johnson, TJ; Kiser, PF; Nebeker, JS; Ponnapalli, S; Smith, EM; Tuitupou, AL, 2012)	0.38
"These data demonstrate that children and adolescents receiving standard TDF dosing of 300 mg once daily achieve higher intracellular TFV-DP concentrations than adults, despite lower plasma TFV concentrations."	( Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults. Acosta, EP; Baheti, G; Fletcher, CV; King, JR, 2013)	0.39
" Use of exact dosing data halved unexplained variability in ATV clearance."	( Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients. Barrail-Tran, A; Descamps, D; Duval, X; Goujard, C; Mentré, F; Nembot, G; Panhard, X; Savic, RM; Taburet, AM; Verstuyft, C; Vrijens, B, 2012)	0.38
" Model-predicated area under the concentration-time curve during the dosing interval (AUC(τ)) and exposure ratios of CVF AUC(τ):BP AUC(τ) were calculated for each drug."	( Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women. Cohen, MS; Dumond, JB; Forrest, A; Garonzik, SM; Kashuba, AD; Kendrick, RN; Nicol, MR; Patterson, KB, 2012)	0.38
" Through dose-response experiments, we established relative inhibitory potencies of NRTIs on in vitro telomerase activity as compared to the inhibitory potencies of the corresponding dideoxynucleotide triphosphates."	( In vitro and ex vivo inhibition of human telomerase by anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) but not by non-NRTIs. Côté, HC; Hukezalie, KR; Thumati, NR; Wong, JM, 2012)	0.38
" Drug concentrations at two trough values of 12 and 24 h after dosing (C(12) and C(24)), area under the concentration-curve values (AUC), maximum drug concentration (C(max)), and the time at which this concentration occurred (T(max)) in plasma were estimated with noncompartmental pharmacokinetic methods and compared to data from a subset of white subjects randomized to the RAL twice a day (plus TDF/FTC) arm of the QDMRK study, a phase III study of the safety and efficacy of once daily versus twice daily RAL in treatment naive patients."	( Raltegravir pharmacokinetics in treatment-naive patients is not influenced by race: results from the raltegravir early therapy in African-Americans living with HIV (REAL) study. Blevins, S; Dumond, JB; Eron, JJ; Floris-Moore, M; Hudgens, MG; Kashuba, AD; Massengale, K; Pittard, D; Ragan, D; Richardson, A; Walsh, K; Wang, R; Wohl, DA, 2013)	0.39
"Phase 0 studies can provide initial pharmacokinetics (PKs) data in humans and help to facilitate early drug development, but their predictive value for standard dosing is controversial."	( Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of zidovudine triphosphate in a microdosing study. Chen, J; Flexner, C; Fuchs, EJ; Hendrix, CW; Liberman, RG; Louissaint, NA; Skipper, PL; Tannenbaum, SR, 2012)	0.38
" Serum concentrations after vaginal dosing were 56-fold lower than after oral dosing (p<0."	( MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. Bumpus, NN; Chen, BA; Gandham, S; Gomez, K; Guddera, V; Hendrix, CW; Hoesley, C; Justman, J; Minnis, AM; Nakabiito, C; Patterson, K; Richardson, BA; Salata, R; Soto-Torres, L, 2013)	0.39
"Compared to oral dosing, vaginal dosing achieved much lower serum concentrations and much higher vaginal tissue concentrations."	( MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. Bumpus, NN; Chen, BA; Gandham, S; Gomez, K; Guddera, V; Hendrix, CW; Hoesley, C; Justman, J; Minnis, AM; Nakabiito, C; Patterson, K; Richardson, BA; Salata, R; Soto-Torres, L, 2013)	0.39
" Blood plasma (for TFV, FTC, EFV, ATV and RTV concentrations) and peripheral blood mononuclear cells [PBMCs; for tenofovir diphosphate (TFV-DP) and emtricitabine triphosphate (FTC-TP) concentrations] were collected at 11 time-points over a 24-hour dosing interval."	( Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study. Adams, JL; Corbett, AH; Dumond, JB; Forrest, A; Jennings, SH; Kashuba, AD; Kendrick, RL; Malone, S; Patterson, KB; Prince, HM; Sykes, C; Wang, R; White, N, 2013)	0.39
" The MEMS-defined adherence for correct dosing (-0."	( Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial. Barrail-Tran, A; Descamps, D; Duval, X; Goujard, C; Mentré, F; Nembot, G; Panhard, X; Parienti, JJ; Taburet, AM; Vigan, M; Vrijens, B, 2013)	0.39
"HIV seroconversion outcomes in preexposure prophylaxis (PrEP) trials of oral tenofovir (TFV)-containing regimens are highly sensitive to drug concentration, yet less-than-daily dosing regimens are under study."	( Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue. Anderson, JR; Bakshi, R; Cao, YJ; Everts, S; Fuchs, EJ; Hendrix, CW; Liberman, RG; Louissaint, NA; Nimmagadda, S; Skipper, PL; Tannenbaum, SR, 2013)	0.39
"Possible designs for a PrEP phase 3 efficacy trial are obtained by considering scenarios for potential experimental PrEP and control regimens, including consideration of placebo and active controls, longer acting PrEP and alternate dosing schedules."	( Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions. Chen, YQ; Donnell, D; Fleming, TR; Hughes, JP; Wang, L, 2013)	0.39
"73 log10 copies per milliliter, including a dose-response relationship for viral load decrease up to 25 mg."	( Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. Berger, D; Bredeek, UF; Callebaut, C; DeJesus, E; Fordyce, MW; Markowitz, M; Ramanathan, S; Rhee, MS; Ruane, PJ; Yale, K; Zhong, L, 2013)	0.39
" This may translate into greater antiviral efficacy, a higher barrier to resistance, and an improved safety profile relative to TDF, supporting further investigation of TAF dosed once daily in HIV-infected patients."	( Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. Berger, D; Bredeek, UF; Callebaut, C; DeJesus, E; Fordyce, MW; Markowitz, M; Ramanathan, S; Rhee, MS; Ruane, PJ; Yale, K; Zhong, L, 2013)	0.39
" No clinically relevant interactions between daclatasvir and tenofovir disoproxil fumarate were observed for either drug, and no dosing adjustments were indicated."	( Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Bertz, R; Bifano, M; Grasela, D; Hartstra, J; Hwang, C; Kandoussi, H; Oosterhuis, B; Sevinsky, H; Tiessen, R; Velinova-Donga, M, 2013)	0.39
"The HIV Prevention Trials Network 057 protocol was a phase 1, open-label study of the pharmacokinetics and safety of tenofovir disoproxil fumarate (TDF) in HIV-infected women during labor and their infants during the first week of life with 4 dosing cohorts: maternal 600 mg doses/no infant dosing; no maternal dosing/infant 4 mg/kg doses on days 0, 3, and 5; maternal 900 mg doses/infant 6 mg/kg doses on days 0, 3, and 5; maternal 600 mg doses/infant 6 mg/kg daily for 7 doses."	( Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life. Emel, L; Eshleman, SH; Fowler, MG; George, K; Herron, C; Hudelson, SE; Joao, E; Kearney, B; Kreitchmann, R; Kumwenda, N; Mirochnick, M; Mofenson, L; Nielsen-Saines, K; Parsons, T; Pinto, J; Richardson, P; Santos, B; Sato, P; Taha, T, 2014)	0.4
"A TDF dosing regimen of 600 mg during labor and daily infant doses of 6 mg/kg maintains infant tenofovir plasma concentration above 50 ng/mL throughout the first week of life and should be used in the studies of TDF efficacy for HIV prevention of mother-to-child transmission and early infant treatment."	( Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life. Emel, L; Eshleman, SH; Fowler, MG; George, K; Herron, C; Hudelson, SE; Joao, E; Kearney, B; Kreitchmann, R; Kumwenda, N; Mirochnick, M; Mofenson, L; Nielsen-Saines, K; Parsons, T; Pinto, J; Richardson, P; Santos, B; Sato, P; Taha, T, 2014)	0.4
" Knowledge of concentrations of Tenofovir and its active form Tenofovir diphosphate, at putative sites of anti-HIV functioning, is central to understanding trial outcomes and design of products and dosage regimens."	( Multicompartmental pharmacokinetic model of tenofovir delivery by a vaginal gel. Gao, Y; Katz, DF, 2013)	0.39
" Thus contrasts predicted by this model can inform design of gels and dosage regimens in clinical trials, and interpretation of PK data."	( Multicompartmental pharmacokinetic model of tenofovir delivery by a vaginal gel. Gao, Y; Katz, DF, 2013)	0.39
" As a fixed-dose combination tablet given once daily, EFV/FTC/TDF was the first available STR combining efficacy, tolerability and convenience, with the simplest dosing schedule and smallest numbers of pills of any ART combination therapy."	( Single-tablet regimens in HIV: does it really make a difference? Aldir, I; Horta, A; Serrado, M, 2014)	0.4
" Intermittently dosed vaginal gels containing the HIV-1 reverse transcriptase inhibitor tenofovir protected pigtailed macaques depending on the timing of viral challenge relative to gel application."	( Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges. Dinh, CT; Hendry, RM; Herold, BC; Kiser, PF; Martin, A; McNicholl, JM; Mesquita, PM; Nagaraja, U; Rastogi, R; Smith, JM; Srinivasan, P; Teller, RS, 2013)	0.39
" Once-daily dosing without requirement for a pharmacokinetic booster makes dolutegravir-based therapy an attractive treatment option for HIV-1-infected treatment-naive patients."	( Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Albrecht, H; Almond, S; Baril, JG; Belonosova, E; Brennan, C; Domingo, P; Gatell, JM; Jaeger, H; Min, S; Quiros-Roldan, E; Raffi, F, 2013)	0.39
" Median MEMS adherence rates were 98% (IQR: 93-100) for daily PrEP regimen, 91% (IQR: 73-97) for fixed intermittent dosing and 45% (IQR: 20-63) for post-coital dosing."	( Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial. Bahemuka, U; Bangsberg, DR; Barin, B; Bwanika, AN; Chetty, P; Fast, P; Haberer, JE; Kamali, A; Katende, D; Kibengo, FM; Mark, D; Priddy, FH; Rooney, JF; Ruzagira, E, 2013)	0.39
"Both daily and intermittent oral PrEP dosing regimens were safe."	( Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial. Bahemuka, U; Bangsberg, DR; Barin, B; Bwanika, AN; Chetty, P; Fast, P; Haberer, JE; Kamali, A; Katende, D; Kibengo, FM; Mark, D; Priddy, FH; Rooney, JF; Ruzagira, E, 2013)	0.39
" The 90% confidence interval (CI) of the geometric mean ratio for rilpivirine, emtricitabine, tenofovir exposure was estimated for fed versus fasted dosing and light versus standard meal, with equivalence boundaries of 80 - 125%."	( Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection. Cheng, A; Custodio, JM; Hepner, M; Kearney, BP; Ling, KH; Ramanathan, S; Yin, X, 2014)	0.4
"At weeks 12 and 24, all 49 dosed subjects remained suppressed on RPV/FTC/TDF."	( Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens. Brinson, C; Cheng, AK; Chuck, SK; Cohen, C; Dejesus, E; Mills, AM; Ramanathan, S; Wang, MH; White, K; Williams, S; Yale, KL, )	0.13
"The objectives of this analysis were to develop a population pharmacokinetic model (PPK) for tenofovir without using potentially unreliable patient reported dosing records and to retrace patient dosing history using pharmacokinetic simulations conditioned on protocol design constraints to assess patient adherence."	( Estimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies. Chaturvedula, A; Fossler, MJ; Hendrix, CW, 2014)	0.4
"NAs are cleared by kidneys and their dosage should be adjusted in patients with creatinine clearance <50 mL/min."	( Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease. Cholongitas, E; Papatheodoridis, G; Pipili, C, 2014)	0.4
" Geometric-mean-ratios compared levels between each pair of dosing conditions."	( Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP). Anderson, PL; Bacchetti, P; Buchbinder, SP; Gandhi, M; Goggin, K; Grant, R; Greenblatt, RM; Huang, Y; Jin, C; Liu, AY; Stojanovski, K; Yang, Q, 2014)	0.4
"This study found a strong linear relationship between frequency of dosing and tenofovir levels in scalp hair."	( Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP). Anderson, PL; Bacchetti, P; Buchbinder, SP; Gandhi, M; Goggin, K; Grant, R; Greenblatt, RM; Huang, Y; Jin, C; Liu, AY; Stojanovski, K; Yang, Q, 2014)	0.4
"Despite improvements in access to antiretroviral therapy and the use of simplified dosing regimens, HIV infection is still an important global public health problem."	( An overview of antiretroviral pre-exposure prophylaxis of HIV infection. McGowan, I, 2014)	0.4
" Adherence support for the before-and-after dosing strategy (BAT 24) was provided at enrolment and at each monthly study visit."	( Adherence in the CAPRISA 004 tenofovir gel microbicide trial. Abdool Karim, Q; Abdool Karim, SS; Baxter, C; Grobler, A; MacQueen, KM; Madlala, BT; Mansoor, LE; Yende-Zuma, N, 2014)	0.4
" A dosage form containing DPV must be able to deliver the drug to the tissue site of action."	( Increased Dapivirine tissue accumulation through vaginal film codelivery of dapivirine and Tenofovir. Akil, A; Cost, M; Devlin, B; Rohan, LC, 2014)	0.4
"Pill burden, dosing frequency, and concerns about safety and tolerability are important obstacles to maintaining adequate medication adherence."	( Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data. Brinson, C; Cao, H; Cheng, A; Crofoot, G; Ebrahimi, R; Garner, W; Kulkarni, R; Mills, A; Ortiz, R; Rashbaum, B; Szwarcberg, J; Towner, W; Ward, D, )	0.13
"Plasma concentrations of tenofovir consistent with daily dosing were highly predictive of protection from HIV acquisition."	( HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. Baeten, JM; Bangsberg, DR; Brantley, J; Bumpus, NN; Celum, C; Donnell, D; Haberer, JE; Hendrix, C; Mugo, N; Mujugira, A; Ndase, P, 2014)	0.4
"Patients with HIV on antiretroviral therapy might benefit from regimen simplification to reduce pill burden and dosing frequency."	( Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results o Arribas, JR; Di Perri, G; Ebrahimi, R; Gathe, J; Nguyen, T; Pialoux, G; Piontkowsky, D; Reynes, J; Tebas, P; White, K, 2014)	0.4
" The granule form carries a risk of dosing errors and has a particularly strong, unpleasant taste."	( Tenofovir in HIV-infected children. Antiretroviral efficacy, but beware of adverse effects on bone and the kidneys. , 2014)	0.4
"Atazanavir/ritonavir 200/100 mg dosing provided adequate ATV AUC 0-24 when used with TDF in HIV-infected Thai children weighing between 25 and 50 kg."	( Pharmacokinetics of atazanavir/ritonavir among HIV-infected Thai children concomitantly taking tenofovir disoproxil fumarate. Ananworanich, J; Bunupuradah, T; Keadpudsa, S; Prasitsuebsai, W; Puthanakit, T; Sahakijpicharn, T; Srimuan, A; Techasaensiri, C; Thammajaruk, N, 2014)	0.4
"Polymeric films can be used as a stable dosage form for the delivery of antiretroviral combinations as microbicides."	( Formulation and characterization of polymeric films containing combinations of antiretrovirals (ARVs) for HIV prevention. Agashe, H; Akil, A; Devlin, B; Dezzutti, CS; Hillier, SL; Moncla, BJ; Rohan, LC; Shi, Y; Uranker, K, 2015)	0.42
"Electrospun fibers containing antiretroviral drugs have recently been investigated as a new dosage form for topical microbicides against HIV-1."	( Manufacturing scale-up of electrospun poly(vinyl alcohol) fibers containing tenofovir for vaginal drug delivery. Krogstad, EA; Woodrow, KA, 2014)	0.4
"The difference in binding affinity of tenofovir (more than two orders of magnitude in terms of local concentration), a 30x higher dosage of the (R)-tenofovir enantiomer as compared to conformational isomeric or rotameric adefovir, and the constrained mutational space due to gene overlap in HBV may explain the absence of resistance mutations after 6 years of tenofovir monotherapy."	( Differential binding of tenofovir and adefovir to reverse transcriptase of hepatitis B virus. Berkhout, B; van Hemert, FJ; Zaaijer, HL, 2014)	0.4
" A dosing regimen according to body-weight-band has been established for pediatric use."	( Review of tenofovir use in HIV-infected children. Aurpibul, L; Puthanakit, T, 2015)	0.42
" Blood, colonic biopsies and rectal and vaginal mucosal fluids were collected after the single oral TDF, the single topical TFV gel dose, and after 7 days of topical TFV gel dosing for extracellular analysis of TFV and intracellular analysis of the active metabolite tenofovir diphosphate (TFVdp) in peripheral blood mononuclear cells (PBMCs) and isolated mucosal mononuclear cells (MMC), including CD4+ and CD4- cell subsets."	( A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate. Anton, PA; Bumpus, N; Cranston, R; Elliott, J; Hendrix, C; Kashuba, AD; Mauck, C; McGowan, I; Richardson-Harman, N; Tanner, K; Yang, KH, 2014)	0.4
"This study was designed to assess the dose-response relationship between tissue, blood, vaginal and rectal compartment concentrations of tenofovir (TFV) and tenofovir diphosphate (TFVdp) and ex vivo rectal HIV suppression following oral tenofovir disoproxil fumarate (TDF) and rectal administration of TFV 1% vaginally-formulated gel."	( Correlation between compartmental tenofovir concentrations and an ex vivo rectal biopsy model of tissue infectibility in the RMP-02/MTN-006 phase 1 study. Anton, PA; Bumpus, NN; Cranston, RD; Elliott, J; Hendrix, CW; Kashuba, A; Mauck, C; McGowan, I; Richardson-Harman, N; Tanner, K; Yang, K, 2014)	0.4
"There was a significant fit for the TFVdp dose-response model for rectal tissue (p = 0."	( Correlation between compartmental tenofovir concentrations and an ex vivo rectal biopsy model of tissue infectibility in the RMP-02/MTN-006 phase 1 study. Anton, PA; Bumpus, NN; Cranston, RD; Elliott, J; Hendrix, CW; Kashuba, A; Mauck, C; McGowan, I; Richardson-Harman, N; Tanner, K; Yang, K, 2014)	0.4
" As these anti-HIV lipid nanoparticles also prolonged plasma drug exposure, they hold promise as a long-acting dosage form for HIV patients in addressing residual virus in cells and tissue."	( Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates. Freeling, JP; Ho, RJ; Koehn, J; Shu, C; Sun, J, 2015)	0.42
" Although effective intracellular drug concentrations persist for several days after stopping PrEP, a reasonable recommendation is to continue PrEP dosing for 4 weeks after the last potential HIV exposure, similar to recommendations for postexposure prophylaxis."	( Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men. Anderson, PL; Bushman, LR; Castillo-Mancilla, JR; Gardner, EM; Glidden, DV; Guida, LA; Kerr, BJ; Klein, B; Meditz, AL; Predhomme, JA; Rower, C; Seifert, SM; Zheng, JH, 2015)	0.42
" These results provide a framework for future early investigations of antiretroviral efficacy in HIV prevention to optimize dosing strategies in clinical investigations."	( Models for predicting effective HIV chemoprevention in women. Cohen, MS; Emerson, CW; Fedoriw, Y; Geller, EJ; Kashuba, AD; Nelson, JA; Nicol, MR; Patterson, KB; Prince, HM; Sykes, C, 2015)	0.42
" Enrolled patients underwent 24 h blood sampling with TDF/FTC/RPV dosing in the fasted state (day 42), with a low-fat meal (11 g of fat/353 kcal, day 49) and with a moderate-fat meal (19 g of fat/589 kcal, day 56; reference)."	( Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults. Back, DJ; Byakika-Kibwika, P; Else, L; Katwere, M; Khoo, SH; Lamorde, M; Merry, C; Mukisa, L; Sempa, JB; Walimbwa, S, 2015)	0.42
" Less-than-daily oral dosing regimens and long-acting injectable medications could reduce pill burdens and facilitate adherence, and local delivery of PrEP medications to genital compartments via gels, rings and films may limit systemic drug exposure and potential toxicities."	( Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges. Krakower, DS; Mayer, KH, 2015)	0.42
" These factors should be considered when adjusting tenofovir dosage regimens to ensure the efficacy and safety of a drug."	( Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients. Avihingsanon, A; Burger, DM; Mitruk, S; Pengsuparp, T; Punyawudho, B; Rungtivasuwan, K; Ruxrungtham, K; Thammajaruk, N, 2015)	0.42
" For each drug, its loaded concentration, gel properties and applied volume, and frequency of dosing can be designed to optimize PK and, thence, PD."	( Vaginal deployment and tenofovir delivery by microbicide gels. Chuchuen, O; Gao, Y; Ham, A; Katz, DF; Yang, KH; Yuan, A, 2015)	0.42
" Adherence to the dosing regimen has emerged as a critical factor determining efficacy outcomes of clinical trials."	( Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis. Baum, MM; Beliveau, M; Fanter, R; Gunawardana, M; Hendrix, CW; Marzinke, MA; Miller, CS; Moss, JA; Remedios-Chan, M; Smith, TJ; Yang, F, 2015)	0.42
" Net BMD loss by week 24 in participants with TFV-DP levels indicative of consistent dosing averaged -1."	( Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. Anderson, PL; Bekker, LG; Buchbinder, S; Chariyalertsak, S; Chodacki, P; de Mendonca, LM; Glidden, DV; Gonzales, P; Grant, RM; Guanira, JV; Lama, JR; Liu, A; McMahan, V; Mulligan, K; Namwongprom, S; Ramirez-Cardich, ME; Schechter, M; Veloso, VG; Wang, F, 2015)	0.42
"Tenofovir disoproxil fumarate (TDF) is increasingly used in the highly active antiretroviral therapy (HAART) regimens of pregnant women, but limited data exist on the pregnancy pharmacokinetics of chronically dosed TDF."	( Pharmacokinetics of tenofovir during pregnancy and postpartum. Best, BM; Burchett, S; Byroads, M; Capparelli, EV; Fletcher, CV; Hawkins, E; Hu, C; Li, H; Mirochnick, M; Smith, E; Stek, A; Wang, J; Watts, DH, 2015)	0.42
" These findings support other clinical research failing to show dose-response relationships for growth and bone outcomes among intrauterine TFV-exposed infants."	( Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected Children. Hazra, R; Himes, SK; Huestis, MA; Jacobson, DL; Kacanek, D; Rich, KC; Siberry, GK; Tassiopoulos, K; Van Dyke, RB; Wu, JW, 2015)	0.42
" These models can be applied to evaluate alternative dosing regimens to optimize drug therapy during pregnancy."	( Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women. Benaboud, S; Blanche, S; Bouazza, N; De Sousa Mendes, M; Foissac, F; Hirt, D; Treluyer, JM; Urien, S; Valade, E, 2015)	0.42
"The CAPRISA 004 trial showed that coitally dosed tenofovir 1% gel reduced HIV acquisition by 39% overall and 54% when used consistently."	( Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness. Abdool Karim, SS; Gengiah, TN; Karim, QA; Kashuba, AD; Werner, L; White, NR; Yang, KH, 2015)	0.42
" This study confirmed that patients with kidney impairment and the concurrent use of atazanavir/ritonavir will require the dosage of tenofovir to be adjusted to ensure efficacy and prevent unwanted toxicities."	( Population pharmacokinetics of tenofovir in HIV/HBV co-infected patients. Avihingsanon, A; Burger, D; Lewin, SR; Matthews, G; Punyawudho, B; Ruxrungtham, K; Thammajaruk, N; Thongpeang, P, 2015)	0.42
" HPTN 066 was conducted to establish objective, quantitative benchmarks for discrete, regular levels of adherence using directly observed dosing of tenofovir (TFV) disoproxil fumarate (TDF)/emtricitabine (FTC)."	( Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066). Anderson, PL; Andrade, A; Bakshi, RP; Bumpus, NN; Bushman, LR; Donnell, D; Elharrar, V; Fuchs, EJ; Hendrix, CW; Kashuba, AD; Li, X; Marzinke, MA; Mayer, KH; McKinstry, L; Moore, A; Patterson, KB; Prince, HA; Radebaugh, C; Richardson, P; Shieh, E; Wang, R; Wiggins, I, 2016)	0.43
" Thus, we conducted a single-dose pharmacokinetic study of TFV gel applied 1 or 24 hours before or 1 hour before and 1 hour after (BAT) sex and compared results with dosing without sex."	( Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel. Chen, BA; Dezzutti, CS; Galaska, B; Hendrix, CW; Herold, BC; Hillier, S; Kelly, CW; Levy, L; Marzinke, MA; McGowan, I; Piper, JM; Salata, RA, 2016)	0.43
"Compared with dosing without sex, median TFV concentrations after sex decreased 72% and 78% (P < ."	( Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel. Chen, BA; Dezzutti, CS; Galaska, B; Hendrix, CW; Herold, BC; Hillier, S; Kelly, CW; Levy, L; Marzinke, MA; McGowan, I; Piper, JM; Salata, RA, 2016)	0.43
" BAT dosing or sustained delivery may be optimal for preexposure prophylaxis."	( Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel. Chen, BA; Dezzutti, CS; Galaska, B; Hendrix, CW; Herold, BC; Hillier, S; Kelly, CW; Levy, L; Marzinke, MA; McGowan, I; Piper, JM; Salata, RA, 2016)	0.43
" On the basis of participants' explanations, we developed a typology of adherence patterns: noninitiation, discontinuation, misimplementation (resulting from visit-driven use, variable taking, modified dosing or regimen) and adherence."	( Disclosure of pharmacokinetic drug results to understand nonadherence. Bennie, T; Cheng, H; Etima, J; Grossman, CI; Hartmann, M; Laborde, N; Levy, L; Marrazzo, J; Mensch, B; Montgomery, ET; Musara, P; Naidoo, S; Piper, J; van der Straten, A, 2015)	0.42
"Animal models have informed our understanding of early viral transmission events, which help guide event-driven PrEP dosing strategies."	( Nondaily preexposure prophylaxis for HIV prevention. Anderson, PL; García-Lerma, JG; Heneine, W, 2016)	0.43
"Event-driven dosing for TFV-based PrEP has promise for HIV prevention in MSM."	( Nondaily preexposure prophylaxis for HIV prevention. Anderson, PL; García-Lerma, JG; Heneine, W, 2016)	0.43
" In May 2014 the Centers for Disease Control and Prevention published updated practice guidelines recommending the use of preexposure prophylaxis (PrEP) with daily oral dosing of tenofovir/emtricitabine to help prevent HIV infection in high-risk individuals (strength of recommendation, A)."	( Preexposure Prophylaxis (PrEP) for HIV Prevention: The Primary Care Perspective. Conniff, J; Evensen, A, )	0.13
"77), 87 versus 86 % as recent dosing (>10 ng/ml; p = 0."	( Does Adherence Change When No One is Looking? Comparing Announced and Unannounced Tenofovir Levels in a PrEP Trial. Baeten, JM; Bangsberg, DR; Haberer, JE; Musinguzi, N; Muwonge, T; Thomas, K, 2016)	0.43
" Prevalence of steady-state daily dosing (SSDD; ≥40 ng/ml) was 74% in a random subset of tenofovir samples obtained from 365 participants."	( Comparison of subjective and objective adherence measures for preexposure prophylaxis against HIV infection among serodiscordant couples in East Africa. Baeten, JM; Bangsberg, DR; Boum, Y; Celum, C; Haberer, JE; Hendrix, CW; Marzinke, MA; Muganzi, CD; Musinguzi, N; Ronald, A, 2016)	0.43
"A new simple, rapid stability indicating assay method has been developed and validated for the determination of emtricitabine, tenofovir disoproxil fumarate, elvitegravir and cobicistat using reverse-phase high-performance liquid chromatography in their pharmaceutical dosage form."	( A Validated Stability Indicating RP-HPLC Method for the Determination of Emtricitabine, Tenofovir Disoproxil Fumarate, Elvitegravir and Cobicistat in Pharmaceutical Dosage Form. Avanapu, SR; Kumar, PR; Runja, C, )	0.13
" Monte-Carlo simulations were then performed to identify minimally effective dosing strategies to protect lower female genital tract and colorectal tissues."	( A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine. Cottrell, ML; Dellon, ES; Hudgens, MG; Kashuba, AD; Madanick, RD; Malone, S; Nelson, JA; Patterson, KB; Prince, HM; Shaheen, NJ; Sykes, C; White, N; Wulff, J; Yang, KH, 2016)	0.43
" These data provide a novel approach for future PrEP investigations that can optimize clinical trial dosing strategies."	( A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine. Cottrell, ML; Dellon, ES; Hudgens, MG; Kashuba, AD; Madanick, RD; Malone, S; Nelson, JA; Patterson, KB; Prince, HM; Shaheen, NJ; Sykes, C; White, N; Wulff, J; Yang, KH, 2016)	0.43
" A significant research thrust in the field has been to characterize different dosage forms for formulation of physicochemically diverse antiretroviral drugs."	( Biophysical characterization of small molecule antiviral-loaded nanolipogels for HIV-1 chemoprophylaxis and topical mucosal application. Golan-Paz, S; Jiang, Y; Ramanathan, R; Read, B; Woodrow, KA, 2016)	0.43
"Use of TDF/FTC did not appear to affect serum MPA levels, however we found lower than expected MPA concentrations at the end of the dosing interval among DMPA users in the FEM-PrEP trial, the cause of which are unknown."	( Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial. Agot, K; Callahan, R; Dorflinger, L; Jenkins, D; Nanda, K; Taylor, D; Van Damme, L; Wang, M, 2016)	0.43
" We evaluated concordance between reports of recent PrEP dosing collected via neutral interviewing and drug quantitation in the iPrEx open-label extension, where participants (n = 1172) had the choice to receive or not receive PrEP."	( Self-reported Recent PrEP Dosing and Drug Detection in an Open Label PrEP Study. Amico, KR; Anderson, P; Avelino-Silva, VI; Grant, R; Guanira, J; McMahan, V; Mehrotra, M; Veloso, VG, 2016)	0.43
"Uncertainties in parameter values in microbicide pharmacokinetics (PK) models confound the models' use in understanding the determinants of drug delivery and in designing and interpreting dosing and sampling in PK studies."	( Sensitivity Analysis of a Pharmacokinetic Model of Vaginal Anti-HIV Microbicide Drug Delivery. Cogan, NG; Gao, Y; Hussaini, MY; Jarrett, AM; Katz, DF, 2016)	0.43
" Clinical dosing with TAF vs."	( High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate. Callebaut, C; Liu, Y; Margot, NA; Miller, MD, 2016)	0.43
"Antiretroviral preexposure prophylaxis (PrEP) with once-daily dosing of tenofovir and tenofovir-emtricitabine was shown to be effective for preventing HIV-1 infection in individuals who had HIV-1-seropositive partners (the Partners PrEP Study)."	( Population Pharmacokinetics of Tenofovir in HIV-1-Uninfected Members of Serodiscordant Couples and Effect of Dose Reporting Methods. Baeten, JM; Bangsberg, D; Celum, CL; Chaturvedula, A; Fossler, MJ; Goti, V; Haberer, JE; Hendrix, CW; Lu, Y; Sale, ME, 2016)	0.43
" Depo-Provera-synchronized mice were dosed vaginally or intraperitoneally with (3)H-TFV, with or without MK571 co-administration, to delineate the function of cervicovaginal Mrp4."	( Expression, regulation, and function of drug transporters in cervicovaginal tissues of a mouse model used for microbicide testing. Hu, M; Pearlman, A; Rohan, LC; Zhou, T, 2016)	0.43
" We determined if emtricitabine triphosphate (FTC-TP) in dried blood spots (DBS) can be used as a marker of recent dosing with tenofovir disoproxil fumarate-emtricitabine (TDF-FTC)."	( Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing. Anderson, PL; Bushman, LR; Campbell, K; Castillo-Mancilla, J; Coleman, S; Gardner, EM; Glidden, DV; Grant, R; Hosek, S; Liu, A; MaWhinney, S; McAllister, K; Seifert, S; Wilson, CM; Zheng, JH, 2016)	0.43
"The first-generation integrase inhibitors (INIs) raltegravir (RAL) and elvitegravir (EVG) have shown efficacy against HIV infection, but they have the limitations of once-more daily dosing and extensive cross-resistance."	( Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials. Chen, H; Guo, W; Huang, J; Jiang, J; Liang, B; Liang, H; Liao, Y; Su, J; Xu, X; Ye, L; Zang, N, 2016)	0.43
" Peak blood and breast milk samples were obtained 1-2 h after the maternal DOT PrEP dose, while maternal trough samples were obtained at the end of the PrEP dosing interval (i."	( Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption. Baeten, JM; Celum, CL; Hendrix, CW; John-Stewart, G; Katabira, ET; Marzinke, M; Mugo, NR; Mugwanya, KK; Muthuri, G; Muwonge, TR; Ngure, K; Semiyaga, NB; Stergachis, A, 2016)	0.43
"Hand/wrist and spine radiographs were obtained at 3 days and 12 weeks of age in infants born to HIV-infected pregnant women enrolled in the HIV Prevention Trials Network 057 pharmacokinetic study of TDF conducted in Malawi and Brazil assigned to 3 TDF dosing cohorts."	( Bone Age and Mineral Density Assessments Using Plain Roentgenograms in Tenofovir-exposed Infants in Malawi and Brazil Enrolled in HIV Prevention Trials Network 057. Boechat, MI; Emel, L; George, K; Joao, E; Kreitchmann, R; Kumwenda, N; Mirochnick, M; Mofenson, L; Nielsen-Saines, K; Osorio, LE; Pinto, J; Santos, B; Sato, P; Swenson, M, 2017)	0.46
" Model simulations of analog:dNTP molar ratios using IPERGAY dosing suggested that FTC significantly contributes to the protective effect of preexposure prophylaxis (PrEP)."	( Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates. Anderson, PL; Bushman, LR; Castillo-Mancilla, JR; Chen, X; Kiser, JJ; MaWhinney, S; Seifert, SM; Zheng, JH, 2016)	0.43
" This study included once-daily dosing regimens of placebo, oral tenofovir disoproxil fumarate (TDF), and TDF in combination with emtricitabine (FTC), administered to HIV-uninfected members of serodiscordant couples."	( Markov Mixed Effects Modeling Using Electronic Adherence Monitoring Records Identifies Influential Covariates to HIV Preexposure Prophylaxis. Baeten, JM; Bangsberg, D; Celum, C; Chaturvedula, A; Fossler, MJ; Haberer, JE; Hendrix, CW; Madrasi, K; Sale, M, 2017)	0.46
"Vaginal TFV gel dosing previously shown to provide 100 or 74% protection when applied either 30 min or 3 days before simian HIV(SHIV) challenge was assessed in pigtailed macaques coinfected with Chlamydia trachomatis/Trichomonas vaginalis and challenged twice weekly with SHIV162p3 for up to 10 weeks (two menstrual cycles)."	( Topical tenofovir protects against vaginal simian HIV infection in macaques coinfected with Chlamydia trachomatis and Trichomonas vaginalis. Aubert, R; Dinh, C; Dobard, C; Garcia-Lerma, GJ; Hanson, D; Heneine, W; Henning, T; Kersh, E; Lipscomb, J; Makarova, N; McNicholl, J; Mitchell, J; Papp, J; Phillips, C; Taylor, A, 2017)	0.46
"Rectal enemas that contain prophylactic levels of anti-HIV microbicides such as tenofovir have emerged as a promising dosage form to prevent sexually transmitted HIV infections."	( Multicompartmental Pharmacokinetic Model of Tenofovir Delivery to the Rectal Mucosa by an Enema. Gao, Y; Katz, DF, 2017)	0.46
" Monitoring of renal function showed no case of the Fanconi syndrome, no significant alterations of median serum creatinine, eGFR and phosphate levels, although a reduction of TDF dosage was required in five patients (8."	( Long-term efficacy and safety of switching from lamivudine+adefovir to tenofovir disoproxil fumarate in virologically suppressed patients. Angarano, G; Fasano, M; Fiore, JR; Leone, A; Maggi, P; Santantonio, TA; Volpe, A, 2017)	0.46
" When dosed once-daily, TAF results in approximately 90% lower levels of plasma TFV and a 4-fold increase in intracellular TFV-diphosphate (TFV-DP) in PBMCs compared with the TFV prodrug tenofovir disoproxil fumarate (TDF)."	( Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations. Babusis, D; Callebaut, C; Kitrinos, K; Liu, Y; Miller, M; Ray, A, 2017)	0.46
"After tenofovir alafenamide dosing in vivo , tenofovir-dp was unquantifiable in most tissues (91%) although cervical and vaginal epithelial cells efficiently formed tenofovir-dp from tenofovir alafenamide in vitro ."	( Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues. Cottrell, ML; Emerson, CW; Garrett, KL; Gay, C; Kashuba, ADM; McCallister, S; Peery, A; Prince, HMA; Rooney, JF; Schauer, A; Sykes, C, 2017)	0.46
" However, adequacy of drug exposures after these administration routes are largely unknown, making dosing recommendations and the attainment of viral suppression challenging in this patient population."	( Decreased Absorption of Dolutegravir and Tenofovir Disoproxil Fumarate, But Not Emtricitabine, in an HIV-Infected Patient Following Oral and Jejunostomy-Tube Administration. Anderson, M; Bailey, B; Balba, G; Brooks, KM; Garrett, KL; George, JM; Kuriakose, SS; Lane, HC; Maldarelli, F; Pau, AK, 2017)	0.46
" Indeed, achieving the desired therapeutic outcome in the absence of an effective means of targeted delivery must rely on dosage escalation, which frequently causes severe toxicity."	( Overcoming the Hydrolytic Lability of a Reaction Intermediate in Production of Protein/Drug Conjugates: Conjugation of an Acyclic Nucleoside Phosphonate to a Model Carrier Protein. Kaltashov, IA; Xu, S, 2017)	0.46
"8% discontinued/adjusted dosing of TDF because of nephrotoxicity."	( Prevalence of Persistent Renal Dysfunction in Perinatally HIV-infected Thai Adolescents. Anugulruengkitt, S; Bunupuradah, T; Chanakul, A; Jantarabenjakul, W; Phupitakphol, T; Prasitsuebsai, W; Puthanakit, T; Ruxrungtham, K; Sopa, B; Sophonphan, J, 2018)	0.48
" The changes in dosing that are needed in the presence of renal impairment, which is a common occurrence with HIV chronic disease progression, will also be discussed."	( Factors Contributing to the Antiviral Effectiveness of Tenofovir. Murphy, RA; Valentovic, MA, 2017)	0.46
" Topical (vaginal and rectal) dosing is a promising regimen for HIV PrEP as it leads to low systematic drug exposure."	( Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice. Baum, MM; Chatterji, U; Gallay, PA; Gandarilla, A; Gunawardana, M; Kirchhoff, A; Marzinke, MA; Moss, JA; Pyles, RB, 2017)	0.46
" They are critical inputs to deterministic transport models that predict the gels' pharmacokinetic performance, which can guide improved design of products and optimization of their dosing regimens."	( Label-free analysis of tenofovir delivery to vaginal tissue using co-registered confocal Raman spectroscopy and optical coherence tomography. Chuchuen, O; Desoto, M; Henderson, MH; Katz, DF; Maher, JR; Rohan, LC; Wax, A, 2017)	0.46
"This is the first demonstration that intracellular atazanavir exposure remains unchanged during pregnancy supporting the standard 300/100 mg atazanavir/ritonavir dosing throughout pregnancy."	( Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients. Bonito, A; Bonora, S; Calcagno, A; Casari, S; Castelli, F; D'Avolio, A; Di Perri, G; Domenighini, E; Focà, E; Quiros Roldan, E; Simiele, M; Trentini, L, 2017)	0.46
"The relative feasibility and acceptability of daily versus non-daily dosing of oral HIV pre-exposure prophylaxis (PrEP) among women are unknown."	( Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial. Amico, KR; Anderson, PL; Bekker, LG; Dye, BJ; Elharrar, V; Eshleman, SH; Grant, RM; Hendrix, CW; Hughes, JP; Li, M; Marzinke, MA; McKinstry, L; Piwowar-Manning, E; Rooney, JF; Roux, S; Sebastien, E; Stirratt, M; Yola, N, 2018)	0.48
" Participants were adult women (age ≥18 years) who received directly observed dosing once a week for 5 weeks followed by random assignment (1:1:1) at week 6 to one of three unblinded PrEP regimens for self-administered dosing over 24 weeks: daily; time-driven (twice a week plus a post-sex dose); or event-driven (one tablet both before and after sex)."	( Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial. Amico, KR; Anderson, PL; Bekker, LG; Dye, BJ; Elharrar, V; Eshleman, SH; Grant, RM; Hendrix, CW; Hughes, JP; Li, M; Marzinke, MA; McKinstry, L; Piwowar-Manning, E; Rooney, JF; Roux, S; Sebastien, E; Stirratt, M; Yola, N, 2018)	0.48
" 178 (93%) completed directly observed dosing and were randomly assigned one of the three PrEP regimens for the self-administered phase: 59 were allocated the daily regimen, 59 the time-driven regimen, and 60 the event-driven regimen."	( Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial. Amico, KR; Anderson, PL; Bekker, LG; Dye, BJ; Elharrar, V; Eshleman, SH; Grant, RM; Hendrix, CW; Hughes, JP; Li, M; Marzinke, MA; McKinstry, L; Piwowar-Manning, E; Rooney, JF; Roux, S; Sebastien, E; Stirratt, M; Yola, N, 2018)	0.48
"Daily PrEP dosing resulted in higher coverage of sex events, increased adherence to the regimen, and augmented drug concentrations than did either time-driven or event-driven dosing."	( Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial. Amico, KR; Anderson, PL; Bekker, LG; Dye, BJ; Elharrar, V; Eshleman, SH; Grant, RM; Hendrix, CW; Hughes, JP; Li, M; Marzinke, MA; McKinstry, L; Piwowar-Manning, E; Rooney, JF; Roux, S; Sebastien, E; Stirratt, M; Yola, N, 2018)	0.48
" These factors should be taken into consideration to guide the individual tenofovir disoproxil fumarate dosage regimen in Thai HIV-infected patients."	( Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients. Avihingsanon, A; Burger, DM; Mitruk, S; Punyawudho, B; Rungtivasuwan, K; Ruxrungtham, K; Sukasem, C; Thammajaruk, N, 2017)	0.46
" Areas covered: The favourable pharmacological profile of TAF allows a marked reduction in dosage (25 mg/day) thus reducing systemic exposure to tenofovir and improving the bone and renal safety, keeping however the same virological efficacy, compared to TDF 300 mg/day."	( Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions? Grossi, G; Lampertico, P; Loglio, A; Viganò, M, 2018)	0.48
"Nondaily dosing of oral preexposure prophylaxis (PrEP) may provide equivalent coverage of sex events compared with daily dosing."	( Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study. Amico, KR; Anderson, PL; Chitwarakorn, A; Curlin, ME; Dye, BJ; Elharrar, V; Eshleman, SH; Grant, RM; Hendrix, CW; Hirsch-Moverman, Y; Holtz, TH; Hughes, JP; Li, M; Loquere, A; Mannheimer, S; Marzinke, MA; McKinstry, L; McNicholl, JM; Piwowar-Manning, E; Rooney, JF; Stirratt, M; van Griensven, F, 2018)	0.48
"At-risk men and transgender women who have sex with men were randomly assigned to 1 of 3 dosing regimens: 1 tablet daily, 1 tablet twice weekly with a postsex dose (time-driven), or 1 tablet before and after sex (event-driven), and were followed for coverage of sex events with pre- and postsex dosing measured by weekly self-report, drug concentrations, and electronic drug monitoring."	( Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study. Amico, KR; Anderson, PL; Chitwarakorn, A; Curlin, ME; Dye, BJ; Elharrar, V; Eshleman, SH; Grant, RM; Hendrix, CW; Hirsch-Moverman, Y; Holtz, TH; Hughes, JP; Li, M; Loquere, A; Mannheimer, S; Marzinke, MA; McKinstry, L; McNicholl, JM; Piwowar-Manning, E; Rooney, JF; Stirratt, M; van Griensven, F, 2018)	0.48
"Daily dosing recommendations increased coverage and protective drug concentrations in the Harlem cohort, while daily and nondaily regimens led to comparably favorable outcomes in Bangkok, where participants had higher levels of education and employment."	( Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study. Amico, KR; Anderson, PL; Chitwarakorn, A; Curlin, ME; Dye, BJ; Elharrar, V; Eshleman, SH; Grant, RM; Hendrix, CW; Hirsch-Moverman, Y; Holtz, TH; Hughes, JP; Li, M; Loquere, A; Mannheimer, S; Marzinke, MA; McKinstry, L; McNicholl, JM; Piwowar-Manning, E; Rooney, JF; Stirratt, M; van Griensven, F, 2018)	0.48
"We estimated the required number of tablets/person/week for dosing regimens used in the HPTN 067/ADAPT (daily/time-driven/event-driven) and IPERGAY (on-demand) trials for different patterns of sexual intercourse."	( In what circumstances could nondaily preexposure prophylaxis for HIV substantially reduce program costs? Amico, KR; Bekker, LG; Boily, MC; Bokoch, K; Chitwarakorn, A; Dimitrov, D; Donnell, D; Grant, RM; Holtz, TH; Hughes, JP; Mannheimer, S; Mitchell, KM; Xia, F, 2018)	0.48
" Electrospun fibers (EFs), in particular, have recently been applied to FRT delivery, resulting in an alternative dosage form with the potential to provide protection and therapeutic effect against a variety of infection types."	( Computational Modeling of Antiviral Drug Diffusion from Poly(lactic- co-glycolic-acid) Fibers and Multicompartment Pharmacokinetics for Application to the Female Reproductive Tract. Frieboes, HB; Halwes, ME; Steinbach-Rankins, JM; Tyo, KM, 2018)	0.48
" Geometric least squares means ratios (coadministration:alone) and 90% confidence intervals were constructed for area under the plasma concentration-time curve over the dosing interval, maximum concentration, and trough, for all analytes."	( Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers. Brainard, DM; Ling, KHJ; Mathias, A; Mogalian, E; Osinusi, A; Shen, G; Stamm, LM, 2018)	0.48
" In 4 macaques dosed subcutaneously, drug levels over 5 weeks in plasma, lymph node mononuclear cells (LNMCs), and peripheral blood mononuclear cells (PBMCs) were analyzed by liquid chromatography-tandem mass spectrometry."	( Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection. Collier, AC; Ho, RJY; Kinman, LM; Koehn, J; Kraft, JC; Lane, S; Lee, W; McConnachie, LA, 2018)	0.48
" Four placebo-controlled randomized clinical trials have demonstrated that preexposure prophylaxis (PrEP) with daily dosing of TDF/emtricitabine significantly reduces HIV acquisition in men who have sex with men, high-risk heterosexuals, and injection drug users who share injection equipment."	( HIV Preexposure Prophylaxis: A Review. Amico, KR; Mayer, KH; Riddell, J, 2018)	0.48
" Offering a choice of dosing regimen to PrEP users may enable further personalization of HIV prevention strategies and enhance up-take, adherence and cost-effectiveness."	( Men who have sex with men more often chose daily than event-driven use of pre-exposure prophylaxis: baseline analysis of a demonstration study in Amsterdam. Achterbergh, RC; Davidovich, U; de Vries, HJ; Hogewoning, A; Hoornenborg, E; Prins, M; Sonder, GJ; van der Helm, JJ; van der Loeff, MFS; van Duijnhoven, YT, 2018)	0.48
"MTN-014 was a phase 1, cross-over, randomized sequence trial comparing the cross-compartment pharmacokinetics and pharmacodynamics of daily TFV reduced-glycerin 1% gel after 14 days each of rectal and vaginal application, with directly observed dosing and a 6-week washout period between phases."	( Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing. Balar, B; Dai, JY; Dezzutti, CS; Galaska, B; Hendrix, CW; Justman, JE; Kunjara Na Ayudhya, RP; Levy, L; Marzinke, MA; McGowan, I; Mushamiri, I; Nair, GL; Pan, Z; Piper, JM; Schwartz, JL, 2018)	0.48
" TFV and TFV diphosphate (TFV-DP) were detected in most samples collected from the dosing compartment."	( Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing. Balar, B; Dai, JY; Dezzutti, CS; Galaska, B; Hendrix, CW; Justman, JE; Kunjara Na Ayudhya, RP; Levy, L; Marzinke, MA; McGowan, I; Mushamiri, I; Nair, GL; Pan, Z; Piper, JM; Schwartz, JL, 2018)	0.48
" Although high TFV concentrations in the dosing compartment may be protective, low cross-compartment tissue concentrations are not likely to be protective."	( Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing. Balar, B; Dai, JY; Dezzutti, CS; Galaska, B; Hendrix, CW; Justman, JE; Kunjara Na Ayudhya, RP; Levy, L; Marzinke, MA; McGowan, I; Mushamiri, I; Nair, GL; Pan, Z; Piper, JM; Schwartz, JL, 2018)	0.48
" Intravaginal dosing with ARVs has shown to result in drug exposures in rectal tissues, thus raising the possibility of dual compartment protection."	( Efficacy of Vaginally Administered Gel Containing Emtricitabine and Tenofovir Against Repeated Rectal Simian Human Immunodeficiency Virus Exposures in Macaques. Dinh, C; Dobard, CW; Garcia-Lerma, G; Heneine, W; Khalil, G; Lipscomb, J; Makarova, N; Martin, A; Mitchell, J; Taylor, A; West-Deadwyler, R, 2018)	0.48
" Using a murine model, we compared the plasma and tissue pharmacokinetics of TFV and various TFV prodrugs, including tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), and hexadecyloxypropyl tenofovir (CMX157), after dosing as enema formulations with varying osmolality and ion content."	( Development of rectal enema as microbicide (DREAM): Preclinical progressive selection of a tenofovir prodrug enema. Bensouda, S; Cone, RA; Date, AA; Ensign, LM; Fuchs, EJ; Gumber, S; Hanes, J; Hendrix, C; Hoang, T; Marzinke, M; Ortiz, JO; Rohan, L; Villinger, F; Xiao, P; Young, TW, 2019)	0.51
" Tenofovir intravenous daily dosing in monkeys for 2 or 4 weeks at 30 mg/kg/day resulted in minimal to moderate tubular degeneration and regeneration, and tenofovir disoproxil fumarate oral dosing in dogs for 10 days at 45 mg/kg/day resulted in mild to marked tubular degeneration, necrosis, and regeneration."	( Performance Assessment of New Urinary Translational Safety Biomarkers of Drug-induced Renal Tubular Injury in Tenofovir-treated Cynomolgus Monkeys and Beagle Dogs. Glaab, WE; Gu, YZ; Pasello Dos Santos, FR; Peiffer, RL; Sistare, FD; Tournade, H; Troth, SP; Vlasakova, K, 2018)	0.48
" This made adherence to the dosing strategy challenging."	( "It Was Not My Aim to Sleep There": The Impact of Timing and Location of Sex on Adherence to Coitally-Dependent HIV Pre-exposure Prophylaxis. Baron, D; Delany-Moretlwe, S; Gray, G; Ikaneng, T; Ju, S; Mabude, Z; Makgopa, S; Malefo, MA; Manenzhe, KN; Mazibuko, T; Nkala, B; Ntjana, H; Palanee-Phillips, T; Rees, H; Scorgie, F; Stadler, J, 2018)	0.48
" Assessing adherence to recommended enema dosing regimens is essential in evaluating the utility of this strategy."	( Fecal Coliform Bacterial Detection to Assess Enema Adherence in HIV Prevention Clinical Studies. Aung, WS; Bakshi, RP; Breakey, J; Fuchs, EJ; Hendrix, CW; Johnson, JE; Marzinke, MA; Weld, E, 2019)	0.51
"The goal of this work was to evaluate dosing strategies for tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), and emtricitabine (FTC) for pre-exposure prophylaxis (PrEP) with injection drug use with a pharmacokinetic/pharmacodynamics analysis of concentration data generated from two single-dose clinical studies conducted in healthy women."	( A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs. Chen, J; Cottrell, ML; Dumond, JB; Garrett, KL; Maas, BM; Prince, HA; Schauer, AP; Sykes, C; White, N, 2018)	0.48
"We assessed tenofovir hair concentrations in HIV-uninfected volunteers randomized to receive 100%, 67%, or 33% of daily dosing of TDF/FTC for 12 weeks (DOT-DBS, NCT02022657)."	( Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine: implications for preexposure prophylaxis adherence monitoring. Anderson, PL; Bacchetti, P; Castillo-Mancilla, J; Gandhi, M; Koss, CA; Kuncze, K; Liu, AY; Louie, A; MaWhinney, S; McHugh, C; Morrow, M; Okochi, H; Seifert, S, 2018)	0.48
" Data collected included demographic data, laboratory tests, antiretroviral treatment history, methadone dosing and drug abstinence."	( Risk factors for kidney disease among HIV-1 positive persons in the methadone program. Firląg-Burkacka, E; Grycner, E; Horban, A; Kowalska, JD; Matłosz, B; Pietraszkiewicz, E, 2019)	0.51
"Intravaginal rings (IVRs) for HIV pre-exposure prophylaxis (PrEP) theoretically overcome some adherence concerns associated with frequent dosing that can occur with oral or vaginal film/gel regimens."	( Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial. Anton, PA; Baum, MM; Butkyavichene, I; Churchman, SA; Cortez, JM; Dawson, L; Fanter, R; Gunawardana, M; Guthrie, KM; Hendrix, CW; Marzinke, MA; Miller, CS; Moss, JA; Olive, TJ; Pyles, RB; Rosen, RK; Vargas, SE; Vincent, KL; Yang, F, 2018)	0.48
" IM SMC concentrations were low relative to PBMC, as were EN concentrations, suggesting differences in cell phenotype and lineage in the MGT; these differences in phenotype and pharmacology may have an impact on selecting and dosing ARVs used in cure strategies."	( Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract. Blake, KH; Chen, J; Cohen, MS; Dumond, JB; Gay, CL; Greene, SA; Kashuba, ADM; Maas, BM; Nelson, JAE; Prince, HMA; Schauer, AP; Sykes, C, 2019)	0.51
" At baseline (pre-switch) and at 12 weeks post-switch, we measured HIV-1 RNA in seminal plasma (SP) and blood plasma (BP), tenofovir (TFV) in SP and BP, and TFV-diphosphate (dp) in peripheral blood mononuclear cells (PBMCs) and seminal mononuclear cells (SMCs) at the end of the dosing interval (C24h)."	( Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40). Cottrell, ML; Garcia, B; Imaz, A; Kashuba, ADM; Morenilla, S; Niubó, J; Perez, E; Podzamczer, D; Tiraboschi, JM, 2019)	0.51
" We examined rank correlations between levels of TFV and emtricitabine in urine, dried blood spots (DBS), and hair and determined the sensitivity and specificity of undetectable urine TFV for predicting dosing cut-offs in DBS."	( Low tenofovir level in urine by a novel immunoassay is associated with seroconversion in a preexposure prophylaxis demonstration project. Buchbinder, SP; Defechereux, P; Gandhi, M; Glidden, DV; Grant, RM; Kuncze, K; Mehrotra, M; Okochi, H; Rodrigues, WC; Spinelli, MA; Vincent, M; Wang, G, 2019)	0.51
" Cisgender men who have sex with men and transwomen in the optional dual-energy X-ray absorptiometry (DXA) substudy of a large, international, open-label PrEP demonstration project, the iPrEx-open-label extension (OLE) study underwent DXA scans and DBS collection every 24 weeks, with average weekly dosing adherence patterns (2, 4, and 7 doses/week) estimated from validated TFV-DP cut-offs."	( Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project. Anderson, PL; Bekker, LG; Buchbinder, SP; Chariyalertsak, S; Defechereux, P; Gandhi, M; Glidden, DV; Grant, RM; Guanira, JV; McMahan, VM; Schechter, M; Spinelli, MA; Veloso, VG, 2019)	0.51
"The USPSTF reviewed the evidence on the benefits of PrEP for the prevention of HIV infection with oral tenofovir disoproxil fumarate monotherapy or combined tenofovir disoproxil fumarate and emtricitabine and whether the benefits vary by risk group, population subgroup, or regimen or dosing strategy; the diagnostic accuracy of risk assessment tools to identify persons at high risk of HIV acquisition; the rates of adherence to PrEP in primary care settings; the association between adherence and effectiveness of PrEP; and the harms of PrEP when used for HIV prevention."	( Preexposure Prophylaxis for the Prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement. Barry, MJ; Cabana, M; Caughey, AB; Curry, SJ; Davidson, KW; Doubeni, CA; Epling, JW; Krist, AH; Kubik, M; Landefeld, CS; Mangione, CM; Owens, DK; Pbert, L; Silverstein, M; Simon, MA; Tseng, CW; Wong, JB, 2019)	0.51
" On-demand (2-1-1 dosing strategy for MSM) and injectable PrEP appear to be acceptable among participants in clinical trials."	( Current and Future PrEP Medications and Modalities: On-demand, Injectables, and Topicals. Beymer, MR; Holloway, IW; Landovitz, RJ; Pulsipher, C, 2019)	0.51
" The pericoital, before-and-after sex, dosing regimen used in the Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004 tenofovir gel trial meant that women who were infected with hepatitis B virus (HBV) were exposed intermittently to tenofovir during their participation."	( Frequency of Hepatitis B Virus Resistance Mutations in Women Using Tenofovir Gel as Pre-Exposure Prophylaxis. Abdool Karim, SS; Baxter, C; Blackard, JT; Ngcapu, S; Penton, PK; Powell, EA, 2019)	0.51
" Participants were randomized to receive controlled TDF/FTC dosing as (1) "perfect" adherence (daily); (2) "moderate" adherence (4 doses/week); or (3) "low" adherence (2 doses/week)."	( Urine Tenofovir Concentrations Correlate With Plasma and Relate to Tenofovir Disoproxil Fumarate Adherence: A Randomized, Directly Observed Pharmacokinetic Trial (TARGET Study). Bacchetti, P; Baeten, JM; Cressey, R; Cressey, TR; Drain, PK; Gandhi, M; Klinbuayaem, V; Kubiak, RW; Okochi, H; Punyati, P; Quame-Amaglo, J; Siriprakaisil, O; Sirirungsi, W; Sukrakanchana, PO; Tanasri, S, 2020)	0.56
"High urine FTC and TFV concentrations could provide an indication of adherence to daily oral dosing with TDF or TAF-based regimens used for treatment and prevention."	( Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men. Conway-Washington, C; Dinh, C; Fountain, J; Haaland, RE; Hall, L; Holder, A; Kelley, CF; Livermont, T; Lupo, LD; Martin, A, 2019)	0.51
" In this paper, we compared the dosage levels of tenofovir exposure in fetuses, breastfed infants, and children receiving tenofovir treatment."	( Guides concerning tenofovir exposure via breastfeeding: A comparison of drug dosages by developmental stage. Hu, X; Wang, L; Xu, F, 2019)	0.51
"The CROPrEP project, a real-world study of PrEP use, will recruit 1000 high-risk HIV-negative MSM participants from four cities in China, who will be able to choose between daily or event-driven dosing regimens, according to their preference."	( Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP). Chu, Z; Ding, H; Geng, W; Jia, Y; Jiang, Y; Leuba, SI; Mei, Z; Shang, H; Wang, H; Xu, J; Zhang, J; Zhang, Y, 2019)	0.51
" The latest strategies for the prevention of the sexual transmission of HIV have moved towards sustained-release dosage forms, so films may be an effective strategy that could also improve the patient's comfort."	( Development of mucoadhesive vaginal films based on HPMC and zein as novel formulations to prevent sexual transmission of HIV. Bedoya, LM; Cazorla-Luna, R; Martín-Illana, A; Notario-Pérez, F; Peña, J; Ruiz-Caro, R; Veiga, MD, 2019)	0.51
"Participants were randomly assigned to one of three self-administered dosing regimens for 24 weeks: daily, time-driven, or event-driven."	( HPTN 067/ADAPT: Correlates of Sex-Related Pre-exposure Prophylaxis Adherence, Thai Men Who Have Sex With Men, and Transgender Women, 2012-2013. Amico, KR; Chitwarakorn, A; Curlin, ME; Grant, RM; Holtz, TH; Hughes, JP; Li, M; Mock, PA; Varangrat, A, 2019)	0.51
" Regardless of these factors, Thai MSM and TGW maintained high adherence levels to oral PrEP dosing regimens and coverage of sexual exposures."	( HPTN 067/ADAPT: Correlates of Sex-Related Pre-exposure Prophylaxis Adherence, Thai Men Who Have Sex With Men, and Transgender Women, 2012-2013. Amico, KR; Chitwarakorn, A; Curlin, ME; Grant, RM; Holtz, TH; Hughes, JP; Li, M; Mock, PA; Varangrat, A, 2019)	0.51
" This study predicted the pharmacokinetics (PK) of three renally excreted antiretroviral drugs in the elderly population and compared them with known exposures in renal impairment, to evaluate the need for dosing adjustments."	( Are Standard Doses of Renally-Excreted Antiretrovirals in Older Patients Appropriate: A PBPK Study Comparing Exposures in the Elderly Population With Those in Renal Impairment. Chetty, M; De Sousa Mendes, M, 2019)	0.51
" The majority of virtual patients had exposures that did not require dosage adjustments."	( Are Standard Doses of Renally-Excreted Antiretrovirals in Older Patients Appropriate: A PBPK Study Comparing Exposures in the Elderly Population With Those in Renal Impairment. Chetty, M; De Sousa Mendes, M, 2019)	0.51
"Comparison of the exposure in the elderly with exposure observed in patients with different levels of renal impairment, indicated that a dosage adjustment may not be required in elderly patients on lamivudine, emtricitabine and the majority of the patients on tenofovir."	( Are Standard Doses of Renally-Excreted Antiretrovirals in Older Patients Appropriate: A PBPK Study Comparing Exposures in the Elderly Population With Those in Renal Impairment. Chetty, M; De Sousa Mendes, M, 2019)	0.51
" We found that standard dosing strategies in preclinical species closely mimicked tissue concentrations in humans for some, but not all, ARVs."	( Antiretroviral Penetration across Three Preclinical Animal Models and Humans in Eight Putative HIV Viral Reservoirs. Adamson, L; Akkina, R; Blake, K; Burgunder, EM; Devanathan, AS; Garcia, JV; Kashuba, ADM; Kovarova, M; Luciw, P; Pirone, JR; Remling-Mulder, L; Rosen, EP; Schauer, AP; Srinivas, N; Sykes, C; White, NR, 2019)	0.51
" Pericoital PrEP dosing seems to be effective in preventing HIV transmission among men who have sex with men, but has not been evaluated in women."	( PrEP 1.0 and Beyond: Optimizing a Biobehavioral Intervention. Allan-Blitz, LT; Mayer, KH, 2019)	0.51
"PrEP has been shown to be safe and effective when used consistently, but new approaches to enhance uptake, adherence, and convenience with less-frequent dosing are under study, suggesting that new models and modalities will evolve to optimize impact."	( PrEP 1.0 and Beyond: Optimizing a Biobehavioral Intervention. Allan-Blitz, LT; Mayer, KH, 2019)	0.51
" With the assistance of therapeutic drug monitoring, dolutegravir dosing was increased to 150 mg daily."	( Successful use of once-daily high-dose darunavir and dolutegravir in multidrug-resistant HIV. Fulco, PP; Gomes, D; Leibrand Kaczmar, CR; Smith, T, 2020)	0.56
" In this perspective, we summarize data related to on-demand PrEP, describe advantages and disadvantages for this alternative dosing strategy, and provide clinical counseling points."	( On-Demand Oral Pre-exposure Prophylaxis with Tenofovir/Emtricitabine: What Every Clinician Needs to Know. Saberi, P; Scott, HM, 2020)	0.56
" Recent dosing measures include antiretroviral levels in plasma or urine, as well as emtricitabine-triphosphate in dried blood spots (DBS) for those on tenofovir-emtricitabine-based therapy."	( Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions. Anderson, PL; Castillo-Mancilla, J; Chai, PR; Gandhi, M; Haberer, JE; Spinelli, MA, 2020)	0.56
"\ Conclusions: The patients were generally satisfied with the change in medication and well nformed about the dosage and advantages of TAF over TDF, but less well informed about the possible adverse effects of TAF."	( Satisfaction and knowledge among patients with HIV after switching from tenofovir to tenofovir alafenamide in regimens containing emtricitabine and rilpivirine Bermejo-Vicedo, T; Gramage-Caro, T; Montero-Llorente, B; Rodríguez-Sagrado, MÁ; Vélez-Díaz-Pallarés, M, 2020)	0.56
"TAF-DBS was a randomized, crossover clinical study of TFV-DP in DBS, following directly observed dosing of 33%, 67%, or 100% of daily TAF (25 mg)/FTC (200 mg)."	( Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study. Anderson, PL; Brooks, KM; Bushman, LR; Castillo-Mancilla, J; Ibrahim, ME; Kiser, JJ; MaWhinney, S; McCallister, S; McHugh, C; Morrow, M; Yager, J, 2020)	0.56
" Together, these moieties provide complementary measures of cumulative adherence and recent dosing for TAF/FTC."	( Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study. Anderson, PL; Brooks, KM; Bushman, LR; Castillo-Mancilla, J; Ibrahim, ME; Kiser, JJ; MaWhinney, S; McCallister, S; McHugh, C; Morrow, M; Yager, J, 2020)	0.56
" Plasma and urine samples were collected regularly during the 6-week dosing phase and for 4 weeks following drug cessation."	( Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate. Baeten, JM; Cressey, R; Cressey, TR; Drain, PK; Gandhi, M; Klinbuayaem, V; Kubiak, RW; Okochi, H; Quame-Amaglo, J; Siriprakaisil, O; Sukrakanchana, PO; Tawon, Y, 2020)	0.56
" Participants in the intervention arm will be provided with remote real-time monitoring equipment that triggers twice just-in-time SMS (Short Messaging Service) medication reminders to PrEP users every half an hour when a scheduled dosage is missed, and followed with just-in-time SMS medication reminders to clinicians half an hour when there is no supplement after the second just-in-time SMS reminder to PrEP users."	( Real-time monitoring and just-in-time intervention for adherence to pre-exposure prophylaxis among men who have sex with men in China: a multicentre RCT study protocol. Bao, R; Chen, Y; Chu, Z; Ding, H; Geng, W; He, X; Hu, Q; Hu, Z; Huang, X; Jiang, Y; Jin, X; Li, H; Li, S; Lv, W; Shang, H; Wang, H; Xu, J; Zhang, J; Zhang, L, 2020)	0.56
" The agents were vaginally dosed individually and in combination, and the efficacy of HIV-1 prevention was analyzed using the established, rigorous median-effect model."	( Highly synergistic drug combination prevents vaginal HIV infection in humanized mice. Baum, MM; Bobardt, M; Gallay, PA; Gunawardana, M; Moss, JA; Ramirez, CM, 2020)	0.56
"Diverging physicochemical properties of HIV drug combinations are challenging to formulate as a single dosage form."	( Controlled Solvent Removal from Antiviral Drugs and Excipients in Solution Enables the Formation of Novel Combination Multi-Drug-Motifs in Pharmaceutical Powders Composed of Lopinavir, Ritonavir and Tenofovir. Ho, RJY; Lane, S; McConnachie, L; Yu, D; Yu, J, 2020)	0.56
"Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)."	( Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022)	0.72
" However, this change was modest, not warranting a change in TFV dosing at this time."	( Methotrexate Decreases Tenofovir Exposure in Antiretroviral-Suppressed Individuals Living With HIV. Aweeka, FT; Currier, JS; Deitchman, AN; Gingrich, D; Hsue, PY; Huang, L; Kantor, A; Ribaudo, HJ; Stein, JH, 2020)	0.56
"02) times as likely to engage in optimal PrEP dosing compared to controls."	( The Impact of a Mobile Gaming Intervention to Increase Adherence to Pre-exposure Prophylaxis. Arnold, T; Brown, LK; Craker, L; Haubrick, KK; Mena, L; Olsen, E; Whiteley, L, 2021)	0.62
"In this study, a green stability indicating chromatographic methods were developed and validated for the quantitative determination of tenofovir alafenamide in the presence of its degradation products in bulk powder as well as in dosage forms."	( Assessment of the greenness of new stability indicating micellar UPLC and HPTLC methods for determination of tenofovir alafenamide in dosage forms. Abdel-Razeq, SA; Nasr, ZA; Said, NS, 2021)	0.62
"A novel method was developed for the simultaneous estimation of the doravirine, lamivudine, and tenofovir disoproxil fumarate in the pharmaceutical dosage form."	( A simple alternative and improved HPLC method for the estimation of doravirine, lamivudine, and tenofovir disoproxil fumarate in solid oral dosage form. Alegete, P; Kancherla, P; Kokkirala, TK; Suryakala, D, 2021)	0.62
" TAF was well tolerated and only 4 patients discontinued therapy due to adverse event during a median duration of TAF dosing of 74 weeks."	( Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV. Bernstein, DE; Fried, MW; Lok, AS; Mospan, AR; Schiff, ER; Smith, CI; Trinh, HN; Zink, RC, 2022)	0.72
" Several studies have shown short but potent intermittent PrEP could provide comparable protection to daily PrEP in men, suggesting such dosing strategy might be useful in Chinese as well."	( Impact of dosing strategies on plasma concentrations of tenofovir: Implications in HIV pre-exposure prophylaxis in China. Alnajebi, B; Huang, A; Ma, Q; Shang, J; Tan, R; Yan, B; Yang, J; Zhang, Y; Zhong, X, 2021)	0.62
"An open label study in 40 Chinese healthy volunteers, randomized to receive the WHO-recommended dose of tenofovir (300mg) at four different dosing intervals: twice weekly for 4 weeks; once daily for 4 weeks with one missing dose in weeks 2-4; once daily for 4 weeks with two missing doses in weeks 2-4; and once every other day for 12 days."	( Impact of dosing strategies on plasma concentrations of tenofovir: Implications in HIV pre-exposure prophylaxis in China. Alnajebi, B; Huang, A; Ma, Q; Shang, J; Tan, R; Yan, B; Yang, J; Zhang, Y; Zhong, X, 2021)	0.62
" The trough concentrations (24h dosing interval) at the steady state were 51."	( Impact of dosing strategies on plasma concentrations of tenofovir: Implications in HIV pre-exposure prophylaxis in China. Alnajebi, B; Huang, A; Ma, Q; Shang, J; Tan, R; Yan, B; Yang, J; Zhang, Y; Zhong, X, 2021)	0.62
" No studies have yet compared TFV-DP in PBMC from lower than daily dosing between prodrugs, which has potential implications for event-driven preexposure prophylaxis and pharmacologic forgiveness."	( Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate. Anderson, PL; Brooks, KM; Bushman, L; Castillo-Mancilla, JR; Ibrahim, M; Kiser, JJ; MaWhinney, S; Morrow, M; Nemkov, C; Peterson, S; Yager, JL, 2021)	0.62
"HIV-negative adults were randomized to two 12-week DOT regimens of 33, 67 or 100% of daily dosing with emtricitabine (F)/TAF 200 mg/25 mg (TAF-DBS) or F/TDF 200 mg/300 mg (DOT-DBS), separated by a 12-week washout."	( Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate. Anderson, PL; Brooks, KM; Bushman, L; Castillo-Mancilla, JR; Ibrahim, M; Kiser, JJ; MaWhinney, S; Morrow, M; Nemkov, C; Peterson, S; Yager, JL, 2021)	0.62
"This is an open-label, randomized, fixed sequence single intravenous dosing study to assess pharmacokinetic interactions between remdesivir and TDF/3TC (Study A, crossover design) or TDF/3TC plus ATV/r (Study B)."	( An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR). Byakika-Kibwika, P; D'Avolio, A; Kaboggoza, JP; Lamorde, M; Waitt, C; Walimbwa, SI, 2021)	0.62
"A simple, selective and rapid ultra performance liquid chromatography-tandem mass spectrometry method was developed and validated for the simultaneous estimation of dolutegravir, lamivudine and tenofovir in bulk and tablet dosage form."	( Development and validation of ultra performance liquid chromatography-tandem mass spectrometry method for the simultaneous estimation of dolutegravir, lamivudine and tenofovir in bulk and tablet dosage form. Dodda, S; Gangarapu, K; Veerareddy, V, 2021)	0.62
" Different dosage forms - including films - for vaginal administration of antiretroviral drugs have been developed for this purpose."	( Eudragit® L100/chitosan composite thin bilayer films for intravaginal pH-responsive release of Tenofovir. Cazorla-Luna, R; Martín-Illana, A; Notario-Pérez, F; Rubio, J; Ruiz-Caro, R; Tamayo, A; Veiga, MD, 2022)	0.72
" Tenofovir is an important component of management, but the associated risk of nephrotoxicity makes dosing a challenge in patients with impaired kidney function."	( Tenofovir alafenamide: An initial experience at Groote Schuur Hospital, Cape Town, South Africa. Barday, Z; Geragotellis, A; Naicker, V; Patel, S; Sanglay, L; Sonderup, M; Spearman, CW; Wearne, N, 2022)	0.72
" Final models were subjected to Monte Carlo simulations to compare drug exposure following once daily and on-demand (IPERGAY 2 + 1 + 1) dosing of F/TDF."	( Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women. Bakshi, RP; Chaturvedula, A; Fuchs, EJ; Hendrix, CW; Marzinke, MA; Shieh, E; Tanaudommongkon, A, 2022)	0.72
" Simulations demonstrated that at least 2, weekly 2 + 1 + 1 cycles of on-demand dosing in TGW on GAHT is necessary for TFV-diphosphate to reach similar exposure after the initial week of on-demand dosing in CGM not on GAHT."	( Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women. Bakshi, RP; Chaturvedula, A; Fuchs, EJ; Hendrix, CW; Marzinke, MA; Shieh, E; Tanaudommongkon, A, 2022)	0.72
"Daily dosing of tenofovir disoproxil fumarate, with or without emtricitabine, has high efficacy in preventing human immunodeficiency virus (HIV) infection when individuals are adherent."	( Characterizing HIV-Preventive, Plasma Tenofovir Concentrations-A Pooled Participant-level Data Analysis From Human Immunodeficiency Virus Preexposure Prophylaxis Clinical Trials. Anderson, P; Baeten, JM; Celum, CL; Choopanya, K; Garcia-Cremades, M; Glidden, DV; Grant, R; Hendrix, CW; Jarlsberg, L; Jayachandran, P; Marrazzo, J; Martin, M; Savic, RM; Vanichseni, S; Vučićević, K, 2022)	0.72
" Dosing simulations indicated that high-risk women require full adherence to maintain protective levels."	( Characterizing HIV-Preventive, Plasma Tenofovir Concentrations-A Pooled Participant-level Data Analysis From Human Immunodeficiency Virus Preexposure Prophylaxis Clinical Trials. Anderson, P; Baeten, JM; Celum, CL; Choopanya, K; Garcia-Cremades, M; Glidden, DV; Grant, R; Hendrix, CW; Jarlsberg, L; Jayachandran, P; Marrazzo, J; Martin, M; Savic, RM; Vanichseni, S; Vučićević, K, 2022)	0.72
" Systemic drug disposition during TAF implant dosing was explained by a multi-compartment pharmacokinetic (PK) model."	( Fundamental aspects of long-acting tenofovir alafenamide delivery from subdermal implants for HIV prophylaxis. Baum, MM; Beliveau, M; Buser, C; Caprioli, RM; Castonguay, AE; Gallay, PA; Gunawardana, M; Hendrix, CW; Kuo, J; Marzinke, MA; Moss, JA; Remedios-Chan, M; Reyzer, ML; Sanchez, D; Trinh, M; Tuck, M; Webster, P; Webster, S, 2022)	0.72
" PrEP could be prescribed as a daily regimen with one pill per day or, in men who have sex with men (MSM) or in transgender women who have sex with men, as an on-demand regimen following the IPERGAY dosing recommendation."	( Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study. Algarte-Genin, M; Assoumou, L; Ben-Mechlia, M; Beniguel, L; Costagliola, D; Delaugerre, C; Ghosn, J; Goldwirt, L; Katlama, C; Le Mestre, S; Liegeon, G; Lourenco, J; Loze, B; Molina, JM; Mouhim, H; Ohayon, M; Pavie, J; Pialoux, G; Rojas-Castro, D; Slama, L; Spire, B; Surgers, L, 2022)	0.72
" At enrolment, 1540 (50·5%) of 3049 participants opted for daily PrEP dosing and 1509 (49·5%) opted for on-demand PrEP dosing; these proportions remained stable during follow-up."	( Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study. Algarte-Genin, M; Assoumou, L; Ben-Mechlia, M; Beniguel, L; Costagliola, D; Delaugerre, C; Ghosn, J; Goldwirt, L; Katlama, C; Le Mestre, S; Liegeon, G; Lourenco, J; Loze, B; Molina, JM; Mouhim, H; Ohayon, M; Pavie, J; Pialoux, G; Rojas-Castro, D; Slama, L; Spire, B; Surgers, L, 2022)	0.72
" We observed significant dose-response relationships between number of HIV risk factors and PrEP drug concentrations."	( Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in South Africa and Zimbabwe: a secondary analysis of the HPTN 082 randomised controlled trial. Anderson, PL; Bekker, LG; Celum, C; Chirenje, ZM; Delany-Moretlwe, S; Donnell, D; Hosek, S; Marzinke, MA; Mgodi, N; Velloza, J, 2022)	0.72
" TDF toxicity is more likely among African patients, it is reversible and TDF may be renal dosed in patients with dysfunction."	( Proximal tubular renal dysfunction among HIV infected patients on Tenofovir versus Tenofovir sparing regimen in western Kenya. Karoney, MJ; Koech, MK; Njiru, EW; Owino Ong'or, WD, 2022)	0.72
" Our existing PK model, supported by an intravenous (IV) dosing dog study, was adapted to analyze mechanistic aspects underlying implant TAF delivery."	( Preclinical Considerations for Long-acting Delivery of Tenofovir Alafenamide from Subdermal Implants for HIV Pre-exposure Prophylaxis. Baum, MM; Beliveau, M; Fanter, R; Gallay, PA; Gunawardana, M; Kuo, J; Marzinke, MA; Moss, JA; Ramirez, CM; Remedios-Chan, M; Sanchez, D; Trinh, M; Webster, P; Webster, S, 2023)	0.91
"Antiretroviral agents with novel mechanisms and dosing intervals could expand treatment options for people with HIV."	( Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial. Baeten, JM; Benson, P; Berhe, M; Crofoot, G; Dvory-Sobol, H; Gupta, SK; Koenig, E; Liu, SY; McDonald, C; Ramgopal, M; Rhee, MS; Ruane, P; Sanchez, WE; Scribner, A; Sims, J; VanderVeen, LA, 2023)	0.91
" Methods: In this randomized, open label, controlled pilot trial, we evaluated RBV (n=4) dosed for the initial 24 weeks of treatment versus no RBV (n=4) in tenofovir recipients dosed over 48 weeks."	( Ribavirin Does Not Enhance Hepatitis B Virus Nucleotide Antiviral Activity: A Pilot Study. Coffin, C; Cooper, C; Crawley, A; Fung, S; Keeshan, A; Ma, M; Mortimer, L; Osiowy, C; Patel, N; Vachon, A, 2022)	0.72
" We characterized DBS TFVdp and FTCtp concentrations across many dosing scenarios."	( A Novel Algorithm to Improve PrEP Adherence Monitoring Using Dried Blood Spots. Anderson, DJC; Cottrell, ML; Devanathan, AS; Dumond, JB; Gay, CL; Kashuba, ADM; Moody, K; Poliseno, AJ; Rosen, EP; Schauer, AP; Sykes, C, 2023)	0.91
"Dolutegravir concentrations are reduced by efavirenz induction effect necessitating twice-daily dolutegravir dosing when coadministered."	( Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial. Griesel, R; Hill, A; Keene, C; Maartens, G; Meintjes, G; Omar, Z; Simmons, B; van Zyl, G; Zhao, Y, 2023)	0.91
"7 ng/mL within 24 h after dosing in the third month postpartum."	( Low levels of tenofovir in breast milk support breastfeeding in HBV-infected mothers treated with tenofovir disoproxil fumarate. Jiang, X; Jiang, Y; Jin, J; Li, S; Lin, N; Ma, Z; Shi, J, 2023)	0.91
" New non-vaccine biomedical products aimed at overcoming this global health challenge need to provide a range of safe, effective, and discreet dosage forms based on the delivery of one or more antiviral compounds."	( Acute antagonism in three-drug combinations for vaginal HIV prevention in humanized mice. Baum, MM; Gallay, PA; Ramirez, CM, 2023)	0.91
" This semimechanistic model describes the population pharmacokinetics of tenofovir when dosed as either TDF or TAF in an African population living with HIV and can be used as a tool for exposure prediction in patients, and to simulate alternative regimes to inform further clinical trials."	( Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population. Chandiwana, N; Denti, P; Kawuma, AN; Maartens, G; Sinxadi, P; Sokhela, SM; Venter, WDF; Wasmann, RE; Wiesner, L, 2023)	0.91
" However, considering its rapid uptake into target cells, we suggest only a cautious increase of tenofovir alafenamide dosage intervals to 2 or 3 days only in case of moderate or severe CKD, respectively."	( Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration. Alves Saldanha, S; Andre, P; Buclin, T; Cavassini, M; Courlet, P; Decosterd, LA; Desfontaine, V; Guidi, M; Kusejko, K; Thoueille, P, 2023)	0.91
" Due to the long dosing interval (8 weeks), long-acting cabotegravir has low compliance requirements for people at high risk of HIV infection."	( Efficacy and safety of long-acting cabotegravir versus oral tenofovir disoproxil fumarate-emtricitabine as HIV pre-exposure prophylaxis: A systematic review and meta-analysis. Chen, X; Kou, L; Li, J; Li, Y; Wei, D; Xie, X, 2023)	0.91
" Daily emtricitabine/TAF was dosed according to World Health Organization (WHO)-recommended weight bands: 120/15 mg in children weighing 14 to <25 kg and 200/25 mg in those weighing ≥25 kg."	( First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial. Bamford, A; Burger, DM; Bwakura-Dangarembizi, M; Chabala, C; Colbers, A; Denti, P; Doerholt, K; Gibb, DM; Griffiths, AL; Makumbi, S; McIlleron, HM; Monkiewicz, LN; Mulenga, V; Mumbiro, V; Musiime, V; Nangiya, J; Szubert, AJ; Waalewijn, H; Wasmann, RE; Wiesner, L, 2023)	0.91
"In children, TAF combined with boosted PIs or dolutegravir and dosed according to WHO-recommended weight bands provides TAF and tenofovir concentrations previously demonstrated to be well tolerated and effective in adults."	( First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial. Bamford, A; Burger, DM; Bwakura-Dangarembizi, M; Chabala, C; Colbers, A; Denti, P; Doerholt, K; Gibb, DM; Griffiths, AL; Makumbi, S; McIlleron, HM; Monkiewicz, LN; Mulenga, V; Mumbiro, V; Musiime, V; Nangiya, J; Szubert, AJ; Waalewijn, H; Wasmann, RE; Wiesner, L, 2023)	0.91
" Although no dosage adjustment is needed for Oral Nirmatrelvir/Ritonavir in patients with mild renal impairment and coronavirus disease 2019, the dosage is reduced to twice daily in those with moderate renal impairment."	( Medication safety in chronic kidney disease. Singh, S, 2023)	0.91
"Cabotegravir plus rilpivirine is the only approved complete long-acting regimen for the maintenance of HIV-1 virological suppression dosed every 2 months."	( Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a random Berni, A; Castagna, A; Cazanave, C; Chounta, V; D'Amico, R; Di Perri, G; Diaz-Brito, V; Dretler, R; Garges, HP; Latham, CL; Oka, S; Osiyemi, O; Pascual Bernáldez, M; Patel, P; Ramgopal, MN; Sims, J; Smith, K; Spreen, WR; Sutherland-Phillips, D; Sutton, K; Van Eygen, V; Van Solingen-Ristea, R; van Wyk, J; Walmsley, S; Zhang, F, 2023)	0.91
" Participants with HIV-1 RNA less than 50 copies per mL were randomly assigned (2:1), stratified by sex at birth and BMI, to either long-acting cabotegravir (600 mg) plus rilpivirine (900 mg) dosed intramuscularly every 2 months or to continue daily oral bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg)."	( Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a random Berni, A; Castagna, A; Cazanave, C; Chounta, V; D'Amico, R; Di Perri, G; Diaz-Brito, V; Dretler, R; Garges, HP; Latham, CL; Oka, S; Osiyemi, O; Pascual Bernáldez, M; Patel, P; Ramgopal, MN; Sims, J; Smith, K; Spreen, WR; Sutherland-Phillips, D; Sutton, K; Van Eygen, V; Van Solingen-Ristea, R; van Wyk, J; Walmsley, S; Zhang, F, 2023)	0.91
"These data support the use of long-acting cabotegravir plus rilpivirine dosed every 2 months as a complete antiretroviral regimen that has similar efficacy to a commonly used integrase strand transfer inhibitor-based first-line regimen, while addressing unmet psychosocial issues associated with daily oral treatment."	( Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a random Berni, A; Castagna, A; Cazanave, C; Chounta, V; D'Amico, R; Di Perri, G; Diaz-Brito, V; Dretler, R; Garges, HP; Latham, CL; Oka, S; Osiyemi, O; Pascual Bernáldez, M; Patel, P; Ramgopal, MN; Sims, J; Smith, K; Spreen, WR; Sutherland-Phillips, D; Sutton, K; Van Eygen, V; Van Solingen-Ristea, R; van Wyk, J; Walmsley, S; Zhang, F, 2023)	0.91
"To develop an injectable dosage form of the daily oral HIV drugs, tenofovir (T), lamivudine (L), and dolutegravir (D), creating a single, complete, all-in-one TLD 3-drug-combination that demonstrates long-acting pharmacokinetics."	( A novel formulation enabled transformation of 3-HIV drugs tenofovir-lamivudine-dolutegravir from short-acting to long-acting all-in-one injectable. Collier, AC; Delle Fratte, R; Eguchi, M; Ho, RJY; Melvin, AJ; Perazzolo, S; Stephen, ZR; Xu, X, 2023)	0.91
" Studies in macaques found that shorter courses of PEP with INSTIs were effective, particularly if dosing occurred close to the time of retroviral exposure."	( Post-exposure prophylaxis to prevent HIV: new drugs, new approaches, and more questions. Allan-Blitz, LT; Mayer, KH, 2023)	0.91

Role	Description
HIV-1 reverse transcriptase inhibitor	An entity which inhibits the activity of HIV-1 reverse transcriptase.
antiviral drug	A substance used in the prophylaxis or therapy of virus diseases.
drug metabolite	null
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
phosphonic acids	HP(=O)(OH)2 (phosphonic acid) and its P-substituted derivatives.
nucleoside analogue	An analogue of a nucleoside, being an N-glycosyl compound in which the nitrogen-containing moiety is a modified nucleotide base. They are commonly used as antiviral products to prevent viral replication in infected cells.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Tenofovir Metabolism Pathway	4	5

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
EWS/FLI fusion protein	Homo sapiens (human)	Potency	0.4686	0.0013	10.1577	42.8575	AID1259255
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cytochrome P450 3A4	Homo sapiens (human)	IC50 (µMol)	45.8000	0.0001	1.7536	10.0000	AID1832362
Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus	IC50 (µMol)	12.9850	0.0040	2.9266	9.9600	AID1805801
Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2	IC50 (µMol)	12.9850	0.0002	2.4585	9.9600	AID1805801
Cytochrome P450 2D6	Homo sapiens (human)	IC50 (µMol)	50.0000	0.0000	2.0151	10.0000	AID1832361
Reverse transcriptase/RNaseH	Human immunodeficiency virus 1	IC50 (µMol)	0.3800	0.0001	1.0768	10.0000	AID289142; AID320326; AID393069
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Capsid protein	Hepatitis B virus	EC50 (µMol)	0.2415	0.0002	0.2603	0.8194	AID1363957
Reverse transcriptase/RNaseH	Human immunodeficiency virus 1	Kd	3.2000	0.0006	2.4059	9.8000	AID341978
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Solute carrier family 22 member 6	Homo sapiens (human)	Km	33.8000	0.4200	4.6183	9.3000	AID544648
Reverse transcriptase/RNaseH	Human immunodeficiency virus 1	Activity	1.3500	0.0009	1.3073	8.0000	AID341976; AID341977; AID341991; AID341992
Reverse transcriptase/RNaseH	Human immunodeficiency virus 1	Km	1,112.5000	0.0700	1.9144	6.9000	AID341979; AID341980; AID341981; AID341982
Solute carrier family 22 member 8	Homo sapiens (human)	Km	770.0000	0.3450	1.3217	3.1000	AID544649
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
ADP biosynthetic process	Adenylate kinase isoenzyme 1	Homo sapiens (human)
nucleoside triphosphate biosynthetic process	Adenylate kinase isoenzyme 1	Homo sapiens (human)
nucleobase-containing small molecule interconversion	Adenylate kinase isoenzyme 1	Homo sapiens (human)
AMP metabolic process	Adenylate kinase isoenzyme 1	Homo sapiens (human)
ATP metabolic process	Adenylate kinase isoenzyme 1	Homo sapiens (human)
nucleoside monophosphate phosphorylation	Adenylate kinase isoenzyme 1	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
symbiont-mediated perturbation of host ubiquitin-like protein modification	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
xenobiotic metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
coumarin metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
isoquinoline alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of cellular organofluorine metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
arachidonic acid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
ADP biosynthetic process	Adenylate kinase 2, mitochondrial	Homo sapiens (human)
nucleobase-containing small molecule interconversion	Adenylate kinase 2, mitochondrial	Homo sapiens (human)
AMP metabolic process	Adenylate kinase 2, mitochondrial	Homo sapiens (human)
ATP metabolic process	Adenylate kinase 2, mitochondrial	Homo sapiens (human)
nucleoside monophosphate phosphorylation	Adenylate kinase 2, mitochondrial	Homo sapiens (human)
monoatomic anion transport	Solute carrier family 22 member 6	Homo sapiens (human)
response to organic cyclic compound	Solute carrier family 22 member 6	Homo sapiens (human)
inorganic anion transport	Solute carrier family 22 member 6	Homo sapiens (human)
organic anion transport	Solute carrier family 22 member 6	Homo sapiens (human)
prostaglandin transport	Solute carrier family 22 member 6	Homo sapiens (human)
alpha-ketoglutarate transport	Solute carrier family 22 member 6	Homo sapiens (human)
xenobiotic transport	Solute carrier family 22 member 6	Homo sapiens (human)
sodium-independent organic anion transport	Solute carrier family 22 member 6	Homo sapiens (human)
transmembrane transport	Solute carrier family 22 member 6	Homo sapiens (human)
metanephric proximal tubule development	Solute carrier family 22 member 6	Homo sapiens (human)
renal tubular secretion	Solute carrier family 22 member 6	Homo sapiens (human)
monoatomic ion transport	Solute carrier family 22 member 8	Homo sapiens (human)
response to toxic substance	Solute carrier family 22 member 8	Homo sapiens (human)
inorganic anion transport	Solute carrier family 22 member 8	Homo sapiens (human)
prostaglandin transport	Solute carrier family 22 member 8	Homo sapiens (human)
xenobiotic transport	Solute carrier family 22 member 8	Homo sapiens (human)
transmembrane transport	Solute carrier family 22 member 8	Homo sapiens (human)
transport across blood-brain barrier	Solute carrier family 22 member 8	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
adenylate kinase activity	Adenylate kinase isoenzyme 1	Homo sapiens (human)
nucleoside diphosphate kinase activity	Adenylate kinase isoenzyme 1	Homo sapiens (human)
ATP binding	Adenylate kinase isoenzyme 1	Homo sapiens (human)
nucleoside triphosphate adenylate kinase activity	Adenylate kinase isoenzyme 1	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
3'-5'-RNA exonuclease activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoesters	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
protein guanylyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
monooxygenase activity	Cytochrome P450 2D6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2D6	Homo sapiens (human)
heme binding	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
adenylate kinase activity	Adenylate kinase 2, mitochondrial	Homo sapiens (human)
protein binding	Adenylate kinase 2, mitochondrial	Homo sapiens (human)
ATP binding	Adenylate kinase 2, mitochondrial	Homo sapiens (human)
solute:inorganic anion antiporter activity	Solute carrier family 22 member 6	Homo sapiens (human)
protein binding	Solute carrier family 22 member 6	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier family 22 member 6	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier family 22 member 6	Homo sapiens (human)
alpha-ketoglutarate transmembrane transporter activity	Solute carrier family 22 member 6	Homo sapiens (human)
antiporter activity	Solute carrier family 22 member 6	Homo sapiens (human)
transmembrane transporter activity	Solute carrier family 22 member 6	Homo sapiens (human)
chloride ion binding	Solute carrier family 22 member 6	Homo sapiens (human)
identical protein binding	Solute carrier family 22 member 6	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Solute carrier family 22 member 6	Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activity	Solute carrier family 22 member 6	Homo sapiens (human)
solute:inorganic anion antiporter activity	Solute carrier family 22 member 8	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier family 22 member 8	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier family 22 member 8	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Solute carrier family 22 member 8	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
outer dense fiber	Adenylate kinase isoenzyme 1	Homo sapiens (human)
cytosol	Adenylate kinase isoenzyme 1	Homo sapiens (human)
extracellular exosome	Adenylate kinase isoenzyme 1	Homo sapiens (human)
cytoplasm	Adenylate kinase isoenzyme 1	Homo sapiens (human)
cytosol	Adenylate kinase isoenzyme 1	Homo sapiens (human)
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
double membrane vesicle viral factory outer membrane	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membrane	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mitochondrion	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2D6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2D6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2D6	Homo sapiens (human)
mitochondrial intermembrane space	Adenylate kinase 2, mitochondrial	Homo sapiens (human)
extracellular exosome	Adenylate kinase 2, mitochondrial	Homo sapiens (human)
sperm mitochondrial sheath	Adenylate kinase 2, mitochondrial	Homo sapiens (human)
cytoplasm	Adenylate kinase 2, mitochondrial	Homo sapiens (human)
mitochondrion	Adenylate kinase 2, mitochondrial	Homo sapiens (human)
plasma membrane	Solute carrier family 22 member 6	Homo sapiens (human)
caveola	Solute carrier family 22 member 6	Homo sapiens (human)
basal plasma membrane	Solute carrier family 22 member 6	Homo sapiens (human)
basolateral plasma membrane	Solute carrier family 22 member 6	Homo sapiens (human)
extracellular exosome	Solute carrier family 22 member 6	Homo sapiens (human)
protein-containing complex	Solute carrier family 22 member 6	Homo sapiens (human)
plasma membrane	Solute carrier family 22 member 8	Homo sapiens (human)
basolateral plasma membrane	Solute carrier family 22 member 8	Homo sapiens (human)
apical plasma membrane	Solute carrier family 22 member 8	Homo sapiens (human)
extracellular exosome	Solute carrier family 22 member 8	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID548820	Antiviral activity against HIV1 isolate 071 harboring reverse transcriptase 65R/S68N/184V mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID549069	Cellular uptake in PHA/IL-2-stimulated human PBMC at 1 uM assessed as TFV-diphosphate level after 24 hrs by MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID548847	Cellular uptake in human PBMC at 10 uM assessed as TFV-diphosphate after 24 hrs by MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID558382	Drug level in HIV-infected pregnant woman amniotic fluid at 300 mg, po QD by LC/MS/MS analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.
AID289144	Antiviral activity against HIV1 with reverse transcriptase 6TAM mutation assessed as reduction of potency relative to wild type	2007	Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16	Synthesis, anti-HIV activity, and resistance profile of thymidine phosphonomethoxy nucleosides and their bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs.
AID544649	Activity of human OAT3 transfected in BHK-21 cells	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation.
AID1636525	Cytotoxicity against human PBMC assessed as reduction in cell viability by XTT assay	2016	Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15	Reduction Sensitive Lipid Conjugates of Tenofovir: Synthesis, Stability, and Antiviral Activity.
AID618320	Cytotoxicity against PAP-activated human H9 cells on day 7 by MTT assay	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID548833	Antiviral activity against HIV1 isolate 201 harboring reverse transcriptase M41L/L210W/T215Y mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID394461	Cmax in Sprague-Dawley rat assessed as tenofovir level at 100 mg/kg, po administered daily for 7 days measured on day 7	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID341184	Cytotoxicity against human MT4 cells by MTT assay	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.
AID322847	Fold resistance, ratio of Lamivudine -adenofir-resistant HBV with reverse transcriptase V173L/L180M/A181V mutant to wildtype HBV genotype E	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID394468	AUC (0 to 24 hrs) in Sprague-Dawley rat assessed as tenofovir level at 10 mg/kg, po administered daily for 7 days measured on day 1	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID1140531	Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of hepatitis B surface antigen secretion by ELISA	2014	Bioorganic & medicinal chemistry letters, May-15, Volume: 24, Issue:10	Synthesis, structure-activity relationships and biological evaluation of dehydroandrographolide and andrographolide derivatives as novel anti-hepatitis B virus agents.
AID1457750	Cytotoxicity against human TZM-bl cells assessed as cell viability by tetrazolium dye assay	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
AID548803	Antiviral activity against HIV1 isolate 201 harboring reverse transcriptase M41L/L210W/T215Y mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID548584	Antiviral activity against HIV1 isolate 160 harboring reverse transcriptase S68G/V75(I/T)/F77L/Y115F/F116Y /Q151M mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID341979	Activity of HIV1 reverse transcriptase assessed as nucleotide excision activity in presence of 0.5 uM dCTP	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.
AID588964	Substrates of transporters of clinical importance in the absorption and disposition of drugs, OAT1	2010	Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3	Membrane transporters in drug development.
AID618434	Antiviral activity against Hepatitis B virus infected in human HuH7 cells assessed as reduction in viral DNA level treated day 3 to day 8 post transfection by real time quantitative PCR analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID548804	Antiviral activity against HIV1 isolate 203 harboring reverse transcriptase M41L/L210W/T215Y/M184V mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID548817	Antiviral activity against HIV1 isolate 067 harboring reverse transcriptase A62V/D67G/T69SVG/V75I/T215I mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID289146	Antiviral activity against HIV with reverse transcriptase M184V mutation assessed as reduction of potency relative to wild type	2007	Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16	Synthesis, anti-HIV activity, and resistance profile of thymidine phosphonomethoxy nucleosides and their bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs.
AID394464	Tmax in Sprague-Dawley rat assessed as tenofovir level at 30 mg/kg, po administered daily for 7 days measured on day 1	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID10054	Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity.
AID392504	Antiviral activity against Cowpox virus	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID548816	Antiviral activity against HIV1 isolate 066 harboring reverse transcriptase 184V mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1186716	Activity of recombinant AK2 (unknown origin) assessed as ADP formation by spectroscopic pyruvate kinase/lactate dehydrogenase coupled assay	2014	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17	Synthesis of {[5-(adenin-9-yl)-2-furyl]methoxy}methyl phosphonic acid and evaluations against human adenylate kinases.
AID1832365	Metabolic stability in human liver microsomes assessed as half life at 3 uM measured up to 30 min in presence of NADPH by LC-MS/MS analysis	2021	Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17	ω-Functionalized Lipid Prodrugs of HIV NtRTI Tenofovir with Enhanced Pharmacokinetic Properties.
AID548835	Antiviral activity against HIV1 isolate 204 harboring reverse transcriptase M41L/L210W/T215Y/M184V mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1457752	Antiviral activity against CCR5 tropic HIV1 BaL infected in human PHA-stimulated PBMC assessed as inhibition of viral replication by measuring reduction in p24 antigen production preincubated with cells for 30 mins followed by viral infection measured on	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
AID1686654	Therapeutic index, ratio of CC50 for uninfected human PBMC to EC50 for HIV1 infected in human PBMC	2016	Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22	Next-Generation Reduction Sensitive Lipid Conjugates of Tenofovir: Antiviral Activity and Mechanism of Release.
AID729827	Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of viral surface antigen production	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Synthesis of hemslecin A derivatives: a new class of hepatitis B virus inhibitors.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID275090	Cytotoxicity against MAGI-CCR5 cells	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID618313	Antiviral activity against 100 TCID50 wild-type Human immunodeficiency virus 1 3B infected in CEM cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID548805	Antiviral activity against HIV1 isolate 204 harboring reverse transcriptase M41L/L210W/T215Y/M184V mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1192287	Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for inhibition of HBV HBeAg secretion in HepG2(2.2.15) cells	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Synthesis of erythrocentaurin derivatives as a new class of hepatitis B virus inhibitors.
AID1599865	Cmax in Sprague-Dawley rat at 20 mg/kg, po administered as single dose and measured after 0.25 to 24 hrs by HPLC analysis	2019	ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6	Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs.
AID341180	Antiviral activity against R5-HIV1MDR/MM assessed as inhibition of p24 Gag protein production in human PHA-PBMC by ELISA	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.
AID618322	Antiviral activity against HIV1 clade B isolate 2101 infected in human H9 cells assessed as inhibition of viral replication	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID557023	Antiviral activity against HIV1 clade A harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID568380	Antiviral activity against HBV infected in human HepG 2.215 cells assessed as inhibition of DNA replication by RT-PCR analysis	2011	Bioorganic & medicinal chemistry, Feb-15, Volume: 19, Issue:4	Synthesis and biological assay of 4-aryl-6-chloro-quinoline derivatives as novel non-nucleoside anti-HBV agents.
AID1636522	Oral bioavailability in mouse	2016	Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15	Reduction Sensitive Lipid Conjugates of Tenofovir: Synthesis, Stability, and Antiviral Activity.
AID394447	Selectivity index, ratio of CC50 for human HepG2 cells to EC50 for HBV	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID125503	Antiproliferative activity was determined against human T-lymphocyte cells -Molt4/C8	2003	Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13	Deoxyribonucleoside 2'- or 3'-mixed disulfides: prodrugs to target ribonucleotide reductase and/or to inhibit HIV reverse transcription.
AID1192289	Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for inhibition of HBV DNA replication in HepG2(2.2.15) cells	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Synthesis of erythrocentaurin derivatives as a new class of hepatitis B virus inhibitors.
AID548837	Antiviral activity against HIV1 isolate 211 harboring reverse transcriptase D67N/K70R/T215F/K219E/M184V mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID341977	Inhibition of HIV1 reverse transcriptase assessed as dCTP level required to form 80% of binary enzyme complex formation with drug-terminated primer in posttranslocation state by site-specific foot printing assay	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.
AID659695	Selectivity ratio of CC50 for human HepG2(2.2.15) cells to IC50 for Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis, structure-activity relationships and biological evaluation of caudatin derivatives as novel anti-hepatitis B virus agents.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID548561	Antiviral activity against HIV1 52534-2 harboring reverse transcriptase 41L//74V/210W/215Y/184V/69SSS mutant gene infected in human PBMC by ELISA	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID423157	Antiviral activity against wild type HIV1 NL4-3 produced from full length pR9deltaApa infected in human MAGIC-5A cells assessed as inhibition of Lac+ foci expression after 40 hrs	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.
AID394465	Tmax in Sprague-Dawley rat assessed as tenofovir level at 30 mg/kg, po administered daily for 7 days measured on day 7	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID548838	Antiviral activity against HIV1 isolate 212 harboring reverse transcriptase L210W/T215Y mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID548557	Antiviral activity against HIV1 7324-1 harboring reverse transcriptase 41L/67N/69N/70R/215F/219E mutant gene infected in human PBMC by ELISA	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1140533	Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of hepatitis B e antigen secretion by ELISA	2014	Bioorganic & medicinal chemistry letters, May-15, Volume: 24, Issue:10	Synthesis, structure-activity relationships and biological evaluation of dehydroandrographolide and andrographolide derivatives as novel anti-hepatitis B virus agents.
AID394457	Antiviral activity against HIV1 LAI in human MT2 cells assessed as inhibition of p24 antigen production by ELISA	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID1186715	Activity of recombinant AK1 (unknown origin) assessed as ADP formation by spectroscopic pyruvate kinase/lactate dehydrogenase coupled assay	2014	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17	Synthesis of {[5-(adenin-9-yl)-2-furyl]methoxy}methyl phosphonic acid and evaluations against human adenylate kinases.
AID548819	Antiviral activity against HIV1 isolate 070 harboring reverse transcriptase 65R/S68G mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID548809	Antiviral activity against HIV1 isolate 215 harboring reverse transcriptase D67N/K70E mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID394477	AUC (0 to infinity) in Sprague-Dawley rat assessed as tenofovir level at 30 mg/kg, po administered daily for 7 days measured on day 7	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID289141	Inhibition of virus-induced cytopathic effect in wild type HIV 3a infected MT2 cells after 5 days	2007	Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16	Synthesis, anti-HIV activity, and resistance profile of thymidine phosphonomethoxy nucleosides and their bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs.
AID1600830	Antiviral activity against hepatitis B virus infected in human HepG2.2.15 cells assessed as reduction in HBeAg secretion at 5 uM incubated for 9 days by ELISA (Rvb = 25.13 +/- 1.93 ng/ml)	2019	Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19	Design, synthesis and biological evaluation of benzamide derivatives as novel NTCP inhibitors that induce apoptosis in HepG2 cells.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID394470	AUC (0 to 24 hrs) in Sprague-Dawley rat assessed as tenofovir level at 30 mg/kg, po administered daily for 7 days measured on day 1	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID322848	Fold resistance, ratio of Lamivudine -adenofir-resistant with HBV reverse transcriptase V173L/L180M/A181V/M204V mutant to wildtype HBV genotype E	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID392513	Antiviral activity against HIV1	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID328845	Inhibition of human MRP3 expressed in MDCK2 cells assessed as increase in intracellular CMF fluorescence at 10 uM by CMFDA assay	2007	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3	Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.
AID105555	In vitro antiviral activity against HIV-1 in MT-4 cells	2001	Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8	Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA.
AID1649794	Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as reduction in viral DNA levels incubated for 6 days by PCR analysis	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	Discovery of (1
AID1186718	Ratio of Kcat to Km for recombinant AK2 (unknown origin)	2014	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17	Synthesis of {[5-(adenin-9-yl)-2-furyl]methoxy}methyl phosphonic acid and evaluations against human adenylate kinases.
AID1561719	Antiviral activity against HIV1 3B infected in human MT4 cells grown under 30 passages in presence of 4-[[4-[[4-[4-[2-cyanovinyl]-2,6-dimethylphenoxy]thieno[3,2-d]pyrimidin-2-yl]amino]-1-piperidyl]methyl]benzenesulfonamide assessed as protection against v
AID548798	Antiviral activity against HIV1 isolate 185 harboring reverse transcriptase T215Y mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID659571	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication by RT-PCR analysis	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis, structure-activity relationships and biological evaluation of caudatin derivatives as novel anti-hepatitis B virus agents.
AID618509	Cytotoxicity against human HEL cells assessed as alteration in cellular morphology by microscopic analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID1599864	Tmax in Sprague-Dawley rat at 20 mg/kg, po administered as single dose and measured after 0.25 to 24 hrs by HPLC analysis	2019	ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6	Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs.
AID322828	Antiviral activity against adenofir-resistant HBV with reverse transcriptase N236T mutant assessed as inhibition of replication	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID328846	Inhibition of human MRP1 expressed in MDCK2 cells assessed as increase in intracellular CMF fluorescence at 10 uM by CMFDA assay	2007	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3	Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.
AID394466	Tmax in Sprague-Dawley rat assessed as tenofovir level at 100 mg/kg, po administered daily for 7 days measured on day 1	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID548564	Selectivity ratio of EC50 for HIV1 7324-1 harboring reverse transcriptase 41L/67N/69N/70R/215F/219E mutant gene infected in human PBMC to EC50 for HIV1 NL 4-3 expressing wild type reverse transcriptase infected in human PBMC	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID98126	Antiproliferative activity was determined against murine leukemia cells (L1210)	2003	Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13	Deoxyribonucleoside 2'- or 3'-mixed disulfides: prodrugs to target ribonucleotide reductase and/or to inhibit HIV reverse transcription.
AID1599863	Half-life in Sprague-Dawley rat at 20 mg/kg, po administered as single dose and measured after 0.25 to 24 hrs by HPLC analysis	2019	ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6	Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1457749	Antiviral activity against CCR5 tropic HIV1 BaL infected in human TZM-bl cells assessed as inhibition of virus-induced cytopathic effect preincubated with cells for 30 mins followed by viral infection measured after 48 hrs in presence of p-24 HIV-1 Ag by	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
AID322833	Fold resistance, ratio of EC50 for lamivudine-adefovir-resistant HBV with reverse transcriptase L180M/M204V/N236T mutant to EC50 for wild-type HBV	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID341368	Antiviral activity against HIV1 NL4-3 replication in human MT4 cells at 0.01 uM pretreated 24 hrs before infection assessed as protection at 1 uM by MTT assay	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.
AID1686646	Retention time in PBS buffer at pH 7.4 using compound 6 by LC-MS analysis	2016	Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22	Next-Generation Reduction Sensitive Lipid Conjugates of Tenofovir: Antiviral Activity and Mechanism of Release.
AID394459	Cmax in Sprague-Dawley rat assessed as tenofovir level at 30 mg/kg, po administered daily for 7 days measured on day 7	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID1192285	Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for inhibition of HBV HBsAg secretion in HepG2(2.2.15) cells	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Synthesis of erythrocentaurin derivatives as a new class of hepatitis B virus inhibitors.
AID341983	Ratio of Kcat to Km for HIV1 reverse transcriptase assessed as nucleotide excision activity in presence of 0.5 uM dCTP	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.
AID478937	Cytotoxicity against human HepG2 cells assessed as inhibition of cellular DNA replication after 14 days	2010	Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10	Discovery of GS-9131: Design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1457748	Antiviral activity against CXCR4-tropic HIV-1 NL4-3 infected in human TZM-bl cells assessed as inhibition of virus-induced cytopathic effect preincubated with cells for 30 mins followed by viral infection measured after 48 hrs in presence of p-24 HIV-1 Ag	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
AID341982	Activity of HIV1 reverse transcriptase M41L/D67N/L210W/T215Y mutant assessed as nucleotide excision activity in presence of 10 uM dCTP	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.
AID82134	Antiviral activity against HIV-1 (IIIB) in CEM (human leukemia) cells.	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity.
AID341986	Ratio of Kcat to Km for HIV1 reverse transcriptase M41L/D67N/L210W/T215Y mutant assessed as nucleotide excision activity in presence of 10 uM dCTP	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID310043	Antiviral activity against Hepatitis B virus infected human HepG2 cells after 9 days by MTT assay	2007	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22	Some new acyclic nucleotide analogues as antiviral prodrugs: synthesis and bioactivities in vitro.
AID557049	Antiviral activity against HIV1 clade G harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID548559	Antiviral activity against HIV1 7303-3 harboring reverse transcriptase 41L/44D/67N/69D/118I/210W/215Y mutant gene infected in human PBMC by ELISA	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID422693	Antiviral activity against HIV1 with reverse transcriptase K70E M184V and K70G M184V mutation by antivirogram biological cutoffs assay relative to wild type HIV1	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.
AID618328	Antiviral activity against HIV1 clade A/E isolate 2165 infected in human H9 cells assessed as inhibition of viral replication	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID1561717	Antiviral activity against HIV1 3B infected in human MT4 cells grown under 30 passages in presence of (E)-4-((4-((4-(4-(2-Cyanovinyl)-2,6-dimethylphenoxy)thieno[2,3- d]pyrimidin-2-yl)amino)piperidin-1-yl)methyl)benzenesulfonamide assessed as protection ag
AID211497	In vitro cytotoxic concentration against MT-4 cells	2001	Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8	Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA.
AID1686656	Cytotoxicity in uninfected human hepG2 assessed as reduction in cell viability by XTT assay	2016	Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22	Next-Generation Reduction Sensitive Lipid Conjugates of Tenofovir: Antiviral Activity and Mechanism of Release.
AID618316	Antiviral activity against 125 TCID50 wild type HIV1 LAI infected in human H9 cells assessed as reduction in viral replication measured on day 7 post infection by reverse transcriptase activity	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID548843	Cellular uptake in human PBMC at 1 uM assessed as TFV-monophosphate level after 24 hrs by MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID142453	Antiviral activity against murine sarcoma virus	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity.
AID618518	Cytotoxicity against human HepAD38 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID341988	Ratio of Kcat/Km for HIV1 reverse transcriptase M41L/D67N/L210W/T215Y mutant to Kcat/Km for wild-type reverse transcriptase assessed as nucleotide excision activity in presence of 10 uM dCTP	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.
AID549089	Cytotoxicity against human bone marrow cells after 24 hrs by BFU-E assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID341981	Activity of HIV1 reverse transcriptase M41L/D67N/L210W/T215Y mutant assessed as nucleotide excision activity in presence of 0.5 uM dCTP	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.
AID548583	Antiviral activity against HIV1 isolate 157 harboring reverse transcriptase L74V/M184V mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID568376	Antiviral activity against HBV infected in human HepG 2.215 cells assessed as inhibition of HBsAg secretion by ELISA	2011	Bioorganic & medicinal chemistry, Feb-15, Volume: 19, Issue:4	Synthesis and biological assay of 4-aryl-6-chloro-quinoline derivatives as novel non-nucleoside anti-HBV agents.
AID341369	Antiviral activity against HIV1 NL4-3 replication in human MT4 cells at 0.01 uM pretreated 48 hrs before infection assessed as protection at 1 uM by MTT assay	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.
AID557022	Antiviral activity against HIV1 CRF01_AE harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID592796	Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 72 hrs by coulter counter analysis	2011	Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7	Synthesis and antiviral activity of N9-[3-fluoro-2-(phosphonomethoxy)propyl] analogues derived from N6-substituted adenines and 2,6-diaminopurines.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID548574	Antiviral activity against HIV1 isolate 060 harboring reverse transcriptase M41L/D67N/K70R/L210W/T215Y/K219E mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID341181	Antiviral activity against X4-HIV1 NL4-3 assessed as inhibition of p24 Gag protein production in human MT4 cells by MTT assay	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.
AID670453	Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication	2012	European journal of medicinal chemistry, Aug, Volume: 54	Design, synthesis, and molecular hybrids of caudatin and cinnamic acids as novel anti-hepatitis B virus agents.
AID1649770	Antiviral activity against HBV infected in human HepAD38 cells assessed as reduction in viral DNA levels incubated for 6 days by PCR analysis	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	Discovery of (1
AID581817	Cytotoxicity against human TZM-bl cells by MTT assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Reverse transcriptase inhibitors as potential colorectal microbicides.
AID1457759	Selectivity ratio of EC50 for tenofovir-resistant CXCR4-tropic HIV-1 NL4-3 harboring reverse transcriptase K65R mutant infected in human MT4 cells to EC50 for CXCR4-tropic HIV-1 NL4-3 infected in human MT4 cells	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
AID1363962	Cytotoxicity in human HepG2.215 cells assessed as reduction in cell viability after 5 days by CCK8 assay	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).
AID322834	Antiviral activity against wild type HBV genotype H assessed as inhibition of replication	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID548566	Selectivity ratio of EC50 for HIV1 7303-3 harboring reverse transcriptase 41L/44D/67N/69D/118I/210W/215Y mutant gene infected in human PBMC to EC50 for HIV1 NL 4-3 expressing wild type reverse transcriptase infected in human PBMC	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID394453	Cytotoxicity against human PBMC by XTT assay	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID422695	Ratio of IC50 for HIV1 with reverse transcriptase K70G mutation to IC50 for wild type HIV1	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.
AID618314	Antiviral activity against 100 TCID50 wild-type Human immunodeficiency virus type 2 ROD infected in C8166 cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID1599867	Oral bioavailability in Sprague-Dawley rat at 20 mg/kg administered as single dose and measured after 0.25 to 24 hrs by HPLC analysis	2019	ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6	Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs.
AID1649795	Cytotoxicity in human HepG2 cells assessed as induction of cell killing	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	Discovery of (1
AID3059	Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity.
AID548576	Antiviral activity against HIV1 isolate 063 harboring reverse transcriptase M41L/D67N/K70R/M184V/L210W/T215Y/K219E mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID394475	AUC (0 to infinity) in Sprague-Dawley rat assessed as tenofovir level at 10 mg/kg, po administered daily for 7 days measured on day 7	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID549087	Cytotoxicity against human HepG2 cells after 24 hrs by XTT assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1363957	Inhibition of hepatitis B virus capsid assembly infected in human HepG2.215 cells assessed as reduction in viral DNA replication measured on day 7 by real time PCR analysis	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).
AID1126831	Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis	2014	European journal of medicinal chemistry, May-06, Volume: 78	PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer.
AID548842	Cellular uptake in human PBMC at 1 uM after 24 hrs by MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID659369	Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for HBV by viral DNA replication detection assay	2012	Bioorganic & medicinal chemistry letters, May-15, Volume: 22, Issue:10	Synthesis, biological evaluation and structure-activity relationships of glycyrrhetinic acid derivatives as novel anti-hepatitis B virus agents.
AID341975	Ratio of Ki/Km for HIV1 reverse transcriptase M41L/D67N/L210W/T215Y mutant to Ki/Km for wild-type reverse transcriptase	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.
AID394472	AUC (0 to 24 hrs) in Sprague-Dawley rat assessed as tenofovir level at 100 mg/kg, po administered daily for 7 days measured on day 1	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID553332	Displacement of Mant-ATP from human recombinant UCK by fluorescence competition assay	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	Novel antiviral C5-substituted pyrimidine acyclic nucleoside phosphonates selected as human thymidylate kinase substrates.
AID581811	Antiviral activity against X4 tropic HIV1 3B infected in human TZM-b1 cells after 2 hrs by luciferase assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Reverse transcriptase inhibitors as potential colorectal microbicides.
AID275078	Stability in pH 5.2 buffer at 37 degC after 72 hrs	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID394471	AUC (0 to 24 hrs) in Sprague-Dawley rat assessed as tenofovir level at 30 mg/kg, po administered daily for 7 days measured on day 7	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID729826	Selectivity index, ratio of CC50 for human HepG2.2.15 cells to IC50 for HBV infected in human HepG2.2.15 cells assessed as inhibition of viral surface antigen production	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Synthesis of hemslecin A derivatives: a new class of hepatitis B virus inhibitors.
AID549085	Cytotoxicity against human ME180 cells after 24 hrs by XTT assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID105556	In vitro antiviral activity against HIV-2 in MT-4 cells	2001	Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8	Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA.
AID548569	Selectivity ratio of EC50 for HIV1 71361-1 harboring reverse transcriptase 65R mutant gene infected in human PBMC to EC50 for HIV1 NL 4-3 expressing wild type reverse transcriptase infected in human PBMC	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID548821	Antiviral activity against HIV1 isolate 153 harboring reverse transcriptase L74V mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID618517	Cytotoxicity against human HuH7 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID618448	Antiviral activity against TK-deficient and ACR-resistant Herpes simplex virus type 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID275081	Stability in pH 9.0 buffer at 37 degC after 72 hrs	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID1186717	Ratio of Kcat to Km for recombinant AK1 (unknown origin)	2014	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17	Synthesis of {[5-(adenin-9-yl)-2-furyl]methoxy}methyl phosphonic acid and evaluations against human adenylate kinases.
AID322830	Antiviral activity against lamivudine-adefovir-resistant HBV with reverse transcriptase L180M/M204V/N236T mutant assessed as inhibition of replication	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID581821	Antiviral activity against X4 tropic HIV1 NL4.3 infected in human PBMC assessed as inhibition of p24 antigen production after 2 hrs by ELISA	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Reverse transcriptase inhibitors as potential colorectal microbicides.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID568377	Selectivity index, CC50 for human HepG 2.215 cells to IC50 for HBV infected in human HepG 2.215 cells assessed as inhibition of HBsAg secretion	2011	Bioorganic & medicinal chemistry, Feb-15, Volume: 19, Issue:4	Synthesis and biological assay of 4-aryl-6-chloro-quinoline derivatives as novel non-nucleoside anti-HBV agents.
AID670447	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral surface antigen secretion by ELISA	2012	European journal of medicinal chemistry, Aug, Volume: 54	Design, synthesis, and molecular hybrids of caudatin and cinnamic acids as novel anti-hepatitis B virus agents.
AID320329	Antiviral activity against HIV with reverse transcriptase 6TAMs mutation assessed as fold resistance relative to wild type	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3	Synthesis and anti-HIV activity of GS-9148 (2'-Fd4AP), a novel nucleoside phosphonate HIV reverse transcriptase inhibitor.
AID95008	Antiviral activity against KOS strain of HSV-1 in E6SM cells.	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity.
AID1832362	Inhibition of human recombinant CYP3A4 expressed in insect microsome using 7-benzyloxy-4-trifluoromethylcoumarin as a substrate incubated for 30 mins followed by addition of NADPH regenerating system measured immediately by fluorescence based analysis	2021	Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17	ω-Functionalized Lipid Prodrugs of HIV NtRTI Tenofovir with Enhanced Pharmacokinetic Properties.
AID393070	Antiviral activity against HIV1 3a infected human MT2 cells assessed as inhibition of viral-induced cytopathic effect after 3 days by XTT assay	2009	Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4	Design, synthesis, and anti-HIV activity of 4'-modified carbocyclic nucleoside phosphonate reverse transcriptase inhibitors.
AID1140532	Selectivity index, ratio of CC50 for human HepG2.2.15 cells to IC50 for HBV infected in human HepG2.2.15 cells assessed as inhibition of hepatitis B surface antigen secretion	2014	Bioorganic & medicinal chemistry letters, May-15, Volume: 24, Issue:10	Synthesis, structure-activity relationships and biological evaluation of dehydroandrographolide and andrographolide derivatives as novel anti-hepatitis B virus agents.
AID544652	Ratio of CC50 for CHO cells to CC50 for CHO cells expressing hOAT1 after 120 hrs by Cell-Titer Glo assay	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation.
AID289143	Cytotoxicity against MT2 cells	2007	Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16	Synthesis, anti-HIV activity, and resistance profile of thymidine phosphonomethoxy nucleosides and their bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID557021	Antiviral activity against HIV1 CRF02_AG harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID394485	Elimination half life in Sprague-Dawley rat assessed as tenofovir level at 100 mg/kg, po administered daily for 7 days measured on day 7	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID729824	Selectivity index, ratio of CC50 for human HepG2.2.15 cells to IC50 for HBV infected in human HepG2.2.15 cells assessed as inhibition of viral e antigen production	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Synthesis of hemslecin A derivatives: a new class of hepatitis B virus inhibitors.
AID1140530	Cytotoxicity against human HepG2.2.15 cells by MTT assay	2014	Bioorganic & medicinal chemistry letters, May-15, Volume: 24, Issue:10	Synthesis, structure-activity relationships and biological evaluation of dehydroandrographolide and andrographolide derivatives as novel anti-hepatitis B virus agents.
AID670452	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication by PCR analysis	2012	European journal of medicinal chemistry, Aug, Volume: 54	Design, synthesis, and molecular hybrids of caudatin and cinnamic acids as novel anti-hepatitis B virus agents.
AID1126841	Cytostatic activity against human HeLa cells after 72 hrs by coulter counting analysis	2014	European journal of medicinal chemistry, May-06, Volume: 78	PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer.
AID1126838	Cytotoxicity against HEL cells assessed as change in cellular morphology by microscopic analysis	2014	European journal of medicinal chemistry, May-06, Volume: 78	PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer.
AID1832358	Antiviral activity against human immunodeficiency virus expressed in HEK293T cells coexpressing firefly luciferase gene incubated for 48 hrs in absence of HSA by Bright-Glo luciferase assay	2021	Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17	ω-Functionalized Lipid Prodrugs of HIV NtRTI Tenofovir with Enhanced Pharmacokinetic Properties.
AID557047	Antiviral activity against HIV1 clade D harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID670448	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral e antigen secretion by ELISA	2012	European journal of medicinal chemistry, Aug, Volume: 54	Design, synthesis, and molecular hybrids of caudatin and cinnamic acids as novel anti-hepatitis B virus agents.
AID1916051	Antiviral activity against HIV-1 IIIb infected in human MT2 cells assessed as reduction in virus induced cytopathic effect and measured after 5 days by XTT assay	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	Tailor-made amino acids in the design of small-molecule blockbuster drugs.
AID1457757	Selectivity index, ratio of CC50 for human PHA-stimulated PBMCs to IC50 for CCR5 tropic HIV1 BaL infected in human PHA-stimulated PBMC	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
AID548568	Selectivity ratio of EC50 for HIV1 52534-2 harboring reverse transcriptase 41L//74V/210W/215Y/184V/69SSS mutant gene infected in human PBMC to EC50 for HIV1 NL 4-3 expressing wild type reverse transcriptase infected in human PBMC	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID618319	Cytotoxicity against PAP-activated human PBMC on day 7 by MTT assay	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID548810	Antiviral activity against HIV1 isolate 217 harboring reverse transcriptase D67N/K70E/M184V mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1561721	Resistance index, ratio of EC50 for antiviral activity against HIV1 3B infected in human MT4 cells grown under 30 passages in presence of 4-[[4-[[4-(4-cyano-2,6-dimethylphenoxy)thieno[3,2-d]pyrimidin-2-yl]amino]-1-piperidyl]methyl]benzenesulfonamide to EC
AID320328	Antiviral activity against HIV with reverse transcriptase K65R mutation assessed as fold resistance relative to wild type	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3	Synthesis and anti-HIV activity of GS-9148 (2'-Fd4AP), a novel nucleoside phosphonate HIV reverse transcriptase inhibitor.
AID568379	Selectivity index, CC50 for human HepG 2.215 cells to IC50 for HBV infected in human HepG 2.215 cells assessed as inhibition of HBeAg secretion	2011	Bioorganic & medicinal chemistry, Feb-15, Volume: 19, Issue:4	Synthesis and biological assay of 4-aryl-6-chloro-quinoline derivatives as novel non-nucleoside anti-HBV agents.
AID549072	Cellular uptake in PHA/IL-2-stimulated human PBMC at 10 uM assessed as TFV-diphosphate after 24 hrs by MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1192286	Inhibition of HBV HBeAg secretion in HepG2(2.2.15) cells after 72 hrs by ELISA method	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Synthesis of erythrocentaurin derivatives as a new class of hepatitis B virus inhibitors.
AID1599856	Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as reduction in cytoplasmic DNA synthesis by reed and munch method	2019	ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6	Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs.
AID581825	Antiviral activity against HIV1 isolate 8415-2 harboring reverse transcriptase K65R mutant co-expressing M184V mutant infected in human TZM-b1 cells after 2 hrs by luciferase assays	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Reverse transcriptase inhibitors as potential colorectal microbicides.
AID392536	Antiviral activity against Vaccinia virus	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID548556	Antiviral activity against HIV1 NL 4-3 expressing wild type reverse transcriptase infected in human PBMC by ELISA	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID548562	Antiviral activity against HIV1 71361-1 harboring reverse transcriptase 65R mutant gene infected in human PBMC by ELISA	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID557020	Antiviral activity against HIV1 clade B harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID341371	Ratio of EC50 for X4-HIV1MDR/C in human PHA-PBMC to EC50 for X4-HIV1NL4-3 in human MT4 cells	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.
AID317371	Inhibition of wild type HIV reverse transcriptase	2007	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 17, Issue:24	Synthesis, anti-HIV activity, and resistance profiles of ribose modified nucleoside phosphonates.
AID548839	Antiviral activity against HIV1 isolate 215 harboring reverse transcriptase D67N/K70E mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1126836	Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity	2014	European journal of medicinal chemistry, May-06, Volume: 78	PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer.
AID1193398	Selectivity index, ratio of CC50 for human HepG2.2.15 cells to IC50 for decrease in hepatitis B viral DNA replication in human HepG2(2.2.15) cells	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Isolation, synthesis and anti-hepatitis B virus evaluation of p-hydroxyacetophenone derivatives from Artemisia capillaris.
AID1193393	Antiviral activity against hepatitis B viral in human HepG2.2.15 cells assessed as surface antigen HBsAg secretion after 72 hrs by ELISA	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Isolation, synthesis and anti-hepatitis B virus evaluation of p-hydroxyacetophenone derivatives from Artemisia capillaris.
AID394476	AUC (0 to infinity) in Sprague-Dawley rat assessed as tenofovir level at 30 mg/kg, po administered daily for 7 days measured on day 1	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID81263	Effective concentration against cytopathicity of HIV-1 strain (HTLV IIIB) in CEM cell line	2003	Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13	Deoxyribonucleoside 2'- or 3'-mixed disulfides: prodrugs to target ribonucleotide reductase and/or to inhibit HIV reverse transcription.
AID549082	Cytotoxicity against PHA/IL-2-stimulated human PBMC after 24 hrs by XTT assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID548834	Antiviral activity against HIV1 isolate 203 harboring reverse transcriptase M41L/L210W/T215Y/M184V mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID322849	Fold resistance, ratio of lamivudine -adenofir-resistant with HBV reverse transcriptase V173L/L180M/A181V/M204V/N236T mutant to wild-type HBV genotype E	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID659569	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as suppression of HBsAg secretion by ELISA	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis, structure-activity relationships and biological evaluation of caudatin derivatives as novel anti-hepatitis B virus agents.
AID72410	Antiviral activity against vaccinia virus in HEL (human erythroleukemia) cells.	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity.
AID659366	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in hepatitis B e-antigen release	2012	Bioorganic & medicinal chemistry letters, May-15, Volume: 22, Issue:10	Synthesis, biological evaluation and structure-activity relationships of glycyrrhetinic acid derivatives as novel anti-hepatitis B virus agents.
AID344319	Antiviral activity against HIV1 3B in CEM/0 cells assessed as inhibition of virus-induced cytopathogenicity	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	Anti-retroviral and cytostatic activity of 2',3'-dideoxyribonucleoside 3'-disulfides.
AID341984	Ratio of Kcat to Km for HIV1 reverse transcriptase assessed as nucleotide excision activity in presence of 10 uM dCTP	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.
AID548573	Antiviral activity against HIV1 isolate 058 harboring reverse transcriptase M41L/D67N/K70R/L210W/T215F/K219Q mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1686657	Therapeutic index, ratio of CC50 for uninfected human HepG2 cells to EC50 for HBV infected in human HepG2 cells	2016	Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22	Next-Generation Reduction Sensitive Lipid Conjugates of Tenofovir: Antiviral Activity and Mechanism of Release.
AID548826	Antiviral activity against HIV1 isolate 174 harboring reverse transcriptase M184V mutant gene obtained as site-directed mutant of NL4-3 by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID618317	Antiviral activity against 6250 TCID50 wild type HIV1 LAI infected in human H9 cells assessed as reduction in viral replication measured on day 7 post infection by reverse transcriptase activity	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID394478	AUC (0 to infinity) in Sprague-Dawley rat assessed as tenofovir level at 100 mg/kg, po administered daily for 7 days measured on day 1	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID341978	Binding affinity to ternary complex of HIV1 reverse transcriptase with primer/template in presence of dCTP substrate	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.
AID1394856	Cytotoxicity against human PBMC assessed as reduction in cell growth after 7 days by MTT assay	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Synthesis of 3'-halo-5'-norcarbocyclic nucleoside phosphonates as potent anti-HIV agents.
AID618325	Antiviral activity against HIV1 clade C isolate 2914 infected in human H9 cells assessed as inhibition of viral replication	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID341182	Antiviral activity against R5-HIV1MDR/C assessed as inhibition of p24 Gag protein production in human PHA-PBMC by ELISA	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.
AID393069	Inhibition on HIV1 reverse transcriptase p66/p51	2009	Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4	Design, synthesis, and anti-HIV activity of 4'-modified carbocyclic nucleoside phosphonate reverse transcriptase inhibitors.
AID322843	Antiviral activity against entecavir-resistant HBV with reverse transcriptase L180M/S202G/M204V mutant	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID405582	Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Selective inhibition of porcine endogenous retrovirus replication in human cells by acyclic nucleoside phosphonates.
AID558396	Ratio of drug level in HIV-infected pregnant woman amniotic fluid to maternal blood plasma at 300 mg, po QD by LC/MS/MS analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.
AID618315	Cytotoxicity against human CEM cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID1599862	AUC(0 to infinity) in Sprague-Dawley rat at 5 mg/kg, iv	2019	ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6	Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs.
AID1264923	Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis	2015	European journal of medicinal chemistry, Dec-01, Volume: 106	Tryptophan dendrimers that inhibit HIV replication, prevent virus entry and bind to the HIV envelope glycoproteins gp120 and gp41.
AID322836	Antiviral activity against lamivudine-resistant HBV with reverse transcriptase L180M/M204V mutant	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID47278	Antiproliferative activity was determined against human T-lymphocyte cells-CEM	2003	Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13	Deoxyribonucleoside 2'- or 3'-mixed disulfides: prodrugs to target ribonucleotide reductase and/or to inhibit HIV reverse transcription.
AID1774088	Anti-HIV activity against HIV infected in human MT2 cells using infectious supernatant from NL4.3 transfected 293T cells assessed as luminescence measured after 48 hrs by recombinant virus assay	2021	Journal of natural products, 10-22, Volume: 84, Issue:10	Withanolide-Type Steroids from
AID548581	Antiviral activity against HIV1 isolate 071 harboring reverse transcriptase 65R/S68N/184V mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID394456	Cytotoxicity against human MT2 cells	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID394249	Cmax in Sprague-Dawley rat assessed as tenofovir level at 10 mg/kg, po administered daily for 7 days measured on day 7	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID548587	Antiviral activity against HIV1 isolate 174 harboring reverse transcriptase M184V mutant gene obtained as site-directed mutant of NL4-3 by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID548829	Antiviral activity against HIV1 isolate 188 harboring reverse transcriptase T215Y/M184V mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID341991	Inhibition of HIV1 reverse transcriptase M41L/D67N/L210W/T215Y mutant assessed as dCTP level required to form 50% of binary enzyme complex formation with drug-terminated primer in posttranslocation state by site-specific foot printing assay	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.
AID544650	Cytotoxicity against CHO cells after 120 hrs by Cell-Titer Glo assay	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation.
AID659363	Cytotoxicity against human HepG2(2.2.15) cells	2012	Bioorganic & medicinal chemistry letters, May-15, Volume: 22, Issue:10	Synthesis, biological evaluation and structure-activity relationships of glycyrrhetinic acid derivatives as novel anti-hepatitis B virus agents.
AID581812	Antiviral activity against R5 tropic HIV1 BaL infected in human TZM-b1 cells after 2 hrs by luciferase assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Reverse transcriptase inhibitors as potential colorectal microbicides.
AID1774089	Cytotoxicity against human MT2 cells assessed as cell viability by CellTiter Glo assay	2021	Journal of natural products, 10-22, Volume: 84, Issue:10	Withanolide-Type Steroids from
AID394484	Elimination half life in Sprague-Dawley rat assessed as tenofovir level at 100 mg/kg, po administered daily for 7 days measured on day 1	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID548801	Antiviral activity against HIV1 isolate 194 harboring reverse transcriptase M41L/T215Y/M184V mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1695188	Antiviral activity against HIV1 LAI infected in human HeLa-P4 cells harboring a stably integrated LTR-linked LacZ reporter gene assessed as inhibition of viral replication preincubated with cells for 2 hrs followed by viral infection and measured after 48	2020	RSC medicinal chemistry, May-01, Volume: 11, Issue:5	Discovery, SAR study and ADME properties of methyl 4-amino-3-cyano-1-(2-benzyloxyphenyl)-1
AID478935	Cytotoxicity against human MT2 cells after 5 days by XTT assay	2010	Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10	Discovery of GS-9131: Design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148.
AID394450	Cytotoxicity against human HepG2(2.2.15) cells after 24 hrs by neutral red uptake assay	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID394482	Elimination half life in Sprague-Dawley rat assessed as tenofovir level at 30 mg/kg, po administered daily for 7 days measured on day 1	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID699541	Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID592797	Cytotoxicity against human CEM cells assessed as minimum concentration required for morphological alteration by microscopic analysis	2011	Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7	Synthesis and antiviral activity of N9-[3-fluoro-2-(phosphonomethoxy)propyl] analogues derived from N6-substituted adenines and 2,6-diaminopurines.
AID1197621	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Linear and branched alkyl-esters and amides of gallic acid and other (mono-, di- and tri-) hydroxy benzoyl derivatives as promising anti-HCV inhibitors.
AID581816	Antiviral activity against X4 tropic HIV1 RF infected in human PBMC assessed as inhibition of p24 antigen production after 2 hrs by ELISA	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Reverse transcriptase inhibitors as potential colorectal microbicides.
AID322851	Fold resistance, ratio of entecavir-resistant HBV with reverse transcriptase L180M/S202G/M204V mutant to wild-type HBV genotype H	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID1290411	Antiviral activity against HIV1 NL4.3 infected in human TZM-bl cells using compound gel formulation incubated for 72 hrs by luciferase based transwell assay	2016	Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6	Development and in Vitro Evaluation of a Microbicide Gel Formulation for a Novel Non-Nucleoside Reverse Transcriptase Inhibitor Belonging to the N-Dihydroalkyloxybenzyloxopyrimidines (N-DABOs) Family.
AID548822	Antiviral activity against HIV1 isolate 157 harboring reverse transcriptase L74V/M184V mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1832361	Inhibition of human recombinant CYP2D6 expressed in insect microsome using (3-[2-(N,N-dimethyl-N-methylammonium)-ethyl]-7-methoxy-4-methylcoumarin iodide as a substrate incubated for 30 mins followed by addition of NADPH regenerating system measured immed	2021	Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17	ω-Functionalized Lipid Prodrugs of HIV NtRTI Tenofovir with Enhanced Pharmacokinetic Properties.
AID612651	Activity of recombinant human ADAL1 expressed in Escherichia coli by UV-spectrophotometry	2011	Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16	Adenosine deaminase-like protein 1 (ADAL1): characterization and substrate specificity in the hydrolysis of N(6)- or O(6)-substituted purine or 2-aminopurine nucleoside monophosphates.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID548571	Antiviral activity against HIV1 isolate 056 expressing wild type reverse transcriptase gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1774090	Selectivity index, ratio of CC50 for human MT2 cells to IC50 for Anti-HIV activity against HIV	2021	Journal of natural products, 10-22, Volume: 84, Issue:10	Withanolide-Type Steroids from
AID322846	Fold resistance, ratio of lamivudine-resistant HBV with reverse transcriptase V173L/L180/M204V mutant to wild-type HBV genotype H	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID557048	Antiviral activity against HIV1 clade F1 harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID394469	AUC (0 to 24 hrs) in Sprague-Dawley rat assessed as tenofovir level at 10 mg/kg, po administered daily for 7 days measured on day 7	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID275082	Stability in pH 11.5 buffer at 37 degC after 72 hrs	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID618447	Antiviral activity against Herpes simplex virus type 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID1636524	Antiviral activity against HIV1 infected in human PBMC assessed as inhibition of viral replication by measuring reverse transcriptase activity in cell supernatant preincubated with cells followed by viral infection measured after 7 days by radioactive inc	2016	Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15	Reduction Sensitive Lipid Conjugates of Tenofovir: Synthesis, Stability, and Antiviral Activity.
AID548585	Antiviral activity against HIV1 isolate 162 harboring reverse transcriptase A62V/V75I/F77L/Y115F/F116Y/Q151M/M184V mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID328843	Inhibition of human MRP3 expressed in MDCK2 cells assessed as increase in intracellular CMF fluorescence by CMFDA assay	2007	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3	Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.
AID1457788	Antiviral activity against CXCR4-tropic HIV-1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by XTT dye based assay	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
AID659570	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as suppression of HbeAg secretion by ELISA	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis, structure-activity relationships and biological evaluation of caudatin derivatives as novel anti-hepatitis B virus agents.
AID1320780	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathic effect after 5 days by XTT assay	2016	Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20	Amidate Prodrugs of Deoxythreosyl Nucleoside Phosphonates as Dual Inhibitors of HIV and HBV Replication.
AID1686653	Cytotoxicity in uninfected human PBMC assessed as reduction in cell viability by XTT assay	2016	Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22	Next-Generation Reduction Sensitive Lipid Conjugates of Tenofovir: Antiviral Activity and Mechanism of Release.
AID548563	Antiviral activity against HIV1 8415-2 harboring reverse transcriptase 65R/184V mutant gene infected in human PBMC by ELISA	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID581823	Cytotoxicity against human PBMC by MTT assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Reverse transcriptase inhibitors as potential colorectal microbicides.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1126837	Antiviral activity against Vaccinia virus Lederle infected in HEL cells assessed as inhibition of virus-induced cytopathicity	2014	European journal of medicinal chemistry, May-06, Volume: 78	PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer.
AID322850	Fold resistance, ratio of Lamivudine -adenofir-resistant with HBV reverse transcriptase V173L/L180M/A181V/N236T mutant to wildtype HBV genotype E	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID1832359	Therapeutic index, ratio of CC50 for cytotoxicity against HEK293T cells to IC50 for antiviral activity against human immunodeficiency virus expressed in HEK293T cells	2021	Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17	ω-Functionalized Lipid Prodrugs of HIV NtRTI Tenofovir with Enhanced Pharmacokinetic Properties.
AID322825	Inhibition of wild type HBV replication in Huh7 cells	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID548807	Antiviral activity against HIV1 isolate 211 harboring reverse transcriptase D67N/K70R/T215F/K219E/M184V mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1193397	Antiviral activity against hepatitis B viral in human HepG2.2.15 cells assessed as decrease in viral DNA replication treated for 7 days by real time PCR analysis	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Isolation, synthesis and anti-hepatitis B virus evaluation of p-hydroxyacetophenone derivatives from Artemisia capillaris.
AID478949	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by XTT assay	2010	Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10	Discovery of GS-9131: Design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148.
AID1457755	Selectivity index, ratio of CC50 for human TZM-bl cells to EC50 for CCR5 tropic HIV1 BaL infected in human TZM-bl cells	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
AID548579	Antiviral activity against HIV1 isolate 069 harboring reverse transcriptase D67E/T69SSG/V75M/M184V/L210W/T215Y mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1192284	Inhibition of HBV HBsAg secretion in HepG2(2.2.15) cells after 72 hrs by ELISA method	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Synthesis of erythrocentaurin derivatives as a new class of hepatitis B virus inhibitors.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1140536	Selectivity index, ratio of CC50 for human HepG2.2.15 cells to IC50 for HBV infected in human HepG2.2.15 cells assessed as inhibition of DNA replication	2014	Bioorganic & medicinal chemistry letters, May-15, Volume: 24, Issue:10	Synthesis, structure-activity relationships and biological evaluation of dehydroandrographolide and andrographolide derivatives as novel anti-hepatitis B virus agents.
AID341980	Activity of HIV1 reverse transcriptase assessed as nucleotide excision activity in presence of 10 uM dCTP	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.
AID422694	Antiviral activity against HIV1 with reverse transcriptase K70E M184V and K70G M184V mutation by vircotype clinical cutoffs assay relative to wild type HIV1	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID729825	Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of viral e antigen production	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Synthesis of hemslecin A derivatives: a new class of hepatitis B virus inhibitors.
AID1599861	Half-life in Sprague-Dawley rat at 5 mg/kg, iv	2019	ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6	Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs.
AID328844	Inhibition of human MRP2 expressed in MDCK2 cells assessed as increase in intracellular CMF fluorescence at 10 uM by CMFDA assay	2007	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3	Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.
AID548812	Antiviral activity against HIV1 isolate 058 harboring reverse transcriptase M41L/D67N/K70R/L210W/T215F/K219Q mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID394467	Tmax in Sprague-Dawley rat assessed as tenofovir level at 100 mg/kg, po administered daily for 7 days measured on day 7	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID322827	Antiviral activity against wild type HBV assessed as inhibition of replication	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID581815	Antiviral activity against R5 tropic HIV1 R8.BaL infected in human TZM-b1 cells after 2 hrs by luciferase assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Reverse transcriptase inhibitors as potential colorectal microbicides.
AID548567	Selectivity ratio of EC50 for HIV1 1617-1 harboring reverse transcriptase 69K/70G/75I/77L/116Y/151M/184V mutant gene infected in human PBMC to EC50 for HIV1 NL 4-3 expressing wild type reverse transcriptase infected in human PBMC	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID548846	Cellular uptake in human PBMC at 10 uM assessed as TFV-monophosphate after 24 hrs by MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID289145	Antiviral activity against HIV1 with reverse transcriptase K65R mutation assessed as reduction of potency relative to wild type	2007	Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16	Synthesis, anti-HIV activity, and resistance profile of thymidine phosphonomethoxy nucleosides and their bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs.
AID328841	Inhibition of human MRP1 expressed in MDCK2 cells assessed as increase in intracellular CMF fluorescence by CMFDA assay	2007	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3	Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID544651	Cytotoxicity against CHO cells expressing hOAT1 after 120 hrs by Cell-Titer Glo assay	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation.
AID83255	Antiviral activity against HIV-2 (ROD) in CEM (human leukemia) cells.	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity.
AID618449	Antiviral activity against Herpes simplex virus type 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID394463	Tmax in Sprague-Dawley rat assessed as tenofovir level at 10 mg/kg, po administered daily for 7 days measured on day 7	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID549088	Cytotoxicity against human bone marrow cells after 24 hrs by GM-CFU assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID659692	Cytotoxicity against human HepG2(2.2.15) cells by MTT assay	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis, structure-activity relationships and biological evaluation of caudatin derivatives as novel anti-hepatitis B virus agents.
AID1600828	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19	Design, synthesis and biological evaluation of benzamide derivatives as novel NTCP inhibitors that induce apoptosis in HepG2 cells.
AID47263	In vitro antiviral activity against HIV-2 in CEM cells	2001	Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8	Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA.
AID659364	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in hepatitis B surface antigen release	2012	Bioorganic & medicinal chemistry letters, May-15, Volume: 22, Issue:10	Synthesis, biological evaluation and structure-activity relationships of glycyrrhetinic acid derivatives as novel anti-hepatitis B virus agents.
AID1600829	Antiviral activity against hepatitis B virus infected in human HepG2.2.15 cells assessed as HBsAg secretion at 5 uM incubated for 9 days by ELISA (Rvb = 8.41+/- 0.54 ng/ml)	2019	Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19	Design, synthesis and biological evaluation of benzamide derivatives as novel NTCP inhibitors that induce apoptosis in HepG2 cells.
AID1192288	Inhibition of HBV DNA replication in HepG2(2.2.15) cells exposed to fresh medium supplemented with compound every other day for additional 5 days by real-time PCR-fluorescent probing method	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Synthesis of erythrocentaurin derivatives as a new class of hepatitis B virus inhibitors.
AID393072	Antiviral activity against HIV1 3a with reverse transcriptase K65R mutation in human MT2 cells assessed as inhibition of viral-induced cytopathic effect by XTT assay relative to wild type	2009	Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4	Design, synthesis, and anti-HIV activity of 4'-modified carbocyclic nucleoside phosphonate reverse transcriptase inhibitors.
AID1599855	Cytotoxicity against human HepG2.2.15 cells infected with HBV	2019	ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6	Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs.
AID618431	Antiviral activity against HIV1 clade G isolate 3187 infected in human H9 cells assessed as inhibition of viral replication	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID618318	Antiviral activity against 100 TCID50 wild type HIV1 LAI infected in human PBMC assessed as reduction in viral replication measured on day 7 post infection by reverse transcriptase activity	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID322842	Antiviral activity against lamivudine-adenofir-resistant HBV with reverse transcriptase V173L/L180M/A181V/N236T mutant	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID394462	Tmax in Sprague-Dawley rat assessed as tenofovir level at 10 mg/kg, po administered daily for 7 days measured on day 1	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID670451	Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral e antigen secretion	2012	European journal of medicinal chemistry, Aug, Volume: 54	Design, synthesis, and molecular hybrids of caudatin and cinnamic acids as novel anti-hepatitis B virus agents.
AID618450	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID548578	Antiviral activity against HIV1 isolate 067 harboring reverse transcriptase A62V/D67G/T69SVG/V75I/T215I mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID557052	Antiviral activity against NRTI-resistant HIV1 harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID322844	Fold resistance, ratio of lamivudine-resistant HBV with reverse transcriptase L180M/M204V mutant to wild-type HBV genotype E	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID317369	Antiviral activity against wild type HIV	2007	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 17, Issue:24	Synthesis, anti-HIV activity, and resistance profiles of ribose modified nucleoside phosphonates.
AID625276	FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI	2011	Drug discovery today, Aug, Volume: 16, Issue:15-16	FDA-approved drug labeling for the study of drug-induced liver injury.
AID1140534	Selectivity index, ratio of CC50 for human HepG2.2.15 cells to IC50 for HBV infected in human HepG2.2.15 cells assessed as inhibition of hepatitis B e antigen secretion	2014	Bioorganic & medicinal chemistry letters, May-15, Volume: 24, Issue:10	Synthesis, structure-activity relationships and biological evaluation of dehydroandrographolide and andrographolide derivatives as novel anti-hepatitis B virus agents.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID592792	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced syncytium formation after 4 to 5 days by microscopic analysis	2011	Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7	Synthesis and antiviral activity of N9-[3-fluoro-2-(phosphonomethoxy)propyl] analogues derived from N6-substituted adenines and 2,6-diaminopurines.
AID557053	Antiviral activity against NRTI-, PI-resistant HIV1 harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID394481	Elimination half life in Sprague-Dawley rat assessed as tenofovir level at 10 mg/kg, po administered daily for 7 days measured on day 7	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID548582	Antiviral activity against HIV1 isolate 153 harboring reverse transcriptase L74V mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID72409	Antiviral activity against G strain of HSV-2 in E6SM cells.	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity.
AID313874	Antiviral activity against HIV1 3B in MT2 cells	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3	Synthesis and anti-HIV activity of 2'-fluorine modified nucleoside phosphonates: analogs of GS-9148.
AID322831	Fold resistance, ratio of EC50 for adenofir-resistant HBV with reverse transcriptase N236T mutant to EC50 for wild-type HBV	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID618323	Antiviral activity against HIV1 clade B isolate 2056 infected in human H9 cells assessed as inhibition of viral replication	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID394479	AUC (0 to infinity) in Sprague-Dawley rat assessed as tenofovir level at 100 mg/kg, po administered daily for 7 days measured on day 7	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID729822	Selectivity index, ratio of CC50 for human HepG2.2.15 cells to IC50 for HBV infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Synthesis of hemslecin A derivatives: a new class of hepatitis B virus inhibitors.
AID275079	Stability in pH 7.4 buffer at 37 degC after 72 hrs	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID659365	Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for HBV by hepatitis B surface antigen release detection assay	2012	Bioorganic & medicinal chemistry letters, May-15, Volume: 22, Issue:10	Synthesis, biological evaluation and structure-activity relationships of glycyrrhetinic acid derivatives as novel anti-hepatitis B virus agents.
AID544648	Activity of human OAT1 transfected in CHO cells	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation.
AID1561718	Antiviral activity against HIV1 3B infected in human MT4 cells grown under 30 passages in presence of 4-[[4-[[4-(4-cyano-2,6-dimethylphenoxy)thieno[3,2-d]pyrimidin-2-yl]amino]-1-piperidyl]methyl]benzenesulfonamide assessed as protection against virus-indu
AID341372	Antiviral activity against R5-HIV1MDR/G assessed as inhibition of p24 Gag protein in human PHA-PBMC by ELISA relative to X4-HIV1NL4-3	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.
AID548832	Antiviral activity against HIV1 isolate 200 harboring reverse transcriptase M41L/L210W/T215Y mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1649793	Antiviral activity against multidrug-resistant HBV infected in human HepG2.1403F cells assessed as reduction in viral replication incubated for 6 days by PCR analysis	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	Discovery of (1
AID1197622	Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Linear and branched alkyl-esters and amides of gallic acid and other (mono-, di- and tri-) hydroxy benzoyl derivatives as promising anti-HCV inhibitors.
AID317374	Antiviral activity against HIV with reverse transcriptase K65R mutation in MT4 cells assessed as fold resistance relative to wild type	2007	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 17, Issue:24	Synthesis, anti-HIV activity, and resistance profiles of ribose modified nucleoside phosphonates.
AID394452	Selectivity index, ratio of CC50 for human PBMC to EC50 for HIV1 clade B HT/92/599 isolate	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID548823	Antiviral activity against HIV1 isolate 160 harboring reverse transcriptase S68G/V75(I/T)/F77L/Y115F/F116Y /Q151M mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID317373	Antiviral activity against HIV with reverse transcriptase 6TAMs mutation in MT4 cells assessed as fold resistance relative to wild type	2007	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 17, Issue:24	Synthesis, anti-HIV activity, and resistance profiles of ribose modified nucleoside phosphonates.
AID548814	Antiviral activity against HIV1 isolate 061 harboring reverse transcriptase M41L/D67N/K70R/M184V/L210W/T215Y/K219E mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID322841	Antiviral activity against Lamivudine -adenofir-resistant HBV with reverse transcriptase V173L/L180M/A181V/M204V/N236T mutant	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID310044	Antiviral activity against HIV1 3B in MT4 cells after 4 days by MTT assay	2007	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22	Some new acyclic nucleotide analogues as antiviral prodrugs: synthesis and bioactivities in vitro.
AID549090	Cmax in PHA/IL-2-stimulated human PBMC	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID548825	Antiviral activity against HIV1 isolate 166 harboring reverse transcriptase L74V mutant gene obtained as site-directed mutant of NL4-3 by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID341179	Antiviral activity against R5-HIV1Ba-L assessed as inhibition of p24 Gag protein production in human PHA-PBMC by ELISA	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.
AID548836	Antiviral activity against HIV1 isolate 206 harboring reverse transcriptase D67N/K70R mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1126834	Antiviral activity against Herpes simplex virus KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity	2014	European journal of medicinal chemistry, May-06, Volume: 78	PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer.
AID322837	Antiviral activity against lamivudine-resistant HBV with reverse transcriptase L180M/A181V mutant	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID548828	Antiviral activity against HIV1 isolate 185 harboring reverse transcriptase T215Y mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID549068	Cellular uptake in PHA/IL-2-stimulated human PBMC at 1 uM assessed as TFV-monophosphate level after 24 hrs by MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1126835	Antiviral activity against Herpes simplex virus G infected in HEL cells assessed as inhibition of virus-induced cytopathicity	2014	European journal of medicinal chemistry, May-06, Volume: 78	PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer.
AID310047	Therapeutic index, Ratio of TC50 for human HepG2 cells to IC50 for HBV-infected human HepG2 cells	2007	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22	Some new acyclic nucleotide analogues as antiviral prodrugs: synthesis and bioactivities in vitro.
AID423281	Selectivity ratio of EC50 for multinucleoside-resistant HIV1 NL4-3 harboring A62V, V75I, F77L, F116Y, Q151M mutation in viral reverse transcriptase to EC50 for wild type HIV1 NL4-3	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.
AID1599860	Clearance in Sprague-Dawley rat at 5 mg/kg, iv	2019	ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6	Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs.
AID322838	Antiviral activity against lamivudine-resistant HBV with reverse transcriptase V173L/L180/M204V mutant	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID394474	AUC (0 to infinity) in Sprague-Dawley rat assessed as tenofovir level at 10 mg/kg, po administered daily for 7 days measured on day 1	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID557045	Antiviral activity against HIV1 CRF17_BF harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID548588	Antiviral activity against HIV1 isolate 180 harboring reverse transcriptase K65R mutant gene obtained as site-directed mutant of NL4-3 by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID618327	Antiviral activity against HIV1 clade D isolate 1649 infected in human H9 cells assessed as inhibition of viral replication	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID1457756	Selectivity index, ratio of CC50 for human PHA-stimulated PBMC to IC50 for CXCR4-tropic HIV-1 NL4-3 infected in human PHA-stimulated PBMC	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
AID729823	Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Synthesis of hemslecin A derivatives: a new class of hepatitis B virus inhibitors.
AID1832350	Therapeutic index, ratio of CC50 for cytotoxicity against HEK293T cells in absence of HSA to IC50 for antiviral activity against human immunodeficiency virus expressed in HEK293T cells in absence of HSA	2021	Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17	ω-Functionalized Lipid Prodrugs of HIV NtRTI Tenofovir with Enhanced Pharmacokinetic Properties.
AID317372	Antiviral activity against HIV with reverse transcriptase M184V mutation in MT4 cells assessed as fold resistance relative to wild type	2007	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 17, Issue:24	Synthesis, anti-HIV activity, and resistance profiles of ribose modified nucleoside phosphonates.
AID1832357	Cytotoxicity against HEK293T cells assessed as reduction in cell viability in absence of HSA measured after 48 hrs by CellTiter 96 Aqueous One Solution reagent based cell proliferation assay	2021	Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17	ω-Functionalized Lipid Prodrugs of HIV NtRTI Tenofovir with Enhanced Pharmacokinetic Properties.
AID393071	Cytotoxicity against human MT2 cells after 5 days	2009	Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4	Design, synthesis, and anti-HIV activity of 4'-modified carbocyclic nucleoside phosphonate reverse transcriptase inhibitors.
AID320327	Cytotoxicity against human MT2 cells	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3	Synthesis and anti-HIV activity of GS-9148 (2'-Fd4AP), a novel nucleoside phosphonate HIV reverse transcriptase inhibitor.
AID548802	Antiviral activity against HIV1 isolate 200 harboring reverse transcriptase M41L/L210W/T215Y mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1743971	Substrate activity at HIV1 reverse transcriptase assessed as incorporation of compound into growing DNA strand at 500 uM incubated for 1 hr using primer and template in presence of MgCl2 by gel based nucleotide incorporation assay	2021	Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1	Tenofovir-Amino Acid Conjugates Act as Polymerase Substrates-Implications for Avoiding Cellular Phosphorylation in the Discovery of Nucleotide Analogues.
AID322826	Effect on cell viability in human Huh7 cells	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID341989	Ratio of Kcat/Km for HIV1 reverse transcriptase in presence of 0.5 uM dCTP to Kcat/Km for reverse transcriptase in presence of 10 uM dCTP by nucleotide excision activity assay	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.
AID322835	Antiviral activity against wild type HBV genotype E assessed as inhibition of replication	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID1599857	Selectivity index, ratio of CC50 for human HepG2.2.15 cells to IC50 for HBV infected in human HepG2.2.15 cells	2019	ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6	Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs.
AID548815	Antiviral activity against HIV1 isolate 063 harboring reverse transcriptase M41L/D67N/K70R/M184V/L210W/T215Y/K219E mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID549081	Cytotoxicity against human dendritic cells after 24 hrs by XTT assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID558375	Drug level in HIV-infected pregnant woman cord blood plasma at 300 mg, po QD by LC/MS/MS analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.
AID581813	Antiviral activity against R5 tropic HIV1 YU.2 infected in human TZM-b1 cells after 2 hrs by luciferase assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Reverse transcriptase inhibitors as potential colorectal microbicides.
AID1832363	Antiviral activity against human immunodeficiency virus expressed in HEK293T cells coexpressing firefly luciferase gene incubated for 48 hrs by Bright-Glo luciferase assay	2021	Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17	ω-Functionalized Lipid Prodrugs of HIV NtRTI Tenofovir with Enhanced Pharmacokinetic Properties.
AID592791	Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced syncytium formation after 4 to 5 days by microscopic analysis	2011	Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7	Synthesis and antiviral activity of N9-[3-fluoro-2-(phosphonomethoxy)propyl] analogues derived from N6-substituted adenines and 2,6-diaminopurines.
AID341990	Ratio of Kcat/Km for HIV1 reverse transcriptase M41L/D67N/L210W/T215Y mutant in presence of 0.5 uM dCTP to Kcat/Km for reverse transcriptase M41L/D67N/L210W/T215Y mutant in presence of 10 uM dCTP by nucleotide excision activity assay	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.
AID568375	Cytotoxicity against human HepG2(2.2.15) cells	2011	Bioorganic & medicinal chemistry, Feb-15, Volume: 19, Issue:4	Synthesis and biological assay of 4-aryl-6-chloro-quinoline derivatives as novel non-nucleoside anti-HBV agents.
AID1264924	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis	2015	European journal of medicinal chemistry, Dec-01, Volume: 106	Tryptophan dendrimers that inhibit HIV replication, prevent virus entry and bind to the HIV envelope glycoproteins gp120 and gp41.
AID659367	Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for HBV by hepatitis B e-antigen release detection assay	2012	Bioorganic & medicinal chemistry letters, May-15, Volume: 22, Issue:10	Synthesis, biological evaluation and structure-activity relationships of glycyrrhetinic acid derivatives as novel anti-hepatitis B virus agents.
AID1782276	Selectivity index, ratio of CC50 for human MT-4 cells to EC50 for HIV-1 infected in MT-4 cells	2021	Journal of medicinal chemistry, 11-25, Volume: 64, Issue:22	Discovery of Modified Amidate (ProTide) Prodrugs of Tenofovir with Enhanced Antiviral Properties.
AID1561720	Resistance index, ratio of EC50 for antiviral activity against HIV1 3B infected in human MT4 cells grown under 30 passages in presence of (E)-4-((4-((4-(4-(2-Cyanovinyl)-2,6-dimethylphenoxy)thieno[2,3- d]pyrimidin-2-yl)amino)piperidin-1-yl)methyl)benzenes
AID394460	Cmax in Sprague-Dawley rat assessed as tenofovir level at 100 mg/kg, po administered daily for 7 days measured on day 1	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID1126832	Cytotoxicity against human CEM cells	2014	European journal of medicinal chemistry, May-06, Volume: 78	PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer.
AID659368	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in viral DNA replication	2012	Bioorganic & medicinal chemistry letters, May-15, Volume: 22, Issue:10	Synthesis, biological evaluation and structure-activity relationships of glycyrrhetinic acid derivatives as novel anti-hepatitis B virus agents.
AID1457753	Cytotoxicity against human PHA-stimulated PBMC assessed as cell viability by tetrazolium dye assay	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
AID556525	Antiviral activity against Human immunodeficiency virus 1 clone 38086 harboring K49R, V60I, I135V, Q145M, Q174H, G196E, Q207E, R211K, V245K mutation in reverse transcriptase by phenosense assay relative to wild type	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
AID548565	Selectivity ratio of EC50 for HIV1 4755-5 harboring reverse transcriptase 41L/44D/67N/69D/118I/210W/215Y/184V mutant gene infected in human PBMC to EC50 for HIV1 NL 4-3 expressing wild type reverse transcriptase infected in human PBMC	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1264925	Cytotoxicity against human CEM cells assessed as cell count after 3 days	2015	European journal of medicinal chemistry, Dec-01, Volume: 106	Tryptophan dendrimers that inhibit HIV replication, prevent virus entry and bind to the HIV envelope glycoproteins gp120 and gp41.
AID83112	Effective concentration against cytopathicity of HIV-2 strain (ROD) in CEM cell line	2003	Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13	Deoxyribonucleoside 2'- or 3'-mixed disulfides: prodrugs to target ribonucleotide reductase and/or to inhibit HIV reverse transcription.
AID394458	Cmax in Sprague-Dawley rat assessed as tenofovir level at 30 mg/kg, po administered daily for 7 days measured on day 1	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID1197620	Antiviral activity against HIV1 3B infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Linear and branched alkyl-esters and amides of gallic acid and other (mono-, di- and tri-) hydroxy benzoyl derivatives as promising anti-HCV inhibitors.
AID317370	Cytotoxicity against human MT2 cells	2007	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 17, Issue:24	Synthesis, anti-HIV activity, and resistance profiles of ribose modified nucleoside phosphonates.
AID341992	Inhibition of HIV1 reverse transcriptase M41L/D67N/L210W/T215Y mutant assessed as dCTP level required to form 80% of binary enzyme complex formation with drug-terminated primer in posttranslocation state by site-specific foot printing assay	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.
AID548808	Antiviral activity against HIV1 isolate 212 harboring reverse transcriptase L210W/T215Y mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID618321	Antiviral activity against HIV1 clade A isolate 4113 infected in human H9 cells assessed as inhibition of viral replication	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID1561716	Antiviral activity against HIV1 3B infected in human MT4 cells grown under 30 passages in absence of test compound assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay
AID581824	Antiviral activity against HIV1 isolate 71361-1 harboring reverse transcriptase K65R mutant infected in human TZM-b1 cells after 2 hrs by luciferase assays	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Reverse transcriptase inhibitors as potential colorectal microbicides.
AID394473	AUC (0 to 24 hrs) in Sprague-Dawley rat assessed as tenofovir level at 100 mg/kg, po administered daily for 7 days measured on day 7	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID1636526	Therapeutic index, ratio of CC50 for human PBMC to EC50 for HIV1 infected in human PBMC	2016	Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15	Reduction Sensitive Lipid Conjugates of Tenofovir: Synthesis, Stability, and Antiviral Activity.
AID275084	Stability in culture medium (RPMI+FBS)	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID320326	Inhibition of wild type HIV 3B reverse transcriptase in MT2 cells	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3	Synthesis and anti-HIV activity of GS-9148 (2'-Fd4AP), a novel nucleoside phosphonate HIV reverse transcriptase inhibitor.
AID328842	Inhibition of human MRP2 expressed in MDCK2 cells assessed as increase in intracellular CMF fluorescence by CMFDA assay	2007	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3	Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.
AID618324	Antiviral activity against HIV1 clade B isolate 1722 infected in human H9 cells assessed as inhibition of viral replication	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID322845	Fold resistance, ratio of lamivudine-resistant HBV with reverse transcriptase L180M/A181V mutant to wild-type HBV genotype E	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID275083	Stability in RPMI-1640 medium	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID1126840	Cytostatic activity against human CEM cells after 72 hrs by coulter counting analysis	2014	European journal of medicinal chemistry, May-06, Volume: 78	PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer.
AID394446	Cytotoxicity against human HepG2 cells by MTS assay	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID548841	Antiviral activity against HIV1 isolate 220 harboring reverse transcriptase K70E/M184V mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID548845	Cellular uptake in human PBMC at 10 uM after 24 hrs by MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID423158	Antiviral activity against wild type HIV2 ROD produced from full length pROD9 infected in human MAGIC-5A cells assessed as inhibition of Lac+ foci expression after 40 hrs	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.
AID549083	Cytotoxicity against human HeLa cells after 24 hrs by XTT assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID322839	Antiviral activity against lamivudine-adenofir-resistant HBV with reverse transcriptase V173L/L180M/A181V mutant	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID548586	Antiviral activity against HIV1 isolate 166 harboring reverse transcriptase L74V mutant gene obtained as site-directed mutant of NL4-3 by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1140535	Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of DNA replication	2014	Bioorganic & medicinal chemistry letters, May-15, Volume: 24, Issue:10	Synthesis, structure-activity relationships and biological evaluation of dehydroandrographolide and andrographolide derivatives as novel anti-hepatitis B virus agents.
AID1192283	Cytotoxicity against human HepG2(2.2.15) cells after 72 hrs by MTT assay	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Synthesis of erythrocentaurin derivatives as a new class of hepatitis B virus inhibitors.
AID423280	Antiviral activity against multinucleoside-resistant HIV1 NL4-3 harboring A62V, V75I, F77L, F116Y, Q151M mutation in viral reverse transcriptase infected in human MAGIC-5A cells assessed as inhibition of Lac+ foci expression after 40 hrs	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.
AID1394855	Antiviral activity against HIV1 LAI infected in PHA-P activated human PBMC assessed as reduction in viral replication preincubated with cells for 30 mins followed by viral infection and measured at day 7 post infection by reverse transcriptase activity-ba	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Synthesis of 3'-halo-5'-norcarbocyclic nucleoside phosphonates as potent anti-HIV agents.
AID548560	Antiviral activity against HIV1 1617-1 harboring reverse transcriptase 69K/70G/75I/77L/116Y/151M/184V mutant gene infected in human PBMC by ELISA	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID394455	Antiviral activity against HIV1 clade B HT/92/599 isolate in human PBMC assessed as reduction in reverse transcriptase	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID670449	Cytotoxicity against human HepG2(2.2.15) cells by modified-MTT assay	2012	European journal of medicinal chemistry, Aug, Volume: 54	Design, synthesis, and molecular hybrids of caudatin and cinnamic acids as novel anti-hepatitis B virus agents.
AID1686655	Antiviral activity against HBV infected in human HepG2 assessed as reduction in viral replication incubated for 6 days by real time Q-PCR analysis	2016	Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22	Next-Generation Reduction Sensitive Lipid Conjugates of Tenofovir: Antiviral Activity and Mechanism of Release.
AID422692	Ratio of IC50 for HIV1 with reverse transcriptase K70G/M184V mutation to IC50 for wild type HIV1	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.
AID394454	Selectivity index, ratio of CC50 for human MT2 cells to EC50 for HIV1 LAI	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID548575	Antiviral activity against HIV1 isolate 061 harboring reverse transcriptase M41L/D67N/K70R/M184V/L210W/T215Y/K219E mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID548800	Antiviral activity against HIV1 isolate 192 harboring reverse transcriptase M41L/T215Y mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID618430	Antiviral activity against HIV1 clade F isolate 2338 infected in human H9 cells assessed as inhibition of viral replication	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.
AID549084	Cytotoxicity against human CEM-SS cells after 24 hrs by XTT assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID313875	Cytotoxicity against human MT2 cells	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3	Synthesis and anti-HIV activity of 2'-fluorine modified nucleoside phosphonates: analogs of GS-9148.
AID422691	Ratio of IC50 for HIV1 with reverse transcriptase K70E/M184V mutation to IC50 for wild type HIV1	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.
AID341985	Ratio of Kcat to Km for HIV1 reverse transcriptase M41L/D67N/L210W/T215Y mutant assessed as nucleotide excision activity in presence of 0.5 uM dCTP	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.
AID55965	Antiviral activity against Davis strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity.
AID341185	Cytotoxicity against human PHA-PBMC cells by MTT assay	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.
AID699539	Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1457758	Antiviral activity against tenofovir-resistant CXCR4-tropic HIV-1 NL4-3 harboring reverse transcriptase K65R mutant infected in human MT4 cells assessed as inhibition of viral replication inhibition of virus-induced cytopathic effect after 6 days by XTT d	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID72026	Antiproliferative activity was determined against murine mammary carcinoma cells (FM3A)	2003	Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13	Deoxyribonucleoside 2'- or 3'-mixed disulfides: prodrugs to target ribonucleotide reductase and/or to inhibit HIV reverse transcription.
AID1599866	AUC(0 to infinity) in Sprague-Dawley rat at 20 mg/kg, po administered as single dose and measured after 0.25 to 24 hrs by HPLC analysis	2019	ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6	Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs.
AID548831	Antiviral activity against HIV1 isolate 194 harboring reverse transcriptase M41L/T215Y/M184V mutant gene by phenosense assay relative to wild type	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID405412	Antiviral activity against PERV infected in human 293T cells assessed as inhibition of proximal DNA synthesis after 24 hrs by RT-PCR	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Selective inhibition of porcine endogenous retrovirus replication in human cells by acyclic nucleoside phosphonates.
AID394480	Elimination half life in Sprague-Dawley rat assessed as tenofovir level at 10 mg/kg, po administered daily for 7 days measured on day 1	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
AID548577	Antiviral activity against HIV1 isolate 066 harboring reverse transcriptase 184V mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1193392	Cytotoxicity against human HepG 2.2.15 cells by MTT assay	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Isolation, synthesis and anti-hepatitis B virus evaluation of p-hydroxyacetophenone derivatives from Artemisia capillaris.
AID275065	Antiviral activity against HIV1 in MAGI-CCR5 cells	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID341370	Ratio of EC50 for R5-HIV1MDR/MM in human PHA-PBMC to EC50 for R5-HIV1Ba-L in human PHA-PBMC	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.
AID147626	Antiviral activity against OKA strain of VZV in HEL (human erythroleukemia) cells.	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity.
AID45994	Cytotoxicity against CEM (human lymphoblastic leukemia) cells in vitro.	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity.
AID548806	Antiviral activity against HIV1 isolate 206 harboring reverse transcriptase D67N/K70R mutant gene by phenosense assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1686652	Antiviral activity against HIV1 infected in human PBMC assessed as reduction in viral replication incubated for 7 days by radioactive incorporation polymerization assay based reverse transcriptase activity detection method	2016	Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22	Next-Generation Reduction Sensitive Lipid Conjugates of Tenofovir: Antiviral Activity and Mechanism of Release.
AID1457751	Antiviral activity against CXCR4-tropic HIV-1 NL4-3 infected in human PHA-stimulated PBMC assessed as inhibition of viral replication by measuring reduction in p24 antigen production preincubated with cells for 30 mins followed by viral infection measured	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
AID393073	Antiviral activity against HIV1 3a with reverse transcriptase M184V mutation in human MT2 cells assessed as inhibition of viral-induced cytopathic effect by XTT assay relative to wild type	2009	Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4	Design, synthesis, and anti-HIV activity of 4'-modified carbocyclic nucleoside phosphonate reverse transcriptase inhibitors.
AID211496	In vitro cytotoxic concentration against CEM cells	2001	Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8	Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA.

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	40 (0.81)	18.2507
2000's	938 (18.92)	29.6817
2010's	2747 (55.42)	24.3611
2020's	1232 (24.85)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	940 (18.15%)	5.53%
Reviews	574 (11.09%)	6.00%
Case Studies	412 (7.96%)	4.05%
Observational	152 (2.94%)	0.25%
Other	3,100 (59.87%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (755)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Pilot Estimation Study to Compare the Safety and Efficacy of Raltegravir+TDF+3TC Versus TDF+3TC+EFV in HBV/HIV Co-infected Patients [NCT01318096]		60 participants (Anticipated)	Interventional	2011-03-31	Not yet recruiting
Efficacy and Safety of Ricovir® in Maintaining Durability of Viral Response in Chronic Hepatitis B Patients Who Have Been Treated With Viread® and Have Undetectable HBV DNA in Serum [NCT05355467]	Phase 4	40 participants (Actual)	Interventional	2019-08-21	Completed
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose [NCT01489046]	Phase 2	297 participants (Actual)	Interventional	2011-02-28	Terminated
A Phase 1b/2a, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of ABI-H0731 in Patients With Chronic Hepatitis B [NCT03109730]	Phase 1/Phase 2	38 participants (Actual)	Interventional	2017-06-15	Completed
Changes in Coagulation and Platelet Reactivity in HIV-1 Infected Patients Switching Between Abacavir and Tenofovir Containing Antiretroviral Regimens [NCT02093585]	Phase 4	43 participants (Actual)	Interventional	2014-01-31	Completed
"A Prospective, Randomized, Multicenter, Open-label, Exploratory Study of Utilizing of Response-Guided-Therapy (RGT) Strategy on Optimal Nucleoside Analogue (NUC)-Experienced Patients" [NCT02560649]	Phase 4	324 participants (Anticipated)	Interventional	2015-05-31	Active, not recruiting
Multicenter, Double-Blind, Randomized, Dose Ranging Study to Compare the Safety and Activity of MK0518 Plus Tenofovir and Lamivudine (3TC) Versus Efavirenz Plus Tenofovir and Lamivudine (3TC) in ART-Naive, HIV-Infected Patients [NCT00100048]	Phase 2	206 participants (Actual)	Interventional	2005-01-31	Completed
Treatment Cohort of HIV-infected Children With Resistance or Intolerance to Non Nucleoside Reverse Transcriptase Inhibitor (NNRTI) First Line and PI Second Line Antiretroviral Therapy [NCT01225406]		56 participants (Actual)	Observational	2010-08-31	Completed
Study on Three Types of Nucleotide/Nucleoside Analogues Treatment in Patients With Hepatitis b Virus Related Acute-on-chronic Liver Failure [NCT03920618]		150 participants (Anticipated)	Interventional	2019-02-01	Recruiting
A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA™ [NCT00369941]	Phase 3	566 participants (Actual)	Interventional	2006-08-31	Completed
[NCT01274780]	Phase 4	180 participants (Actual)	Interventional	2011-05-31	Completed
Microbicide Safety and Acceptability in Young Men [NCT01283360]	Phase 1	249 participants (Actual)	Interventional	2010-10-31	Completed
A Prospective, Multi-center, Cohort Study to Evaluate the Efficacy and Safety of Tenofovir Alafenamide (TAF) for Prevention of Mother-to-child Transmission of Hepatitis B Virus Among Pregnant Women With High Level HBV DNA [NCT05177926]	Phase 4	330 participants (Anticipated)	Interventional	2021-04-04	Recruiting
Bictegravir in the Elderly Living With HIV: Impact of Polypharmacy and Multimorbidity (BICEP) [NCT05064020]		162 participants (Anticipated)	Observational	2020-08-01	Active, not recruiting
Clinical Trial of CNS Penetrating ART to Prevent NeuroAIDS in China [NCT01340950]	Phase 4	250 participants (Actual)	Interventional	2010-07-31	Completed
Use of Immune Modulatory Properties of Ribavirin to Enhance Hepatitis B Virus Nucleotide Analog Antiviral Activity: Proposal for Pilot Clinical Trial [NCT03759782]	Phase 3	24 participants (Anticipated)	Interventional	2019-01-10	Recruiting
UNCPM 22314 - Evaluating the Safety of Pregnancy, Infant and Maternal Health Outcomes Among PrEP Users in Malawi [NCT06158126]		621 participants (Anticipated)	Observational [Patient Registry]	2024-01-01	Not yet recruiting
A Phase 2 Open-label Trial to Evaluate Safety, Efficacy, Tolerability, and Pharmacodynamics of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs, and a PD-1 Inhibitor in Chronic Hepatitis B Patients [NCT05275023]	Phase 2	37 participants (Actual)	Interventional	2022-06-30	Active, not recruiting
A Phase 1b, Open-label, Single-arm, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Treatment With JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, HBeAg-negative Participants With Chronic Hepatitis B Vi [NCT05123599]	Phase 1	24 participants (Actual)	Interventional	2021-12-06	Active, not recruiting
A Phase 2 Randomized, Open-label, Parallel-group, Multicenter Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Response to Combination Regimens Containing JNJ-73763989 and Nucleos(t)Ide Analog With or Without JNJ [NCT04585789]	Phase 2	24 participants (Actual)	Interventional	2021-03-11	Active, not recruiting
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled Study With Deferred Active Treatment to Investigate the Efficacy, Safety, and Pharmacokinetics of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hep [NCT04535544]	Phase 2	52 participants (Actual)	Interventional	2020-09-17	Active, not recruiting
A Phase 2, Randomized, Open-label, Multicenter Study to Evaluate Efficacy, Pharmacokinetics, Safety, and Tolerability of Treatment With JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog With or Without JNJ-56136379 in Treatment-naive Patie [NCT04439539]	Phase 2	54 participants (Actual)	Interventional	2020-09-14	Active, not recruiting
Pharmacokinetics of Tenofovir and Tenofovir-diphosphate, Emtricitabine and Emtricitabine-triphosphate, and Efavirenz Once Daily Over 10 Days Following Drug Intake Cessation in Healthy Volunteers [NCT01108926]	Phase 1	19 participants (Actual)	Interventional	2010-06-30	Completed
Maternal Tenofovir-containing Combination Drug Regimen During the Second and Third Trimesters of Pregnancy for Prevention of Mother-to-child Transmission of HIV and HBV in HIV-HBV Co-infected Mothers [NCT01125696]	Phase 2	45 participants (Actual)	Interventional	2012-05-31	Completed
Phase 3B, Randomized, Open-Label, Safety, and Drug Detection Study of Dapivirine Vaginal Ring and Oral TRUVADA® in Breastfeeding Mother-Infant Pairs [NCT04140266]	Phase 3	394 participants (Actual)	Interventional	2020-09-24	Completed
A Prospective, Randomized, Open Label Study to Evaluate the Safety and Tolerability of Raltegravir + Truvada Versus Kaletra + Truvada, for Post-exposure Prophylaxis in Health Care Workers [NCT01234116]	Phase 4	16 participants (Actual)	Interventional	2011-02-28	Completed
Virtual PrEP: Rendering PrEP Delivery More Efficient Using an mHealth Intervention and TAF/FTC [NCT05159531]	Phase 4	142 participants (Anticipated)	Interventional	2023-05-01	Recruiting
F/TAF Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis (TAF4TRANS) [NCT04616963]	Phase 4	64 participants (Actual)	Interventional	2019-10-24	Active, not recruiting
Immediate Initiation of Antiretroviral Therapy During Acute HIV Infection [NCT02656511]	Phase 4	74 participants (Anticipated)	Interventional	2015-12-31	Active, not recruiting
Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in HBeAg-positive and HBeAg-negative Chronic Hepatitis B [NCT01369212]	Phase 3	201 participants (Actual)	Interventional	2012-11-30	Completed
Phase 2 Comparison of Low-Dose Naltrexone vs ARV Effectiveness in HIV+ Progression [NCT01174914]	Phase 2	171 participants (Actual)	Interventional	2008-03-31	Completed
Tenofovir Disoproxil Fumarat 300 mg - Phyllanthus Urinaria 300mg - Adenosma Glutinosum 150mg - Eclipta Prostrata 150mg, Ascorbic Acid 500 mg Daily is Effective in the Long-term Treatment of Chronic and Acute Hepatitis B. [NCT01198860]		0 participants	Expanded Access		Approved for marketing
A Real-world Clinical Study on Effectiveness and Safety of Long-term TAF Treatment in Chronic Hepatitis B Patients in China [NCT03752658]		500 participants (Anticipated)	Observational	2019-01-25	Recruiting
A Multicenter, Randomized, Double-Blind, Comparative Trial Of Maraviroc + Darunavir/Ritonavir Versus Emtricitabine/Tenofovir + Darunavir/Ritonavir For The Treatment Of Antiretroviral-Naive Hiv-Infected Patients With Ccr5-Tropic Hiv-1 [NCT01345630]	Phase 3	813 participants (Actual)	Interventional	2011-09-30	Terminated(stopped due to See termination reason in detailed description.)
Optimal Combination Therapy After Nevirapine Exposure [NCT00089505]	Phase 3	745 participants (Actual)	Interventional	2006-11-30	Completed
A Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731 as Adjunctive Therapy in Virally-suppressed Patients With Chronic Hepatitis B [NCT03576066]	Phase 2	73 participants (Actual)	Interventional	2018-06-11	Completed
Randomized, Open-Label, Active Comparator, Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Hepatitis B Virus (HBV) Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic HBV Infection [NCT04629976]	Phase 1	21 participants (Actual)	Interventional	2021-01-12	Completed
A Single Arm, Phase 3 Study, Exploring the Safety of Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV, a Pilot Switch Study Strategy in South Africa [NCT04433780]	Phase 3	133 participants (Actual)	Interventional	2021-01-04	Completed
A Study of the Safety and Efficacy of Entecavir Plus Tenofovir in Adults With Chronic Hepatitis B Virus Infection With Previous Nucleoside/Nucleotide Treatment Failure [NCT01063036]	Phase 3	144 participants (Actual)	Interventional	2010-05-31	Completed
A Multi-Center, Randomized, Open-label, Parallel, Active-controlled, Non-inferiority, Phase IV Clinical Trial to Evaluate the Safety and Efficacy of Switching to Tenolid Tab From Viread Tab in Chronic Hepatitis B Patients on Treatment With Tenofovir Disop [NCT05282407]	Phase 4	118 participants (Actual)	Interventional	2017-11-20	Completed
Bioequivalence of Tenofovir and Emtricitabine Following Overencapsulation [NCT02968576]		25 participants (Actual)	Interventional	2016-12-31	Completed
Pre-exposure Prophylaxis of HIV Infection Among Men Who Have Sex With Men (MSM) and Transgender Women (TG) in Suburban Yangon, Myanmar [NCT04781426]		200 participants (Actual)	Observational	2020-10-28	Completed
A Phase 4, Single-arm, Open-label Study to Evaluate the Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Once Daily Fixed-dose Combination (FDC) Regimen in Antiretroviral Treatment-experienced Human Immunodeficie [NCT04388904]	Phase 4	75 participants (Actual)	Interventional	2021-09-01	Active, not recruiting
An Open-Label Study to Investigate the Effect of Renal Impairment on the Pharmacokinectics of Tenofovir Exalidex [NCT03284164]	Phase 1	16 participants (Actual)	Interventional	2017-09-28	Completed
Investigation of Efficacy of Tenofovir Monotherapy in Comparison With Lamivudine Plus Adefovir in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Lamivudine Plus Adefovir Combination Therapy - Multicenter Randomiz [NCT03236584]	Phase 3	76 participants (Actual)	Interventional	2015-09-01	Active, not recruiting
The Study of Starting to Use Tenofovir Disoproxil Fumarate(TDF) Antiviral Treatment From the 32 Weeks of Gestation to Block Mother-to-child Transmission of Hepatitis B Virus(HBV MTCT) and Withdrawal Time [NCT03209908]		380 participants (Anticipated)	Observational	2017-01-01	Recruiting
A Randomized, Double-Blind Study Evaluating Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus the Combination of Emtricitabine and Tenofovir DF for the Treatment of Chronic Hepatitis B [NCT00507507]	Phase 2	126 participants (Actual)	Interventional	2007-09-30	Completed
I-BrEATHe - Interactions Between Antiretrovirals And Transgender Hormones [NCT04050371]	Phase 4	48 participants (Actual)	Interventional	2017-08-03	Completed
A Phase 2, Open-label, Multicenter Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Treatment With JNJ-73763989, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Patients With Chronic Hepatitis B Virus Infection [NCT05005507]	Phase 2	1 participants (Actual)	Interventional	2021-11-03	Terminated(stopped due to A strategic decision was made to not further execute the study. This decision was not based on a safety concern.)
Simplified Model of Linkage and Retention to Healthcare System, Using a Mobil Unit and a Same-day Test and Treat Approach Among Excluded Population. [NCT05405751]	Phase 4	100 participants (Actual)	Interventional	2022-07-04	Active, not recruiting
Two Randomized, Open-labeled, Parallel Designed Multiple-dose Clinical Trials to Evaluate Pharmacokinetics of Ritonavir-unboosted and Ritonavir-boosted Atazanavir Used Alone or Co-administered With Tenofovir DF in Healthy Korean and Caucasian Male Volunte [NCT01368783]	Phase 1	32 participants (Anticipated)	Interventional	2011-06-30	Not yet recruiting
Dose Proportionality of TFV-DP in Mucosal Tissue, and Endogenous Nucleotide Quantification, After a Single Dose of GS-7340 in Women [NCT02357602]	Phase 1	24 participants (Actual)	Interventional	2015-03-31	Completed
A Phase IV, Open-label Three-arm Study Investigating the Impact of a Combination of Tenofovir Disoproxil Fumarate/Emtricitabine With Raltegravir or Dolutegravir or Elvitegravir/Cobicistat on Renal Tubular Function and Renal Transporters in HIV-1 Antiretro [NCT02351908]	Phase 4	60 participants (Actual)	Interventional	2015-03-31	Completed
Prevention of Hepatitis B Virus (HBV) Mother-to-Child (MTC) Transmission by Serovaccination of Newborns and Use of Tenofovir DF During the Last Trimester of Pregnancy in Mothers With HBV DNA Above 100, 000 I.U/mL [NCT02039362]	Phase 4	37 participants (Actual)	Interventional	2012-07-31	Completed
An Open Label Study Evaluating the Safety and Efficacy of Switching From Rilpivirine/Emtricitabine/Tenofovir Alafenamide in Combination With Dolutegravir, to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Combination With Doravirine, in Male HIV+ Subj [NCT04538040]	Phase 4	20 participants (Actual)	Interventional	2019-12-19	Completed
An Open-label, Randomized Study to Compare the Efficacy and Safety of P1101 Plus Tenofovir Alafenamide With or Without Ursodeoxycholic Acid in Patients With Chronic Hepatitis B and Hepatitis D Virus Co-Infection [NCT05467553]	Phase 2	30 participants (Anticipated)	Interventional	2023-02-24	Not yet recruiting
Assessing Virologic Success and Metabolic Changes in Patients Switching From a TDF to TAF Containing Antiretroviral Therapy Regimen [NCT03646370]		110 participants (Actual)	Observational	2018-07-25	Completed
Antiretroviral Activity and Tolerability of Once Daily Etravirine in Treatment-Naïve Adults With HIV-1 Infection [NCT00959894]	Phase 2	80 participants (Actual)	Interventional	2009-09-30	Completed
A Phase 1, Open-label, 2-cohort, Multiple Dose, Drug-drug Interaction, Safety and Tolerability, Fixed-sequence Study to Investigate the Potential Interaction Between ATI-2173 When Coadministered With Tenofovir Disoproxil Fumarate in Healthy Subjects [NCT05137548]	Phase 1	32 participants (Actual)	Interventional	2021-10-27	Completed
A Phase 2, Exploratory Study Evaluating the Safety and Antiviral Efficacy of Inarigivir Soproxil in Non-cirrhotic Treatment-Naive Subjects Infected With Chronic Hepatitis B Virus [NCT04059198]	Phase 2	5 participants (Actual)	Interventional	2019-10-10	Terminated(stopped due to Evidence of liver injury in a separate Inarigavir study)
A Open-label, Single Center Drug Interaction Study of Morphothiadine Mesilate/Ritonavir , Entecavir and Tenofovir Disoproxil Fumarate in Healthy Subjects [NCT03662568]	Phase 1	56 participants (Actual)	Interventional	2018-06-26	Completed
"Assessment of a New Boosting Strategy for HIV Pre-exposure Prophylaxis in Healthy Volunteers" [NCT03202511]	Early Phase 1	15 participants (Actual)	Interventional	2017-06-23	Completed
Pilot Study to Assess the Antiviral Activity and Safety of Besifovir Dipivoxil 150mg and L-carnitine 660mg Compared to Tenofovir Alafenamide 25mg in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver [NCT03604016]	Phase 4	76 participants (Anticipated)	Interventional	2018-09-23	Not yet recruiting
A Randomised Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis [NCT02238860]	Phase 4	100 participants (Anticipated)	Interventional	2014-09-30	Recruiting
A Sequential Phase 1a/1b Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ARC-521 in Normal Adult Volunteers and Patients With Chronic Hepatitis B [NCT02797522]	Phase 1	47 participants (Actual)	Interventional	2016-06-30	Terminated(stopped due to Company decision to discontinue trial)
A Phase 3 Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir Once-Daily in HIV-1 Infected Treatment-Naïve Participants [NCT04233879]	Phase 3	599 participants (Actual)	Interventional	2020-02-28	Active, not recruiting
Extracellular and Intracellular TFV/FTC Residues After a Single Dose in HIV-Negative Men and Women: Implications for Pre-exposure HIV Prophylaxis Dosing of Truvada® [NCT01326221]		12 participants (Actual)	Observational	2008-10-31	Completed
A Multi-centre, One-arm Prospective Study to Evaluate Efficacy and Safety of Switching From Entecavir (ETV) to Tenofovir Disoproxil Fumarate (TDF) in Japanese Chronic Hepatitis B HBeAg-positive and HBV-DNA Undetectable Subjects [NCT03258710]	Phase 4	75 participants (Actual)	Interventional	2017-10-02	Completed
A Rollover Protocol to Provide Subjects From Taiwan Continued Access to Tenofovir Disoproxil Fumarate After Completing Study GS-US-174-0108 [NCT01334567]	Phase 2	30 participants (Actual)	Interventional	2010-08-31	Completed
Real-life Data of Switching From Tenofovir Disoproxi Fumarate (TDF) to Tenofovir Alafenamide (TAF) in Virologically Suppressed Chronic Hepatitis B Patients With Antiviral Resistance [NCT03566030]		300 participants (Anticipated)	Observational	2018-09-01	Not yet recruiting
The Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment Experienced Patients [NCT03789968]		411 participants (Actual)	Observational	2019-09-01	Completed
Treatment Efficacy and Safety of Tenofovir Alafenamide (TAF) Switch Therapy in Patients Who Have Been Treated With Tenofovir Disoproxil Fumarate (TDF) in naïve Chronic Hepatitis B: a Real Life Multicenter Cohort Study in Korea [NCT03559790]		400 participants (Anticipated)	Observational	2018-07-18	Recruiting
Efficacy of Addition of Fecal Microbiota Transplant (FMT) and Plasma Exchange to Tenofovir in Comparison to Monotherapy With Tenofovir in ACLF-HBV [NCT04431375]		70 participants (Anticipated)	Interventional	2020-06-22	Recruiting
Pharmacokinetic and Pharmacodynamic Study of Tenofovir 1% Gel Using the Bat 24 Regimen Versus Daily and Pericoital Dosing [NCT01369303]	Phase 1	194 participants (Actual)	Interventional	2012-01-31	Completed
"Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir in Virologically-suppressed HIV-infected Rwandans (Near-Rwanda)" [NCT02104700]	Phase 2/Phase 3	150 participants (Actual)	Interventional	2014-04-30	Completed
Bioequivalence of Crushed and Whole Genvoya Tablets (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate) [NCT03717129]	Phase 4	12 participants (Actual)	Interventional	2019-04-15	Completed
A Phase 2a, Randomized, Double-blind, Placebo-controlled Study of Oral FXR Modulator EYP001a Combined With Nucleos(t)Ide Analogues (NA) in Virologically Suppressed Chronic Hepatitis B Patients to Improve Functional Cure Rates [NCT04465916]	Phase 2	26 participants (Actual)	Interventional	2020-05-12	Terminated(stopped due to DSMC reviewed results of 26 subjects. New randomizations were stopped. Already randomized subjects were followed up to W40.)
Body Composition Sub-study of the D2EFT Trial [NCT03675815]	Phase 4	155 participants (Actual)	Interventional	2019-12-05	Active, not recruiting
An Exploratory, Randomized, Controlled Study of Tenofovir Plus Telbivudine Versus Monotherapy With Either Drug Alone in HBeAg Negative Chronic Hepatitis B Patients [NCT01260610]		0 participants (Actual)	Interventional	2011-06-30	Withdrawn(stopped due to lack of funds)
Phase IIa, 90-Day Safety, Adherence, and Acceptability Study of Intravaginal Rings Releasing Tenofovir With and Without Levonorgestrel Among Women in Western Kenya [NCT03762382]	Phase 2	50 participants (Anticipated)	Interventional	2018-12-12	Active, not recruiting
Study of the Safety and Efficacy of Daily Tenofovir to Prevent HIV Infection Among Injection Drug Users in Bangkok, Thailand [NCT00119106]	Phase 2/Phase 3	2,413 participants (Actual)	Interventional	2005-06-30	Completed
A Phase IIIB, Randomized Trial of Open-Label Efavirenz or Atazanavir With Ritonavir in Combination With Double-Blind Comparison of Emtricitabine/Tenofovir or Abacavir/Lamivudine in Antiretroviral-Naive Subjects [NCT00118898]	Phase 3	1,864 participants (Actual)	Interventional	2005-09-30	Completed
Maintaining Options for Mothers Study (MOMS): A Phase II Randomized Comparison of Three Antiretroviral Strategies Administered for 7 or 21 Days to Reduce the Emergence of Nevirapine Resistant HIV-1 Following a Single Intrapartum Dose of Nevirapine [NCT00099632]	Phase 2	484 participants (Actual)	Interventional	2006-03-31	Completed
Reversibility of Mitochondrial Toxicity in HIV Lipoatrophy [NCT00119379]	Phase 2	50 participants (Actual)	Interventional	2005-04-30	Completed
A Phase 3, Randomized, Multicenter Study of the Treatment of Antiretroviral-Naive HIV-1 Infected Subjects Comparing Tenofovir Disoproxil Fumarate and Emtricitabine in Combination With Efavirenz vs Combivir (Lamivudine/Zidovudine) and Efavirenz [NCT00112047]	Phase 3	517 participants (Actual)	Interventional	2003-07-31	Completed
Arresting Vertical Transmission of Hepatitis B Virus in the Democratic Republic of the Congo: The AVERT-HBV Study [NCT03567382]	Phase 4	179 participants (Actual)	Interventional	2018-09-24	Completed
An Evaluation of the Uptake and Safety of, and Adherence to Antiretroviral Treatment Among Individuals With CD4 ≥ 250 Cells/mm3 and HIV Virus Load ≥ 50,000 cp/mL [NCT01583439]		11 participants (Actual)	Interventional	2012-09-30	Terminated(stopped due to Low Accrual.)
Advanced HIV: Outcomes for Rapid ART [NCT05526118]		50 participants (Anticipated)	Observational	2022-08-30	Not yet recruiting
The Clinical Efficacy of Tenofovir Alafenamide-switching Therapy in Patients With Chronic Hepatitis B Experiencing Clinical Flare-up After Discontinuation of Nucleos[t]Ide Analogues Therapy [NCT04496882]	Phase 4	260 participants (Anticipated)	Interventional	2020-09-09	Recruiting
Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in PR-CoNCRA (San Juan, Puerto Rico)- Part B [NCT03120494]	Phase 4	75 participants (Actual)	Interventional	2016-11-30	Enrolling by invitation
COVER - Continuing Observation After Vicriviroc (VCV) Exposure Registry [NCT00705419]		180 participants (Actual)	Observational	2007-07-31	Completed
DOR/TDF/3TC Maintenance Therapy Among Patients Harboring M184V/I Mutation: a Pilot Open-label Study [NCT06034938]	Phase 2	32 participants (Anticipated)	Interventional	2023-12-01	Not yet recruiting
Changes in Insulin Resistance in Healthy Volunteers on STRIBILD® Medication - A Controlled, Mono Center, Three-arm, Randomized Phase I Study. [NCT02203461]	Phase 1	30 participants (Actual)	Interventional	2014-07-31	Completed
Bioequivalence Study of Efavirenz, Emtricitabine and Tenofovir in Healthy Volunteers, After Administering a Single Dose of a Fixed Dose Combination of the Test Formulation With Respect to the Reference Product, Atripla ® From Gador S.A [NCT03309566]	Phase 4	24 participants (Actual)	Interventional	2016-09-04	Completed
OPTIMA: A Randomized, Open-label, 156-week Treatment Study to Evaluate the Efficacy and Safety of Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept [NCT01379508]	Phase 4	241 participants (Actual)	Interventional	2011-03-21	Completed
Multicenter Study of Options for Second-Line Effective Combination Therapy (SELECT) [NCT01352715]	Phase 3	515 participants (Actual)	Interventional	2012-03-13	Completed
Switching Tenofovir/Emtricitabine/Efavirenz to Tenofovir/Emtricitabine/Rilpivirine Versus Continuing Tenofovir/Emtricitabine/Efavirenz in HIV1-infected Patients With Complete Virological Suppression [NCT03251690]		246 participants (Actual)	Interventional	2016-10-27	Completed
A Prospective, Randomized, Multicenter, Open-label, Exploratory Study of Utilizing of Peginterferon Alfa-2a on the Relapse Rate of the Subjects With Hepatocellular Carcinoma Who Have Been Treated by Resection [NCT03253250]	Phase 4	432 participants (Anticipated)	Interventional	2017-09-01	Recruiting
To Study the Efficacy of 'Tenofovir Pulse and Peg Interferon Alpha 2b' Therapy in HBeAg-positive Patients With Normal ALT - A Randomized Control Trial [NCT02454764]		0 participants (Actual)	Interventional		Withdrawn(stopped due to lack of funds)
A Single-Dose, Open-Label, Randomized, Crossover Study to Assess the Bioequivalence of Darunavir 800 mg, Emtricitabine 200 mg, and Tenofovir Alafenamide 10 mg, in the Presence of Cobicistat 150 mg, Administered as Either a Fixed-Dose Combination Tablet or [NCT02578550]	Phase 1	126 participants (Actual)	Interventional	2015-11-30	Completed
[NCT02287857]		360 participants (Anticipated)	Interventional	2014-09-30	Recruiting
Structural and Partnership Factors Affecting Adherence to Pre-exposure Prophylaxis (PREP)Among Young Men Who Have Sex With Men [NCT02411630]		167 participants (Actual)	Observational	2013-06-30	Completed
Prospective Cohort Study to Assess the Safety and Efficacy of Replacing Tenofovir Disoproxil Fumarate by Tenofovir Alafenamide in HIV/HBV-coinfected Patients With Mild or Moderate Renal Dysfunction [NCT03115736]	Phase 2	24 participants (Actual)	Interventional	2017-05-23	Completed
"Efficacy, Safety, and Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1 Infection." [NCT03502005]	Phase 4	100 participants (Actual)	Interventional	2018-03-01	Completed
A Prospective, Randomized, Blank Control, Multicenter Study to Evaluate the Efficacy and Safety of Alanine Aminotransferase（TMF）in the Treatment of Chronic Hepatitis B Patients With Normal Alanine Aminotransferase. [NCT05797714]		200 participants (Anticipated)	Interventional	2022-06-23	Recruiting
A Maternal Short Course of Tenofovir Disoproxil Fumarate and Infant Vaccine to Prevent Mother-to-child Transmission of Hepatitis B Virus [NCT03343431]	Phase 3	504 participants (Actual)	Interventional	2018-08-02	Active, not recruiting
The Cellular Pharmacology of F-TAF in Dried Blood Spots [NCT02962739]	Phase 1	38 participants (Actual)	Interventional	2016-03-31	Completed
Demonstration Project of Early Antiretroviral Therapy and Pre-exposure Prophylaxis for HIV Prevention Among Female Sex Workers in Cotonou, Benin [NCT02237027]	Phase 4	361 participants (Actual)	Interventional	2014-10-31	Completed
Pre-exposure Option for Reducing HIV in the UK: an Open-label Randomisation to Immediate or Deferred Daily Truvada for HIV Negative Gay Men.(PROUD) [NCT02065986]	Phase 4	544 participants (Actual)	Interventional	2012-10-31	Completed
Phase I One-Month Safety, Pharmacokinetic, Pharmacodynamic, and Acceptability Study of Intravaginal Rings Releasing Tenofovir and Levonorgestrel or Tenofovir Alone [NCT02235662]	Phase 1	86 participants (Actual)	Interventional	2014-10-31	Completed
Efficacy of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-naïve Adults Without Baseline Genotyping Test (D2ARLING Study) [NCT04549467]	Phase 4	244 participants (Actual)	Interventional	2020-11-17	Active, not recruiting
Evaluating Inflammatory and Immunological Changes of HIV-positive Patients Switching to DTG Dual Regimen Compared to Those Switching to a Triple Drugs Regimen (B/F/TAF) [NCT04054089]	Phase 4	66 participants (Anticipated)	Interventional	2019-09-30	Not yet recruiting
Intensive Pharmacokinetic Studies of Antiretroviral Drug Combinations in Children [NCT00260078]	Phase 1/Phase 2	75 participants (Actual)	Interventional	2006-02-28	Completed
A Randomized Phase 2a, Multicenter, Open-Label, Multiple-Cohort Study Evaluating Regimens Containing Vebicorvir in Subjects With Chronic Hepatitis B Virus Infection [NCT04820686]	Phase 2	65 participants (Actual)	Interventional	2021-05-07	Terminated(stopped due to Sponsor decision)
Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Switch Followed by Sofosbuvir/Velpatasvir (SOF/VEL) Antiviral HCV Therapy Followed by Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Simplification in HIV-HCV [NCT03549312]	Phase 4	25 participants (Anticipated)	Interventional	2018-02-01	Recruiting
Phase III Multicenter Randomized Trial Evaluating in Patients at the Time of the Primary HIV-1 Infection, the Impact on the Viral Reservoir of a Combination Including Tenofovir/Emtricitabine and Dolutegravir or Tenofovir/Emtricitabine and Darunavir/Cobici [NCT02987530]	Phase 3	101 participants (Actual)	Interventional	2017-04-11	Completed
The Effect of Anti-viral Drugs Used in Late Pregnancy in Mothers With Hepatitis B Virus Infection on Long-term Development of Children [NCT02301650]		400 participants (Anticipated)	Observational	2014-10-31	Enrolling by invitation
Stop Hep B @ Birth: Community-Oriented Care Model for the Prevention of Mother-To-Child Transmission of Hepatitis B in Peri-Urban Yangon [NCT04998838]		110 participants (Anticipated)	Interventional	2018-07-01	Recruiting
DOT Diary Longitudinal Pilot: A Mobile App for Pre-Exposure Prophylaxis Adherence in Young Men [NCT03771638]	Phase 4	100 participants (Actual)	Interventional	2019-02-01	Completed
A Phase III, Randomised, Double-blind, Multicentre, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-n [NCT02831764]	Phase 3	722 participants (Actual)	Interventional	2016-07-18	Completed
A Multi-centre Phase III Study to Evaluate Pre-emptive Tenofovir for Prevention of Hepatitis B Virus Reactivation in HBsAg Negative/Anti-HBc Positive Individuals Undergoing Anti-CD20-based Chemotherapy for Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leu [NCT02186574]	Phase 3	184 participants (Anticipated)	Interventional	2015-05-31	Recruiting
A Phase IIa Multicenter, Open-Label Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A in Treatment-Naïve HIV-1 Infected Subjects With Selected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Transmitted Resistance Mutations [NCT02629822]	Phase 2	10 participants (Actual)	Interventional	2016-01-14	Completed
Maternal Screening and Antiviral Therapy in Pregnant Women to Reduce Mother-to-infant Transmission of Hepatitis B Virus [NCT03695029]	Phase 4	120 participants (Anticipated)	Interventional	2010-12-29	Recruiting
A Prospective, Cohort Study of Renal and Bone Outcome After Changing Tenofovir in Patients With Renal Toxicity According to Antiretroviral Strategy [NCT02209740]		245 participants (Actual)	Observational	2014-07-31	Completed
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Vir [NCT02831673]	Phase 3	719 participants (Actual)	Interventional	2016-07-21	Completed
TAF (Tenofovir Alafenamide) for Preventing Progression of Liver Disease in Non-cirrhotic Chronic HBV Infection With Normal ALT and Low Viral Load - a Randomized Controlled Trial [NCT05195450]		200 participants (Anticipated)	Interventional	2022-02-23	Recruiting
A Phase 1, Open-label Study in Healthy Participants to Investigate the Effect of Multiple-dose JNJ-56136379 on the Single-dose Pharmacokinetics of Bictegravir, Emtricitabine, and Tenofovir Alafenamide [NCT04853524]	Phase 1	0 participants (Actual)	Interventional	2021-05-06	Withdrawn(stopped due to Sponsor Decision)
Safety and Efficacy of Tenofovir Alafenamide to Prevent Perinatal Transmission of Hepatitis B (TAF-PPT): A Multicentre, Prospective, Open-label, Randomized Controlled Trial [NCT04850950]	Phase 4	240 participants (Anticipated)	Interventional	2021-04-26	Not yet recruiting
A Multinational, Multicenter, Open-label, Randomized Controlled Trial to Investigate the Effectiveness of Tenofovir Alafenamide in Reducing Clinical Events in Chronic Hepatitis B Patients Beyond Treatment Indications by Current Guidelines [NCT03753074]	Phase 4	780 participants (Anticipated)	Interventional	2019-02-18	Recruiting
A Prosp., Multic., Randomized, Open-label Trial to Assess the Safety, Tolerability and Efficacy of Dual Therapy With Boosted Darunavir + Dolutegravir When Switching From SOC ART in HIV-patients With Sustained Virological Suppr. [NCT02486133]	Phase 3	269 participants (Actual)	Interventional	2015-07-31	Completed
HIV Drug Resistance Profiles Among Individuals Failing Tenofovir/Lamivudine and Dolutegravir First Line Regimen in Brazil [NCT04453436]		2,500 participants (Anticipated)	Observational [Patient Registry]	2020-09-01	Not yet recruiting
A Phase I, Open Label, Single Sequence,Drug Interaction Study Evaluating Plasma GSK1349572 and Tenofovir Pharmacokinetics in Healthy Adult Subjects (ING111604) [NCT00726336]	Phase 1	16 participants (Anticipated)	Interventional	2008-08-31	Completed
A Phase III, Multi-center, Randomized, Double-blinded, Parallel Study to Assess the Antiviral Activity and Safety Endpoints for the Treatment of Besifovir 150mg Compared to Tenofovir 300mg in Chronic Hepatitis B Patients Who Have Resistance to Nucleoside [NCT02792088]	Phase 3	146 participants (Actual)	Interventional	2015-07-31	Completed
Change in Sleep Architecture and Neuropsychological Performance Following Switch From Atripla to Stribild. [NCT02283060]	Phase 4	30 participants (Anticipated)	Interventional	2014-09-30	Recruiting
HIV Infection and Gut Mucosal Immune Function: Longitudinal Analyses of Intestinal CD4+ and Th17 T Cells in HIV-infected Individuals on Short-term Antiretroviral Therapy [NCT02097381]		10 participants (Actual)	Interventional	2010-04-30	Active, not recruiting
Implementation and Evaluation of an HIV-2 Viral Load and ARV Resistance Informed Algorithm for 2nd-line ART in HIV-2 Infected Patients in the Initiative Sénégalaise d'Accès Aux Antirétroviraux (ISAARV) Program [NCT03394196]		152 participants (Actual)	Interventional	2018-07-04	Terminated(stopped due to COVID-19 and Funding)
ANRS HB 05 : A Randomized, Double Blind, Multicenter Study Evaluating Efficacy and Safety of Clevudine Monotherapy Versus Tenofovir Monotherapy Versus Combination Therapy of Clevudine and Tenofovir for 96 Weeks in HBeAg Negative Patients With Chronic Hepa [NCT00823342]	Phase 3	150 participants (Anticipated)	Interventional	2008-12-14	Terminated(stopped due to safety aspects)
Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability and Pharmacokinetics Study of Birinapant in Subjects With Chronic Hepatitis B [NCT02288208]	Phase 1	7 participants (Actual)	Interventional	2014-11-30	Terminated(stopped due to Due to cranial nerve palsies observed)
Prevention of Liver Fibrosis and Cancer in Africa. Observational Study of Screening, Assessment and Treatment for Chronic Hepatitis B Virus Infection [NCT02129829]		1,079 participants (Actual)	Observational	2011-10-31	Completed
Effect of SwitChing AtriPla to Eviplera on Neurocognitive and Emotional Functioning, ESCAPE Study [NCT02308332]	Phase 4	58 participants (Actual)	Interventional	2015-02-28	Completed
A Phase 2, Open-label, Randomized, Two-part, Multiple Dose Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic Hepatitis B Virus [NCT02751996]	Phase 2	80 participants (Actual)	Interventional	2016-05-31	Completed
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint? [NCT00090779]	Phase 2	130 participants (Actual)	Interventional	2005-01-31	Terminated(stopped due to The DSMB concluded that the findings regarding the primary analysis would persist and that no additional study goals would be achieved by continuing the study.)
A Prospective, Multi-center, Cohort Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) Therapy in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis [NCT02224456]	Phase 4	197 participants (Actual)	Interventional	2015-03-25	Completed
An Open, Multi-center Clinical Study of Combination Therapy With Tenofovir Disoproxil Fumarate and Peginterferon Alpha 2a in Nucleos(t)Ide Analogs Experienced Patients With HBV Related Hepatic Fibrosis. [NCT03957629]		186 participants (Anticipated)	Interventional	2019-11-06	Recruiting
Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum [NCT00042289]		1,578 participants (Actual)	Observational	2003-06-09	Completed
A Phase IV, Open-label, Multicenter Study of Treatment With TRIZIVIR (Abacavir 300mg/Lamivudine 150mg/Zidovudine 300mg) Twice Daily and Tenofovir 300mg Once-daily for 48 Weeks in HIV-infected Subjects Experiencing Early Virologic Failure (ZIAGEN Intensifi [NCT00038506]	Phase 4	100 participants	Interventional	2002-03-31	Completed
Open-Label, Multiple-Dose, Drug Interaction Study to Assess the Effect of Famotidine With or Without Tenofovir on the Pharmacokinetics of Atazanavir When Given With Ritonavir in HIV-Infected Subjects [NCT00384904]	Phase 4	40 participants (Actual)	Interventional	2006-12-31	Completed
Initiation of a Once Daily Regimen of Tenofovir, Lamivudine and Efavirenz After 4 Weeks Versus 12 Weeks of Tuberculosis Treatment in HIV-1 Infected Patients (Time Study) [NCT01014481]	Phase 4	156 participants (Actual)	Interventional	2009-10-31	Terminated(stopped due to this study was ended prematurely by ethical committees with a reason of the final outcome was achieved with no longer recruitment was needed.)
A Phase III, Randomized, 2x2 Factorial Trial to Assess the Efficacy of Antiviral Therapy in Women and Infants in Reducing Vertical Transmission of Hepatitis B in Africa [NCT04704024]	Phase 3	450 participants (Anticipated)	Interventional	2021-09-03	Recruiting
An Open Label, Comparative, Randomized , Phase IV Pilot Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load [NCT05898841]	Phase 4	75 participants (Anticipated)	Interventional	2023-05-26	Recruiting
A Phase IV Open-label, Multi-centre, Randomised, Dual-arm, Pilot Study to Assess the Feasibility of Switching Individuals Receiving Efavirenz With Continuing Central Nervous System (CNS) Toxicity, to Dolutegravir [NCT02285374]	Phase 4	40 participants (Anticipated)	Interventional	2014-11-30	Not yet recruiting
A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral Activity, and Pharmacokinetics of MK-8591 Given in Combination With Doravirine (DOR) and Lamivudine (3TC) [NCT03272347]	Phase 2	123 participants (Actual)	Interventional	2017-11-27	Completed
Study on Optimized Treatment of Peginterferon Alfa 2a or 2b in Anti-virus Treatment Experienced Patients With Hepatitis b Virus Related Liver Fibrosis [NCT03920605]		100 participants (Anticipated)	Interventional	2019-02-01	Recruiting
A Phase 1 Randomized, Double-Blinded, Placebo-Controlled Rectal Safety and Acceptability Study of Tenofovir 1% Gel [NCT01232803]	Phase 1	65 participants (Actual)	Interventional	2010-10-31	Completed
Induction of HBsAg Decline Using an add-on Treatment of Peginterferon Alfa-2a in HBeAg-negative Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogous (PAS) [NCT01373684]	Phase 4	90 participants (Actual)	Interventional	2012-05-25	Completed
A Randomized, Open-label, Controlled, Exploratory Trial to Characterize the Results of Daily Oral Administration of Telbivudine 600 mg and Tenofovir Disproxil Fumarate 300 mg in Combination or Telbivudine 600 mg or Tenofovir Disproxil Fumarate 300 mg Mono [NCT00804622]	Phase 2	15 participants (Actual)	Interventional	2008-12-31	Completed
DOT Diary (D2): Developing a Mobile App With Combined Automated DOT and Daily Sexual Diary for Monitoring and Improving PrEP Adherence: DOT Diary Optimization Pilot [NCT03387462]	Phase 4	20 participants (Actual)	Interventional	2018-02-28	Completed
Decreasing Risk of Recurrence by TAF in HCC Patients After Curative Treatment With Low HBV Viral Load [NCT04290936]	Phase 4	402 participants (Anticipated)	Interventional	2020-10-16	Recruiting
Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population [NCT01180075]		85 participants (Actual)	Observational	2010-05-31	Completed
Phase II Pilot Study of Simplification to Maraviroc - Raltegravir Dual Therapy After 6 Months of Maraviroc - Raltegravir - Tenofovir - Emtricitabine Quadruple Therapy in ARV Treatment-naive, HIV-1-infected Patients With CCR5- Virus [NCT01291459]	Phase 2	40 participants (Anticipated)	Interventional	2011-09-30	Active, not recruiting
A Multicenter, Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With Chronic Hepatitis B Virus (HBV) Infection [NCT02738008]	Phase 2	12 participants (Actual)	Interventional	2016-03-31	Terminated(stopped due to Company decision to discontinue trial)
Safety, PK/PD, Acceptability, and Desirability of a Novel HIV Prevention Douche Among Adolescent Men (DREAM) [NCT04686279]	Phase 1	8 participants (Actual)	Interventional	2021-04-01	Completed
A Phase IV, Open-label, Multi Centre Pilot Study to Assess Changes in Cerebral Function Parameters in Patients Without Perceived Central Nervous System (CNS) Symptoms When Switched From a Fixed Dose Combination of Tenofovir/Emtricitabine/Efavirenz (Atripl [NCT02529059]	Phase 4	40 participants (Anticipated)	Interventional	2015-11-30	Completed
Study on Optimized Treatment of Peginterferon Alfa 2a or 2b in Anti-virus Treatment Naive Patients With Hepatitis b Virus Related Liver Fibrosis [NCT03919565]		120 participants (Anticipated)	Interventional	2019-02-01	Recruiting
A Phase 2a Randomized, Double-blinded, Placebo-controlled, Multi Center, Dose Ranging Study of the Safety and Efficacy of ATI-2173 and Vebicorvir in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection [NCT05238844]	Phase 2	2 participants (Actual)	Interventional	2022-04-11	Terminated(stopped due to Sponsor stopped due to partner collaboration ending)
Expanded Safety Investigation of Tenofovir 1% Gel in Pregnancy and Lactation [NCT01136759]	Phase 1	232 participants (Actual)	Interventional	2011-03-31	Completed
"Prevention of HIV in Île-de-France" [NCT03113123]		3,257 participants (Anticipated)	Interventional	2017-05-03	Recruiting
A Phase III, Multi-Centre, Randomized Controlled Trial to Assess the Safety and Effectiveness of the Vaginal Microbicide 1% Tenofovir Gel in the Prevention of Human Immunodeficiency Virus Type 1 Infection in Women, and to Examine Effects of the Microbicid [NCT01386294]	Phase 3	2,059 participants (Actual)	Interventional	2011-10-31	Completed
A Multicenter, Open-label, Randomised, Comparative, Parallel-Arm, Phase II Study to Assess Efficacy and Safety of Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delt [NCT02888106]	Phase 2	90 participants (Actual)	Interventional	2016-04-30	Completed
Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir-boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)-Naive Adults or Adults Recommencing ART. [NCT01258439]	Phase 4	25 participants (Actual)	Interventional	2010-11-30	Completed
MULTICENTRE STUDY TO ASSESS CHANGES IN BONE MINERAL DENSITY OF THE SWITCH FROM TENOFOVIR TO ABACAVIR IN HIV-1-INFECTED SUBJECTS WITH LOSS OF BONE MINERAL DENSITY [NCT01153217]	Phase 3	54 participants (Actual)	Interventional	2010-07-31	Completed
Modifiers of Tenofovir Exposure in the Female Genital Tract of African Women on Depo-provera [NCT03377608]		50 participants (Actual)	Observational	2017-11-17	Completed
Pilot Single-Arm Clinical Trial to Evaluate the Efficacy, PK Interactions and Safety of Dolutegravir Plus 2 NRTIs in HIV-1-Infected Solid Organ Transplant Patients [NCT03360682]	Phase 4	20 participants (Anticipated)	Interventional	2018-04-12	Active, not recruiting
Pharmacokinetics of EFV 400mg Once Daily During Pregnancy in HIV+ Women [NCT02499874]	Phase 1	26 participants (Actual)	Interventional	2015-08-31	Completed
Efficacy and Safety of Switching to Tenofovir Alafenamide for Chronic Hepatitis B Patients With Advanced Fibrosis and Partial Virologic Responses to Oral Nucleos(t)Ide Analogues [NCT03798119]	Phase 4	80 participants (Anticipated)	Interventional	2019-02-25	Recruiting
Single Observed Dose Administration of Truvada® to Establish Single Dose Pharmacokinetic Standards in Healthy Individuals [NCT03719053]	Phase 1	44 participants (Actual)	Interventional	2018-10-25	Completed
Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants [NCT03048422]	Phase 3	643 participants (Actual)	Interventional	2018-01-19	Completed
Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals [NCT01293123]		2 participants (Actual)	Interventional	2011-12-31	Terminated(stopped due to Did not meet enrollment goals)
Acceptability and Feasibility of a Pre-Exposure Prophylaxis (PrEP) Trial With Young Men Who Have Sex With Men (YMSM) [NCT01033942]	Phase 2	68 participants (Actual)	Interventional	2009-08-31	Completed
Open-Label, Multiple-Dose, Drug Interaction Study to Assess the Effect of Famotidine on the Pharmacokinetics of Atazanavir in HIV-Infected Subjects Receiving Atazanavir With Ritonavir and Tenofovir [NCT01232127]	Phase 4	25 participants (Actual)	Interventional	2011-02-28	Completed
Atazanavir (BMS-232632) for HIV Infected Individuals Completing Atazanavir Clinical Trials: An Extended Access Study [NCT01003990]	Phase 3	710 participants (Actual)	Interventional	2002-10-31	Completed
Real World Study of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate to Prevent Vertical Transmission of Hepatitis B in Mothers With High Viral Load [NCT04211805]		450 participants (Anticipated)	Observational	2020-01-27	Recruiting
A Pilot Study--randomized, Prospective, Single Site Trial Evaluating Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients [NCT00762892]	Phase 4	33 participants (Actual)	Interventional	2009-01-31	Completed
Phase 2B Safety and Effectiveness Study of Tenofovir 1% Gel, Tenofovir Disproxil Fumarate Tablet and Emtricitabine/Tenofovir Disoproxil Fumarate Tablet for the Prevention of HIV Infection in Women [NCT00705679]	Phase 2	5,029 participants (Actual)	Interventional	2009-08-31	Completed
The Use of Tenofovir Disoproxil Fumarate (TDF) in the Management of Patients With Inactive Chronic Hepatitis B (CHB) Infection [NCT02600117]	Phase 3	50 participants (Actual)	Interventional	2016-01-26	Completed
Efficacy and Safety of Tenofovir Alafenamide in Chronic Hepatitis B Patients With Suboptimal Response Following Nucleos(t)Ide Therapy [NCT04201808]	Phase 4	100 participants (Anticipated)	Interventional	2021-05-01	Recruiting
A Multicenter, Randomized, Double-blind, Parallel Design, Phase III Clinical Trial to Evaluate the Efficacy and Safety of CKD-390 Tablet and Viread® Tablet in Chronic Hepatitis B Patients [NCT02805738]	Phase 3	158 participants (Anticipated)	Interventional	2016-04-30	Recruiting
A Randomized, Open-label Trial to Compare the Efficacy and Safety of Early Initiation of cART With or Without Autologous HIV-1 Specific Cytotoxic T Lymphocyte (CTL) Infusion in Treatment-Naïve Acute HIV-1 Infected Adults [NCT02231281]	Phase 3	65 participants (Anticipated)	Interventional	2014-08-31	Active, not recruiting
A Randomized, Non-comparative, Phase IIb, Unblinded Trial, Evaluating the Efficacy and Safety of Tenofovir-emtricitabine or Lamivudine Plus Zidovudine, Lopinavir/Ritonavir, or Raltegravir, Among ARV-naïve HIV-2 Infected Adult Patients, in West Africa [NCT02150993]	Phase 2/Phase 3	210 participants (Actual)	Interventional	2016-01-26	Completed
A Long Term Follow-up Registry of Subjects Treated in A Gilead-Sponsored Trial in Subjects With Chronic Hepatitis B Infection [NCT02258581]		241 participants (Actual)	Observational	2014-12-09	Terminated
Evaluation of the Capacity of a Weekly Strategy of 4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV-1 Infected Patients With Undetectable Viral Load for at Least 12 Months, to Maintain a Virological Success With This Intermittent M [NCT02157311]	Phase 3	100 participants (Actual)	Interventional	2014-07-31	Completed
Comparison of the Pharmacokinetics and Pharmacodynamics of Single Dose Tenofovir Vaginal Gel and Film Formulation [NCT02280109]	Early Phase 1	10 participants (Actual)	Interventional	2014-11-30	Completed
Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites [NCT04301661]		25 participants (Actual)	Observational	2020-03-06	Completed
Effectiveness of the Use of Personal Protective Equipment in Addition to Tenofovir/Emtricitabine for the Prevention of the Transmission of SARS-COV-2 to Health Care Personnel. Randomized Clinical Trial [NCT04519125]	Phase 2/Phase 3	950 participants (Anticipated)	Interventional	2020-08-30	Not yet recruiting
Efficacy of HBV Therapeutic Vaccine in Consolidation of Nucleos(t)Ide Analogues Therapy: a Pilot Study [NCT02505009]	Phase 4	116 participants (Actual)	Interventional	2015-05-01	Completed
Phase IIb, Double-Blinded, Multicenter, Randomized Study to Assess the Effect on Central Nervous System (CNS) Toxicity of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppre [NCT02652260]	Phase 2	86 participants (Actual)	Interventional	2016-03-04	Active, not recruiting
A Randomized Study to Compare the Efficacy of Vorinostat/Hydroxychloroquine/Maraviroc (VHM) in Controlling HIV After Treatment Interruption in Subjects Who Initiated ART During Acute HIV Infection [NCT02475915]	Phase 1/Phase 2	15 participants (Actual)	Interventional	2015-01-31	Completed
Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF) in Treatment-Naive CHB Related Fibrosis/Cirrhosis: a 96w Open-label Multicenter Study [NCT04939441]	Phase 4	100 participants (Anticipated)	Interventional	2021-04-20	Active, not recruiting
A Single-dose, Open-label, Randomized, Crossover Study to Assess the Impact of Food on the Pharmacokinetics of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Administered as a Fixed-dose Combination Tablet, and the Relative Bioavailabilit [NCT02475135]	Phase 1	72 participants (Actual)	Interventional	2015-06-01	Completed
Prevention of Mother-to-child Transmission of Hepatitis B Virus: a One Arm, Open Label Intervention Study to Estimate the Optimal Timing of Tenofovir (TDF) in Pregnancy [NCT02995005]	Phase 1/Phase 2	98 participants (Actual)	Interventional	2018-05-24	Completed
Sustainable Healthcenter Implementation PrEP Pilot Study [NCT02074891]		1,200 participants (Anticipated)	Observational	2014-10-31	Recruiting
Effect of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Bictegravir/Emtricitabine/Tenofovir Alafenamide on the Circulatory microRNA Profile in Treatment naïve HIV Patients, and Its Correlation With Change in Body Weight [NCT05463783]	Phase 4	30 participants (Anticipated)	Interventional	2023-03-14	Recruiting
The Efficacy and Safety of 12-week SOF/VEL Regimen Combined With Prophylactic Use of TAF for Treatment-naïve Genotype 1-6 HCV/HBV Co-infection Adult Patients With or Without Compensated Cirrhosis in China : a Mutil-center,Prospective,Single-arm,Open-label [NCT04997564]	Phase 4	120 participants (Anticipated)	Interventional	2021-08-31	Recruiting
A Phase 2a Crossover Trial Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population [NCT03074786]	Phase 2	0 participants (Actual)	Interventional	2017-11-30	Withdrawn(stopped due to Study was transferred to partner who will conduct under its own IND)
The Role of Home Packs of HIV Post-Exposure Prophylaxis for Sexual Exposure (PEPSE) to Improve the Speed and Appropriate Uptake of PEPSE in High Risk Individuals [NCT04965662]	Phase 4	139 participants (Actual)	Interventional	2018-01-01	Completed
Switching From Tenofovir Disoproxil Fumarate(TDF) to Tenofovir AlaFenamide(TAF) vs. Maintaining TDF Monotherapy in Chronic Hepatitis B Patients With Genotypic Resistance to Adefovir or Entecavir [NCT03241641]	Phase 4	174 participants (Actual)	Interventional	2017-10-26	Completed
The Pharmacokinetic and Pharmacodynamic Impacts of Depot Medroxyprogesterone Acetate on HIV Pre-exposure Prophylaxis (PrEP) [NCT03197961]	Early Phase 1	15 participants (Actual)	Interventional	2017-11-17	Completed
A 48-week, Randomized, Open-label, 2-arm Study to Compare the Efficacy of Saquinavir/Ritonavir Twice Daily (BID) Plus Emtricitabine/Tenofovir Once Daily (QD) Versus Lopinavir/Ritonavir BID Plus Emtricitabine/Tenofovir QD in Treatment-naïve Human Immunodef [NCT00105079]	Phase 3	337 participants (Actual)	Interventional	2005-04-30	Completed
Randomized Clinical Trial to Evaluate the Efficacy of Different Treatments in Patients With COVID-19 [NCT04890626]	Phase 3	2,193 participants (Anticipated)	Interventional	2020-04-04	Recruiting
An Open Label Randomized Clinical Trial, to Evaluate the Treatment With Darunavir/Ritonavir + Lamivudine Once Daily Versus Continuing With Darunavir/Ritonavir Once Daily + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject With Suppres [NCT02159599]	Phase 4	249 participants (Actual)	Interventional	2014-07-31	Completed
Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers [NCT03510468]	Phase 1	51 participants (Actual)	Interventional	2018-06-12	Completed
A Single Centre, Open-Label, Randomised, Parallel, Multiple Dose Comparison of the Effects of Tipranavir 500 mg and Ritonavir 100 mg or Tipranavir 750 mg and Ritonavir 200 mg Twice a Day for 11.5 Days on the Pharmacokinetic Characteristics of Tenofovir Di [NCT02251145]	Phase 1	49 participants (Actual)	Interventional	2002-05-31	Completed
A Multicenter, Randomized, Double-blind, Placebo-controlled Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Positive, [NCT02604212]	Phase 2	32 participants (Actual)	Interventional	2015-11-30	Terminated(stopped due to Company decision to discontinue trial)
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching From a Regimen of Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF in HIV-1 Infected Subjects Who Are Virologica [NCT02603120]	Phase 3	567 participants (Actual)	Interventional	2015-11-11	Completed
An Open-label, Randomized, Single Administration, Full Replicated Crossover Phase 1 Clinical Trial to Compare Pharmacokinetics and Safety Between JLP-1901 and JC-001 in Healthy Subjects [NCT06171880]	Phase 1	48 participants (Actual)	Interventional	2022-02-15	Completed
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infe [NCT02016924]	Phase 2/Phase 3	130 participants (Anticipated)	Interventional	2014-01-16	Recruiting
Effect of Reducing Nucleotide Exposure on Bone Health (ReNew) [NCT03549689]	Phase 2	0 participants (Actual)	Interventional	2019-08-01	Withdrawn(stopped due to Withdrawn by drug manufacturer)
Tenofovir Pharmacokinetics in HIV-infected Thai Adults With Moderate Renal Function Impairment Receiving Either a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based or Lopinavir/Ritonavir-based Antiretroviral Therapy [NCT01671982]	Phase 1	40 participants (Actual)	Interventional	2012-08-31	Completed
Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized, Open. [NCT02198443]	Phase 4	160 participants (Actual)	Interventional	2015-06-06	Completed
Implementation of HIV Preexposure Prophylaxis With Antiretroviral Medications Among People at High Risk for HIV Infection: A Demonstration Project [NCT02206555]	Phase 4	327 participants (Actual)	Interventional	2014-11-14	Completed
Study of Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz in Antiretroviral-Naive, HIV-1 Infected Adult Subjects [NCT00549198]	Phase 4	392 participants (Actual)	Interventional	2007-06-30	Completed
Pre-Exposure Prophylaxis and Timed Intercourse for HIV-Discordant Couples [NCT02572505]		0 participants (Actual)	Interventional	2015-11-30	Withdrawn
An Open-label, Randomized, Active Controlled, Parallel Comparison Study of the Safety and Efficacy of REP 2139-Mg in Combination With Pegasys® and Viread® and REP 2165-Mg in Combination With Pegasys® and Viread® in Patients With HBeAg Negative Chronic Hep [NCT02565719]	Phase 2	40 participants (Actual)	Interventional	2016-03-31	Completed
The Efficacy and Safety of TAF as a Prophylactic Antiviral Agent for HBsAg-positive Cancer Patients Receiving Chemotherapy [NCT04619082]	Phase 4	150 participants (Anticipated)	Interventional	2021-07-01	Recruiting
Phase IIb Pilot Study for the Evaluation of the Safety and the Feasibility of Treatment Simplification to Tenofovir+Emtricitabine+Raltegravir or to Lamivudine+Abacavir+Raltegravir in Patients With Optimal Virological Control and Toxicity to the Current Co [NCT00958100]	Phase 2	40 participants (Actual)	Interventional	2009-08-31	Completed
A Randomized, Prospective, Multicenter, Open-label Study to Evaluate the Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir in HBeAg-positive Chronic Hepatitis B Patients [NCT01588912]	Phase 4	104 participants (Anticipated)	Interventional	2012-04-30	Recruiting
Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study) [NCT04636437]	Phase 4	222 participants (Anticipated)	Interventional	2021-05-20	Recruiting
Adherence to a One Pill, Once-a-day Antiretroviral Regimen [NCT00990600]	Phase 3	212 participants (Actual)	Interventional	2008-04-30	Completed
IMPAACT P1058A: Intensive Pharmacokinetic Studies of New Classes of Antiretroviral Drug Combinations in Children, Adolescents and Young Adults [NCT00977756]		168 participants (Actual)	Observational	2002-08-31	Completed
A Multicenter Randomised Study Comparing the Antiviral Efficacy of Pegylated Interferon-alfa-2a Plus Placebo vs. Pegylated Interferon-alfa-2a Plus Tenofovir for the Treatment of Chronic Delta Hepatitis [NCT01088659]	Phase 3	50 participants (Actual)	Interventional	2010-02-16	Completed
A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy Plus HIV Primary Care Versus HIV Primary Care Alone to Prevent the Sexual Transmission of HIV-1 in Serodiscordant Couples [NCT00074581]	Phase 3	3,526 participants (Actual)	Interventional	2005-02-28	Completed
The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants [NCT04424264]	Phase 1	18 participants (Actual)	Interventional	2019-12-05	Completed
Effects of Sofosbuvir/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir [NCT02588287]		14 participants (Actual)	Interventional	2015-11-30	Completed
"A Phase Randomized Open Labelled Controlled Dose Escalation Study of Repeated Administration of CYT107 (Glyco-r-hIL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B-infected Patients" [NCT01027065]	Phase 1/Phase 2	24 participants (Anticipated)	Interventional	2009-12-31	Active, not recruiting
ADORE: A Single-arm, Phase 3, Pilot Study Investigating the Efficacy of Doravirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With Non-nucleoside Reverse Transcriptase Inhibitor Resistan [NCT04429152]	Phase 3	25 participants (Anticipated)	Interventional	2021-02-09	Recruiting
Phase III Open Label Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV [NCT00035932]	Phase 3	571 participants (Actual)	Interventional	2001-11-30	Completed
An Open-Label One-way Interaction Clinical Trial to Evaluate the Pharmacokinetic Interactions Between GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Subjects [NCT03836729]	Phase 1	16 participants (Actual)	Interventional	2019-02-11	Completed
Safety, Tolerability, and Adherence to a Raltegravir-based Antiretroviral Regimen for HIV Non-occupational Postexposure Prophylaxis [NCT01087840]	Phase 4	120 participants (Actual)	Interventional	2010-07-31	Completed
An Open-Label Study to Evaluate the Pharmacokinetics of Rilpivirine/Tenofovir/Emtricitabine After a Single-Oral Administration of a Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine Fixed-Dose Combination Tablet in Healthy Japanese Adult Male Subjec [NCT02530060]	Phase 4	8 participants (Actual)	Interventional	2015-08-31	Completed
Pre-Exposure Prophylaxis With TDF/FTC to Prevent HIV-1 Acquisition in Young Men and Transgender Women of Color Who Have Sex With Men [NCT02367807]		50 participants (Actual)	Observational	2015-02-28	Completed
International Trial of Modified Directly Observed Therapy Versus Self-Administered Therapy for Participants With First Virologic Failure on a Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Antiretroviral Regimen [NCT00608569]		529 participants (Actual)	Interventional	2009-03-31	Completed
Chronic HBV Infection in Pregnant Women Taking TAF to Prevent Mother-to-child Transmission in the Third Trimester: a Multicenter, Prospective Study [NCT04237376]		600 participants (Anticipated)	Observational	2019-04-09	Recruiting
A Multicenter Randomised Study Comparing the Efficacy of PegIFN-alfa2a Plus Placebo vs. PegIFN-alfa2a Plus Tenofovir for the Treatment of Chronic Delta Hepatitis-The Hep-Net International Delta Hepatitis Interventional Trial II (HIDIT-II) [NCT00932971]	Phase 2	70 participants (Actual)	Interventional	2009-06-30	Completed
A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women [NCT03164564]	Phase 3	3,224 participants (Actual)	Interventional	2017-11-07	Active, not recruiting
Multicentric, Non-inferiority, Randomized, Non-blinded Phase 3 Trial Comparing Virological Response at 48 Weeks of 3 Antiretroviral Treatment Regimens in HIV-1-infected Patients With Treatment Failure After 1st Line Antiretroviral Therapy (Cameroon, Burki [NCT00928187]	Phase 3	454 participants (Actual)	Interventional	2009-11-30	Completed
A Phase 4, Randomized, Open Label, Controlled Study of Boosted Darunavir and Lamivudine Versus Boosted Darunavir and Emtricitabine/Tenofovir or Lamivudine/Tenofovir in Naïve HIV-1 Infected Subjects [NCT02770508]	Phase 4	145 participants (Actual)	Interventional	2015-11-30	Completed
A Cohort Study of Tenofovir on Blocking HBV Intrauterine Infection [NCT02719808]		500 participants (Anticipated)	Observational	2015-03-31	Recruiting
A Phase 2, Randomized, Open-label, Ascending, Sequential Dose Group, Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of CMX157 in HBV-infected Subjects [NCT02710604]	Phase 2	62 participants (Actual)	Interventional	2016-05-31	Completed
APT-POCT-01: An Open Label, Pharmacokinetic Study of Plasma/Urine/Salivary Drug Concentrations Over Fourteen Days Following Drug Intake Cessation, In HIV-Uninfected Healthy Volunteers Dosing to Steady-state to Further Development of Point of Care Diagnost [NCT04302896]	Early Phase 1	30 participants (Actual)	Interventional	2020-08-31	Completed
Institute of HIV Research and Innovation (IHRI) [NCT04593680]		40 participants (Anticipated)	Interventional	2020-10-01	Recruiting
Change of Renal Function and Bone Mineral Density Marker in Chronic Hepatitis B Patients Switching From TDF to TAF vs. Maintaining TDF [NCT03356834]	Phase 4	1,000 participants (Anticipated)	Interventional	2017-12-01	Recruiting
TMC125-TiDP2-C238: A Randomized, Exploratory, Open-label 48-week Trial to Investigate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Etravirine (ETR) in Combination With Ritonavir-boosted Atazanavir (ATV/Rtv) and 1 NRTI in Treatment- [NCT00896051]	Phase 2	50 participants (Actual)	Interventional	2009-08-31	Completed
Efficacy and Safety of Switching From AZT to Tenofovir [NCT00647244]	Phase 4	40 participants (Actual)	Interventional	2008-06-30	Completed
A Phase II, Open-Label, Multicentre, Randomised, Comparator Study of Substitution With Tenofovir or Abacavir in HIV-1 Infected Individuals, With a Viral Load < 50 Copies/mL, Receiving a Thymidine Analogue (Zidovudine or Stavudine) as Part of Their Highly [NCT00647946]	Phase 2	100 participants (Actual)	Interventional	2003-02-28	Completed
First-Phase Viral Decay Rates in Treatment-Naive Subjects Initiating Treatment With Raltegravir (RAL) and Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF): A Pilot Study [NCT00660972]	Phase 1	40 participants (Actual)	Interventional	2008-05-31	Completed
An Exploratory Study to Evaluate The Efficacy And Safety of HLX10, A Humanized Monoclonal Antibody Targeting Programmed Death-1 (PD-1) Protein In Chronic Hepatitis B Patients [NCT04133259]	Phase 2	44 participants (Anticipated)	Interventional	2019-12-31	Recruiting
A Randomized Prospective Open-label Trial for Comparing Combination Therapy Peg-Interferon Alfa-2a/Adefovir Dipivoxil and Peg-Interferon Alfa-2a/Tenofovir Disoproxil Fumarate Versus no Treatment in HBeAg Negative Chronic Hepatitis B Patients With Low Vira [NCT00973219]		151 participants (Actual)	Interventional	2009-09-30	Completed
Open Label Study of Nucleus(t)Ide Treated Patients Randomised to Tenofovir, or Tenofovir + Telbivudine [NCT02774837]	Phase 4	146 participants (Actual)	Interventional	2016-04-30	Active, not recruiting
The Different Effects of Nucleotide and Nucleoside Analogues on the Prognosis of Hepatitis B Virus-Related Hepatocellular Carcinoma Patients After Curative Resection：a Randomized Controlled Trial [NCT04032860]	Phase 4	104 participants (Actual)	Interventional	2017-07-01	Active, not recruiting
A Study to Evaluate Clinical Benefits and Drawbacks of Antiretroviral Drugs as Pre-exposure Prophylaxis to Prevent HIV Infection Under Real-life Conditions Among Persons Who Pursue High-risk Sexual Practices: The Seville HIV PrEP Cohort [NCT05492565]		500 participants (Anticipated)	Observational [Patient Registry]	2020-01-01	Enrolling by invitation
A Study Comparing Efficacy and Tolerance of Two Maintenance Strategies : a Monotherapy With Lopinavir/Ritonavir or a Single-tablet Triple Therapy by Efavirenz/Emtricitabin/Tenofovir in HIV-1 Infected Patients With HIV RNA Below 50 cp/mL [NCT00946595]	Phase 2/Phase 3	420 participants (Anticipated)	Interventional	2009-11-30	Completed
Cellular Pharmacology of Tenofovir and Emtricitabine for HIV Prophylaxis (Cell Prep) [NCT01040091]	Phase 1	34 participants (Actual)	Interventional	2009-12-31	Completed
"The Effect of Prior Short Course Combination Antiretroviral Therapy Administered for the Prevention of Mother-to-Child Transmission (pMTCT) of HIV-1 on Subsequent Treatment Efficacy in Treatment-Nearly Naive Participants" [NCT00442962]	Phase 4	54 participants (Actual)	Interventional	2007-05-31	Completed
A Two-site, Phase 1, Partially-blinded, Placebo-controlled Safety, Acceptability and Pharmacokinetic Trial of Topical, Vaginally-formulated Tenofovir 1% Gel Applied Rectally Compared With Oral 300 mg Tenofovir Disoproxil Fumarate in HIV-1 Seronegative Adu [NCT00984971]	Phase 1	18 participants (Actual)	Interventional	2009-09-30	Completed
Closing a Critical HIV Prevention Gap: Demonstrating Safety and Effective Delivery of Daily Oral Pre-exposure Prophylaxis (PrEP) as Part of an HIV Combination Preventive Intervention for Sex Workers in Kolkata and Mysore-Mandya, India [NCT02148094]	Early Phase 1	1,325 participants (Actual)	Interventional	2016-01-31	Completed
A Pilot Study of Daily TDF/FTC-based PrEP Among High-risk Toronto MSM:The PREPARATORY-5 Study [NCT02149888]	Phase 4	52 participants (Actual)	Interventional	2014-10-31	Completed
A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D [NCT03546621]	Phase 2	120 participants (Actual)	Interventional	2016-02-16	Completed
A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB) [NCT04891770]	Phase 2	103 participants (Actual)	Interventional	2021-08-14	Active, not recruiting
Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention During Pregnancy and Postpartum in Adolescents and Young Women and Their Infants [NCT03386578]	Phase 2	390 participants (Actual)	Interventional	2018-07-03	Active, not recruiting
The Stability and Bioequivalence of Tenofovir, Emtricitabine and Efavirenz (Atripla) in an Extemporaneously Prepared Oral Liquid Formulation Compared With the Commercially Available Tablet Formulation [NCT00862823]	Phase 4	14 participants (Actual)	Interventional	2009-02-28	Completed
Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in Healthy Women [NCT00869960]	Phase 4	24 participants (Actual)	Interventional	2009-03-31	Completed
Nucleoside-Sparing Combination Therapy With Lopinavir/Ritonavir (LPV/r) + Raltegravir (RAL) vs. Efavirenz (EFV) + Tenofovir Disoproxil Fumarate + Emtricitabine (TDF/FTC) in Antiretroviral-Naïve Patients [NCT00752856]	Phase 2	51 participants (Actual)	Interventional	2008-08-26	Completed
A Single-arm, Multinational, Two Year Study Evaluating the Efficacy and Safety of lead-in Telbivudine for 24 Weeks With or Without Tenofovir Treatment Intensification in Adult Patients With HBeAg-positive Chronic Hepatitis B. [NCT00651209]	Phase 4	105 participants (Actual)	Interventional	2008-02-29	Completed
Pilot Study Of Novel Combination Of Maraviroc + Atazanavir/Ritonavir vs. Atazanavir/Ritonavir + Emtricitabine/Tenofovir For The Treatment Of Naïve HIV-Infected Patients With R5 HIV-1 [NCT00827112]	Phase 2	129 participants (Actual)	Interventional	2009-03-31	Completed
A Phase 2, Open-label, Single-arm, Multicenter Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Treatment With JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Patients [NCT04667104]	Phase 2	48 participants (Actual)	Interventional	2021-02-01	Completed
An Open-Label Phase 2 Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Tenofovir in Naive Patients With Chronic Hepatitis b: a Multicenter, Randomized, Positive Controlled Clinical Trial [NCT04157699]	Phase 2	100 participants (Anticipated)	Interventional	2019-07-26	Recruiting
CID 0706 - Safety, Tolerability, Pharmacokinetic, and Metabolic Features of Raltegravir Among African-American Men and Women With HIV Infection [NCT00667433]	Phase 1	38 participants (Actual)	Interventional	2008-06-30	Completed
Effects of Antiviral Therapies on Epstein-Barr Virus Replication [NCT05957913]	Phase 2	50 participants (Anticipated)	Interventional	2023-06-05	Enrolling by invitation
Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism in ARV-naive HIV-infected Subjects [NCT00759070]	Phase 4	50 participants (Anticipated)	Interventional	2008-09-30	Active, not recruiting
Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis: A Multicenter, Real-world and Respective Study [NCT04160897]		4,000 participants (Anticipated)	Observational	2019-10-22	Enrolling by invitation
A Randomized, Open-label, Two-way Crossover Study to Assess the Safety and Pharmacokinetics of DA-2802 319mg and Viread 300mg After a Single Oral Dose in Healthy Male Volunteers [NCT02557594]	Phase 1	36 participants (Actual)	Interventional	2015-10-06	Completed
[NCT02920931]	Phase 1	50 participants (Actual)	Interventional	2016-02-29	Completed
Randomized Controlled Trial Comparing the Efficacy and Safety of FMT in Hepatitis B Reactivation Leads to Acute on Chronic Liver Failure. [NCT02689245]		64 participants (Actual)	Interventional	2016-02-26	Completed
Evaluation of Intrahepatic Immune and Virological Response to Tenofovir Alafenamide With Fine Needle Aspiration Biopsy in Chronic Hepatitis B: an Investigator-Initiated, Cohort Study [NCT04070079]	Phase 4	15 participants (Anticipated)	Interventional	2019-01-29	Recruiting
Study of the Safety and Efficacy of Daily Oral Antiretroviral Use for the Prevention of HIV Infection in Heterosexually Active Young Adults in Botswana [NCT00448669]	Phase 2/Phase 3	1,219 participants (Actual)	Interventional	2007-03-31	Completed
A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Adolescents With Chronic Hepatitis B Infection [NCT00734162]	Phase 3	106 participants (Actual)	Interventional	2008-12-31	Completed
A Randomized, Open-label Study of Lopinavir/Ritonavir 400/100 mg Tablet Twice Daily + Co-formulated Emtricitabine/Tenofovir Disoproxil Fumarate 200/300 mg Once Daily Versus Lopinavir/Ritonavir 400/100 mg Tablet Twice Daily + Raltegravir 400 mg Twice Daily [NCT00711009]	Phase 3	206 participants (Actual)	Interventional	2008-07-31	Completed
A Phase IV Study to Evaluate the Efficacy, Safety and Tolerability of Tenofovir DF in Asian-American Adults With Chronic Hepatitis B Infection [NCT00736190]	Phase 4	90 participants (Actual)	Interventional	2008-08-31	Completed
Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg. [NCT02583464]	Phase 1	24 participants (Actual)	Interventional	2014-09-30	Completed
Phase 2a Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV - An Extended Safety Evaluation [NCT00122512]	Phase 2	500 participants	Interventional		Terminated
Direct Antiviral Agents for the Treatment of Chronic HCV/HBV Co-infection Patients [NCT02555943]	Phase 2/Phase 3	23 participants (Actual)	Interventional	2015-02-28	Completed
CID 0805 - Treatment of Acute HIV Infection With a Once Daily Regimen of Emtricitabine, Tenofovir and Efavirenz - A Pilot Study of Response to Therapy and HIV Pathogenesis [NCT00924898]	Phase 4	92 participants (Actual)	Interventional	2005-01-31	Completed
A Phase IV, Randomized, Double-Blind, Placebo-Controlled, Two-Phase Crossover Study of the Metabolic Impact of Tenofovir Disoproxil Fumarate on HIV-1 Seronegative Healthy Adult Males [NCT00648817]	Phase 4	8 participants (Actual)	Interventional	2006-07-31	Completed
Open Randomized Study to Assess the Evolution of Plasma Lipid Profile by Lipidomic in Patients Infected With Human Immunodeficiency Virus (HIV-1) With Viral Suppression That Change Atripla® to Eviplera® Compared to Continue With Atripla® [NCT02547844]	Phase 4	30 participants (Actual)	Interventional	2015-09-30	Completed
Quantification of Estradiol's Impact on Nucleotides in Different Cellular Populations of the Lower Gastrointestinal Tract [NCT03917420]	Phase 1	10 participants (Actual)	Interventional	2019-03-26	Completed
A Prospective,Multi-center,Cohort Trial: the Efficacy and Safety of Tenofovir Alafenamide Fumarate Tablets (TAF) in Blocking Mother-to-child Transmission of Hepatitis B Virus(HBV) [NCT04065230]		330 participants (Anticipated)	Observational [Patient Registry]	2019-08-31	Recruiting
Effectiveness and Safety of Tenofovir Alafenamide for HBV Prophylaxis in HBV Negative Recipients Received Orthotopic Liver Transplant With HBcAb+ Donors [NCT04703465]		30 participants (Anticipated)	Interventional	2021-04-01	Not yet recruiting
Pharmacokinetics and Safety of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants [NCT04862975]		200 participants (Anticipated)	Observational	2024-01-08	Not yet recruiting
A Randomized, Open-Label, Parallel, Multi-Center, Non-inferiority, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Switching to Besifovir Dipivoxil Maleate From Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B Patients Who Pretrea [NCT04202536]	Phase 4	152 participants (Anticipated)	Interventional	2019-05-29	Recruiting
Decay Kinetics of HIV With the Integrase Inhibitor Raltegravir [NCT00863668]		0 participants (Actual)	Interventional	2009-03-31	Withdrawn
CID 0708 - Sex, Aging and Antiretroviral Pharmacokinetics [NCT00666055]		11 participants (Actual)	Observational	2008-03-31	Completed
Steady-state Pharmacokinetics of Efavirenz (Sustiva/Stocrin) 400 mg Once Daily in the Presence of Rifampicin and Isoniazid (Rifinah or the Local Generics) [NCT02832778]	Phase 1	35 participants (Anticipated)	Interventional	2016-11-21	Recruiting
An Open-Label Phase 2 Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Entecavir or Tenofovir in Patients With Chronic Hepatitis b Who Have Received Nucleoside (Acid) Therapy : a Multicenter, Randomized, Positive Controlled Clin [NCT04157257]	Phase 2	60 participants (Anticipated)	Interventional	2019-07-26	Recruiting
Clinical Investigation About Therapeutic Effects and Long-term Follow-up After Ending Anti-hepatitis B Virus Therapy With Nucleos(t)Ide Analogs in Patients With Chronic Hepatitis b [NCT02883647]		100 participants (Anticipated)	Observational	2014-01-31	Recruiting
A Perspective Study of the Antiviral Efficacy and Safety of Switching to TAF Treatment in CHB Adults With Suboptimal Response (SOR) or Intolerant to Entecavir [NCT04034368]	Phase 4	8 participants (Anticipated)	Interventional	2019-08-31	Not yet recruiting
Exploratory Study on Antiviral Therapy for Patients With Chronic Hepatitis B Virus Infection (Immune Tolerance Period) [NCT05382351]	Phase 2	238 participants (Anticipated)	Interventional	2022-05-10	Recruiting
A Phase I, Open-label, Randomized, Crossover Trial in 20 Healthy Subjects to Investigate the Pharmacokinetic Interactions Between the Combination of Efavirenz and Tenofovir Disoproxil Fumarate and Different Dosages of Telaprevir. [NCT00828789]	Phase 1	20 participants (Actual)	Interventional	2009-02-28	Completed
Antiretroviral Therapy and the Hepatitis C Virus [NCT00545558]	Phase 1	18 participants (Actual)	Interventional	2006-04-30	Completed
Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects [NCT00551018]	Phase 2	218 participants (Actual)	Interventional	2007-12-31	Completed
Safety and Efficacy of Tenofovir Alafenamide for Chronic Hepatitis B Patients With Decompensated Liver Disease [NCT04683341]	Phase 4	100 participants (Anticipated)	Interventional	2020-09-01	Recruiting
TDF Combined With LDT for the Treatment of HBeAg-positive Hepatitis B Patients With Poor Response to TDF for Twelve Months [NCT04650828]		200 participants (Anticipated)	Observational [Patient Registry]	2020-12-01	Recruiting
An Omnibus Protocol to Characterize Patients With Hepatitis B and C (the HOPE Study) With Hepatitis B Treatment Sub-study [NCT02995252]		550 participants (Anticipated)	Observational	2014-12-31	Recruiting
Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa [NCT06138600]	Phase 3	200 participants (Anticipated)	Interventional	2023-11-01	Active, not recruiting
Randomized Trial of Tenofovir Disoproxil Fumerate Dose Adjustment VS. Switching to Tenofovir Alafenamide in Tenofovir Disoproxil Fumarate-experienced Chronic Hepatitis B Patients With Renal Impairment [NCT04391608]	Phase 4	80 participants (Anticipated)	Interventional	2019-11-09	Recruiting
Safety and Efficacy of Emtricitabine/Tenofovir Alafenamide as Part of Salvage Antiretroviral Regimens in Patients With Uncontrolled Viremia and Drug-Resistant HIV Infection [NCT02556333]	Phase 2	1 participants (Actual)	Interventional	2015-09-16	Terminated
A Pilot Trial of Simvastatin Alone and Added to Tenofovir or Entecavir for the Treatment of Chronic Hepatitis B [NCT00994773]	Phase 1	32 participants (Actual)	Interventional	2009-12-31	Completed
A Phase III, Randomized, Open-Label Study Comparing the Safety and Efficacy of Switching Stavudine or Zidovudine to Tenofovir Disoproxil Fumarate Versus Continuing Stavudine or Zidovudine in Virologically Suppressed HIV-Infected Children Taking Highly Act [NCT00528957]	Phase 3	97 participants (Actual)	Interventional	2006-12-28	Completed
The Optimization of HAART for Chinese--a RCT Study [NCT02945163]	Phase 4	184 participants (Actual)	Interventional	2018-03-05	Completed
A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Preexposure Prophylaxis in Cisgender Women at High Risk for HIV-1 Infection [NCT04644029]	Phase 3	730 participants (Actual)	Interventional	2021-02-24	Active, not recruiting
Role of Exogenous and Endogenous Sex Hormones on Tenofovir and Emtricitabine [NCT03218085]		50 participants (Anticipated)	Observational	2017-07-14	Recruiting
Cell Cycle Independent Antiretroviral Therapy: Combination of Nevirapine, FTC, and Tenofovir [NCT00344461]	Phase 4	54 participants (Actual)	Interventional	2004-03-31	Completed
A Multicenter, Open-label, Randomized Study to Assess the Metabolics, Efficacy, and Safety of Once-daily Darunavir Versus Atazanavir in HIV-infected Treatment-naive Adult Patients [NCT00757783]	Phase 4	68 participants (Actual)	Interventional	2008-10-31	Completed
Randomized, Double-blind, Placebo-controlled Phase Ib/IIa Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment-naïve Patients and Treated Patients With Chronic He [NCT06150014]	Phase 1/Phase 2	64 participants (Anticipated)	Interventional	2023-12-07	Recruiting
A Phase 2, Randomized, Double-Blind Study Exploring the Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine Plus Tenofovir DF Fixed-Dose Combination Therapy in Subjects Currently Being Treated With Adef [NCT00307489]	Phase 2	106 participants (Actual)	Interventional	2006-03-31	Completed
A Multicenter, Randomized, Open-Label, Active-Controlled Pilot Study to Evaluate the Safety and Antiretroviral Activity of Unboosted Atazanavir BID Plus Raltegravir BID and Boosted Atazanavir QD in Combination With Tenofovir/Emtricitabine QD in Treatment [NCT00768989]	Phase 2	167 participants (Actual)	Interventional	2008-11-30	Terminated(stopped due to Efficacy endpoint met, but overall experimental dosing regimen not considered optimal to support further clinical development in this population.)
The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment [NCT00811954]	Phase 3	1,814 participants (Actual)	Interventional	2009-05-31	Completed
A Phase III Randomized, Open Label Trial to Evaluate Dolutegravir Versus Efavirenz 400 mg, Both Combined With Tenofovir Disoproxil Fumarate + Lamivudine for the Initial Management of HIV Infected Adults in Resource-limited Settings [NCT02777229]	Phase 3	616 participants (Actual)	Interventional	2016-07-31	Completed
A Prospective, Randomized, Open Label Phase IV Study to Evaluate the Rationale of Switching From Fixed Dose Abacavir (ABC)/Lamivudine (3TC) to Fixed Dose Tenofovir DF (TDF)/Emtricitabine (FTC) in Virologically Suppressed, HIV-1 Infected Patients Maintaine [NCT00724711]	Phase 4	312 participants (Actual)	Interventional	2008-07-31	Completed
A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Compare the Safety and Pharmacokinetics of CKD-390 Tablet (Tenofovir Disoproxil Aspartate) With Viread® Tablet (Tenofovir Disoproxil Fumarate) in Healthy Male Volunteers [NCT02589457]	Phase 1	40 participants (Actual)	Interventional	2015-10-31	Completed
A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy [NCT02585947]	Phase 4	90 participants (Anticipated)	Interventional	2015-11-30	Recruiting
A Phase 2, Double-Blind, Multi-center, Randomized Study Comparing Tenofovir Disoproxil Fumarate, Emtricitabine Plus Tenofovir Disoproxil Fumarate, and Entecavir in the Treatment of Chronic Hepatitis B Subjects With Decompensated Liver Disease and in the P [NCT00298363]	Phase 2	112 participants (Actual)	Interventional	2006-04-30	Completed
Severe Impairment of Solute-Free Water Clearance in Patients With HIV Infection [NCT01869010]		30 participants (Actual)	Observational	2010-01-31	Completed
Study to Evaluate the Pharmacokinetic, Safety, and Efficacy of TAF in HBV-Infected Pregnant Women [NCT05853718]	Phase 4	50 participants (Anticipated)	Interventional	2021-05-06	Recruiting
A Randomized, Phase II, Open Label Study to Compare Twice Daily and Once Daily Potent Antiretroviral Therapy and to Compare Self-Administered Therapy and Therapy Administered Under Direct Observation [NCT00036452]	Phase 2	402 participants (Actual)	Interventional		Completed
A Prospective Study to Investigate the Relationship Between Hepatitis B Surface Antigen (HBsAg) Loss and the Dynamics in Host and Viral Markers After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment in Chronic Hepatitis B E-antigen Negative Patients [NCT05550519]	Early Phase 1	0 participants (Actual)	Interventional	2022-10-31	Withdrawn(stopped due to Sponsor decision after reevaluation of strategy in the context of recruitment timelines projection)
Correcting Pre-Exposure Prophylaxis (PrEP) Dosing and Adherence Benchmarks in Pregnancy to Optimize HIV Prevention (PrEP-P): A Randomized Comparative Pharmacokinetic Trial [NCT03834909]	Phase 1	0 participants (Actual)	Interventional	2022-04-30	Withdrawn(stopped due to Study was not funded)
US Expanded Access Program of Tenofovir Disoproxil Fumarate in the Treatment of HIV-1 Infected Patients Who Have Limited Treatment Options [NCT00011089]		0 participants	Interventional	2001-02-28	Active, not recruiting
Switching to Tenofovir Alafenamide Fumarate or Abacavir in Patients With Tenofovir Disoproxil Fumarate Associated eGFR Decline. A Randomized Trial. [NCT02957864]	Phase 4	80 participants (Anticipated)	Interventional	2016-10-31	Recruiting
IN-US-276-1340: Pre-Exposure Prophylaxis to Prevent HIV Acquisition in US Women: A Demonstration Project [NCT03058835]	Phase 4	125 participants (Actual)	Interventional	2016-09-30	Active, not recruiting
Randomized Controlled Trail (RCT) of Emtricitabine, Tenofovir Disoproxil and Raltegravir for Patients With Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid (UDCA) [NCT03954327]	Phase 2	37 participants (Actual)	Interventional	2021-03-01	Active, not recruiting
Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl. A Prospective, Randomized, Multicentre, Open Clinical Study. [NCT00532168]	Phase 4	108 participants (Actual)	Interventional	2007-09-30	Completed
Optimization of Antiretroviral Therapy [NCT02935075]	Phase 4	184 participants (Actual)	Interventional	2018-03-05	Completed
A Phase 1 Pharmacokinetic Study of Varying Dosing Patterns on Tenofovir Concentrations in Hair [NCT00903084]	Phase 1	24 participants (Actual)	Interventional	2009-06-30	Completed
A Randomized Evaluation of Antiretroviral Therapy Alone or With Delayed Chemotherapy Versus Antiretroviral Therapy With Immediate Adjunctive Chemotherapy for Treatment of Limited Stage AIDS-KS in Resource-Limited Settings (REACT-KS) AMC 067 [NCT01352117]	Phase 3	192 participants (Actual)	Interventional	2011-11-18	Completed
Effect of Tenofovir/Emtricitabine Short Course on Viral Clearance in Patients Recently Infected With SARS-COV2 (Covid-19) Not Requiring Hospitalization: a Phase IIB/III Multicenter Open-label Randomized Controlled Trial [NCT04685512]	Phase 2/Phase 3	60 participants (Actual)	Interventional	2020-11-18	Completed
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Tenofovir DF as Part of an Optimized Antiretroviral Regimen in HIV-1-Infected Adolescents [NCT00352053]	Phase 3	87 participants (Actual)	Interventional	2006-06-30	Completed
A Comparative Study of Entecavir vs. Adefovir Plus Lamivudine vs Combination Entecavir Plus Adefovir in Lamivudine-resistant Chronic Hepatitis B Subjects: The DEFINE Study [NCT00410202]	Phase 3	629 participants (Actual)	Interventional	2008-03-31	Completed
Optimisation of Primary HIV1 Infection Treatment (ANRS 147 OPTIPRIM) [NCT01033760]	Phase 3	90 participants (Actual)	Interventional	2010-04-30	Completed
A Comparative Study of Chronic Hepatitis B Subjects Treated With Entecavir Plus Tenofovir Combination Therapy vs. Entecavir Monotherapy in Adults Who Are Treatment-Naive to Nucleosides and Nucleotides: The BE-LOW Study [NCT00410072]	Phase 3	669 participants (Actual)	Interventional	2007-04-30	Completed
A Pilot Study of Lopinavir/Ritonavir in Participants Experiencing Virologic Relapse on NNRTI-Containing Regimens [NCT00357552]		123 participants (Actual)	Interventional	2008-01-31	Completed
Nucleosides And Darunavir/Dolutegravir In Africa (NADIA): a Randomised Controlled Trial of Darunavir Versus Dolutegravir and Tenofovir Versus Zidovudine in Second-line Antiretroviral Therapy Regimens for the Public Health Approach in Sub-Saharan Africa [NCT03988452]	Phase 3	465 participants (Actual)	Interventional	2019-07-30	Active, not recruiting
A Randomised, Open-label, 96-week Study Comparing the Safety and Efficacy of Three Different Combination Antiretroviral Regimens as Initial Therapy for HIV Infection. [NCT00335322]	Phase 4	329 participants (Actual)	Interventional	2007-02-28	Completed
A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Patients With Chronic Hepatitis B Infection [NCT01651403]	Phase 3	90 participants (Actual)	Interventional	2012-12-06	Active, not recruiting
Tenofovir Reduces Morbidity and Mortality in Patients With Spontaneous Reactivation of Hepatitis B Presenting as Acute-on-chronic Liver Failure (ACLF): A Randomized Placebo Controlled Trial [NCT01074645]	Phase 4	27 participants (Actual)	Interventional	2007-11-30	Completed
Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed [NCT04132674]	Phase 4	40 participants (Anticipated)	Interventional	2018-11-26	Recruiting
Treatment Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in naïve Chronic Hepatitis B : a Real Life Multicenter Cohort Study in Korea [NCT02533544]		572 participants (Actual)	Observational	2015-10-31	Completed
An Open-label Randomised Two-year Trial Comparing Two First-line Regimens in HIV-infected Antiretroviral naïve Subjects: Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir (ANRS 143/NEAT 001) [NCT01066962]	Phase 3	800 participants (Actual)	Interventional	2010-08-31	Completed
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PE [NCT00084136]	Phase 4	1,571 participants (Actual)	Interventional	2005-05-31	Completed
A Phase 1, Randomized Pharmacokinetic and Safety Study of a 90 Day Intravaginal Ring Containing Tenofovir [NCT03670355]	Phase 1	49 participants (Actual)	Interventional	2018-12-07	Completed
Switching HIV-positive Women on Tenofovir/Emtricitabine Plus Boosted Atazanavir to RALtegravir Plus Boosted ATazanavir: A Pilot Randomized Clinical Trial Investigating 48-weeks Changes in Bone Mineral Density [NCT01902186]	Phase 4	4 participants (Actual)	Interventional	2014-09-30	Terminated(stopped due to Low enrollment)
Safety, Tolerability, and Adherence to Co-formulated Emtricitabine-rilpivirine-tenofovir Used as HIV Nonoccupational Post Exposure Prophylaxis in Men Who Have Sex With Men (EPEP) [NCT01715636]	Phase 4	100 participants (Actual)	Interventional	2012-12-31	Completed
[NCT01918631]		36 participants (Actual)	Interventional	2013-08-31	Completed
A Phase Ⅲ, Multi-center, Randomized, Double-blinded, Parallel Study to Assess the Antiviral Activity and Safety of Besifovir 150 mg Compared to Tenofovir 300 mg in Chronic Hepatitis B Patients for 48 Weeks [NCT01937806]	Phase 3	197 participants (Actual)	Interventional	2013-10-31	Active, not recruiting
Addition of Single-dose, Maternal Tenofovir and Emtricitabine to Reduce Non-nucleoside Reverse Transcriptase Inhibitor Resistance Mutations in the Setting of Zidovudine and Nevirapine for Prevention of Mother-to-child HIV Transmission [NCT00204308]	Phase 2	400 participants (Actual)	Interventional	2005-03-31	Completed
Evaluate the Efficacy and Safety of Switching to Tenofovir Disoproxil From Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients Who Pretreated With Tenofovir Disoproxil Fumarate [NCT03485534]	Phase 4	189 participants (Actual)	Interventional	2018-01-23	Completed
Tenofovir, Emtricitabine, and Nevirapine for Recently HIV-Infected Subjects: Can Short-Course, Once Daily Therapy Reduce the Viral Load at 12 Months From Estimated Date of Infection? [NCT00087464]		0 participants (Actual)	Interventional		Withdrawn(stopped due to study was withdrawn before any participants were recruited and enrolled)
Single Dose and 14-Day Once or Twice-Daily Pharmacokinetic Study of the Vaginal Microbicide Agent 1% Tenofovir Gel [NCT00561496]	Phase 1	49 participants (Actual)	Interventional	2007-03-31	Completed
Phase 2 Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV [NCT00122486]	Phase 2	1,200 participants	Interventional	2004-07-31	Completed
Implementation of the Pre-Exposure Prophylaxis (PrEP) to HIV: A Demonstrative Project. [NCT01989611]		400 participants (Anticipated)	Interventional	2014-06-30	Active, not recruiting
A Phase I Trial to Assess the Safety of Tenofovir Gel and Film Formulations: FAME 04 [NCT01989663]	Phase 1	78 participants (Actual)	Interventional	2013-11-30	Completed
Phase 3 Randomized Trial Evaluating the Virological Efficacy and the Tolerance of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Dakar and Yaounde [NCT00573001]	Phase 3	120 participants (Actual)	Interventional	2008-07-31	Completed
A Prospective, Randomized, Three-period Crossover, Interaction Study to Evaluate the Pharmacokinetics of Doravirine and Tenofovir Disoproxil Fumarate Co-administered With Cross-sex Hormonal Therapy in Adult HIV-negative Transgender Women [NCT04283656]	Phase 1	7 participants (Actual)	Interventional	2022-02-14	Completed
CHAMPS: Choices For Adolescent Prevention Methods For South Africa. Pilot Study B: 'PlusPills' [NCT02213328]	Phase 2	148 participants (Actual)	Interventional	2015-04-30	Completed
HPTN 091: Integrating HIV Prevention, Gender-Affirmative Medical Care, and Peer Health Navigation for Transgender Women in the Americas: A Vanguard Study [NCT04742491]	Phase 2/Phase 3	307 participants (Actual)	Interventional	2021-03-26	Active, not recruiting
Randomized, Double-blinded, Controlled Trial of Intensive HAART Including Raltegravir, and Maraviroc, on HIV-1 Pro-viral DNA and Reservoir Decay in HIV-1-infected Individuals During the Acute/Early Infection [NCT01154673]	Phase 2/Phase 3	32 participants (Actual)	Interventional	2011-11-30	Completed
A Randomized, Pilot Study on the Antiviral Activity and Immunological Effects of Lopinavir/Ritonavir vs. Efavirenz in Treatment-naïve HIV-Infected Patients With CD4 Cell Counts Below 100 Cells/mm3 [NCT00386659]	Phase 4	60 participants	Interventional		Terminated
A Phase 2 Randomized Cross-Over Design Study of the Early Metabolic Effects of Dolutegravir or Tenofovir Alafenamide in Healthy Volunteers [NCT05652478]	Phase 2	120 participants (Anticipated)	Interventional	2024-01-03	Recruiting
Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals [NCT02251236]		14 participants (Actual)	Interventional	2016-01-31	Completed
HIV Pre-exposure Prophylaxis Implementation Study in South Korea [NCT04583267]		200 participants (Anticipated)	Interventional	2018-08-28	Recruiting
Optimizing Access to Non-occupational Post Exposure Prophylaxis for HIV Using Contingency Management in Stimulant-Using Men Who Have Sex With Men [NCT01140880]	Phase 2	170 participants (Actual)	Interventional	2010-05-31	Completed
A Randomized, Single-Dose, Parallel-Group Study to Evaluate thePharmacokinetic Profiles of Two Formulations of Tenofovir Disoproxil Fumarate After Oral Administration in Healthy Volunteers Under Fasting Conditions [NCT04671563]	Phase 4	28 participants (Actual)	Interventional	2019-04-22	Completed
A Phase IV Open-label Evaluation of Safety, Tolerability and Acceptability of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Disoproxil Fumarate Single-tablet Regimen for Non-occupational Prophylaxis Following Potential Exposure to HIV-1 [NCT01855867]	Phase 4	100 participants (Actual)	Interventional	2013-05-31	Completed
The Tolerability of, and Adherence to, Dolutegravir With Co-formulated Tenofovir-emtricitabine for HIV Non-occupational Post-exposure Prophylaxis [NCT02211690]	Phase 4	100 participants (Actual)	Interventional	2014-08-31	Completed
Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Multi-center, Double-Blind, Randomized, Positive Control, Phase3 Study [NCT04543565]	Phase 3	900 participants (Anticipated)	Interventional	2020-09-30	Recruiting
A Comparative Study of the Efficacy and Safety of Entecavir and Tenofovir Versus Entecavir Alone in the Treatment of Hepatitis B DNA-positive Patients With Lymphomas [NCT04539119]	Phase 3	120 participants (Anticipated)	Interventional	2020-07-03	Recruiting
Study on the Impact of Triptolide Woldifiion on HIV-1 Reservoir of Chinese HIV/AIDS Patients In Acute HIV-1 Infection [NCT02219672]	Phase 3	18 participants (Anticipated)	Interventional	2014-07-31	Recruiting
Transgender Men and HIV in Uganda: PrEP Uptake and Persistence [NCT04867798]		75 participants (Actual)	Observational	2021-09-16	Completed
DREAM-01: Optimization of a Tenofovir Enema for HIV Prevention [NCT02750540]	Phase 1	21 participants (Actual)	Interventional	2016-10-31	Completed
A Phase IV Open-label Evaluation of Safety, Tolerability and Patient Acceptance of Atazanavir Boosted With Ritonavir Combined With a Fixed-dose Formulation of Tenofovir DF and Emtricitabine for Non-occupational Prophylaxis Following Potential Exposure to [NCT01602822]	Phase 4	11 participants (Actual)	Interventional	2012-02-29	Terminated(stopped due to Grade 3 elevation in liver function tests)
Phase 1 Evaluation of the Impact of Coitus on Pharmacokinetics and Pharmacodynamics of Tenofovir 1% Gel Following Pericoital or Daily Gel Dosing [NCT01687205]	Phase 1	31 participants (Actual)	Interventional	2012-11-30	Completed
Effect of Multiple Dosing With 240 mg BID BI 201335 on the Steady State Pharmacokinetics of 300mg QD Tenofovir and Effect of Multiple Dosing With 300mg QD Tenofovir on Steady State BI 201335 Pharmacokinetics in Healthy Male and Female Volunteers [NCT01340196]	Phase 1	16 participants (Actual)	Interventional	2011-04-30	Completed
Phase III Open-label Randomized Multicenter Trial to Assess the Non-inferiority of Raltegravir Compared With EFavirenz, Both in Combination With LAmivudine and TEnofovir, in ART-naïve HIV-1-infected Patients Receiving Rifampin for Active TuBerculosis [NCT02273765]	Phase 3	460 participants (Actual)	Interventional	2015-09-11	Completed
An Open-Label, Randomized Study Evaluating a Switch From a Regimen of Two Nucleoside Reverse Transcriptase Inhibitors Regimen Plus Any Third Agent to Either a Regimen of Atazanavir/Ritonavir Once Daily and Raltegravir Twice Daily or to a Regimen of Atazan [NCT01332227]	Phase 4	132 participants (Actual)	Interventional	2011-10-31	Completed
Safety and Efficacy of the Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations in Pregnant and Breastfeeding Women to Prevent mother-to Child Transmission of HIV-1 o, Resource-limited Settings: A Multicentre Randomized Phase 3 Clinical Trial [NCT00936195]	Phase 3	0 participants (Actual)	Interventional	2010-01-31	Withdrawn(stopped due to faillure to obtain insurance because of refusal from insurance companies)
Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine. [NCT00808002]	Phase 3	30 participants (Actual)	Interventional	2009-02-28	Completed
The Impact of in Utero and Breastfeeding Exposure to Tenofovir on Renal Function in HIV-exposed Uninfected Children in Cameroon: The PREVENT-IT Study [NCT04070482]		400 participants (Anticipated)	Observational	2017-10-01	Active, not recruiting
Phase I Exploratory Pharmacodynamic Study of Tenofovir-Based Products [NCT02722343]	Phase 1	25 participants (Actual)	Interventional	2016-04-30	Completed
Biobehavioral Interventions for HIV-negative Methamphetamine-using MSM [NCT00856323]	Phase 2	53 participants (Actual)	Interventional	2009-01-31	Completed
Open Label Extension (OLE) of the Study of the Safety and Efficacy of Daily Oral Antiretroviral Use for the Prevention of HIV Infection in Heterosexually Active Young Adults in Botswana [NCT04318210]		229 participants (Actual)	Interventional	2012-10-31	Completed
Cardiovascular, Anthropometric, and Skeletal Effects of Antiretroviral Therapy (ART) Initiation With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Plus Atazanavir/Ritonavir (ATV/r), Darunavir/Ritonavir (DRV/r), or Raltegravir (RAL): Metabolic Subs [NCT00851799]		334 participants (Actual)	Observational	2009-06-30	Completed
Tenofovir Disoproxil Fumarate Alone Versus Its Combination With Emtricitabine for Treatment of Chronic Hepatitis B [NCT00524173]	Phase 2	35 participants (Actual)	Interventional	2007-08-29	Terminated
The Effects of Switching From Dolutegravir/Lamivudine/Abacavir (d/l/a) to Bictegravir/Emtricitabine/Tenofovir Alafenamide (b/f/Taf) in Patients With Suppressed Viral Load on Neuropsychiatric Side Effects and Neurocognitive Function [NCT04155554]	Phase 3	100 participants (Anticipated)	Interventional	2020-01-29	Recruiting
Evaluation of Safety and Efficacy of Raltegravir/Darunavir Combination in Antiretroviral-Naive Patients [NCT00677300]	Phase 4	85 participants (Actual)	Interventional	2009-01-31	Completed
A Phase II of Randomized, Double-blind, Placebo-controlled, Multi-center Study of Hepalatide for Injection Combined With Pegylated Interferon and TAF as Finite Treatment in Chronic Hepatitis B Patients [NCT05244057]	Phase 2	30 participants (Anticipated)	Interventional	2022-08-23	Recruiting
Phase 1 Safety and Pharmacokinetic Study of a Polyurethane Tenofovir Disoproxil Fumarate Vaginal Ring in Sexually Active Women (TDF IVR-002) [NCT02762617]	Phase 1	17 participants (Actual)	Interventional	2017-02-24	Terminated(stopped due to Safety-related)
Adjunctive Therapy With Telmisartan Instituted With ART During Acute HIV Infection to Reduce the Establishment of CNS Reservoirs of HIV and Lymph Node Fibrosis [NCT02750059]	Phase 2	21 participants (Actual)	Interventional	2015-01-31	Completed
Simplifying Treatment and Monitoring for HIV (STREAM HIV): Point-of-Care Urine Tenofovir Adherence and Viral Load Testing to Improve HIV Outcomes in South Africa [NCT04341779]		540 participants (Anticipated)	Interventional	2021-02-04	Recruiting
A Phase I, Open-label Multiple Dose Safety, Pharmacokinetic, Pharmacodynamic, and Acceptability Study of Tenofovir Rectal Douche [NCT04016233]	Phase 1	9 participants (Actual)	Interventional	2020-01-10	Completed
Point of Care PrEP Delivery for Young Black/African American Men Who Have Sex With Men and Young Transgender Women at High Risk for HIV Infection [NCT04329442]		0 participants (Actual)	Interventional	2020-04-01	Withdrawn(stopped due to COVID-19 caused substantial barriers to recruitment.)
Use of Tenofovir/Emtricitabine With Immediate or Deferred Doxycycline 100mg PO Daily for Combination HIV and Syphilis Pre-exposure Prophylaxis in HIV-negative Men Who Have Sex With Men: a Pilot Study of Dual Daily HIV and Syphilis PrEP. (The DuDHS Trial). [NCT02844634]	Phase 4	52 participants (Actual)	Interventional	2018-05-15	Active, not recruiting
A Randomised, Double-Blind, Multi-Centre, Parallel-Group Phase 3b Study to Demonstrate Non-inferiority of Stavudine (20 mg Twice Daily) Compared With Tenofovir Disoproxil Fumarate (300 mg Once Daily) When Administered in Combination With Lamivudine and Ef [NCT02670772]	Phase 3	1,077 participants (Actual)	Interventional	2012-07-31	Completed
ART Drug Dosage Adjustment Using FSCII in Chinese HIV-infected Population [NCT02632474]	Phase 4	10 participants (Actual)	Interventional	2015-04-30	Completed
Defining the PrEP Care Continuum Among Recently Incarcerated Men at High-Risk for HIV Infection [NCT04240509]	Phase 4	100 participants (Anticipated)	Interventional	2019-11-01	Enrolling by invitation
A Randomized, Open-label, Controlled, Exploratory Trial to Characterize the Results of Daily Oral Administration of Telbivudine 600 mg and Tenofovir Disproxil Fumarate 300 mg in Combination or Telbivudine 600 mg or Tenofovir Disproxil Fumarate 300 mg Mono [NCT00805675]	Phase 3	83 participants (Actual)	Interventional	2008-11-30	Completed
A Phase IV Open-Label Evaluation of Safety, Tolerability and Patient Acceptance of Raltegravir (MK-0518) Combined With a Fixed-Dose Formulation of Tenofovir Following Potential Exposure to HIV-1 [NCT00594646]	Phase 4	100 participants (Actual)	Interventional	2008-02-29	Completed
Breastfeeding Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere) [NCT01061151]	Phase 3	3,747 participants (Actual)	Interventional	2011-03-01	Completed
Phase I Study of the Maternal Single-Dose Pharmacokinetics and Placental Transfer of Tenofovir 1% Vaginal Gel Among Healthy Term Gravidas [NCT00540605]	Phase 1	21 participants (Actual)	Interventional		Completed
A Randomized, Phase II, Controlled Trial Comparing the Efficacy of Adefovir Dipivoxil and Tenofovir Disoproxil Fumarate for the Treatment of Lamivudine-Resistant Hepatitis B Virus in Subjects Who Are Co-Infected With HIV [NCT00033163]	Phase 2	90 participants	Interventional		Completed
[NCT02902523]	Phase 1	50 participants (Actual)	Interventional	2016-09-30	Completed
Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in HIV-Infected Women [NCT01394133]		0 participants (Actual)	Observational	2011-07-31	Withdrawn(stopped due to Lack of enrollment)
Determination of Plasma and Intracellular Levels of Nucleoside Reverse Transcriptase Inhibitors (NRTI) and of Nucleotide Analog Tenofovir Disoproxil Fumarate (TDF) in Patients Treated With Abacavir and/or Lamivudine Given With or Without TDF. [NCT00335192]	Phase 4	32 participants (Actual)	Interventional	2005-01-31	Completed
Assessing the Effect of Contraception and the Menstrual Cycle on Pharmacokinetics, Pharmacodynamics, and Vaginal Safety in Tenofovir Vaginal Gel Users [NCT01421368]	Phase 1	72 participants (Actual)	Interventional	2012-03-31	Completed
An Open-label, Randomized, Controlled Clinical Trial to Determine the Optimal Time for Tenofovir of Anti-HBV Treatment During the Pregnancy Among Chronic HBV-infected Pregnant Women With Normal Liver Function [NCT02510963]		300 participants (Anticipated)	Interventional	2015-11-30	Recruiting
Analysis of Lipodystrophy in HIV-Infected Individuals A Prospective, Non-randomised, 48 Week Study of the Effect of PI Containing and Non-PI Containing Antiretroviral Regimens on the Expression of Adipocyte Specific Genes, Protein Levels and Cellular Stru [NCT00192660]	Phase 4	80 participants (Actual)	Interventional	2003-02-28	Completed
Virological and Clinical Anti-HBV Efficacy of Tenofovir and Emtricitabine in Antiretroviral Naïve Patients With HIV/HBV co-Infection [NCT00127959]	Phase 4	24 participants	Interventional	2004-03-31	Completed
Clinical, Control, Double-blind, Randomized Experimentation With Tenofovir Disoproxyl Fumarate and Emtricitabine for COVID-19 [NCT04712357]		219 participants (Anticipated)	Interventional	2020-11-09	Recruiting
Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males - A Sub-study of HPTN 083 [NCT04692077]	Phase 2	9 participants (Actual)	Interventional	2020-02-19	Completed
A Phase II, Open Label, Single Arm Trial to Evaluate the Pharmacokinetics,Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Antiretroviral Naive HIV-1 Infected Adolescents and Children Aged >= 6 to <18 Years [NCT00799864]	Phase 2	54 participants (Actual)	Interventional	2011-01-07	Completed
A Randomized, Double-blind, Double-simulated, Active-controlled，Phase III Clinical Study Evaluating the Efficacy and Safety of Azvudine Combined With Tenofovir Fumarate and Efavirenz in Hiv-infected Treatment Naive Patients [NCT04303598]	Phase 3	720 participants (Anticipated)	Interventional	2020-04-01	Not yet recruiting
A Single-Dose, Open-Label, Randomized, Replicate Crossover Pivotal Bioequivalence Study in Healthy Subjects to Assess the Bioequivalence of Darunavir 675 mg, Emtricitabine 200 mg, and Tenofovir Alafenamide 10 mg in the Presence of Cobicistat 150 mg When A [NCT04236453]	Phase 1	16 participants (Actual)	Interventional	2020-01-23	Terminated(stopped due to COVID-19 pandemic impacted the BE assessment of the trial. The clinical team decided to terminate the trial in order to start a new pivotal BE trial)
A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate the Pharmacokinetics and Safety of Twice Yearly Long-Acting Subcutaneous Lenacapavir for Pre-Exposure Prophylaxis in People Who Inject Drugs [NCT06101342]	Phase 2	250 participants (Anticipated)	Interventional	2023-12-13	Recruiting
Pilot Trial to Evaluate the Efficacy and Tolerance of a Simple Once Daily Combined Regimen Including Tenofovir (TDF), Emtricitabine (FTC) and Efavirenz (EFV) in HIV-1 Infected Patients Naive to Prior Antiretroviral Treatment in Senegal [NCT00158457]	Phase 3	40 participants (Actual)	Interventional	2004-06-30	Completed
Study on Screening, Verification and Intervention of High-risk Patients With Liver Cancer [NCT05721300]		2,215 participants (Anticipated)	Interventional	2023-02-10	Recruiting
A Prospective, Randomized, Trial to Investigate the Effect of Continued Adefovir Versus Combination Regimens of Telbivudine Plus Adefovir, and Telbivudine Plus Tenofovir in Patients With Chronic Hepatitis B and Suboptimal Viral Suppression (PROACTIV Study [NCT00409019]	Phase 4	0 participants (Actual)	Interventional		Withdrawn(stopped due to Study cancelled: Withdrawn before enrollment of any participants)
Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine in Virologically-suppressed Adults Living With HIV on Bictegravir/Tenofovir Alafenamide/emtricitabine-the DYAD Study [NCT04585737]	Phase 4	222 participants (Actual)	Interventional	2020-09-22	Completed
Efficacy, Safety, and Tolerability of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults With HIV-HBV Coinfection [NCT03797014]	Phase 4	28 participants (Actual)	Interventional	2019-04-30	Completed
Tenofovir Versus Lamivudine for Patients of Chronic Hepatitis B With Severe Acute Exacerbation [NCT01848743]	Phase 3	120 participants (Anticipated)	Interventional	2013-04-30	Recruiting
A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL Study. [NCT00192634]	Phase 4	357 participants (Actual)	Interventional	2005-12-31	Completed
Pegylated Interferon Alfa-2a Versus Emtricitabine / Tenofovir +/- Pegylated Interferon Alfa-2a for the Treatment of Chronic HBe-Ag Positive Hepatitis B Infection in HIV-Coinfected Patients - the PEGPLUS Trial [NCT00221286]	Phase 3	2 participants (Actual)	Interventional	2004-09-30	Terminated(stopped due to Lack of accrual)
Tenofovir Disoproxil Fumarate Improves Outcomes Following Palliative Transarterial Chemoembolization for Hepatitis B Virus Related Hepatocellular Carcinoma [NCT01872988]	Phase 3	320 participants (Anticipated)	Interventional	2012-09-30	Terminated(stopped due to Difficult in patient enrollment)
Optimizing the Delivery of HIV Post-exposure Prophylaxis: A Randomized Controlled Trial of Text Messaging Support and Physician to Nurse Task-shifting [NCT03259698]	Phase 2	434 participants (Anticipated)	Interventional	2021-11-04	Recruiting
Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome [NCT03304717]	Phase 1/Phase 2	34 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
Randomized, Double-blind, Placebo-controlled Trial of TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study) [NCT04405271]	Phase 3	1,378 participants (Anticipated)	Interventional	2020-07-31	Not yet recruiting
An Open-label, Randomized Study to Evaluate the Acute Immunologic Responses in Asian Subjects With E Antigen Positive Chronic Hepatitis B Following Initiation of Therapy for Hepatitis B With Pegasys, Nucleoside Analogues, or Both. [NCT00962871]	Phase 1	30 participants (Actual)	Interventional	2009-08-31	Completed
ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-Adherence [NCT03218592]	Phase 4	36 participants (Actual)	Interventional	2017-06-28	Completed
Tenofovir Disoproxil Fumarate in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus in Highly Viremic Mothers [NCT01488526]	Phase 4	200 participants (Actual)	Interventional	2012-03-01	Completed
Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens [NCT03976752]	Phase 1	41 participants (Actual)	Interventional	2019-03-13	Completed
Open Label Randomized Controlled Trial to Assess the Impact of Prophylactic Exposure to Tenofovir Gel on the Efficacy of Subsequent Tenofovir-containing Antiretroviral Therapy on Viral Suppression [NCT01387022]		59 participants (Actual)	Interventional	2011-06-30	Completed
Phase 2 Expanded Safety Study of Tenofovir Gel in Pregnancy [NCT01490671]	Phase 2	0 participants (Actual)	Interventional		Withdrawn
Randomized Trial of Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Who Have Undergone Lamivudine/Adefovir Add-on Treatment [NCT01491295]	Phase 4	160 participants (Anticipated)	Interventional	2012-09-30	Recruiting
The Pharmacokinetics of Co-formulated Emtricitabine/Tenofovir/Efavirenz in HIV-infected Patients With Smear-positive Pulmonary Tuberculosis in the Kilimanjaro Region, Tanzania [NCT00474435]	Phase 2	30 participants (Anticipated)	Interventional	2008-11-30	Recruiting
Open-Label, Part-Randomized Study Designed to Evaluate the PK Profile of Tenofovir Exalidex (TXL) Following Single Dose of Oral Formulations in Comparison to a Reference IR TXL Tablet in Healthy Subjects [NCT03279146]	Phase 1	29 participants (Actual)	Interventional	2017-09-06	Completed
Phase I, 90-Day Safety, Pharmacokinetic, And Pharmacodynamic Study Of Intravaginal Rings Releasing Tenofovir And Levonorgestrel [NCT03279120]	Phase 1	66 participants (Actual)	Interventional	2017-09-28	Completed
The ADAPT Study: A Phase II, Randomized, Open-Label, Pharmacokinetic and Behavioral Study of the Use of Intermittent Oral Emtricitabine/Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis (PrEP) Pre-Exposure Prophylaxis (PrEP) [NCT01327651]	Phase 2	622 participants (Actual)	Interventional	2011-08-31	Completed
A Randomized, Multicenter, Prospective Study to Compare Antiviral Efficacy and Safety of Switching to ETV Plus TDF Versus Maintaining LAM/LDT Plus ADF Combination in CHC With PVR to LAM/LDF Plus ADF Combination Rescue Therapy for YMDD Mutation [NCT01597934]	Phase 4	104 participants (Anticipated)	Interventional	2012-08-31	Active, not recruiting
Pilot Study to Measure Exposure to Atazanavir, as a Component of Pharmacokinetic Parameters and Adherence Measured With MEMS in Naive HIV-infected Patients Treated Once Daily With Atazanavir Combined to Ritonavir and to Tenofovir/Emtricitabine. ANRS 134 C [NCT00528060]	Phase 2	35 participants (Actual)	Interventional	2008-01-31	Completed
Randomized, Non-inferiority Trial Comparing a Dual Maintenance Therapy Strategy With Dolutegravir + Lamivudine (DTG/3TC) or Atazanavir/Ritonavir + Lamivudine (ATV/r+3TC) Versus the Standard WHO First Line Triple Therapy Tenofovir + Lamivudine + Efavirenz [NCT04022967]	Phase 3	480 participants (Actual)	Interventional	2020-09-21	Active, not recruiting
Tenofovir As Prevention Of Hepatitis b Mother-to-child Transmission [NCT02937779]	Phase 4	933 participants (Anticipated)	Interventional	2017-10-04	Active, not recruiting
Pharmacokinetics of Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Pre-exposure Prophylaxis in Transgender Women Receiving Feminizing Hormone Therapy [NCT03270969]	Phase 1	15 participants (Actual)	Interventional	2018-01-05	Completed
Effect of Repeated Applications of Tenofovir Gel on Mucosal Mediators of Immunity and Intrinsic Antimicrobial Activity of Cervicovaginal Secretions in Women at Low Risk for HIV-1 Infection [NCT00594373]	Phase 1	30 participants (Actual)	Interventional		Completed
Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-term Observational Study [NCT00537966]		2,017 participants (Anticipated)	Interventional	2002-01-31	Recruiting
A Randomized, Open Label, Multicenter Study Comparing the Safety and Efficacy of Once Daily Regimen Containing Epzicom or Truvada Combined With Ritonavir Boosted Atazanavir as Initial Therapy for HIV-1 Infection (ET Study) [NCT00544128]	Phase 4	109 participants (Actual)	Interventional	2007-10-31	Completed
A Phase 1a/1b, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of ABI-H0731 in Healthy Volunteers and Patients With Chronic Hepatitis B [NCT02908191]	Phase 1	86 participants (Actual)	Interventional	2016-11-30	Completed
A Multicentre, Randomized Controlled Trial in HBsAg Seroclearance After Receiving Combined Therapy of Peginterferon and Tenofovir in Nucleos(t)Ide Analogue-treated Patients With HBV Related Liver Fibrosis. [NCT04640129]	Phase 4	272 participants (Anticipated)	Interventional	2020-11-30	Not yet recruiting
Exploratory Pharmacokinetic and Pharmacodynamic Study of Oral F/TAF for the Prevention of HIV Acquisition [NCT02904369]	Phase 1	73 participants (Actual)	Interventional	2016-10-06	Completed
The Effectiveness and Safety of Tenofovir Alafenamide in the Treatment of Chronic Hepatitis B Patients With Mildly Elevated Alanine Aminotransferase and Significant Liver Injury [NCT04674423]	Phase 4	40 participants (Anticipated)	Interventional	2020-05-14	Recruiting
A Pilot Study of Rapid HIV Treatment Initiation, Access and Engagement in Care (RHAE) [NCT03512964]		32 participants (Actual)	Interventional	2016-11-29	Completed
Treating HIV-infected Elite Controllers as a Model of HIV Remission [NCT01025427]	Phase 4	16 participants (Actual)	Interventional	2009-12-31	Completed
Effect of Tenofovir on Genital HSV Shedding: a Randomized, Double-blind, Placebo-controlled Clinical Trial [NCT01448616]	Phase 4	73 participants (Actual)	Interventional	2012-02-29	Completed
An Open-Label, Pilot, Randomized, Multi-Center Study to Compare Efficacy and Safety of Tenofovir Monotherapy Alone With Tenofovir Monotherapy Followed by Concurrent Combination of Pegylated Interferon-Alpha-2b and Tenofovir or Tenofovir Monotherapy Follow [NCT01727271]	Phase 4	0 participants (Actual)	Interventional	2013-08-31	Withdrawn
The Efficacy of TAF as a Prophylactic Antiviral Agent for HBsAg-positive Patients Receiving Biological DMARDs (bDMARDs) [NCT05001672]	Phase 4	108 participants (Anticipated)	Interventional	2021-08-15	Not yet recruiting
Switching to Tenofovir Disoproxil Fumarate vs. Continuing Entecavir in Chronic Hepatitis B Patients With Partial Virologic Response During Entecavir Therapy: STEEP Study [NCT01711567]	Phase 4	60 participants (Actual)	Interventional	2013-04-30	Completed
A Prospective, Randomized, Multicenter, Open-label Study of Optimal Antiviral Treatment in HBeAg Positive Chronic Hepatitis B Patients [NCT03013556]	Phase 4	180 participants (Anticipated)	Interventional	2016-11-30	Recruiting
A Phase 4, Open-Label Study to Investigate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (Viread(R)) in Preventing Hepatocellular Carcinoma Recurrence in Chronic Hepatitis B Virus Infected Patients With Low Viral Load at Baseline Treated With R [NCT02308319]	Phase 4	124 participants (Anticipated)	Interventional	2015-01-31	Not yet recruiting
Open-Label, Single-Centre, Randomised Pilot Study to Evaluate Immunovirological and Clinical Evolution of a Combination With Nucleoside Analogues/Nucleotides (Trizivir +Tenofovir) in Multiresistant Patients With Virological Failure [NCT00356616]	Phase 4	24 participants (Actual)	Interventional	2005-09-30	Terminated(stopped due to terminated)
Prospective Study on the Incidence of Hepatitis B Virus Reactivation in Untreated Patients With Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide [NCT03804372]	Phase 2	180 participants (Anticipated)	Interventional	2020-07-07	Recruiting
Comparison Atazanavir/Ritonavir (ATV/r) vs Nevirapine (NVP) Twice a Day (Bid) on Truvada Backbone [NCT00552240]	Phase 4	154 participants (Actual)	Interventional	2007-09-30	Completed
An Open Label Trial of STRIBILD™ (Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate) for ARV-naïve HIV-2 Infected Adults in Dakar, Senegal [NCT02180438]	Phase 4	30 participants (Actual)	Interventional	2014-09-30	Completed
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA™ Once-Daily in Treatment-Naïve HIV-1 Infected Subjects [NCT02403674]	Phase 3	734 participants (Actual)	Interventional	2015-06-05	Completed
On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men [NCT01473472]	Phase 3	400 participants (Actual)	Interventional	2012-01-31	Completed
A Phase III, Open Label, Randomized, Comparative Study of the Antiviral Efficacy of ARV Therapy With Lopinavir/Ritonavir (LPV/r-Kaletra) in Combination With Tenofovir (TDF) Versus Standard of Care (Kaletra in Combination With 2 Nucleoside RTIs) in naïve-H [NCT00234910]	Phase 3	152 participants (Actual)	Interventional	2005-01-31	Completed
A Phase I Study of the Safety, Tolerance, and Pharmacokinetics of Tenofovir Disoproxil Fumarate (TDF) and the Combination of TDF Plus Emtricitabine in HIV-1 Infected Pregnant Women and Their Infants [NCT00076791]	Phase 1	66 participants (Actual)	Interventional	2004-03-31	Completed
An Open-Label, Randomized Study to Determine the Impact of Antiretroviral Treatment in HCV/HIV-Coinfected Subjects With High CD4+ Cell Count on the Efficacy of Hepatitis C Treatment With Pegylated Interferon Alfa-2A and Ribavirin [NCT00100581]		2 participants (Actual)	Interventional		Completed
A Multicenter Randomized Controlled Open-label Trial of Tenofovir Plus Entecavir Combination vs. Tenofovir Monotherapy in Chronic Hepatitis B Patients With Genotypic Resistance to Adefovir and Partial Virologic Response to Ongoing Treatment [NCT01639066]	Phase 4	102 participants (Actual)	Interventional	2012-09-25	Completed
Phase II, Open-Label,Randomised, Comparator Study of Substitution w/Tenofovir or Abacavir in HIV-1 Infected Individuals, w/Viral Load Less 50 Copies/mL, Receiving a Thymidine Analogue (Zidovudine or Stavudine) as Part of HAART. [NCT00270556]	Phase 2	100 participants	Interventional	2003-01-31	Completed
Open-Label Study With Rilpivirine in Treatment-naïve Indian Subjects With HIV-1 Infection to Determine Safety and Efficacy [NCT03563742]	Phase 3	58 participants (Actual)	Interventional	2018-09-24	Terminated(stopped due to High SF rate (less treatment-naïve subjects & subjects with viral load <100000). Reevaluation in scientific position in India after internal discussion.)
Study of the Safety and Efficacy of Daily Tenofovir Disoproxil Fumarate for the Prevention of HIV Infection in Heterosexually Active Young Adults in Botswana [NCT00111150]	Phase 2/Phase 3	1,200 participants	Interventional	2005-09-30	Terminated(stopped due to Consenting participants entered tenofovir/emtricitabine oral prophylaxis trial)
Study of Daily Oral Tenofovir (Tenofovir Disoproxil Fumarate) to Prevent HIV-1 Infection Among Sex Workers in Cambodia [NCT00078182]	Phase 2/Phase 3	0 participants (Actual)	Interventional		Withdrawn
A Phase I Clinical Trial Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Disintegration Time of Vaginal Tablets Containing Tenofovir and/or Emtricitabine [NCT01694407]	Phase 1	48 participants (Actual)	Interventional	2013-02-28	Completed
A Phase I Open Label Trial of the Safety and Pharmacokinetics of Tenofovir Disoproxil Fumarate in HIV-1 Infected Pregnant Women and Their Infants [NCT00120471]	Phase 1	122 participants (Actual)	Interventional	2006-11-30	Completed
A Randomized, Open-Label Study Assessing Safety, Tolerability and Efficacy of an Induction-Maintenance Treatment Strategy Including Lopinavir/Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine Versus Efavirenz Plus Tenofovir Disoproxil Fumarat [NCT00121017]	Phase 2	200 participants	Interventional		Withdrawn
A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Preexposure Prophylaxis in Cisgender Men and Transgender Women Who Have Sex With Men, and Are at High Risk for HIV [NCT04652700]	Phase 3	494 participants (Actual)	Interventional	2021-03-15	Completed
Randomized Open Label Study Assessing the Antiviral Activity, Toxicity and Pharmacologic Interaction of Tenofovir DF/Atazanavir Enhanced With Low Dose of Ritonavir as Part of a Salvage Regimen in HIV Infected Patients With Multiple Treatment Failures (ANR [NCT00122577]	Phase 2	50 participants	Interventional	2002-03-31	Terminated
Empiric Treatment for Suspected Acute HIV Infection in the Emergency Department [NCT03711253]	Phase 4	40 participants (Anticipated)	Interventional	2019-10-14	Active, not recruiting
Clinical Trial: Backup With Combivir (AZT/3TC) or Single Dose (sd) Truvada (FTC/TDF) in Order to Avoid NNRTI Resistance After sd Nevirapine for the Prevention of Mother-to-child Transmission (MTCT) [NCT00346567]		566 participants (Actual)	Interventional	2006-06-30	Completed
"Analysis of Proximal Renal Tubular Function of Real World Chronic Hepatitis B (CHB) Patients Who Are Suppressed on TDF and Switched to TAF" [NCT02957994]	Phase 4	82 participants (Actual)	Interventional	2016-12-22	Active, not recruiting
A Phase II, Randomized, Open-Label Study to Evaluate the Safety and Effectiveness of Two Antiretroviral Therapeutic Strategies: A Dual PI-Based HAART Regimen Versus a Multi-NRTI ART Regimen, in ART-Experienced Children and Youth Who Have Experienced Virol [NCT00102206]	Phase 2	6 participants (Actual)	Interventional		Completed
A Phase 4, Single-Arm Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Tenofovir Disoproxil Fumarate in Combination With Emtricitabine in HIV-1 Infected Patients Experiencing Various Degrees of Renal Impairment [NCT00106379]	Phase 4	52 participants	Interventional	2004-10-31	Completed
Phase IIb Trial to Assess the Safety and Effectiveness of the Vaginal Microbicide 1% Tenofovir Gel for the Prevention of HIV Infection in Women in South Africa [NCT00441298]	Phase 2	889 participants (Actual)	Interventional	2007-05-31	Completed
A Randomized Comparison of Protease Inhibitor-based Versus Non-nucleoside Reverse Transcriptase Inhibitor-based Antiretroviral Therapy for Initial Treatment of Individuals With AIDS-related Kaposi's Sarcoma in Sub-Saharan Africa [NCT00444379]	Phase 4	224 participants (Actual)	Interventional	2007-04-30	Completed
A Phase 3b, Multi-center, Randomized, Parallel-group, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Oral Dolutegravir/Lamivudine Once-daily as a First-line Regimen Compared to Oral Bictegravir/Emtricitabine/Tenofov [NCT05979311]	Phase 3	412 participants (Anticipated)	Interventional	2023-12-29	Not yet recruiting
A Phase I Trial for the Evaluation of the Two-way Pharmacokinetic-pharmacodynamic (PD) Interaction of Gender Affirming Exogenous Estrogen (With Testosterone Suppression) on TDF/FTC PrEP in Transgender Women (TGW) [NCT04760691]	Phase 1	20 participants (Anticipated)	Interventional	2021-03-01	Recruiting
Prevention of SARS-CoV-2 (COVID-19) Through Pre-Exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial Controlled With Placebo [NCT04334928]	Phase 3	1,002 participants (Actual)	Interventional	2020-04-15	Completed
Phase 3, Multi-center, Double-blind, Randomized, Placebo-controlled Effectiveness and Safety Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women [NCT00625404]	Phase 3	2,120 participants (Actual)	Interventional	2009-05-31	Completed
A Multi-Center Comparison of Raltegravir to Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV-Infected Individuals Naive to Antiretroviral Therapy [NCT00632970]	Phase 4	6 participants (Actual)	Interventional	2008-02-29	Terminated(stopped due to no patients completed)
An Open Label Study to Investigate the Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of Age [NCT01335620]	Phase 4	19 participants (Actual)	Interventional	2011-04-30	Completed
Interferon Alfa Sensitivity in HIV/HCV Coinfected Persons Before and After Antiretroviral Therapy [NCT01285050]	Phase 4	20 participants (Actual)	Interventional	2011-01-31	Completed
An Open-Label Study to Assess the Anti-HIV-1 Activity of Tenofovir Disoproxil Fumarate (TDF) in Antiretroviral-Naive Patients Who Are Chronically Infected With HIV-1 [NCT00016588]		0 participants	Interventional	2001-05-31	Completed
Contribution of the Integrase Inhibitor Dolutegravir to Obesity and Cardiovascular Disease in Persons Living With HIV [NCT04340388]	Phase 4	10 participants (Actual)	Interventional	2020-09-17	Completed
Open-label Multicenter Study to Assess the Efficacy, the Tolerability and the Adherence of a Once Daily (QD) Taken Antiretroviral Therapy (ART) Containing the NtRTI Tenofovir DF 300 mg in Combination With the Best Suitable Once a Day Regimen Being 1 NRTI [NCT00324688]	Phase 4	60 participants	Interventional	2003-03-31	Completed
Randomized Order, Controlled, Double Blind, Crossover Early Phase 1 Pilot Study to Assess Safety and Pharmacokinetics of a Tenofovir Disoproxil Fumarate and Emtricitabine (TDF-FTC) Releasing IVR Over 28 Days Compared to Placebo [NCT03255915]	Early Phase 1	15 participants (Actual)	Interventional	2018-09-20	Active, not recruiting
A Pilot Study of the Novel Antiretroviral Combination of Atazanavir and Raltegravir in HIV-1 Infected Subjects With Virologic Suppression on a Standard Regimen of Boosted Atazanavir, Tenofovir and Emtricitabine [NCT00931801]	Phase 4	43 participants (Actual)	Interventional	2009-12-31	Completed
Phase II Trial, Multicentre, Opened Label Evaluating the Pharmacokinetics and the Safety and Toxicity of the Tenofovir-Emtricitabine Combination in Pregnant Women and Infants in Africa and Asia [NCT00334256]	Phase 2	72 participants (Actual)	Interventional	2006-10-31	Completed
A Study to Probe The Safety And Durability of Tenofovir And a Cell Cycle Agent to Maintain Viral Suppression [NCT00344981]		9 participants (Actual)	Interventional	2003-06-30	Completed
A Multi-centre, Double Blind, Double Dummy, Randomised, Controlled Study to Evaluate the Efficacy and Safety of TDF 300mg Once Daily (QD) Versus Adefovir Dipivoxil (ADV) 10mg QD in Chinese Subjects With CHB [NCT01300234]	Phase 3	512 participants (Actual)	Interventional	2011-03-30	Completed
A Randomized Controlled Trial to Compare the Effects of Highly Active Antiretroviral Therapy (HAART) Versus Statin Therapy on Endothelial Function and Markers of Inflammation/Coagulation In HIV-Infected Individuals With High CD4 Cell Counts [NCT01515813]	Phase 2	0 participants (Actual)	Interventional	2011-11-30	Withdrawn(stopped due to On 05/08/12, team working on revising protocol and re-open study under version 2.0)
Efficacy of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients With High Viral Load But Slight Aminotransferase Elevation [NCT01522625]	Phase 4	160 participants (Actual)	Interventional	2012-01-31	Completed
A Phase I/II Study of Safety and Efficacy of Lamivudine (EPIVIR®) and Tenofovir Disoproxil Fumarate (VIREAD®) Used to Lower the Plasma Level of Viral RNA of HERV-K(HML2) in Patients With Lymphoma [NCT01528865]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2015-12-31	Withdrawn(stopped due to Funding was removed.)
A Pilot Study to Determine the Impact on Dyslipidemia of the Addition of Tenofovir to Stable Background Antiretroviral Therapy in HIV-Infected Subjects [NCT00109603]		17 participants (Actual)	Interventional	2005-05-31	Completed
Phase II Expanded Safety and Acceptability Study of the Vaginal Microbicide 1% Tenofovir Gel [NCT00111943]	Phase 2	200 participants (Actual)	Interventional		Completed
A Phase 3, Open-Label, Multicenter Study of the Safety of Tenofovir Disoproxil Fumarate Administered in Combination With Other Antiretroviral Agents for the Treatment of HIV-1 Infected Patients [NCT00007436]	Phase 3	0 participants	Interventional		Active, not recruiting
Pilot Trial Evaluating Once Daily Triple Combination Antiretroviral Therapy With Tenofovir-Emtricitabine and Efavirenz in HIV-1 Infected Patients With Mycobacterium Tuberculosis Infection ANRS129 BKVIR [NCT00115609]	Phase 3	70 participants (Actual)	Interventional	2006-01-31	Completed
Phase II Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men [NCT00131677]	Phase 2	400 participants (Actual)	Interventional	2005-02-28	Completed
Early Intensification of Combination Antiretroviral Therapy Including FUZEON® in the Treatment of Progressive Multifocal Leucoencephalopathy During HIV-1 Infection ANRS 125 Trial [NCT00120367]	Phase 2	30 participants	Interventional	2005-04-30	Completed
Phase I Safety and Acceptability Study of the Vaginal Microbicide Agent PMPA Gel [NCT00028132]	Phase 1	120 participants	Interventional		Completed
A Randomized, Comparative Study of Lopinavir/Ritonavir Versus GW433908 and Ritonavir Versus Lopinavir/Ritonavir and GW433908 (In Combination With Tenofovir Disoproxil Fumarate and One or Two Nucleoside Reverse Transcriptase Inhibitors) in HIV-1-Infected S [NCT00028366]		56 participants	Interventional		Completed
Safety and Efficacy of Finite Versus Continuous Nucleos(t)Ide Analogues Therapy in Patients With Chronic Hepatitis B: A Multicenter Randomized Controlled Trial [NCT05793268]		360 participants (Anticipated)	Interventional	2022-12-20	Active, not recruiting
Pilot Study on Efficacy and Tolerance of Peg-interferon Alpha-2a (Pegasys) Added to Tenofovir DF and Emtricitabine (Truvada) in AGHBe Positive HBV-HIV Co-infected Patients. ANRS HB 01 EMVIPEG. [NCT00391638]	Phase 2/Phase 3	56 participants (Actual)	Interventional	2007-01-31	Completed
A Phase 1/2, Randomized, Double-Blind, Active Controlled, Dose Escalation Study of the Safety, Tolerance, Pharmacokinetic,, and Antiviral Activity of GS-7340-02 in Antiretroviral-Naive Patients Who Are Chronically Infected With HIV-1 [NCT00036634]	Phase 1/Phase 2	30 participants (Actual)	Interventional	2002-03-31	Completed
A Randomized, Open-Label Study of 800 Mg Lopinavir/200 Mg Ritonavir QD in Combination With Tenofovir and Emtricitabine Vs. 400 Mg Lopinavir /100 Mg Ritonavir BID in Combination With Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects [NCT00043966]	Phase 3	200 participants	Interventional	2002-07-31	Completed
A Phase II, Randomized, Open-Label Study Comparing Fixed-Dose Versus Concentration-Adjusted Lopinavir/Ritonavir Therapy in HIV-Infected Subjects on Salvage Therapy [NCT00046033]	Phase 2	118 participants	Interventional		Completed
Open Randomized Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: TENOFOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC [NCT01533272]	Phase 4	240 participants (Actual)	Interventional	2012-02-29	Completed
A Phase III, Randomized, Open-label, Multicenter Study of the Safety and Efficacy of Efavirenz Versus Tenofovir When Administered in Combination With the Abacavir/Lamivudine Fixed-dose Combination Tablet as a Once-daily Regimen in Antiretroviral-naive HIV [NCT00053638]	Phase 3	345 participants	Interventional	2003-02-28	Completed
A Phase IV Study of Antiretroviral Therapy for HIV Infected Adults Presenting With Acute Opportunistic Infections: Immediate Versus Deferred Initiation of Antiretroviral Therapy [NCT00055120]	Phase 4	283 participants (Actual)	Interventional	2003-03-31	Completed
A Phase II Study of the Predictive Value of Pharmacokinetic-Adjusted Phenotypic Susceptibility (C12h/IC50) on Antiretroviral Response to Ritonavir-Enhanced Protease Inhibitors in Subjects With Failure of Previous Protease Inhibitor-Based Regimens [NCT00027339]	Phase 2	53 participants (Actual)	Interventional		Completed
A Multicenter Clinical Trial to Evaluate the Feasibility and Outcome of Same-day Antiretroviral Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) Among Patients Testing Positive by HIV Confirmatory Tests [NCT04712058]		200 participants (Anticipated)	Interventional	2021-01-20	Recruiting
Immunologic Consequences of Antiretroviral Therapy Intensification in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315/375 [NCT00034086]		22 participants	Interventional		Completed
A Phase I/II, Open Label Study to Evaluate the Ability of Combination Therapy With ABT-378/Ritonavir (Kaletra), Lamivudine (Epivir), Efavirenz (Sustiva)and Tenofovir DF to Completely Suppress Viral Replication in Subjects Infected With HIV-1 [NCT00038220]	Phase 2	40 participants	Interventional	2000-07-31	Completed
Efficacy and Safety of TAF for 48 Weeks in HBeAg Positive CHB Patients [NCT04864366]		150 participants (Actual)	Observational	2021-04-30	Active, not recruiting
A Multicenter, Open-label, Prospective Study to Evaluate Antiviral Efficacy and Safety of Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection [NCT01594905]	Phase 4	90 participants (Anticipated)	Interventional	2012-08-31	Active, not recruiting
A Single-dose, Open-label, Randomized, Crossover Study to Assess the Relative Bioavailability of the Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Administered Orally as a Whole Tablet, as a Split Table [NCT02984852]	Phase 1	30 participants (Actual)	Interventional	2016-12-31	Completed
A Phase III, Randomized, Open-Label Comparison of Lopinavir/Ritonavir Plus Efavirenz Versus Lopinavir/Ritonavir Plus 2 NRTIs Versus Efavirenz Plus 2 NRTIs as Initial Therapy for HIV-1 Infection [NCT00050895]	Phase 3	775 participants	Interventional		Completed
A Pilot Study to Measure the Clearance of Replication-Competent HIV-1 in Resting Memory CD4+ Cells in HIV-1-Infected Subjects Who Receive Enfuvirtide Plus Oral Combination Antiretroviral Therapy [NCT00051831]		19 participants (Actual)	Interventional	2003-10-31	Completed
A Phase I Study of Tenofovir Disoproxil Fumarate (PMPA Prodrug), A Novel Nucleotide Analog Reverse Transcriptase Inhibitor in Children With HIV Infection [NCT00024986]	Phase 1	30 participants	Interventional	2001-10-31	Completed
Phase III Clinical Trial to Evaluate the Antiviral Activity and Safety of DA-2802(Tenofovir Disoproxil Orotate) and Viread®(Tenofovir Disoproxil Fumarate) in Chronic Hepatitis B Patients [NCT02967939]	Phase 3	123 participants (Actual)	Interventional	2017-03-28	Completed
A Multi-centre, Single-arm, Open-label Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate(TDF) Treatment in Chinese Chronic Hepatitis B (CHB) Subjects Following Failure of Multiple Nucleos(t)Ide Analogues(NAs) [NCT02195518]	Phase 4	213 participants (Actual)	Interventional	2015-03-18	Completed
A Phase 3, Randomized, Double-Blind, Multicenter Study of the Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavir [NCT00158821]	Phase 3	180 participants (Anticipated)	Interventional	2000-03-31	Completed
See Detailed Description [NCT00044577]	Phase 3	166 participants	Interventional	2002-07-16	Completed
Virological and Clinical Anti-HBV Efficacy of Tenofovir in Antiretroviral naïve Patients With HIV/HBV Co-infection [NCT00192595]	Phase 4	36 participants (Actual)	Interventional	2004-01-31	Completed
Adjuvant Entecavir or Tenofovir for Hepatitis B Virus Related Hepatocellular Carcinoma After Curative Hepatic Resection [NCT02650271]	Phase 3	240 participants (Anticipated)	Interventional	2021-02-02	Recruiting
Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya (6-12 Month RCT) [NCT00427297]	Phase 3	34 participants (Actual)	Interventional	2007-09-30	Terminated(stopped due to There is no longer equipoise. DSMB recommended termination.)
Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents [NCT03332095]	Phase 1/Phase 2	55 participants (Actual)	Interventional	2018-07-02	Completed
Efficacy of Tenofovir Disoproxil on Mother-to-child Transmission of HBV in Tokombéré, Cameroon in Pregnant Women Infected With Hepatitis B Virus (HBeAg Positive or With a High Viral Load) and Whose Newborns Had Been Vaccinated at Birth [NCT05403047]	Phase 4	150 participants (Anticipated)	Interventional	2022-07-31	Not yet recruiting
IPrEP, Study #2: Evaluating the Effectiveness, Feasibility and Acceptability of Enhanced Pre-exposure Prophylaxis (PrEP) Packages for Young Female Sex Workers in Kisumu, Kenya [NCT03988387]		200 participants (Actual)	Interventional	2019-10-31	Completed
Entecavir Intensification for Persistent Hepatitis B Virus (HBV) Viremia in HIV-HBV Infection [NCT00662545]	Phase 4	10 participants (Actual)	Interventional	2008-04-30	Completed
A Phase 2a Crossover Trial Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population [NCT03593655]	Phase 2	247 participants (Actual)	Interventional	2019-01-14	Completed
A Phase 4, Single-Arm Study of the Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Patients With Active Illicit Substance Use [NCT03998176]	Phase 4	43 participants (Actual)	Interventional	2019-10-09	Completed
Acute HIV Infection - A Key Link for Transmission Prevention: A Randomized Pilot Study [NCT01450189]		46 participants (Actual)	Interventional	2011-10-31	Completed
Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum [NCT04518228]		325 participants (Anticipated)	Observational	2021-06-08	Recruiting
Compassionate Use Access to REP 2139-Mg for the Treatment of Chronic HBV Infection or Chronic HBV / HDV Co-infection [NCT05683548]		0 participants	Expanded Access		Available
An Open Label Study to Examine the Characteristics of HIV Decay Following Introduction of Combination Antiretroviral Therapy Including Raltegravir During Primary and Chronic HIV Infection [NCT00641641]		16 participants (Actual)	Interventional	2008-03-31	Completed
A Multicenter Controlled Open-label Trial of Evaluating Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate and Entecavir in Acute-on-chronic Liver Failure of Chronic Hepatitis B Patients [NCT03640728]		200 participants (Anticipated)	Observational	2019-01-25	Recruiting
WRHI 060 (ADVANCE): A Randomised, Phase 3 Non-inferiority Study of DTG + TAF + FTC Compared With DTG + TDF + FTC and EFV + TDF + FTC in Patients Infected With HIV-1 Starting First-line Antiretroviral Therapy - Extension to 192 Weeks [NCT03122262]	Phase 3	1,110 participants (Actual)	Interventional	2017-01-16	Completed
Higher Risk of Kidney Function Decline With Entecavir Than Tenofovir Alafenamide in Patients With HBV Related Acute-on-chronic Liver Failure: Real-World Study [NCT05453448]		272 participants (Actual)	Interventional	2022-05-01	Completed
Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen [NCT01929759]		10 participants (Actual)	Interventional	2014-01-31	Completed
Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan Africa: a Phase 3b, Open-label, Hybrid Type 2 Implementation and Effectiveness Trial [NCT06133686]	Phase 3	400 participants (Anticipated)	Interventional	2024-04-01	Not yet recruiting
A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors [NCT03887702]	Phase 3	444 participants (Anticipated)	Interventional	2020-01-17	Active, not recruiting
Molecular, Biochemical and Clinical Differences Between Stavudine and Tenofovir, Each Combined With Lamivudine and Efavirenz in South African HIV-infected Patients [NCT01601899]	Phase 4	60 participants (Actual)	Interventional	2008-10-31	Terminated(stopped due to DSMB decision to begin closeout process in view of April 2010 SA HAART guideline)
A Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine Once Daily Compared to Atazanavir and Ritonavir Plus Tenofovir/Emtricitabine Once Daily in HIV-1 Infected Antiretroviral Therapy Naïve Women [NCT01910402]	Phase 3	499 participants (Actual)	Interventional	2013-08-22	Completed
Defining the Rectal Mucosa in Men Who Have Sex With Men at Risk of HIV Infection [NCT02401230]	Phase 4	86 participants (Actual)	Interventional	2015-03-31	Completed
Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF) [NCT03471624]	Phase 4	270 participants (Actual)	Interventional	2018-05-01	Completed
A Phase 3, Open Label, Randomised, Parallel Group Study to Compare the Effect on Prevention and Resolution of Treatment Related Adverse Events of a Simplified, Once Daily Regimen of a Fixed Dose Combination Tablet of Emtricitabine and Tenofovir DF Versus [NCT00323544]	Phase 3	220 participants	Interventional	2004-10-31	Completed
Enfuvirtide for the Initial Phase of Antiretroviral Therapy in HIV-infected Patients With High Risk of Clinical Progression : ANRS 130 APOLLO [NCT00302822]	Phase 3	195 participants (Actual)	Interventional	2006-04-30	Completed
Viral Decay Kinetics During Induction Therapy With or Without the Use of Enfuvirtide in HAART-naÃ-ve Patients With Advanced HIV [NCT00344760]	Phase 4	2 participants (Anticipated)	Interventional	2005-01-31	Completed
Evaluation of Pre-Exposure Prophylaxis (PrEP) Initiation, Retention, and Adherence in Pregnant and Breastfeeding Women [NCT03902418]		1,200 participants (Actual)	Observational	2019-08-01	Active, not recruiting
A 48-Week, Randomized, Open-Label Phase 3B Study Comparing the Antiviral Efficacy and Safety of ATV/RTV 3TC With ATV/RTV Plus TDF/FTC In HIV-1-Infected, Treatment-Naïve Subjects, Followed By a 48-Week Period on ATV/RTV Plus 3TC [NCT01620944]	Phase 3	3 participants (Actual)	Interventional	2012-07-31	Terminated(stopped due to Business objectives have changed)
Maraviroc Switch Central Nervous System (CNS) Substudy: a Substudy of MARCH, a Randomised, Open-label Study to Evaluate the Efficacy and Safety of Maraviroc (MVC) as a Switch for Either Nucleoside or Nucleotide Analogue Reverse Transcriptase Inhibitors (N [NCT01637233]		28 participants (Actual)	Observational	2012-06-30	Completed
Maraviroc Switch Collaborative Study Renal Substudy [NCT01637259]	Phase 4	76 participants (Actual)	Interventional	2012-06-30	Completed
A Multicenter Randomized Controlled Open-label Trial of Tenofovir vs. Tenofovir Plus Entecavir in Chronic Hepatitis B Patients With Genotypic Resistance to Entecavir and Partial Virologic Response to Ongoing Treatment [NCT01639092]	Phase 4	88 participants (Actual)	Interventional	2012-09-28	Completed
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of Tenofovir Disoproxil Fumarate in Combination With Other Antiretroviral Agents for the Treatment of HIV-1 Infected Patients [NCT00002450]	Phase 3	600 participants	Interventional		Completed
Changes in Weight After Switch to Dolutegravir/Lamivudine or Doravirine/Tenofovir/Lamivudine Compared to Continued Treatment With Dolutegravir/Tenofovir/Lamivudine for Virologically Suppressed HIV Infection. AVERTAS-2 [NCT04903847]	Phase 4	126 participants (Anticipated)	Interventional	2021-02-02	Recruiting
A Randomized, Double Blind, Placebo-controlled Phase 2b Study to Evaluate Efficacy, Pharmacokinetics, and Safety of 48-week Study Intervention With JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Viro [NCT04129554]	Phase 2	130 participants (Actual)	Interventional	2019-11-06	Completed
Economic Evaluation of Treatment of HIV With Zidovudine/Stavudine and Tenofovir Regimen: A Cost Effectiveness Study [NCT01694017]	Phase 4	68 participants (Actual)	Interventional	2012-11-30	Completed
Phase 2 Adherence and Pharmacokinetics Study of Oral and Vaginal Preparations of Tenofovir [NCT00592124]	Phase 2	168 participants (Actual)	Interventional	2008-06-30	Completed
The Pharmacokinetic Parameters of Tenofovir (TFV) in Maternal Blood and Breast Milk in Women Treated With Daily Tenofovir Disoproxil Fumarate (TDF; 300mg) for Prevention of Mother to Child Transmission (PMTCT) of Hepatitis B Virus (HBV) Mono-infection [NCT04114890]	Phase 2	27 participants (Actual)	Interventional	2021-01-08	Active, not recruiting
What is the Impact of Current HIV Medication Regimens on Endothelial Dysfunction? [NCT03782142]		22 participants (Actual)	Observational	2018-11-01	Completed
A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine [NCT01701882]	Phase 3	40 participants (Actual)	Interventional	2012-09-30	Completed
A Prospective and Open-Label Study of the Effect on Proximal Tubular Function in Asian-American Patients Receiving Tenofovir Disoproxil Fumarate (TDF) or Entecavir (ETV) for HBV Treatment [NCT01715987]		48 participants (Actual)	Observational	2012-10-31	Terminated
A Prospective Randomized Controlled Study to Compare the Efficacy of Combined Tenofovir Plus Telbuvidine vs Tenofovir Alone in Patients With Spontaneous Reactivation of Hepatitis B. [NCT01732224]		69 participants (Actual)	Interventional	2012-11-30	Completed
Randomized Trial of Tenofovir Versus Lamivudine Plus Adefovir in Lamivudine Plus Adefovir Treated Lamivudine-resistant Chronic Hepatitis B Patients With Undetectable Hepatitis B Virus DNA. [NCT01732367]	Phase 4	171 participants (Actual)	Interventional	2012-11-30	Completed
A Phase IIa, Randomized, Double-blind, Active-controlled, 12-week Study of Amdoxovir (Two Doses) Versus Tenofovir DF, in Combination With Zidovudine in HIV-1 Treatment-experienced Subjects With M184I/V Mutation in Addition to 0-2 Confirmed Thymidine Analo [NCT01737359]	Phase 2	2 participants (Actual)	Interventional	2012-12-31	Terminated
Long-term Study to Observe Safety and Efficacy of TAF in Patients With Chronic Hepatitis B [NCT03489239]	Phase 3	27 participants (Actual)	Interventional	2017-11-16	Active, not recruiting
Nevirapine vs Ritonavir-boosted Lopinavir in ART HIV-infected Adults in a Resource-limited Setting; a Randomized, Multicenter, Parallel Group Study [NCT01772940]	Phase 4	425 participants (Actual)	Interventional	2008-12-31	Completed
Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine [NCT01778413]	Phase 4	60 participants (Actual)	Interventional	2013-05-31	Completed
In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal Products [NCT01813162]	Phase 1	101 participants (Actual)	Interventional	2013-12-31	Completed
Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine With the Omission of Immune Globulin to Prevent Hepatitis B Transmission in Mother With High Viral Load: A Multi-Center, Prospective, Randomized and Open-Label Study [NCT03476083]	Phase 4	280 participants (Anticipated)	Interventional	2018-06-10	Recruiting
Efficacy and Safety Evaluation of TDF-based Regimen in Thai HIV-infected Children [NCT01815255]		36 participants (Actual)	Observational	2010-12-31	Completed
A Pilot Demonstration Project to Operationalize Pre-exposure Prophylaxis as Part of Combination HIV Prevention Among Men Who Have Sex With Men (MSM) and Transgender Women in Los Angeles County [NCT01781806]	Phase 4	328 participants (Actual)	Interventional	2013-05-31	Completed
A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) [NCT02397096]	Phase 3	673 participants (Actual)	Interventional	2015-06-09	Completed
ANRS 159 VIH-2 : Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients [NCT01605890]	Phase 2	30 participants (Actual)	Interventional	2012-07-31	Completed
Phase 3, Randomized Clinical Trial to Assess the Efficacy and Safety of Tenofovir in Hepatitis B Virus Infected, s and e Antigen Positive, Pregnant Women to Prevent Perinatal Transmission Despite Infant Passive-active HBV Immunization. [NCT01745822]	Phase 3	654 participants (Actual)	Interventional	2013-01-31	Completed
Effects of Biectegravir-Emtricitabine-Tenofovir Alafenamide on Coronary Flow Reserve in Stable HIV Patients (B/F/TAF-CFR) - Pilot Study [NCT03656783]	Phase 3	25 participants (Actual)	Interventional	2018-09-14	Completed
The Efficacy and Safety of Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection [NCT04296695]	Phase 4	250 participants (Anticipated)	Interventional	2021-07-14	Active, not recruiting
Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-955176 (Double-Blinded) and BMS-955176 With Atazanavir +/- Ritonavir (Open-Labeled) in HIV-1 Infected Subjects [NCT01803074]	Phase 2	107 participants (Actual)	Interventional	2013-04-04	Completed
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Antiviral Activity of the Addition of PMPA Prodrug to Combination Antiretroviral Regimens in Treatment-Experienced HIV-Infected Patients [NCT00002415]	Phase 2	175 participants	Interventional		Completed
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic [NCT01400412]	Phase 2	262 participants (Actual)	Interventional	2012-01-17	Completed
Study on Therapeutic Effects and Safety of Three Types of Nucleotide/Nucleoside Analogues in Patients With Chronic Hepatitis b [NCT04195074]		300 participants (Anticipated)	Interventional	2019-01-01	Recruiting
Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women An Open-Label Randomised Control Study [NCT03227731]	Phase 2/Phase 3	540 participants (Actual)	Interventional	2017-09-28	Completed
A Prospective Cohort Study of Tenofovir Alafenamide Switching Therapy in Kidney or Liver Transplant Recipients With Chronic Hepatitis B Virus Infection [NCT05410496]	Phase 4	50 participants (Anticipated)	Interventional	2021-06-22	Recruiting
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia: A Pragmatic Randomized Controlled Trial [NCT04359095]	Phase 2/Phase 3	650 participants (Actual)	Interventional	2020-08-18	Completed
Effects of Ledipasvir/Sofosbuvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF) in Patients With HIV. [NCT03126370]	Phase 4	10 participants (Actual)	Interventional	2018-01-08	Completed
Investigation on Antiviral Therapy of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B Patients Based on Detection of Interferon Gene Mutation and Interferon Receptor [NCT02973646]	Phase 4	100 participants (Anticipated)	Interventional	2016-01-31	Recruiting
Efficacy Comparison Between Two Kind of Chinese Herbal Formulas on Traditional Chinese Medicine Syndromes Among Chronic Hepatitis Patients [NCT03018821]		250 participants (Anticipated)	Interventional	2017-01-31	Recruiting
A Randomized Comparison of Three Regimens of Chemotherapy With Compatible Antiretroviral Therapy for Treatment of Advanced AIDS-KS in Resource-Limited Settings [NCT01435018]	Phase 3	334 participants (Actual)	Interventional	2013-10-01	Completed
A Phase II Acceptability Study of Oral Emtricitabine/Tenofovir Alafenamide (F/TAF) vs Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for the Prevention of HIV Acquisition in Adolescent Girls and Young Women (AGYW) [NCT05458765]	Phase 2	330 participants (Actual)	Interventional	2022-06-21	Active, not recruiting
A Pilot Study to Evaluate the Effectiveness of a Tenofovir Raltegravir Switch in Resolving Tenofovir Induced Proteinuria in HIV Infected Individuals With Undetectable HIV Viral Loads [NCT01044771]		20 participants (Actual)	Interventional	2010-01-31	Completed
A Phase III, Open-label, Single Centre, Single-arm, Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Efavirenz With Continuing Central Nervous System (CNS) Toxicity, to Raltegravir [NCT01195467]	Phase 3	40 participants (Actual)	Interventional	2010-10-31	Completed
Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (ECF/TAF) Switch Followed by Ledipasvir-Sofosbuvir HCV Therapy in HIV-HCV Co-Infection: A CIHR Canadian HIV Trials Network-Gilead Pilot Trial Proposal [NCT02660905]	Phase 3	25 participants (Actual)	Interventional	2016-04-30	Completed
Clinical Efficacy and Safety of Tenofovir Disoproxil Fumarate and Entcavir in Treatment of Chronic Hepatitis B Patients in Upper Egypt [NCT05874440]		100 participants (Anticipated)	Observational	2023-04-15	Recruiting
The Impact and Cost-effectiveness of Safer Conception Strategies for HIV-discordant Couples [NCT03049176]		46 participants (Actual)	Observational	2017-03-13	Completed
Prospective, Randomised, Crossover, Double-Blind, Placebo-Controlled Trial To Assess The Lipid-Lowering Effect Of Adding Tenofovir/Emtricitabine Co-Formulation Vs Placebo To Hiv-1-Infected Subjects With Dyslipidemia And Sustained Viral Load Suppression Un [NCT01458977]	Phase 4	48 participants (Actual)	Interventional	2012-01-31	Completed
Demonstration Project on the Feasibility to Implement a Pre-Exposure Oral Prophylaxis Program in Men Who Have Sex With Other Men and Transgender Women at Risk of Acquiring HIV [NCT03043326]		1,000 participants (Anticipated)	Observational	2017-01-23	Recruiting
A Phase 2, Open-label, Multicenter, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Acceptability of Twice Yearly Long-acting Subcutaneous Lenacapavir for Pre-Exposure Prophylaxis in Cisgender Women in the United States [NCT06101329]	Phase 2	250 participants (Anticipated)	Interventional	2023-11-17	Recruiting
TEN Switch - An Observational Phase IV Study to Evaluate the Safety and Efficacy of Substituting Tenofovir for Didanosine in Virologically Controlled HIV-infected Patients Co-infected With Hepatitis C Virus. [NCT00358696]	Phase 4	30 participants (Anticipated)	Interventional	2006-07-31	Completed
A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Positive, [NCT02452528]	Phase 2	4 participants (Actual)	Interventional	2015-08-31	Terminated(stopped due to Company decision to discontinue trial)
The Efficacy and Safety of Tenofovir Alafenamide Fumarate Compared With Other Nucleoside Analogues (Acid) to Treat Patients With Low-level Viremia of HBV [NCT04501224]		200 participants (Anticipated)	Interventional	2020-08-03	Recruiting
A Phase 2b Study to Evaluate the Efficacy, Safety and PK of a Combination of Bictegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate for Treatment of HIV-1 Infection in Patients With Drug-susceptible Tuberculosis on a Rifampicin-based Regimen [NCT04734652]	Phase 2	120 participants (Anticipated)	Interventional	2022-02-18	Recruiting
A Multicenter, Open-Label Study to Evaluate ARC-520 Administered Alone and in Combination With Other Therapeutics in Patients With Chronic Hepatitis B Virus (HBV) Infection (MONARCH) [NCT02577029]	Phase 2	79 participants (Actual)	Interventional	2015-12-31	Terminated(stopped due to Company decision to discontinue trial)
A Phase 1, Drug-Drug Interaction Study to Evaluate the Safety, Tolerability, and the Induction Potential of TBAJ-876 on CYP3A4 and P-glycoprotein and the Inhibition Potential of TBAJ-876 on P-glycoprotein in Healthy Adult Subjects [NCT05526911]	Phase 1	28 participants (Actual)	Interventional	2022-07-20	Completed
A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Negative, [NCT02604199]	Phase 2	58 participants (Actual)	Interventional	2015-09-30	Terminated(stopped due to Company decision to discontinue trial)
Phase 2B Safety and Effectiveness Study of Tenofovir 1% Gel, Tenofovir Disproxil Fumarate Tablet and Emtricitabine/Tenofovir Disoproxil Fumarate Tablet for the Prevention of HIV Infection in Women [NCT00729573]		518 participants (Actual)	Observational	2009-11-30	Completed
A Randomized, Double Blind Phase 1 Safety, Acceptability, and Pharmacokinetic Study Comparing Three Formulations of Tenofovir 1% Gel Administered Rectally to HIV-1 Seronegative Adults [NCT01575405]	Phase 1	13 participants (Actual)	Interventional	2013-03-31	Completed
An Exploratory, Double-Blinded, Randomized, Pharmacokinetic and Safety Study of Three Rectally-Applied Tenofovir 1% Microbicide Gel Formulations [NCT01575418]	Phase 1	9 participants (Actual)	Interventional	2013-03-31	Completed
Open Randomized Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir [NCT01576731]	Phase 4	240 participants (Actual)	Interventional	2012-07-31	Completed
Efficacy and Safety of TAF in Pregnant Women With Chronic Hepatitis B Infection [NCT04507607]	Early Phase 1	50 participants (Anticipated)	Interventional	2020-08-01	Recruiting
A Study to Evaluate the Potential Drug-Drug Interaction Between Danoprevir When Coadministered With Low-Dose Ritonavir and Tenofovir Disoproxil Fumarate or Atazanavir in Healthy Adult Volunteers [NCT01592305]	Phase 1	40 participants (Actual)	Interventional	2012-05-31	Completed
Randomized Study Comparing Nucleoside Analogues Plus Tenofovir and Nucleoside Analogues Plus Adefovir in Chronic Hepatitis B Patients With Suboptimal Response to Adefovir-based Combination Therapy Due to Nucleoside Analogues Resistance [NCT01595633]	Phase 4	124 participants (Anticipated)	Interventional	2012-03-31	Recruiting
Bone Health in Aging HIV Infected Women: Improvement or Prevention of Changes in Bone Mineral Density by Switching Antiretroviral Agents. Is There an Optimal Time to Intervene? [NCT02815566]	Phase 4	34 participants (Actual)	Interventional	2017-09-12	Completed
Randomized Controlled Pilot Study of Highly Active Anti-Retroviral Therapy for Patients With Primary Biliary Cirrhosis [NCT01614405]		13 participants (Actual)	Interventional	2012-06-30	Completed
A Phase 1 Open Label Study Evaluating the Distribution of a Tenofovir Douche in Combination With Tap Water Douching and Simulated Receptive Anal Intercourse (DREAM-02) [NCT04195776]	Phase 1	6 participants (Actual)	Interventional	2021-06-01	Completed
Implementation of the Pre-Exposure Prophylaxis (PrEP) to HIV in Brazilian Transgender Women [NCT03220152]	Phase 4	120 participants (Anticipated)	Interventional	2017-07-10	Recruiting
CCTG584: Viral Dynamics and Pharmacokinetics of Tenofovir and Abacavir Monotherapy Versus the Combination Therapy of TDF-ABC in HIV-Infected Treatment Naive Patients [NCT00214890]	Phase 2	21 participants (Actual)	Interventional	2004-12-07	Completed
Serologic and Virologic Outcomes of Tenofovir in Asian Chronic Hepatitis B Patients With Prior Nucleoside Analogue Exposure [NCT01728935]		141 participants (Actual)	Interventional	2008-04-30	Completed
A Phase I/II Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerance, and Pharmacokinetics, and Antiviral Activity of 9-[(R)-2-(Phosphonomethoxy)Propyl] Adenine (PMPA) in HIV-Infected Patients [NCT00002180]	Phase 1	0 participants	Interventional		Completed
PrEP Adherence Monitoring Using Dried Blood Spots [NCT02022657]	Phase 1/Phase 2	52 participants (Actual)	Interventional	2014-04-30	Completed
A Phase 3, Randomized, Active-controlled, Double-blind Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Once Daily Fixed Dose Combination Regimen Versus a Regimen Consisting of Darunavir/Cobicis [NCT02431247]	Phase 3	725 participants (Actual)	Interventional	2015-07-06	Completed
SWITCH OR ADD PEGYLATED-INTERFERON IN CHRONIC HEPATITIS B PATIENTS ON LONG TERM NUCLEOS(T)IDE THERAPY (SWAP TRIAL) [NCT01928511]	Phase 4	254 participants (Actual)	Interventional	2014-01-31	Completed
Management Using the Latest Technologies in Resource-limited Settings to Optimize Combination Therapy After Viral Failure (MULTI-OCTAVE) [NCT01641367]	Phase 4	545 participants (Actual)	Interventional	2013-02-22	Completed
A Switch Clinical Trial of Antiretrovirals to Compare the Impact of Doravirine Versus Integrase Inhibitors With Backbone of Emtricitabine and Tenofovir Alafenamide on Instigators of Atherosclerosis in Persons With Chronic Treated HIV. [NCT04820933]	Early Phase 1	20 participants (Anticipated)	Interventional	2024-02-01	Not yet recruiting
Phase 3b, Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring and Oral TRUVADA® Use in Pregnancy [NCT03965923]	Phase 3	859 participants (Actual)	Interventional	2020-01-09	Active, not recruiting
A Single-Dose, Open-Label, Randomized, Replicate Crossover Pivotal Bioequivalence Study in Healthy Adult Participants to Assess the Bioequivalence of Darunavir 675 mg, Emtricitabine 200 mg, and Tenofovir Alafenamide 10 mg in the Presence of Cobicistat 150 [NCT04661397]	Phase 1	37 participants (Actual)	Interventional	2021-01-05	Completed
A Phase IV Open-label Evaluation of Safety, Tolerability, and Acceptability of a Fixed-dose Formulation of Bictegravir, Emtricitabine/Tenofovir Alafenamide (B/F/TAF) for Non-occupational Prophylaxis Following Potential Exposure to HIV-1 [NCT03499483]	Phase 4	52 participants (Actual)	Interventional	2019-01-24	Completed
Express Testing and Same-day Initiation of PrEP [NCT05690815]		816 participants (Anticipated)	Observational	2023-01-24	Recruiting
Parallel Comparison of Tenofovir and Emtricitabine/Tenofovir Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples [NCT00557245]	Phase 3	4,758 participants (Actual)	Interventional	2008-05-31	Completed
Randomized, Open-Label, Multiple-Dose Study to Evaluate the Effect of Famotidine on the Pharmacokinetics of Atazanavir/Ritonavir/Tenofovir in Healthy Subjects [NCT00365339]	Phase 1	40 participants	Interventional	2006-04-30	Completed
Chronic Kidney Disease Progression in Chronic Hepatitis B Patients on Tenofovir Alafenamide (TAF) Versus Entecavir [NCT05423834]		1,800 participants (Anticipated)	Observational [Patient Registry]	2022-09-01	Active, not recruiting
Pharmacokinetic Study of an Optimized Dose Ratio of Dolutegravir/Emtricitabine/Tenofovir Alafenamide Fumarate: Expediting a UNIVERSAL First Line Regimen for All Children Living With HIV in Africa [NCT05993767]	Phase 2	50 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
Finding the Right Tenofovir/Emtricitabine Regimen for Pre-Exposure Prophylaxis (PrEP) in Transgender Women [NCT03060785]	Phase 1	16 participants (Actual)	Interventional	2016-03-08	Completed
Phase IV, Open-Label, Randomized, Multicenter Study Evaluating Efficacy and Tolerability of Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir DF Compared to Unmodified HAART in HIV-1 Infected Subjects Who Have Achieved Virological Suppression on [NCT00365612]	Phase 4	300 participants (Anticipated)	Interventional	2006-07-31	Completed
Feasibility of Short-Term PrEP Uptake for MSM With Episodic High-Risk for HIV [NCT02495779]		54 participants (Actual)	Interventional	2015-07-31	Completed
Gender-Specific Combination HIV Prevention for Youth in High Burden Settings (MP3-Youth) [NCT01571128]		1,215 participants (Actual)	Interventional	2014-11-30	Completed
A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs [NCT03537404]	Phase 1	36 participants (Actual)	Interventional	2017-04-24	Completed
A Phase 3b, Randomized, Open-label Clinical Study to Demonstrate Non-inferiority in Virologic Response Rates of HIV-1 RNA Suppression <400 Copies/mL of TDF/FTC/RPV Versus TDF/FTC/EFV in First-line Antiretroviral NNRTI-based Suppressed Patients. Switching [NCT01709084]	Phase 3	426 participants (Actual)	Interventional	2013-10-02	Completed
HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS) [NCT02437110]	Phase 1	122 participants (Actual)	Interventional	2019-04-01	Active, not recruiting
Combination Therapy of Tenofovir and Telbivudine in Immune-tolerant Patients With Chronic Hepatitis B Awaiting Assisted Reproduction [NCT02338674]	Phase 1/Phase 2	121 participants (Actual)	Interventional	2014-10-31	Completed
Open-Label Randomized Controlled Trial to Assess the Implementation Effectiveness and Safety of 1% Tenofovir Gel Provision Through Family Planning Services in KwaZulu-Natal, South Africa [NCT01691768]	Phase 2/Phase 3	372 participants (Actual)	Interventional	2012-10-31	Completed
Western Australian Pre-exposure Prophylaxis for HIV Implementation Trial [NCT03327155]	Phase 3	900 participants (Actual)	Interventional	2017-11-16	Completed
Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis [NCT04880577]	Phase 2	0 participants (Actual)	Interventional	2022-09-15	Withdrawn(stopped due to Funding)
Investigating Influence of Pregnancy-induced Changes in Antiretroviral Pharmacokinetics, Together With Polymorphisms in Drug Disposition Genes, on Viral Decay Dynamics in HIV Positive Women Starting Therapy Late in Pregnancy and Postpartum [NCT03284645]		194 participants (Actual)	Observational	2017-12-22	Completed
A Phase I/II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerance, Pharmacokinetics, and Antiviral Activity of 9-[2-(R)-[[Bis[[(Isopropoxycarbonyl)- Oxy]Methoxy]Phosphinoyl]Methoxy]Propyl]Adenine Fumarate (PMPA Prodrug) in HIV-Infe [NCT00002396]	Phase 1	60 participants	Interventional		Active, not recruiting
Study of the Feasibility and Acceptability of an Adherence Promotion Package for Postpartum Women on Pre-exposure Prophylaxis (PrEP) [NCT04897737]		106 participants (Actual)	Interventional	2020-11-05	Completed
Project ADHERE: Clinical Proof-of-Concept of a Tenofovir (TFV) Aptamer-Based Biosensor for Determining Adherence Using Different Dosing Regimens of Disoproxil Fumarate/Emtricitabine (TDF/FTC) [NCT04870671]	Early Phase 1	14 participants (Actual)	Interventional	2021-03-08	Completed
Switching From Regimens Consisting of a RTV-Boosted Protease Inhibitor Plus TDF/FTC to a Combination of Raltegravir Plus Nevirapine and Lamivudine in HIV Patients With Suppressed Viremia and Impaired Renal Function (RANIA Study) (Pilot Study) Protocol MK- [NCT02116660]	Phase 2	11 participants (Actual)	Interventional	2014-09-03	Terminated(stopped due to This study was terminated early due to poor recruitment.)
Pharmacokinetics Study of Tenofovir in HIV-infected Thai Children Using Tenofovir-based Regimen [NCT02404259]		32 participants (Actual)	Interventional	2010-06-30	Completed
Comprehensive HIV Prevention Package for MSM in Port Elizabeth [NCT02449733]		101 participants (Actual)	Interventional	2015-05-31	Completed
An Open-Label, Multicenter, Compassionate Access Study of the Safety of Tenofovir Disoproxil Fumarate Administered in Combination With Other Antiretroviral Agents for the Treatment of HIV-1 Infected Patients [NCT00002453]		300 participants	Interventional	1999-12-31	Completed
A Prospective Cohort Study of Tenofovir Alafenamide Switch Therapy in Chronic Hepatitis B Patients Who Are Unsatisfied to Entecavir Therapy [NCT05583006]		60 participants (Anticipated)	Observational	2023-11-06	Recruiting
A Multiple-Center, Randomized, Partially Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Effects of 12-Week Treatment With RO6864018 in Virologically Suppressed Patients Wit [NCT02391805]	Phase 2	31 participants (Actual)	Interventional	2015-05-17	Completed
Baseline Characteristics and Long Term Clinical Outcomes of Patients Using Malawi's New First Line Antiretroviral Regimen at Lighthouse: The Lighthouse Tenofovir Cohort [NCT02381275]		1,500 participants (Actual)	Observational	2014-08-14	Active, not recruiting
Efficacy and Safety of Albuvirtide for Injection Combined With LPV/r for Treatment of HIV-1-Infected Patients Failed First-line Antiretroviral Therapy [NCT02369965]	Phase 3	418 participants (Actual)	Interventional	2014-02-19	Completed
Study on Therapeutic Effects and Safety of Nucleoside (Acid) Analogues Treatment in Patients With Chronic Hepatitis B With Normal Alanine Aminotransferase and Positive Hepatitis B Virus DNA: a Randomized Controlled Trial [NCT04231565]		100 participants (Anticipated)	Interventional	2021-01-31	Recruiting
A Feasibility Study to Assess Protection of Vaginal and Cervical Tissues From Ex-Vivo HIV-1 Challenge Following Oral Administration of Maraviroc and Tenofovir [NCT02039323]	Phase 1	6 participants (Actual)	Interventional	2014-02-28	Completed
Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females - A Sub-study of HPTN 084 [NCT04824131]	Phase 2	50 participants (Actual)	Interventional	2020-11-04	Completed
A Pilot Study to Assess Virologic Suppression and Immune Recovery With Raltegravir and Lopinavir/Ritonavir and Raltegravir and Emtricitabine/Tenofovir in HIV-1 Infected Treatment-naïve Subjects [NCT00654147]	Phase 2	44 participants (Actual)	Interventional	2008-04-30	Completed
A Multi-centre, Open Label, Parallel Group Trial to Evaluate the Pharmacokinetic Interactions Between BI 207127 (600 mg t.i.d. or 600 mg b.i.d.) and BI 201335 (120 mg q.d.) Given in Combination With Ribavirin for 24 Weeks, and Their Combined Effect on the [NCT01525628]	Phase 1	72 participants (Actual)	Interventional	2012-04-30	Completed
A Single-center, Randomized, Open-label, Active-controlled Phase Ic/IIb Study to Evaluate the Efficacy，Safety and Pharmacokinetics of Hepenofovir Fumarate Tablets in Patients With CHB [NCT06122454]	Phase 1/Phase 2	48 participants (Anticipated)	Interventional	2022-11-10	Recruiting
A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus TRUVADA Administered in Combination With KALETRA in Antiretroviral-Naive HIV-1 Infected Subjects [NCT00244712]	Phase 4	688 participants (Actual)	Interventional	2005-07-31	Completed
Comparative Safety Study of Pre-Filled Plastic and User-Filled Paper Vaginal Applicators With Candidate Microbicide, Tenofovir [NCT01283555]		25 participants (Actual)	Interventional	2011-01-31	Completed
Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study [NCT02245022]	Phase 2/Phase 3	60 participants (Actual)	Interventional	2017-03-14	Completed
Artery Elasticity After Switch From Epzicom to Truvada [NCT00998582]	Phase 4	27 participants (Actual)	Interventional	2009-10-31	Terminated(stopped due to Low enrollment)
A Phase 2b Randomized, Active-Controlled, Staged, Open-Label Trial to Investigate Safety and Efficacy of BMS-955176/GSK3532795 in Combination With Dolutegravir and Atazanavir (With or Without Ritonavir) in Treatment-Experienced HIV-1 Infected Adults [NCT02386098]	Phase 2	86 participants (Actual)	Interventional	2015-07-08	Terminated(stopped due to GI Intolerability)
Study on Therapeutic Effects and Safety of Three Types of Nucleotide/Nucleoside Analogues in Patients With Hepatitis b Virus Related Compensated Cirrhosis [NCT04196998]		150 participants (Anticipated)	Interventional	2019-01-01	Recruiting
Parrying the Pitfalls of PrEP: Preventing Premature PrEP Discontinuation and STIs Among MSM [NCT05072093]	Phase 4	200 participants (Anticipated)	Interventional	2021-11-20	Recruiting
A Prospective, Randomized, Open-label Study of the Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC [NCT03084250]	Phase 4	150 participants (Anticipated)	Interventional	2017-03-10	Active, not recruiting
Pharmacoepidemiology Study to Define the Long-term Safety Profile of Tenofovir Disoproxil Fumarate (Tenofovir DF, Viread®) and Describe the Management of Tenofovir DF-associated Renal and Bone Toxicity in Chronic Hepatitis B (CHB)-Infected Adolescents Age [NCT02479880]	Phase 4	30 participants (Actual)	Interventional	2015-07-03	Terminated
Project PrEPare - An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM) in the United States [NCT01769456]	Phase 2	78 participants (Actual)	Interventional	2013-03-31	Completed
Hellenic Multicenter Real-life Clinical Study for Bulevirtide Therapy in Chronic Hepatitis D: HERACLIS-BLV [NCT05928000]		80 participants (Anticipated)	Observational [Patient Registry]	2023-05-01	Recruiting
A Prospective Randomized Controlled Trial of Tenofovir and Entecavir in the Treatment of Long-term Prognosis in Patients With Hepatitis B-related Hepatocellular Carcinoma After Curative Resection [NCT04392700]	Phase 3	706 participants (Anticipated)	Interventional	2019-07-25	Recruiting
Dose-Proportionality and Intra-Individual Variability of Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate In Healthy Volunteers [NCT01276600]	Phase 1	32 participants (Actual)	Interventional	2011-01-31	Completed
Maternal and Infant Monitoring for Evidence of Toxicity Related to Tenofovir Exposure: The Bone and Kidney Health Substudy of the IMPAACT 1077 PROMISE Protocol (Promoting Maternal and Infant Survival Everywhere) [NCT01066858]		1,765 participants (Actual)	Observational	2011-03-22	Completed
Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection [NCT00885664]	Phase 4	60 participants (Actual)	Interventional	2005-10-31	Completed
A Multicenter, Open-label, Single Arm Trial for the Effectiveness of Antiviral Treatment in Cirrhotic Patients With Low-level Hepatitis B Virus DNA Levels With a Comparison to Matched Historical Controls (ATTACH) [NCT04780204]	Phase 4	200 participants (Anticipated)	Interventional	2021-08-23	Recruiting
A Multi-center, Open-label, Long-term Extension Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients [NCT03780543]	Phase 2	92 participants (Actual)	Interventional	2018-12-20	Terminated(stopped due to Sponsor decision)
Delivery of Pre-exposure Prophylaxis to Individuals With High Sexual Risk of HIV Infection in Hong Kong - an Implementation Study [NCT04367688]		400 participants (Anticipated)	Observational	2020-03-01	Recruiting
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected Treatment-naive Participants. There is a 36 Week, Open-label, Extension Phase for Eligible Participants. [NCT00350272]	Phase 2	76 participants (Actual)	Interventional	2006-05-31	Completed
A Multi-Center, Randomized, Open-label, Parallel, Active-controlled, Non-inferiority, Phase IV Clinical Trial to Evaluate the Safety and Efficacy of Switching to Tenolid Tab (Tenofovir Disoproxil) From Viread Tab (Tenofovir Disoproxil Fumarate) in Chronic [NCT05286346]	Phase 4	113 participants (Actual)	Interventional	2018-10-12	Completed
A Phase 2A Randomized, Double-blinded, Placebo-controlled, Multicenter, Dose Ranging Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepat [NCT04847440]	Phase 2	40 participants (Actual)	Interventional	2021-03-30	Terminated(stopped due to Terminated by the Sponsor)
Pilot Study of Raltegravir/Tenofovir/Emtricitabine Versus Efavirenz/Tenofovir/Emtricitabine for Adults With Acute HIV-1 Infection: Exploring the Role of Integrase Inhibition in Early HIV Pathogenesis [NCT00734344]		18 participants (Actual)	Interventional	2008-09-30	Completed
A Phase IIb, Dose Ranging Study of Oral GSK1265744 in Combination With Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus -1 (HIV-1) Virologic Suppression Followed by an Evaluation of Maintenance of Virologic Suppres [NCT01641809]	Phase 2	244 participants (Actual)	Interventional	2012-08-06	Completed
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and Antiretroviral Therapy (ART) [NCT01903031]	Phase 2	84 participants (Actual)	Interventional	2014-12-30	Completed
A Randomized, Open-label, Multi-part Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers [NCT03032536]	Phase 1	54 participants (Actual)	Interventional	2017-01-31	Terminated(stopped due to Sponsor decision.)
A Pilot Project to Operationalize the Prevention Strategy of Post Exposure Prophylaxis Following Sexual Exposure to HIV in Combination With Educational Programming and Behavioral Risk Reduction Strategies in Los Angeles County [NCT00949234]	Phase 2	267 participants (Actual)	Interventional	2010-03-31	Completed
Effect of Substituting Truvada for Combivir or Trizivir vs Continuing Combivir or Trizivir on Physiologic Correlates of Mitochondrial Function in Subjects Infected With Human Immunodeficiency Virus on Highly Active Antiretroviral Therapy [NCT00960622]	Phase 4	17 participants (Actual)	Interventional	2006-08-31	Completed
PrEP Point-of-Care Brief-Intervention for Adherence Among Young Men Who Have Sex With Men [NCT05353283]		60 participants (Anticipated)	Interventional	2023-09-01	Recruiting
IPrEP: A Combination HIV Prevention Strategy for Young Women at Risk for HIV in Kisumu, Kenya IPrEP Men's Study: Expanding the Reach of Prevention for Men in Kisumu, Kenya [NCT04898699]		120 participants (Anticipated)	Interventional	2021-10-31	Not yet recruiting
DTG/3TC vs. BIC/FTC/TAF Maintenance Therapy in People Living With HIV: an Open-label Randomized Clinical Trial [NCT04884139]	Phase 4	555 participants (Anticipated)	Interventional	2021-07-14	Active, not recruiting
Decrease of Neuropsychiatric and Neurocognitive Side Effects Prevalence [NCT02447016]	Phase 4	25 participants (Actual)	Interventional	2015-05-31	Terminated(stopped due to no more participants taking atripla)
Effectiveness and Safety of Tenofovir Alafenamide for HBV Prophylaxis in Post Orthotopic Liver Transplant With HBV-related Disease [NCT05063071]	Phase 4	150 participants (Anticipated)	Interventional	2021-07-29	Active, not recruiting
An Open-label, Randomized, Crossover Study to Evaluate the Effect of PAS on the Pharmacokinetics of Tenofovir in Healthy Subjects [NCT03070405]	Phase 1	20 participants (Anticipated)	Interventional	2016-10-31	Active, not recruiting
A Phase 1, Blinded, Randomized, Placebo-controlled, First-in-human Study of Orally Administered JNJ-64457744 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single and Multiple Ascending Doses [NCT05423106]	Phase 1	60 participants (Actual)	Interventional	2022-07-04	Terminated(stopped due to Strategic business decision, not due to safety concerns)
An Open-Label Randomized Clinical Trial to Evaluate the Efficacy and Safety of Short Course Antiretroviral Therapy for Acute or Recent HIV-1 Infection in Zimbabwe and the United States [NCT00414518]		16 participants (Actual)	Interventional	2007-01-31	Completed
A Comparative Study of the Antiviral Efficacy and Safety of Entecavir Plus Tenofovir Versus Adefovir Added to Continuing Lamivudine in Adults With Lamivudine- Resistant Chronic Hepatitis B Virus Infection [NCT00605384]	Phase 3	4 participants (Actual)	Interventional	2008-08-31	Terminated(stopped due to Business Objectives Have Changed)
A Randomized Controlled Pilot Trial Comparing Continued Antiretroviral Therapy With Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) With Switch to Tenofovir/Emtricitabine/Raltegravir (TDF/FTC/RAL) on Changes in Endothelial Function and Markers of Bone Met [NCT01270802]	Phase 4	30 participants (Actual)	Interventional	2011-04-30	Completed
A Pilot Project to Assess the Safety and Tolerability of Truvada Plus Raltegravir as Post-exposure Prophylaxis (nPEP) Following Sexual Exposure to Human Immunodeficiency Virus (HIV) [NCT01214759]	Phase 4	103 participants (Actual)	Interventional	2011-05-31	Completed
A Real-World Study of Sequential Combination Therapy With Pegylated Interferon In Nucleoside-treated Patients With Chronic Hepatitis B [NCT03357822]	Phase 4	2,000 participants (Anticipated)	Interventional	2018-01-25	Recruiting
The Stay Study: A Demonstration Project Advancing PrEP Delivery in the San Francisco Bay Area Transgender Community [NCT03120936]	Phase 4	158 participants (Actual)	Interventional	2017-08-08	Completed
Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses [NCT02859558]	Phase 2	195 participants (Actual)	Interventional	2017-01-31	Active, not recruiting
Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive. Randomized Clinical, Not Masked, Trial Comparing DRVr3TC, ABC3TC (Kivexa) RPV, or EVG COBI FTC TDF (Stribild) for 48 Weeks [NCT02470650]	Phase 4	150 participants (Anticipated)	Interventional	2015-06-30	Recruiting
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 [NCT01777997]	Phase 4	38 participants (Actual)	Interventional	2013-04-25	Completed
Treatment of Hepatitis B in Resource-limited Settings - a Pilot Program in East Africa [NCT02344498]		1,350 participants (Actual)	Observational	2015-01-31	Active, not recruiting
A Phase 2 Randomized Sequence Open Label Expanded Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel [NCT01687218]	Phase 2	195 participants (Actual)	Interventional	2013-09-25	Completed
Comparison of Pharmacokinetics of Tenofovir Alafenamide (TAF) With Tenofovir Disoproxil (TDF) in Pregnant and Postpartum Women and Their Infants in PrEP-PP Study [NCT04937881]	Phase 3	50 participants (Actual)	Interventional	2022-06-13	Completed
A Phase IIb Randomized, Controlled, Partially-Blinded Trial to Investigate Safety, Efficacy and Dose-Response of BMS-663068 in Treatment-experienced HIV-1 Subjects, Followed by an Open-Label Period on the Recommended Dose [NCT01384734]	Phase 2	254 participants (Actual)	Interventional	2011-07-26	Completed
Combined HIV Adolescent PrEP and Prevention: On Demand Pre-exposure Prophylaxis to Provide Protection From HIV in Men - Using Foreskin Tissue to Estimate Protection (Phase II) [NCT03986970]	Phase 2	72 participants (Actual)	Interventional	2019-11-11	Completed
Community-based Venues for Delivery of Healthcare Services in Umlazi, South Africa: Proof of Concept Pilot Conducted in Hair Salons [NCT04222504]		500 participants (Anticipated)	Interventional	2021-02-08	Recruiting
A Phase I, Single-center, Open Label Clinical Study, to Evaluate the Pharmacokinetic Character of GLS4 Combined With RTV or TAF Alone or GLS4 and RTV and TAF Combination Administration in Healthy Subjects [NCT04551261]	Phase 1	28 participants (Actual)	Interventional	2021-01-10	Completed
Randomized Clinical Trial to Evaluate the Interest of a Down-scaled Treatment Strategy Using Dual Therapy (Nucleoside Analogs) in HIV Infected Patients Already Being Treated Using Triple Therapy, Who Present With a Successful Virological Control and for W [NCT02302547]	Phase 3	224 participants (Actual)	Interventional	2014-12-31	Completed
A Multi-centre, Prospective, Randomised Trial of Short Course Alendronate Therapy or Placebo Combined With Vitamin D and Calcium to Prevent Loss of Bone Mineral Density in Antiretroviral-naïve, HIV-1 Infected Subjects Initiating Antiretroviral Therapy [NCT02322099]	Phase 4	53 participants (Actual)	Interventional	2016-05-31	Terminated(stopped due to Due to the COVID-19 pandemic the study was terminated prematurely)
The Safety of Anti-viral Therapy in Preventing Mother-to-child Transmission of Hepatitis B Virus in Pregnant Women After Discontinuation [NCT03468907]	Phase 4	111 participants (Actual)	Interventional	2015-06-01	Completed
An Experimental Study on the Effect of Tenofovir Amibufenamide on Blood Lipid During Anti-HBV Treatment [NCT05398393]		150 participants (Anticipated)	Interventional	2022-01-01	Enrolling by invitation
A Phase 1b Randomized, Open Label, Active-Controlled Study to Assess the Safety, Viral Kinetics, and Anti-HBV Activity of GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B (CHB) Infection [NCT01671787]	Phase 1	51 participants (Actual)	Interventional	2012-03-31	Completed
A Phase II Randomized, Double-Blind, Study of the Safety and Tolerability of Maraviroc (MVC), Maraviroc + Emtricitabine (MVC+FTC), Maraviroc + Tenofovir Disoproxil Fumarate (MVC+TDF), or Tenofovir Disoproxil Fumarate + Emtricitabine (TDF+FTC) For Pre-Expo [NCT01505114]	Phase 2	594 participants (Actual)	Interventional	2012-06-30	Completed
Prospective Pilot Study of the Efficacy, Safety and Tolerability of Bictegravir-Based HIV ART Same-Day Treatment Evaluations (B-HASTE) [NCT04249037]	Phase 4	10 participants (Actual)	Interventional	2020-12-15	Terminated(stopped due to Insufficient enrollment)
Project PrEPare - An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among Young Men Who Have Sex With Men (YMSM) in the United States [NCT01772823]	Phase 2	200 participants (Actual)	Interventional	2012-11-30	Completed
Advancing New Computer-based Health Outreach Regarding Sexual Behavior (ANCHORS) Study: UH3 Project [NCT04331704]	Phase 4	88 participants (Anticipated)	Interventional	2021-01-12	Recruiting
An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of Plasmodium Falciparum Subclinical Parasitemia in HIV-infected Adults With CD4+ Counts >200 and <500 Cells/mm^3 [NCT01632891]	Phase 1/Phase 2	52 participants (Actual)	Interventional	2014-01-10	Completed
An Open-label Rollover Study in Chinese Patients After Finishing a 3-year Randomize Trial for Chronic Hepatitis B With High Serum Viral Load But Mild Elevated Aminotransferase [NCT02463019]	Phase 4	160 participants (Anticipated)	Interventional	2015-01-31	Enrolling by invitation
Simplifying Hepatitis B Care in Pregnancy by Combining Birth-dose Vaccine and Tenofovir: The COMBAT HBV Feasibility Trial [NCT05705427]	Phase 4	560 participants (Anticipated)	Interventional	2023-08-17	Recruiting
Utilization of Hepatitis B Virus Nucleic Acid Test Positive Donors for Hepatitis B Vaccinated Lung Transplant Candidates [NCT05404919]	Phase 2	10 participants (Anticipated)	Interventional	2022-09-06	Recruiting
Investigation of Efficacy of Tenofovir Monotherapy in Comparison With Entecavir Plus Tenofovir in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Entecavir Plus Tenofovir Combination Therapy-Multicenter Randomized [NCT03236610]	Phase 3	112 participants (Anticipated)	Interventional	2016-01-01	Recruiting
"Phase IV, Single-center, Open Study to Evaluate the Benefits of the Start of Immediate Treatment Without Immunovirological Data (Same Day Treatment) Compared to Conventional Treatment With BIC / FTC / TAF (Bictegravir/Emtricitabina/Tenofovir) in Naive Pa [NCT05606055]	Phase 4	100 participants (Actual)	Interventional	2020-12-01	Completed
The Incidence of Postpartum Hepatitis in Pregnant Women With High HBVDNA Loads [NCT03214302]		560 participants (Anticipated)	Interventional	2017-01-01	Recruiting
Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B: An Open Label, Randomized Controlled Trial [NCT03933384]	Phase 4	420 participants (Anticipated)	Interventional	2019-08-19	Recruiting
Bictegravir/FTC/TAF for the Treatment of Primary HIV Infection [NCT04483674]	Phase 2	66 participants (Anticipated)	Interventional	2020-12-04	Recruiting
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects With Chronic Hepatitis B and Who Are Currently Not on Treatment [NCT02174276]	Phase 2	195 participants (Actual)	Interventional	2014-07-24	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00035932 (38) [back to overview]	Participants Achieving Virologic Half Log Suppression (LOQ = 50 c/mL) at Week 24
NCT00035932 (38) [back to overview]	Participants Achieving Treatment Response (LOQ = 50 c/mL) Without Prior Failure at Week 24
NCT00035932 (38) [back to overview]	Participants Achieving Treatment Response (LOQ = 400 c/mL) Without Prior Failure at Week 96
NCT00035932 (38) [back to overview]	Participants Achieving Treatment Response (LOQ = 400 c/mL) Without Prior Failure at Week 48
NCT00035932 (38) [back to overview]	Participants Achieving Treatment Response (LOQ = 400 c/mL) Without Prior Failure at Week 24
NCT00035932 (38) [back to overview]	Mean Change From Baseline in HIV RNA at Week 96
NCT00035932 (38) [back to overview]	Mean Change From Baseline in HIV RNA at Week 48
NCT00035932 (38) [back to overview]	Mean Change From Baseline in HIV RNA at Week 2
NCT00035932 (38) [back to overview]	Mean Change From Baseline in HIV Ribonucleic Acid (RNA) at Week 24
NCT00035932 (38) [back to overview]	Fasting Glucose Mean Change From Baseline at Week 48
NCT00035932 (38) [back to overview]	HIV IC50 at Week 24
NCT00035932 (38) [back to overview]	PR Interval and Change From Baseline by Analysis Time Point
NCT00035932 (38) [back to overview]	Participants Achieving Virologic Half Log Suppression (LOQ = 400 c/mL) at Week 48, (Overall and by PI Sensitivity)
NCT00035932 (38) [back to overview]	Participants Achieving Virologic Half Log Suppression (Limit of Quantification [LOQ] = 400 c/mL) at Week 24 (Overall and by Protease Inhibitor [PI] Sensitivity)
NCT00035932 (38) [back to overview]	Most Common AEs and AEs of Interest Through Week 48
NCT00035932 (38) [back to overview]	Mean Score of European Quality of Life-5 Dimensions (EQ-5D) Visual Analog Scale (VAS) at Baseline, Mid-Study (Week 24), and Final (Week 48)
NCT00035932 (38) [back to overview]	Mean Score of European Quality of Life-5 Dimensions (EQ-5D) Health Index Score at Baseline, Mid-Study (Week 24), and Final (Week 48)
NCT00035932 (38) [back to overview]	Mean ATV, RTV and SQV Minimum Concentration (Cmin) Values
NCT00035932 (38) [back to overview]	Lipid Mean Percent Change From Baseline at Week 96, Observed Values
NCT00035932 (38) [back to overview]	Lipid Mean Percent Change From Baseline at Week 48
NCT00035932 (38) [back to overview]	Lipid Mean Percent Change From Baseline at Week 24
NCT00035932 (38) [back to overview]	HIV RNA Level - Treated Subjects With Evaluable Cmins at Week 24
NCT00035932 (38) [back to overview]	Grade 3/4 Laboratory Abnormalities Through Week 48
NCT00035932 (38) [back to overview]	Fridericia-corrected QT (QTcF) Interval and Change From Baseline by Analysis Time Point
NCT00035932 (38) [back to overview]	Deaths, Serious Adverse Events (SAEs), and Adverse Events (AEs) Through Week 48
NCT00035932 (38) [back to overview]	Inhibitory Quotient at Week 24
NCT00035932 (38) [back to overview]	Correlation of ATV Minimum Plasma Concentration (Cmin) Inhibitory Quotient (IQ), and Number of PI Mutations at Baseline and CD4 Cell Count Change From Baseline at Week 24
NCT00035932 (38) [back to overview]	Adherence to Regimen Though Week 48 Based on MACS the Multicenter AIDS Cohort Study (MACS) Adherence Questionnaire
NCT00035932 (38) [back to overview]	Participants Achieving Virologic Half Log Suppression (LOQ = 50 c/mL) at Week 96
NCT00035932 (38) [back to overview]	Participants Achieving Virologic Half Log Suppression (LOQ = 50 c/mL) at Week 48
NCT00035932 (38) [back to overview]	Participants Achieving Virologic Half Log Suppression (LOQ = 400 c/mL) at Week 96
NCT00035932 (38) [back to overview]	Participants Achieving Treatment Response (LOQ = 50 c/mL) Without Prior Failure at Week 96
NCT00035932 (38) [back to overview]	Participants Achieving Treatment Response (LOQ = 50 c/mL) Without Prior Failure at Week 48
NCT00035932 (38) [back to overview]	Correlation of ATV Minimum Plasma Concentration (Cmin), Inhibitory Quotient (IQ), and Number of Protease Inhibitor (PI) Mutations at Baseline With HIV RNA Change From Baseline at Week 24
NCT00035932 (38) [back to overview]	Change From Baseline in CD4 Cell Count at Week 24
NCT00035932 (38) [back to overview]	Change From Baseline in CD4 Cell Count at Week 48
NCT00035932 (38) [back to overview]	Change From Baseline in CD4 Cell Count at Week 96
NCT00035932 (38) [back to overview]	Fasting Glucose Mean Change From Baseline at Week 24
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (95% CI) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C12) With Geometric Mean (95% CI) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C12) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C12) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C24) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Geometric Mean (95% CI) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	Pharmacokinetic (PK) Parameter: Infant Plasma Washout Concentration of ARVs and TB Drugs
NCT00042289 (26) [back to overview]	Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs
NCT00042289 (26) [back to overview]	Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs
NCT00042289 (26) [back to overview]	Area Under the Curve From 0 to 24 Hours (AUC24) of ARVs for Contraceptive Arms
NCT00042289 (26) [back to overview]	Area Under the Curve From 0 to 12 Hours (AUC12) of ARVs for Contraceptive Arms
NCT00042289 (26) [back to overview]	Plasma Concentration for Contraceptives
NCT00042289 (26) [back to overview]	PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	Pharmacokinetic (PK) Parameter: Infant Plasma Washout Half-life (T1/2) of ARVs and TB Drugs
NCT00074581 (2) [back to overview]	Linked Partner HIV Infection Rates in Early-ART and Delayed-ART Arms
NCT00074581 (2) [back to overview]	All Partner HIV Infection Rates in Early-ART and Delayed-ART Arms
NCT00084136 (18) [back to overview]	Time to Loss of Virologic Response at Week 96 (Defined by FDA TLOVR Algorithm - Excluding Study Allowed ARV Substitutions)(NRTI Comparison)
NCT00084136 (18) [back to overview]	Time to Loss of Virologic Response at Week 96 (Defined by FDA TLOVR Algorithm - Including All ARV Substitutions)(NRTI Comparison)
NCT00084136 (18) [back to overview]	Time to Loss of Virologic Response by Week 48 (Defined by FDA TLOVR Algorithm - Excluding Study Allowed ARV Substitutions)(PI Comparison)
NCT00084136 (18) [back to overview]	Time to Treatment Failure (NRTI Comparison)
NCT00084136 (18) [back to overview]	Time to Treatment Failure (PI Comparison)
NCT00084136 (18) [back to overview]	Change in CD4 Count From Screening to Weeks 24, 48, 96 (PI Comparison)
NCT00084136 (18) [back to overview]	Change in CD4 Count From Screening to Weeks 24, 48, 96 (NRTI Comparison)
NCT00084136 (18) [back to overview]	Time to Discontinuation of Initial Antiretroviral (ARV) Therapy (PI Comparison)
NCT00084136 (18) [back to overview]	Plasma HIV-1 Viral Load Fewer Than 400 Copies/ml (NRTI Comparison)
NCT00084136 (18) [back to overview]	Plasma HIV-1 Viral Load Fewer Than 400 Copies/ml (PI Comparison)
NCT00084136 (18) [back to overview]	Time to Discontinuation of Initial Antiretroviral (ARV) Therapy (NRTI Comparison)
NCT00084136 (18) [back to overview]	Time to First Dose Modification or Grade 3 or 4 Adverse Event (NRTI Comparison)
NCT00084136 (18) [back to overview]	Time to First Dose Modification or Grade 3 or 4 Adverse Event (PI Comparison)
NCT00084136 (18) [back to overview]	Time to Immunologic Failure (NRTI Comparison)
NCT00084136 (18) [back to overview]	Time to Immunologic Failure (PI Comparison)
NCT00084136 (18) [back to overview]	Time to Loss of Virologic Response at Week 48 (Defined by FDA TLOVR Algorithm - Excluding Study Allowed ARV Substitutions)(NRTI Comparison)
NCT00084136 (18) [back to overview]	Time to Loss of Virologic Response at Week 48 (Defined by FDA TLOVR Algorithm - Including All ARV Substitutions)(NRTI Comparison)
NCT00084136 (18) [back to overview]	Time to Loss of Virologic Response at Week 48 (Defined by FDA TLOVR Algorithm - Including All ARV Substitutions)(PI Comparison)
NCT00089505 (9) [back to overview]	Percent of Participants Who Reported to Never Missed Any of the Study Drug Regimen in the Past Month
NCT00089505 (9) [back to overview]	Time From Randomization to Virologic Failure or Death for Participants Without SD NVP Exposure Prior to Study Entry
NCT00089505 (9) [back to overview]	Time From Randomization to Virologic Failure or Death for Participants Who Had SD NVP Exposure Prior to Study Entry
NCT00089505 (9) [back to overview]	Number of Participants Who Experienced Treatment-related Toxicity That Led to Discontinuation of Randomized Regimen.
NCT00089505 (9) [back to overview]	Number of Participants Who Experienced Virologic Failure or Died.
NCT00089505 (9) [back to overview]	Number of Participants Who Received NVP-containing Regimens at Randomization and Experienced NVP-associated Rash or Grade 2+ Liver Lab Abnormality
NCT00089505 (9) [back to overview]	CD4 Count Change From Randomization
NCT00089505 (9) [back to overview]	Number of Participants Who Experienced HIV-related Disease Progression or Death
NCT00089505 (9) [back to overview]	Percent of Participants Who Experienced Virologic Failure or Died
NCT00090779 (9) [back to overview]	Number of Participants in IT Arm Off Treatment Before 36 Weeks
NCT00090779 (9) [back to overview]	Number of Participants Meeting Clinical, Virologic, or Immunologic Criteria for Treatment Initiation or Re-initiation
NCT00090779 (9) [back to overview]	Time From Study Entry in DT Arm Participants or From Week 36 in IT Arm Participants to Meeting the Clinical, Virologic, or Immunologic Criteria for Treatment Initiation or Re-initiation
NCT00090779 (9) [back to overview]	Ranked Log10 HIV-1 RNA Viral Load (log10 Copies/mL) Averaged at 72 and 76 Weeks for the IT Arm and DT Arm
NCT00090779 (9) [back to overview]	Ranked log10 HIV-1 RNA Viral Load (log10 Copies/mL) Averaged at Weeks 72 and 76 for the IT Arm and Ranked log10 HIV-1 RNA Viral Load (log10 Copies/mL) Averaged at Weeks 36 and 40 for the DT Arm
NCT00090779 (9) [back to overview]	Number of Participants Experiencing Either a CDC Category B or C Diagnosis, CD4<200 Cells/mm^3 or CD4 Percent <14%.
NCT00090779 (9) [back to overview]	Change in CD4 Counts Cells/mm^3 From Week 36 for IT Arm and From Week 0 for DT Arm
NCT00090779 (9) [back to overview]	Time to Treatment Initiation or Death
NCT00090779 (9) [back to overview]	Time to Meeting the Clinical, Virologic, or Immunologic Criteria for Treatment Initiation or Re-initiation
NCT00099632 (5) [back to overview]	Number of Participants With New Circulating Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI)-Resistant Variants as Detected by Standard Composite (Bulk) Genotyping
NCT00099632 (5) [back to overview]	Number of Participants With New Circulating NRTI-resistant Variants Detected by Standard Composite (Bulk) Genotyping.
NCT00099632 (5) [back to overview]	Number of Participants With New PI-resistant Variants as Detected by Standard Composite (Bulk) Genotyping.
NCT00099632 (5) [back to overview]	Severe (Grade 3) and Higher Adverse Events and Any Grade Adverse Event That Leads to a Treatment Change From First Day of Study Treatment to Week 12
NCT00099632 (5) [back to overview]	Number of Participants Who Discontinued Study Treatment Prematurely
NCT00100048 (26) [back to overview]	Change From Baseline in CD4 Cell Count at Week 96
NCT00100048 (26) [back to overview]	Change From Baseline in Cluster of Differentiation 4 (CD4) Cell Count at Week 24 (Cohort II)
NCT00100048 (26) [back to overview]	Change From Baseline in Plasma HIV RNA at Week 24 (Cohort II)
NCT00100048 (26) [back to overview]	Change From Baseline in Plasma HIV RNA at Week 240
NCT00100048 (26) [back to overview]	Change From Baseline in Plasma HIV RNA at Week 96
NCT00100048 (26) [back to overview]	Change From Baseline in Plasma Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) on Day 10 (Cohort I)
NCT00100048 (26) [back to overview]	Number of Participants With HIV RNA Levels Below 400 Copies/mL at Week 24 (Cohort II)
NCT00100048 (26) [back to overview]	Number of Participants With HIV RNA Levels Below 400 Copies/mL at Week 240
NCT00100048 (26) [back to overview]	Number of Participants With HIV RNA Levels Below 400 Copies/mL at Week 48
NCT00100048 (26) [back to overview]	Number of Patients With Laboratory Adverse Experiences (LAEs)
NCT00100048 (26) [back to overview]	Number of Patients With Serious CAEs and Non-serious CAEs at Week 144
NCT00100048 (26) [back to overview]	Change From Baseline in CD4 (T-helper) Cell Count at Week 240
NCT00100048 (26) [back to overview]	Number of Patients With HIV RNA Level Below 50 Copies/mL and HIV RNA Level Below 400 Copies/mL at Week 96
NCT00100048 (26) [back to overview]	Number of Patients With Drug-related LAEs
NCT00100048 (26) [back to overview]	Number of Patients With Drug-related CAEs
NCT00100048 (26) [back to overview]	Number of Patients With Clinical Adverse Experiences (CAEs) and Number of Patients With Serious CAEs at Day 10 (Cohort I)
NCT00100048 (26) [back to overview]	Number of Patients With Clinical Adverse Experiences (CAEs)
NCT00100048 (26) [back to overview]	Number of Patients That Discontinued With LAEs
NCT00100048 (26) [back to overview]	Number of Patients That Discontinued With CAEs
NCT00100048 (26) [back to overview]	Number of Participants With Clinical Adverse Experiences (AEs)and Serious Adverse Experiences (SAEs)
NCT00100048 (26) [back to overview]	Number of Patients With Serious LAEs
NCT00100048 (26) [back to overview]	Number of Patients With Serious Drug-related LAEs
NCT00100048 (26) [back to overview]	Number of Patients With Serious Drug-related CAEs
NCT00100048 (26) [back to overview]	Number of Patients With Serious CAEs (Cohort I and II Combined)
NCT00100048 (26) [back to overview]	Number of Participants With HIV RNA (Human Immunodeficiency Virus Ribonucleic Acid) Levels Below 50 Copies/mL at Week 240
NCT00100048 (26) [back to overview]	Number of Participants With HIV RNA Levels Below 50 Copies/mL at Week 24 (Cohort II)
NCT00105079 (6) [back to overview]	Number of Participants Assessed for Adverse Events (AEs)
NCT00105079 (6) [back to overview]	Change From Baseline in Cluster Differentiation Antigen 4 Positive (CD4+) Lymphocyte Count
NCT00105079 (6) [back to overview]	Change From Baseline in HIV-1 RNA Viral Load
NCT00105079 (6) [back to overview]	Number of Patients With HIV-1 RNA Viral Load <50 and <400 Copies/mL
NCT00105079 (6) [back to overview]	Number of Patients With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) Viral Load <50 Copies/mL
NCT00105079 (6) [back to overview]	Number of Patients Who Discontinued Treatment Due to Abnormal Laboratory Parameters
NCT00112047 (53) [back to overview]	Percentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 240 (Atripla Week 96) Defined by the FDA TLOVR Algorithm
NCT00112047 (53) [back to overview]	Percentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 48 (Defined by FDA TLOVR Algorithm)
NCT00112047 (53) [back to overview]	Change in Limb Fat (kg) From Week 48 to Week 96
NCT00112047 (53) [back to overview]	Percentage of Participants With HIV-1 RNA < 50 c/mL at Week 48
NCT00112047 (53) [back to overview]	Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) at Week 144
NCT00112047 (53) [back to overview]	Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) at Week 48
NCT00112047 (53) [back to overview]	Percentage of Participants With Pure Virologic Failure (HIV-1 RNA < 50 c/mL) at Week 96
NCT00112047 (53) [back to overview]	Change in Total Body Fat (kg) From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) at Week 96
NCT00112047 (53) [back to overview]	Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) From Week 144 (Atripla Baseline) Through Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) at Week 144
NCT00112047 (53) [back to overview]	Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) at Week 48
NCT00112047 (53) [back to overview]	Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) From Week 144 (Atripla Baseline) Through Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA < 400 c/mL at Week 144
NCT00112047 (53) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA < 400 c/mL at Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA < 400 c/mL at Week 48.
NCT00112047 (53) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Week 144
NCT00112047 (53) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Percentage of Participants With Pure Virologic Failure (HIV-1 RNA < 400 c/mL) at Week 48
NCT00112047 (53) [back to overview]	Percentage of Participants With Pure Virologic Failure (HIV-1 RNA < 400 c/mL) at Week 96
NCT00112047 (53) [back to overview]	Percentage of Participants With Pure Virologic Failure (HIV-1 RNA < 50 c/mL) at Week 48
NCT00112047 (53) [back to overview]	Percentage of Participants With Pure Virological Failure (HIV-1 RNA < 400 c/mL) at Week 144
NCT00112047 (53) [back to overview]	Percentage of Participants With Pure Virological Failure (HIV-1 RNA < 400 c/mL) Through Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Percentage of Participants With Pure Virological Failure (HIV-1 RNA < 50 c/mL) at Week 144
NCT00112047 (53) [back to overview]	Percentage of Participants With Pure Virological Failure (HIV-1 RNA < 50 c/mL) Through Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Quality of Life (SF-12v2 Health Survey: Mental Component Summary) Change From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Quality of Life (SF-12v2 Health Survey: Physical Component Summary) Change From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Treatment Satisfaction Questionnaire (Bothered With the Side Effects of Current Treatment Regimen): Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.
NCT00112047 (53) [back to overview]	Treatment Satisfaction Questionnaire (General Satisfaction With Current Treatment Regimen): Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.
NCT00112047 (53) [back to overview]	Treatment Satisfaction Questionnaire (Satisfaction With Convenience and Simplicity of Current Treatment Regimen): Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.
NCT00112047 (53) [back to overview]	Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) at Week 96
NCT00112047 (53) [back to overview]	Treatment Satisfaction Questionnaire (Satisfaction With Current Treatment Regimen to Control HIV): Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.
NCT00112047 (53) [back to overview]	Treatment Satisfaction Questionnaire (Satisfaction With Tolerability of Current Treatment Regimen) Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.
NCT00112047 (53) [back to overview]	Change in Limb Fat (kg) From Week 48 to Week 144
NCT00112047 (53) [back to overview]	Change in Limb Fat (kg) From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Change From Study Baseline in HIV-1 RNA (Log10 c/mL) at Week 96
NCT00112047 (53) [back to overview]	Percentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 96 (Defined by FDA TLOVR Algorithm)
NCT00112047 (53) [back to overview]	Change From Study Baseline in HIV-1 RNA (Log10 c/mL) at Week 48
NCT00112047 (53) [back to overview]	Change From Study Baseline in HIV-1 RNA (Log10 c/mL) at Week 144
NCT00112047 (53) [back to overview]	Change From Study Baseline in CD4 Cell Count (Cells/mm^3) at Week 96
NCT00112047 (53) [back to overview]	Change From Study Baseline in CD4 Cell Count (Cells/mm^3) at Week 48
NCT00112047 (53) [back to overview]	Change From Study Baseline in CD4 Cell Count (Cells/mm^3) at Week 144
NCT00112047 (53) [back to overview]	Change in Total Body Fat (kg) From Week 48 to Week 144
NCT00112047 (53) [back to overview]	Change in Total Body Fat (kg) From Week 48 to Week 96
NCT00112047 (53) [back to overview]	Change in Trunk Fat (kg) From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Change From Baseline in CD4 Cell Count (Cells/mm^3) at Week 240 (Atripla Week 96)
NCT00112047 (53) [back to overview]	Change in Trunk Fat (kg) From Week 48 to Week 144
NCT00112047 (53) [back to overview]	Change in Trunk Fat (kg) From Week 48 to Week 96
NCT00112047 (53) [back to overview]	Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 144 (Defined by FDA TLOVR Algorithm)
NCT00112047 (53) [back to overview]	Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 240 (Atripla Week 96) Defined by the FDA TLOVR Algorithm
NCT00112047 (53) [back to overview]	Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm
NCT00112047 (53) [back to overview]	Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 96 (Defined by FDA TLOVR Algorithm)
NCT00112047 (53) [back to overview]	Percentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 144 (Defined by FDA TLOVR Algorithm)
NCT00118898 (22) [back to overview]	Number of Participants With HIV-1 RNA Levels Less Than 200 Copies/mL
NCT00118898 (22) [back to overview]	Change in Fasting High-density Lipoprotein (HDL) Cholesterol Level From Baseline
NCT00118898 (22) [back to overview]	Number of Participants Experiencing Certain Targeted Clinical Events, Including Death, AIDS-defining Illness, and HIV-1 Related Events.
NCT00118898 (22) [back to overview]	Cumulative Probability of Not Experiencing Treatment Modification
NCT00118898 (22) [back to overview]	Cumulative Probability of Not Experiencing Regimen Failure
NCT00118898 (22) [back to overview]	Cumulative Probability of Not Experiencing a Grade 3/4 Safety Event
NCT00118898 (22) [back to overview]	Change in Fasting Total Cholesterol Level From Baseline
NCT00118898 (22) [back to overview]	Change in Fasting Non-high Density Lipoprotein (Non-HDL) Cholesterol Level From Baseline
NCT00118898 (22) [back to overview]	Change in CD4 Count (Cells/mm3) From Baseline
NCT00118898 (22) [back to overview]	Number of Participants With Virologic Failure and Emergence of Major Resistance
NCT00118898 (22) [back to overview]	Number of Participants With Virologic Failure
NCT00118898 (22) [back to overview]	Cumulative Probability of Not Experiencing Virologic Failure
NCT00118898 (22) [back to overview]	Change in Fasting Triglyceride Level From Baseline
NCT00118898 (22) [back to overview]	The Number of Participants With HIV-1 RNA Levels Less Than 50 Copies/mL
NCT00118898 (22) [back to overview]	Time From Randomization to Virologic Failure
NCT00118898 (22) [back to overview]	Time From Treatment Dispensation to a Grade 3/4 Safety Event
NCT00118898 (22) [back to overview]	Time From Treatment Dispensation to Regimen Failure (First Occurrence of Virologic Failure or Treatment Modification)
NCT00118898 (22) [back to overview]	Time From Treatment Dispensation to Treatment Modification
NCT00118898 (22) [back to overview]	Number of Participants With a Grade 3/4 Safety Event
NCT00118898 (22) [back to overview]	Number of Participants With Regimen Failure
NCT00118898 (22) [back to overview]	Number of Participants With Treatment Modification
NCT00118898 (22) [back to overview]	Amount of Study Follow-up
NCT00119106 (8) [back to overview]	Adverse Events
NCT00119106 (8) [back to overview]	HIV Viral Load Copies/mL Measured at First Positive HIV Test Result by Group
NCT00119106 (8) [back to overview]	Number of Participants Reporting Injecting and Sharing Needles
NCT00119106 (8) [back to overview]	Number of Participants With Tenofovir-associated Resistance Mutations.
NCT00119106 (8) [back to overview]	Number Participants Who Reported More Than One Sexual Partner at Baseline
NCT00119106 (8) [back to overview]	Rates of HIV Seroconversion
NCT00119106 (8) [back to overview]	Adherence to Study Drug/Placebo
NCT00119106 (8) [back to overview]	Renal Toxicity
NCT00119379 (6) [back to overview]	Change in Fat mtDNA Content
NCT00119379 (6) [back to overview]	Change in Lumbar Spine Bone Mineral Density (BMD)
NCT00119379 (6) [back to overview]	Change in Trunk Fat
NCT00119379 (6) [back to overview]	Change in PBMC mtDNA
NCT00119379 (6) [back to overview]	Change in Limb Fat
NCT00119379 (6) [back to overview]	Change in Hip Bone Mineral Density (BMD)
NCT00131677 (6) [back to overview]	>5% Bone Mineral Density Decline at Femoral Neck
NCT00131677 (6) [back to overview]	Adherence to Study Drug
NCT00131677 (6) [back to overview]	Number of Breakthrough HIV Infections
NCT00131677 (6) [back to overview]	Clinical Safety--Hypophosphatemia
NCT00131677 (6) [back to overview]	Clinical Safety--Creatinine Elevations
NCT00131677 (6) [back to overview]	Behavioral Safety--Unprotected Anal Sex (UAS)
NCT00214890 (6) [back to overview]	Evaluate Change in Cellular Regulatory Enzymes Involved With Nucleoside Analogue Transport Across Cell Membranes as Assessed by RT-PCR of Specific mRNA Transcripts
NCT00214890 (6) [back to overview]	Compare the Plasma Data of the Two Monotherapy Regimens to the Dual NRTI Regimen
NCT00214890 (6) [back to overview]	Compare the Intracellular Pharmacokinetic (PK) Data of the Two Monotherapy Regimens to the Dual NRTI Regimen
NCT00214890 (6) [back to overview]	Change in Short-term Virologic Response
NCT00214890 (6) [back to overview]	Determine Total Number of NRTI-associated Mutations After 7 Days of ABC or TDF Monotherapy or After 7 Days of Dual NRTI Therapy With ABC + TDF
NCT00214890 (6) [back to overview]	Compare the Relative Viral Potency of TDF Monotherapy Versus ABC Monotherapy
NCT00244712 (14) [back to overview]	Number of Participants Who Reported a Suspected Abacavir Hypersensitivity Reaction (ABC HSR) Reaction or Proximal Renal Tubule Dysfunction
NCT00244712 (14) [back to overview]	Percentage of Participants With HIV-1 RNA <400 Copies/mL at Weeks 48 and 96
NCT00244712 (14) [back to overview]	Percentage of Participants With HIV-1 RNA <400 Copies/mL at Weeks 48 and 96 in Participants With Baseline HIV-1 RNA <100,000 Copies/mL
NCT00244712 (14) [back to overview]	Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 48
NCT00244712 (14) [back to overview]	Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 96
NCT00244712 (14) [back to overview]	Percentage of Participants With HIV-1 RNA <50 Copies/mL at Weeks 48 and 96 in Participants With Baseline HIV-1 RNA <100,000 Copies/mL
NCT00244712 (14) [back to overview]	Percentage of Participants With HIV-1 RNA <50 Copies/mL at Weeks 48 and 96 in Participants With Baseline HIV-1 RNA >=100,000 Copies/mL
NCT00244712 (14) [back to overview]	Median Change From Baseline in CD4+ Cells at Weeks 48 and 96
NCT00244712 (14) [back to overview]	Median Change From Baseline in HIV-1 RNA at Week 48 and 96
NCT00244712 (14) [back to overview]	Number of Confirmed Virologic Failure Participants at Week 96 With Genotypic Resistance to Lamivudine (3TC) and Emtricitabine (FTC) and Had Phenotypic Reduced Susceptibility
NCT00244712 (14) [back to overview]	Number of Confirmed Virologic Failure Participants Who Had Treatment-emergent Genotypic Resistance Through 96 Weeks
NCT00244712 (14) [back to overview]	Number of Participants Who Meet the Protocol-defined Virologic Failure (PDVF) Criteria at Week 96
NCT00244712 (14) [back to overview]	Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 48 by Missing=Failure (M=F), Switched Included Analysis.
NCT00244712 (14) [back to overview]	Percentage of Participants With HIV-1 RNA <400 Copies/mL at Weeks 48 and 96 in Participants With Baseline HIV-1 RNA >=100,000 Copies/mL
NCT00298363 (38) [back to overview]	Median DAVG in Plasma HBV DNA Levels at 96 Weeks Relative to Baseline
NCT00298363 (38) [back to overview]	Median DAVG in Plasma HBV DNA Levels at 168 Weeks Relative to Baseline
NCT00298363 (38) [back to overview]	Median DAVG in Plasma HBV DNA Levels at 144 Weeks Relative to Baseline
NCT00298363 (38) [back to overview]	Median Change in Model for End-Stage Liver Disease (MELD) Score From Baseline at Week 48
NCT00298363 (38) [back to overview]	Median Change in MELD Score From Baseline at Week 96
NCT00298363 (38) [back to overview]	Median Change in MELD Score From Baseline at Week 168
NCT00298363 (38) [back to overview]	Median Change in MELD Score From Baseline at Week 144
NCT00298363 (38) [back to overview]	In the Subset of Participants Undergoing Liver Transplantation, Time to Recurrence of Hepatitis B, Defined as 2 Consecutive Plasma HBV DNA Concentrations ≥ 400 Copies/mL or 2 Consecutive HBsAg(+) Results
NCT00298363 (38) [back to overview]	Percentage of Participants With HBeAg Loss and HBeAg Seroconversion at Week 96 (for Participants Who Were HBeAg Positive at Baseline)
NCT00298363 (38) [back to overview]	Percentage of Participants With HBeAg Loss and HBeAg Seroconversion at Week 168 (for Participants Who Were HBeAg Positive at Baseline)
NCT00298363 (38) [back to overview]	Percentage of Participants With HBeAg Loss and HBeAg Seroconversion at Week 144 (for Participants Who Were HBeAg Positive at Baseline)
NCT00298363 (38) [back to overview]	Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 96
NCT00298363 (38) [back to overview]	Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 48
NCT00298363 (38) [back to overview]	Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 168
NCT00298363 (38) [back to overview]	Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 144
NCT00298363 (38) [back to overview]	Percentage of Participants With Only Baseline Lamivudine-resistance (LAM-R) Mutations Achieving HBV DNA < 400 Copies/mL by 168 Weeks
NCT00298363 (38) [back to overview]	Percentage of Participants With Only Baseline Adefovir Dipivoxil Resistance (ADV-R) Mutations Achieving HBV DNA < 400 Copies/mL by 168 Weeks
NCT00298363 (38) [back to overview]	Percentage of Participants With Normalized ALT (for Subjects With Elevated ALT at Baseline) at Week 96
NCT00298363 (38) [back to overview]	Percentage of Participants With Normalized ALT (for Subjects With Elevated ALT at Baseline) at Week 168
NCT00298363 (38) [back to overview]	Percentage of Participants With Normalized ALT (for Subjects With Elevated ALT at Baseline) at Week 144
NCT00298363 (38) [back to overview]	Percentage of Participants With Normalized Alanine Aminotransferase (ALT) (for Subjects With Elevated ALT at Baseline) at Week 48
NCT00298363 (38) [back to overview]	Percentage of Participants With Baseline ADV-R + LAM-R Mutations Achieving HBV DNA < 400 Copies/mL by 168 Weeks
NCT00298363 (38) [back to overview]	Percentage of Participants With an Increase in CPT Score of ≥ 2 Points at Week 96
NCT00298363 (38) [back to overview]	Percentage of Participants With an Increase in CPT Score of ≥ 2 Points at Week 168
NCT00298363 (38) [back to overview]	Percentage of Participants With an Increase in CPT Score of ≥ 2 Points at Week 144
NCT00298363 (38) [back to overview]	Percentage of Participants With an Increase in Child-Pugh Turcotte (CPT) Score of ≥ 2 Points at Weeks 48
NCT00298363 (38) [back to overview]	Percentage of Participants With a Decrease in CPT Score of ≥ 2 Points From Baseline at Week 96
NCT00298363 (38) [back to overview]	Percentage of Participants With a Decrease in CPT Score of ≥ 2 Points From Baseline at Week 48
NCT00298363 (38) [back to overview]	Percentage of Participants With a Decrease in CPT Score of ≥ 2 Points From Baseline at Week 168
NCT00298363 (38) [back to overview]	Percentage of Participants With a Decrease in CPT Score of ≥ 2 Points From Baseline at Week 144
NCT00298363 (38) [back to overview]	Percent Probability of Tolerability Failure
NCT00298363 (38) [back to overview]	Percent Probability of a Confirmed Increase in Serum Creatinine of ≥ 0.5 mg/dL From Baseline or a Confirmed Serum Phosphorus Level < 2.0 mg/dL
NCT00298363 (38) [back to overview]	Median Time-averaged Change (DAVG) in Plasma Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels at 48 Weeks Relative to Baseline
NCT00298363 (38) [back to overview]	Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss and HBsAg Seroconversion at Week 48
NCT00298363 (38) [back to overview]	Percentage of Participants With Hepatitis B Early Antigen (HBeAg) Loss and HBeAg Seroconversion at Week 48 (for Participants Who Were HBeAg Positive at Baseline)
NCT00298363 (38) [back to overview]	Percentage of Participants With HBsAg Loss and HBsAg Seroconversion at Week 96
NCT00298363 (38) [back to overview]	Percentage of Participants With HBsAg Loss and HBsAg Seroconversion at Week 168
NCT00298363 (38) [back to overview]	Percentage of Participants With HBsAg Loss and HBsAg Seroconversion at Week 144
NCT00307489 (19) [back to overview]	Percentage of Participants With Normal ALT at Week 48
NCT00307489 (19) [back to overview]	Percentage of Participants With Normalized ALT at Week 168
NCT00307489 (19) [back to overview]	Percentage of Participants With Normalized ALT at Week 48
NCT00307489 (19) [back to overview]	Percentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 168
NCT00307489 (19) [back to overview]	Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 168
NCT00307489 (19) [back to overview]	Percentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 48
NCT00307489 (19) [back to overview]	Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 168
NCT00307489 (19) [back to overview]	Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 48
NCT00307489 (19) [back to overview]	Change From Baseline in log10 Plasma HBV DNA Levels at Week 168
NCT00307489 (19) [back to overview]	Change From Baseline in log10 Plasma HBV DNA Levels at Week 48
NCT00307489 (19) [back to overview]	HBeAg Seroconversion at Week 48
NCT00307489 (19) [back to overview]	HBsAg Loss at Week 168
NCT00307489 (19) [back to overview]	HBsAg Loss at Week 48
NCT00307489 (19) [back to overview]	Hepatitis B Early Antigen (HBeAg) Loss at Week 168
NCT00307489 (19) [back to overview]	Hepatitis B Early Antigen (HBeAg) Loss at Week 48
NCT00307489 (19) [back to overview]	Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 48
NCT00307489 (19) [back to overview]	Percentage of Participants With Normal ALT at Week 168
NCT00307489 (19) [back to overview]	Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 168
NCT00307489 (19) [back to overview]	Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 48
NCT00335322 (2) [back to overview]	Time Weighted Mean Change From Baseline Plasma HIV-RNA
NCT00335322 (2) [back to overview]	Time-weighted Mean Change From Baseline Plasma HIV-RNA.
NCT00344461 (6) [back to overview]	Patients With Plasma HIV RNA < 50 Copies/mL
NCT00344461 (6) [back to overview]	Number of Participants With Sustained Virologic Response
NCT00344461 (6) [back to overview]	Patients With Grade 2, 3 and 4 Adverse Events and Laboratory Toxicities
NCT00344461 (6) [back to overview]	Patients With Plasma HIV RNA < 400 Copies/mL
NCT00344461 (6) [back to overview]	Change in Plasma HIV RNA From Baseline to Week 96
NCT00344461 (6) [back to overview]	Changes in CD4 Cell Count From Baseline and Week 96
NCT00350272 (2) [back to overview]	The Proportion Of Participants With Virologic Response For 10 mg/Day Elvucitabine In HIV-1-Infected Participants By 12 Weeks Compared With The Proportion Of Participants With Lamivudine 300 mg/Day
NCT00350272 (2) [back to overview]	The Safety Profile Of Elvucitabine.
NCT00352053 (45) [back to overview]	Change From Baseline to Week 288 in CD4 Percentage
NCT00352053 (45) [back to overview]	Change From Baseline to Week 288 in CD4 Count
NCT00352053 (45) [back to overview]	Change From Baseline to Week 240 in HIV-1 RNA
NCT00352053 (45) [back to overview]	Change From Baseline to Week 240 in CD4 Percentage
NCT00352053 (45) [back to overview]	Change From Baseline to Week 240 in CD4 Count
NCT00352053 (45) [back to overview]	Change From Baseline to Week 24 in Cluster Determinant 4 (CD4) Count
NCT00352053 (45) [back to overview]	Change From Baseline to Week 24 in CD4 Percentage
NCT00352053 (45) [back to overview]	Change From Baseline to Week 192 in HIV-1 RNA
NCT00352053 (45) [back to overview]	Change From Baseline to Week 192 in CD4 Percentage
NCT00352053 (45) [back to overview]	Change From Baseline to Week 192 in CD4 Count
NCT00352053 (45) [back to overview]	Change From Baseline to Week 144 in HIV-1 RNA
NCT00352053 (45) [back to overview]	Change From Baseline to Week 144 in CD4 Percentage
NCT00352053 (45) [back to overview]	Change From Baseline to Week 144 in CD4 Count
NCT00352053 (45) [back to overview]	Time-weighted Average Change From Baseline Through Week 48 (DAVG48) in Plasma HIV-1 RNA
NCT00352053 (45) [back to overview]	Time-weighted Average Change From Baseline Through Week 24 (DAVG24) in Plasma HIV-1 RNA
NCT00352053 (45) [back to overview]	Percentage of Participants With Virologic Failure Through Week 48
NCT00352053 (45) [back to overview]	Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96
NCT00352053 (45) [back to overview]	Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48
NCT00352053 (45) [back to overview]	Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 288
NCT00352053 (45) [back to overview]	Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 240
NCT00352053 (45) [back to overview]	Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24
NCT00352053 (45) [back to overview]	Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 192
NCT00352053 (45) [back to overview]	Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 144
NCT00352053 (45) [back to overview]	Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 96
NCT00352053 (45) [back to overview]	Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 48
NCT00352053 (45) [back to overview]	Change From Baseline to Week 24 in HIV-1 RNA
NCT00352053 (45) [back to overview]	Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 288
NCT00352053 (45) [back to overview]	Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 240
NCT00352053 (45) [back to overview]	Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 24
NCT00352053 (45) [back to overview]	Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 192
NCT00352053 (45) [back to overview]	Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 144
NCT00352053 (45) [back to overview]	Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0log 10 Copies/mL From Baseline to Week 288
NCT00352053 (45) [back to overview]	Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 96
NCT00352053 (45) [back to overview]	Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 48
NCT00352053 (45) [back to overview]	Change From Baseline to Week 48 in CD4 Count
NCT00352053 (45) [back to overview]	Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 24
NCT00352053 (45) [back to overview]	Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 192
NCT00352053 (45) [back to overview]	Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 144
NCT00352053 (45) [back to overview]	Change From Baseline to Week 96 in HIV-1 RNA
NCT00352053 (45) [back to overview]	Change From Baseline to Week 96 in CD4 Percentage
NCT00352053 (45) [back to overview]	Change From Baseline to Week 96 in CD4 Count
NCT00352053 (45) [back to overview]	Change From Baseline to Week 48 in HIV-1 RNA
NCT00352053 (45) [back to overview]	Change From Baseline to Week 48 in CD4 Percentage
NCT00352053 (45) [back to overview]	Change From Baseline to Week 288 in HIV-1 RNA
NCT00352053 (45) [back to overview]	Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 240
NCT00357552 (11) [back to overview]	Change in CD4+ Cell Counts From Study Entry to Week 104
NCT00357552 (11) [back to overview]	Proportion of Participants With Plasma HIV-1 RNA Levels < 400 Copies/mL From Baseline to Week 104
NCT00357552 (11) [back to overview]	Percentage of Subjects Reporting Not Skipping Medications in the Last Month.
NCT00357552 (11) [back to overview]	Number of Screened Subjects With at Least One NNRTI, or NRTI-associated Resistance Mutation at A5230 Screening.
NCT00357552 (11) [back to overview]	Level of HIV-1 RNA as Ascertained From Paired DBS and Plasma
NCT00357552 (11) [back to overview]	Time to Treatment Failure, Defined as the First Occurrence of Death, Disease Progression, or Virologic Failure.
NCT00357552 (11) [back to overview]	Time to First New Grade 3 or 4 Sign or Symptom or Laboratory Toxicity Following LPV/r Intensification
NCT00357552 (11) [back to overview]	Probability of Grade 3 or 4 Sign or Symptom, or Laboratory Toxicity Over 24 Weeks on Study.
NCT00357552 (11) [back to overview]	Percentage of Enrolled Participants With Virologic Success at Week 24 on LPV/r Monotherapy
NCT00357552 (11) [back to overview]	Number of Subjects With at Least One New PI-associated Resistance Mutation at Time of Virologic Failure.
NCT00357552 (11) [back to overview]	Number of Participants With Study-targeted Diagnoses and Clinical Events
NCT00369941 (73) [back to overview]	Change From Baseline in CD4 Cell Count at Week 240
NCT00369941 (73) [back to overview]	Change From Baseline in CD4 Cell Count at Week 96
NCT00369941 (73) [back to overview]	Change From Baseline in Cluster of Differentiation Antigen 4 (CD4) Cell Count at Week 48
NCT00369941 (73) [back to overview]	Number of Participants Who Achieved HIV RNA <400 Copies/mL at Week 156
NCT00369941 (73) [back to overview]	Number of Participants Who Achieved HIV RNA <400 Copies/mL at Week 240
NCT00369941 (73) [back to overview]	Number of Participants Who Achieved HIV RNA <400 Copies/mL at Week 48
NCT00369941 (73) [back to overview]	Number of Participants Who Achieved HIV RNA <400 Copies/mL at Week 96
NCT00369941 (73) [back to overview]	Number of Participants Who Achieved HIV RNA <50 Copies/mL at Week 156
NCT00369941 (73) [back to overview]	Number of Participants Who Achieved HIV RNA <50 Copies/mL at Week 240
NCT00369941 (73) [back to overview]	Number of Participants Who Achieved HIV RNA <50 Copies/mL at Week 96
NCT00369941 (73) [back to overview]	Number of Participants Who Achieved Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) <50 Copies/mL at Week 48
NCT00369941 (73) [back to overview]	Number of Participants Discontinued With Drug-related LAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants Discontinued With Drug-related LAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants Discontinued With Drug-related LAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants Discontinued With Drug-related LAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants Discontinued With LAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants Discontinued With LAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants Discontinued With LAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants Discontinued With LAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants That Died by Week 156
NCT00369941 (73) [back to overview]	Number of Participants That Died by Week 240
NCT00369941 (73) [back to overview]	Number of Participants That Died by Week 48
NCT00369941 (73) [back to overview]	Number of Participants That Died by Week 96
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With CAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With CAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With CAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With CAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Drug-related CAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Drug-related CAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Drug-related CAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Drug-related CAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Serious CAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Serious CAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Serious CAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Serious CAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Serious Drug-related CAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Serious Drug-related CAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Serious Drug-related CAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants That Discontinued With Serious Drug-related CAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants With CAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants With CAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants With CAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants With Clinical Adverse Experiences (CAEs) at Week 48
NCT00369941 (73) [back to overview]	Number of Participants With Drug-related CAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants With Drug-related CAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants With Drug-related CAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants With Drug-related CAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants With Drug-related LAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants With Drug-related LAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants With Drug-related LAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants With Drug-related LAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants With Laboratory Adverse Experiences (LAEs) at Week 48
NCT00369941 (73) [back to overview]	Number of Participants With LAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants With LAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants With Nervous System Symptoms Assessed by Review of Accumulated Safety Data up to Week 8
NCT00369941 (73) [back to overview]	Number of Participants With Serious CAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants With Serious CAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants With Serious CAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants With Serious CAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants With Serious Drug-related CAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants With Serious Drug-related CAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants With Serious Drug-related CAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants With Serious Drug-related CAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants With Serious Drug-related LAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants With Serious Drug-related LAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants With Serious Drug-related LAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants With Serious Drug-related LAEs at Week 96
NCT00369941 (73) [back to overview]	Number of Participants With Serious LAEs at Week 156
NCT00369941 (73) [back to overview]	Number of Participants With Serious LAEs at Week 240
NCT00369941 (73) [back to overview]	Number of Participants With Serious LAEs at Week 48
NCT00369941 (73) [back to overview]	Number of Participants With Serious LAEs at Week 96
NCT00369941 (73) [back to overview]	Change From Baseline in CD4 Cell Count at Week 156
NCT00369941 (73) [back to overview]	Number of Participants With LAEs at Week 240
NCT00410072 (16) [back to overview]	Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Weeks 48 and 96
NCT00410072 (16) [back to overview]	Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss at Weeks 48 and 96
NCT00410072 (16) [back to overview]	Percentage of Participants With HBsAg Seroconversion at Weeks 48 and 96
NCT00410072 (16) [back to overview]	Percentage of Participants With HBeAg Seroconversion [( at Weeks 48 and 96
NCT00410072 (16) [back to overview]	Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Weeks 48 and 96
NCT00410072 (16) [back to overview]	Percentage of Participants Who Achieved HBV DNA Levels
NCT00410072 (16) [back to overview]	Percentage of Participants Who Achieved HBV DNA Levels
NCT00410072 (16) [back to overview]	Percentage of Participants Who Achieved HBV DNA Levels <50 IU/mL by PCR at Week 48 and Week 96 by Hepatitis B e Antigen (HBeAg) Status
NCT00410072 (16) [back to overview]	Number of Participants With Virologic Breakthrough at Week 96
NCT00410072 (16) [back to overview]	Number of Participants With HBV Resistance Through Week 48
NCT00410072 (16) [back to overview]	Number of Participants With HBV Resistance at Week 96
NCT00410072 (16) [back to overview]	Number of Participants With HBV DNA in Relevant Categories at Weeks 48 and 96
NCT00410072 (16) [back to overview]	Number of Participants With Adverse Events, Serious Adverse Events, and Discontinuations From Study Drug Due to Adverse Events or Laboratory Abnormalities
NCT00410072 (16) [back to overview]	Mean Log 10 HBV DNA at Weeks 48 and 96
NCT00410072 (16) [back to overview]	Percentage of Participants Who Achieved Hepatitis B Virus DNA (HBV DNA) Levels <50 IU/mL by Polymerase Chain Reaction (PCR) at Week 96
NCT00410072 (16) [back to overview]	Number of Participants With Virologic Breakthrough at Week 48
NCT00410202 (25) [back to overview]	Percentage of Participants With HBV DNA by PCR Category at Week 48
NCT00410202 (25) [back to overview]	Participants With Adverse Events (AE), Serious Adverse Events (SAE), and Discontinuations Due to Adverse Events or Laboratory Abnormalities During Treatment
NCT00410202 (25) [back to overview]	Number of Participants With Laboratory Abnormalities: Serum Chemistry
NCT00410202 (25) [back to overview]	Number of Participants With Laboratory Abnormalities: Hematology
NCT00410202 (25) [back to overview]	Cumulative Probability of Emergent Genotypic Resistance at Year 2
NCT00410202 (25) [back to overview]	Cumulative Probability of Emergent Genotypic Resistance at Year 1
NCT00410202 (25) [back to overview]	Change in Mean log10 From Baseline in HBV DNA at Week 48
NCT00410202 (25) [back to overview]	Percentage of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) < 50 IU/mL (Approximately 300 Copies/mL) by Polymerase Chain Reaction (PCR) at Week 48
NCT00410202 (25) [back to overview]	Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 96
NCT00410202 (25) [back to overview]	Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 48
NCT00410202 (25) [back to overview]	Percentage of Participants With HBV DNA < 50 IU/mL (Approximately 300 Copies/mL) by PCR at Week 96
NCT00410202 (25) [back to overview]	Percentage of Participants With HBsAg Seroconversion at Week 96
NCT00410202 (25) [back to overview]	Percentage of Participants With HBsAg Seroconversion at Week 48
NCT00410202 (25) [back to overview]	Percentage of Participants With HBeAg Seroconversion at Week 96 (Treated HBeAg-positive Participants Only)
NCT00410202 (25) [back to overview]	Percentage of Participants With HBeAg Seroconversion at Week 48 (Treated HBeAg-positive Participants Only)
NCT00410202 (25) [back to overview]	Percentage of Participants With Confirmed HBeAg Loss at Week 96 (Treated HBeAg Positive Participants Only)
NCT00410202 (25) [back to overview]	Percentage of Participants With Confirmed HBeAg Loss at Week 48 (Treated HBeAg Positive Participants Only)
NCT00410202 (25) [back to overview]	Percentage of Participants With Alanine Aminotransferase (ALT) > 1 x Upper Limit of Normal (ULN) at Baseline Who Achieve ALT Normalization at Week 96
NCT00410202 (25) [back to overview]	Percentage of Participants With Alanine Aminotransferase (ALT) > 1 x Upper Limit of Normal (ULN) at Baseline Who Achieve ALT Normalization at Week 48
NCT00410202 (25) [back to overview]	Percentage of Participants With HBV DNA by PCR Category at Week 96
NCT00410202 (25) [back to overview]	Percentage of Participants Who Achieve HBV DNA < Lower Limit of Quantitation (LOQ = 29 IU/mL [Approximately 169 Copies/mL]) at Week 48
NCT00410202 (25) [back to overview]	Percentage of Participants Who Achieve HBV DNA < Lower Limit of Detection (LOD = 10 IU/mL [Approximately 58 Copies/mL]) at Week 96
NCT00410202 (25) [back to overview]	Percentage of Participants Who Achieve HBV DNA < Lower Limit of Detection (LOD = 10 IU/mL [Approximately 58 Copies/mL]) at Week 48
NCT00410202 (25) [back to overview]	Change in Mean log10 From Baseline in HBV DNA at Week 96
NCT00410202 (25) [back to overview]	Percentage of Participants Who Achieve HBV DNA < Lower Limit of Quantitation (LOQ = 29 IU/mL [Approximately 169 Copies/mL]) at Week 96
NCT00414518 (3) [back to overview]	Number of Participants Experiencing Either an AIDS-defining Event, a Grade 3 or 4 Adverse Event, or Acute Retroviral Syndrome
NCT00414518 (3) [back to overview]	Plasma HIV-1 Viral Load (Copies/ml) at Week 24 as Compared Between the Two Arms
NCT00414518 (3) [back to overview]	Viral Set Point
NCT00427297 (4) [back to overview]	Immunologic Failure
NCT00427297 (4) [back to overview]	Incidence of Severe Adverse Events (Excluding Mortality)
NCT00427297 (4) [back to overview]	Viral Failure
NCT00427297 (4) [back to overview]	Incidence of Mortality
NCT00442962 (11) [back to overview]	Time to First Dose Modification
NCT00442962 (11) [back to overview]	Percentage of Participants With Early Virologic Suppression
NCT00442962 (11) [back to overview]	Percentage of Participants With Early Virologic Response
NCT00442962 (11) [back to overview]	Percentage of Participants With Late Virologic Suppression
NCT00442962 (11) [back to overview]	Early Changes in CD4 Count From Baseline
NCT00442962 (11) [back to overview]	Time to First Safety Event
NCT00442962 (11) [back to overview]	Time to Initial Virologic Response
NCT00442962 (11) [back to overview]	Time to Initial Virological Failure
NCT00442962 (11) [back to overview]	Late Change in CD4 Count From Baseline
NCT00442962 (11) [back to overview]	Time to Loss of Virologic Response by Week 48 (Defined by FDA TLOVR Algorithm)
NCT00442962 (11) [back to overview]	Percentage of Participants With Late Virologic Response
NCT00448669 (6) [back to overview]	Rates of Adherence to Study Medication
NCT00448669 (6) [back to overview]	Changes in Condom Use During Study: Number of Participants With >=1 Condomless Sex Acts
NCT00448669 (6) [back to overview]	Antiretroviral (ARV) Resistance Patterns in Seroconverters
NCT00448669 (6) [back to overview]	CD4 Evaluation After HIV Seroconversion
NCT00448669 (6) [back to overview]	HIV Incidence in the Tenofovir/Emtricitabine and Placebo Arms
NCT00448669 (6) [back to overview]	Percentage of Participants With Adverse Drug Reactions in the Tenofovir/Emtricitabine and Placebo Arms
NCT00507507 (13) [back to overview]	Number of Participants With Hepatitis B e Antigen (HBeAg) Loss at Weeks 48, 96, 144, and 192
NCT00507507 (13) [back to overview]	Number of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Weeks 48, 96, 144, and 192
NCT00507507 (13) [back to overview]	Number of Participants With Normal Alanine Aminotransferase (ALT) at Weeks 48, 96, 144, and 192
NCT00507507 (13) [back to overview]	Number of Participants With Seroconversion to Antibody Against HBeAg (Anti-HBe) at Weeks 48, 96, 144, and 192
NCT00507507 (13) [back to overview]	Number of Participants With Seroconversion to Antibody to HBsAg (Anti-HBs) at Weeks 48, 96, 144, and 192
NCT00507507 (13) [back to overview]	Occurrence of HBV Resistance Mutations
NCT00507507 (13) [back to overview]	Percentage of Participants With HBV DNA < 169 Copies/mL at Weeks 48, 96, 144, and 192
NCT00507507 (13) [back to overview]	Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 48, 96, and 144
NCT00507507 (13) [back to overview]	Change From Baseline in HBV DNA at Week 192
NCT00507507 (13) [back to overview]	Change From Baseline in HBV DNA at Week 144
NCT00507507 (13) [back to overview]	Change From Baseline in HBV DNA at Week 48
NCT00507507 (13) [back to overview]	Change From Baseline in HBV DNA at Week 96
NCT00507507 (13) [back to overview]	Percentage of Participants With HBV DNA < 400 Copies/mL at Week 192
NCT00524173 (4) [back to overview]	Number of Participants With HBV DNA <1000 IU/ml at Week 192
NCT00524173 (4) [back to overview]	Number of Participants With Loss of HBsAg
NCT00524173 (4) [back to overview]	Number of Participants With Normalized Alanine Aminotransferase (ALT)
NCT00524173 (4) [back to overview]	Number of Subjects With Hepatitis b Virus (HBV) DNA <1000 IU/ml at Week 48
NCT00528957 (46) [back to overview]	Change From Baseline in CD4 Cell Count (Cells/mm^3) at 384 Weeks
NCT00528957 (46) [back to overview]	Change From Baseline in CD4 Cell Count (Cells/mm^3) at 432 Weeks
NCT00528957 (46) [back to overview]	Change From Baseline in CD4 Cell Count (Cells/mm^3) at 48 Weeks
NCT00528957 (46) [back to overview]	Change From Baseline in CD4 Cell Count (Cells/mm^3) at 480 Weeks
NCT00528957 (46) [back to overview]	Change From Baseline in CD4 Cell Count (Cells/mm^3) at 528 Weeks
NCT00528957 (46) [back to overview]	Change From Baseline in CD4 Cell Count (Cells/mm^3) at 96 Weeks
NCT00528957 (46) [back to overview]	Change From Baseline in CD4 Percentage at 144 Weeks
NCT00528957 (46) [back to overview]	Change From Baseline in CD4 Percentage at 192 Weeks
NCT00528957 (46) [back to overview]	Change From Baseline in CD4 Percentage at 240 Weeks
NCT00528957 (46) [back to overview]	Change From Baseline in CD4 Percentage at 288 Weeks
NCT00528957 (46) [back to overview]	Change From Baseline in CD4 Percentage at 336 Weeks
NCT00528957 (46) [back to overview]	Change From Baseline in CD4 Percentage at 384 Weeks
NCT00528957 (46) [back to overview]	Change From Baseline in CD4 Percentage at 432 Weeks
NCT00528957 (46) [back to overview]	Change From Baseline in CD4 Percentage at 48 Weeks
NCT00528957 (46) [back to overview]	Change From Baseline in CD4 Percentage at 480 Weeks
NCT00528957 (46) [back to overview]	Change From Baseline in CD4 Percentage at 528 Weeks
NCT00528957 (46) [back to overview]	Change From Baseline in CD4 Percentage at 96 Weeks
NCT00528957 (46) [back to overview]	Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 192 Weeks
NCT00528957 (46) [back to overview]	Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 240 Weeks
NCT00528957 (46) [back to overview]	Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 288 Weeks
NCT00528957 (46) [back to overview]	Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 336 Weeks
NCT00528957 (46) [back to overview]	Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 384 Weeks
NCT00528957 (46) [back to overview]	Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 432 Weeks
NCT00528957 (46) [back to overview]	Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 480 Weeks
NCT00528957 (46) [back to overview]	Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 528 Weeks
NCT00528957 (46) [back to overview]	Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 144
NCT00528957 (46) [back to overview]	Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 48
NCT00528957 (46) [back to overview]	Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 96
NCT00528957 (46) [back to overview]	Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 144 Weeks
NCT00528957 (46) [back to overview]	Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 192 Weeks
NCT00528957 (46) [back to overview]	Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 240 Weeks
NCT00528957 (46) [back to overview]	Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 288 Weeks
NCT00528957 (46) [back to overview]	Virologic Success at 48 Weeks (HIV-1 RNA Cutoff at 50 Copies/mL, Snapshot)
NCT00528957 (46) [back to overview]	Virologic Success at 48 Weeks (HIV-1 RNA Cutoff at 400 Copies/mL, Snapshot)
NCT00528957 (46) [back to overview]	Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 96 Weeks
NCT00528957 (46) [back to overview]	Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 528 Weeks
NCT00528957 (46) [back to overview]	Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 480 Weeks
NCT00528957 (46) [back to overview]	Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 48 Weeks
NCT00528957 (46) [back to overview]	Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 432 Weeks
NCT00528957 (46) [back to overview]	Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 384 Weeks
NCT00528957 (46) [back to overview]	Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 336 Weeks
NCT00528957 (46) [back to overview]	Change From Baseline in CD4 Cell Count (Cells/mm^3) at 144 Weeks
NCT00528957 (46) [back to overview]	Change From Baseline in CD4 Cell Count (Cells/mm^3) at 192 Weeks
NCT00528957 (46) [back to overview]	Change From Baseline in CD4 Cell Count (Cells/mm^3) at 240 Weeks
NCT00528957 (46) [back to overview]	Change From Baseline in CD4 Cell Count (Cells/mm^3) at 288 Weeks
NCT00528957 (46) [back to overview]	Change From Baseline in CD4 Cell Count (Cells/mm^3) at 336 Weeks
NCT00549198 (58) [back to overview]	Number of Participants With Decline From Baseline in Estimated GFR, Calculated by MDRD and Cockcroft-Gault Equations, of >=10 mL/Min/1.73m^2 (mL/Min for Cockcroft-Gault), >=20 mL/Min/1.72m^2, >=10%, and >=20% at Week 96
NCT00549198 (58) [back to overview]	Number of Participants With Decline From Baseline in Estimated GFR, Calculated by MDRD and Cockcroft-Gault Equations, of >=10 mL/Min/1.73m^2 (mL/Min for Cockcroft-Gault), >=20 mL/Min/1.72m^2, >=10%, and >=20% at Week 48
NCT00549198 (58) [back to overview]	Number of Participants With Decline From Baseline in Estimated GFR, Calculated by MDRD and Cockcroft-Gault Equations, of >=10 mL/Min/1.73 m^2 (mL/Min for Cockcroft-Gault), >=20 mL/Min/1.72 m^2, >=10%, and >=20% at Week 24
NCT00549198 (58) [back to overview]	Number of Participants With a Decline From Baseline in Lumbar Spine and Hip Bone Mineral Density (BMD) >=2.0% and >=6.0% at Week 96
NCT00549198 (58) [back to overview]	Number of Participants With a Decline From Baseline in Lumbar Spine and Hip Bone Mineral Density (BMD) >=2.0% and >=6.0% at Week 48
NCT00549198 (58) [back to overview]	Number of Participants With a Decline From Baseline in Lumbar Spine and Hip Bone Mineral Density (BMD) >=2.0% and >=6.0% at Week 24
NCT00549198 (58) [back to overview]	Number of Participants Meeting World Health Organization (WHO) Criteria for Osteopenia (T-score of -2.5 to -1.0) and Osteoporosis (T-score of <-2.5) at Week 96
NCT00549198 (58) [back to overview]	Exploratory Analysis of Change From Baseline in Osteocalcin at Week 96
NCT00549198 (58) [back to overview]	Exploratory Analysis of Change From Baseline in N-acetyl-B-glucosaminidase (NAG) as a Ratio to Urine Creatinine at Week 96
NCT00549198 (58) [back to overview]	Exploratory Analysis of Change From Baseline in Bone Specific Alkaline Phosphatase (BSAP) at Week 96
NCT00549198 (58) [back to overview]	Exploratory Analysis of Change From Baseline in Beta 2 Microglobulin (B2M) as a Ratio to Urine Creatinine at Week 96
NCT00549198 (58) [back to overview]	Change From Baseline in Cluster Difference 4 (CD4+) Cell Count at Week 48
NCT00549198 (58) [back to overview]	Mean Change From Baseline in Estimated GFR, Calculated by Cockcroft-Gault Equation, at Week 96
NCT00549198 (58) [back to overview]	Change From Baseline in Cluster Difference 4 (CD4+) Cell Count at Week 24
NCT00549198 (58) [back to overview]	Exploratory Analysis of Change From Baseline in Procollagen Type 1 Amino-terminal Propeptide (P1NP) at Week 96
NCT00549198 (58) [back to overview]	Exploratory Analysis of Change From Baseline in Albumin as a Ratio to Urine Creatinine at Week 96
NCT00549198 (58) [back to overview]	Change From Baseline in Cluster Difference 4 (CD4+) Cell Count at Week 96
NCT00549198 (58) [back to overview]	Number of Participants Meeting World Health Organization (WHO) Criteria for Osteopenia (T-score of -2.5 to -1.0) and Osteoporosis (T-score of <-2.5) at Week 48
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Total Cholesterol at Week 48
NCT00549198 (58) [back to overview]	Number of Participants Meeting World Health Organization (WHO) Criteria for Osteopenia (T-score of -2.5 to -1.0) and Osteoporosis (T-score of <-2.5) at Week 24
NCT00549198 (58) [back to overview]	Number of Participants Experiencing an Adverse Event (AE) Leading to Discontinuation by Week 96
NCT00549198 (58) [back to overview]	Number of Participants Experiencing an Adverse Event (AE) Leading to Discontinuation by Week 48
NCT00549198 (58) [back to overview]	Number of Participants Experiencing an Adverse Event (AE) Leading to Discontinuation by Week 24
NCT00549198 (58) [back to overview]	Number of Participants Classified as Protocol-defined Failures With Treatment-emergent Resistance to Study Drug in the Indicated Viruses at Week 96
NCT00549198 (58) [back to overview]	"Number of Participants Who Indicated Yes or No to the Question of Whether Unplanned Healthcare Resources Were Utilized"
NCT00549198 (58) [back to overview]	Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 96
NCT00549198 (58) [back to overview]	Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 48
NCT00549198 (58) [back to overview]	Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 24
NCT00549198 (58) [back to overview]	Percent Change From Baseline in Hip Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 96
NCT00549198 (58) [back to overview]	Percent Change From Baseline in Hip Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 48
NCT00549198 (58) [back to overview]	Percent Change From Baseline in Hip Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 24
NCT00549198 (58) [back to overview]	Mean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 96
NCT00549198 (58) [back to overview]	Mean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 48
NCT00549198 (58) [back to overview]	Mean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 24
NCT00549198 (58) [back to overview]	Mean Change From Baseline in Estimated GFR, Calculated by Cockcroft-Gault Equation, at Week 48
NCT00549198 (58) [back to overview]	Mean Change From Baseline in Estimated GFR, Calculated by Cockcroft-Gault Equation, at Week 24
NCT00549198 (58) [back to overview]	Exploratory Analysis of Change From Baseline in Retinol Binding Protein (RBP) as a Ratio to Urine Creatinine at Week 96
NCT00549198 (58) [back to overview]	Number of Participants With HIV-1 RNA <50 Copies/Milliliter (c/mL) and 400 c/mL at Week 24
NCT00549198 (58) [back to overview]	Number of Participants With HIV-1 RNA <50 Copies/Milliliter (c/mL) and 400 c/mL at Week 48
NCT00549198 (58) [back to overview]	Number of Participants With HIV-1 RNA <50 Copies/Milliliter (c/mL) and 400 c/mL at Week 96
NCT00549198 (58) [back to overview]	Number of Participants With National Kidney Foundation Chronic Kidney Disease Stage 1, 2, 3, 4, or 5 Categories of Renal Function at Week 24
NCT00549198 (58) [back to overview]	Number of Participants With National Kidney Foundation Chronic Kidney Disease Stage 1, 2, 3, 4, or 5 Categories of Renal Function at Week 48
NCT00549198 (58) [back to overview]	Number of Participants With National Kidney Foundation Chronic Kidney Disease Stage 1, 2, 3, 4, or 5 Categories of Renal Function at Week 96
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting High-density Lipoprotein (HDL) at Week 24
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting High-density Lipoprotein (HDL) at Week 48
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting High-density Lipoprotein (HDL) at Week 96
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Total Cholesterol at Week 24
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Total Cholesterol at Week 96
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Triglycerides at Week 24
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Triglycerides at Week 48
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Triglycerides at Week 96
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Low-density Lipoprotein (LDL) at Week 24
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Low-density Lipoprotein (LDL) at Week 48
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Low-density Lipoprotein (LDL) at Week 96
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Treatment-emergent Division of AIDS (DAIDS) Toxicities at Week 24
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Treatment-emergent Division of AIDS (DAIDS) Toxicities at Week 48
NCT00549198 (58) [back to overview]	Number of Participants With the Indicated Treatment-emergent Division of AIDS (DAIDS) Toxicities at Week 96
NCT00549198 (58) [back to overview]	Exploratory Analysis of Change From Baseline in Type 1 Collagen Cross-linked C-telopeptide at Week 96
NCT00552240 (46) [back to overview]	Proportion of Patients Reporting CNS Side Effects of Any Severity
NCT00552240 (46) [back to overview]	Change in Framingham Score
NCT00552240 (46) [back to overview]	Change in Fasting Total Cholesterol to High Density Lipoprotein (HDL) Ratio
NCT00552240 (46) [back to overview]	Change in Fasting Plasma Triglycerides Level
NCT00552240 (46) [back to overview]	Change in Fasting Plasma Total Cholesterol Level
NCT00552240 (46) [back to overview]	Change in Fasting Low Density Lipoprotein (LDL)Cholesterol Level
NCT00552240 (46) [back to overview]	Change in Fasting High Density Lipoprotein (HDL) Cholesterol Level
NCT00552240 (46) [back to overview]	Change in CD4+ Cell Count From Baseline to Week 8.
NCT00552240 (46) [back to overview]	Change in CD4+ Cell Count From Baseline to Week 6.
NCT00552240 (46) [back to overview]	Change in CD4+ Cell Count From Baseline to Week 48.
NCT00552240 (46) [back to overview]	Change in CD4+ Cell Count From Baseline to Week 4.
NCT00552240 (46) [back to overview]	Change in CD4+ Cell Count From Baseline to Week 36.
NCT00552240 (46) [back to overview]	Change in CD4+ Cell Count From Baseline to Week 24.
NCT00552240 (46) [back to overview]	Change in CD4+ Cell Count From Baseline to Week 2.
NCT00552240 (46) [back to overview]	Change in CD4+ Cell Count From Baseline to Week 12.
NCT00552240 (46) [back to overview]	AIDS Progression and Death: Number of Patients With a Treatment-emergent AIDS Defining Illness or an AIDS-defining Illness Leading to Death
NCT00552240 (46) [back to overview]	Change in Glomerular Filtration Rate (GFR) From Baseline to Week 48
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 4 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 400 Copies/ml at Week 4 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 400 Copies/ml at Week 48 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 400 Copies/ml at Week 6 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 400 Copies/ml at Week 8 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 12 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 2 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 48
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 48 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 6 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 8 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With Loss of Virologic Response Following Confirmed Virologic Response
NCT00552240 (46) [back to overview]	Number of Participants With Virologic Response (VR)
NCT00552240 (46) [back to overview]	Number of Participants With Virologic Response According to the Time to Loss of Virologic Response (TLOVR) Algorithm
NCT00552240 (46) [back to overview]	Number of Participants With Virologic Success (FDA Definition)
NCT00552240 (46) [back to overview]	Number of Patients With Virologic Rebound to >400 Copies/ml
NCT00552240 (46) [back to overview]	Proportion of Patients With DAIDS Grade >= 2 Laboratory Abnormalities
NCT00552240 (46) [back to overview]	Percentage Adherence by Pill Count
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 400 Copies/ml at Week 24 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 400 Copies/ml at Week 36 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 36 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 400 Copies/ml at Week 2 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 400 Copies/ml at Week 12 of Treatment
NCT00552240 (46) [back to overview]	Incidence of Patients With AIDS Progression at Each Visit
NCT00552240 (46) [back to overview]	Time to Virologic Response (First Confirmed Viral Load < 50 Copies/ml), Only Participants With Confirmed Viral Load < 50 Copies/ml
NCT00552240 (46) [back to overview]	Time to Virologic Response (First Confirmed Viral Load < 50 Copies/ml), All Participants
NCT00552240 (46) [back to overview]	Proportion of Patients Reporting Rash of Any Severity
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 24 of Treatment
NCT00552240 (46) [back to overview]	Proportion of Patients Reporting Hepatic Events of Any Severity
NCT00557245 (11) [back to overview]	Head Circumference Among Infants Born to Female Participants Taking Study Drug
NCT00557245 (11) [back to overview]	Incidence of HIV-1 Seroconversion Among HIV-1 Uninfected Participants
NCT00557245 (11) [back to overview]	Length Among Infants Born to Female Participants Taking Study Drug
NCT00557245 (11) [back to overview]	Number of Participants With a Sexually Transmitted Infection (STI) During Follow-up
NCT00557245 (11) [back to overview]	Study Drug Adherence: Self-reported Missed Doses of Study Drug
NCT00557245 (11) [back to overview]	Weight Among Infants Born to Female Participants Taking Study Drug
NCT00557245 (11) [back to overview]	Prevalence of Unprotected Sex During Follow-up
NCT00557245 (11) [back to overview]	Congenital Abnormalities Among Infants Born to Female Participants Taking Study Drug.
NCT00557245 (11) [back to overview]	Number of Seroconverters With an HIV-1 Mutation Conferring Resistance to TDF or FTC
NCT00557245 (11) [back to overview]	Number of Participants With Serious Adverse Events (SAEs)
NCT00557245 (11) [back to overview]	Study Drug Adherence: Total Number of Study Drug Doses Taken of the Total Dispensed Doses.
NCT00592124 (9) [back to overview]	Length of Time Vaginal Sexual Intercourse Took Place After Using Gel.
NCT00592124 (9) [back to overview]	Number of Days Product Missed
NCT00592124 (9) [back to overview]	Grade 3 or Higher Toxicity for Systemic and Local Effects as Defined by the Protocol
NCT00592124 (9) [back to overview]	Systemic and Local PK Among Three Regimens of Tenofovir (Oral, Vaignal, and Dual Use)
NCT00592124 (9) [back to overview]	Self-reported Adherence to Each Regimen
NCT00592124 (9) [back to overview]	Reported Sharing of Product
NCT00592124 (9) [back to overview]	Length of Time Vaginal Sexual Intercourse Took Place Before Using Tablet.
NCT00592124 (9) [back to overview]	Length of Time Vaginal Sexual Intercourse Took Place Before Using Gel.
NCT00592124 (9) [back to overview]	Length of Time Vaginal Sexual Intercourse Took Place After Using Tablet.
NCT00594646 (2) [back to overview]	Number of HIV-1 Infected Participants
NCT00594646 (2) [back to overview]	Medication Regimen Completion Rates
NCT00605384 (1) [back to overview]	Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs or Laboratory Abnormalities
NCT00608569 (8) [back to overview]	Time to First Grade 3 or 4 Lab Event
NCT00608569 (8) [back to overview]	Time to First Grade 3 or 4 Lab or Sign/Symptom Event
NCT00608569 (8) [back to overview]	Adherence to Second Line HAART Regimen
NCT00608569 (8) [back to overview]	Time to First Grade 3 or 4 Sign or Symptom
NCT00608569 (8) [back to overview]	CD4 Count at Follow-up Visits
NCT00608569 (8) [back to overview]	CD8 Count at Follow-up Visits
NCT00608569 (8) [back to overview]	Confirmed Virologic Failure at or Prior to Week 24
NCT00608569 (8) [back to overview]	Confirmed Virologic Failure at or Prior to Week 48
NCT00625404 (12) [back to overview]	Participant Report of Change in Number of Sexual Partners
NCT00625404 (12) [back to overview]	HIV Infection
NCT00625404 (12) [back to overview]	FTC and/or Tenofovir Resistance
NCT00625404 (12) [back to overview]	Frequency of Adverse Events (AEs) During and Within 4 Weeks After Study Product Administration
NCT00625404 (12) [back to overview]	Confirmed Grade 3 or Higher AST Elevation
NCT00625404 (12) [back to overview]	Confirmed Grade 3 or Higher ALT Elevation
NCT00625404 (12) [back to overview]	CD4+ T-cell Count
NCT00625404 (12) [back to overview]	Confirmed Grade 3 or Higher Reduction in Phosphorus
NCT00625404 (12) [back to overview]	Confirmed Grade 2 or Higher Serum Creatinine Toxicity
NCT00625404 (12) [back to overview]	Pregnancy Complications
NCT00625404 (12) [back to overview]	Pill Counts and Participant Report of Adherence to Once-daily Pill Taking
NCT00625404 (12) [back to overview]	Plasma HIV RNA Level (HIV-1 Viral Load)
NCT00632970 (1) [back to overview]	Absolute Change in CD4 Cell Counts
NCT00641641 (1) [back to overview]	Mean Change From Baseline Plasma HIV RNA (Log Copies/mL)
NCT00654147 (6) [back to overview]	Time to Virologic Failure
NCT00654147 (6) [back to overview]	Time to Confirmed Virologic Failure
NCT00654147 (6) [back to overview]	Study Medication Toxicity-related Discontinuation .
NCT00654147 (6) [back to overview]	Study Medication Tolerability
NCT00654147 (6) [back to overview]	Weeks to HIV-1 RNA <200 Copies/ml
NCT00654147 (6) [back to overview]	Change From Baseline CD4+ and CD8+ Cell Counts
NCT00662545 (5) [back to overview]	HIV RNA < 75 Copies/ml
NCT00662545 (5) [back to overview]	Hepatitis B Virus (HBV) DNA
NCT00662545 (5) [back to overview]	Incidence of Permanent Discontinuation Due to Toxicity
NCT00662545 (5) [back to overview]	Incidence of New Hepatic Decompensation( Ascites, Variceal Hemorrhage, Encephalopathy)
NCT00662545 (5) [back to overview]	Incidence of ALT Flares
NCT00705679 (11) [back to overview]	Incidence Rate of HIV-1 Infections of Oral TDF-FTC and Oral Placebo Arms
NCT00705679 (11) [back to overview]	Incidence Rate of HIV-1 Infections of Tenofovir 1% Gel and Vaginal Placebo Gel Arms
NCT00705679 (11) [back to overview]	Number of HIV-1 Infections of Oral TDF and Oral Placebo Arms
NCT00705679 (11) [back to overview]	Number of HIV-1 Infections of Oral TDF-FTC and Oral Placebo Arms
NCT00705679 (11) [back to overview]	Number of HIV-1 Infections of Tenofovir 1% Gel and Vaginal Placebo Gel Arms
NCT00705679 (11) [back to overview]	Person-years of Follow-up of Oral TDF and Oral Placebo Arms
NCT00705679 (11) [back to overview]	Person-years of Follow-up of Oral TDF-FTC and Oral Placebo Arms
NCT00705679 (11) [back to overview]	Person-years of Follow-up of Tenofovir 1% Gel and Vaginal Placebo Gel Arms
NCT00705679 (11) [back to overview]	Frequency of HIV-1 Drug Resistance in Women Who Acquire HIV-1 Infection While Using Study Product
NCT00705679 (11) [back to overview]	Extended Safety of Daily Tenofovir 1% Gel, Oral TDF, and Oral FTC/TDF in Women at Risk for Sexually Transmitted HIV Infection Based on Occurrence of Grade 2, 3, and 4 Adverse Events
NCT00705679 (11) [back to overview]	Incidence Rate of HIV-1 Infections of Oral TDF and Oral Placebo Arms
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Eosinophils (x 10^9/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Fasting Glucose (Millimoles/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Hematocrit (Fraction)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Inorganic Phosphate (Micromoles/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Hips Measurement (cm)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in High Density Lipoprotein Cholesterol (HDL) (Micromoles/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Aspartate Aminotransferase (Units/Liter)
NCT00711009 (82) [back to overview]	Change From Baseline on Physical Component Score of the Medical Outcomes Study HIV Health Survey
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Basophils (x 10^9/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Bicarbonate (Micromoles/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Blood Urea Nitrogen (Micromoles/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Dual Energy X-ray Absorptiometry (DEXA) Scan of Trunk Fat (Grams)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Dual Energy X-ray Absorptiometry (DEXA) Scan of Trunk Lean Mass (Grams)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Dual Energy X-ray Absorptiometry (DEXA) Scan of Trunk Mass (Grams)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Dual Energy X-ray Absorptiometry (DEXA) Scan of Upper Extremity Fat (Grams)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Dual Energy X-ray Absorptiometry (DEXA) Scan of Upper Extremity Lean Mass (Grams)
NCT00711009 (82) [back to overview]	Change From Baseline on Mental Component of Medical Outcomes Study HIV Health Survey
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Calcium (Micromoles/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Calculated Creatinine Clearance (Milliliters/Second)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Chest Measurement (cm)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Chloride (Micromoles/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Cholesterol (Micromoles/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Creatine Phosphokinase (Units/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Creatinine (Micromoles/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Adiponectin (Micrograms/Milliliter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Alanine Aminotransferase (Units/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Dual Energy X-ray Absorptiometry (DEXA) Scan of Upper Extremity Total Mass (Grams)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Albumin (Grams/Liter)
NCT00711009 (82) [back to overview]	Primary Outcome: Percentage of Participants With Potentially Clinically Significant Laboratory Values
NCT00711009 (82) [back to overview]	Percentage of Participants With Moderate or Severe Treatment-emergent, Drug-related Adverse Events
NCT00711009 (82) [back to overview]	Percentage of Participants Responding (Plasma HIV-1 RNA Levels Below 40 Copies/Milliliter [mL]) at Each Visit Based on the FDA Time to Loss of Virologic Response (TLOVR) Algorithm
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Alkaline Phosphatase (Units/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Hemoglobin (Grams/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in DEXA Scan of Lower Extremity Lean Mass (Grams)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Dual Energy X-ray Absorptiometry (DEXA) Scan of Bone Mineral Content (Grams)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Dual Energy X-ray Absorptiometry (DEXA) Scan of Bone Mineral Density (Grams/cm^2)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Dual Energy X-ray Absorptiometry (DEXA) Scan of Lower Extremity Fat (Grams)
NCT00711009 (82) [back to overview]	Number of Participants Who Developed Resistance to Each Drug in the Study Regimen, as Defined by the International AIDS Society-USA (IAS-USA) Panel.
NCT00711009 (82) [back to overview]	Mean Change in CD4+ T-Cell Counts From Baseline to Each Visit
NCT00711009 (82) [back to overview]	Time to Loss of Virologic Response - Percentage of Participants Still Categorized as Responders at Day 672
NCT00711009 (82) [back to overview]	Score on Side Effects Scale of Treatment Satisfaction Questionnaire for Medication
NCT00711009 (82) [back to overview]	Score on Global Satisfaction Scale of Treatment Satisfaction Questionnaire for Medication
NCT00711009 (82) [back to overview]	Score on Effectiveness Scale of Treatment Satisfaction Questionnaire for Medication (TSQM)
NCT00711009 (82) [back to overview]	Percentage of Participants Responding (Plasma HIV-1 Ribonucleic Acid [RNA] Levels Less Than 40 Copies/Milliliter [mL]) at Week 48 Based on the Food and Drug Administration (FDA) Time to Loss of Virologic Response (TLOVR) Algorithm
NCT00711009 (82) [back to overview]	Number of Participants Who Developed Resistance, Defined Conservatively, to Lopinavir
NCT00711009 (82) [back to overview]	Mean Change From Baseline in White Blood Cell Count (x 10^9/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Weight (kg)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Waist Measurement (cm)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Urine Specific Gravity
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Urine pH
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Uric Acid (Micromoles/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Triglycerides (Micromoles/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Total Protein (Grams/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Total Bilirubin (Micromoles/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Temperature (°F)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Soluble Tumor Necrosis Factor Receptor-2 (Picograms/Milliliter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Soluble Tumor Necrosis Factor Receptor-1 (Picograms/Milliliter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Sodium (Micromoles/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Sitting Systolic Blood Pressure (mm Hg)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Sitting Heart Rate (Beats Per Minute)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Sitting Diastolic Blood Pressure (mm Hg)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Red Blood Cell Count (x 10^12/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Potassium (Micromoles/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Platelet Count (x 10^9/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Dual Energy X-ray Absorptiometry (DEXA) Scan of Lower Extremity Total Mass (Grams)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Dual Energy X-ray Absorptiometry (DEXA) Scan of Total Body Fat (Grams)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Dual Energy X-ray Absorptiometry (DEXA) Scan of Total Body Lean Mass (Grams)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Dual Energy X-ray Absorptiometry (DEXA) Scan of Total Body Mass (Grams)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Neutrophils (x 10^9/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Monocytes (x 10^9/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Mid-Thigh Measurement (cm)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Mid-Arm Measurement (cm)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Magnesium (Millimoles/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Lymphocytes (x 10^9/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Low Density Lipoprotein (LDL): High Density Lipoprotein (HDL) Ratio (Ratio)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Low Density Lipoprotein (LDL) (Micromoles/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Lipase (Units/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Leptin (Nanograms/Milliliter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Lactate Dehydrogenase (Units/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Lactate (Millimoles/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Interleukin-6 (Nanograms/Liter)
NCT00711009 (82) [back to overview]	Mean Change From Baseline in Insulin (Picomoles/Liter)
NCT00724711 (14) [back to overview]	Percentage of Participants With HIV-1 RNA < 200 Copies/mL at Week 48
NCT00724711 (14) [back to overview]	Change From Baseline Interleukin-6 (IL-6), Interleukin-10 (IL-10), and Tumor Necrosis Factor-alpha (TNF-alpha) at Week 48
NCT00724711 (14) [back to overview]	Change From Baseline Fasting Lipid Parameters at Week 48
NCT00724711 (14) [back to overview]	Percentage of Participants With Pure Virologic Response (PVR) for HIV-1 RNA Cutoff at 50 Copies/mL Through Week 48
NCT00724711 (14) [back to overview]	Percentage of Participants With Pure Virologic Response (PVR) for HIV-1 RNA Cutoff at 200 Copies/mL Through Week 48
NCT00724711 (14) [back to overview]	Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) < 200 Copies/mL Through Week 48 Based on Time to Loss of Virologic Response (TLOVR) Algorithm
NCT00724711 (14) [back to overview]	Change From Baseline in Cluster Determinant 4 (CD4) Cell Count at Week 48
NCT00724711 (14) [back to overview]	Change From Baseline Fasting Glucose at Week 48
NCT00724711 (14) [back to overview]	Change From Baseline Estimated Glomerular Filtration Rate (eGFR) by Modified Diet in Renal Disease (MDRD) at Week 48
NCT00724711 (14) [back to overview]	Change From Baseline Ratio of Fasting Total Cholesterol Over High-density Lipoprotein (HDL) Cholesterol at Week 48
NCT00724711 (14) [back to overview]	Change From Baseline Calculated Creatinine Clearance (CLcr) Using Ideal Body Weight by Cockcroft-Gault Method at Week 48
NCT00724711 (14) [back to overview]	Change From Baseline C-Reactive Protein at Week 48
NCT00724711 (14) [back to overview]	Change From Baseline Fibrinogen at Week 48
NCT00724711 (14) [back to overview]	Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48
NCT00734162 (37) [back to overview]	Change From Baseline in Z-score for Whole Body BMD at Week 192
NCT00734162 (37) [back to overview]	Percentage of Participants With Abnormal ALT at Baseline Who Had HBV DNA < 400 Copies/mL and Normalized ALT at Weeks 48, 72, 96, 144, and 192
NCT00734162 (37) [back to overview]	Percentage of Participants With Abnormal ALT at Baseline Who Had Normalized ALT at Weeks 48, 72, 96, 144, and 192
NCT00734162 (37) [back to overview]	Percentage of Participants With at Least a 6% Decrease From Baseline in Spine BMD at Weeks 48, 96, 144, and 192
NCT00734162 (37) [back to overview]	Percentage of Participants With HBsAg Seroconversion at Weeks 48, 72, 96, 144, and 192
NCT00734162 (37) [back to overview]	Percentage of Participants With HBV DNA < 169 Copies/mL at Weeks 48, 72, 96, 144, and 192
NCT00734162 (37) [back to overview]	Percentage of Participants With HBV DNA < 400 Copies/mL at Week 72
NCT00734162 (37) [back to overview]	Percentage of Participants With at Least a 6% Decrease From Baseline in Bone Mineral Density (BMD) of the Spine at Week 72
NCT00734162 (37) [back to overview]	Percent Change From Baseline in Whole Body BMD at Week 96
NCT00734162 (37) [back to overview]	Percent Change From Baseline in Whole Body BMD at Week 72
NCT00734162 (37) [back to overview]	Percent Change From Baseline in Whole Body BMD at Week 48
NCT00734162 (37) [back to overview]	Percent Change From Baseline in Whole Body BMD at Week 192
NCT00734162 (37) [back to overview]	Percentage of Participants With HBV DNA < 400 Copies/mL and Normal ALT at Weeks 48, 72, 96, 144, and 192
NCT00734162 (37) [back to overview]	Percent Change From Baseline in Whole Body BMD at Week 144
NCT00734162 (37) [back to overview]	Percent Change From Baseline in Spine Bone Mineral Density (BMD) at Week 48
NCT00734162 (37) [back to overview]	Percent Change From Baseline in Spine BMD at Week 96
NCT00734162 (37) [back to overview]	Percent Change From Baseline in Spine BMD at Week 72
NCT00734162 (37) [back to overview]	Percent Change From Baseline in Spine BMD at Week 192
NCT00734162 (37) [back to overview]	Percent Change From Baseline in Spine BMD at Week 144
NCT00734162 (37) [back to overview]	Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 48, 96, 144, and 192
NCT00734162 (37) [back to overview]	Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Weeks 48, 72, 96, 144, and 192
NCT00734162 (37) [back to overview]	Percentage of Participants With Normal Alanine Aminotransferase (ALT) at Weeks 48, 72, 96, 144, and 192
NCT00734162 (37) [back to overview]	Change From Baseline in Z-score for Whole Body BMD at Week 96
NCT00734162 (37) [back to overview]	Change From Baseline in Z-score for Whole Body BMD at Week 72
NCT00734162 (37) [back to overview]	Change From Baseline in Z-score for Whole Body BMD at Week 48
NCT00734162 (37) [back to overview]	Change From Baseline in Z-score for Whole Body BMD at Week 144
NCT00734162 (37) [back to overview]	Change From Baseline in Z-score for Spine BMD at Week 96
NCT00734162 (37) [back to overview]	Number of Participants With Changes in Drug-Resistant Mutations During the Study
NCT00734162 (37) [back to overview]	Change From Baseline in Z-score for Spine BMD at Week 72
NCT00734162 (37) [back to overview]	Change From Baseline in Z-score for Spine BMD at Week 48
NCT00734162 (37) [back to overview]	Change From Baseline in Z-score for Spine BMD at Week 192
NCT00734162 (37) [back to overview]	Change From Baseline in Z-score for Spine BMD at Week 144
NCT00734162 (37) [back to overview]	Percentage of Participants With at Least a 6% Decrease From Baseline in Whole Body BMD at Weeks 48, 72, 96, 144, and 192
NCT00734162 (37) [back to overview]	Percentage of Participants Who Were HBeAg-Positive With Abnormal ALT at Baseline Who Had HBV DNA < 400 Copies/mL, Normalized ALT, and HBeAg Loss/Seroconversion at Weeks 48, 72, 96, 144, and 192
NCT00734162 (37) [back to overview]	Percentage of Participants Who Were HBeAg-Positive at Baseline Who Had HBV DNA < 400 Copies/mL, Normal ALT, and HBeAg Loss/Seroconversion at Weeks 48, 72, 96, 144, and 192
NCT00734162 (37) [back to overview]	Percentage of Participants Who Were HBeAg-Positive at Baseline and Who Had HBeAg Seroconversion at Weeks 48, 72, 96, 144, and 192
NCT00734162 (37) [back to overview]	Percentage of Participants Who Were HBeAg-Positive at Baseline and Who Had HBeAg Loss at Weeks 48, 72, 96, 144, and 192
NCT00734344 (32) [back to overview]	Mean Hematocrit Between Treatment Groups at 2 Months
NCT00734344 (32) [back to overview]	Mean CD4 Count Between Treatment Groups at 4 Months
NCT00734344 (32) [back to overview]	Mean CD4 Count Between Treatment Groups at 5 Months
NCT00734344 (32) [back to overview]	Mean Hematocrit Between Treatment Groups at 4 Months
NCT00734344 (32) [back to overview]	Mean CD4 Count Between Treatment Groups at 6 Months
NCT00734344 (32) [back to overview]	Mean CD4 Count Between Treatment Groups at 7 Months
NCT00734344 (32) [back to overview]	Mean Hematocrit Between Treatment Groups at 6 Months
NCT00734344 (32) [back to overview]	Mean White Blood Cell Count Between Treatment Groups at 8 Months
NCT00734344 (32) [back to overview]	Mean White Blood Cell Count Between Treatment Groups at 6 Months
NCT00734344 (32) [back to overview]	Mean CD4 Count Between Treatment Groups at 8 Months
NCT00734344 (32) [back to overview]	Mean White Blood Cell Count Between Treatment Groups at 4 Months
NCT00734344 (32) [back to overview]	Mean CD4 Count Between Treatment Groups at 2 Months
NCT00734344 (32) [back to overview]	Mean White Blood Cell Count Between Treatment Groups at 14 Months
NCT00734344 (32) [back to overview]	Mean CD4 Count Between Treatment Groups at 9 Months
NCT00734344 (32) [back to overview]	Mean Hematocrit Between Treatment Groups at 10 Months
NCT00734344 (32) [back to overview]	Mean CD4 Count Between Treatment Groups at 11 Months
NCT00734344 (32) [back to overview]	Mean CD4 Count Between Treatment Groups at 10 Months
NCT00734344 (32) [back to overview]	Mean CD4 Count Between Treatment Groups at 1 Months
NCT00734344 (32) [back to overview]	Mean Platelet Count Between Treatment Groups at 10 Months
NCT00734344 (32) [back to overview]	Mean Platelet Count Between Treatment Groups at 12 Months
NCT00734344 (32) [back to overview]	Mean Platelet Count Between Treatment Groups at 14 Months
NCT00734344 (32) [back to overview]	Mean CD4 Count Between Treatment Groups at 3 Months
NCT00734344 (32) [back to overview]	Mean Platelet Count Between Treatment Groups at 2 Months
NCT00734344 (32) [back to overview]	Mean Hematocrit Between Treatment Groups at 8 Months
NCT00734344 (32) [back to overview]	Mean Platelet Count Between Treatment Groups at 4 Months
NCT00734344 (32) [back to overview]	Mean Platelet Count Between Treatment Groups at 6 Months
NCT00734344 (32) [back to overview]	Mean Platelet Count Between Treatment Groups at 8 Months
NCT00734344 (32) [back to overview]	Mean White Blood Cell Count Between Treatment Groups at 10 Months
NCT00734344 (32) [back to overview]	Mean White Blood Cell Count Between Treatment Groups at 12 Months
NCT00734344 (32) [back to overview]	Mean Hematocrit Between Treatment Groups at 12 Months
NCT00734344 (32) [back to overview]	Mean Hematocrit Between Treatment Groups at 14 Months
NCT00734344 (32) [back to overview]	Mean White Blood Cell Count Between Treatment Groups at 2 Months
NCT00736190 (10) [back to overview]	Number of Participants With HBV DNA < 169 Copies/mL (<29 IU/mL) at Week 48
NCT00736190 (10) [back to overview]	Summary of Resistance Surveillance for Participants Without Virologic Breakthrough
NCT00736190 (10) [back to overview]	Summary of Resistance Surveillance for Participants With Virologic Breakthrough
NCT00736190 (10) [back to overview]	Summary of Resistance Surveillance for Participants Who Discontinued the Study Early
NCT00736190 (10) [back to overview]	Number of Participants With HBeAg/Hepatitis B Surface Antigen (HBsAg) Loss and Seroconversion
NCT00736190 (10) [back to overview]	Number of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <400 Copies/mL (<69 IU/mL)
NCT00736190 (10) [back to overview]	Number of Participants With Composite Endpoint of Hepatitis B Virus (HBV) DNA <400 Copies/mL (<69 IU/mL) and Normal ALT at Week 48
NCT00736190 (10) [back to overview]	Number of Participants With ALT Normalized (Baseline Values > ULN [34 U/L] and <= ULN at a Subsequent Visit) at Week 48
NCT00736190 (10) [back to overview]	Number of Participants With Alanine Aminotransferase (ALT) Normal at Week 48
NCT00736190 (10) [back to overview]	Change From Baseline in FibroTest Value
NCT00752856 (4) [back to overview]	To Compare the Phase 1 Viral Decay Rates Between LPV/r + RAL vs. EFV/TDF/FTC Treatment Combinations.
NCT00752856 (4) [back to overview]	Compare Late Activated CD4+ T-cell Recovery Rates Between Treatment Regimens From Baseline to Week 48
NCT00752856 (4) [back to overview]	Compare Early Activated CD4+ T-cell Recovery Rates From Baseline to Week 4.
NCT00752856 (4) [back to overview]	Viral Suppression Efficacy at 48 Weeks
NCT00757783 (16) [back to overview]	Change From Baseline in Glucose at Week 12 and 48.
NCT00757783 (16) [back to overview]	Change From Baseline in Total Cholesterol (TC) Levels in the LE Set at Week 12 and 48
NCT00757783 (16) [back to overview]	Change From Baseline in Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) at Week 12 and 48.
NCT00757783 (16) [back to overview]	Change From Baseline in Insulin at Week 12 and 48.
NCT00757783 (16) [back to overview]	Change From Baseline in Cluster of Differentiation (CD) 4 Cell Count at Week 12 and 48, Last Observation Carried Forward (LOCF).
NCT00757783 (16) [back to overview]	Change From Baseline in HIV-1 RNA Viral Load at Week 12 and 48.
NCT00757783 (16) [back to overview]	Change From Baseline in High Density Lipoprotein (HDL) in the LE Set at Week 12 and 48.
NCT00757783 (16) [back to overview]	Change From Baseline in Fasting Triglyceride (TG) Levels in the Lipid Evaluable (LE) Set at Week12
NCT00757783 (16) [back to overview]	Change From Baseline in CD4 Cell Count at Week 12 and 48, Observed Values.
NCT00757783 (16) [back to overview]	Change From Baseline in Apolipoprotein B in the LE Set at Week 12 and 48.
NCT00757783 (16) [back to overview]	Change From Baseline in Apolipoprotein A1 in the LE Set at Week 12 and 48.
NCT00757783 (16) [back to overview]	Antiviral Activity, Human Immunodeficiency Virus Type 1 (HIV-1) RNA.
NCT00757783 (16) [back to overview]	Change From Baseline in Low Density Lipoprotein (LDL) Direct in the LE Set at Week 12 and 48.
NCT00757783 (16) [back to overview]	Number of Participants With Antiviral Activity, HIV-1 RNA, Missing Values as Treatment Failure (M=F)
NCT00757783 (16) [back to overview]	Change From Baseline in Cluster of Differentiation (CD) 4 Percent at Week 12 and 48, Last Observation Carried Forward (LOCF).
NCT00757783 (16) [back to overview]	Change From Baseline in TC/HDL Ratio in the LE Set at Week 12 and 48.
NCT00762892 (5) [back to overview]	Change From Baseline in Interleukin-6 (IL-6) at 48 Weeks
NCT00762892 (5) [back to overview]	Change From Baseline in Homocysteine at 6 Months
NCT00762892 (5) [back to overview]	Change From Baseline in CD4 Count at 48 Weeks
NCT00762892 (5) [back to overview]	Change From Baseline in Lipids at 48 Weeks
NCT00762892 (5) [back to overview]	Change From Baseline in Log HIV Viral Load at 48 Weeks
NCT00768989 (28) [back to overview]	Number of Participants With Blood Chemistry Laboratory Test Results With Worst Toxicity of Grades 1 to 4 (Continued)
NCT00768989 (28) [back to overview]	Atazanavir Maximum Observed Plasma Concentration (Cmax) in 1 Dosing Interval
NCT00768989 (28) [back to overview]	Number of Participants With Hematology Laboratory Test Results With Worst Toxicity of Grades 1 to 4 Among All Treated Participants
NCT00768989 (28) [back to overview]	Number of Participants With HIV RNA Levels <400 Copies/mL at Week 24
NCT00768989 (28) [back to overview]	Number of Participants With Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) Level <50 Copies/mL at Week 24
NCT00768989 (28) [back to overview]	Atazanavir Trough Plasma Concentration (Cmin) 12 Hours Postdose
NCT00768989 (28) [back to overview]	Atazanavir Time of Maximum Observed Plasma Concentration (Tmax)
NCT00768989 (28) [back to overview]	Number of Participants With Enzyme and Urine Laboratory Test Results With Worst Toxicity of Grades 1 to 4
NCT00768989 (28) [back to overview]	Atazanavir Terminal Elimination Half Life
NCT00768989 (28) [back to overview]	Atazanavir Individual Inhibitory Quotient (IQ)
NCT00768989 (28) [back to overview]	Raltegravir Cmin 12 Hours Postdose
NCT00768989 (28) [back to overview]	Raltegravir Cmax in 1 Dosing Interval
NCT00768989 (28) [back to overview]	Raltegravir AUC (0-12h) in 1 Dosing Interval
NCT00768989 (28) [back to overview]	Number of Participants With HIV RNA Levels <50 Copies/mL at Weeks 48 and 96
NCT00768989 (28) [back to overview]	Atazanavir Cmin Prior to the Morning Dose
NCT00768989 (28) [back to overview]	Atazanavir Area Under the Concentration Curve From Time 0 to 24 Hours (AUC [0-24h]) in 1 Dosing Interval
NCT00768989 (28) [back to overview]	Raltegravir Cmin Prior to the Morning Dose
NCT00768989 (28) [back to overview]	Raltegravir Terminal Elimination Half Life
NCT00768989 (28) [back to overview]	Atazanavir Area Under the Concentration Curve From Time 0 to 12 Hours (AUC [0-12h]) in 1 Dosing Interval
NCT00768989 (28) [back to overview]	Raltegravir Tmax
NCT00768989 (28) [back to overview]	Baseline and Mean Change From Baseline in Total Cholesterol Levels
NCT00768989 (28) [back to overview]	Number of Participants With Blood Chemistry Laboratory Test Results With Worst Toxicity of Grades 1 to 4
NCT00768989 (28) [back to overview]	Mean Change From Baseline in Electrocardiogram Findings
NCT00768989 (28) [back to overview]	Mean Change From Baseline in Total Bilirubin Level
NCT00768989 (28) [back to overview]	Number of Nonresponders at Week 8
NCT00768989 (28) [back to overview]	Number of Participants With HIV RNA Levels <400 Copies/mL at Week 48
NCT00768989 (28) [back to overview]	Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Death as Outcome, AEs Leading to Discontinuation, SAEs Leading to Discontinuation
NCT00768989 (28) [back to overview]	Mean Change From Baseline in Absolute Cluster of Differentiation 4 Cell Count
NCT00805675 (9) [back to overview]	Percentage of Patients Who Are Polymerase Chain Reaction(PCR)Negative at Week 12
NCT00805675 (9) [back to overview]	Change in Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Level From Baseline to Weeks 2, 4 and 8.
NCT00805675 (9) [back to overview]	Characterization of Very Early Viral Kinetics Through Efficiency Factor of Blocking Virus Production.
NCT00805675 (9) [back to overview]	"Percentage of Patients Who Achieve Hepatitis B e Antigen (HBeAg) Loss and HBeAg Seroconversion at Week 12"
NCT00805675 (9) [back to overview]	Change in Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Level From Baseline to Week 12.
NCT00805675 (9) [back to overview]	Characterization of Very Early Viral Kinetics Through Estimated Viral Load
NCT00805675 (9) [back to overview]	Characterization of Very Early Viral Kinetics Through Half-live of Free Virus
NCT00805675 (9) [back to overview]	Characterization of Very Early Viral Kinetics Through Rate of Infected Cell Loss
NCT00805675 (9) [back to overview]	Characterization of Very Early Viral Kinetics Through Viral Clearance
NCT00811954 (19) [back to overview]	Cumulative Probability of Time to Loss of Virologic Response (TLOVR) by Week 96
NCT00811954 (19) [back to overview]	Cumulative Incidence of Discontinuation of the RAL or PI Component of Randomized Treatment for Toxicity by Week 96
NCT00811954 (19) [back to overview]	Cumulative Incidence of First Adverse Event by Week 96
NCT00811954 (19) [back to overview]	Cumulative Probability of First Virologic Failure by Week 96
NCT00811954 (19) [back to overview]	Incidence of Death or AIDS Defining Events (CDC Category C)
NCT00811954 (19) [back to overview]	Incidence of Targeted Serious Non-AIDS Defining Events (Renal Failure, Liver Disease, Serious Metabolic Disorder, and CVD)
NCT00811954 (19) [back to overview]	Presence of Mutations Associated With ATV/RTV or DRV/RTV Resistance
NCT00811954 (19) [back to overview]	Presence of Mutations Associated With INI Resistance
NCT00811954 (19) [back to overview]	Presence of Mutations Associated With NRTI Resistance
NCT00811954 (19) [back to overview]	Change in Waist Circumference From Baseline
NCT00811954 (19) [back to overview]	Change in Framingham 10-year Risk of MI or Coronary Death From Baseline
NCT00811954 (19) [back to overview]	Change in Fasting Triglycerides Level From Baseline
NCT00811954 (19) [back to overview]	Change in Fasting Total Cholesterol Level From Baseline
NCT00811954 (19) [back to overview]	Change in Fasting Plasma Glucose Level From Baseline
NCT00811954 (19) [back to overview]	Change in Fasting HDL Cholesterol Level From Baseline
NCT00811954 (19) [back to overview]	CD4+ T-cell Count Changes From Baseline
NCT00811954 (19) [back to overview]	CD4+ T-cell Count
NCT00811954 (19) [back to overview]	Change in Waist:Height Ratio From Baseline
NCT00811954 (19) [back to overview]	Self-reported Adherence
NCT00827112 (16) [back to overview]	Number of Participants With Phenotypic Resistance
NCT00827112 (16) [back to overview]	Time-Averaged Difference (TAD) in log10 Viral Load
NCT00827112 (16) [back to overview]	Percentage of Participants With Less Than 50 Copies/mL of HIV-1 RNA
NCT00827112 (16) [back to overview]	Change From Baseline in Cluster of Differentiation 4+T Lymphocyte (CD4) Cell Counts at Weeks 16, 24, 48 and 96
NCT00827112 (16) [back to overview]	Number of Participants With Genotypic Resistance
NCT00827112 (16) [back to overview]	Average Observed Plasma Concentration (Cavg) of Maraviroc
NCT00827112 (16) [back to overview]	HIV-1 RNA Levels at Baseline
NCT00827112 (16) [back to overview]	Minimum Observed Plasma Concentration (Cmin) of Maraviroc
NCT00827112 (16) [back to overview]	Percentage of Participants With Less Than 400 Copies/mL of HIV-1 RNA
NCT00827112 (16) [back to overview]	Number of Participants With HIV-1 RNA Tropism Status Using Trofile Assay
NCT00827112 (16) [back to overview]	Change From Baseline in Plasma log10 Viral Load at Weeks 16, 24, 48 and 96
NCT00827112 (16) [back to overview]	Time to Loss of Virological Response (TLOVR)
NCT00827112 (16) [back to overview]	Change From Baseline in HIV-1 RNA Levels of First 15 Participants at Days 4, 7, 10 and 14
NCT00827112 (16) [back to overview]	Percentage of Participants With Plasma Human Immuno Deficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) Levels Less Than 50 Copies/Milliliter (mL)
NCT00827112 (16) [back to overview]	Change From Baseline in Cluster of Differentiation 8+T Lymphocyte (CD8) Cell Count at Weeks 16, 24, 48 and 96
NCT00827112 (16) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Maraviroc
NCT00851799 (27) [back to overview]	Fold Change in Soluble CD14 From Study Entry to Weeks 48 and 96
NCT00851799 (27) [back to overview]	Fold Change in Soluble CD163 From Study Entry to Weeks 48 and 96
NCT00851799 (27) [back to overview]	Annual Rate of Change in Right Common Carotid Artery Intima-media Thickness (CIMT)
NCT00851799 (27) [back to overview]	Percent Change in Bone Mineral Density (BMD) of the Lumber Spine From Study Entry to Week 96
NCT00851799 (27) [back to overview]	CD4+ T-cell Count at Study Entry and Weeks 24, 48, 96 and 144
NCT00851799 (27) [back to overview]	Fold Change in Percent Expression of CD38+HLADR+ on CD4+ (Percent) From Study Entry to Weeks 24 and 96
NCT00851799 (27) [back to overview]	Change in Brachial Artery (BA) Flow Mediated Dilation (FMD) From Study Entry to Week 24
NCT00851799 (27) [back to overview]	Percent Change in Bone Mineral Density (BMD) of the Hip From Study Entry to Week 96
NCT00851799 (27) [back to overview]	Fold Change in Interleukin-6 (IL-6) From Study Entry to Weeks 48 and 96
NCT00851799 (27) [back to overview]	Change in Absolute Flow Mediated Dilation (FMD) From Study Entry to Weeks 4, 24 and 48
NCT00851799 (27) [back to overview]	Change in Brachial Artery Flow Mediated Dilation (FMD) From Study Entry to Weeks 4 and 48
NCT00851799 (27) [back to overview]	Percent Change in Subcutaneous Abdominal Fat (SAT) From Study Entry to Week 96
NCT00851799 (27) [back to overview]	Percent Change in Lean Mass From Study Entry to Week 96
NCT00851799 (27) [back to overview]	Change in CD4+ T-cell Count From Study Entry to Weeks 24, 48, 96 and 144
NCT00851799 (27) [back to overview]	Change in Fasting Calculated Low-density Lipoprotein Cholesterol (LDL-C) From Study Entry to Weeks 4, 24, 48 and 96
NCT00851799 (27) [back to overview]	Change in Fasting Glucose Level From Study Entry to Weeks 4, 24, 48 and 96
NCT00851799 (27) [back to overview]	Percent Change in Total Limb Fat From Study Entry to Week 96
NCT00851799 (27) [back to overview]	Change in Fasting Insulin Level From Study Entry to Weeks 4, 24, 48 and 96
NCT00851799 (27) [back to overview]	Percent Change in Trunk Fat From Study Entry to Week 96
NCT00851799 (27) [back to overview]	Change in Fasting Total Cholesterol (TC) From Study Entry to Weeks 4, 24, 48 and 96
NCT00851799 (27) [back to overview]	Change in Fasting Triglyceride (TG) From Study Entry to Weeks 4, 24, 48 and 96
NCT00851799 (27) [back to overview]	Percent Change in Bone Mineral Density (BMD) of the Total Body From Study Entry to Week 96
NCT00851799 (27) [back to overview]	Fold Change in D-dimer From Study Entry to Weeks 48 and 96
NCT00851799 (27) [back to overview]	Fold Change in High Sensitivity C-reactive Protein (hsCRP) From Study Entry to Weeks 48 and 96
NCT00851799 (27) [back to overview]	Change in Fasting High-density Lipoprotein Cholesterol (HDL-C) From Study Entry to Weeks 4, 24, 48 and 96
NCT00851799 (27) [back to overview]	Percent Change in Visceral Abdominal Fat (VAT) From Study Entry to Week 96
NCT00851799 (27) [back to overview]	Fold Change in Percent Expression of CD38+HLADR+ on CD8+ (Percent) From Study Entry to Weeks 24 and 96
NCT00856323 (4) [back to overview]	Self-reported Methamphetamine Use in Previous 30 Days.
NCT00856323 (4) [back to overview]	Post-Exposure Prophylaxis Medication Adherence
NCT00856323 (4) [back to overview]	HIV-related Sexual Risk Behaviors in Previous 30 Days.
NCT00856323 (4) [back to overview]	Description of Incident STI Infections.
NCT00862823 (2) [back to overview]	Area Under the Concentration Time Curve for Tenofovir, Emtricitabine and Efavirenz
NCT00862823 (2) [back to overview]	Maximum Concentration for Tenofovir, Emtricitabine and Efavirenz
NCT00869960 (8) [back to overview]	Atazanavir Systemic Exposure During the Follicular Phase (Days 6-10 After Menses)
NCT00869960 (8) [back to overview]	Ritonavir Systemic Exposure During the Luteal Phase (Days 20-25 After Menses)
NCT00869960 (8) [back to overview]	Tenofovir Systemic Exposure During the Follicular Phase (Days 6-10 After Menses)
NCT00869960 (8) [back to overview]	Tenofovir Systemic Exposure During the Luteal Phase (Days 20-25 After Menses)
NCT00869960 (8) [back to overview]	Ritonavir Systemic Exposure During the Follicular Phase (Days 6-10 After Menses)
NCT00869960 (8) [back to overview]	Emtricitabine Systemic Exposure During the Luteal Phase (Days 20-25 After Menses)
NCT00869960 (8) [back to overview]	Emtricitabine Systemic Exposure During the Follicular Phase (Days 6-10 After Menses)
NCT00869960 (8) [back to overview]	Atazanavir Systemic Exposure During the Luteal Phase (Days 20-25 After Menses)
NCT00885664 (11) [back to overview]	IL-10
NCT00885664 (11) [back to overview]	IL-4
NCT00885664 (11) [back to overview]	IL-6
NCT00885664 (11) [back to overview]	IL-7
NCT00885664 (11) [back to overview]	IL-8
NCT00885664 (11) [back to overview]	INF Gamma
NCT00885664 (11) [back to overview]	TNF Alpha
NCT00885664 (11) [back to overview]	Symptom Score
NCT00885664 (11) [back to overview]	SF-12 Physical Capacity Score
NCT00885664 (11) [back to overview]	SF-12 Mental Capacity Score
NCT00885664 (11) [back to overview]	IL-1 Beta
NCT00896051 (18) [back to overview]	Pharmacokinetic Results of Atazanavir (ATV): Treatment B: ATV/Low-Dose Ritonavir (Rtv) 400/100 mg (Results for AUC24hr)
NCT00896051 (18) [back to overview]	Pharmacokinetic Results of Etravirine (ETR) (Results for AUC12hr)
NCT00896051 (18) [back to overview]	Pharmacokinetic Results of Low-Dose Ritonavir (Rtv): Treatment A: Atazanavir (ATV)/Rtv 300/100 mg (Results for AUC24hr)
NCT00896051 (18) [back to overview]	Pharmacokinetic Results of Low-Dose Ritonavir (Rtv): Treatment B: Atazanavir (ATV)/Rtv 400/100 mg (Results for AUC24hr)
NCT00896051 (18) [back to overview]	Change From Pre-Baseline in Log10 Viral Load Over Time
NCT00896051 (18) [back to overview]	Pharmacokinetic Results of Atazanavir (ATV): Treatment A: ATV/Low-Dose Ritonavir (Rtv) 300/100 mg (Results for C0h, Cmin, and Cmax)
NCT00896051 (18) [back to overview]	Pharmacokinetic Results of Etravirine (ETR) (Results for C0h, Cmin, and Cmax)
NCT00896051 (18) [back to overview]	Pharmacokinetic Results of Low-Dose Ritonavir (Rtv): Treatment A: Atazanavir (ATV)/Rtv 300/100 mg (Results for C0h, Cmin, and Cmax)
NCT00896051 (18) [back to overview]	Pharmacokinetic Results of Low-Dose Ritonavir (Rtv): Treatment B: Atazanavir (ATV)/Rtv 400/100 mg (Results for C0h, Cmin, and Cmax)
NCT00896051 (18) [back to overview]	The Percentage of Participants With a Virologic Response (Plasma Viral Load < 50 Copies/mL) at Week 48 Using the Snapshot Analysis Method
NCT00896051 (18) [back to overview]	The Percentage of Participants With a Virologic Response Using the Non-Completing = Failure (NC=F) Imputation Method
NCT00896051 (18) [back to overview]	The Percentage of Participants With a Virologic Response Using the Time to Loss of Virologic Response (TLOVR) Imputation Method
NCT00896051 (18) [back to overview]	Time to Confirmed Virologic Response
NCT00896051 (18) [back to overview]	Time to Virologic Failure
NCT00896051 (18) [back to overview]	Pharmacokinetic Results of Atazanavir (ATV): Treatment B: ATV/Low-Dose Ritonavir (Rtv) 400/100 mg (Results for C0h, Cmin, and Cmax)
NCT00896051 (18) [back to overview]	Change From Prebaseline in CD4+ Cell Count Over Time
NCT00896051 (18) [back to overview]	Pharmacokinetic Results of Atazanavir (ATV): Treatment A: ATV/Low-Dose Ritonavir (Rtv) 300/100 mg (Results for AUC24hr)
NCT00896051 (18) [back to overview]	Percentage of Participants With Undetectable Plasma Viral Load (VL) Values (<50 Copies/mL) at Week 48
NCT00924898 (6) [back to overview]	Number of Participants Without Virologic Failure at Week 48
NCT00924898 (6) [back to overview]	Number of Participants Without Virologic Failure at Week 24
NCT00924898 (6) [back to overview]	Number of Participants With HIV RNA Suppression at Week 96
NCT00924898 (6) [back to overview]	Number of Participants With Baseline Genotypic Resistance to One or More Antiretroviral Drugs in the Study Treatment
NCT00924898 (6) [back to overview]	Number of Participants With Baseline Genotypic Resistance to Antiretroviral Medications
NCT00924898 (6) [back to overview]	Time to HIV RNA Suppression <50 Copies/mL
NCT00928187 (13) [back to overview]	Patients With Plasma HIV RNA < 200 Copies/ml
NCT00928187 (13) [back to overview]	Number of Patients With WHO Stage 3 and 4 HIV Related Events
NCT00928187 (13) [back to overview]	Number of Patients With Resistance Mutations
NCT00928187 (13) [back to overview]	Number of Patients With Plasma HIV RNA < 50 Copies/mL
NCT00928187 (13) [back to overview]	Number of Patients With HIV Plasma Viral Load < 50 Copies/ml
NCT00928187 (13) [back to overview]	Number of Patients With HIV Plasma Viral Load < 200 Copies/ml
NCT00928187 (13) [back to overview]	Tolerance: Neuropathies (Grade 1 to 4)
NCT00928187 (13) [back to overview]	Adherence
NCT00928187 (13) [back to overview]	Development of Metabolic Syndrome
NCT00928187 (13) [back to overview]	Gain in CD4 Cells Between Baseline and W48
NCT00928187 (13) [back to overview]	Number of Patients Discontinuing Study Treatment
NCT00928187 (13) [back to overview]	Tolerance: Gastrointestinal Complains
NCT00928187 (13) [back to overview]	Tolerance: Equal or Superior to a 25% Reduction in eGFR (Glomerular Filtration Rate)
NCT00931801 (4) [back to overview]	Change in Quality of Life From Baseline to 48 Weeks of Study Treatment
NCT00931801 (4) [back to overview]	The Change in Adherence to Study Treatment Arm From Baseline to Week 48
NCT00931801 (4) [back to overview]	The Difference in CD4 From Baseline to Week 48
NCT00931801 (4) [back to overview]	Maintenance of Virologic Suppression
NCT00959894 (25) [back to overview]	Change in Limb and Trunk Fat Distribution as Measured by DEXA Scan, in the Same Subgroup of up to 40 Participants (as in Aim 8), From Baseline to Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	Change in Limb and Trunk Fat Distribution as Measured by DEXA Scan, in the Same Subgroup of up to 40 Participants (as in Aim 8), From Baseline to Week 24 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	The Proportion of Participants With HIV RNA <50 Copies/mL at Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	The Proportion of Participants With HIV RNA <50 Copies/mL at Week 48 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	Change in the Lipid Profile and Glucose Metabolism, in a Subgroup of up to 40 Participants, From Baseline to Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	The Proportion of Participants With HIV RNA <200 Copies/mL at Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	The Proportion of Participants With HIV RNA <200 Copies/mL at Week 48 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	The Proportion of Participants With HIV RNA <200 Copies/mL at Week 24 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	Probability of Remaining Free of a Safety/Tolerability Event at 96 Weeks
NCT00959894 (25) [back to overview]	Population Pharmacokinetics of Etravirine 400 mg Once Daily, in Combination With Fixed-dose Emtricitabine-tenofovir Among Treatment-naïve HIV-1 Infected Adults
NCT00959894 (25) [back to overview]	Resistance Mutations in the Subset of Patients With Confirmed Virologic Failure Who Have HIV RNA >500 Copies/mL and Genotype Resistance Results
NCT00959894 (25) [back to overview]	Population Pharmacokinetics of Etravirine 400 mg Once Daily, in Combination With Fixed-dose Emtricitabine-tenofovir Among Treatment-naïve HIV-1 Infected Adults: Etravirine AUC-24 Hours at Steady State
NCT00959894 (25) [back to overview]	Tolerability of Etravirine in HIV-1 Infected Adults Initiating Antiretroviral Therapy
NCT00959894 (25) [back to overview]	Pharmacokinetics of Etravirine in Genital Secretions of up to 10 Men and up to 10 Women at Week 4 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	Change in Glucose Metabolism (Insulin Resistance), in a Subgroup of up to 40 Participants, From Baseline to Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	Change in Glucose Metabolism (Insulin Resistance), in a Subgroup of up to 40 Participants, From Baseline to Week 48 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	Change in Glucose Metabolism (Insulin Resistance), in a Subgroup of up to 40 Participants, From Baseline to Week 24 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	Change in Fat Mass Ratio as Measured by DEXA Scan, in the Same Subgroup of up to 40 Participants (as in Aim 8), From Baseline to Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	Change in Fat Mass Ratio as Measured by DEXA Scan, in the Same Subgroup of up to 40 Participants (as in Aim 8), From Baseline to Week 24 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	Change in CD4+ Cell Count From Baseline to Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	Change in CD4+ Cell Count From Baseline to Week 48 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	The Antiretroviral Activity of Etravirine 400 mg Given Once Daily, With Fixed-dose Truvada Once Daily, Among Treatment-naïve HIV-1 Infected Adults as Measured by the Percentage of Participants With HIV RNA < 50 Copies/mL at Week 24
NCT00959894 (25) [back to overview]	Change in CD4+ Cell Count From Baseline to Week 24 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	Change in the Lipid Profile and Glucose Metabolism, in a Subgroup of up to 40 Participants, From Baseline to Week 48 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00959894 (25) [back to overview]	Change in the Lipid Profile and Glucose Metabolism, in a Subgroup of up to 40 Participants, From Baseline to Week 24 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine
NCT00960622 (1) [back to overview]	Change in Peak Oxygen Uptake.
NCT00962871 (2) [back to overview]	Mean Change From Baseline in HBV-DNA log10
NCT00962871 (2) [back to overview]	Mean Change From Baseline in Viral Quantitative e Antibody
NCT00998582 (2) [back to overview]	Change in Small Artery Elasticity (mL/mmHg x100) From Baseline to Week 24
NCT00998582 (2) [back to overview]	Outcome Was Change in Large Artery Elasticity (mL/mmHg x100) From Baseline to Week 24
NCT01003990 (1) [back to overview]	Number of Participants With Serious Adverse Events (SAEs), Treatment Related SAEs, Treatment Related Adverse Events (AEs), AEs Leading to Discontinuation of Study Therapy, Grade 3 to Grade 4 AEs, Grade 3 to Grade 4 AEs, CDC Class C AIDS Events, or Death
NCT01025427 (1) [back to overview]	Mean Change in Estimated Ultrasensitive Plasma HIV RNA Levels Between Baseline and Week 24
NCT01033942 (96) [back to overview]	Frequency of Missing Study Pills Because Participant Didn't Think it Was Needed Because he/She Was Not Engaged in Risky Sex
NCT01033942 (96) [back to overview]	Frequency of Missing Study Pills Because Participant Fell Asleep/Slept Through Dose Time
NCT01033942 (96) [back to overview]	Frequency of Missing Study Pills Because Participant Felt Depressed/Overwhelmed
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 12: Less Worried About Having Unprotected Sex Due to the Availability of PrEP
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 12: Participant Has Already Risked Getting HIV Infected Through Unprotected Sex While on This PrEP Study
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 12: Willingness to Take a Chance of Getting HIV Infected Because Participating in This PrEP Study
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 16: Less Concerned About Unprotected Anal Sex Because Participating in This PrEP Study
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 16: Less Worried About 'Slipping up' Now That PrEP May be Taken Prior to Unprotected Sex
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 16: Less Worried About Having Unprotected Sex Due to the Availability of PrEP
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 16: Participant Has Already Risked Getting HIV Infected Through Unprotected Sex While on This PrEP Study
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 12: Less Worried About 'Slipping up' Now That PrEP May be Taken Prior to Unprotected Sex
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 16: Willingness to Take a Chance of Getting HIV Infected Because Participating in This PrEP Study
NCT01033942 (96) [back to overview]	Frequency of Missing Study Pills Because Participant Wanted to Avoid Side Effects
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 20: Less Concerned About Unprotected Anal Sex Because Participating in This PrEP Study
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 20: Less Worried About 'Slipping up' Now That PrEP May be Taken Prior to Unprotected Sex
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 20: Less Worried About Having Unprotected Sex Due to the Availability of PrEP
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 20: Participant Has Already Risked Getting HIV Infected Through Unprotected Sex While on This PrEP Study
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 20: Willingness to Take a Chance of Getting HIV Infected Because Participating in This PrEP Study
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 24: Less Concerned About Unprotected Anal Sex Because Participating in This PrEP Study
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 24: Less Worried About 'Slipping up' Now That PrEP May be Taken Prior to Unprotected Sex
NCT01033942 (96) [back to overview]	Actual Number of Study Visits Completed by 24 Weeks
NCT01033942 (96) [back to overview]	Number of Missed Doses Based on Medication Refill Dates-Overall
NCT01033942 (96) [back to overview]	Number of Missed Doses Based on Medication Refill Dates-Week 12
NCT01033942 (96) [back to overview]	Number of Missed Doses Based on Medication Refill Dates-Week 16
NCT01033942 (96) [back to overview]	Number of Missed Doses Based on Medication Refill Dates-Week 20
NCT01033942 (96) [back to overview]	Number of Missed Doses Based on Medication Refill Dates-Week 4
NCT01033942 (96) [back to overview]	Number of Missed Doses Based on Medication Refill Dates-Week 8
NCT01033942 (96) [back to overview]	Number of Missed Doses Based on Self-Report Calendar Data-Week 12
NCT01033942 (96) [back to overview]	Number of Missed Doses Based on Self-Report Calendar Data-Week 16
NCT01033942 (96) [back to overview]	Number of Missed Doses Based on Self-Report Calendar Data-Week 20
NCT01033942 (96) [back to overview]	Number of Missed Doses Based on Self-Report Calendar Data-Week 24
NCT01033942 (96) [back to overview]	Number of Missed Doses Based on Self-Report Calendar Data-Week 4
NCT01033942 (96) [back to overview]	Number of Missed Doses Based on Self-Report Calendar Data-Week 8
NCT01033942 (96) [back to overview]	Number of Missed Doses Over Time Based on Self-Report Calendar Data
NCT01033942 (96) [back to overview]	Number of Participants Reporting No High-Risk Man With Man Sex Acts at Baseline
NCT01033942 (96) [back to overview]	Number of Participants Who Thought They Were on Placebo vs. Pre-Exposure Prophylaxis (PrEP) at Week 8
NCT01033942 (96) [back to overview]	Number of Participants Reporting No High-Risk Man With Man Sex Acts at Week 12
NCT01033942 (96) [back to overview]	Number of Participants Reporting No High-Risk Man With Man Sex Acts at Week 16
NCT01033942 (96) [back to overview]	Number of Participants Reporting No High-Risk Man With Man Sex Acts at Week 20
NCT01033942 (96) [back to overview]	Number of Participants Reporting No High-Risk Man With Man Sex Acts at Week 24
NCT01033942 (96) [back to overview]	Number of Participants Reporting No High-Risk Man With Man Sex Acts at Week 4
NCT01033942 (96) [back to overview]	Number of Participants Reporting No High-Risk Man With Man Sex Acts at Week 8
NCT01033942 (96) [back to overview]	Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Baseline
NCT01033942 (96) [back to overview]	Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Week 12
NCT01033942 (96) [back to overview]	Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Week 16
NCT01033942 (96) [back to overview]	Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Week 20
NCT01033942 (96) [back to overview]	Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Week 24
NCT01033942 (96) [back to overview]	Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Week 4
NCT01033942 (96) [back to overview]	Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Week 8
NCT01033942 (96) [back to overview]	Acceptability of Being Contacted by the Research Team in Between Visits
NCT01033942 (96) [back to overview]	Acceptability of Being Randomly Assigned to a Group
NCT01033942 (96) [back to overview]	Acceptability of Having an HIV Test at Every Visit
NCT01033942 (96) [back to overview]	Acceptability of Health Clinic for Study Visits
NCT01033942 (96) [back to overview]	Acceptability of Participating in Group Sessions
NCT01033942 (96) [back to overview]	Acceptability of Physical Examination by a Doctor
NCT01033942 (96) [back to overview]	Frequency of Missing Study Pills Because Participant Felt Sick or Ill
NCT01033942 (96) [back to overview]	Frequency of Missing Study Pills Because Participant Had a Change in Daily Routine
NCT01033942 (96) [back to overview]	Frequency of Missing Study Pills Because Participant Had Too Many Study Pills to Take
NCT01033942 (96) [back to overview]	Frequency of Missing Study Pills Because Participant Ran Out of Study Pills
NCT01033942 (96) [back to overview]	Frequency of Missing Study Pills Because Participant Simply Forgot
NCT01033942 (96) [back to overview]	Frequency of Missing Study Pills Because Participant Was Away From Home
NCT01033942 (96) [back to overview]	Frequency of Missing Study Pills Because Participant Was Too Busy With Other Things
NCT01033942 (96) [back to overview]	Number of Participants Who Thought They Were on Placebo vs. Pre-Exposure Prophylaxis (PrEP) at Week 12
NCT01033942 (96) [back to overview]	Number of Participants Who Thought They Were on Placebo vs. Pre-Exposure Prophylaxis (PrEP) at Week 16
NCT01033942 (96) [back to overview]	Number of Participants Who Thought They Were on Placebo vs. Pre-Exposure Prophylaxis (PrEP) at Week 20
NCT01033942 (96) [back to overview]	Number of Participants Who Thought They Were on Placebo vs. Pre-Exposure Prophylaxis (PrEP) at Week 24
NCT01033942 (96) [back to overview]	Number of Participants Who Thought They Were on Placebo vs. Pre-Exposure Prophylaxis (PrEP) at Week 4
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 12: Less Concerned About Unprotected Anal Sex Because Participating in This PrEP Study
NCT01033942 (96) [back to overview]	Acceptability of Questions About Sexual Behavior at Every Visit
NCT01033942 (96) [back to overview]	Acceptability of Risk Reduction Counseling at Every Visit
NCT01033942 (96) [back to overview]	Acceptability of Size of Pill
NCT01033942 (96) [back to overview]	Acceptability of Taking Part in the Study
NCT01033942 (96) [back to overview]	Acceptability of Taking the Pill Everyday
NCT01033942 (96) [back to overview]	Acceptability of the Color of the Pill
NCT01033942 (96) [back to overview]	Acceptability of the Taste of the Pill
NCT01033942 (96) [back to overview]	Frequency of Missing Pills Because Participant Felt Like the Study Pill Was Toxic/Harmful
NCT01033942 (96) [back to overview]	Frequency of Missing Study Pills Because Participant Did Not Want Others to Notice Participant Was Taking Medications
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 24: Less Worried About Having Unprotected Sex Due to the Availability of PrEP
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 24: Participant Has Already Risked Getting HIV Infected Through Unprotected Sex While on This PrEP Study
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 24: Willingness to Take a Chance of Getting HIV Infected Because Participating in This PrEP Study
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 4: Less Concerned About Unprotected Anal Sex Because Participating in This PrEP Study
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 4: Less Worried About 'Slipping up' Now That PrEP May be Taken Prior to Unprotected Sex
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 4: Less Worried About Having Unprotected Sex Due to the Availability of PrEP
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 4: Participant Has Already Risked Getting HIV Infected Through Unprotected Sex While on This PrEP Study
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 4: Willingness to Take a Chance of Getting HIV Infected Because Participating in This PrEP Study
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 8: Less Concerned About Unprotected Anal Sex Because Participating in This PrEP Study
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 8: Less Worried About 'Slipping up' Now That PrEP May be Taken Prior to Unprotected Sex
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 8: Less Worried About Having Unprotected Sex Due to the Availability of PrEP
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 8: Participant Has Already Risked Getting HIV Infected Through Unprotected Sex While on This PrEP Study
NCT01033942 (96) [back to overview]	Perceived HIV Risk Reduction at Week 8: Willingness to Take a Chance of Getting HIV Infected Because Participating in This PrEP Study
NCT01033942 (96) [back to overview]	Perceived Risk of Becoming HIV Positive at Week 12
NCT01033942 (96) [back to overview]	Perceived Risk of Becoming HIV Positive at Week 16
NCT01033942 (96) [back to overview]	Perceived Risk of Becoming HIV Positive at Week 20
NCT01033942 (96) [back to overview]	Perceived Risk of Becoming HIV Positive at Week 24
NCT01033942 (96) [back to overview]	Perceived Risk of Becoming HIV Positive at Week 4
NCT01033942 (96) [back to overview]	Perceived Risk of Becoming HIV Positive at Week 8
NCT01044771 (2) [back to overview]	Patients Without HIV Re-bound
NCT01044771 (2) [back to overview]	Patients With Reduced or Resolved Proteinuria
NCT01061151 (28) [back to overview]	Maternal Health Component: Other Targeted Medical Conditions
NCT01061151 (28) [back to overview]	Maternal Health Component: Incidence Rate of Progression to AIDS-defining Illness, Death, or a Serious Non-AIDS Cardiovascular, Hepatic, or Renal Event
NCT01061151 (28) [back to overview]	Maternal Health Component: Incidence Rate of Death or Any Condition of Particular Concern
NCT01061151 (28) [back to overview]	Maternal Health Component: Incidence Rate of Cardiovascular or Other Metabolic Events
NCT01061151 (28) [back to overview]	Maternal Health Component: Incidence of Tuberculosis
NCT01061151 (28) [back to overview]	Maternal Health Component: Incidence of Progression to AIDS-defining Illness or Death
NCT01061151 (28) [back to overview]	Maternal Health Component: Toxicity: Incidence of Grade 3 or Greater Laboratory Results or Signs and Symptoms and Selected Grade 2 Hematologic, Renal, and Hepatic Laboratory Results
NCT01061151 (28) [back to overview]	Maternal Health Component: Incidence of HIV/AIDS-related Event or World Health Organization (WHO) Clinical Stage 2 or 3 Events
NCT01061151 (28) [back to overview]	Postpartum Component: Proportion of Mother-Infant Pairs With no Death or HIV Diagnosis Through 24 Months Post-delivery
NCT01061151 (28) [back to overview]	Maternal Health Component: Incidence of Death
NCT01061151 (28) [back to overview]	Maternal Health Component: Incidence of AIDS-defining Illness
NCT01061151 (28) [back to overview]	Antepartum Component: Number of Infant HIV Infections
NCT01061151 (28) [back to overview]	Antepartum Component: Number of Confirmed Infant HIV Infections
NCT01061151 (28) [back to overview]	Maternal Health Component: Incidence of HIV/AIDS-related Events
NCT01061151 (28) [back to overview]	Antepartum Component: Number of Mothers With Adverse Pregnancy Outcomes (e.g.,Stillbirth, Preterm Delivery (< 37 Weeks), Low Birth Weight (< 2,500 Grams), and Congenital Anomalies)
NCT01061151 (28) [back to overview]	Antepartum Component: Number of Mothers With Adverse Pregnancy Outcomes (e.g.,Stillbirth, Preterm Delivery (< 37 Weeks), Low Birth Weight (< 2,500 Grams), and Congenital Anomalies)
NCT01061151 (28) [back to overview]	Antepartum Component: Number of Mothers With Grade 3 or Higher Toxicities and Selected Grade 2 Hematologic, Renal, and Hepatic Adverse Events
NCT01061151 (28) [back to overview]	Antepartum Component: Number of Mothers With Grade 3 or Higher Toxicities and Selected Grade 2 Hematologic, Renal, and Hepatic Adverse Events
NCT01061151 (28) [back to overview]	Antepartum Component: Number of Mothers With Obstetrical Complications
NCT01061151 (28) [back to overview]	Antepartum Component: Number of Mothers With Obstetrical Complications
NCT01061151 (28) [back to overview]	Antepartum Component: Probability of Overall and HIV-free Infant Survival Until 104 Weeks of Age, by Antepartum Arm (in Conjunction With Infants in the Postpartum Component)
NCT01061151 (28) [back to overview]	Maternal Health Component: Incidence of HIV/AIDS-related Event or Death
NCT01061151 (28) [back to overview]	Postpartum Component: Adherence to the Maternal and/or Infant ARV Regimens, as Measured by Maternal Report and Hair Measures
NCT01061151 (28) [back to overview]	Antepartum Component: Maternal HIV RNA Less Than 400 Copies/mL at Delivery
NCT01061151 (28) [back to overview]	Postpartum Component: Proportion of Infants Alive Through 12 and 24 Months Post-delivery
NCT01061151 (28) [back to overview]	Postpartum Component: Incidence of Confirmed Infant HIV Infection
NCT01061151 (28) [back to overview]	Antepartum Component: Probability of Overall and HIV-free Infant Survival Until 104 Weeks of Age, by Antepartum Arm (in Conjunction With Infants in the Postpartum Component)
NCT01061151 (28) [back to overview]	Postpartum Component: Incidence of Grade 3 or Higher Adverse Events and Selected Grade 2 Hematologic, Renal, and Hepatic Adverse Events
NCT01063036 (11) [back to overview]	Percentage of Participants With a Virologic Response at Week 48 - Treated Population
NCT01063036 (11) [back to overview]	Change From Baseline in Mean log10 HBV DNA at Weeks 12, 24, 48, and 96 - Treated Evaluable Population
NCT01063036 (11) [back to overview]	Number of Participants on Treatment With Study Drug With Laboratory Test Abnormalities Meeting Selected Criteria on Treatment - Treated Population
NCT01063036 (11) [back to overview]	Number of Participants With Emergence of Genotypic Resistance to Study Drugs at Weeks 48 and 96- Treated Population
NCT01063036 (11) [back to overview]	Percentage of Participants With a Virologic Response at Week 24 and at Week 96 - Treated Population
NCT01063036 (11) [back to overview]	Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Seroconversion at Weeks 24, 48, and 96 - Treated Population Who Were HBsAg-Positive at Baseline
NCT01063036 (11) [back to overview]	Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Weeks 24, 48, 96 - Treated Population Who Were HBsAg-Positive at Baseline
NCT01063036 (11) [back to overview]	Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss at Weeks 24, 48, and 96 - Treated Population Who Were HBeAg Positive at Baseline
NCT01063036 (11) [back to overview]	Percentage of Participants With HBV DNA Less Than the Lower Limit of Detection (LLD) at Weeks 24, 48, and 96 - Treated Population
NCT01063036 (11) [back to overview]	Percentage of Participants With HBe Seroconversion at Weeks 24, 48, and 96 - Treated Population Who Were HBeAg-positive at Baseline
NCT01063036 (11) [back to overview]	Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) on Treatment, and Discontinuation of Study Drug Due to Adverse Events (AE) - Treated Population
NCT01140880 (4) [back to overview]	Abstinence From Stimulant Drug Use (Cocaine, Amphetamine, Methamphetamine)
NCT01140880 (4) [back to overview]	Course Completion
NCT01140880 (4) [back to overview]	Medication Adherence
NCT01140880 (4) [back to overview]	Time From Exposure to Truvada Initiation
NCT01154673 (1) [back to overview]	Change in Proviral HIV-1 DNA in Total CD4+ T-cells From Baseline to Week 48 in Participants Randomized to the Intensified Arm Versus the Control Arm Who Received Placebo in Addition to Standard HAART.
NCT01195467 (2) [back to overview]	The Rate of Neuropsychiatric and Central Nervous System (CNS) Toxicity of Raltegravir Therapy After 4 Weeks on Treatment
NCT01195467 (2) [back to overview]	The Rate of Neuropsychiatric and Central Nervous System (CNS) Toxicity of Raltegravir Therapy After 12 Weeks on Treatment
NCT01214759 (2) [back to overview]	Safety and Tolerability as Assessed by the Number of Participants Who Completed the 28-day Course of the Antiretroviral Drugs Being Explored in This Study
NCT01214759 (2) [back to overview]	Efficacy as Assessed by the Number of Participants Who Were HIV Positive at 6 Months
NCT01232127 (7) [back to overview]	Number of Participants With Abnormalities in Laboratory Test Results
NCT01232127 (7) [back to overview]	Time of Maximum Observed Plasma Concentration (Tmax) for Atazanavir and Ritonavir
NCT01232127 (7) [back to overview]	Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, AES, and AEs of Clinical Interest
NCT01232127 (7) [back to overview]	Number of Participants With Abnormalities in Vital Signs
NCT01232127 (7) [back to overview]	Number of Participants With Abnormalities in Electrocardiogram (ECG) Findings
NCT01232127 (7) [back to overview]	Maximum Observed Plasma Concentration (Cmax) and Trough Observed Plasma Concentration (Ctrough) for Atazanavir and Ritonavir
NCT01232127 (7) [back to overview]	Area Under the Plasma Concentration-time Curve in 1 Dosing Interval (Time 0 to 24 Hours Postdose) (AUC[TAU]) for Atazanavir and Ritonavir
NCT01270802 (2) [back to overview]	Change in Flow-mediated Dilation (FMD) of the Brachial Artery
NCT01270802 (2) [back to overview]	Change in Serum Levels of Vitamin D
NCT01283555 (23) [back to overview]	Number of Participants Reporting Suggestions Regarding Ease of Use or Comfort
NCT01283555 (23) [back to overview]	Number of Participants Reporting Applicator Preference (User-filled or Prefilled) Across a Variety of Factors
NCT01283555 (23) [back to overview]	Number of Participants Reporting Applicator Easy to Insert
NCT01283555 (23) [back to overview]	Number of Participants Reporting Applicator Easy to Fill
NCT01283555 (23) [back to overview]	Number of Participants Reporting That They Would Use the User-filled Applicator in the Future if it Came With a Gel for HIV Prevention
NCT01283555 (23) [back to overview]	Number of Colposcopic Findings (Baseline and After One Week of Product Use)
NCT01283555 (23) [back to overview]	Number of Respondents Reporting Confidence With Filling the User-filled Applicator
NCT01283555 (23) [back to overview]	Reasons Given by Participants for Knowing When the Applicator Was Filled Correctly
NCT01283555 (23) [back to overview]	Number of Participants Reporting That Both Applicators Were Acceptable
NCT01283555 (23) [back to overview]	Filling Precision (5% Range)
NCT01283555 (23) [back to overview]	Filling Precision (10% Range)
NCT01283555 (23) [back to overview]	Number of Participants Reporting That the Instructions for Use Were Helpful
NCT01283555 (23) [back to overview]	Filled Volume
NCT01283555 (23) [back to overview]	Dosing Volume (Expressed Volume)
NCT01283555 (23) [back to overview]	Dosing Precision, 5% (Expressed Volume)
NCT01283555 (23) [back to overview]	Dosing Precision, 10% (Expressed Volume)
NCT01283555 (23) [back to overview]	Filling Accuracy (% of Target Dose)
NCT01283555 (23) [back to overview]	Dosing Accuracy (% of Target Dose Delivered)
NCT01283555 (23) [back to overview]	Number of Participants Reporting That the Gel Was Easy to Dispense
NCT01283555 (23) [back to overview]	Number of Participants Reporting That They Would Not Want to Use the User-filled Applicator in the Future if it Came With a Gel for HIV Prevention
NCT01283555 (23) [back to overview]	Number of Participants Reporting That They Would Recommend the User-filled Applicator for HIV Prevention
NCT01283555 (23) [back to overview]	Number of Participants Reporting That the Cost of the Applicator Would Influence Their Choice of Applicator
NCT01283555 (23) [back to overview]	Number of Participants Reporting That Applicator Was Comfortable to Use
NCT01285050 (1) [back to overview]	HCV RNA
NCT01300234 (15) [back to overview]	Number of HBeAg-negative Participants Achieving HBsAg Loss and HBsAg Seroconversion at Weeks 24, 48, 96, 144, 192, 240
NCT01300234 (15) [back to overview]	Number of Participants With Histological Improvement at Weeks 48 and 240 Who Had a Baseline Knodell Necroinflammatory Score (KNS) >=2.
NCT01300234 (15) [back to overview]	Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <400 Copies/Milliliter (mL) at Week 48
NCT01300234 (15) [back to overview]	Number of Participants in the Indicated Category for Renal Laboratory Abnormalities
NCT01300234 (15) [back to overview]	Number of Participants With the Indicated Grade 3 and Grade 4 Treatment-emergent (TE) Laboratory Abnormalities (LAs)
NCT01300234 (15) [back to overview]	Participants With HBV DNA <400 Copies/mL at Weeks 96, 144, 192, and 240
NCT01300234 (15) [back to overview]	Number of Participants With Any Serious Adverse Event (SAE) and Any Non-serious Adverse Event (AE)
NCT01300234 (15) [back to overview]	Number of Participants With the Indicated Treatment-emergent Laboratory Abnormalities for Serum Creatinine and Serum Phosphorus
NCT01300234 (15) [back to overview]	Number of Participants With Virological Breakthrough at Weeks 48, 96, 144, 192 and 240
NCT01300234 (15) [back to overview]	Change From Baseline of Log 10 Copies/mL HBV DNA at Weeks 48, 96, 144, 192 and 240
NCT01300234 (15) [back to overview]	Number of Participants With Alanine Aminotransferase (ALT) Normalization at Weeks 48, 96, 144, 192 and 240 in Participants Who Had Abnormal ALT at Baseline
NCT01300234 (15) [back to overview]	Number of Participants Achieving Durable HBsAg Loss From Weeks 96 to Week 240
NCT01300234 (15) [back to overview]	Number of Participants Achieving Durable HBsAg Loss From Weeks 24 to Week 48
NCT01300234 (15) [back to overview]	Number of HBeAg-positive Participants Achieving Hepatitis B Surface Antigen (HBsAg) Loss and HBsAg Seroconversion at Weeks 24, 48, 96, 144, 192 and 240
NCT01300234 (15) [back to overview]	Number of HBeAg-positive Participants Achieving HBeAg Loss and HBeAg Seroconversion at Weeks 24, 48, 96, 144, 192 and 240.
NCT01327651 (28) [back to overview]	A Listing of Adverse Events (AEs) by Grade, Relationship to Study Product, and Arm
NCT01327651 (28) [back to overview]	Measurement of TFV-DP (Tenofovir Diphosphate) in PBMC (Peripheral Blood Mononuclear Cell)
NCT01327651 (28) [back to overview]	Proportion of Sexual Exposures Covered by Pre- and Post-exposure Dosing
NCT01327651 (28) [back to overview]	Self-reported Side Effect or Symptom Scores
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing of Adverse Events (AEs) by Grade, Relationship to Study Product, and Arm
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	The Total Pills Actually Used Over the Follow-up Period
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01327651 (28) [back to overview]	The Percentage of Correctly Timed Adherence (Number of Pills Taken Within the Recommended Time Frame/Number of Pills Recommended) During 24 Weeks of Follow-up Based on Weekly Interviews and Adjusted EDM (Electronic Drug Monitoring) Data
NCT01327651 (28) [back to overview]	The (Minimum) Total Number of Pills Needed for 100% Coverage Over the Follow-up Period (Based on Randomization Arm and Self-reported Sexual History in the Weekly Interviews)
NCT01327651 (28) [back to overview]	A Listing, by Arm, of Drug Resistance Test Results and Plasma HIV RNA Levels Among All Participants Who Seroconvert While on Study
NCT01332227 (7) [back to overview]	Mean Changes in Fasting Lipid Levels From Baseline to Week 48
NCT01332227 (7) [back to overview]	Percentage of Participants With HIV-1 RNA Level <40 c/mL at Week 24
NCT01332227 (7) [back to overview]	Percentage of Participants With HIV-1 RNA Level <40 c/mL at Week 48
NCT01332227 (7) [back to overview]	Number of Participants With Genotypable/Phenotypable Isolates, Emergent Genotypic Substitutions in Patients With Genotypable Isolates, and Phenotypic Resistance in Patients With Phenotypable Isolates at Week 48
NCT01332227 (7) [back to overview]	Number of Participants With Virologic Rebound at Weeks 24 and 48
NCT01332227 (7) [back to overview]	Number of Participants With Genotypable/Phenotypable Isolates, Emergent Genotypic Substitutions in Patients With Genotypable Isolates, and Phenotypic Resistance in Patients With Phenotypable Isolates at Week 24
NCT01332227 (7) [back to overview]	Number of Patients With Death as Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, Treatment-emergent Adverse Events (AEs) Leading to Discontinuation, and Treatment-emergent AEs
NCT01335620 (2) [back to overview]	Cerebral Function; Changes in Global Cognitive Z-score
NCT01335620 (2) [back to overview]	Drug Levels in Blood
NCT01340196 (8) [back to overview]	Steady-state Pharmacokinetics of C12hr of Faldaprevir on Day 15 and on Day 22
NCT01340196 (8) [back to overview]	Steady-state Pharmacokinetics of AUC0-24 of Tenofovir on Day 7 and on Day 15
NCT01340196 (8) [back to overview]	Steady-state Pharmacokinetics of AUC0-12 of Faldaprevir on Day 15 and on Day 22
NCT01340196 (8) [back to overview]	Number of Patients With Drug Related Adverse Events During the Trial
NCT01340196 (8) [back to overview]	Clinical Relevant Abnormalities for Physical Examination, Vital Signs, Safety Laboratory Tests and 12-lead ECG
NCT01340196 (8) [back to overview]	Steady-state Pharmacokinetics of Cmax of Faldaprevir on Day 15 and Day 22
NCT01340196 (8) [back to overview]	Steady-state Pharmacokinetics of C24hr of Tenofovir on Day 7 and on Day 15
NCT01340196 (8) [back to overview]	Steady-state Pharmacokinetics of Cmax of Tenofovir on Day 7 and on Day 15
NCT01345630 (25) [back to overview]	The Relationship Between the Proportion of Participants With Plasma HIV-1 RNA <50 Copies/mL at the Week 48 and the Screening Tropism Test (Genotype Test or ESTA).
NCT01345630 (25) [back to overview]	Number of Participants With Viral Resistance to Maraviroc (Maraviroc Treated Participants Only) in Participants Meeting PDTF Criteria.
NCT01345630 (25) [back to overview]	Change in Bone Turnover Markers From Baseline and at Week 48 - Blood Osteocalcin
NCT01345630 (25) [back to overview]	Virologic Outcomes at Week 48 Using Protocol-Defined Treatment Failure (PDTF).
NCT01345630 (25) [back to overview]	Tropism Change Between Screening or Baseline and PDTF
NCT01345630 (25) [back to overview]	Change in Bone Turnover Markers From Baseline and at Week 48 - Type 1 Collagen Peptide (CTX-1)
NCT01345630 (25) [back to overview]	Changes in Bone Mineral Density (Using DEXA Scan and Serum Markers) From Baseline and at Week 48 - AP Lumbar Spine (L1 - L4) BMD
NCT01345630 (25) [back to overview]	Changes in Bone Mineral Density (Using DEXA Scan and Serum Markers) From Baseline and at Week 48 - Femoral Neck BMD
NCT01345630 (25) [back to overview]	Severity of Abnormal Laboratory Values
NCT01345630 (25) [back to overview]	Percent Change From Baseline in Immune Cell Function at Week 48: Lymphocyte Activation Marker CD8 (%)
NCT01345630 (25) [back to overview]	Percent Change From Baseline in Immune Cell Function at Week 48: Lymphocyte Activation Marker CD4 (%)
NCT01345630 (25) [back to overview]	Number of Participants With Resistance to Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI), Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI), and Protease Inhibitors (PI) in Participants Meeting PDTF Criteria
NCT01345630 (25) [back to overview]	Number of Participants With Abnormal Laboratory Values
NCT01345630 (25) [back to overview]	Changes in Peripheral Fat Distribution Using Dual Energy X-ray Absorptiometry [DEXA] Scan From Baseline and at Week 48.
NCT01345630 (25) [back to overview]	Absolute Change in CD4+/CD8+ Ratio From Baseline to Week 48
NCT01345630 (25) [back to overview]	Absolute Change From Baseline in Immune Cell Function at Week 48: Lymphocyte Marker Cluster of Differentiation 8 (CD8, Cell/mm^3)
NCT01345630 (25) [back to overview]	Absolute Change From Baseline in Immune Cell Function at Week 48: Lymphocyte Marker Cluster of Differentiation 4 (CD4, Cell/mm^3)
NCT01345630 (25) [back to overview]	Changes in Trunk to Limb Fat Distribution Using DEXA Scan From Baseline and at Week 48
NCT01345630 (25) [back to overview]	Changes in Bone Mineral Density (Using DEXA Scan and Serum Markers) From Baseline and at Week 48 - Total Hip BMD
NCT01345630 (25) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL.
NCT01345630 (25) [back to overview]	Number of Treatment-related AEs
NCT01345630 (25) [back to overview]	Number of Participants With Treatment-emergent Serious Adverse Events
NCT01345630 (25) [back to overview]	Number of Participants With Grade 3 or 4 AEs
NCT01345630 (25) [back to overview]	Number of Participants Who Discontinued Due to AEs
NCT01345630 (25) [back to overview]	Frequency of Adverse Events (AE).
NCT01352117 (12) [back to overview]	Percentage of Participants With Etoposide Dose Modification
NCT01352117 (12) [back to overview]	Percentage of Participants With ARV Dose Modification
NCT01352117 (12) [back to overview]	Change in Peripheral Blood CD4+ Lymphocyte Cell Count
NCT01352117 (12) [back to overview]	Change in Peripheral Blood CD4+ Lymphocyte Cell Count
NCT01352117 (12) [back to overview]	Number of Participants With Grade 3 or Higher Adverse Events
NCT01352117 (12) [back to overview]	Cumulative Incidence of KS-IRIS
NCT01352117 (12) [back to overview]	Cumulative Incidence of KS Response After Initiation of Delayed Etoposide in Arm A
NCT01352117 (12) [back to overview]	Cumulative Incidence of KS Progressive Disease After Initiation of Delayed Etoposide in Arm A
NCT01352117 (12) [back to overview]	Cumulative Incidence of Initial KS Progressive Disease by Week 96
NCT01352117 (12) [back to overview]	Cumulative Incidence of Initial KS Partial or Complete Response by Week 96
NCT01352117 (12) [back to overview]	Percentage of Participants With HIV-1 RNA Suppression
NCT01352117 (12) [back to overview]	Percentage of Participants With HIV-1 RNA Suppression
NCT01352715 (9) [back to overview]	Number of Participants With a New AIDS-defining Events or Death
NCT01352715 (9) [back to overview]	Number of Participants Discontinuing Randomized Treatment for Toxicity
NCT01352715 (9) [back to overview]	Number of Participants With HIV-1 Drug Resistance Mutations in Protease, Reverse Transcriptase, and Integrase in Participants With Virologic Failure at Baseline and at Time of Virologic Failure
NCT01352715 (9) [back to overview]	Changes in Fasting Total Cholesterol, High-density Lipoprotein (HDL) Cholesterol, Low-density Lipoprotein (LDL) Cholesterol, Triglycerides, and Glucose From Baseline
NCT01352715 (9) [back to overview]	Number of Participants With Grade 3 or Higher Adverse Event (AE) at Least One Grade Higher Than Baseline
NCT01352715 (9) [back to overview]	Number of Participants With a Targeted Serious Non-AIDS-defining Event or Death
NCT01352715 (9) [back to overview]	Change in CD4+ Cell Count From Baseline to Week 48
NCT01352715 (9) [back to overview]	Cumulative Probability of Virologic Failure by Week 48
NCT01352715 (9) [back to overview]	Percentage of Time Spent in Hospital
NCT01369212 (18) [back to overview]	Number of Participants With HBV DNA<1000 IU/mL at Week 192
NCT01369212 (18) [back to overview]	Number of Participants With HBsAg Seroconversion at Week 240
NCT01369212 (18) [back to overview]	Number of Participants With HBsAg Seroconversion at Week 192
NCT01369212 (18) [back to overview]	Number of Participants With HBeAg Seroconversion at Week 240
NCT01369212 (18) [back to overview]	Number of Participants With HBeAg Seroconversion at Week 192
NCT01369212 (18) [back to overview]	Number of Participants With HBeAg Loss at Week 240
NCT01369212 (18) [back to overview]	Number of Participants With Alanine Transaminase(ALT) Levels <= 38 U/L for Males and <=25 for Females at Week 192
NCT01369212 (18) [back to overview]	Cumulative Percent of Participants With HBsAg Loss at Week 192
NCT01369212 (18) [back to overview]	Number of Participants With Adverse Events
NCT01369212 (18) [back to overview]	Cumulative Percent of Participants With HBsAg Loss at Week 240
NCT01369212 (18) [back to overview]	Number of Participants With Serious Adverse Events
NCT01369212 (18) [back to overview]	Percent of Participants With Hepatitis B Surface Antigen (HBsAg) Loss by Week 240
NCT01369212 (18) [back to overview]	Number of Participants With Normal Alanine Transaminase (ALT) Levels at Week 240
NCT01369212 (18) [back to overview]	Number of Participants With Normal Alanine Transaminase (ALT) Levels at Week 192
NCT01369212 (18) [back to overview]	Number of Participants With Hepatitis B e Antigen (HBeAg) Loss at Week 192
NCT01369212 (18) [back to overview]	Number of Participants With HBV DNA<20 IU/mL at Week 240
NCT01369212 (18) [back to overview]	Number of Participants With HBV DNA<20 IU/mL at Week 192
NCT01369212 (18) [back to overview]	Number of Participants With HBV DNA<1000 IU/mL at Week 240
NCT01379508 (4) [back to overview]	eGFR Change From Baseline in Telbivudine Arm vs Tenofovir Arm Over the Course of the Study
NCT01379508 (4) [back to overview]	Percentage of Participants Achieving HBV DNA < 300 Copies/mL (51 IU/mL) at Week 52 (rITT Population) -
NCT01379508 (4) [back to overview]	Percentage of Participants Achieving Secondary Efficacy Endpoints at Week 156 (mITT)
NCT01379508 (4) [back to overview]	Percentage of Patients Achieving Secondary Efficacy Endpoints (rITT)
NCT01384734 (17) [back to overview]	Change From Monotherapy Baseline in Cluster of Differentiation (CD)4+ and CD8+ T-cell Counts During Monotherapy
NCT01384734 (17) [back to overview]	Change From Monotherapy Baseline in log10 HIV RNA of the Monotherapy Period
NCT01384734 (17) [back to overview]	Number of Participants With Newly-emergent Genotypic Substitutions at Week 24
NCT01384734 (17) [back to overview]	Number of Participants With Newly-emergent Genotypic Substitutions at Week 96
NCT01384734 (17) [back to overview]	Number of Participants With SAE and Discontinuation Due to AEs During Monotherapy Period
NCT01384734 (17) [back to overview]	Number of Participants With SAE and Discontinuation Due to AEs During Primary Study
NCT01384734 (17) [back to overview]	Number of Participants With Serious Adverse Events (SAE) and Discontinuation Due to AEs up to Week 24
NCT01384734 (17) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Primary Study
NCT01384734 (17) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Day 8 of the Monotherapy Period
NCT01384734 (17) [back to overview]	Number of Participants With Newly-emergent Genotypic Substitutions at Week 48
NCT01384734 (17) [back to overview]	Change From Baseline in IC50 Fold Change Among Participants With VF at Week 48
NCT01384734 (17) [back to overview]	Change From Baseline in IC50 Fold Change Among Participants With VF at Week 96
NCT01384734 (17) [back to overview]	Maximum Change From Baseline in Inhibitory Concentration at 50% (IC50) Fold Change Among Participants With VF at Week 24
NCT01384734 (17) [back to overview]	Maximum Decrease From Monotherapy Baseline in log10 Plasma HIV-1 RNA
NCT01384734 (17) [back to overview]	Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) < 50 Copies Per Milliliter (c/mL) at Week 24
NCT01384734 (17) [back to overview]	Change From Baseline in CD4+ T-cell Count
NCT01384734 (17) [back to overview]	Change From Monotherapy Baseline in CD4+ and CD8+ T-cell Proportion During Monotherapy
NCT01387022 (4) [back to overview]	Change in CD4+ Cell Count From Randomisation to 12 Months Post-randomisation
NCT01387022 (4) [back to overview]	Reported Adverse Events With Severity Grades 3 and 4 Based on the DAIDS Toxicity Grading Tables
NCT01387022 (4) [back to overview]	Tenofovir Resistance, Defined as Presence of K65R, K70E or Any of the TAMS Mutations
NCT01387022 (4) [back to overview]	The Antiretroviral Treatment Failure Rate at 12 Months.
NCT01400412 (20) [back to overview]	Percentage Change in Expression of CD38+/HLA-DR+ on CD8+ T Cells From Baseline to Week 48
NCT01400412 (20) [back to overview]	Percentage Change in Expression of CD38+/HLA-DR+ on CD4+ T Cells From Baseline to Week 48
NCT01400412 (20) [back to overview]	Percent Change in Lumbar Spine Bone Mineral Density (BMD)
NCT01400412 (20) [back to overview]	Percent Change in Expression of RANKL+ on CD8+ T Cells From Baseline to Week 48
NCT01400412 (20) [back to overview]	Percent Change in Expression of CD57+ on CD8+ T Cells From Baseline to Week 48
NCT01400412 (20) [back to overview]	Percent Change in Expression of CD28+ on CD8+ T Cells From Baseline to Week 48
NCT01400412 (20) [back to overview]	Percent Change From Baseline in Total Hip Bone Mineral Density (BMD)
NCT01400412 (20) [back to overview]	Number of Participants Who Died During the Study
NCT01400412 (20) [back to overview]	Number of Participants Who Developed Grade 3 or 4 Primary Adverse Events
NCT01400412 (20) [back to overview]	Change in CD4 Count From Baseline to Week 24
NCT01400412 (20) [back to overview]	Percent Change in Expression of CD28+/CD57+ on CD8+ T Cells From Baseline to Week 48
NCT01400412 (20) [back to overview]	CD8+ T-cell Change From Baseline to Week 48
NCT01400412 (20) [back to overview]	Change in Level of IP-10 From Baseline to Week 48
NCT01400412 (20) [back to overview]	Change in Levels of D-dimer From Baseline
NCT01400412 (20) [back to overview]	Change in Levels of IL-6 From Baseline to Week 48
NCT01400412 (20) [back to overview]	Change in Levels of sCD14 From Baseline
NCT01400412 (20) [back to overview]	Number of Participants Who Experienced Bone Fractures
NCT01400412 (20) [back to overview]	Change in Levels of sCD163 From Baseline to Week 48
NCT01400412 (20) [back to overview]	Cumulative Probability of Virologic Failure by Week 48
NCT01400412 (20) [back to overview]	Change in CD4 Count From Baseline to Week 48
NCT01435018 (37) [back to overview]	Self-reported Adherence to ART Therapy
NCT01435018 (37) [back to overview]	Number of Participants With Treatment-related Toxicities and Adverse Events (AEs)
NCT01435018 (37) [back to overview]	Number of Participants With Symptomatic Peripheral Neuropathy (SPN)
NCT01435018 (37) [back to overview]	Number of Participants With Peripheral Neuropathy (PN)
NCT01435018 (37) [back to overview]	Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 4
NCT01435018 (37) [back to overview]	Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 3
NCT01435018 (37) [back to overview]	Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 2
NCT01435018 (37) [back to overview]	Changes in CD4+ Lymphocyte Cell Count for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Changes in CD4+ Lymphocyte Cell Count for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Time to IERC-confirmed KS Progression or Death for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Time to IERC-confirmed KS Progression or Death for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Number of Participants With Objective Response for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Number of Participants With Objective Response for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Number of Participants With Kaposi's Sarcoma-Immune Reconstitution Inflammatory Syndrome (KS-IRIS) for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Number of Participants With Kaposi's Sarcoma-Immune Reconstitution Inflammatory Syndrome (KS-IRIS) for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Duration of Objective Response for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Duration of Objective Response for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of Progression-Free Survival by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of Progression-Free Survival by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of KS Progression, Death, or AIDS Defining Event by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of KS Progression, Death, or AIDS Defining Event by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of KS Progression, Death, AIDS Defining Event, Virologic Failure, or KS-IRIS by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of KS Progression, Death, AIDS Defining Event, Virologic Failure, or KS-IRIS by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of KS Progression, Death, AIDS Defining Event, or Virologic Failure by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of KS Progression, Death, AIDS Defining Event, or Virologic Failure by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of IERC-confirmed KS Progression by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of IERC-confirmed KS Progression by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of HIV-1 RNA Virologic Failure by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of Death for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of Death for BV+ART vs PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of Death by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of Death by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of Change in KS Treatment by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of Change in KS Treatment by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of AIDS-defining Event by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of AIDS-defining Event by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]	Cumulative Rate of HIV-1 RNA Virologic Failure by Week 48 for BV+ART vs. PTX+ART
NCT01448616 (4) [back to overview]	HSV Shedding Rate in Those Receiving Oral TDF, Vaginal TFV, or Double Placebo
NCT01448616 (4) [back to overview]	Within-person Changes in Log-copy Numbers of HSV
NCT01448616 (4) [back to overview]	Genital Lesion Rate
NCT01448616 (4) [back to overview]	Asymptomatic Shedding (Shedding on Days Without Genital Lesions)
NCT01450189 (30) [back to overview]	Cumulative Incidence Herpes Simplex Virus Type 2
NCT01450189 (30) [back to overview]	Number of Adverse Events
NCT01450189 (30) [back to overview]	Unprotected Sex Acts in Previous One Week - 52 Weeks
NCT01450189 (30) [back to overview]	Number of Partners Reporting for HIV Testing
NCT01450189 (30) [back to overview]	Proportion of Participants Completing Full Course of ARVs in Arm BIA
NCT01450189 (30) [back to overview]	Proportion of Participants in Arm BI and BIA (Combined) Who Complete the 4 Behavioral Sessions Within 3 Weeks of Enrollment.
NCT01450189 (30) [back to overview]	Proportion of Partners Reporting for HIV Testing
NCT01450189 (30) [back to overview]	Proportion of Persons Agreeing to be Screened for Acute HIV Infection Among Those Offered Screening
NCT01450189 (30) [back to overview]	Proportion of Persons Completing All Scheduled Visits in Each Study Arm
NCT01450189 (30) [back to overview]	Prevalence of AHI Among Persons Screened
NCT01450189 (30) [back to overview]	Genital HIV RNA Concentration - Week 26, Women
NCT01450189 (30) [back to overview]	Proportion of Persons With AHI Successfully Recruited Into the Study
NCT01450189 (30) [back to overview]	Suppression of HIV RNA to <1000c/ml at 12 Weeks
NCT01450189 (30) [back to overview]	Genital HIV RNA Concentration - Week 52, Women
NCT01450189 (30) [back to overview]	Genital HIV RNA Concentration - Week 52, Men
NCT01450189 (30) [back to overview]	Genital HIV RNA Concentration - Week 26, Men
NCT01450189 (30) [back to overview]	Genital HIV RNA Concentration - Week 12, Women
NCT01450189 (30) [back to overview]	Genital HIV RNA Concentration - Week 12, Men
NCT01450189 (30) [back to overview]	Cumulative Incidence of Gonorrhea, Chlamydial Infection and Trichomoniasis (Composite)
NCT01450189 (30) [back to overview]	Cumulative Incidence of Gonorrhea, Chlamydial Infection and Trichomoniasis (Composite)
NCT01450189 (30) [back to overview]	Unprotected Sex Acts in Previous One Month - 52 Weeks
NCT01450189 (30) [back to overview]	Cumulative Incidence Herpes Simplex Virus Type 2
NCT01450189 (30) [back to overview]	Blood HIV RNA Concentration at Week 52
NCT01450189 (30) [back to overview]	Blood HIV RNA Concentration at Week 26
NCT01450189 (30) [back to overview]	Blood HIV RNA Concentration at Week 12
NCT01450189 (30) [back to overview]	Time to HIV RNA Suppression <1000 c/ml
NCT01450189 (30) [back to overview]	Unprotected Sex Acts in Previous One Month - 12 Weeks
NCT01450189 (30) [back to overview]	Unprotected Sex Acts in Previous One Month - 26 Weeks
NCT01450189 (30) [back to overview]	Unprotected Sex Acts in Previous One Week - 12 Weeks
NCT01450189 (30) [back to overview]	Unprotected Sex Acts in Previous One Week - 26 Weeks
NCT01505114 (1) [back to overview]	Occurrence of Grade 3 or Higher Adverse Events (AEs)
NCT01525628 (24) [back to overview]	AUC 0-6hr of Deleobuvir Metabolite Acyl-glucuronide (BI 208333)
NCT01525628 (24) [back to overview]	AUC 0-6hr of Deleobuvir Reduction Metabolite CD 6168
NCT01525628 (24) [back to overview]	Cmax of Deleobuvir (BI 207127)
NCT01525628 (24) [back to overview]	Cmax of 1-OH-Midazolam (1-hydroxy-midazolam)
NCT01525628 (24) [back to overview]	AUC 0-6hr of Deleobuvir Metabolite CD 6168 ag (Acylglucuronide)
NCT01525628 (24) [back to overview]	Cmax of Tolbutamide
NCT01525628 (24) [back to overview]	Cmax of Midazolam
NCT01525628 (24) [back to overview]	Cmax of Faldaprevir (BI 201335)
NCT01525628 (24) [back to overview]	Cmax of Deleobuvir Reduction Metabolite CD 6168
NCT01525628 (24) [back to overview]	Cmax of Deleobuvir Metabolite CD 6168 ag (Acylglucuronide)
NCT01525628 (24) [back to overview]	Cmax of Deleobuvir Metabolite Acyl-glucuronide (BI 208333)
NCT01525628 (24) [back to overview]	C6hr of Deleobuvir Metabolite Acyl-glucuronide (BI 208333)
NCT01525628 (24) [back to overview]	C6hr of Deleobuvir Metabolite CD 6168 ag (Acylglucuronide)
NCT01525628 (24) [back to overview]	C6hr of Deleobuvir Reduction Metabolite CD 6168
NCT01525628 (24) [back to overview]	Cmax of Caffeine
NCT01525628 (24) [back to overview]	C6hr of Deleobuvir (BI 207127)
NCT01525628 (24) [back to overview]	C24hr of Faldaprevir (BI 201335)
NCT01525628 (24) [back to overview]	AUC 0-infinity of Tolbutamide
NCT01525628 (24) [back to overview]	AUC 0-infinity of Midazolam
NCT01525628 (24) [back to overview]	AUC 0-infinity of Caffeine
NCT01525628 (24) [back to overview]	AUC 0-infinity of 1-OH-Midazolam (1-hydroxy-midazolam)
NCT01525628 (24) [back to overview]	AUC 0-6hr of Deleobuvir (BI 207127)
NCT01525628 (24) [back to overview]	Area Under the Concentration-time Curve (AUC) of Faldaprevir (BI 201335) From 0 to 24 Hours
NCT01525628 (24) [back to overview]	Number of Participants With Sustained Virological Response (SVR12)
NCT01605890 (12) [back to overview]	Number of Participants With Treatment Switch or Discontinuation
NCT01605890 (12) [back to overview]	Number of Participants With >6 Copies of HIV-2 DNA in Plasma at Week 48
NCT01605890 (12) [back to overview]	Median Change of CD4 Lymphocytes at Week 48
NCT01605890 (12) [back to overview]	Percentage of Participants in Therapeutic Success
NCT01605890 (12) [back to overview]	Number of Participants With >6 Copies of HIV-2 DNA in Plasma at Week 24
NCT01605890 (12) [back to overview]	Number of Clinical and Biological Events
NCT01605890 (12) [back to overview]	Median Change in CD4 Lymphocytes Count at Week 12
NCT01605890 (12) [back to overview]	Number of Participants With Clinical Progression
NCT01605890 (12) [back to overview]	Percentage of Patients With Plasma HIV-2 RNA < 40 Copies/mL
NCT01605890 (12) [back to overview]	Number of Virological Failure Participants With Resistance Mutations
NCT01605890 (12) [back to overview]	Minimal Median of the Lower Dimension Out of the 4 Dimensions of the Quality of Life Questionnaire
NCT01605890 (12) [back to overview]	Minimal Observed Percentage of Participants With Moderate to Good Adherence Evaluated With ANRS Self-administered Questionnaire of Adherence
NCT01632891 (7) [back to overview]	Change in log10(Pf Gametocyte Density) From Entry to Day 30
NCT01632891 (7) [back to overview]	Number of Participants With Detectable Pf Gametocyte Density
NCT01632891 (7) [back to overview]	Proportion of Participants With Plasmodium Falciparum (Pf) Subclinical Parasitemia (SCP) Clearance
NCT01632891 (7) [back to overview]	Change in log10(Pf Parasite Density) From Entry to Day 30
NCT01632891 (7) [back to overview]	Number of Participants With Uncomplicated Clinical Malaria
NCT01632891 (7) [back to overview]	Time to First Pf SCP Clearance
NCT01632891 (7) [back to overview]	Log10(Pf Parasite Density)
NCT01641367 (60) [back to overview]	Change From Baseline in Fasting Values of Total Cholesterol
NCT01641367 (60) [back to overview]	Change From Baseline in Fasting Values of High-density Lipoprotein Cholesterol [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Change From Baseline in Fasting Values of High-density Lipoprotein Cholesterol
NCT01641367 (60) [back to overview]	Change From Baseline in Fasting Values of Glucose [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Change From Baseline in Fasting Values of Glucose
NCT01641367 (60) [back to overview]	Change From Baseline in Fasting Values of Calculated Low-density Lipoprotein Cholesterol [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Change From Baseline in Fasting Values of Calculated Low-density Lipoprotein Cholesterol
NCT01641367 (60) [back to overview]	Change From Baseline in CD4+ T-cell Count [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Change From Baseline in CD4+ T-cell Count
NCT01641367 (60) [back to overview]	Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 72 Weeks [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 72 Weeks
NCT01641367 (60) [back to overview]	Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 48 Weeks [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Number of Participants With Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study
NCT01641367 (60) [back to overview]	Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 48 Weeks
NCT01641367 (60) [back to overview]	Time to First Dose Modification Due to Grade 3 or 4 Toxicity
NCT01641367 (60) [back to overview]	Time to Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study, With a New Resistance-associated Mutation Detected in Population-based Sequencing [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Time to Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study, With a New Resistance-associated Mutation Detected in Population-based Sequencing
NCT01641367 (60) [back to overview]	Time to Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Time to Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study
NCT01641367 (60) [back to overview]	Time From Study Entry/Randomization to Treatment Modification or Discontinuation.
NCT01641367 (60) [back to overview]	Time From Study Entry/Randomization to Treatment Modification or Discontinuation Due to Toxicity [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Time From Study Entry/Randomization to Treatment Modification or Discontinuation [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Time From Study Entry/Randomization to the First of Death, an AIDS-defining Event or a Non-AIDS-defining Event [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Time From Study Entry/Randomization to the First of Death, an AIDS-defining Event or a Non-AIDS-defining Event
NCT01641367 (60) [back to overview]	Time From Study Entry/Randomization to the First of Death or Hospitalization.
NCT01641367 (60) [back to overview]	Number of Weeks of Follow-up [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Number of Weeks of Follow-up
NCT01641367 (60) [back to overview]	Number of Participants With Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study, With a New Resistance-associated Mutation Detected in Population-based Sequencing [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Number of Participants With Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study, With a New Resistance-associated Mutation Detected in Population-based Sequencing
NCT01641367 (60) [back to overview]	Number of Participants With Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Percent of Participants With Confirmed Virologic Failure by Week 48 [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Percent of Participants With Confirmed Virologic Failure by Week 48
NCT01641367 (60) [back to overview]	Percent of Participants With a Dose Modification Due to Grade 3 or 4 Toxicity by Week 48 [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Percent of Participants With a Dose Modification Due to Grade 3 or 4 Toxicity by Week 48
NCT01641367 (60) [back to overview]	Percent of Participants That Developed Immune Reconstitution Inflammatory Syndrome (IRIS) by Week 48 [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 24 Weeks [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Percent of Participants With Treatment Modification or Discontinuation Due to Toxicity by Week 48
NCT01641367 (60) [back to overview]	Time From Study Entry/Randomization to Treatment Modification or Discontinuation Due to Toxicity
NCT01641367 (60) [back to overview]	Percent of Participants With Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study, With a New Resistance-associated Mutation Detected in Population-based Sequencing, by Week 48 [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Percent of Participants With Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study, With a New Resistance-associated Mutation Detected in Population-based Sequencing, by Week 48
NCT01641367 (60) [back to overview]	Percent of Participants With Death or Hospitalization by Week 48
NCT01641367 (60) [back to overview]	Percent of Participants With Death or Hospitalization by Week 48 [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Percent of Participants With Treatment Modification or Discontinuation by Week 48
NCT01641367 (60) [back to overview]	Percent of Participants With Treatment Modification or Discontinuation by Week 48 [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Percent of Participants With Treatment Modification or Discontinuation Due to Toxicity by Week 48 [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Time to First Dose Modification Due to Grade 3 or 4 Toxicity [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 24 Weeks
NCT01641367 (60) [back to overview]	Change From Baseline in Fasting Values of Total Cholesterol [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Change From Baseline in Fasting Values of Triglycerides
NCT01641367 (60) [back to overview]	Change From Baseline in Fasting Values of Triglycerides [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Time From Study Entry/Randomization to Death
NCT01641367 (60) [back to overview]	Time From Study Entry/Randomization to Death [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Time From Study Entry/Randomization to the Development of Immune Reconstitution Inflammatory Syndrome (IRIS)
NCT01641367 (60) [back to overview]	Time From Study Entry/Randomization to the Development of Immune Reconstitution Inflammatory Syndrome (IRIS) [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Time From Study Entry/Randomization to the First of Death or Hospitalization [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Percent of Participants That Developed Immune Reconstitution Inflammatory Syndrome (IRIS) by Week 48
NCT01641367 (60) [back to overview]	Percent of Participants Experiencing Death, AIDS-defining Event or a Non-AIDS-defining Event by Week 48 [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Percent of Participants Experiencing Death, AIDS-defining Event or a Non-AIDS-defining Event by Week 48
NCT01641367 (60) [back to overview]	Percent of Participants Experiencing Death by Week 48 [CPI+SOC v SOC]
NCT01641367 (60) [back to overview]	Percent of Participants Experiencing Death by Week 48
NCT01641809 (57) [back to overview]	Change From Baseline in Estimated Creatinine Clearance Over Time by Visit
NCT01641809 (57) [back to overview]	Absolute Values for Cluster of Differentiation 4+ (CD4+) Cell Count During Double-blind Randomized Treatment Until Week 96
NCT01641809 (57) [back to overview]	Absolute Values for ALT, AST, CK During Double-blind Randomized Treatment Until Week 96
NCT01641809 (57) [back to overview]	Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/Milliliter (mL) at Week 48 Using the Missing, Switch, Discontinuation Equals Failure (MSDF) Algorithm
NCT01641809 (57) [back to overview]	Percentage of Participants Who Discontinued Treatment Due to Adverse Events-Maintenance Phase
NCT01641809 (57) [back to overview]	Percentage of Participants Who Discontinued Treatment Due to Adverse Events-Induction Phase
NCT01641809 (57) [back to overview]	Percentage of Participants Who Discontinued Investigational Product Due to Adverse Events
NCT01641809 (57) [back to overview]	Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings
NCT01641809 (57) [back to overview]	Percentage of Participants With HIV-1 RNA <50 Copies/mL From Week 24 Through Week 96 by Visit Using MSDF Algorithm-Maintenance Phase
NCT01641809 (57) [back to overview]	Concentration at the End of a Dosing Interval (Ctau) for GSK1265744 at Week 2
NCT01641809 (57) [back to overview]	Area Under the Concentration Time Curve Over the Dosing Interval (AUC[0-tau]) for GSK1265744 at Week 2
NCT01641809 (57) [back to overview]	Absolute Values for Plasma Logarithm to the Base 10 (log10) HIV-1 RNA Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in Estimated Creatinine Clearance Over Time by Visit
NCT01641809 (57) [back to overview]	Number of Participants With AEs and SAEs Over Time
NCT01641809 (57) [back to overview]	Number of Participants With AEs and SAEs-Induction Phase
NCT01641809 (57) [back to overview]	Number of Participants With Maximum Treatment-emergent Clinical Chemistry Toxicities Over Time
NCT01641809 (57) [back to overview]	Number of Participants With Maximum Treatment-emergent Clinical Chemistry Toxicities-Maintenance Phase
NCT01641809 (57) [back to overview]	Change From Baseline in Estimated Creatinine Clearance Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in Estimated Creatinine Clearance Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in Creatinine and Total Bilirubin Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in Creatinine and Total Bilirubin Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in CD4+ Cell Count Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in CD4+ Cell Count Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in ALT, AST and CK Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in ALT, AST and CK Over Time by Visit
NCT01641809 (57) [back to overview]	Number of Participants With Maximum Treatment-emergent Clinical Chemistry Toxicity-Induction Phase
NCT01641809 (57) [back to overview]	Absolute Values for Platelet Count, Total Neutrophils and WBC Count During Double-blind Randomized Treatment Until Week 96
NCT01641809 (57) [back to overview]	Number of Participants With Maximum Treatment-emergent Hematology Toxicities Over Time
NCT01641809 (57) [back to overview]	Number of Participants With Maximum Treatment-emergent Hematology Toxicities-Induction Phase
NCT01641809 (57) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL Over Time by Visit Using Observed Case Analysis
NCT01641809 (57) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL Over Time by Visit Using Observed Case Analysis
NCT01641809 (57) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL Over Time by Visit Using the MSDF Algorithm
NCT01641809 (57) [back to overview]	Number of Participants With Maximum Treatment-emergent Hematology Toxicities-Maintenance Phase
NCT01641809 (57) [back to overview]	Number of Participants With Post-Baseline HIV-1 Associated Conditions Progression of Disease
NCT01641809 (57) [back to overview]	Number of Participants With Treatment Emergent Genotypic Mutations Associated With Development of Resistance
NCT01641809 (57) [back to overview]	Number of Participants With Treatment Emergent Phenotypic Resistance
NCT01641809 (57) [back to overview]	Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 16 and Week 24 Using MSDF Algorithm-Induction Phase
NCT01641809 (57) [back to overview]	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Maintenance Phase
NCT01641809 (57) [back to overview]	Number of Participants With Adherence to Study Treatment
NCT01641809 (57) [back to overview]	Absolute Values for Plasma Logarithm to the Base 10 (log10) HIV-1 RNA Over Time by Visit
NCT01641809 (57) [back to overview]	Absolute Values for Hemoglobin During Double-blind Randomized Treatment Until Week 96
NCT01641809 (57) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <400 Copies/mL Until Week 96 Using the MSDF Algorithm
NCT01641809 (57) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <400 Copies/mL Until Week 96 Using the Observed Case Analysis
NCT01641809 (57) [back to overview]	Absolute Values for Estimated Creatinine Clearance During Double-blind Randomized Treatment Until Week 96
NCT01641809 (57) [back to overview]	Absolute Values for Estimated Creatinine Clearance During Double-blind Randomized Treatment Until Week 96
NCT01641809 (57) [back to overview]	Absolute Values for Estimated Creatinine Clearance During Double-blind Randomized Treatment Until Week 96
NCT01641809 (57) [back to overview]	Absolute Values for Estimated Creatinine Clearance During Double-blind Randomized Treatment Until Week 96
NCT01641809 (57) [back to overview]	Absolute Values for Creatinine and Total Bilirubin During Double-blind Randomized Treatment Until Week 96
NCT01641809 (57) [back to overview]	Number of Participants With Adherence to Study Treatment
NCT01641809 (57) [back to overview]	Number of Participants With Adherence to Study Treatment
NCT01641809 (57) [back to overview]	Change From Baseline in Total Neutrophils, Platelet Count and WBC Count Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in Total Neutrophils, Platelet Count and WBC Count Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in Plasma log10 HIV-1 RNA Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in Plasma log10 HIV-1 RNA Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in Hemoglobin Level Over Time by Visit
NCT01641809 (57) [back to overview]	Change From Baseline in Hemoglobin Level Over Time by Visit
NCT01641809 (57) [back to overview]	Maximum Observed Concentration (Cmax) for GSK1265744 at Week 2
NCT01651403 (29) [back to overview]	Number of Participants With Sequence Changes From Baseline Within the HBV Polymerase for Participants Who Were Viremic (HBV DNA ≥ 400 Copies/mL [69 IU/mL]) Including Participants With Confirmed Virologic Breakthrough at Week 48
NCT01651403 (29) [back to overview]	Number of Participants With Sequence Changes From Baseline Within the HBV Polymerase for Participants Who Were Viremic (HBV DNA ≥ 400 Copies/mL [69 IU/mL]) Including Participants With Confirmed Virologic Breakthrough at Week 96
NCT01651403 (29) [back to overview]	Percent Change From Baseline in BMD of Spine at Week 192
NCT01651403 (29) [back to overview]	Percent Change From Baseline in BMD of Spine at Week 48
NCT01651403 (29) [back to overview]	Percentage of Participants With ≥ 4% Decrease From Baseline in Spine BMD at Week 192
NCT01651403 (29) [back to overview]	Percentage of Participants With ≥ 4% Decrease From Baseline in Spine Bone Mineral Density (BMD) at Week 48
NCT01651403 (29) [back to overview]	Percentage of Participants With HBsAg Loss at Week 192
NCT01651403 (29) [back to overview]	Percentage of Participants With HBsAg Loss at Week 48
NCT01651403 (29) [back to overview]	Percentage of Participants With HBsAg Seroconversion at Week 192
NCT01651403 (29) [back to overview]	Percentage of Participants With HBsAg Seroconversion at Week 48
NCT01651403 (29) [back to overview]	Percentage of Participants With HBV DNA < 169 Copies/mL (29 IU/mL) at Week 48
NCT01651403 (29) [back to overview]	Percentage of Participants With Hepatitis B e Antigen (HBeAg) Seroconversion at Week 48
NCT01651403 (29) [back to overview]	Percentage of Participants With Normal Alanine Aminotransferase (ALT) at Week 48, Based on the American Association for the Study of Liver Diseases (AASLD) Normal Range
NCT01651403 (29) [back to overview]	Percentage of Participants With Normal ALT at Week 192, Based on the AASLD Normal Range
NCT01651403 (29) [back to overview]	Percentage of Participants With Normal ALT at Week 192, Based on the Central Lab Normal Range
NCT01651403 (29) [back to overview]	Percentage of Participants With Normal ALT at Week 48, Based on the Central Lab Normal Range
NCT01651403 (29) [back to overview]	Percentage of Participants With Normalized ALT at Week 192, Based on the AASLD Normal Range
NCT01651403 (29) [back to overview]	Percentage of Participants With Normalized ALT at Week 192, Based on the Central Lab Normal Range
NCT01651403 (29) [back to overview]	Percentage of Participants With Normalized ALT at Week 48, Based on the AASLD Normal Range
NCT01651403 (29) [back to overview]	Percentage of Participants With Normalized ALT at Week 48, Based on the Central Lab Normal Range
NCT01651403 (29) [back to overview]	Percentage of Participants With Serum HBV DNA < 400 Copies/mL (69 IU/mL) at Week 48 (Missing = Excluded Approach)
NCT01651403 (29) [back to overview]	Percentage of Participants With Serum HBV DNA < 400 Copies/mL (69 IU/mL) at Week 48 (Missing = Failure Approach)
NCT01651403 (29) [back to overview]	Percentage of Participants With HBV DNA < 169 Copies/mL (29 IU/mL) at Week 192
NCT01651403 (29) [back to overview]	Composite Endpoint of Percentage of Participants With HBV DNA < 400 Copies/mL (69 IU/mL) and Normalized ALT (Based on AASLD Normal Range) at Week 192
NCT01651403 (29) [back to overview]	Composite Endpoint of Percentage of Participants With HBV DNA < 400 Copies/mL (69 IU/mL) and Normalized ALT (Based on AASLD Normal Range) at Week 48
NCT01651403 (29) [back to overview]	Composite Endpoint of Percentage of Participants With HBV DNA < 400 Copies/mL (69 IU/mL) and Normalized ALT (Based on Central Lab Normal Range) at Week 192
NCT01651403 (29) [back to overview]	Composite Endpoint of Percentage of Participants With HBV DNA < 400 Copies/mL (69 IU/mL) and Normalized ALT (Based on Central Lab Normal Range) at Week 48
NCT01651403 (29) [back to overview]	Number of Participants With Sequence Changes From Baseline Within the HBV Polymerase for Participants Who Were Viremic (HBV DNA ≥ 400 Copies/mL [69 IU/mL]) Including Participants With Confirmed Virologic Breakthrough at Week 144
NCT01651403 (29) [back to overview]	Number of Participants With Sequence Changes From Baseline Within the HBV Polymerase for Participants Who Were Viremic (HBV DNA ≥ 400 Copies/mL [69 IU/mL]) Including Participants With Confirmed Virologic Breakthrough at Week 192
NCT01687218 (12) [back to overview]	Pharmacokinetics: End Period Emtricitabine (FTC) Concentrations (log10 ng/mg) in Rectal Tissue
NCT01687218 (12) [back to overview]	Pharmacokinetics: End Period Tenofovir (TFV) Concentrations (log10 ng/mg) in Rectal Tissue
NCT01687218 (12) [back to overview]	Pharmacokinetics: End Period Tenofovir-Diphosphate (TFV-DP) Concentrations (log10 ng/mg) in Rectal Tissue
NCT01687218 (12) [back to overview]	Safety: Grade 2 or Higher Adverse Events
NCT01687218 (12) [back to overview]	Acceptability: Participant Self-report of Ease of Use. I1-Overall How Easy or Difficult Was it to Use the Product?
NCT01687218 (12) [back to overview]	Acceptability: Participant Self-report of Likelihood of Product Use if Shown to be Effective. N1-If This Product Provides Some Protection How Likely Would You be to Take it?
NCT01687218 (12) [back to overview]	Acceptability: Participant Self-report of Liking the Product. H1-Overall How do You Feel About the Product You Used Recently?
NCT01687218 (12) [back to overview]	Adherence: Percentage of Prescribed Doses Taken Orally or Administered Rectally in an 8-week Period
NCT01687218 (12) [back to overview]	Pharmacokinetics: Emtricitabine (FTC) Concentrations (log10 ng/mg) in Rectal Sponge
NCT01687218 (12) [back to overview]	Pharmacokinetics: Emtricitabine (FTC) Concentrations (log10 ng/mL) in Blood Plasma
NCT01687218 (12) [back to overview]	Pharmacokinetics: Tenofovir (TFV) Concentrations (log10 ng/mg) in Rectal Sponge
NCT01687218 (12) [back to overview]	Pharmacokinetics: Tenofovir (TFV) Concentrations (log10 ng/mL) in Blood Plasma
NCT01691768 (8) [back to overview]	Human Papillomavirus Incidence Rates
NCT01691768 (8) [back to overview]	Percentage of Participants With Detectable Tenofovir Levels From Vaginal Samples at 12 Months of Follow-up
NCT01691768 (8) [back to overview]	Mean Number of Returned Used Applicators Per Month (i.e in 30 Days)
NCT01691768 (8) [back to overview]	Pregnancy Incidence Rates
NCT01691768 (8) [back to overview]	Percentage of Participants Achieving Adherence >80%.
NCT01691768 (8) [back to overview]	Product Acceptability
NCT01691768 (8) [back to overview]	HIV Viral Load Among HIV Seroconverters
NCT01691768 (8) [back to overview]	HIV Incidence Rates
NCT01709084 (6) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA Levels < 50 Copies/mL at Week 48
NCT01709084 (6) [back to overview]	Percentage of Participant With Treatment Adherence Based on Tablet Count
NCT01709084 (6) [back to overview]	Number of Participants With Treatment-Emergent Nucleoside Reverse Transcriptase Inhibitor (N[t]RTI) or Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (NNRTI) Mutations
NCT01709084 (6) [back to overview]	Percentage of Participants With Plasma Human Immunodeficiency Virus - Type 1 Ribonucleic Acid (HIV-1 RNA) Levels Less Than (<) 400 Copies Per Milliliter (Copies/mL) at Week 48
NCT01709084 (6) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA Levels More Than or Equal to (>=) 400 Copies/mL at Week 48 Based on Time to Loss of Virologic Response (TLOVR) [Non-virologic Failure Censored] Imputation Method.
NCT01709084 (6) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA Levels >= 50 Copies Per Milliliter (Copies/mL) at Week 48 Based on Time to Loss of Virologic Response (TLOVR) [Non-virologic Failure Censored] Imputation Method.
NCT01745822 (5) [back to overview]	Percentage of Infants With Hepatitis B Infection at or After 6 Months Through 12 Months of Age
NCT01745822 (5) [back to overview]	Percentage of Participants With Flares After Study Treatment Interruption
NCT01745822 (5) [back to overview]	Percentage of Participants With Adverse Events
NCT01745822 (5) [back to overview]	Weight, Height and Head Circumference for Age
NCT01745822 (5) [back to overview]	Percentage of Infants With Hepatitis B Infection at 6 Months of Age
NCT01769456 (12) [back to overview]	Total Hip Bone Mineral Density: Percent Change From Baseline to Week 48
NCT01769456 (12) [back to overview]	Number of Participants Using Text Messaging Reminders
NCT01769456 (12) [back to overview]	Number of Participants With Decrease in Bone Mineral Density
NCT01769456 (12) [back to overview]	Acceptability of PrEP Regimen and Study Visits
NCT01769456 (12) [back to overview]	Behavioral Disinhibition/Risk Compensation: Number of Participants Reporting Unprotected Sex
NCT01769456 (12) [back to overview]	Femoral Neck Bone Mineral Density: Percent Change From Baseline to Week 48
NCT01769456 (12) [back to overview]	Estimation of Medication Adherence by Dried Blood Spot (DBS) Results
NCT01769456 (12) [back to overview]	Rating of the Reasons for Missing Medications on a 4-point Likert Scale.
NCT01769456 (12) [back to overview]	Number of Participants With Serum Creatinine Event of Grade 1 or Higher Over the Course of the Study
NCT01769456 (12) [back to overview]	Lumbar Spine Bone Mineral Density: Percent Change From Baseline to Week 48
NCT01769456 (12) [back to overview]	Behavioral Disinhibition/Risk Compensation: Number of Male Sexual Partners
NCT01769456 (12) [back to overview]	Total Body Bone Mineral Density: Percent Change From Baseline to Week 48
NCT01772823 (15) [back to overview]	Demographic and/or Behavioral Difference Between Study Groups. Behavioral Disinhibition/Risk Compensation Endpoints Will be Compared. (Age)
NCT01772823 (15) [back to overview]	Acceptability and Feasibility of Text Message Reminders: Number Using Text Messaging Reminders
NCT01772823 (15) [back to overview]	Lumbar Spine Bone Mineral Density at Baseline and at Week 48
NCT01772823 (15) [back to overview]	Measured Levels of Drug Exposure (DBS RBC FTC-TP) When YMSM Are Provided Open Label FTC/TDF (Truvada®)
NCT01772823 (15) [back to overview]	Acceptability and Feasibility of Text Message Reminders: Number Discontinuing Text Messaging Reminders
NCT01772823 (15) [back to overview]	Femoral Neck Bone Mineral Density at Baseline and at Week 48
NCT01772823 (15) [back to overview]	Number of Participants With Decrease in Absolute Bone Mineral Density (BMD) From Baseline to Week 48
NCT01772823 (15) [back to overview]	Number of Participants With Unprotected Sex Acts
NCT01772823 (15) [back to overview]	Number of Sex Partners
NCT01772823 (15) [back to overview]	Total Body Bone Mineral Density at Baseline and at Week 48
NCT01772823 (15) [back to overview]	Measured Levels of Drug Exposure (DBS RBC TFV-DP) When YMSM Are Provided Open Label FTC/TDF (Truvada®)
NCT01772823 (15) [back to overview]	Total Hip Bone Mineral Density at Baseline and at Week 48
NCT01772823 (15) [back to overview]	Number of Participants With Serum Creatinine Event of Grade 1 or Higher
NCT01772823 (15) [back to overview]	Patterns of Use, Rates of Adherence and Measured Levels of Open Label FTC/TDF (Truvada®) Drug Exposure
NCT01772823 (15) [back to overview]	Demographic and/or Behavioral Difference Between Study Groups. Behavioral Disinhibition/Risk Compensation Endpoints Will be Compared. (Log 10 Viral Load)
NCT01777997 (9) [back to overview]	Plasma HIV-1 RNA Level Measured by Single Copy Assay Using Primer in Integrase (iSCA) as the Proportion of Participants Below the Limit of the Assay
NCT01777997 (9) [back to overview]	Change in Quality of Life (QoL) Index
NCT01777997 (9) [back to overview]	Change in Levels of D-dimer
NCT01777997 (9) [back to overview]	Change in Levels of CD8+ T-cell Activation
NCT01777997 (9) [back to overview]	Change in CD4+ T-cell Count
NCT01777997 (9) [back to overview]	Change in Levels of CD4+ T-cell Activation (Defined as the Percentage HLA-DR+/CD38+)
NCT01777997 (9) [back to overview]	Number of Subjects Who Experience Grade 3 or 4 Signs and Symptoms or Laboratory Abnormalities, Diagnoses (Any Grade), or Other Serious Adverse Events (SAEs)
NCT01777997 (9) [back to overview]	Change in Levels of CD8+ T-cell Activation (Defined as the Percentage HLA-DR+/CD38+) From Baseline to Weeks 24 and 48 on ART
NCT01777997 (9) [back to overview]	Change in Levels of Interleukin (IL)-6
NCT01781806 (3) [back to overview]	Number of Participants With a Grade 2 or Higher Adverse Event by Cohort
NCT01781806 (3) [back to overview]	Number of HIV Seroconversions by Cohort.
NCT01781806 (3) [back to overview]	Cohort H PrEP Engagement by Study Visit
NCT01803074 (28) [back to overview]	Change From Baseline in Cluster of Differentiation (CD) 4+ and CD8+ Lymphocyte Counts - Part B
NCT01803074 (28) [back to overview]	Maximum Observed Plasma Concentrations (Cmax) - Part B
NCT01803074 (28) [back to overview]	Maximum Observed Plasma Concentrations (Cmax) - Part A and C
NCT01803074 (28) [back to overview]	Change From Baseline in Cluster of Differentiation (CD) 4+ and CD8+ Lymphocyte Counts - Part A and C
NCT01803074 (28) [back to overview]	Area Under The Plasma Concentration - Time Curve Over the Dosing Interval (AUC[Tau]) - Part B
NCT01803074 (28) [back to overview]	Area Under The Plasma Concentration - Time Curve Over the Dosing Interval (AUC([Tau]) - Part A and C
NCT01803074 (28) [back to overview]	Accumulation Index (AI): Part A and C
NCT01803074 (28) [back to overview]	Time to Maximum Decline in Log 10 HIV-1 RNA - Part B
NCT01803074 (28) [back to overview]	Plasma Half-life: Part A and C
NCT01803074 (28) [back to overview]	Change in Plasma Log10 HIV-1 Ribonucleic Acid (RNA) Levels From Baseline to Day 11
NCT01803074 (28) [back to overview]	Apparent Total Body Clearance: Part A and C
NCT01803074 (28) [back to overview]	Average Observed Plasma Concentration at Steady State (Css-avg): Part A and C
NCT01803074 (28) [back to overview]	Degree of Fluctuation (DF): Part A and C
NCT01803074 (28) [back to overview]	Maximum Decline From Baseline in Log10 HIV-1 RNA - Part A and C
NCT01803074 (28) [back to overview]	Maximum Decline From Baseline in Log10 HIV-1 RNA - Part B
NCT01803074 (28) [back to overview]	Number of Participants With Clinically Significant Changes in Heart Rate
NCT01803074 (28) [back to overview]	Time to Maximum Decline in Log 10 HIV-1 RNA - Part A and C
NCT01803074 (28) [back to overview]	Time to Reach Maximum Plasma Concentration (Tmax) - Part B
NCT01803074 (28) [back to overview]	Time to Reach Maximum Plasma Concentration (Tmax) - Part A and C
NCT01803074 (28) [back to overview]	Plasma Concentration 24 Hours Post-Dose (C24) - Part B
NCT01803074 (28) [back to overview]	Plasma Concentration 24 Hours Post-Dose (C24) - Part A and C
NCT01803074 (28) [back to overview]	Percent Change From Baseline in Cluster of Differentiation (CD) 4+ and CD8+ Lymphocyte Percent - Part B
NCT01803074 (28) [back to overview]	Percent Change From Baseline in Cluster of Differentiation (CD) 4+ and CD8+ Lymphocyte Percent - Part A and C
NCT01803074 (28) [back to overview]	Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Related SAEs, Discontinuations Due to SAEs, Adverse Events (AEs), and Discontinuations Due to AEs During the Study
NCT01803074 (28) [back to overview]	Number of Participants With Clinically Significant Grade 3/4 Laboratory Abnormalities From Baseline
NCT01803074 (28) [back to overview]	Number of Participants With Clinically Significant Changes in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
NCT01803074 (28) [back to overview]	Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG)
NCT01803074 (28) [back to overview]	Number of Participants With Abnormal Changes in Physical Examination
NCT01855867 (3) [back to overview]	Number of Participants With Self-Reported Missed Doses
NCT01855867 (3) [back to overview]	nPEP Failure (HIV Infection During Study Participation)
NCT01855867 (3) [back to overview]	Number of Adverse Event Occurrences
NCT01903031 (21) [back to overview]	ATV PK Parameter Cmax Determined Based on ATV Levels From Individual Participants Enrolled in Arm C
NCT01903031 (21) [back to overview]	Proportion of Participants With Progesterone Levels Greater Than 5 ng/mL.
NCT01903031 (21) [back to overview]	Ritonavir (RTV) PK Parameter AUC(0-24h) Calculated Based on Intensive RTV PK Samples Obtained From Individual Participants Enrolled in Arm C
NCT01903031 (21) [back to overview]	RTV PK Parameter CLss/F Determined Based on RTV Levels From Individual Participants Enrolled in Arm C
NCT01903031 (21) [back to overview]	RTV PK Parameter Cmax Determined Based on RTV Levels From Individual Participants Enrolled in Arm C
NCT01903031 (21) [back to overview]	RTV PK Parameter Tmax Determined Based on RTV Levels From Individual Participants Enrolled in Arm C
NCT01903031 (21) [back to overview]	Ethinyl Estradiol Concentrations at Study Day 21
NCT01903031 (21) [back to overview]	Etonogestrel Concentrations at Study Day 21
NCT01903031 (21) [back to overview]	Percentage of Participants With Signs and Symptoms of Grade 2 or Higher Deemed Possibly, Probably or Definitely Related to Study Treatment
NCT01903031 (21) [back to overview]	ATV PK Parameter AUC(0-24h) Calculated Based on Intensive Atazanavir (ATV) PK Samples Obtained From Individual Participants Enrolled in Arm C
NCT01903031 (21) [back to overview]	ATV PK Parameter CLss/F Determined Based on ATV Levels From Individual Participants Enrolled in Arm C
NCT01903031 (21) [back to overview]	RTV PK Parameter Cmin Determined Based on RTV Levels From Individual Participants Enrolled in Arm C
NCT01903031 (21) [back to overview]	ATV PK Parameter Cmin Determined Based on ATV Levels From Individual Participants Enrolled in Arm C
NCT01903031 (21) [back to overview]	ATV PK Parameter Time to Cmax (Tmax) Determined Based on ATV Levels From Individual Participants Enrolled in Arm C
NCT01903031 (21) [back to overview]	EFV PK Parameter Area Under the Concentration-Time Curve (AUC0-24hours) Calculated Based on Intensive EFV PK Samples Obtained From Individual Participants Enrolled in Arm B
NCT01903031 (21) [back to overview]	EFV PK Parameter Clearance (CLss/F) Determined Based on EFV Levels From Individual Participants Enrolled in Arm B
NCT01903031 (21) [back to overview]	EFV PK Parameter Maximum Plasma Concentration (Cmax) Determined Based on EFV Levels From Individual Participants Enrolled in Arm B
NCT01903031 (21) [back to overview]	EFV PK Parameter Minimum Plasma Concentration (Cmin) Determined Based on EFV Levels From Individual Participants Enrolled in Arm B
NCT01903031 (21) [back to overview]	Ethinyl Estradiol Concentrations Obtained on Study Days 7 and 14.
NCT01903031 (21) [back to overview]	Etonogestrel Concentrations Obtained on Study Days 7 and 14
NCT01903031 (21) [back to overview]	Proportion of Participants With Plasma HIV-1 RNA Levels <40 Copies/mL
NCT01910402 (48) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL at Week 48 by Subgroups
NCT01910402 (48) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 c/mL in Continuation Phase
NCT01910402 (48) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 and <400 c/mL Over Time-Randomized Phase
NCT01910402 (48) [back to overview]	Number of Participants With Treatment Emergent Resistances for DTG 50 mg/ABC 600 mg/3TC 300 mg QD (Randomized + Continuation Phase)
NCT01910402 (48) [back to overview]	Number of Participants With Treatment Emergent Resistances for ATV 300 mg+RTV 100 mg+TDF 300 mg/FTC 200mg QD (Randomized Phase)
NCT01910402 (48) [back to overview]	Number of Participants With Post-Baseline HIV-1 Disease Progression-Randomized Phase
NCT01910402 (48) [back to overview]	Number of Participants With Post-Baseline HIV-1 Disease Progression for DTG 50 mg/ABC 600 mg/3TC 300 mg QD (Randomized + Continuation Phase)
NCT01910402 (48) [back to overview]	Number of Participants With Maximum Post-Baseline Emergent Hematology Toxicities-Randomized Phase
NCT01910402 (48) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL at Week 48 by Subgroups
NCT01910402 (48) [back to overview]	Change From Baseline in Carbon Dioxide, Electrolytes, Lipids, Glucose, Urea at Indicated Time Points
NCT01910402 (48) [back to overview]	Change From Baseline in Bone Specific Alkaline Phosphatase, Osteocalcin and Procollagen 1 N-terminal Propeptide at Indicated Timepoints
NCT01910402 (48) [back to overview]	Change From Baseline in Bilirubin and Creatinine at Indicated Timepoints
NCT01910402 (48) [back to overview]	Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes at Indicated Time Points
NCT01910402 (48) [back to overview]	Change From Baseline in Albumin at Indicated Timepoints
NCT01910402 (48) [back to overview]	Absolute Values in CD4+ Cell Count at Indicated Timepoints-Randomized Phase
NCT01910402 (48) [back to overview]	Absolute Values in Plasma HIV-1 RNA at Indicated Time Points-Continuation Phase
NCT01910402 (48) [back to overview]	Absolute Values in Plasma HIV-1 RNA at Indicated Time Points-Randomized Phase
NCT01910402 (48) [back to overview]	Change From Baseline in Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Creatine Kinase at Indicated Time Points
NCT01910402 (48) [back to overview]	Change From Baseline in CD4+ Cell Count at Indicated Timepoints-Continuation Phase
NCT01910402 (48) [back to overview]	Bone Specific Alkaline Phosphatase, Osteocalcin, Procollagen 1 N-terminal Propeptide, Type 1 Collagen C-Telopeptide, Vitamin D Ratio of Week 48 Results Over Baseline
NCT01910402 (48) [back to overview]	Change From Baseline at Week 48 in SF-12 Total Score, MCS and PCS
NCT01910402 (48) [back to overview]	Change From Baseline in TC/HDL Ratio at Week 48
NCT01910402 (48) [back to overview]	Change From Baseline in Triglycerides at Week 48
NCT01910402 (48) [back to overview]	Number of Participants Who Withdrew From Treatment Due to AEs-Continuation Phase
NCT01910402 (48) [back to overview]	Number of Participants Who Withdrew From Treatment Due to AEs-Randomized Phase
NCT01910402 (48) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL at Week 48
NCT01910402 (48) [back to overview]	Absolute Values in CD4+ Cell Count at Indicated Timepoints-Continuation Phase
NCT01910402 (48) [back to overview]	Change From Baseline in CD4+ Cell Count at Indicated Timepoints-Randomized Phase
NCT01910402 (48) [back to overview]	Number of Participants With AEs by Maximum Toxicity-Continuation Phase
NCT01910402 (48) [back to overview]	Change From Baseline in Carbon Dioxide, Electrolytes, Lipids, Glucose, Urea at Indicated Time Points
NCT01910402 (48) [back to overview]	Change From Baseline in Creatinine Clearance at Indicated Time Points
NCT01910402 (48) [back to overview]	Change From Baseline in Erythrocyte Mean Corpuscular Volume at Indicated Time Points
NCT01910402 (48) [back to overview]	Change From Baseline in Erythrocytes at Indicated Time Points
NCT01910402 (48) [back to overview]	Change From Baseline in Hematocrit Count at Indicated Time Points
NCT01910402 (48) [back to overview]	Change From Baseline in Lipase at Indicated Timepoints
NCT01910402 (48) [back to overview]	Change From Baseline in Plasma HIV-1 RNA at Indicated Time Points-Continuation Phase
NCT01910402 (48) [back to overview]	Change From Baseline in Plasma HIV-1 RNA at Indicated Time Points-Randomized Phase
NCT01910402 (48) [back to overview]	Change From Baseline in Total CHLS/HDL CHLS Ratio at Indicated Timepoints
NCT01910402 (48) [back to overview]	Change From Baseline in Type I Collagen C-telopeptides at Indicated Timepoints
NCT01910402 (48) [back to overview]	Change From Baseline in Urine Albumin Creatinine Ratio at Indicated Time Points
NCT01910402 (48) [back to overview]	Change From Baseline in Vitamin D, Vitamin D2 and Vitamin D3 at Week 24 and Week 48
NCT01910402 (48) [back to overview]	HIVTSQs Total Score at Indicated Timepoints
NCT01910402 (48) [back to overview]	Number of Participants With AEs by Maximum Toxicity-Randomized Phase
NCT01910402 (48) [back to overview]	Number of Participants With Any Adverse Events (AEs), and Serious Adverse Events (SAEs)-Randomized Phase
NCT01910402 (48) [back to overview]	Number of Participants With Any AEs, and SAEs in Continuation Phase
NCT01910402 (48) [back to overview]	Number of Participants With Maximum Post-Baseline Emergent Chemistry Toxicities-Continuation Phase
NCT01910402 (48) [back to overview]	Number of Participants With Maximum Post-Baseline Emergent Chemistry Toxicities-Randomized Phase
NCT01910402 (48) [back to overview]	Number of Participants With Maximum Post-Baseline Emergent Hematology Toxicities-Continuation Phase
NCT01929759 (8) [back to overview]	Neurocognitive Changes
NCT01929759 (8) [back to overview]	Change in Neurometabolites Based on Magnetic Resonance Spectroscopy (MRS)
NCT01929759 (8) [back to overview]	Change in Other Neurometabolite Measured by MRS Between Week 0 and Week 8
NCT01929759 (8) [back to overview]	Effect of EFV and Its Metabolites
NCT01929759 (8) [back to overview]	Fasting Lipid Profile
NCT01929759 (8) [back to overview]	Markers of Immune Activation
NCT01929759 (8) [back to overview]	Neural Activation Networks Using Functional Magnetic Resonance Imaging (fMRI)
NCT01929759 (8) [back to overview]	Sleep Quality
NCT02022657 (1) [back to overview]	Steady State Concentrations of TFV-DP for Different Dosing Patterns of Truvada
NCT02116660 (1) [back to overview]	Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)
NCT02174276 (19) [back to overview]	Composite Endpoint Measuring the Percentage of Participants With HBeAg Loss and HBeAg Seroconversion at Week 48
NCT02174276 (19) [back to overview]	Mean Change in Serum HBsAg From Baseline to Week 24
NCT02174276 (19) [back to overview]	Number of Participants With Drug-Resistance Mutations at Week 48 or at the Last Visit Available
NCT02174276 (19) [back to overview]	Percentage of Participants Experiencing Virologic Breakthrough at Week 24
NCT02174276 (19) [back to overview]	Percentage of Participants Experiencing Virologic Breakthrough at Week 48
NCT02174276 (19) [back to overview]	Percentage of Participants With HBeAg Loss at Week 24
NCT02174276 (19) [back to overview]	Percentage of Participants With HBeAg Loss at Week 48
NCT02174276 (19) [back to overview]	Percentage of Participants With HBsAg Loss at Week 24
NCT02174276 (19) [back to overview]	Percentage of Participants With HBsAg Loss at Week 48
NCT02174276 (19) [back to overview]	Percentage of Participants With HBV DNA < LLOQ at Week 48
NCT02174276 (19) [back to overview]	Percentage of Participants With HBV DNA < Lower Limit of Quantification (LLOQ) at Week 24
NCT02174276 (19) [back to overview]	Percentage of Participants With a ≥ 0.5 Log10 IU/mL or a ≥ 1.0 Log10 IU/mL Decline in HBsAg at Week 12
NCT02174276 (19) [back to overview]	Percentage of Participants With a ≥ 0.5 Log10 IU/mL or a ≥ 1.0 Log10 IU/mL Decline in HBsAg at Week 48
NCT02174276 (19) [back to overview]	Composite Endpoint Measuring the Percentage of Participants With HBeAg Loss and HBeAg Seroconversion at Week 24
NCT02174276 (19) [back to overview]	Percentage of Participants With a ≥ 0.5 Log10 IU/mL or a ≥ 1.0 Log10 IU/mL Decline in HBsAg at Week 24
NCT02174276 (19) [back to overview]	Composite Endpoint Measuring the Percentage of Participants With HBsAg Loss and HBsAg Seroconversion at Week 24
NCT02174276 (19) [back to overview]	Composite Endpoint Measuring the Percentage of Participants With HBsAg Loss and HBsAg Seroconversion at Week 48
NCT02174276 (19) [back to overview]	Mean Change in HBsAg From Baseline to Week 12
NCT02174276 (19) [back to overview]	Mean Change in HBsAg From Baseline to Week 48
NCT02180438 (12) [back to overview]	Interim Analysis at 24 Weeks of Grade 3 and 4 Adverse Events
NCT02180438 (12) [back to overview]	Virologic Failure, FDA Snapshot (HIV-2 Plasma Viral Load >50 and >400 Copies/ml)
NCT02180438 (12) [back to overview]	Interim 24 Weeks Analysis of Death
NCT02180438 (12) [back to overview]	Grade 3 or 4 Adverse Events
NCT02180438 (12) [back to overview]	Development of Drug Resistance Mutations to Elvitegravir or Emtricitabine or Tenofovir DF
NCT02180438 (12) [back to overview]	< 50 CD4 T-cell Increase at 48 Weeks From Baseline
NCT02180438 (12) [back to overview]	CD4 T-cell Count at 48 Weeks < Baseline
NCT02180438 (12) [back to overview]	Death
NCT02180438 (12) [back to overview]	Switching Off Stribild Prior to 48 Weeks
NCT02180438 (12) [back to overview]	New WHO Stage 3 or 4 Event
NCT02180438 (12) [back to overview]	Interim Analysis at 24 Weeks of New WHO Stage 3 or 4 Event
NCT02180438 (12) [back to overview]	Interim Analysis at 24 Weeks of HIV-2 Virologic Failure
NCT02195518 (18) [back to overview]	Change From Baseline in Hemoglobin (Hb)
NCT02195518 (18) [back to overview]	Percentage of Participants With Serum HBV DNA <20 IU/mL and Serum HBV DNA <69 IU/mL at Weeks 48 and 96
NCT02195518 (18) [back to overview]	Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Weeks 48, 96, and 144 in Participants Who Had Abnormal ALT at Baseline
NCT02195518 (18) [back to overview]	Percentage of Participants Who Experienced Viral Breakthrough up to Week 144
NCT02195518 (18) [back to overview]	Percentage of Participants in the Subgroup With Confirmed Multi-drug Resistance Mutations at Baseline With Serum HBV DNA <20 IU/mL and Serum HBV DNA <69 IU/mL at Weeks 48, 96 and 144
NCT02195518 (18) [back to overview]	Percentage of Hepatitis B e Antigen (HBeAg) Positive Participants Achieving HBeAg Loss, HBeAg Seroconversion or Hepatitis B s Antigen (HBsAg) Loss and HBsAg Seroconversion at Weeks 48, 96, and 144
NCT02195518 (18) [back to overview]	Percentage of HBeAg Negative Participants Achieving HBsAg Loss and HBsAg Seroconversion at Weeks 48, 96, and 144
NCT02195518 (18) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and Non-serious TEAEs
NCT02195518 (18) [back to overview]	Change From Baseline in Red Blood Cells (RBC)
NCT02195518 (18) [back to overview]	Change From Baseline in Logarithm to the Base 10 (Log 10) Reduction in Serum HBV DNA at Week 48, 96 and 144
NCT02195518 (18) [back to overview]	Change From Baseline in Hematology Parameters: White Blood Cells (WBC), Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets
NCT02195518 (18) [back to overview]	Change From Baseline in Chemistry Parameters: Total Billirubin, Direct Bilirubin, Serum Creatinine
NCT02195518 (18) [back to overview]	Change From Baseline in Chemistry Parameters: ALT, Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-Glutamyltransferase (GGT), Creatinine Phosphokinase (CK), Lactose Dehydrogenase (LDH)
NCT02195518 (18) [back to overview]	Change From Baseline in Chemistry Parameters: Albumin, Total Protein
NCT02195518 (18) [back to overview]	Change From Baseline in Chemistry Parameter: Estimated Glomerular Filtration Rate (eGFR)
NCT02195518 (18) [back to overview]	Change From Baseline in Chemistry Parameter: Creatinine Clearance Rate
NCT02195518 (18) [back to overview]	Change From Baseline in Chemistry Parameter: Blood Urea Nitrogen (BUN), Potassium, Sodium, Chloridian, Phosphorus, Calcium and Fasting Blood Glucose.
NCT02195518 (18) [back to overview]	Percentage of Participants With Serum Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <20 International Unit Per Milliliter (IU/mL) at Week 144
NCT02213328 (11) [back to overview]	Number of Participants With Acceptability as Per Questionnaire Administered at Week 48
NCT02213328 (11) [back to overview]	The Percentage of Participants Who Report Willingness to Use the Study Regimen, Take up PrEP, and Remain on PrEP as Part of a Comprehensive Prevention Package
NCT02213328 (11) [back to overview]	Reported Alcohol and Substance Use as Evidenced by Participant Responses to Interviewer-administered Questionnaires at the Enrolment Visit
NCT02213328 (11) [back to overview]	Proportion of Adolescents With Detectable Drug Levels Who Report Using PrEP
NCT02213328 (11) [back to overview]	Number of Participants With Grades 2, 3, and 4 Clinical and Laboratory Adverse Events
NCT02213328 (11) [back to overview]	Number of Adolescents Who Continue to Use PrEP (as Indicated by Dried Blood Spot [DBS] Levels) After the Initial 3-month Period
NCT02213328 (11) [back to overview]	Number of Adolescents Enrolled and Retained in the Study
NCT02213328 (11) [back to overview]	Reported Consistent Condom Use as Evidenced by Participant Responses to Interviewer-administered Questionnaires Adminstered at the Enrolment Visit
NCT02213328 (11) [back to overview]	Percentage of Study Participants Who Seroconverted During the Study, Measured Until Month 52
NCT02213328 (11) [back to overview]	Number of Participants Reporting Multiple Partners in the Preceding Year as Evidenced by Participant Responses to Interviewer Administered Questionnaires at Enrolment
NCT02213328 (11) [back to overview]	Number of Participants Who Used PrEP at Any Time Point During the Study, Measured With Drug Levels at M4/8/12/24/36
NCT02224456 (24) [back to overview]	Incidence Rate of Newly Diagnosed Hepatocellular Carcinoma (HCC) at Week 240
NCT02224456 (24) [back to overview]	Change From Baseline in Red Blood Cells (RBC)
NCT02224456 (24) [back to overview]	Change From Baseline in Logarithm to the Base 10 (Log 10) Serum HBV DNA
NCT02224456 (24) [back to overview]	Change From Baseline in Hemoglobin (Hb)
NCT02224456 (24) [back to overview]	Change From Baseline in Hematology Parameters: White Blood Cells (WBC), Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets
NCT02224456 (24) [back to overview]	Change From Baseline in Chemistry Parameters: Total Bilirubin, Direct Bilirubin, Serum Creatinine
NCT02224456 (24) [back to overview]	Change From Baseline in Chemistry Parameters: Estimated Glomerular Filtration Rate (eGFR)
NCT02224456 (24) [back to overview]	Change From Baseline in Chemistry Parameters: Albumin and Total Protein
NCT02224456 (24) [back to overview]	Change From Baseline in Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-Glutamyltransferase (GGT), Creatinine Phosphokinase (CK), Lactose Dehydrogenase (LDH)
NCT02224456 (24) [back to overview]	Change From Baseline in Chemistry Parameter: Blood Urea Nitrogen (BUN), Potassium, Sodium, Chloridion, Phosphorus, Calcium and Fasting Blood Glucose
NCT02224456 (24) [back to overview]	Mean Change From Baseline in Liver Stiffness Measure at Week 48, Week 96, Week 144, Week 192 and Week 240
NCT02224456 (24) [back to overview]	Number of Participants With Newly Diagnosed Hepatocellular Carcinoma (HCC) at Week 48, Week 96, Week 144 and Week 192
NCT02224456 (24) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and Non-serious TEAEs
NCT02224456 (24) [back to overview]	Percentage of HBeAg Negative Participants Achieving HBsAg Loss and HBsAg Seroconversion at Week 48, Week 96, Week 144, Week 192 and Week 240
NCT02224456 (24) [back to overview]	Percentage of Hepatitis B e Antigen (HBeAg) Positive Participants Achieving HBeAg Loss, HBeAg Seroconversion at Week 48, Week 96, Week 144, Week 192 and Week 240.
NCT02224456 (24) [back to overview]	Percentage of Participants Who Experienced Viral Breakthrough
NCT02224456 (24) [back to overview]	Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 48, Week 96, Week 144, Week 192 and Week 240 in Participants Who Had Abnormal ALT at Baseline
NCT02224456 (24) [back to overview]	Percentage of Participants With Newly Diagnosed Hepatocellular Carcinoma (HCC) at Week 48, Week 96, Week 144, Week 192 and Week 240
NCT02224456 (24) [back to overview]	Percentage of Participants With Serum Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <20 International Units Per Milliliter (IU/mL) at Weeks 48, 96, 144, 192 and 240
NCT02224456 (24) [back to overview]	Percentage of Participants With Histological Improvement at Week 216
NCT02224456 (24) [back to overview]	Percentage of Participants With Disease Progression at Week 240
NCT02224456 (24) [back to overview]	Percentage of Participants With Disease Progression at Week 48, Week 96, Week 144, Week 192 and Week 240
NCT02224456 (24) [back to overview]	Percentage of Participants With Cirrhosis Reversal at Week 216
NCT02224456 (24) [back to overview]	Change From Baseline in Chemistry Parameters: Creatinine Clearance Rate
NCT02251236 (4) [back to overview]	Concentration of Elvitegravir in Cerebrospinal Fluid at Baseline
NCT02251236 (4) [back to overview]	Concentration of Elvitegravir in Cerebrospinal Fluid at Week 24
NCT02251236 (4) [back to overview]	Concentration of Tenofovir in Cerebrospinal Fluid at Week 24
NCT02251236 (4) [back to overview]	Concentration of Tenofovir in Cerebrospinal Fluid at Baseline
NCT02386098 (8) [back to overview]	Number of Participants With Occurrence of New Acquired Immunodeficiency Syndrome (AIDS) Defining Events-Stage 1
NCT02386098 (8) [back to overview]	Percentage of Participants With Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) <40 Copies Per Milliliter (c/mL) at Week 24-Stage 1
NCT02386098 (8) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <40 c/mL at Weeks 48 and 96-Stage 1
NCT02386098 (8) [back to overview]	Percentage of Participants With HIV-1 RNA <200 c/mL at Weeks 24, 48 and 96-Stage 1
NCT02386098 (8) [back to overview]	Number of Participants With Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Discontinuation (AELD)-Stage 1
NCT02386098 (8) [back to overview]	Change From Baseline in Percentage of CD4+ Cells Over Time-Stage 1
NCT02386098 (8) [back to overview]	Change From Baseline in Logarithm to the Base 10 (log10) HIV-1 RNA Over Time-Stage 1
NCT02386098 (8) [back to overview]	Change From Baseline in Cluster of Differentiation 4+ (CD4+) Cell Count Over Time-Stage 1
NCT02397096 (12) [back to overview]	Percentage of Participants Discontinuing From Study Medication Due to an AE(s)
NCT02397096 (12) [back to overview]	Percentage of Participants Experiencing ≥1 Adverse Event (AE)
NCT02397096 (12) [back to overview]	Percentage of Participants Experiencing ≥1 Serious Adverse Event (SAE)
NCT02397096 (12) [back to overview]	Percentage of Participants Maintaining HIV-1 RNA <40 Copies/mL
NCT02397096 (12) [back to overview]	Percentage of Participants Maintaining HIV-1 RNA <40 Copies/mL
NCT02397096 (12) [back to overview]	Percentage of Participants Maintaining Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) <50 Copies/mL
NCT02397096 (12) [back to overview]	Percentage of Participants With HIV-1 RNA >=50 Copies/mL
NCT02397096 (12) [back to overview]	Mean Change From Baseline in Cluster of Differentiation (CD4) Cell Counts
NCT02397096 (12) [back to overview]	Mean Change From Baseline in Fasting Low-density Lipoprotein Cholesterol (LDL-C)
NCT02397096 (12) [back to overview]	Mean Change From Baseline in Fasting Non-high-density Lipoprotein Cholesterol (Non-HDL-C)
NCT02397096 (12) [back to overview]	Mean Change From Baseline in Cluster of Differentiation (CD4) Cell Counts
NCT02397096 (12) [back to overview]	Percentage of Participants Maintaining HIV-1 RNA <50 Copies/mL
NCT02401230 (13) [back to overview]	Median Peripheral Blood Mononuclear Cell (PBMC) Deoxyadenosine Triphosphate (dATP) Concentration
NCT02401230 (13) [back to overview]	Median Cumulative Amount of p24
NCT02401230 (13) [back to overview]	Median Rectal Tissue Tenofovir (TDF) Concentration
NCT02401230 (13) [back to overview]	Median Rectal Tissue Emtricitabine (FTC) Concentration
NCT02401230 (13) [back to overview]	Median Rectal Secretion Tenofovir (TDF) Concentration
NCT02401230 (13) [back to overview]	Median Rectal Secretion Emtricitabine (FTC) Concentration
NCT02401230 (13) [back to overview]	Median Plasma Tenofovir (TDF) Concentration
NCT02401230 (13) [back to overview]	Median Plasma Emtricitabine (FTC) Concentration
NCT02401230 (13) [back to overview]	Median Peripheral Blood Mononuclear Cell (PBMC) Tenofovir (TDF) Concentration
NCT02401230 (13) [back to overview]	Median Peripheral Blood Mononuclear Cell (PBMC) Emtricitabine (FTC) Concentration
NCT02401230 (13) [back to overview]	Median Rectal Tissue Deoxyadenosine Triphosphate (dATP) Concentration
NCT02401230 (13) [back to overview]	Median Rectal Tissue Deoxycytidine Triphosphate (dCTP) Concentration
NCT02401230 (13) [back to overview]	Median Percentage of CD4 Positive T-Cells
NCT02403674 (14) [back to overview]	Change From Baseline in Fasting Non-HDL-C at Week 48
NCT02403674 (14) [back to overview]	Change From Baseline in Fasting Triglycerides at Week 48
NCT02403674 (14) [back to overview]	Percentage of Participants Discontinuing From Study Medication Due to an AE(s)
NCT02403674 (14) [back to overview]	Percentage of Participants Experiencing ≥1 AE
NCT02403674 (14) [back to overview]	Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48
NCT02403674 (14) [back to overview]	Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 48
NCT02403674 (14) [back to overview]	Percentage of Participants With HIV-1 RNA Below the Limit of Quantification (BLoQ) at Week 48
NCT02403674 (14) [back to overview]	Percentage of Participants With Tier-1 Neuropsychiatric Adverse Events (AEs)
NCT02403674 (14) [back to overview]	Percentage of Participants With Tier-2 Neuropsychiatric AEs
NCT02403674 (14) [back to overview]	Plasma Concentration of Doravirine at Week 48
NCT02403674 (14) [back to overview]	Change From Baseline in CD4 Cell Counts at Week 48
NCT02403674 (14) [back to overview]	Change From Baseline in Fasting Cholesterol at Week 48
NCT02403674 (14) [back to overview]	Change From Baseline in Fasting HDL-C at Week 48
NCT02403674 (14) [back to overview]	Change From Baseline in Fasting LDL-C at Week 48
NCT02431247 (64) [back to overview]	Change From Reference in log10 HIV-1 RNA Levels at Week 96
NCT02431247 (64) [back to overview]	Change From Reference in Estimated Glomerular Filtration Rate Based on Serum Cystatin C (eGFRcyst) by CKD-EPI Formula
NCT02431247 (64) [back to overview]	Change From Reference in Serum Creatinine
NCT02431247 (64) [back to overview]	Change From Reference in UACR
NCT02431247 (64) [back to overview]	Change From Reference in UB2MGCR
NCT02431247 (64) [back to overview]	Change From Reference in UPCR
NCT02431247 (64) [back to overview]	Change From Reference in URBPCR
NCT02431247 (64) [back to overview]	Percent Change From Baseline in Urine Fractional Excretion of Phosphate (FEPO4) at Week 48
NCT02431247 (64) [back to overview]	Percent Change From Reference in Urine FEPO4
NCT02431247 (64) [back to overview]	Percentage of Participants With HIV-1 RNA <50 Copies Per mL at Week 96 Defined by FDA Snapshot Approach
NCT02431247 (64) [back to overview]	Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Less Than (<) 50 Copies Per Milliliter (Copies Per mL) (Virologic Response) at Week 48 Defined by Food and Drug Administration (FDA) Snapshot Approach
NCT02431247 (64) [back to overview]	Plasma Concentrations 2 Hours After Dosing (C0-2h) of Tenofovir Alafenamide
NCT02431247 (64) [back to overview]	Predose (Trough) Plasma Concentration (C0h) of Darunavir
NCT02431247 (64) [back to overview]	CD4+ Cell Count Post-Week From 96 to End of Extension
NCT02431247 (64) [back to overview]	Change From Baseline in Alkaline Phosphatase (ALP) Levels at Weeks 24 and 48
NCT02431247 (64) [back to overview]	Change From Baseline in BMD T-score of Hip and Spine
NCT02431247 (64) [back to overview]	Change From Baseline in Levels of 25-Hydroxyvitamin D (25-OH Vitamin D), at Week 24 and 48
NCT02431247 (64) [back to overview]	Change From Baseline in Levels of Parathyroid Hormone (PTH) at Weeks 24 and 48
NCT02431247 (64) [back to overview]	Change From Baseline in Levels of Serum Collagen Type 1 Beta Carboxy Telopeptide (CTX) at Weeks 24 and 48
NCT02431247 (64) [back to overview]	Change From Baseline in Levels of Serum Procollagen 1 N-Terminal Propeptide (P1NP) at Weeks 24 and 48
NCT02431247 (64) [back to overview]	Change From Reference in BMD T-score of Hip and Spine at Week 96
NCT02431247 (64) [back to overview]	Number of Participants With ARV Resistance
NCT02431247 (64) [back to overview]	Percent Change From Baseline in Hip and Spine Bone Mineral Density (BMD)
NCT02431247 (64) [back to overview]	Percent Change From Reference in Hip and Spine BMD
NCT02431247 (64) [back to overview]	Percentage of Participants With >95% Treatment Adherence Assessed by Drug Accountability
NCT02431247 (64) [back to overview]	Percentage of Participants With >95% Treatment Adherence Assessed by Drug Accountability
NCT02431247 (64) [back to overview]	Percentage of Participants With >95% Treatment Adherence Assessed by Drug Accountability
NCT02431247 (64) [back to overview]	Percentage of Participants With Grade 3 and 4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Premature Discontinuations Due to Adverse Events Through Week 48
NCT02431247 (64) [back to overview]	Percentage of Participants With Grade 3 and 4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Premature Discontinuations Due to Adverse Events Through Week 96
NCT02431247 (64) [back to overview]	Percentage of Participants With Grade 3 and 4 AEs, SAEs, and Premature Discontinuations Due to Adverse Events Post-Week 96 to End of Extension
NCT02431247 (64) [back to overview]	Percentage of Participants With HIV RNA <50, <20, and <200 Copies/mL Post-week 96 to End of Extension
NCT02431247 (64) [back to overview]	Percentage of Participants With HIV-1 RNA < 20, 50, and 200 Copies Per mL at Week 48 and 96 Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
NCT02431247 (64) [back to overview]	Percentage of Participants With HIV-1 RNA < 20, 50, and 200 Copies Per mL at Week 48 and 96 Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
NCT02431247 (64) [back to overview]	Percentage of Participants With HIV-1 RNA < 20, 50, and 200 Copies Per mL at Week 48 and 96 Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
NCT02431247 (64) [back to overview]	Change From Reference in Estimated Glomerular Filtration Rate Based on Serum Creatinine by Cockcroft-Gault Formula
NCT02431247 (64) [back to overview]	Change From Reference in eGFRcr by CKD-EPI Formula
NCT02431247 (64) [back to overview]	Change From Reference in CD4+ Cell Count at Week 96
NCT02431247 (64) [back to overview]	Change From Reference in ALP Levels
NCT02431247 (64) [back to overview]	Change From Baseline in Urine Retinol Binding Protein To Creatinine Ratio (URBPCR) at Week 48
NCT02431247 (64) [back to overview]	Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) at Week 48
NCT02431247 (64) [back to overview]	Change From Baseline in Urine Beta-2 Microglobulin to Creatinine Ratio (UB2MGCR) at Week 48
NCT02431247 (64) [back to overview]	Change From Baseline in Urine Albumin to Creatinine Ratio (UACR) at Week 48
NCT02431247 (64) [back to overview]	Change From Baseline in Serum Creatinine at Week 48
NCT02431247 (64) [back to overview]	Change From Baseline in log10 HIV-1 RNA Levels at Week 48
NCT02431247 (64) [back to overview]	Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Cystatin C (eGFRcyst) by CKD-EPI Formula at Week 48
NCT02431247 (64) [back to overview]	Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine by (Cockcroft-Gault Formula) at Week 48
NCT02431247 (64) [back to overview]	Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine (eGFRcr) by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Formula at Week 48
NCT02431247 (64) [back to overview]	Change From Baseline in Cluster of Differentiation-4 (CD4+) Cell Count at Week 48
NCT02431247 (64) [back to overview]	Area Under the Plasma Concentration-Time Curve From Time of Administration to 24 Hours Post-dose (AUC0-24h) of Darunavir
NCT02431247 (64) [back to overview]	Area Under the Plasma Concentration Time Curve Across the Dosing Interval (AUCtau) of Tenofovir Alafenamide
NCT02431247 (64) [back to overview]	Percentage of Participants With HIV-1 RNA <20 and 200 Copies Per mL at Weeks 48 and 96 Defined by FDA Snapshot Approach
NCT02431247 (64) [back to overview]	Percentage of Participants With HIV-1 RNA <20 and 200 Copies Per mL at Weeks 48 and 96 Defined by FDA Snapshot Approach
NCT02431247 (64) [back to overview]	Percentage of Participants With HIV-1 RNA <20 and 200 Copies Per mL at Weeks 48 and 96 Defined by FDA Snapshot Approach
NCT02431247 (64) [back to overview]	Percentage of Participants With Non-PDVF by Kaplan-Meier Estimates
NCT02431247 (64) [back to overview]	Percentage of Participants With PDVF Post-week 96 to End of Extension
NCT02431247 (64) [back to overview]	Percentage of Participants With Protocol-defined Virologic Failure (PDVF)
NCT02431247 (64) [back to overview]	Percentage of Participants With Protocol-defined Virologic Failure (PDVF)
NCT02431247 (64) [back to overview]	Percentage of Participants With Protocol-defined Virologic Failure (PDVF)
NCT02431247 (64) [back to overview]	Percentage of Participants With Time to Treatment Failure by Kaplan-Meier Estimates
NCT02431247 (64) [back to overview]	Percentage of Participants With Time to Treatment Failure by Kaplan-Meier Estimates
NCT02431247 (64) [back to overview]	Change From Reference in Levels of Serum CTX
NCT02431247 (64) [back to overview]	Change From Reference in Levels of PTH
NCT02431247 (64) [back to overview]	Change From Reference in Levels of 25-OH Vitamin D
NCT02431247 (64) [back to overview]	Change From Reference in Levels of Serum P1NP
NCT02452528 (1) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Deaths, and Discontinuations Due to Adverse Events (AEs)
NCT02479880 (1) [back to overview]	Percentage of Participants With Bone-Related Adverse Events and/or a ≥ 4% Reduction in Bone Mineral Density (BMD) From Baseline to Week 96
NCT02495779 (1) [back to overview]	Number of Participants With PrEP Adherence
NCT02556333 (1) [back to overview]	HIV RNA Change From Baseline to Day 10
NCT02577029 (1) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs Considered Possibly or Probably Related to Treatment
NCT02603120 (7) [back to overview]	Spine Bone Mineral Density (BMD) at Baseline
NCT02603120 (7) [back to overview]	Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Defined by the US FDA-defined Snapshot Algorithm
NCT02603120 (7) [back to overview]	Percentage Change From Baseline in Spine BMD at Week 48
NCT02603120 (7) [back to overview]	Percentage Change From Baseline in Hip BMD at Week 48
NCT02603120 (7) [back to overview]	Hip Bone Mineral Density at Baseline
NCT02603120 (7) [back to overview]	Change From Baseline in CD4+ Cell Count at Week 48
NCT02603120 (7) [back to overview]	Percentage of Participants With Virologic Failure (HIV-1 RNA ≥ 50 Copies/mL) as Defined by the Modified US FDA-defined Snapshot Algorithm
NCT02604199 (3) [back to overview]	Change From Baseline in Quantitative Hepatitis B Surface Antigen (Log qHBsAg) at Day 113
NCT02604199 (3) [back to overview]	Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths and Discontinuations Due to AEs
NCT02604199 (3) [back to overview]	Change From Baseline in Quantitative Hepatitis B Surface Antigen (Log qHBsAg) Over Time
NCT02604212 (26) [back to overview]	Change From Baseline at Day 29 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 15 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 15 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 15 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 113 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 113 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 85 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline in Quantitative Hepatitis B Surface Antigen (Log qHBsAg) at Day 113
NCT02604212 (26) [back to overview]	Change From Baseline at Day 113 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs
NCT02604212 (26) [back to overview]	Change From Baseline in Log qHBsAg Over Time
NCT02604212 (26) [back to overview]	Change From Baseline at Day 99 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 99 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 99 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 85 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 85 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 71 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 71 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 71 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 57 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 57 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 57 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 43 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 43 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 43 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 29 in Log qHBsAg, by Category
NCT02629822 (14) [back to overview]	Percentage of Participants Achieving HIV-1 Ribonucleic Acid (RNA) <40 Copies/mL of Plasma at Week 96
NCT02629822 (14) [back to overview]	Change From Baseline in CD4 Cell Count at Week 48
NCT02629822 (14) [back to overview]	Change From Baseline in CD4 Cell Count at Week 192
NCT02629822 (14) [back to overview]	Time to Loss of Virologic Response
NCT02629822 (14) [back to overview]	Change From Baseline in CD4 Cell Count at Week 96
NCT02629822 (14) [back to overview]	Percentage of Participants Who Discontinued Treatment Due to an AE up to Week 96
NCT02629822 (14) [back to overview]	Percentage of Participants Who Discontinued Treatment Due to an AE up to Week 48.
NCT02629822 (14) [back to overview]	Percentage of Participants Experiencing ≥1 Adverse Events (AE) up to Week 96
NCT02629822 (14) [back to overview]	Percentage of Participants Experiencing ≥1 Adverse Events (AE) up to Week 48
NCT02629822 (14) [back to overview]	Percentage of Participants Achieving HIV-1 Ribonucleic Acid (RNA) <50 Copies/mL of Plasma at Week 96
NCT02629822 (14) [back to overview]	Percentage of Participants Achieving HIV-1 Ribonucleic Acid (RNA) <50 Copies/mL of Plasma at Week 48
NCT02629822 (14) [back to overview]	Percentage of Participants Achieving HIV-1 Ribonucleic Acid (RNA) <50 Copies/mL of Plasma at Week 192
NCT02629822 (14) [back to overview]	Percentage of Participants Achieving HIV-1 Ribonucleic Acid (RNA) <40 Copies/mL of Plasma at Week 192
NCT02629822 (14) [back to overview]	Percentage of Participants Achieving HIV-1 Ribonucleic Acid (RNA) <40 Copies/mL of Plasma at Week 48
NCT02652260 (20) [back to overview]	Number of Participants With One or More Drug-related SAEs Through Study Week 12
NCT02652260 (20) [back to overview]	Percentage of Participants With HIV-1 RNA <50 and <40 Copies/ml at Week 24 Post-switch for the Combined Treatment Groups
NCT02652260 (20) [back to overview]	CNS Toxicity Scores at Time of Switch, and at 24 Weeks Post-switch for the Combined Treatment Groups
NCT02652260 (20) [back to overview]	Change in Fasting Lipids Between Time of Switch and Week 24 Post-switch for the Combined Treatment Groups
NCT02652260 (20) [back to overview]	Change From Baseline in Fasting Lipids at Week 12
NCT02652260 (20) [back to overview]	Percentage of Participants With at Least One CNS Toxicity of at Least Grade 2 Intensity at Week 4
NCT02652260 (20) [back to overview]	Percentage of Participants With at Least One CNS Toxicity of at Least Grade 2 Intensity at Time of Switch, and at 24 Weeks Post-switch for the Combined Treatment Groups
NCT02652260 (20) [back to overview]	Percentage of Participants With at Least One Central Nervous System (CNS) Toxicity of at Least Grade 2 Intensity at Week 12
NCT02652260 (20) [back to overview]	Number of Participants With One or More Serious Adverse Events (SAEs) Through Study Week 12
NCT02652260 (20) [back to overview]	Number of Participants With One or More SAEs for the Combined Treatment Groups 24 Weeks After the Switch
NCT02652260 (20) [back to overview]	Number of Participants With One or More Drug-related SAEs for the Combined Treatment Groups 24 Weeks After the Switch
NCT02652260 (20) [back to overview]	Number of Participants With One or More Drug-related AEs Through Study Week 12
NCT02652260 (20) [back to overview]	Change From Baseline in CNS Toxicity Score at Week 12
NCT02652260 (20) [back to overview]	Number of Participants With One or More Drug-related AEs for the Combined Treatment Groups 24 Weeks After the Switch
NCT02652260 (20) [back to overview]	Number of Participants With One or More AEs for the Combined Treatment Groups 24 Weeks After the Switch
NCT02652260 (20) [back to overview]	Number of Participants With One or More Adverse Events (AEs) Through Study Week 12
NCT02652260 (20) [back to overview]	Number of Participants Who Discontinued Treatment Due to an AE Through Study Week 12
NCT02652260 (20) [back to overview]	Number of Participants Who Discontinued Treatment Due to an AE for the Combined Treatment Groups 24 Weeks After the Switch
NCT02652260 (20) [back to overview]	Change From Baseline in CNS Toxicity Score at Week 4
NCT02652260 (20) [back to overview]	Change From Time of Switch to Week 24 Post Switch in CD4 T-cell Count for the Combined Treatment Groups
NCT02738008 (1) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
NCT02797522 (2) [back to overview]	Number of Participants With TEAEs: CHB Participants
NCT02797522 (2) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs): Healthy Volunteers
NCT02815566 (2) [back to overview]	% Change in Bone Mineral Density From Baseline at the Femoral Neck
NCT02815566 (2) [back to overview]	Percent Change in Bone Mineral Density From Baseline at the Lumbar Spine
NCT02831673 (64) [back to overview]	Changes From Baseline in CD4+ Cell Counts at Week 96
NCT02831673 (64) [back to overview]	Ratio to Baseline in Renal Biomarkers-Urine and Serum Beta-2 Microglobulin (B2M), Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine, Urine RBP 4 and Urine RBP 4/Urine Creatinine at Weeks 24, 48
NCT02831673 (64) [back to overview]	Ratio to Baseline in Renal Biomarkers- Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine at Week 96
NCT02831673 (64) [back to overview]	Ratio to Baseline in Renal Biomarkers- Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine at Week 144
NCT02831673 (64) [back to overview]	Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Weeks 24, 48
NCT02831673 (64) [back to overview]	Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count, Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 24
NCT02831673 (64) [back to overview]	Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 96
NCT02831673 (64) [back to overview]	Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 48
NCT02831673 (64) [back to overview]	Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 144
NCT02831673 (64) [back to overview]	Percentage Change From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Weeks 24, 48
NCT02831673 (64) [back to overview]	Percentage Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Weeks 24, 48
NCT02831673 (64) [back to overview]	Number of Participants With Treatment-emergent Phenotypic Resistance up to Week 144
NCT02831673 (64) [back to overview]	Number of Participants With Treatment-emergent Genotypic Resistance up to Week 144
NCT02831673 (64) [back to overview]	Changes From Baseline in CD4+ Cell Counts at Week 48 by Subgroups
NCT02831673 (64) [back to overview]	Changes From Baseline in CD4+ Cell Counts at Week 24 by Subgroups
NCT02831673 (64) [back to overview]	Changes From Baseline in CD4+ Cell Counts at Week 24 and 48
NCT02831673 (64) [back to overview]	Changes From Baseline in CD4+ Cell Counts at Week 144 by Subgroups
NCT02831673 (64) [back to overview]	Change From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using CKD-EPI and Serum or Plasma GFR From Creatinine Adjusted for BSA Using CKD-EPI Method at Week 96
NCT02831673 (64) [back to overview]	Change From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using CKD-EPI and Serum or Plasma GFR From Creatinine Adjusted for BSA Using CKD-EPI Method at Week 144
NCT02831673 (64) [back to overview]	Change From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and Serum or Plasma GFR From Creatinine Adjusted Using CKD-EPI at Weeks 24, 48
NCT02831673 (64) [back to overview]	Change From Baseline in Renal Biomarkers-Serum Cystatin C and Serum Retinol Binding Protein (RBP) at Weeks 24, 48
NCT02831673 (64) [back to overview]	Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Weeks 24, 48
NCT02831673 (64) [back to overview]	Change From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Week 96
NCT02831673 (64) [back to overview]	Change From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Week 144
NCT02831673 (64) [back to overview]	Change From Baseline in EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L) Utility Score at Weeks 4, 24, 48
NCT02831673 (64) [back to overview]	Change From Baseline in EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L) Thermometer Scores at Weeks 4, 24 48
NCT02831673 (64) [back to overview]	Change From Baseline in Bone Biomarkers-Serum Bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type I CTX-1 at Week 96
NCT02831673 (64) [back to overview]	Change From Baseline in Bone Biomarkers-Serum Bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type I CTX-1 at Week 144
NCT02831673 (64) [back to overview]	Change From Baseline in Bone Biomarkers-Serum Bone Specific Alkaline Phosphatase (Bone-ALP), Serum Osteocalcin, Serum Procollagen 1 N-Terminal Propeptide (PINP) and Serum Type I Collagen C-Telopeptides (CTX-1) at Weeks 24, 48
NCT02831673 (64) [back to overview]	Change From Baseline in Bone Biomarker-Serum Vitamin D at Weeks 24, 48
NCT02831673 (64) [back to overview]	CD4+ Cell Counts at Weeks 24 and 48
NCT02831673 (64) [back to overview]	Time to Viral Suppression (HIV-1 RNA <50 c/mL) up to Week 144
NCT02831673 (64) [back to overview]	Percentage of Participants With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/mL (c/mL) at Week 48
NCT02831673 (64) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 96
NCT02831673 (64) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 24
NCT02831673 (64) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 144
NCT02831673 (64) [back to overview]	Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Week 96
NCT02831673 (64) [back to overview]	Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Week 144
NCT02831673 (64) [back to overview]	Number of Participants Who Discontinue Treatment Due to AEs Over Week 144
NCT02831673 (64) [back to overview]	Number of Participants Who Discontinue Treatment Due to AEs Over Weeks 24, 48, 96
NCT02831673 (64) [back to overview]	Changes From Baseline in CD4+ Cell Counts at Week 144
NCT02831673 (64) [back to overview]	Change From Baseline in Renal Biomarker-Serum RBP at Week 96
NCT02831673 (64) [back to overview]	Change From Baseline in Renal Biomarker-Serum RBP at Week 144
NCT02831673 (64) [back to overview]	Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Week 96
NCT02831673 (64) [back to overview]	Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Week 144
NCT02831673 (64) [back to overview]	Change From Baseline in Renal Biomarker-Serum Cystatin C at Week 96
NCT02831673 (64) [back to overview]	Change From Baseline in Renal Biomarker-Serum Cystatin C at Week 144
NCT02831673 (64) [back to overview]	Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Week 96
NCT02831673 (64) [back to overview]	Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Week 144
NCT02831673 (64) [back to overview]	Change From Baseline in EQ-5D-5L Utility Score at Week 96
NCT02831673 (64) [back to overview]	Change From Baseline in EQ-5D-5L Utility Score at Week 144
NCT02831673 (64) [back to overview]	Changes From Baseline in CD4+ Cell Counts at Week 96 by Subgroups
NCT02831673 (64) [back to overview]	Change From Baseline in EQ-5D-5L Thermometer Scores at Week 144
NCT02831673 (64) [back to overview]	Change From Baseline in Bone Biomarker-Serum Vitamin D at Week 96
NCT02831673 (64) [back to overview]	Change From Baseline in Bone Biomarker-Serum Vitamin D at Week 144
NCT02831673 (64) [back to overview]	CD4+ Cell Counts at Week 96
NCT02831673 (64) [back to overview]	Number of Participants With AEs by Maximum Severity Grades up to Week 144
NCT02831673 (64) [back to overview]	Number of Participants With Any AE and SAE up to Week 148
NCT02831673 (64) [back to overview]	Number of Participants With Any Drug Related AEs and Drug Related AEs by Maximum Grade up to Week 144
NCT02831673 (64) [back to overview]	Number of Participants With HIV-1 Disease Progression up to Week 144
NCT02831673 (64) [back to overview]	Number of Participants With Maximum Post-Baseline Emergent Chemistry Toxicities up to Week 144
NCT02831673 (64) [back to overview]	Number of Participants With Maximum Post-Baseline Emergent Hematology Toxicities up to Week 144
NCT02831673 (64) [back to overview]	CD4+ Cell Counts at Week 144
NCT02831673 (64) [back to overview]	Change From Baseline in EQ-5D-5L Thermometer Scores at Week 96
NCT02831764 (64) [back to overview]	Change From Baseline in Renal Biomarker-Serum RBP at Week 144
NCT02831764 (64) [back to overview]	Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Week 96
NCT02831764 (64) [back to overview]	Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Week 144
NCT02831764 (64) [back to overview]	Change From Baseline in Renal Biomarker-Serum Cystatin C at Week 96
NCT02831764 (64) [back to overview]	Change From Baseline in Renal Biomarker-Serum Cystatin C at Week 144
NCT02831764 (64) [back to overview]	Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Week 96
NCT02831764 (64) [back to overview]	Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Week 144
NCT02831764 (64) [back to overview]	Change From Baseline in EQ-5D-5L Utility Score at Week 144
NCT02831764 (64) [back to overview]	Change From Baseline in EQ-5D-5L Thermometer Scores at Week 96
NCT02831764 (64) [back to overview]	Change From Baseline in EQ-5D-5L Thermometer Scores at Week 144
NCT02831764 (64) [back to overview]	Change From Baseline in Bone Biomarker-Serum Vitamin D at Week 96
NCT02831764 (64) [back to overview]	Change From Baseline in Bone Biomarker-Serum Vitamin D at Week 144
NCT02831764 (64) [back to overview]	CD4+ Cell Counts at Week 96
NCT02831764 (64) [back to overview]	CD4+ Cell Counts at Week 144
NCT02831764 (64) [back to overview]	Change From Baseline in EQ-5D-5L Utility Score at Week 96
NCT02831764 (64) [back to overview]	Time to Viral Suppression (HIV-1 RNA <50 c/mL) up to Week 144
NCT02831764 (64) [back to overview]	Ratio to Baseline in Renal Biomarkers-Urine and Serum Beta-2 Microglobulin (B2M), Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine, Urine RBP 4 and Urine RBP 4/Urine Creatinine at Weeks 24, 48
NCT02831764 (64) [back to overview]	Ratio to Baseline in Renal Biomarkers- Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine at Week 96
NCT02831764 (64) [back to overview]	Ratio to Baseline in Renal Biomarkers- Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine at Week 144
NCT02831764 (64) [back to overview]	Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Weeks 24, 48
NCT02831764 (64) [back to overview]	Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count, Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 24
NCT02831764 (64) [back to overview]	Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 96
NCT02831764 (64) [back to overview]	Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 48
NCT02831764 (64) [back to overview]	Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 144
NCT02831764 (64) [back to overview]	Percentage Change From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma High Density Lipoprotein (HDL) Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Weeks 24, 48
NCT02831764 (64) [back to overview]	Percentage Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Weeks 24, 48
NCT02831764 (64) [back to overview]	Number of Participants With Treatment-emergent Phenotypic Resistance up to Week 144
NCT02831764 (64) [back to overview]	Number of Participants With Treatment-emergent Genotypic Resistance up to Week 144
NCT02831764 (64) [back to overview]	Number of Participants With Maximum Post-Baseline Emergent Hematology Toxicities up to Week 144
NCT02831764 (64) [back to overview]	Number of Participants With Maximum Post-Baseline Emergent Chemistry Toxicities up to Week 144
NCT02831764 (64) [back to overview]	Number of Participants With HIV-1 Disease Progression up to Week 144
NCT02831764 (64) [back to overview]	Number of Participants With Any Drug Related AEs and Drug Related AEs by Maximum Grade up to Week 148
NCT02831764 (64) [back to overview]	Number of Participants With Any Adverse Event (AE) and Serious AE (SAE) up to Week 148
NCT02831764 (64) [back to overview]	Number of Participants With AEs by Maximum Severity Grades up to Week 148
NCT02831764 (64) [back to overview]	Number of Participants Who Discontinue Treatment Due to AEs Over Weeks 24, 48, 96
NCT02831764 (64) [back to overview]	Changes From Baseline in CD4+ Cell Counts at Week 96 by Subgroups
NCT02831764 (64) [back to overview]	Changes From Baseline in CD4+ Cell Counts at Week 48 by Subgroups
NCT02831764 (64) [back to overview]	Changes From Baseline in CD4+ Cell Counts at Week 24 by Subgroups
NCT02831764 (64) [back to overview]	Changes From Baseline in CD4+ Cell Counts at Week 24 and 48
NCT02831764 (64) [back to overview]	Changes From Baseline in CD4+ Cell Counts at Week 144 by Subgroups
NCT02831764 (64) [back to overview]	Change From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using CKD-EPI and Serum or Plasma GFR From Creatinine Adjusted for BSA Using CKD-EPI Method at Week 96
NCT02831764 (64) [back to overview]	Change From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using CKD-EPI and Serum or Plasma GFR From Creatinine Adjusted for BSA Using CKD-EPI Method at Week 144
NCT02831764 (64) [back to overview]	Change From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and Serum or Plasma GFR From Creatinine Adjusted Using CKD-EPI at Weeks 24, 48
NCT02831764 (64) [back to overview]	Change From Baseline in Renal Biomarkers-Serum Cystatin C and Serum Retinol Binding Protein (RBP) at Weeks 24, 48
NCT02831764 (64) [back to overview]	Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Weeks 24, 48
NCT02831764 (64) [back to overview]	Change From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Week 96
NCT02831764 (64) [back to overview]	Change From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Week 144
NCT02831764 (64) [back to overview]	Change From Baseline in EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L) Thermometer Scores at Weeks 4, 24, 48
NCT02831764 (64) [back to overview]	Change From Baseline in European Quality of Life [EuroQoL] - 5 Dimensions - 5 Levels (EQ-5D-5L) Utility Score at Weeks 4, 24, 48
NCT02831764 (64) [back to overview]	Change From Baseline in Bone Biomarkers-Serum Bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type I CTX-1 at Week 96
NCT02831764 (64) [back to overview]	Change From Baseline in Bone Biomarkers-Serum Bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type I CTX-1 at Week 144
NCT02831764 (64) [back to overview]	Change From Baseline in Bone Biomarkers-Serum Bone Specific Alkaline Phosphatase (Bone-ALP), Serum Osteocalcin, Serum Procollagen 1 N-Terminal Propeptide (PINP) and Serum Type I Collagen C-Telopeptides (CTX-1) at Weeks 24, 48
NCT02831764 (64) [back to overview]	Change From Baseline in Bone Biomarker-Serum Vitamin D at Weeks 24, 48
NCT02831764 (64) [back to overview]	CD4+ Cell Counts at Weeks 24 and 48
NCT02831764 (64) [back to overview]	Percentage of Participants With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/mL (c/mL) at Week 48
NCT02831764 (64) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 96
NCT02831764 (64) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 24
NCT02831764 (64) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 144
NCT02831764 (64) [back to overview]	Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Week 96
NCT02831764 (64) [back to overview]	Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Week 144
NCT02831764 (64) [back to overview]	Number of Participants Who Discontinue Treatment Due to AEs Over Week 144
NCT02831764 (64) [back to overview]	Changes From Baseline in CD4+ Cell Counts at Week 96
NCT02831764 (64) [back to overview]	Changes From Baseline in CD4+ Cell Counts at Week 144
NCT02831764 (64) [back to overview]	Change From Baseline in Renal Biomarker-Serum RBP at Week 96
NCT02859558 (4) [back to overview]	Proportion of Participants With Undetectable Cell-associated HIV-1 DNA (CAHD) Prior to ART Initiation
NCT02859558 (4) [back to overview]	Proportion of Participants With Undetectable Cell-associated HIV-1 DNA (CAHD)
NCT02859558 (4) [back to overview]	HIV-1-specific CD8+ and T-cell Responses to Nef, Gag, Pol and Env by Flow Cytometry
NCT02859558 (4) [back to overview]	HIV-1-specific CD4+ and T-cell Responses to Nef, Gag, Pol and Env by Flow Cytometry
NCT02888106 (13) [back to overview]	Percentage of Patients With HBsAg Negativation
NCT02888106 (13) [back to overview]	Percentage of Patients With HВsAg Response
NCT02888106 (13) [back to overview]	Percentage of Patients With Negative HBV DNA by PCR
NCT02888106 (13) [back to overview]	Percentage of Patients With Normalized ALT
NCT02888106 (13) [back to overview]	The Intensity of Liver Fibrosis Based on Results of Transient Elastometry of Liver at Weeks 48 and 72.
NCT02888106 (13) [back to overview]	Percentage of Patients With Negative HDV RNA by PCR
NCT02888106 (13) [back to overview]	Number of Participants With Change (Improvement / Worsening) in Fibrosis and Histological Activity Stage From Baseline to Post-treatment
NCT02888106 (13) [back to overview]	Change in Molecular Analyses of Relative HDV RNA Expression, Relative HBV Pregenomic Expression, Relative Total HBV RNA Expression (X Region), Relative HBV RNA Expression (S Region).
NCT02888106 (13) [back to overview]	Change in Molecular Analyses of Total HBV DNA (X Region) Copies/Cell, HBV DNA (S Region) Copies/Cell, cccDNA Copies/Cell From Baseline to Post-treatment.
NCT02888106 (13) [back to overview]	Change in Molecular Analysis of HDAg Positive Hepatocytes (%) From Baseline to Post-treatment
NCT02888106 (13) [back to overview]	Change in the Gene Expression Analyses From Baseline to Post-treatment
NCT02888106 (13) [back to overview]	Percentage of Patients With Combined Response
NCT02888106 (13) [back to overview]	Percentage of Patients With Negative HDV RNA by PCR
NCT02962739 (1) [back to overview]	Steady State Concentrations of TFV-DP for Different Dosing Patterns of Descovy
NCT02968576 (2) [back to overview]	Area Under the Concentration-time Curve (AUC)
NCT02968576 (2) [back to overview]	Peak Plasma Concentration (Cmax)
NCT03048422 (23) [back to overview]	Cumulative Probability of Women Experiencing Grade 3 or Higher Adverse Event
NCT03048422 (23) [back to overview]	Maternal Change in Creatinine Clearance
NCT03048422 (23) [back to overview]	Percentage of Infants Born Small for Gestational Age
NCT03048422 (23) [back to overview]	Percentage of Mother-infant Pairs With an Adverse Pregnancy Outcome
NCT03048422 (23) [back to overview]	Percentage of Mother-Infant Pairs With an Adverse Pregnancy Outcome
NCT03048422 (23) [back to overview]	Percentage of Mother-infant Pairs With an Adverse Pregnancy Outcome or Major Congenital Anomaly
NCT03048422 (23) [back to overview]	Percentage of Mothers With HIV-1 ARV Drug Resistance Mutations at the Time of Maternal Virologic Failure
NCT03048422 (23) [back to overview]	Percentage of Mothers With HIV-1 RNA Less Than 200 Copies/mL at 50 Weeks Postpartum
NCT03048422 (23) [back to overview]	Percentage of Mothers With HIV-1 RNA Less Than 50 Copies/mL at Delivery Measured at Central Laboratory
NCT03048422 (23) [back to overview]	Percentage of Mothers With Virologic Success of HIV-1 RNA Less Than 200 Copies/mL at 50 Weeks Postpartum Based on FDA Snapshot Algorithm
NCT03048422 (23) [back to overview]	Percentage of Mothers With Virologic Success of HIV-1 RNA Less Than 200 Copies/mL at Delivery Based on FDA Snapshot Algorithm
NCT03048422 (23) [back to overview]	Time to First HIV-1 RNA Less Than 200 Copies/mL Through Delivery
NCT03048422 (23) [back to overview]	Change in Maternal Weight Antepartum
NCT03048422 (23) [back to overview]	Change in Maternal Weight Overall
NCT03048422 (23) [back to overview]	Change in Maternal Weight Postpartum
NCT03048422 (23) [back to overview]	Count of Infants With HIV-1 Antiretroviral Drug Resistance Mutations at the Time of Infant HIV Diagnosis
NCT03048422 (23) [back to overview]	Infant Creatinine Clearance
NCT03048422 (23) [back to overview]	Percentage of Mothers With HIV-1 RNA Viral Load Less Than 200 Copies/mL at Delivery
NCT03048422 (23) [back to overview]	Percentage of Mother-Infant Pairs With Preterm Deliveries
NCT03048422 (23) [back to overview]	Cumulative Probability of Infant Deaths
NCT03048422 (23) [back to overview]	Cumulative Probability of Infant HIV-infection
NCT03048422 (23) [back to overview]	Cumulative Probability of Infants Experiencing Grade 3 or Higher Adverse Event
NCT03048422 (23) [back to overview]	Cumulative Probability of Infants Experiencing Grade 3 or Higher Adverse Event
NCT03126370 (6) [back to overview]	Change From Week 12 Plasma Tenofovir Area Under the Plasma Concentration vs. Time Curve From Time 0 to 24 Hours (AUC0-24) at 24 and 28 Weeks
NCT03126370 (6) [back to overview]	Change From Week 12 Tenofovir-diphosphate (TFV-DP) in Dried Blood Spots (DBS)
NCT03126370 (6) [back to overview]	Change From Week 12 Tenofovir-diphosphate (TFV-DP) in Peripheral Blood Mononuclear Cells (PBMCs) at 24 and 28 Weeks
NCT03126370 (6) [back to overview]	Change in Estimated Glomerular Filtration Rate (eGFR) and Renal Biomarkers: eGFR
NCT03126370 (6) [back to overview]	Change in Estimated Glomerular Filtration Rate (eGFR) and Renal Biomarkers: UPCR
NCT03126370 (6) [back to overview]	Change in Estimated Glomerular Filtration Rate (eGFR) and Renal Biomarkers: B2M/Cr Ratio, and RBP/Cr Ratio
NCT03164564 (2) [back to overview]	Number of Participants Who Experienced Grade 2 or Higher Clinical and Laboratory Adverse Events (AEs) in Steps 1 and 2
NCT03164564 (2) [back to overview]	Number of Pariicipants With Documented Incident HIV Infections
NCT03202511 (2) [back to overview]	PBMC TFV-DP AUC GMR
NCT03202511 (2) [back to overview]	Plasma TFV AUC0-INF GMR
NCT03218592 (4) [back to overview]	Whole Blood Antiretroviral Concentrations
NCT03218592 (4) [back to overview]	Plasma Antiretroviral Concentrations
NCT03218592 (4) [back to overview]	Peripheral Blood Mononuclear Cells (PBMC) Antiretroviral Concentrations
NCT03218592 (4) [back to overview]	Hair Antiretroviral Imaging
NCT03258710 (36) [back to overview]	Percentage of Eosinophils at Indicated Time Points
NCT03258710 (36) [back to overview]	Percentage of Basophils at Indicated Time Points
NCT03258710 (36) [back to overview]	Number of Participants With Worst Case Post-Baseline Electrocardiogram (ECG) Values
NCT03258710 (36) [back to overview]	Number of Participants With Abnormal Urinalysis Values at Weeks 60, 72, 84 and 96
NCT03258710 (36) [back to overview]	Absolute Values for Hematology Parameter: Hemoglobin
NCT03258710 (36) [back to overview]	Absolute Values for Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
NCT03258710 (36) [back to overview]	Absolute Values for Hematology Parameter: Prothrombin Time
NCT03258710 (36) [back to overview]	Absolute Values for Hematology Parameter: Red Blood Cell (RBC) Count
NCT03258710 (36) [back to overview]	Absolute Values for Hematology Parameter: Hematocrit
NCT03258710 (36) [back to overview]	Absolute Values for Heart Rate
NCT03258710 (36) [back to overview]	Absolute Values for Clinical Chemistry Parameters: Direct Bilirubin, Total Bilirubin, Creatinine and Uric Acid
NCT03258710 (36) [back to overview]	Absolute Values for Clinical Chemistry Parameters: Calcium, Chloride, Glucose, Potassium, Lactic Acid, Sodium, Phosphorus and Blood Urea Nitrogen (BUN)
NCT03258710 (36) [back to overview]	Absolute Values for Clinical Chemistry Parameters: Amylase and Lipase
NCT03258710 (36) [back to overview]	Percentage of Participants Who Achieved HBeAg/Ab Seroconversion at Weeks 24, 48 and 96
NCT03258710 (36) [back to overview]	Absolute Values for Clinical Chemistry Parameters: Alkaline Phosphate (ALP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Creatinine Kinase (CPK), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH)
NCT03258710 (36) [back to overview]	Absolute Values for Clinical Chemistry Parameters: Albumin and Total Protein
NCT03258710 (36) [back to overview]	Absolute Values for Clinical Chemistry Parameter: Glomerular Filtration Rate (GFR)
NCT03258710 (36) [back to overview]	Absolute Values for Clinical Chemistry Parameter: Creatinine Clearance
NCT03258710 (36) [back to overview]	Absolute Values for Clinical Chemistry Parameter: Alpha-fetoprotein (AFP)
NCT03258710 (36) [back to overview]	Absolute Values for Hematology Parameters: Platelet Count and White Blood Cell (WBC) Count
NCT03258710 (36) [back to overview]	Percentage of Participants Who Achieved 0.25 Log10 HBsAg Reduction From the Baseline at Weeks 24 and 96
NCT03258710 (36) [back to overview]	Absolute Values for Temperature
NCT03258710 (36) [back to overview]	Change From Baseline Log Values for HBcrAg Titer at Weeks 24, 48 and 96
NCT03258710 (36) [back to overview]	Change From Baseline Log Values for HBsAg Titer at Weeks 24, 48 and 96
NCT03258710 (36) [back to overview]	Change From Baseline Values for Beta-2-microglobulin
NCT03258710 (36) [back to overview]	Change From Baseline Values for Bone Density
NCT03258710 (36) [back to overview]	Change From Baseline Values for Urine Creatinine Concentration and Urine Phosphate
NCT03258710 (36) [back to overview]	Number of Participants Who Reported Serious Adverse Events (SAEs) and Non-serious Adverse Events (Non-SAEs)
NCT03258710 (36) [back to overview]	Number of Participants With Abnormal Urinalysis Values at Weeks 4, 12, 24, 36 and 48
NCT03258710 (36) [back to overview]	Percentage of Total Neutrophils at Indicated Time Points
NCT03258710 (36) [back to overview]	Percentage of Participants Who Achieved HBsAg/Ab Seroconversion at Weeks 24, 48 and 96
NCT03258710 (36) [back to overview]	Percentage of Participants Who Achieved HBsAg Loss at Weeks 24, 48 and 96
NCT03258710 (36) [back to overview]	Percentage of Participants Who Achieved HBeAg Loss at Weeks 24, 48 and 96
NCT03258710 (36) [back to overview]	Percentage of Participants Who Achieved 0.25 Logarithm to the Base 10 (Log10) Hepatitis B Surface Antigen (HBsAg) Reduction From the Baseline at Week 48
NCT03258710 (36) [back to overview]	Percentage of Monocytes at Indicated Time Points
NCT03258710 (36) [back to overview]	Percentage of Lymphocytes at Indicated Time Points
NCT03272347 (18) [back to overview]	Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 48
NCT03272347 (18) [back to overview]	Change From Baseline in Mature T-helper (CD4+ T)-Cell Count at Week 24
NCT03272347 (18) [back to overview]	Change From Baseline in CD4+ T-cell Count at Week 96
NCT03272347 (18) [back to overview]	Change From Baseline in CD4+ T-cell Count at Week 192 (Part 4)
NCT03272347 (18) [back to overview]	Percentage of Participants With HIV-1 RNA <50 Copies/mL up to 48 Weeks After Starting Open-label Doravirine/Islatravir Regimen (Part 4)
NCT03272347 (18) [back to overview]	Percentage of Participants With HIV-1 RNA <50 Copies/mL up to 48 Weeks After 3TC and Placebo Are Discontinued From the Regimen
NCT03272347 (18) [back to overview]	Percentage of Participants With HIV-1 RNA <50 Copies/mL up to 24 Weeks After 3TC and Placebo Are Discontinued From the Regimen
NCT03272347 (18) [back to overview]	Number of Participants Discontinuing Study Drug Due to AEs up to Week 144
NCT03272347 (18) [back to overview]	Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 24
NCT03272347 (18) [back to overview]	Number of Participants Experiencing AEs Through 24 Weeks After 3TC and Placebo Are Discontinued From the Regimen
NCT03272347 (18) [back to overview]	Number of Participants Experiencing AEs From Week 96 Through Study Duration
NCT03272347 (18) [back to overview]	Number of Participants Experiencing AEs During Open Label Doravirine/Islatravir Treatment After Week 144 up to Week 192 (Part 4)
NCT03272347 (18) [back to overview]	Change From Baseline in CD4+ T-cell Count at Week 144
NCT03272347 (18) [back to overview]	Number of Participants Discontinuing Study Drug Due to AEs During Open Label Doravirine/Islatravir Treatment After Week 144 up to Week 192 (Part 4)
NCT03272347 (18) [back to overview]	Number of Participants Discontinuing Study Drug Due to AEs From Week 96 Through Study Duration
NCT03272347 (18) [back to overview]	Number of Participants Discontinuing Study Drug Due to AEs Through 24 Weeks After 3TC and Placebo Are Discontinued From the Regimen
NCT03272347 (18) [back to overview]	Number of Participants Experiencing Adverse Events (AEs) up to Week 144
NCT03272347 (18) [back to overview]	Change From Baseline in CD4+ T-cell Count at Week 48
NCT03332095 (38) [back to overview]	Summary of Changes in CD4 Count From Baseline to Week 96 (Cohort 2)
NCT03332095 (38) [back to overview]	Summary of Changes in CD4 Count From Baseline to Week 48 (Cohort 2)
NCT03332095 (38) [back to overview]	Summary of Changes in CD4 Count From Baseline to Week 24 (Cohort 2)
NCT03332095 (38) [back to overview]	PK Parameter: Single-dose Maximum Concentration (Cmax) of DOR (Cohort 1)
NCT03332095 (38) [back to overview]	PK Parameter: Single-dose 24 Hour-concentration (C24hr) of DOR (Cohort 1)
NCT03332095 (38) [back to overview]	PK Parameter: Cmax of Tenofovir (Cohort 2)
NCT03332095 (38) [back to overview]	PK Parameter: Cmax of DOR (Cohort 2)
NCT03332095 (38) [back to overview]	PK Parameter: Cmax of 3TC (Cohort 2)
NCT03332095 (38) [back to overview]	PK Parameter: C24hr of DOR (Cohort 2)
NCT03332095 (38) [back to overview]	PK Parameter: C24hr of 3TC (Cohort 2)
NCT03332095 (38) [back to overview]	Percentage of Participants With Permanent Discontinuation of Study Drug Due to Adverse Events Assessed as Related to Study Drug
NCT03332095 (38) [back to overview]	Percentage of Participants With Grade 5 Adverse Events (Death) Regardless of Relationship to Study Drug (Cohort 2) Through End of Study
NCT03332095 (38) [back to overview]	Summary of log10 Drop From Baseline to Week 48 in Plasma HIV-1 RNA (ART-naive Participants) (Cohort 2)
NCT03332095 (38) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA Less Than 50 Copies/mL at Week 24 (Cohort 2)
NCT03332095 (38) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA Less Than 50 Copies/mL at Week 48 (Cohort 2)
NCT03332095 (38) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA Less Than 50 Copies/mL at Week 96 (Cohort 2)
NCT03332095 (38) [back to overview]	Percentage of Participants With Serious Adverse Events (SAEs) Assessed as Related to Study Drug
NCT03332095 (38) [back to overview]	Percentage of Participants With Serious Adverse Events Assessed as Related to Study Drug (Cohort 2) Through End of Study
NCT03332095 (38) [back to overview]	Pharmacokinetic (PK) Parameter: Single-dose Area-under-the-curve (AUC0-∞) of Doravirine (DOR) (Cohort 1)
NCT03332095 (38) [back to overview]	PK Parameter: AUC0-24hr of 3TC (Cohort 2)
NCT03332095 (38) [back to overview]	PK Parameter: AUC0-24hr of DOR (Cohort 2)
NCT03332095 (38) [back to overview]	PK Parameter: AUC0-24hr of Tenofovir (Cohort 2)
NCT03332095 (38) [back to overview]	Percentage of Participants With Grade 3 or Higher Adverse Events Assessed as Related to Study Drug (Cohort 2) Through End of Study
NCT03332095 (38) [back to overview]	Percentage of Participants With Grade 3 or Higher Adverse Events (AEs) Assessed as Related to Study Drug
NCT03332095 (38) [back to overview]	Percentage of Participants With Grade 5 Adverse Events (Death) Regardless of Relationship to Study Drug
NCT03332095 (38) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA Less Than 40 Copies/mL at Week 48 (Cohort 2)
NCT03332095 (38) [back to overview]	PK Parameter: C24hr of Tenofovir (Cohort 2)
NCT03332095 (38) [back to overview]	Summary of log10 Drop From Baseline to Week 96 in Plasma HIV-1 RNA (ART-naive Participants) (Cohort 2)
NCT03332095 (38) [back to overview]	Summary of log10 Drop From Baseline to Week 24 in Plasma HIV-1 RNA (ART-naive Participants) (Cohort 2)
NCT03332095 (38) [back to overview]	Summary of Changes in CD4% From Baseline to Week 96 (Cohort 2)
NCT03332095 (38) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA Less Than 40 Copies/mL at Week 96 (Cohort 2)
NCT03332095 (38) [back to overview]	Summary of Changes in CD4% From Baseline to Week 48 (Cohort 2)
NCT03332095 (38) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA Less Than 40 Copies/mL at Week 24 (Cohort 2)
NCT03332095 (38) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA Less Than 200 Copies/mL at Week 96 (Cohort 2)
NCT03332095 (38) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA Less Than 200 Copies/mL at Week 48 (Cohort 2)
NCT03332095 (38) [back to overview]	Percentage of Participants With Plasma HIV-1 RNA Less Than 200 Copies/mL at Week 24 (Cohort 2)
NCT03332095 (38) [back to overview]	Percentage of Participants With Permanent Discontinuation of Study Drug Due to Adverse Events Assessed as Related to Study Drug (Cohort 2) Through End of Study
NCT03332095 (38) [back to overview]	Summary of Changes in CD4% From Baseline to Week 24 (Cohort 2)
NCT03387462 (4) [back to overview]	DOT Diary Mobile App Ease of Use
NCT03387462 (4) [back to overview]	Adherence and Persistence of Use of the DOT and Sexual Diary Components of DOT Diary by Young MSM on PrEP
NCT03387462 (4) [back to overview]	Assessment of Situations and Reasons for Sub-optimal Use of the App
NCT03387462 (4) [back to overview]	DOT Diary Mobile App Acceptability
NCT03471624 (4) [back to overview]	The Mean Bone Mass Density (T-score) Change
NCT03471624 (4) [back to overview]	Number of Participants With Normal Alanine Aminotransferase (ALT).
NCT03471624 (4) [back to overview]	Calculated eGFR
NCT03471624 (4) [back to overview]	Number of Participants With HBV DNA <20 IU Per mL
NCT03510468 (1) [back to overview]	Plasma Area Under the Curve (AUC) for Tenofovir (TFV) During the Dosing Interval of 0 to 24 Hours (AUC0-24hr)
NCT03512964 (4) [back to overview]	Number of Patients Who Accepted Rapid HIV Treatment Initiation
NCT03512964 (4) [back to overview]	Rapid HIV Treatment Initiation Acceptability as Assessed by the Number of Patients Who Respond Yes to Starting ART Same Day
NCT03512964 (4) [back to overview]	Number of Patients Who Receive Rapid HIV Treatment Initiation
NCT03512964 (4) [back to overview]	Number of Patients Offered Rapid HIV Treatment Initiation
NCT03537404 (10) [back to overview]	AUCtau of Raltegravir
NCT03537404 (10) [back to overview]	AUCtau of Narlaprevir
NCT03537404 (10) [back to overview]	AUCtau of Tenofovir
NCT03537404 (10) [back to overview]	Number of Patients With Abnormal ECG Changes
NCT03537404 (10) [back to overview]	Number of Patients With Changes in Vital Signs
NCT03537404 (10) [back to overview]	Number of Patients With Adverse Events
NCT03537404 (10) [back to overview]	Cmax of Tenofovir
NCT03537404 (10) [back to overview]	Cmax of Raltegravir
NCT03537404 (10) [back to overview]	Cmax of Narlaprevir
NCT03537404 (10) [back to overview]	Number of Patients With Abnormal Laboratory Values
NCT03546621 (8) [back to overview]	Number of Participants With Improvement of Histological Findings According to the Liver Biopsy Results
NCT03546621 (8) [back to overview]	Combined Response: HDV RNA Response and Normal ALT at Treatment Week 24
NCT03546621 (8) [back to overview]	Durability of HDV RNA Response
NCT03546621 (8) [back to overview]	Changes in ALT Values
NCT03546621 (8) [back to overview]	Change in Hepatitis B Surface Antigen
NCT03546621 (8) [back to overview]	Change (Absence of Increase) in Fibrosis Marker
NCT03546621 (8) [back to overview]	Absence of a Fibrosis Progression According to the Findings of Transient Elastometry
NCT03546621 (8) [back to overview]	Change in HBV DNA Levels at Week 24 and Week 48 Compared to Baseline
NCT03567382 (5) [back to overview]	Number of Infants Receiving Timely Birth Dose Vaccination
NCT03567382 (5) [back to overview]	Number of Participants With Lab Testing Acceptability Survey Scores >80%
NCT03567382 (5) [back to overview]	Number of Mothers With Infant Vaccination Acceptability Survey Scores >80%
NCT03567382 (5) [back to overview]	Number of Mothers With High-risk HBV Demonstrating Adherence to Tenofovir Therapy
NCT03567382 (5) [back to overview]	Number of Infants With HBV Positivity at 6 Months of Life to Indicate Mother-to-Child Transmission of HBV
NCT03576066 (12) [back to overview]	Trough Levels of Tenofovir Disoproxil Fumarate (TDF) on ABI-H0731 + SOC NUC Therapy as Compared With Placebo + SOC NUC Therapy
NCT03576066 (12) [back to overview]	Number of Participants With a Clinically-significant Change in Vital Signs
NCT03576066 (12) [back to overview]	Number of Participants With a Clinically-significant Electrocardiogram Abnormality
NCT03576066 (12) [back to overview]	Number of Participants With Abnormal Alanine Aminotransferase (ALT) at Baseline Who Have Normal ALT at Week 24 on ABI-H0731 + NUC Therapy as Compared With Placebo + NUC Therapy
NCT03576066 (12) [back to overview]	Number of Participants With One or More Abnormal Safety Laboratory Result
NCT03576066 (12) [back to overview]	Number of Participants With One or More Adverse Events
NCT03576066 (12) [back to overview]	Number of Participants With Premature Study Discontinuation
NCT03576066 (12) [back to overview]	Change in Mean log10 Serum HBeAg From Baseline (Day 1) to Week 24 on ABI-H0731 + SOC NUC as Compared to Placebo + SOC NUC
NCT03576066 (12) [back to overview]	Change in Mean log10 Serum HBsAg From Baseline (Day 1) to Week 24 on ABI-H0731 + SOC NUC as Compared to Placebo + SOC NUC
NCT03576066 (12) [back to overview]	Trough Levels of ABI-H0731 on ABI-H0731 + SOC NUC Therapy
NCT03576066 (12) [back to overview]	Trough Levels of Entecavir (ETV) on ABI-H0731 + SOC NUC Therapy as Compared With Placebo + SOC NUC Therapy
NCT03576066 (12) [back to overview]	Trough Levels of Tenofovir Alafenamide (TAF) on ABI-H0731 + SOC NUC Therapy as Compared With Placebo + SOC NUC Therapy
NCT03593655 (4) [back to overview]	Percentage of Participants Reporting Preference for Dapivirine VR as Compared to FTC/TDF Oral Tablets
NCT03593655 (4) [back to overview]	Number of Participant-Visits Reporting Acceptability of Study Product
NCT03593655 (4) [back to overview]	Number of Participants With Grade 2 or Higher Adverse Events (AEs)
NCT03593655 (4) [back to overview]	Number of Participant-Visits With No Product Use
NCT03656783 (5) [back to overview]	Change in Serum Biomarkers of Inflammation (Hs-CRP (in mg/L))
NCT03656783 (5) [back to overview]	Change in Myocyte Injury and Strain (hs Troponin (in ng/L))
NCT03656783 (5) [back to overview]	Change in Myocyte Injury and Strain (NT-proBNP (in pg/mL))
NCT03656783 (5) [back to overview]	Change in Peak Stress Global MBF
NCT03656783 (5) [back to overview]	Change in Global CFR
NCT03717129 (9) [back to overview]	EVG Cmax
NCT03717129 (9) [back to overview]	AUC0-∞ for FTC
NCT03717129 (9) [back to overview]	Area Under the Curve From 0 to Infinity (AUC0-∞) for EVG
NCT03717129 (9) [back to overview]	TFV Half-life
NCT03717129 (9) [back to overview]	TFV Cmax
NCT03717129 (9) [back to overview]	FTC Half-life
NCT03717129 (9) [back to overview]	EVG Half-life
NCT03717129 (9) [back to overview]	FTC Cmax
NCT03717129 (9) [back to overview]	AUC0-∞ for Tenofovir (TFV)
NCT03780543 (5) [back to overview]	Number of Subjects With Suppression/Loss of Viral HBeAg Antigen/DNA on Combination Treatment Whose Viral Antigens Rebound Off Therapy
NCT03780543 (5) [back to overview]	Sustained Viral Response (SVR) at 24 Weeks Off Treatment
NCT03780543 (5) [back to overview]	Number of Subjects With Abnormal Alanine Aminotransferase (ALT) at Baseline Who Have Normal ALT at End of Treatment (EOT) and End of Study (EOS)
NCT03780543 (5) [back to overview]	Number of Subjects With Adverse Events
NCT03780543 (5) [back to overview]	Number of Subjects With Suppression/Loss of Viral Core-related Antigen/DNA on Combination Treatment Whose Viral Antigens Rebound Off Therapy
NCT03797014 (10) [back to overview]	ALT Normalization at Week 24
NCT03797014 (10) [back to overview]	HBeAg Loss at Week 48
NCT03797014 (10) [back to overview]	CD4 Cell Count Change at Week 24
NCT03797014 (10) [back to overview]	CD4 Cell Count Change at Week 48
NCT03797014 (10) [back to overview]	HBsAg Loss at Week 48
NCT03797014 (10) [back to overview]	HBV DNA at Week 24
NCT03797014 (10) [back to overview]	HBV DNA at Week 48
NCT03797014 (10) [back to overview]	HIV-1 RNA at Week 24
NCT03797014 (10) [back to overview]	HIV-1 RNA at Week 48
NCT03797014 (10) [back to overview]	ALT Normalization at Week 48
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Hematology Parameter of MCV
NCT03836729 (107) [back to overview]	Period 2: Time of Maximum Observed Concentration (Tmax) of GSK3640254
NCT03836729 (107) [back to overview]	Period 2: Tmax of FTC
NCT03836729 (107) [back to overview]	Period 2: Tmax of TAF
NCT03836729 (107) [back to overview]	Period 2: Tmax of TFV
NCT03836729 (107) [back to overview]	Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAE)
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of Blood Pressure
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of Chemistry Parameters of Lipase and Amylase
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of Clinical Chemistry Parameter of Alkaline Phosphatase, ALT, AST, LDH, GGT, and CK
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of Specific Gravity of Urine
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of Respiratory Rate
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of Pulse Rate
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of pH of Urine
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of Pulse Rate
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of Heart Rate
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF Interval, and QTcB Interval
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of Clinical Chemistry Parameter of Total Protein, Albumin and Globulin
NCT03836729 (107) [back to overview]	Period 1: Area Under the Plasma Concentration-time Curve From Time 0 to the End of the Dosing Interval at Steady State (AUC [0-tau]) of TAF
NCT03836729 (107) [back to overview]	Period 1: AUC (0-tau) of FTC
NCT03836729 (107) [back to overview]	Period 1: AUC (0-tau) of Tenofovir (TFV)
NCT03836729 (107) [back to overview]	Period 1: Cmax of TFV
NCT03836729 (107) [back to overview]	Period 1: Ctau of TFV
NCT03836729 (107) [back to overview]	Period 1: Maximum Observed Concentration (Cmax) of TAF
NCT03836729 (107) [back to overview]	Period 1: Plasma Concentration at the End of the Dosing Interval (Ctau) of FTC
NCT03836729 (107) [back to overview]	Period 1: Tmax of FTC
NCT03836729 (107) [back to overview]	Period 1: Tmax of TAF
NCT03836729 (107) [back to overview]	Period 1: Tmax of TFV
NCT03836729 (107) [back to overview]	Period 1:Cmax of FTC
NCT03836729 (107) [back to overview]	Period 2: AUC (0-tau) of FTC
NCT03836729 (107) [back to overview]	Period 2: AUC (0-tau) of GSK3640254
NCT03836729 (107) [back to overview]	Period 2: AUC (0-tau) of TAF
NCT03836729 (107) [back to overview]	Period 2: AUC (0-tau) of TFV
NCT03836729 (107) [back to overview]	Period 2: Cmax of GSK3640254
NCT03836729 (107) [back to overview]	Period 2: Cmax of TAF
NCT03836729 (107) [back to overview]	Period 2: Cmax of TFV
NCT03836729 (107) [back to overview]	Period 2: Ctau of FTC
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Blood Pressure
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Clinical Chemistry Parameter of Alkaline Phosphatase, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Lactate Dehydrogenase (LDH), Gamma-glutamyl Transferase (GGT), and Creatine Phosphokinase (CK)
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Clinical Chemistry Parameter of Glucose, Anion Gap, Cholesterol, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), Carbon Dioxide (CO2), Chloride and Phosphorus
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Clinical Chemistry Parameter of Lipase and Amylase
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Clinical Chemistry Parameter of Total Bilirubin, Direct Bilirubin, and Creatinine
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Clinical Chemistry Parameter of Total Protein, Albumin and Globulin
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF) Interval, and Bazett QT Correction Formula (QTcB) Interval
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Heart Rate
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Hematology Parameter of Erythrocytes
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Hematology Parameter of Hematocrit
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Hematology Parameter of Hemoglobin
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Hematology Parameter of Mean Corpuscle Hemoglobin (MCH)
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Hematology Parameter of Platelet Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Potential of Hydrogen (pH) of Urine
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Pulse Rate
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Respiratory Rate
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Specific Gravity of Urine
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Temperature
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Urine Urobilinogen
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of Blood Pressure
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of Chemistry Parameters of Lipase and Amylase
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of Clinical Chemistry Parameter of Alkaline Phosphatase, ALT, AST, LDH, GGT, and CK
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of Clinical Chemistry Parameter of Glucose, Anion Gap, Cholesterol, Calcium, Potassium, Sodium, BUN, CO2, Chloride and Phosphorus
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of Clinical Chemistry Parameter of Total Bilirubin, Direct Bilirubin, and Creatinine
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of Clinical Chemistry Parameter of Total Protein, Albumin and Globulin
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF Interval, and QTcB Interval
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of Heart Rate
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of pH of Urine
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of Respiratory Rate
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of Specific Gravity of Urine
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of Temperature
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of the Hematology Parameter of Platelet Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of the Hematology Parameter: Erythrocytes
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of the Hematology Parameter: Hematocrit
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of the Hematology Parameter: Hemoglobin
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of the Hematology Parameter: MCH
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of the Hematology Parameter: MCV
NCT03836729 (107) [back to overview]	Period 2: Absolute Values of Urine Urobilinogen
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Blood Pressure
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Clinical Chemistry Parameter of Alkaline Phosphatase, ALT, AST, LDH, GGT, and CK
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Clinical Chemistry Parameter of Glucose, Anion Gap, Cholesterol, Calcium, Potassium, Sodium, BUN, CO2, Chloride and Phosphorus
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Clinical Chemistry Parameter of Lipase and Amylase
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Clinical Chemistry Parameter of Total Bilirubin, Direct Bilirubin, and Creatinine
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Clinical Chemistry Parameter of Total Protein, Albumin and Globulin
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF Interval, and QTcB Interval
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Heart Rate
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Hematology Parameter of Erythrocytes
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Hematology Parameter of Hematocrit
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Hematology Parameter of Hemoglobin
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Hematology Parameter of MCH
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Hematology Parameter of Platelet Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in pH of Urine
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Pulse Rate
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Respiratory Rate
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Specific Gravity of Urine
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Temperature
NCT03836729 (107) [back to overview]	Period 2: Change From Baseline in Urine Urobilinogen
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of Clinical Chemistry Parameter of Glucose, Anion Gap, Cholesterol, Calcium, Potassium, Sodium, BUN, CO2, Chloride and Phosphorus
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of Urine Urobilinogen
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of the Hematology Parameter: MCV
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of the Hematology Parameter: MCH
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of the Hematology Parameter: Hemoglobin
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of the Hematology Parameter: Hematocrit
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of the Hematology Parameter: Erythrocytes
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of the Hematology Parameter of Platelet Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of Temperature
NCT03836729 (107) [back to overview]	Period 2: Ctau of GSK3640254
NCT03836729 (107) [back to overview]	Period 2: Ctau of TFV
NCT03836729 (107) [back to overview]	Period 1: Absolute Values of Clinical Chemistry Parameter of Total Bilirubin, Direct Bilirubin, and Creatinine
NCT03836729 (107) [back to overview]	Period 2:Cmax of FTC
NCT03836729 (107) [back to overview]	Period 1: Change From Baseline in Hematology Parameter of Mean Corpuscle Volume (MCV)
NCT03917420 (11) [back to overview]	Average Tenofovir Concentrations in Plasma.
NCT03917420 (11) [back to overview]	Average Tenofovir Diphosphate Concentrations Measured in Mixed Rectal Cells During the Late (High Estradiol) Follicular Phases of the Menstrual Cycle.
NCT03917420 (11) [back to overview]	Average Emtricitabine Concentrations in Peripheral Blood Mononuclear Cells.
NCT03917420 (11) [back to overview]	Average Emtricitabine Concentrations in Plasma.
NCT03917420 (11) [back to overview]	Average Emtricitabine Triphosphate Concentrations Measured in Mixed Rectal Cells During the Early (Low Estradiol) Follicular Phases of the Menstrual Cycle.
NCT03917420 (11) [back to overview]	Average Emtricitabine Triphosphate Concentrations Measured in Mixed Rectal Cells During the Late (High Estradiol) Follicular Phases of the Menstrual Cycle.
NCT03917420 (11) [back to overview]	Average Tenofovir Diphosphate Concentrations in Peripheral Blood Mononuclear Cells.
NCT03917420 (11) [back to overview]	Average Tenofovir Diphosphate Concentrations in Mixed Rectal Cells During the Early (Low Estradiol) Follicular Phases of the Menstrual Cycle.
NCT03917420 (11) [back to overview]	Average Progesterone Concentrations in Serum.
NCT03917420 (11) [back to overview]	Average Estradiol Concentrations in Serum.
NCT03917420 (11) [back to overview]	Average Testosterone Concentrations in Serum.
NCT03976752 (40) [back to overview]	Peripheral Blood Mononuclear Cell (PBMC) Concentration of Emtricitabine-triphosphate (FTC-TP)
NCT03976752 (40) [back to overview]	Peripheral Blood Mononuclear Cell (PBMC) Concentration of Emtricitabine-triphosphate (FTC-TP)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Elvitegravir (EVG)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Tenofovir-diphosphate (TFV-DP)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Tenofovir-diphosphate (TFV-DP)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Tenofovir-diphosphate (TFV-DP)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Tenofovir-diphosphate (TFV-DP)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Tenofovir (TFN)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Tenofovir (TFN)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Tenofovir (TFN)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Tenofovir (TFN)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Emtricitabine-triphosphate (FTC-TP)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Emtricitabine-triphosphate (FTC-TP)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Emtricitabine-triphosphate (FTC-TP)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Emtricitabine-triphosphate (FTC-TP)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Emtricitabine (FTC)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Emtricitabine (FTC)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Emtricitabine (FTC)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Emtricitabine (FTC)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Elvitegravir (EVG)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Elvitegravir (EVG)
NCT03976752 (40) [back to overview]	Rectal Tissue Concentration of Elvitegravir (EVG)
NCT03976752 (40) [back to overview]	Plasma Concentration of Tenofovir (TFV)
NCT03976752 (40) [back to overview]	Plasma Concentration of Tenofovir (TFV)
NCT03976752 (40) [back to overview]	Plasma Concentration of Tenofovir (TFV)
NCT03976752 (40) [back to overview]	Plasma Concentration of Tenofovir (TFV)
NCT03976752 (40) [back to overview]	Plasma Concentration of Emtricitabine (FTC)
NCT03976752 (40) [back to overview]	Plasma Concentration of Emtricitabine (FTC)
NCT03976752 (40) [back to overview]	Plasma Concentration of Emtricitabine (FTC)
NCT03976752 (40) [back to overview]	Plasma Concentration of Emtricitabine (FTC)
NCT03976752 (40) [back to overview]	Plasma Concentration of Elvitegravir (EVG)
NCT03976752 (40) [back to overview]	Plasma Concentration of Elvitegravir (EVG)
NCT03976752 (40) [back to overview]	Plasma Concentration of Elvitegravir (EVG)
NCT03976752 (40) [back to overview]	Plasma Concentration of Elvitegravir (EVG)
NCT03976752 (40) [back to overview]	Peripheral Blood Mononuclear Cell (PBMC) Concentration of Tenofovir-diphosphate (TFV-DP)
NCT03976752 (40) [back to overview]	Peripheral Blood Mononuclear Cell (PBMC) Concentration of Tenofovir-diphosphate (TFV-DP)
NCT03976752 (40) [back to overview]	Peripheral Blood Mononuclear Cell (PBMC) Concentration of Tenofovir-diphosphate (TFV-DP)
NCT03976752 (40) [back to overview]	Peripheral Blood Mononuclear Cell (PBMC) Concentration of Tenofovir-diphosphate (TFV-DP)
NCT03976752 (40) [back to overview]	Peripheral Blood Mononuclear Cell (PBMC) Concentration of Emtricitabine-triphosphate (FTC-TP)
NCT03976752 (40) [back to overview]	Peripheral Blood Mononuclear Cell (PBMC) Concentration of Emtricitabine-triphosphate (FTC-TP)
NCT03998176 (4) [back to overview]	Percentage of Participants With Grade 3 or Greater Adverse Events
NCT03998176 (4) [back to overview]	Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Determined by the FDA-defined Snapshot Algorithm
NCT03998176 (4) [back to overview]	Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Determined by the FDA-defined Snapshot Algorithm
NCT03998176 (4) [back to overview]	Percentage of Participants With Grade 3 or Greater Adverse Events
NCT04050371 (3) [back to overview]	Tenofovir Diphosphate Concentration in Dried Blood Spots (DBS)
NCT04050371 (3) [back to overview]	Estradiol Concentration
NCT04050371 (3) [back to overview]	Total Testosterone
NCT04140266 (26) [back to overview]	Number of Infant Participants With Grade 3 or Higher AEs in Both Study Arms
NCT04140266 (26) [back to overview]	Participant Willingness to Use Their Assigned Study Products During Breastfeeding in the Future (Y/N)
NCT04140266 (26) [back to overview]	Proportion of Participants Who Find Their Study Product to be at Least as Acceptable as Other HIV Prevention Methods
NCT04140266 (26) [back to overview]	Geometric Mean of Infant DPV Concentrations From Plasma by Visit
NCT04140266 (26) [back to overview]	Geometric Mean of Infant FTC-TP Concentration by Visit
NCT04140266 (26) [back to overview]	Geometric Mean of Maternal DPV Concentrations From Breastmilk by Visit
NCT04140266 (26) [back to overview]	Number and Proportion of Mothers With Detectable Breastmilk TFV Concentrations
NCT04140266 (26) [back to overview]	Number and Proportion of Mothers With Detectable Breastmilk FTC Concentrations
NCT04140266 (26) [back to overview]	Geometric Mean of Maternal TFV-DP Concentrations by Visit
NCT04140266 (26) [back to overview]	Geometric Mean of Maternal TFV Concentrations From Breastmilk by Visit
NCT04140266 (26) [back to overview]	Geometric Mean of Maternal FTC-TP Concentrations by Visit
NCT04140266 (26) [back to overview]	Geometric Mean of Maternal FTC Concentrations From Breastmilk by Visit
NCT04140266 (26) [back to overview]	Geometric Mean of Maternal DPV Concentrations From Plasma by Visit
NCT04140266 (26) [back to overview]	Number and Proportion of Mothers With Detectable Emtricitabine Triphosphate (FTC-TP) Concentrations
NCT04140266 (26) [back to overview]	Number and Proportion of Mothers With Detectable Breastmilk DPV Concentrations
NCT04140266 (26) [back to overview]	Geometric Mean of Infant TFV-DP Concentrations by Visit
NCT04140266 (26) [back to overview]	Number of Mother Participants With Serious Adverse Events (SAEs) Including Maternal Deaths in Both Study Arms
NCT04140266 (26) [back to overview]	Number and Proportion of Infants With Detectable TFV-DP Concentrations
NCT04140266 (26) [back to overview]	Number and Proportion of Infants With Detectable Plasma DPV Concentrations
NCT04140266 (26) [back to overview]	Number and Proportion of Infants With Detectable FTC-TP Concentrations
NCT04140266 (26) [back to overview]	Number and Proportion of Mothers With Detectable Plasma Dapivirine (DPV) Concentrations
NCT04140266 (26) [back to overview]	The Number of Mothers Non-adherent to Study Product for Each Month of Product Use by Study Product
NCT04140266 (26) [back to overview]	Residual Drug Levels in Returned VRs
NCT04140266 (26) [back to overview]	Number and Proportion of Mothers With Detectable Tenofovir Diphosphate (TFV-DP) Concentrations
NCT04140266 (26) [back to overview]	Number of Mother Participants With Grade 3 or Higher Adverse Events (AEs) in Both Study Arms
NCT04140266 (26) [back to overview]	Number of Infant Participants With SAEs Including Infant Deaths in Both Study Arms
NCT04233879 (8) [back to overview]	Change From Baseline in Body Weight at Week 48
NCT04233879 (8) [back to overview]	Change From Baseline in Cluster of Differentiation 4+ (CD4+) T-Cell Counts at Week 48
NCT04233879 (8) [back to overview]	Incidence of Viral Resistance-Associated Substitutions (RASs) at Week 48
NCT04233879 (8) [back to overview]	Percentage of Participants Who Discontinued Study Treatment Due to an AE up to Week 48
NCT04233879 (8) [back to overview]	Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 48
NCT04233879 (8) [back to overview]	Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48
NCT04233879 (8) [back to overview]	Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 48
NCT04233879 (8) [back to overview]	Percentage of Participants Who Experienced an Adverse Event (AE) up to Week 48
NCT04318210 (7) [back to overview]	Number of Sex Acts by Condom Usage
NCT04318210 (7) [back to overview]	Self-reported Drug Adherence Over the Past 3 Days
NCT04318210 (7) [back to overview]	Serious Adverse Events
NCT04318210 (7) [back to overview]	Number of Sex Partners
NCT04318210 (7) [back to overview]	HIV Seroconversion
NCT04318210 (7) [back to overview]	Extracellular Tenofovir (TFV) for Recent Drug Exposure
NCT04318210 (7) [back to overview]	Intracellular Tenofovir-diphosphate (TFV-DP)
NCT04465916 (2) [back to overview]	HBsAg Change (Δ log10) From Day 1 to Week 16 of Treatment
NCT04465916 (2) [back to overview]	Virologic Failure Rate
NCT04686279 (3) [back to overview]	Acceptability of TFV Douche as Assessed by Product Acceptability Questionnaire
NCT04686279 (3) [back to overview]	Safety of TFV Douche as Assessed by the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events
NCT04686279 (3) [back to overview]	Tenofovir Diphosphate (TFV-DP) Concentration
NCT04820686 (20) [back to overview]	Change From Baseline in Mean log10 Serum Hepatitis B Surface Antigen (HBsAg) Off-Treatment
NCT04820686 (20) [back to overview]	Change From Baseline in Mean log10 Serum Hepatitis B Surface Antigen (HBsAg) Off-Treatment
NCT04820686 (20) [back to overview]	Change From Baseline in Mean log10 HBV RNA Off-Treatment
NCT04820686 (20) [back to overview]	Number of Participants With One or More Adverse Events (AEs)
NCT04820686 (20) [back to overview]	Number of Participants With One or More Abnormal Laboratory Result
NCT04820686 (20) [back to overview]	Change From Baseline in Mean log10 Hepatitis B Core-related Antigen (HBcrAg) On-Treatment
NCT04820686 (20) [back to overview]	Change From Baseline in Mean log10 Serum Hepatitis B Surface Antigen (HBsAg) On-Treatment
NCT04820686 (20) [back to overview]	Change From Baseline in Mean log10 HBV RNA On-Treatment
NCT04820686 (20) [back to overview]	Number of Participants With Premature Treatment Discontinuation Due to AEs
NCT04820686 (20) [back to overview]	Number of Participants With Premature Treatment Discontinuation Due to AEs
NCT04820686 (20) [back to overview]	Change From Baseline in Mean log10 Hepatitis B Core-related Antigen (HBcrAg) Off-Treatment
NCT04820686 (20) [back to overview]	Change From Baseline in Mean log10 Hepatitis B Core-related Antigen (HBcrAg) Off-Treatment
NCT04820686 (20) [back to overview]	Change From Baseline in Mean log10 HBV RNA On-Treatment
NCT04820686 (20) [back to overview]	Change From Baseline in Mean log10 HBV RNA Off-Treatment
NCT04820686 (20) [back to overview]	Change From Baseline in Mean log10 HBV RNA Off-Treatment
NCT04820686 (20) [back to overview]	Number of Participants With Premature Treatment Discontinuation Due to AEs
NCT04820686 (20) [back to overview]	Change From Baseline in Mean log10 HBV RNA Off-Treatment
NCT04820686 (20) [back to overview]	Change From Baseline in Mean log10 Serum Hepatitis B Surface Antigen (HBsAg) Off-Treatment
NCT04820686 (20) [back to overview]	Change From Baseline in Mean log10 Serum Hepatitis B Surface Antigen (HBsAg) Off-Treatment
NCT04820686 (20) [back to overview]	Change From Baseline in Mean log10 Serum Hepatitis B Surface Antigen (HBsAg) On-Treatment
NCT04897737 (2) [back to overview]	Participant Partners Who Tested for HIV
NCT04897737 (2) [back to overview]	Recent PrEP Adherence

Participants Achieving Virologic Half Log Suppression (LOQ = 50 c/mL) at Week 24

(NCT00035932)
Timeframe: Week 24

Intervention	participants (Number)
ATV 300 mg / RTV	95
ATV 400 mg / SQV	74
LPV / RTV	93

Intervention	msec (Mean)
	Baseline Mean (n=119, 110, 118)	Mean Change at Week 4 predose (n=117, 104, 110)	Mean Change Wk 4 2-3 hrs postdose (n=113,102,106)	Mean Change Wk 4 6-12 hrs postdose (n=112,101,105)	Mean Change at Week 12 (n=110, 97, 107)	Mean Change at Week 24 (n=108, 92, 109)	Mean Change at Week 48 (n=89, 75, 97)
ATV 300 mg / RTV	153	4	1	2	5	2	0
ATV 400 mg / SQV	155	9	6	6	7	7	2
LPV / RTV	154	3	1	2	8	5	4

Intervention	participants (Number)
	Overall (n=120, 115, 123)	PI Sensitive (n=88, 84, 88)	PI Resistant (n=32, 30, 33)
ATV 300 mg / RTV	77	65	12
ATV 400 mg / SQV	60	52	7
LPV / RTV	84	67	16

Intervention	participants (Number)
	Overall (n=120, 115, 123)	PI Sensitive (n=88, 83, 88)	PI Resistant (n=32, 30, 33)
ATV 300 mg / RTV	95	79	16
ATV 400 mg / SQV	74	58	15
LPV / RTV	93	72	19

Intervention	participants (Number)
	Diarrhea (Most Common)	Headache (Most Common)	Nausea (Most Common)	Jaundice (AE of Interest)	Ocular Icterus (AE of Interest)	Hyperbilirubinemia (AE of Interest)
ATV 300 mg / RTV	25	21	19	19	13	24
ATV 400 mg / SQV	29	24	24	6	3	8
LPV / RTV	54	18	15	0	0	1

Intervention	units on a scale (Mean)
	Baseline (n=98, 85, 101)	Mid-Study (n=102, 83, 97)	Final (n=95, 81, 96)
ATV 300 mg / RTV	81.33	84.89	82.77
ATV 400 mg / SQV	81.72	83.34	85.80
LPV / RTV	81.52	85.09	86.16

Intervention	units on a scale (Mean)
	Baseline (n=99, 86, 100)	Mid-Study (n=103, 83, 95)	Final (n=93, 84, 96)
ATV 300 mg / RTV	0.83	0.87	0.84
ATV 400 mg / SQV	0.85	0.86	0.85
LPV / RTV	0.86	0.89	0.88

Intervention	ng/mL (Mean)
	ATV (n=40,23)	RTV (n=40,0)	SQV (n=0,19)
ATV 300 mg / RTV	719.53	154.83	NA
ATV 400 mg / SQV	312.01	NA	52.15

Intervention	percent change in lipid values (Number)
	Total Cholesterol (n=60, 46, 54)	HDL Cholesterol (n=60, 46, 54)	Fasting LDL Cholesterol (n=52, 39, 43)	Fasting Triglycerides (n=52, 40, 43)
ATV 300 mg / RTV	-7	-5	-11	-2
ATV 400 mg / SQV	-1	3	-7	4
LPV / RTV	9	7	1	30

Intervention	percent change in lipid values (Number)
	Total Cholesterol	HDL Cholesterol	Fasting LDL Cholesterol	Fasting Triglycerides
ATV 300 mg / RTV	-8	-7	-10	-4
ATV 400 mg / SQV	-4	4	-3	-14
LPV / RTV	6	2	1	30

Intervention	percent change (Number)
	Total Cholesterol	High Density Lipoprotein (HDL) Cholesterol	Fasting Low Density Lipoprotein (LDL) Cholesterol	Fasting Triglycerides
ATV 300 mg / RTV	-8	-7	-10	-2
ATV 400 mg / SQV	-9	-1	-11	-14
LPV / RTV	3	0	-4	31

Intervention	log10 c/mL (Mean)
	Baseline Values	Week 24 Values	Change from Baseline at Week 24
ATV 300 mg / RTV	4.53	2.62	-1.91
ATV 400 mg / SQV	4.41	2.83	-1.57

Intervention	participants (Number)
	Neutrophil Reduction	Platelet Reduction	ALT Elevation	AST Elevation	Total Bilirubin Elevation
ATV 300 mg / RTV	8	2	5	4	58
ATV 400 mg / SQV	8	4	4	2	22
LPV / RTV	10	3	4	4	1

Intervention	participants (Number)
	Deaths (n = 120, 115, 123)	AEs leading to discontinuation (n = 119, 110, 118)	SAEs (n = 120, 115, 123)	AEs, grades 1-4 (n = 119, 110, 118)	AEs, grades 3-4 (n = 119, 110, 118)
ATV 300 mg / RTV	0	6	12	97	11
ATV 400 mg / SQV	1	8	14	93	18
LPV / RTV	1	5	11	103	12

Intervention	Pearson Correlation Coefficient (Number)
	ATV Cmin	IQ (<10; >=10)	# of PI Mutations at baseline (<4; >=4)
ATV 300 mg / RTV	0.37	0.376	-0.395
ATV 400 mg / SQV	-0.21	0.105	-0.227

Intervention	participants (Number)
	Adherent at Baseline (n=27, 25, 33)	Adherent at Week 24 (n=18, 11, 25)	Adherent at Week 48 (n=11, 4, 20)
ATV 300 mg / RTV	12	10	8
ATV 400 mg / SQV	10	5	2
LPV / RTV	18	23	13

Intervention	mg*hour/L (Median)
	2nd Trimester	3rd Trimester	Postpartum
ETR 200mg b.i.d.	4.5	8.3	5.3
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)	14.9	16.1	27.1
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.	72	96	133
RAL 400mg b.i.d.	6.6	5.4	11.6

Intervention	mcg/mL (Median)
	2-10 hours after birth	18-28 hours after birth	36-72 hours after birth	5-9 days after birth
DRV/COBI 800/150 mg q.d.	0.35	1.43	1.87	1.72
DTG 50mg q.d.	1.73	1.53	1.00	0.06
EFV 600 mg q.d. (Outside THA)	1.1	1.0	0.9	0.4
EVG/COBI 150/150mg q.d.	0.132	0.032	0.005	0.005

Intervention	Participants (Count of Participants)
	3rd Trimester	Postpartum
EFV 600mg q.d.	20	21
MVC 150 or 300mg b.i.d.	8	7

Intervention	mcg*hr/mL (Median)
	Before contraceptive initiation	After contraceptive initiation
ATV/RTV/TFV 300/100/300mg q.d. With ENG	53.96	55.25
EFV 600mg q.d. With ENG	53.64	56.65

Intervention	mcg*hr/mL (Median)
	Before contraceptive initiation	After contraceptive initiation
LPV/RTV 400/100 b.i.d. With ENG	115.97	100.20

tenofovir

Description

Cross-References

Synonyms (107)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (3)

Drug Classes (2)

Pathways (1)

Protein Targets (11)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (46)

Molecular Functions (50)

Ceullar Components (17)

Bioassays (576)

Research

Studies (4,957)

Study Types

Clinical Trials (755)

Trial Overview

Trial Outcomes

Participants Achieving Virologic Half Log Suppression (LOQ = 50 c/mL) at Week 24

Participants Achieving Treatment Response (LOQ = 50 c/mL) Without Prior Failure at Week 24

Participants Achieving Treatment Response (LOQ = 400 c/mL) Without Prior Failure at Week 96

Participants Achieving Treatment Response (LOQ = 400 c/mL) Without Prior Failure at Week 48

Participants Achieving Treatment Response (LOQ = 400 c/mL) Without Prior Failure at Week 24

Mean Change From Baseline in HIV RNA at Week 96

Mean Change From Baseline in HIV RNA at Week 48

Mean Change From Baseline in HIV RNA at Week 2

Mean Change From Baseline in HIV Ribonucleic Acid (RNA) at Week 24

Fasting Glucose Mean Change From Baseline at Week 48

HIV IC50 at Week 24

PR Interval and Change From Baseline by Analysis Time Point

Participants Achieving Virologic Half Log Suppression (LOQ = 400 c/mL) at Week 48, (Overall and by PI Sensitivity)

Participants Achieving Virologic Half Log Suppression (Limit of Quantification [LOQ] = 400 c/mL) at Week 24 (Overall and by Protease Inhibitor [PI] Sensitivity)

Most Common AEs and AEs of Interest Through Week 48

Mean Score of European Quality of Life-5 Dimensions (EQ-5D) Visual Analog Scale (VAS) at Baseline, Mid-Study (Week 24), and Final (Week 48)

Mean Score of European Quality of Life-5 Dimensions (EQ-5D) Health Index Score at Baseline, Mid-Study (Week 24), and Final (Week 48)

Mean ATV, RTV and SQV Minimum Concentration (Cmin) Values

Lipid Mean Percent Change From Baseline at Week 96, Observed Values

Lipid Mean Percent Change From Baseline at Week 48

Lipid Mean Percent Change From Baseline at Week 24

HIV RNA Level - Treated Subjects With Evaluable Cmins at Week 24

Grade 3/4 Laboratory Abnormalities Through Week 48

Fridericia-corrected QT (QTcF) Interval and Change From Baseline by Analysis Time Point

Deaths, Serious Adverse Events (SAEs), and Adverse Events (AEs) Through Week 48

Inhibitory Quotient at Week 24

Correlation of ATV Minimum Plasma Concentration (Cmin) Inhibitory Quotient (IQ), and Number of PI Mutations at Baseline and CD4 Cell Count Change From Baseline at Week 24

Adherence to Regimen Though Week 48 Based on MACS the Multicenter AIDS Cohort Study (MACS) Adherence Questionnaire

Participants Achieving Virologic Half Log Suppression (LOQ = 50 c/mL) at Week 96

Participants Achieving Virologic Half Log Suppression (LOQ = 50 c/mL) at Week 48

Participants Achieving Virologic Half Log Suppression (LOQ = 400 c/mL) at Week 96

Participants Achieving Treatment Response (LOQ = 50 c/mL) Without Prior Failure at Week 96

Participants Achieving Treatment Response (LOQ = 50 c/mL) Without Prior Failure at Week 48

Correlation of ATV Minimum Plasma Concentration (Cmin), Inhibitory Quotient (IQ), and Number of Protease Inhibitor (PI) Mutations at Baseline With HIV RNA Change From Baseline at Week 24

Change From Baseline in CD4 Cell Count at Week 24

Change From Baseline in CD4 Cell Count at Week 48

Change From Baseline in CD4 Cell Count at Week 96

Fasting Glucose Mean Change From Baseline at Week 24

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (Range) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (IQR) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (Range) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (95% CI) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (IQR) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C12) With Geometric Mean (95% CI) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C12) With Median (IQR) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C12) With Median (Range) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C24) With Median (IQR) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs

Intervention	unitless (Median)
TAF 10mg q.d. w/COBI	0.97
EFV 600 mg q.d. (Outside THA)	0.67
EFV 600mg q.d.	0.49
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.	0.2
RAL 400mg b.i.d.	1.5
ETR 200mg b.i.d.	0.52
MVC 150 or 300mg b.i.d.	0.33
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.	0.14
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.	0.16
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.	0.19
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)	0.12
RPV 25mg q.d.	0.55
ATV/RTV 300/100mg q.d. or TFV/ATV/RTV 300/300/100mg q.d.	0.18
DRV/RTV 800/100mg q.d. or DRV/RTV 600/100mg b.i.d.	0.18

Intervention	unitless (Median)
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.	0.15
DTG 50mg q.d.	1.25
EVG/COBI 150/150mg q.d.	0.91
DRV/COBI 800/150 mg q.d.	0.07
ATV/COBI 300/150 mg q.d.	0.07
TFV 300mg q.d.	0.88

Intervention	hour (Median)
DTG 50mg q.d.	32.8
EVG/COBI 150/150mg q.d.	7.6
DRV/COBI 800/150 mg q.d.	NA
EFV 600 mg q.d. (Outside THA)	65.6

Intervention	weeks (Number)
	5th percentile	10th percentile	25th percentile
TDF/FTC+EFV	0	24	NA
ZDV/3TC+EFV	0	16	NA

Intervention	cells/mm^3 (Median)
	Change from screening to week 24 (N=490; N=502)	Change from screening to week 48 (N=474; N=477)	Change from screening to week 96 (N= 188; N=188)
ddI+FTC+ATV	146.5	187.0	256.0
ZDV/3TC+EFV	112.5	152.0	216.0

Intervention	cells/mm^3 (Median)
	Change from screening to week 24 (N=490; N=498)	Change from screening to week 48 (N=480; N=485)	Change from screening to week 96 (N=458; N=471)
TDF/FTC+EFV	120.5	159	226
ZDV/3TC+EFV	112.5	151.5	220.5

Intervention	participants (Number)
	Week 24: Number with RNA <400 c/mL (N=495; N=500)	Week 48: Number with RNA <400 c/mL (N=482; N=487)
TDF/FTC+EFV	448	455
ZDV/3TC+EFV	459	442

Intervention	participants (Number)
	Week 24: Number with RNA <400 c/mL (N=495; N=506)	Week 48: Number with RNA <400 c/mL (N=476; N=478)
ddI+FTC+ATV	431	424
ZDV/3TC+EFV	459	437

Intervention	weeks (Number)
	10th percentile	25th percentile	50th percentile
TDF/FTC+EFV	4	32	224
ZDV/3TC+EFV	4	12	112

Intervention	weeks (Number)
	1st percentile	5th percentile	10th percentile
TDF/FTC+EFV	48	104	NA
ZDV/3TC+EFV	48	128	NA